2022 Warning Letters – Health Fraud

FDA: 2022 Warning Letters – Health Fraud 2022 Warning Letters – Health Fraud Anonymous (not verified) Tue, 04/23/2024 – 12:52

Detailed Description
2022 Warning Letters – Health Fraud

Examples of FDA Warning Letters that cite unapproved or unsubstantiated claims, tainted products or other health fraud* – related violations. For all FDA Warning Letters, click here.

Letter Issue Date Firm Name Issuing Office Subject
12/05/2022 Thriftmaster Texas, LLC. d/b/a ThriftMaster Global Holdings, Inc. and TM Global Biosciences, LLC Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated Human Foods
11/16/2022 Infusionz, LLC Center for Food Safety and Applied Nutrition (CFSAN) Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
11/16/2022 Newhere Inc dba CBDFX Center for Food Safety and Applied Nutrition (CFSAN) Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
11/16/2022 11-11-11 Brands Center for Food Safety and Applied Nutrition (CFSAN) Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
11/16/2022 Naturally Infused LLC Center for Food Safety and Applied Nutrition (CFSAN) Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
11/16/2022 CBD American Shaman, LLC Center for Food Safety and Applied Nutrition (CFSAN) Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
11/16/2022 Essential Elements Center for Food Safety and Applied Nutrition (CFSAN) New Drug/Misbranded
11/16/2022 iwi Center for Food Safety and Applied Nutrition (CFSAN) New Drug/Misbranded
11/16/2022 BergaMet North America LLC Center for Food Safety and Applied Nutrition (CFSAN) New Drug/Misbranded
11/16/2022 Healthy Trends Worldwide, LLC Center for Food Safety and Applied Nutrition (CFSAN) New Drug/Misbranded
11/16/2022 Chambers’ Apothecary Center for Food Safety and Applied Nutrition (CFSAN) New Drug/Misbranded
11/16/2022 Anabolic Laboratories Inc Center for Food Safety and Applied Nutrition (CFSAN) New Drug/Misbranded
11/14/2022 The Truth Company, LLC Center for Food Safety and Applied Nutrition (CFSAN) New Drug/Misbranded
11/14/2022 Calroy Health Sciences, LLC Center for Food Safety and Applied Nutrition (CFSAN) New Drug/Misbranded
11/07/2022 Todos Medical Ltd aka Todos Medical USA Inc Center for Food Safety and Applied Nutrition (CFSAN) Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
11/01/2022 Alternative Health Distribution LLC d/b/a CannaAid Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)
10/28/2022 Amazon.com, Inc. Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
10/28/2022 Latin Foods Market Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
10/28/2022 Walmart Inc. Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
10/24/2022 Lakpura LLC Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
09/23/2022 Saffron USA LLC Division of Human and Animal Food Operations East IV Unapproved New Drugs/Misbranded
09/23/2022 Muscle Sports Products, LLC Office of Human and Animal Food Operations East – Division 1 Unapproved New Drugs/Misbranded
09/20/2022 South Pork Ranch Equipment LLC Center for Veterinary Medicine Unapproved New Animal Drug/Adulterated
08/15/2022

The Elderberry Fairy & Co., LLC

closeout letter: 04/28/2023

Office of Human and Animal Food Operations East Division 6 Unapproved New Drugs/Misbranded
08/04/2022

Leaf of Life LLC

closeout letter: 01/23/2023

Office of Human and Animal Food- West Division II Unapproved New Drugs/Misbranded
08/04/2022 FluxxLab LLC Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
08/04/2022 Amazon.com, Inc. Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug
08/04/2022 JB Exchange Inc./Justified Laboratories Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug
08/04/2022 Ariella Naturals Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug
07/29/2022 Deggeh Foods, Inc. Office of Human and Animal Food Operations East – Division 1 Unapproved New Drugs/Misbranded
07/05/2022 Living Foods LLC Office of Human and Animal Food- West Division II Unapproved New Drugs/Misbranded
07/01/2022 MKS Enterprise, LLC Center for Food Safety and Applied Nutrition (CFSAN) Interstate Commerce/Food/Adulterated
07/01/2022 Thirsty Run LLC / US Royal Honey LLC Center for Food Safety and Applied Nutrition (CFSAN) Internet Marketing of Unapproved and Misbranded Drugs
07/01/2022 1am USA Incorporated dba Pleasure Products USA Center for Food Safety and Applied Nutrition (CFSAN) Internet Marketing of Unapproved and Misbranded Drugs
06/30/2022 Herbsens Botanicals Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug
06/30/2022 Klarity Kratom Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug
06/30/2022 Kratom Exchange Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug
06/30/2022 Omni Consumer Products LLC d/b/a YoKratom Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug
06/30/2022 MONQ, LLC Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug
06/14/2022 H2 Beverages, Inc. Division of Human and Animal Food Operations West III Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
06/10/2022 Young Living Essential Oils Corporate Office of Human and Animal Food Operations – West Division 4 New Drug/Misbranded
06/08/2022 New Sun Inc. Office of Human and Animal Foods- East Division 3 Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
05/26/2022 Hope Botanicals, LLC Center for Veterinary Medicine Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
05/26/2022 Plantacea, LLC dba Kahm Center for Veterinary Medicine Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
05/26/2022 Haniel Concepts, Inc. DBA Free State Oils, LLC Center for Veterinary Medicine Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
05/26/2022 Golden Lab LLC Office of Human and Animal Food Operations East Division IV Unapproved New Drugs/Misbranded
05/19/2022 Santhigram Kerala Ayurvedic Co. of U.S., Inc. Center for Drug Evaluation and Research | CDER Unapproved New Drugs
05/19/2022 Ayuryoga, Inc. Center for Drug Evaluation and Research | CDER Unapproved New Drug
05/16/2022 Equine Podiatry Solutions, LLC Center for Veterinary Medicine Unapproved New Animal Drug Products
05/04/2022 BioMD Plus LLC Center for Drug Evaluation and Research | CDER Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
05/04/2022 M Six Labs, Inc. Center for Drug Evaluation and Research | CDER Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
05/04/2022 Kingdom Harvest Center for Drug Evaluation and Research | CDER Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
05/04/2022 Delta 8 Hemp Center for Drug Evaluation and Research | CDER Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
05/04/2022 ATLRx, Inc. Center for Drug Evaluation and Research | CDER Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
04/20/2022 C R Supplements, LLC Office of Human and Animal Food Operations – West Division 6 Unapproved New Drugs/Misbranded
04/19/2022 Kleenhanz, LLC Center for Drug Evaluation and Research | CDER Unapproved Drug Products Related to Coronavirus Disease 2019 (COVID-19)
04/13/2022 Elements Brands Inc. Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 Skin Authority, L.L.C. Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 AMBI Enterprises LLC Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 Genomma Lab USA, Inc. Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 M & M Beauty and Wellness, LLC Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 True Earth Health Products, LLC Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 SkinPro Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 Skin PS Brands Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 Clinical Formula LLC Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 Dr. Thomas Balshi/Intilight Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 Ultimark Products Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/13/2022 Neoteric Cosmetics, Incorporated/Scott’s Liquid Gold, Inc. Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded
04/06/2022 Sensory Cloud, Inc Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
04/05/2022 CofixRx, LLC Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/28/2022 Greenway Herbal Products LLC Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/28/2022 Cureganics Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/28/2022 Functional Remedies, LLC D/B/A Synchronicity Hemp Oil Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)
03/28/2022 UPSY LLC Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/28/2022 Heaven’s Organic LLC Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/28/2022 CBD Social Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/28/2022 Nature’s Highway Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/25/2022 Iodine Products Inc Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/24/2022 Applied Biological Laboratories Inc. Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)
03/15/2022 Honey Feast, Inc. Office of Human and Animal Food Operations East Division IV New Drug/Misbranded
03/15/2022 Iotech International, LLC Center for Drug Evaluation and Research | CDER Unapproved New Drug and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/10/2022 Soda Pharm Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
03/07/2022 Viraldine, LLC Center for Drug Evaluation and Research | CDER Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)
02/23/2022 Princess Lifestyles, LLC Office of Human and Animal Food Operations –West Division 5 Unapproved New Drugs/Misbranded
02/17/2022 Vital Health & Wellness Office of Human and Animal Foods Operations-East V New Drug/Misbranded
02/11/2022 Rena’s Organic Office of Human and Animal Foods Division 4 East Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
02/09/2022 Bea Lydecker’s Naturals, Inc. Division of Human and Animal Food Operations West VI Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products
02/04/2022 Crystal Clear Supplements Center for Drug Evaluation and Research | CDER Unapproved New Drugs/Misbranded
02/03/2022 Pharmacy2Home/LandiCom Holding LTD Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)
02/01/2022 New Earth Healing Essentials, LLC d/b/a 5D Full Disclosure Center for Drug Evaluation and Research | CDER Unapproved New Drugs/Misbranded
01/19/2022 Glenn Burkett Naples Corporation Office of Human and Animal Food Operations East Division IV Unapproved New Drugs/Misbranded
01/03/2022 Amcyte Pharma, Inc. Center for Drug Evaluation and Research | CDER Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)
*The FDA defines health fraud as the deceptive promotion, advertising, distribution, or sale of a product represented as being effective to prevent, diagnose, treat, cure or lessen an illness or condition, or provide another beneficial effect on health, but that has not been scientifically proven safe and effective for such purposes.

 

 

 

Short Title
2022 Warning Letters – Health Fraud

Source Organization

Publish Date
Tue, 04/23/2024 – 14:13

Review Date
Wed, 04/23/2025 – 12:00

Last Reviewed Date
Tue, 04/23/2024 – 12:00

Site Structure

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Tue, 04/23/2024 – 13:29

Generic Boolean
Off

Regulated Product*

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/consumers/health-fraud-scams/2022-warning-letters-health-fraud April 23, 2024 4:52 pm

Regulate MJ Like Hemp or Regulate Hemp Like MJ

Either regulate Marijuana tightly like in Hemp, or regulate Hemp loosely like in Marijuana

While the current state of marijuana regulation in the states is a sad, bad joke, with open and flagrant THC inflation fraud and the tacit approval of regulators, THC testing in hemp is highly-controlled.

In hemp, a law enforcement officer collects the sample and delivers it to a state drug lab, maintaining legal chain of custody in case of prosecution over literally tenths of one percent THC, 0.3% THC is compliant but 0.4% isn’t in most jurisdictions. That’s 100-times less than the THC percentage many claim for marijuana.

And now some are making delta-8, -9, and -10 THC from hemp CBD often from cheap Chinese isolate or crude, with dozens of bizarre “Frankenoids” created in the process. And since there has been little federal enforcement it appears “legal,” although states are banning it one-by-one. The next Farm Bill will likely put that to bed.

It’s a crazy world, up is down and left is right.

And Talking Joints Memo quoted me on it:

“Last week, Richard Rose, a legend in the hemp world and author of The Richard Rose Report… This Week newsletter on the subject, mocked the general state of his industry:

We tell them we want to feed and clothe people so they legalize and then we end up making dirty bathtub THC for vape pens to be sold to teens in southern states. There’s a huge lesson to be learned from all this,” Rose wrote. “Either regulate marijuana like hemp or regulate hemp like marijuana.””

Read more at: https://talkingjointsmemo.com/tension-and-confusion-mount-over-hemp-derived-thc-products-in-mass/

Here are current studies on the hemp delta-8/Frankenoid problem. TL;DR: the issue is not the delta-8/9/10 per se, it’s the bizarre chemicals the dirty process creates. It’s as much hemp as a synthetic vitamin B pill is a leaf of spinach.

Cannabidiol-Derived Cannabinoids: The Unregulated Designer Drug Market Following the 2018 Farm Bill

Cannabinoids 2023, A guide to the current cannabinoids

Delta-8-THC craze concerns chemists, Unidentified by-products and lack of regulatory oversight spell trouble for cannabis products synthesized from CBD

Missouri company at center of cannabis recall used hemp instead of marijuana in products

Industry’s failure to address intoxicating hemp products is height of irresponsibility

Where Is Delta-8 THC Legal and Where Is It Banned?

New Canada Hemp Regs Recommended

Legislative Review of the Cannabis Act: Final Report of the Expert Panel has been released. As it relates to hemp, here is what the Canadian Hemp Trade Alliance has to say:

Where Hemp is Mentioned
The words “hemp” or “industrial hemp” appear 19 times in the 91-page final report of the Expert Panel.
Page 13: Recommendation 29 – Health Canada, in consultation with Agriculture and Agri-Food Canada, should establish and support an expert advisory body to conduct a timely review of the regulation of industrial hemp and make recommendations about the most appropriate regulatory framework.
Page 22: The federal framework – Under the Act, the Government of Canada is responsible for licensing various activities with respect to the production of cannabis (including industrial hemp), including cultivation, processing and testing, as well as associated activities, such as possession, distribution, sale
and research with cannabis.
Page 23: Protecting public safety – Prohibiting production, distribution and sale, unless authorized; Prohibiting distribution and sale to youth; Prohibiting import and export, with exceptions for licence holders with a permit and only for a scientific; or medical purpose (or in respect of industrial hemp)
Page 51: Reviewing the regulation of Industrial Hemp – Industrial hemp (that is, varieties of cannabis with 0.3% THC or less in their leaves and flowers) is also regulated under the Act. Representatives of the industrial hemp industry noted that while cannabis and hemp come from the same plant family, the
products that result from their cultivation are entirely different and carry very different risks. They told us that the industrial hemp industry in Canada has been negatively impacted by the legalization of cannabis, with less industrial hemp production and sales today than in 2017. They advocated for a new
approach to the regulation of industrial hemp that sees it treated as an agricultural commodity, with changes that would increase the maximum allowable limit of THC in industrial hemp and associated derivatives. The industry also raised other issues related to potential uses of industrial hemp (including industrial hemp-derived cannabinoids or biomass).
We did not have an opportunity to delve deeply into the regulation of industrial hemp, but we recognize this is a topic that deserves careful and detailed consideration.
Recommendation 29: Health Canada, in consultation with Agriculture and Agri-Food Canada, should establish and support an expert advisory body to conduct a timely review of the regulation of industrial hemp and make recommendations about the most appropriate regulatory framework.
Page 52: Supporting a diverse legal cannabis industry – Health Canada should develop a specialized program for applicants from under-represented communities that provides pre- and post-licensing supports. This should include information about opportunities other than cultivation and processing
licences, such as licences for industrial hemp and analytical testing. Acknowledging the submission by the Competition Bureau entitled Planting the seeds for competition: Competition Bureau submission to Health Canada and the Expert Panel to support the Cannabis Act legislative review, which dealt with this issue, we believe that Health Canada should consider whether the requirement that applicants for licences have a pre-built site could be eliminated for equity-deserving and small business applicants.
Page 55: Improving the monitoring of environmental impacts – Although the environmental impact of cannabis was not raised often during engagement, some participants highlighted concerns about cannabis product packaging. They raised issues about single-use plastic packaging and the limited use of
packaging composed of cannabis and industrial hemp plant by-products. We also heard about the high rates of energy required for indoor cultivation. Some stakeholders discussed innovative approaches to reducing the environmental footprint of cannabis cultivation, such as the use of organic and regenerative
farming practices, using cannabis as a bio-accumulator to help remediate the soil, making use of solar energy and the secondary use of cannabis by-product waste.
Recommendation 36: The Government of Canada should establish indicators related to the environmental impacts of the cannabis industry, collect baseline data and continue to monitor these indicators and their trends. The Government of Canada should publish this information in a timely manner to allow the public to monitor progress.

The Canadian hemp industry requires specific regulatory relief to move forward

  1. Moving all produce- and processor-facing hemp regulatory oversight and operations from Health Canada to Agriculture and Agri-Food Canada;
  2. Move hemp the List of Approved Cultivar (LOAC) registration process from Health Canada to the Canadian Seed Growers Association;
  3. Replacing expense and unnecessary 100% THC testing of all hemp food lots with statistically valid sampling for monitoring purposes;
  4. Establishing Maximum Residue Levels for hemp flowers and leaves sold to licensed cannabis processors for the purpose of extracting concentrated and isolated cannabinoids;
  5. Clarifying several regulatory issues that have arisen from Health Canada’s confusion between adult use/medical Cannabis and hemp, including at least:
    a. natural background cannabinoid levels in hemp foods are: natural constituents; not contaminants; and not restricted by Health Canada’s prescription drug regulations;
    b. hemp-derived products that do not contain concentrated or isolated cannabinoids are not subject to cannabis restrictions (i.e. mixing with other food or natural health product ingredients);
    c. there are no maximum regulated non-THC cannabinoid concentrations for any hemp derived product that has not been supplemented with concentrated or isolated cannabinoids; and,
    d. processed hemp products with detectable levels of non-THC cannabinoids (i.e. natural background levels of CBD) can be sold in domestic and international markets without restriction;
  6. Increasing the maximum allowable THC in the flowers and leaves in hemp inflorescence from 0.3% to 1.0%;
  7. Increasing the maximum allowable THC content in hemp foods from 10pmm to 50ppm in hempseed oil and 20 ppm in all other hemp foods; [note: USA is 3,000 ppm]
  8. Allowing tissue culture propagation of hemp from LOAC-compliant parent plants;
  9. Exempting all hemp products – except for flowers and leaves sold to licensed cannabis processors – from the Cannabis Act.”

Position Paper on the Development of Bioeconomy Value Chains with Focus on Hemp

This report, “Position paper on the development of bioeconomy value chains with focus on hemp,” is from the HempClub of Czechia, on hemp in the E.U.

They make the case I’ve been making for 30 years, that food from the grain is the way forward for hemp. And they make that case over and over, but blame regulations on the lack of market development instead of focusing on the way out of the maze, namely demand creation. It is mentioned but not emphasized.

Maximum THC in the E.U. in food is generally 10 ppm, just like Canada which built a billion-dollar hemp food industry the last 25 years anyway. In the ’90s in the U.S. it was 1 ppm but we persevered, flourished even. Demand is the problem, not rules.

Canada proved the best path for hemp is to grow for seed, sell value-added branded foods globally, and get way more biomass for fibre projects thereby reducing the net cost of both.

Food already has the most consumers, retailers, companies, products, sales, profits, and acres the last 25 years, and the largest potential market (everyone eats). Hemp food is a win-win for the industry.

It’s unfortunate that when assembling multi-disciplinary teams, Marketers always seem to get left behind. Farmer, processor, labs, breeder, consultants, lawyers, lobbyists… everyone is there but a Marketer.

But when it comes to demand creation and adding value, who else is going to do it but a Marketer? That is literally their job, profession, career. Ignoring demand creation is a fatal flaw for an industry desperately in need of more sales to simply remain viable.

This report also highlights an important fact: it was funded by government grant. Like in the E.U. and Canada, the U.S. federal and state governments need to step up and inject needed capital into this nascent industry before it withers away.

Here are some excerpts from the report:

Position paper on the development of bioeconomy value chains with focus on hemp

The strategy prioritizes sustainable food and resource management, reduced reliance on non-renewables, climate change mitigation, and competitiveness and job creation.

Hemp, or Cannabis sativa, distinguishes itself with negligible THC levels, making it a versatile plant for textiles, ropes, building materials, and bioplastics, thus, to be an important player in the bioeconomy revolution. Its ecological benefits, including phytoremediation, contribute to sustainability in various sectors, aligning with the United Nations’ 17 Sustainable Development Goals (SDGs) and supporting the European Green Deal. Despite hemp’s potential, challenges such as stigma, regulatory complexity, and the absence of global standards hinder its growth. Addressing these issues requires policy reform, standardization, education, and collaboration across sectors.

The exploration of promising value chains for industrial hemp focuses on establishing sustainable and collaborative supply chains. Building trust among key stakeholders is identified as crucial for successful collaboration. This document outlines a strategic process for building localized value chains, involving farmers, refining factories, local markets, and scaling up to industrial levels.

Governmental support, particularly through legislation encouraging collaboration, is deemed essential. Identified key value chains for hemp across sectors, such as textiles, construction, automotive, nutraceuticals, bio-composites are detailed. Examples of innovative hemp-based products within these sectors are highlighted, alongside opportunities for overcoming regulatory hurdles, addressing THC limits, and strengthening networking and collaboration.
[…]
The main objective of the HempClub project was to create an interconnected and interregional supply chain between operators in primary production, agri-food processing, and green chemistry by strengthening industrial symbiosis and sustainable and renewable business models.
[…]
Now, while China and the USA are vying for the lead in bio-based production, Europe is proving uncertain, amidst directives and regulations that often contradict each other and which, due to a silo approach do not fully grasp the opportunities of some strongly interdisciplinary and holistic sectors such as the Bioeconomy in which bio-based products, bioenergy, waste and by-products from the agro-food and wood supply chains, bioprocesses, and system redesign are strongly connected and can really contribute to the decarbonisation of the economy
[…]
The EU Bioeconomy Strategy defines five objectives that a sustainable and circular EU bioeconomy should achieve: i) Ensuring food and nutrition security; ii) Managing natural resources sustainably; iii) Reducing dependence on nonrenewable, unsustainable resources, whether sourced domestically or from abroad; iv) Mitigating and adapting to climate change; v) Strengthening European competitiveness and creating jobs. In detail:

Ensuring food and nutrition security. Food availability indicators are seen to be generally stable, which is in line with other recent assessments on food security made by the European Commission. The indicators contributing to the understanding of accessibility to food are showing that while there is more overall food security in the EU, the food purchasing power has slightly declined in the past 5 years (it is stable on a 10-year average).
[…]
Isolating food waste generation from biowaste, we do not see any significant change in time at any step of the supply chain. Assessing food waste by food category, we do see that there has been, in the past five years, a significant decline in food waste generation for cereals, fish and oil crops.
[…]
The share of manufacture of food and beverages activities registered a stable to positive trend in the analyzed periods. More traditional non-food biomass-processing activities show a stable evolution (e.g. wood products and paper) or, in the case of textiles, a structural decline.
[…]
The strategy’s objectives highlight the need for sustainable food and resource management, reduced reliance on non-renewables, climate change mitigation, and boosting competitiveness and job creation.
[…]
Furthermore, the seeds and oil derived from hemp are highly nutritious and rich in essential fatty acids, proteins, and minerals, making them valuable in food and or animal feed additives.
[…]
Food and Beverages

Food and Beverages include hemp seed-derived products but also, more recently, flowers and leaves extracts. Hemp food is a relatively new market, although its use in the kitchen is testified from the Middle Ages. In Europe, the hemp food sector was unlocked in the second half of the 1990s, becoming more and more relevant in the food sector, being classified today as a “superfood”.

Today Canadian companies were the first to unlock the potential market of hemp food. Since 2000, they have been the unique suppliers of the huge US market, taking advantage of the fact that until 2018 hemp food could be sold but not produced inside the USA. The food and beverages market holds great potential for hemp-based products looking to benefit from recent trends toward health and sustainable eating.

The largest European grower of hemp, France, produces over 11,500 tons of hemp grain per year. In 2016, 44% of the French hemp seed production was employed for animal feed, 43% for human consumption, and 13% for oil production. The largest French producer of hemp seed, La Chanvrière de l’Aube, claims to supply 30-50% of Europe’s hemp seed demand each year.

The second European hemp seed producer is the Lithuanian company Allive contracting organic farmers all around Europe for their BRC quality production of hemp food ingredients on more than 8000 ha.
[…]
For example, under SDG 2 (Zero Hunger), hemp seeds, rich in proteins and fatty acids, contribute to food security. Again:

SDG 12 (Responsible Consumption and Production): Hemp’s sustainability in production and versatility in usage exemplify responsible consumption.

SDG 13 (Climate Action): Hemp’s carbon sequestration abilities make it vital for climate action efforts.

SDG 15 (Life on Land): Hemp farming supports soil health and biodiversity.
[…]
Industrial strategy for a clean and circular economy EU Industrial strategy Hemp value chains can provide growth in rural areas, manufacturing and food processing industries. Processing requires highly skilled workers ideally in proximity to the cultivation facilities.
[…]
Proposal for a legislative framework for sustainable food systems Hemp is a sustainable multipurpose crop. Nothing goes to waste and everything is upcycled. Local supply chains will need to be established to fully harness the potential of the hemp economy.
[…]
Determine the best modalities for setting minimum mandatory criteria for sustainable food procurement to promote healthy and sustainable diets, including organic products, in schools and public institutions

Hemp seeds are particularly rich in high-quality proteins and have a unique essential fatty acid spectrum. Hemp feed can also serve as an enhancer for the nutritional profile of animal products, particularly meat and eggs.
[…]
Review of the EU promotion programme for agricultural and food products with a view to enhancing its contribution to sustainable production and consumption

Funding should be granted to products respecting particularly high sustainable standards. Promotion programs could greatly benefit hemp fibres and encourage the reconstitution of textile value chains in Europe.
[…]
Greening the Common Agricultural Policy / ‘Farm to Fork’ Strategy

Proposal for a revision of the Sustainable Use of Pesticides Directive to significantly reduce use and risk and dependency on pesticides and enhance Integrated Pest Management

Hemp already requires a low level of phytosanitary products and is a perfect crop for organic agriculture. It has a positive impact on the yield of subsequent crops when used in rotation and can be utilized as a pioneer crop.

Proposal for a legislative framework for sustainable food systems

Hemp is a sustainable multipurpose crop. Nothing goes to waste and everything is upcycled. Local supply chains will need to be established to fully harness the potential of the hemp economy.

Determine the best modalities for setting minimum mandatory criteria for sustainable food procurement to promote healthy and sustainable diets, including organic products, in schools and public institutions

Hemp seeds are particularly rich in high-quality proteins and have a unique essential fatty acid spectrum. Hemp feed can also serve as an enhancer for the nutritional profile of animal products, particularly meat and eggs.

Review of the EU promotion programme for agricultural and food products with a view to enhancing its contribution to sustainable production and consumption

Funding should be granted to products respecting particularly high sustainable standards. Promotion programs could greatly benefit hemp fibres and encourage the reconstitution of textile value chains in Europe.

Review of the EU school scheme

legal framework with a view to refocus the scheme on healthy and sustainable food

EU school scheme should encompass a wider range of products, including hemp seed and hemp seed oil, rich in fatty acids and other nutrients, particularly adapted for a healthy diet

EU carbon farming initiative

Hemp could represent a great crop for carbon farming purposes. Its use should be encouraged with the aim of capturing carbon in the soils or in manufactured goods.

Examination of the draft national strategic plans, with reference to the ambitions of the European Green Deal and the Farm to Fork Strategy

Hemp being a rotation crop, it can bring additional revenues to farmers and give impetus to EU rural areas. Sectoral interventions coupled by rural development interventions will be key in enabling a fully-fledged circular bio economy based on hemp.
[…]
Nutraceuticals, food additives, and beverages: Hemp seeds are experiencing a resurgence as prominent ingredients in food products, beverages, and nutritional supplements. This resurgence can be attributed to several factors, including the distinctive composition of its fatty acids spectrum, a growing interest in the valorization of agro-food industry residues, and the exploration of new sources of protein. The utilization of hemp seeds is primarily observed in three forms: whole seeds, seeds for oil, and de-hulled seeds.

Notably, a rapidly advancing market in the realm of plant-based foods and beverages is driving the demand for hemp-derived products. These encompass a variety of offerings derived directly from hemp seeds, including whole seeds, as well as processed forms such as meal, flour, protein powder, oil, and bioactive substances.

The oil extracted from hemp seeds stands out as an exceptionally rich source of two essential fatty acids: linoleic acid (omega-6) and alpha-linolenic acid (omega-3). This nutritional profile positions hemp seed oil as a more concentrated source of nutrients and proteins compared to soybean, the nearest vegan alternative.

Consequently, the nutritional value of hemp seeds and their oil makes them particularly appealing in the context of the nutraceutical domain. Despite these promising attributes, the nutraceutical domain necessitates further advancements through a meticulous functional characterization of the component proteins within hemp seeds. Achieving a comprehensive understanding of these proteins is crucial for unlocking the full potential of hemp seeds in the nutraceutical industry.

Relevant examples applied to this sector are:

Hempeat (Poland) produces meat alternatives based on hemp seed protein.

Good System (Slovakia) produces vegan plant-based protein shakes for EU markets with 50% hemp seed protein.

Ansce Bio Generic (Italy) produces a line called Hempy that includes i) nutraceuticals (hemp seed oil for multifunctional physiological support) and ii) aromaceuticals (hemp terpenes for food applications).

Canah International SRL (Romania) produces shelled seeds, natural hemp protein, hemp seed snacks/protein bars, protein shakes, Muesli/Granola, hemp chocolate, hemp oil, dietary supplements/capsules with hemp oil, Omega 3+, recipes for food preparations that include oil, flour or hemp seeds, cosmetics (anti-aging creams/serums; moisturizing serums in various forms) and export in all EU Member States except Denmark.
[…]
Get the report at: https://clustercollaboration.eu/sites/default/files/profile-article/HempCluB_Deliverable_D2.9_SPRING_final.docx__1.pdf

List of “Frankenoids”

From Institut für Hanfanalytik of Austria, on the semi-synthetic cannabinoid byproduct “Frankenoids” created by using strong acids, chemicals or metals on “legal hemp” CBD to create forms of “legal” THC such as delta-8, -9, and -10. Those byproducts have unknown effects long-term. I suggest visiting the link for a more complete list of phytocannabinoids and neocannabinoids:

SSC – Semi-Synthetic Cannabinoids – Conversion Products

SSC refers to a group of substances converted from natural cannabinoids using simple chemical processes (mostly hydrogenation). Therefore, products containing SSC are called conversion products. SSCs usually have the typical properties of cannabinoids (e.g., psychoactivity) but were not regulated by law when they appeared on the European market (2021/2022). In the meantime, many psychoactive SSCs are subject to legal regulations in European countries (Austria, France, Poland, Finland, etc.) and may no longer be traded. Scientific studies on the mechanisms of action of SSCs are still lacking.

HHC – Hexahydrocannabinol

HHC is a psychoactive derivative of THC. It is produced by hydrogenation of THC, retaining the basic structure of THC Chemical structures d9-THC vs. HHC vs. THCP Although often presented this way, it is not biosynthesized in the cannabis plant. Those two publications that found HHC in minimal traces in heavily aged plant material also tend to suggest an aging process. Within the EU, the EMCDDA 2023 “Technical Report: HHC and related substances” is of legal relevance, which excludes biosynthesis and, thus, the natural origin of HHC.

HHC-O – Hexahydrocannabinol Acetat

HHCO is an HHC derivative. It is believed to act as a pro-drug, similar to THC-O, which is hydrolyzed to HHC in the body after consumption. Scientific studies on HHCO are still lacking.

HHCP – Hexahydrocannabiphorol

HHCP is a very strongly psychoactive substance. It is assumed that the more substantial psychotropic effect compared to HHC is mainly due to the extended alkyl side chain (7 carbon atoms instead of 5 as in HHC).

CBND – Cannabinodiol

CBND is a psychoactive cannabinoid. In American forum posts, it is heralded as one of the successors of HHC, which is why we have categorized it as SSC. Chemically, it was first found in low concentrations in hemp flowers in 1974. It is mentioned in only a few scientific publications. Its structure corresponds to a complete aromatization of CBD, analogous to the structures of CBN to THC. This would rather speak for a degradation product. Apart from its psychoactive property, there are no data on the mode of action of CBND.

CBN-O – Cannabinol-O-Acetate

CBN-O is a derivative of CBN. It is believed to act as a pro-drug, similar to THC-O, which is hydrolyzed to CBN in the body and then exerts its effects as CBN. Scientific studies still need to be included.

H4CBD – Tetrahydrocannabidiol, Hydrated CBD, Cyclohexyl-CBD

H4CBD is obtained by catalytic hydrogenation of CBD. In the wake of the international price drop of CBD, starting in 2022, a CBD product with a higher price was created and offered as H4CBD under a new name. H4CBD is believed to have the same properties as CBD but to a greater degree. Scientific studies are still lacking.

THC-O – THC-O-Acetate

THC-O is the acetate ester of THC. It is a metabolic pro-drug, i.e., hydrolyzed in the body to THC, which only develops its effect as THC after hydrolysis. The strength of the psychoactive effect depends on whether it was synthesized from d9-THC or d8-THC.

THCP – Tetrahydrocannabiphorol

THCP is a potent psychoactive synthetic homolog of THC. It is believed that, like HHC, the extended alkyl side chain (7 carbon atoms instead of 5 as in THC) results in a stronger psychotropic effect than THC. Isomers with the double bond in position delta 8 and delta 9 are probably.

By-products and impurities from SSC production

SSC products may be contaminated with either extraction residues or synthetic by-products and may contain traces of heavy metals originating from the catalyst used for hydrogenation. Here are some substances involved in the production processes of semi-synthetic cannabinoids. Depending on the process and substance, they are desirable intermediates or undesirable byproducts and are sometimes still present as impurities in finished products for end users. These byproducts get the most attention as an unexpected laboratory result, both in product testing as part of quality assurance and in post-consumer drug testing.

d6a10a-THC – d6a10a-Tetrahydrocannabinol – d3-Tetrahydrocannabinol

Depending on the manufacturing process, d6a10a-THC may be an intermediate or by-product in the production of HHC. Depending on the ratio of the two enantiomers (R, S), d6a,10a-THC has little to hardly any psychoactive effect.

d8-iso-THC – trans-d8-iso-Tetrahydrocannabinol and d4(8)-iso-THC – trans-d4,8-iso-Tetrahydrocannabinol

d8-iso-THC and d4(8)-iso-THC are formed during the cyclization of CBD to THC.

d10-THC – d10-Tetrahydrocannabinol

d10-THC is a THC isomer with approximately 30-40% of the psychoactive potency of d9-THC. D10-THC has rarely been detected, and then only as a trace component, in cannabis plants. Therefore, d10-THC is presumably a degradation product similar to CBN. However, it is also frequently found as an impurity in synthetic d8-THC produced from CBD. For this reason, we have categorized d10-THC as a byproduct. From another perspective, it can also be considered a degradation product or SSC.

d11-THC – Delta-11-Tetrahydrocannabinol – exo-THC – Pentahydrocannabinol – PHC

d11-THC is a synthetic isomer of THC that is produced, among other substances, as an impurity in the production of dronabinol (d9-THC). It can be synthesized as SSC from d8-THC in several ways. In experiments with mice, d11-THC has shown a psychoactive strength of only about 25% compared to d9-THC. Chemically, d11-THC is no longer a “tetrahydro”-cannabinoid because the double bond is outside the name-giving ring between positions 9 and 11. See Figure 1 IUPAC numbering. When viewed from the ring, the double bond is on the outside (exo), and only 5 carbon atoms are hydrogenated in the ring itself. Therefore, the compound could be called pentahydrocannbinol.

Read more at: https://www.hanfanalytik.at/en/cannabinoids-2023

Proposed Federal Regulation Framework

This is a proposed Federal Regulation Framework for Cannabis policy in the U.S., the efforts of the Federal Regulatory Framework (FRF) Working Group, a collaboration between the Foundation of Cannabis Unified Standards (FOCUS) and the Association of Food and Drug Officials (AFDO).

The Working Group’s goal is to develop a comprehensive and relevant roadmap for the regulatory framework of these unique consumer packaged goods (CPG), addressing critical challenges and enhancing consumer confidence in the safety of the products they purchase and consume. The complexity within the food and beverage industry stems from cannabis not having approval as a food additive, and as a result, cannabis companies are producing new consumer products categorized as food without comprehensive regulation or oversight by food safety experts and regulatory bodies.

It’s a great start, here are my suggestions for improvement:

1) In hemp, there is no “0” nor should there be. While a Type V is theoretically possible, where is an example today? And further, why “0”? Even if hemp today is 3,000 ppm (0.3%), if the testing LOQ is say 1 ppm (0.00001%) then why is “0.000000” necessary? It’s just reefer madness, use of seed certified to be compliant by a government agency should suffice.

2) Food and ingredients must be separated into pre- and post-harvest, USDA and FDA. Otherwise, it’s like FDA regulating soybean farming or USDA regulating UHT soymilk; it makes no sense.

3) In this age of delta-8/9/10 gummies sold to teens in gas stations in the south, hemp food needs “THC-free” labeling if compliant, such as what alcohol-free and fat-free enjoy if <0.5% and <0.5g, respectively. That’ll be on Congress to fix, like it did those two.

4) The Tenth Amendment complicates the Therapeutic/Psychotropic issue immensely, and it is ignored here. “Sub Agency” could be a federal Office of Cannabis under NIH or FDA, or maybe it’s the state which already has an entire marijuana regulatory infrastructure funded and in place?

Read more at: https://www.food-safety.com/articles/9104-cultivating-cannabis-regulations-ensuring-food-safety-in-an-evolving-industry

Hemp Food Association Letter to Congress

Hemp Food Association
Colorado, USA

To:
[email protected]
[email protected]

August 17, 2023

Dear Honorable Representatives and Senators—

The Hemp Food Association is the only trade group dedicated to food made from the Hempseed (grain) and has been since 1998. I am the founder and Director and have been active in commercial Hemp product importation and marketing even longer, since 1994.

Long before most heard of CBD, certain Hemp products sold for several millions of dollars annually in the U.S., and have for years. Foods containing Hemp grain have long been in almost every supermarket, sometimes dozens of products.

Consumer and industrial food made from the proteinaceous Hempseed is the one segment with the most companies, consumers, retailers, sales, and acres already. It was accepted as GRAS by FDA in 2018. Sold worldwide, it has the most potential consumers globally. It is 100% legal to regulators everywhere. It is such an important segment that USDA tracks retail ads, prices, and imports of them.

Even before Canada legalized Hemp in 1998, foods from Hempseed were in national distribution in the U.S. and Canada, appearing on national TV not as a joke but as legitimate new commercial foods. I made a Hemp potato salad on CBS-TV wearing all Hemp clothes. National magazines like Rolling Stone, Details, and New York Times Sunday had positive stories, as did thousands of newspapers and hundreds of radio stations.

One Hemp burger had a legal health claim for “reduces risk of heart disease.” Another had a legal Structure-function claim for organic Hemp corn chips. All this literally in the last century. That became 90% of Canadian Hemp and our first billion-dollar segment.

As one of the Hemp entrepreneurs from the last century still living, please know that the current state of Hemp is NOT AT ALL what was envisioned all these decades. We saw fields of waving Hemp grain and fire-proof houses and clothes from the stalk, not disposable vape pens filled with psychoactive cannabinoids ostensibly from Hemp sold in gas stations across the land.

Frankly, in 2018 I had no clue this would happen, and neither did Congress. It was the nexus of new laws and newer chemistry. Understand that it is just an opportunistic workaround for a regulatory conundrum, namely Cannabis in the Controlled Substances Act, making it the nation’s least-popular law. One way to address the psychoactive Hemp cannabinoid issue is to turn marijuana regulation over to the states, since forty-seven already have laws contra Cannabis in Schedule I and the CSA.

It’s obvious that a bifurcation of the Hemp industry into grain/fiber and cannabinoids has already occurred, therefore Congress needs to recognize that reality in the next Farm Bill. All aspects of Hemp will continue to be hurt until then, USDA appears reluctant to throw its full weight behind Hemp until it knows it will be just a grain/fiber crop, and not a trichome crop feeding the gray market.

Congress could go a long way to assist by approving the recommendations of Hemp Exemption exempting certified grain/fiber farmers from onerous and unnecessary regulations, as well as “THC-free” labeling for compliant foods made from the Hempseed.

Please keep Hemp true to what we’ve labored all these decades for, namely grain and fiber, and not let it continue to be hijacked by this emergent segment, a regulatory anomaly.

Richard Rose
Hemp Food Association
https://the-HFA.org

Whack-a-mole Drugs

CNR: Whack-a-mole Drugs

New psychoactive substances like Tianeptine or “gas station heroin” are popping up in North Carolina, and our Legislature is struggling with the problem.  https://www.wbtv.com/2024/02/14/nc-lawmakers-working-ban-gas-station-drug-that-mimics-effects-opioids/

But as soon as the Legislature bans substances, copycat drugs pop up, maybe with a molecule in a complex organic compound changed here or there.

To go beyond listing dangerous drugs that are out there already, I’m trying to find catch-all language that would list or cover “whack-a-mole” new drugs that people would discover or invent.

It took me years to get up to speed on marijuana taxation, so I don’t imagine I can grasp new psychoactive substances very readily.  Here’s what I’ve found so far, mainly to show how little I know.  There is language from New Zealand and from the United Kingdom that may be helpful.

New Zealand has this language:

Broadly speaking, a psychoactive substance is anything:

·  that is capable of producing a psychoactive effect in an individual who uses the substance (ie, affects the mind of the user in any way) AND

·  whose primary purpose is to induce a psychoactive effect in an individual who uses the substance or product AND

·  that is not a medicine, controlled drug, precursor substance, herbal remedy, food, dietary supplement, tobacco product or alcohol.

https://www.health.govt.nz/our-work/regulation-health-and-disability-system/psychoactive-substances-regulation/definitions-and-history-psychoactive-substances

New Zealand’s effort is not getting glowing reviews, but I wonder if it’s better than nothing.  

https://www.health.govt.nz/publication/review-psychoactive-substances-act-2013

The UK has a similar approach:

Meaning of “psychoactive substance” etc

(1)In this Act “psychoactive substance” means any substance which—

(a)is capable of producing a psychoactive effect in a person who consumes it, and

(b)is not an exempted substance (see section 3).

(2)For the purposes of this Act a substance produces a psychoactive effect in a person if, by stimulating or depressing the person’s central nervous system, it affects the person’s mental functioning or emotional state; and references to a substance’s psychoactive effects are to be read accordingly.

https://www.cps.gov.uk/legal-guidance/psychoactive-substances#:~:text=The%20Psychoactive%20Substances%20Act%202016,is%20seven%20years%27%20imprisonment).

I don’t know how the UK system is working.  There are criticisms (and details) at  https://en.wikipedia.org/wiki/Psychoactive_Substances_Act_2016.

A friend from CANN-RA, the Cannabis Regulators Association,writes:

ASTM has a standard defining “intoxicating cannabinoids” out for balloting. It starts by categorizing all cannabinoids as “potentially intoxicating” until there’s evidence on which to make a determination. But the standard focuses only on CB1-mediated intoxication (effects like THC), so if something is intoxicating by a different mechanism, it counts as “non-intoxicating.” It also doesn’t necessarily account for human metabolism: If test tube studies show that the substance doesn’t activate human CB1 receptors, it’s non-intoxicating… even if enzymes in the liver or blood convert the substance into an intoxicating derivative when a person ingests it. And it has a very narrow definition of cannabinoid that doesn’t include a lot of synthetic cannabinoids. This is in the “too narrow” category.

The New Zealand standard looks like it may go the other direction, being too broad. Or maybe it’s really broad on the surface, but in practice the exceptions make it hard to navigate. Regulation of psychoactive substances is really not coherent, because the regulatory approach to each emerges out of the historical and cultural context that gave rise to the regulation. Caffeine is a popular drug, but is not a “psychoactive substance” under this definition because it is widely accepted and has been folded into regulation as a food, dietary supplement, and medicine. Tobacco and alcohol each have their own unique regulatory structures because of their long history of use in America. On the other hand, I’m not at all clear where betel (areca nut) falls under America’s regulatory system because it wasn’t historically widely used or noticed here, despite being the fourth most commonly used drug worldwide (behind caffeine, alcohol, and tobacco). Kava happened to be present in the dietary supplement market prior to 1994, so it’s grandfathered into that regulatory scheme, although I suspect it would not be allowed as a new dietary ingredient if it didn’t pre-date DSHEA and was submitted as a new dietary ingredient for consideration today. Under New Zealand’s scheme, I’m not sure where something like nitrous oxide would fall: It’s definitely psychoactive, but is it’s primary purpose to induce psychoactive effects or as a propellant for whipped cream? Or is it exempt anyway because it’s a medicine (used as an anaesthetic), despite the psychoactive use being outside of the medical context.

+++

I suppose there would need to be a body or agency of some kind that makes ongoing determinations very quickly as new drugs pop up.  

The DEA handled fentanyl:  “When a new analog appeared on the streets, the DEA would list it as illegal, and the illicit labs would respond by creating a new, legal analog. This deadly game of ‘Whack-A-Mole’  . . . continued until 2018 when the DEA listed all drugs related to fentanyl as illegal — a move referred to as class-wide scheduling.”    

https://nij.ojp.gov/topics/articles/fighting-uphill-war-against-illicit-drugs-and-overdose-deaths-detecting-emerging

But the DEA hasn’t acted on tianeptine or other drugs that are problematic.


#CBD #Hemp

Whack-a-mole Drugs


March 1, 2024 6:55 pm

NCTR Participation at 2023 SOT Annual Meeting

FDA: NCTR Participation at 2023 SOT Annual Meeting NCTR Participation at 2023 SOT Annual Meeting Anonymous (not verified) Wed, 02/21/2024 – 15:53

Detailed Description
SOT 62nd Annual Meeting and ToxExpo featured more than 70 scientific sessions, 2,000 presentations, 250 exhibitors, and 5,000 attendees

Audience

The SOT 62nd Annual Meeting and ToxExpo featured more than 70 scientific sessions, 2,000 presentations, 250 exhibitors, and 5,000 attendees.

 

2023 SOT Platform, Poster, or Workshop Sessions

Title

NCTR Author

NCTR Division

POSTER SESSION: ALTERNATIVES TO MAMMALIAN MODELS I “Lessons Learned in Establishing a Reliable and Low-Cost Assay for Urea Production in Human Primary Hepatocytes Cultured in a Liver Chip for the Study of Drug Hepatotoxicity” Shi, Q. DSB
POSTER SESSION: ALTERNATIVES TO MAMMALIAN MODELS I “AnimalGAN: A Generative AI Alternative to Animal Clinical Pathology Testing” Chen, X. DBB
POSTER SESSION: ALTERNATIVES TO MAMMALIAN MODELS I “Cardiotoxicity Assessment of HESI Reference Compounds Using Human iPSC-CMs” Bagam, P. DSB
POSTER SESSION: ALTERNATIVES TO MAMMALIAN MODELS I “Performance of the Three-Dimensional HepaRG Micronucleus Assay for In Vitro Genotoxicity Testing” Guo, X. DGMT
POSTER SESSION: EPIDEMIOLOGY AND PUBLIC HEALTH “A Systematic Analysis and Data Mining of Opioid-Related Adverse Events Submitted to the FAERS Database” Le, H. DBB
POSTER SESSION: EPIDEMIOLOGY AND PUBLIC HEALTH “Assessment of Modified Sandwich Estimator for Generalized Estimating Equations with Application to Opioid Poisoning in MIMIC-IV ICU Patients” Rogers, P. DBB
POSTER SESSION: EPIDEMIOLOGY AND PUBLIC HEALTH “RxNorm for Drug Name Normalization: A Case Study of Prescription Opioids in the US FDA Adverse Events Reporting System” Zou, W. DBB
POSTER SESSION: REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY I “Assessing the Developmental Toxicity of Busulfan in an In Vitro Human Placental Barrier-Embryo Co-culture System” Wang, Y. DGMT
POSTER SESSION: CARCINOGENICITY “DNA Methylation and Transcriptomic Alterations Induced by Extended Treatment of Normal Human MCF10A Mammary Gland Epithelial Cells with Non-cytotoxic Doses of Lorcaserin” Willett, R. DBT
PLATFORM SESSION: EXPLORING TIME AND CELL DIVERSITY IN TOXICOGENOMICS SPACE

“Effect of Food-Grade Titanium Dioxide on DNA Methylation in Human Cells”

Wells, C. DBT
WORKSHOP SESSION: UNDERSTANDING THE CONCEPT OF SIMILARITY AND ITS APPLICATIONS TO TOXICOLOGICAL RESEARCH AND RISK ASSESSMENT “Structure Similarity Based on Chemical Descriptors, Fingerprints, and Structural Alerts” Hong, H. DBB
POSTER SESSION: DNA DAMAGE AND REPAIR “Evaluation of Newly Developed 14 Human TK6-Derived Cell Lines That Individually Express a Human Cytochrome P450 for Toxicity Studies” Mei, N. DGMT
POSTER SESSION: DNA DAMAGE AND REPAIR “Nitrosamine Drug Impurities Induce Genotoxicity in Human Lymphoblastoid TK6 Cells” Li, X. DGMT
POSTER SESSION: DNA DAMAGE AND REPAIR “Actein Contributes to Black Cohosh Extract-Induced Genotoxicity in Human TK6 Cells” Le, Y. DGMT
POSTER SESSION: DNA DAMAGE AND REPAIR “Assessment of DNA Damage-Induced by 10 Nitrosamine Impurities Using 2D and 3D HepaRG Models” Seo, J.-E. DGMT
POSTER SESSION: DNA DAMAGE AND REPAIR “Evaluation of the DNA Mutagenicity of N-hydroxycytidine in Mouse Lymphoma Cells by HiFi and Clone Sequencing” Revollo, J. DGMT
POSTER SESSION: DNA DAMAGE AND REPAIR “HiFi Sequencing for Detecting In Vivo Somatic Mutation” Dobrovolsky, V. DGMT
POSTER SESSION: DNA DAMAGE AND REPAIR “HiFi Sequencing Detects the On- and Off-Target Effects of a Cytosine-to-Thymine Base Editor in E. coli Miranda, J. DGMT
POSTER SESSION: BIOTRANSFORMATION/CYTOCHROME P450 “Study of the Roles of Cytochrome P450 (CYPs) in the Metabolism and Cytotoxicity of Perhexiline” Chen, S. DBT
POSTER SESSION: COMPUTATIONAL TOXICOLOGY I “Using Language Model to Facilitate COVID-19-Associated Neurological Disorder Literature Analysis: A BERTox Research” Wu, L. DBB
POSTER SESSION: COMPUTATIONAL TOXICOLOGY I “Development of Random Forest Model for Predicting SARS-CoV-2 Main Protease Binders as Potential Candidates for Repurposing to COVID-19 Treatment” Xu, L. DBB
POSTER SESSION: COMPUTATIONAL TOXICOLOGY I “Opioid Agonist/Antagonist Database (OADB): A Database to Facilitate Opioid Drug Development” Dong, F. DBB
POSTER SESSION: COMPUTATIONAL TOXICOLOGY I “Machine Learning Models for Rat Multigeneration Reproductive Toxicity Prediction” Liu, J. DBB
POSTER SESSION: COMPUTATIONAL TOXICOLOGY II “Machine Learning for Predicting Risk of Drug-Induced Autoimmune Diseases by Structural Alerts and Daily Dose” Chen, M. DBB
POSTER SESSION: SYSTEMS BIOLOGY “Assessment of the Toxicity of Cannabidiol (CBD) in Rats upon Oral Developmental Exposure” Camacho, L. DBT
POSTER SESSION: REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY III “Cannabidiol-Induced Transcriptomic Changes and Cellular Senescence in Human Sertoli Cells” Li, Y. DBT
POSTER SESSION: REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY III “COVID-19 Effects on Pregnancy, Prenatal, and Postnatal Development” Bidarimath, M. DSB
POSTER SESSION: SAFETY ASSESSMENT: PHARMACEUTICAL-DRUG DEVELOPMENT II “Obtain Drug Safety Rankings through Meta-analysis of Clinical Trial Data Using Penalized Bayesian Model” Wang, D. DBB
POSTER SESSION: BIOMARKERS “T2-MRI Mapping as a Minimally Invasive Correlate of Central Nervous System (CNS) Toxicity in a Cuprizone Model: A Biomarker Study” Imam, S. DNT
POSTER SESSION: EPIGENETICS “Effect of the Weight-Loss Drug Lorcaserin on DNA Methylation in Mammary Glands of Sprague Dawley Rats” Roudachevski, I. DBT
PLATFORM SESSION: ENHANCING TOXICOLOGY WITH MACHINE LEARNING “PathologAI – A Deep Learning Framework for Whole Slide Classification in Preclinical Pathology” Xu, J. DBB
POSTER SESSION: ALTERNATIVES TO MAMMALIAN MODELS II
Chair: Qiang Shi (DSB)
“Whole Genome Sequencing Analysis of Mutagenicity of N-Nitrosodiethylamine Using Caenorhabditis elegans Models” Chen, T. DGMT
POSTER SESSION: BIOINFORMATICS “Deep Learning-Based Genotype Imputation for Enhancing Toxicogenomic Data” Song, M. DBB
POSTER SESSION: BIOINFORMATICS “Statistical Methods for Exploring Spontaneous Adverse Event Reporting Databases for Drug-Host Factor Interactions” Lu, Z. DBB
POSTER SESSION: BIOINFORMATICS “Development of a Large List of Drugs for the Study of Nephrotoxicity in Drug Discovery” Connor, S. DBB
POSTER SESSION: BIOINFORMATICS “Random Forest Model for Predicting μ Opioid Receptor Binding Activity for Assisting Development of Opioid Drugs” Li, Z. DBB
POSTER SESSION: BIOINFORMATICS “DeepAmes: Deep Learning-Powered Ames Test Prediction Using Model-Level Representation” Li, T. DBB
POSTER SESSION: RISK ASSESSMENT II “Informing Selection of Drugs for COVID-19 Treatment through Analysis of Adverse Events” Guo, W.  DBB
POSTER SESSION: NEUROTOXICITY: DEVELOPMENTAL I “Cytokine-Mediated Chemotherapy-Induced Cognitive Impairment in Cisplatin and Methotrexate Treated Sprague Dawley Rats” Yeary, J. DNT
POSTER SESSION: NEUROTOXICITY: DEVELOPMENTAL I “Examining Immune Modulatory Effects of Perinatal Cannabidiol Exposure in Sprague Dawley Rats” Gill, W. DNT
POSTER SESSION: NEUROTOXICITY: DEVELOPMENTAL I “The Neurotoxic Potential of a Single Dose of Ketamine in Adolescent and Adult Rats” Talpos, J. DNT
POSTER SESSION: NEUROTOXICITY: DEVLEOPMENTAL II “Behavioral Effects of Cisplatin and Methotrexate Treatment in Juvenile Sprague Dawley Rats” Flanigan, T. DNT
POSTER SESSION: NEUROTOXICITY: DEVLEOPMENTAL II “Investigation of the Developmental Neurotoxicity of Opioids Using Human-Induced Pluripotent Stem Cells” Cai, C. DSB
POSTER SESSION: NEUROTOXICITY: GENERAL “A Modified Approach of Fluoro-Jade C Labeling for Neurotoxicity Assessments” Gu, Q. DNT
POSTER SESSION: IMMUNOTOXICITY I “Sex-Based Differences in Inflammatory Responses to Silver Nanoparticles” Canup, B. DBT
WORKSHOP SESSION 1195: MOVING STEM CELL-DERIVED NEW APPROACH METHODS TOWARD REGULATORY ACCEPTANCE
Chair: Li Pang (DSB)
“Predicting Interindividual Variability of Doxorubicin Cardiotoxicity with Induced Pluripotent Stem Cell-Derived Cardiomyocytes” Pang, L. DSB
POSTER SESSION: BIOLOGICAL MODELING “A Multiscale Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Plasma Concentration and the Tissue Distribution of Doxorubicin” Li, M. DBT
POSTER SESSION: BIOLOGICAL MODELING “Using Various Machine-Learning Algorithms to Determine the Best Method for Predicting Population Physiologically Based Pharmacokinetic Model Plasma Profiles” Fairman, K. DBT
POSTER SESSION: KIDNEY “Evaluating Renal Pathology in Post-COVID-19 Human Autopsy Tissues” Masters, E. DSB
POSTER SESSION: SKIN AND DERMAL TOXICITY “Parallel Evaluation of Alternative Skin Barrier Models and Excised Human Skin for Dermal Absorption Studies In Vitro” Salminen, A. DBT
POSTER SESSION: LIVER I: IN VIVO
Chair: Si Chen (DBT)
“Gene Expression Changes Predict the Severity of NAFLD-Like Liver Injury in Male Collaborative Cross Mice” Tryndyak, V. DBT
POSTER SESSION: LIVER II: IN VIVO “hnRNP-Q and hnRNP-L Influence Drug Metabolism and Toxicity by Regulating mRNA Processing of Drug Metabolizing Enzymes and Nuclear Receptors in HepaRG Cells” Li, D. DBB
POSTER SESSION: LIVER II: IN VIVO “hnRMP-Q and hnRMP-L Influence Drug Metabolism and Toxicity by Regulating mRNA Processing of Drug Metabolizing Enzymes and Nuclear Receptors in HepaRG Cells” Li, D. DBB
POSTER SESSION: RESPIRATORY TOXICOLOGY I “Establishing a Continuous Aerosol Exposure Method for Evaluating the Respiratory Toxicity of Ortho-Phthalaldehyde” Sun, Y. DGMT
POSTER SESSION: LATE-BREAKING 2-4 “Potential Link of High-Fat Diet on the Expression of Alzheimer’s Disease-Related Genes in the Ileal Mucosa of Alzheimer’s Disease Model of Rats” Karn, K. DM
POSTER SESSION: LATE-BREAKING 2-4 “The Effects of Cannabidiol and Its Main Metabolites on Human Neural Stem Cells” Latham, L. DNT
POSTER SESSION: LATE-BREAKING 2-4 “Comparison of the Effects of Delta-9 Tetrahydrocannabinol and Cannabidiol on Human Neural Stem Cells” Liu, F. DNT
POSTER SESSION: LATE-BREAKING 2-4 “Assessment of Potential Developmental Neurotoxicity of Purified Cannabidiol in Sprague Dawley Rats” Shen, A. DNT

 

Communication Type

Short Title
NCTR Participation at 2023 Society of Toxicology

Source Organization

Short Description
Society of Toxicology (SOT) Annual Meeting and ToxExpo, March 19-23, 2023

Publish Date
Wed, 02/21/2024 – 17:00

Review Date
Fri, 02/21/2025 – 00:00

Last Reviewed Date
Wed, 02/21/2024 – 00:00

Site Structure

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
On

First Publish Date
Wed, 02/21/2024 – 16:17

Generic Boolean
Off

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/about-fda/science-research-nctr/nctr-participation-2023-sot-annual-meeting February 21, 2024 8:53 pm

Quoted in Christian Science Monitor

CNR: Quoted in Christian Science Monitor

Good article by Simon Westlake, https://www.csmonitor.com/USA/2024/0123/Growing-like-a-weed-Taking-stock-10-years-after-legalization-began

While a handful of smaller conservative states rejected pro-cannabis ballot measures in 2022, there’s no sign of a wider national rollback. In November 2023, Republican-run Ohio voted to become the 24th state to legalize pot. “Nobody has retracted or retreated,” says Pat Oglesby, a tax lawyer who teaches a cannabis policy class at the University of Virginia. “I think the momentum is for a loosening, not a tightening, of state marijuana sales.” 

+++

Another policy tool is taxation. New York and Connecticut levy excise taxes on cannabis that increase with potency, just as liquor is taxed at higher rates than beer. But regulators have also found that high taxes on cannabis, while healthy for state coffers, can make illegal weed more attractive. A combination of high taxes, stringent regulations, and a lack of dispensaries has hamstrung California’s legal recreational market, while illegal producers are thriving.  

California faces a law enforcement challenge in shutting down its entrenched illegal industry, says Mr. Oglesby, the tax lawyer, who has advised the state’s regulators. “Cops don’t want to arrest people,” he says. “And juries might not convict them.” 


#CBD #Hemp

Quoted in Christian Science Monitor


January 24, 2024 1:06 pm

East Fork Cultivars – 654211 – 12/22/2023

FDA: East Fork Cultivars – 654211 – 12/22/2023 East Fork Cultivars – 654211 – 12/22/2023 Anonymous (not verified) Tue, 12/26/2023 – 06:28

Company Name

FEIN

Short Title
East Fork Cultivars

WARNING LETTER

December 22, 2023

East Fork Hemp, LLC
6258 SE Foster Rd
Portland, Oregon 97206

RE: # 654211

Dear Mason Walker and Tricia Chin:

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https://eastforkcultivars.com/ and https://eastforkhemp.com/ in September 2023 and has determined that you take orders there for various products which you promote as products containing cannabidiol (CBD).1 We also reviewed your social media websites at https://www.facebook.com/EastForkCultivars/ and https://www.instagram.com/eastforkcultivars/, where you direct consumers to your websites, https://eastforkcultivars.com/ and https://eastforkhemp.com/, to purchase your products. The claims on your websites establish that your CBD products including, but not limited to, all strengths and varieties of your Rescue Rub CBD, CBD Oil, and Peak CBD Solution tinctures for humans (also referred to as “your CBD products”) are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1).

Unapproved New Drugs and Misbranded Drugs

Based on our review of your website and social media websites listed above, your CBD products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.

Examples of claims observed on your websites that establish the intended use of your CBD products as drugs include, but may not be limited to, the following:

From your website https://eastforkcultivars.com/blog:

  • A March 15, 2022 blog post titled “Cannabis And COVID-19: Understanding New Scientific Studies” which contains claims such as “Each aspect offered new evidence that CBD (cannabidiol) can inhibit infection by SARS-CoV-2. In human cells, CBD above a certain threshold concentration was effective at blocking replication early in the infection cycle and six hours after the virus had already infected the cell. (It did not affect the ability of SARS-CoV-2 to enter the cell.) In live mice, pretreatment with CBD for one week prior to infection with SARS-CoV-2 suppressed infection both in their lung and nasal passages, indicating that CBD can prevent viral replication in live animals.”
  • A November 12, 2020 blog post titled “CBD, COVID-19, And The Novel Coronavirus” which contains claims such as “On the more promising side of research, a research team based out of Augusta University (GA) found a potential protective role for CBD as part of the treatment of COVID-19. . .. The researchers concluded, ‘Our results… may extend CBD as part of the treatment of COVID-19 by reducing the cytokine storm, protecting pulmonary tissues, and re-establishing inflammatory homeostasis.’”

From your website https://eastforkhemp.com/ and your February 15, 2023 posts on your social media websites https://www.facebook.com/EastForkCultivars/ and https://www.instagram.com/eastforkcultivars/:

  • From the post titled “Does CBD Need THC to Work?” which contains claims such as “Experimental evidence is limited and more research is needed, but studies on pain and inflammation, breast cancer, epilepsy, and other conditions have found a greater therapeutic effectiveness of whole-plant or full-spectrum cannabis products than isolated cannabinoids.”

From your social media website https://www.instagram.com/eastforkcultivars/:

  • A March 17, 2022 post which references your March 15, 2022 blog post: “University of Chicago Study:⁠ – Offered new evidence that CBD can inhibit infection by SARS-CoV-2.⁠ – The COVID-blocking effects of CBD were demonstrated ONLY by high concentrations of CBD isolate.⁠ – CBDA, CBDV and THC were also tested, but did NOT show the same infection-blocking ability as CBD.”

⁠From your social media website https://www.facebook.com/EastForkCultivars/:

  • A November 15, 2020 post which references your November 12, 2020 blog post: “CBD, COVID-19, and the Novel Coronavirus

Have you heard people saying that cannabis can prevent infection by the novel coronavirus, or that CBD is a possible treatment for COVID-19? . . .
Specifically, the potential therapeutic ECS mechanisms include: reducing overactive inflammatory mechanisms (including cytokine storm) that worsen COVID-19; and…
Head to our blog to keep reading this article by our Director of Education and Director of Cannabis Class, Anna Symonds: https://eastforkcultivars.com/…/cbd-covid19-and…”

Your CBD products are not generally recognized as safe and effective for their above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for your CBD products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

In addition, your CBD products are misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layman can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Your CBD products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your CBD products are not exempt from the requirement that their labeling bear adequate directions for use because no FDA-approved applications are in effect for these products. The introduction or delivery for introduction into interstate commerce of misbranded drugs is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).

This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.

Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research/Office of Compliance/Office of Unapproved Drugs and Labeling Compliance by e-mail to [email protected].

Sincerely,
/S/

CAPT Tina Smith
Director
Office of Unapproved Drugs and Labeling Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

__________________________

1 You can find specific information about how FDA regulates CBD at https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.

Tue, 12/26/2023 – 09:20
Review Date
Thu, 12/26/2024 – 09:20

Source Organization

Recipient Name
Mason Walker, Co-Owner and CEO

Recipient Title
Tricia Chin, Co-Owner

Last Reviewed Date
Tue, 12/26/2023 – 09:20

Site Structure

Letter Issue Date
December 22, 2023

Issuing Office Building Name
Office of Unapproved Drugs and Labeling Compliance

Next Review Date
1 Year

Detailed Description
Finished Pharmaceuticals/Unapproved New Drug/Misbranded

[email protected]
[email protected]
Delivery Method

MARCS CMS ID

Bulk Approved
Off

Address

United States

Display Short Description
Off

Regulated Product*

Sender Address

United States

Recipient Address

1420 Queen of Bronze Rd
Takilma, OR 97523
United States

Language

Address

United States

Add Subscription Box
Off

Secondary Issuing Offices

United States

#CBD #Hemp http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/east-fork-cultivars-654211-12222023 December 26, 2023 11:28 am

Caulkins on Cannabis: Illicit Market Share and Social Equity

CNR: Caulkins on Cannabis: Illicit Market Share and Social Equity

Here from the public record is my friend Jon Caulkins’s written submission to the Pennsylvania Legislature on cannabis legalization – about expectations for the illicit market and about social equity.

On the illicit market:  “I think two-thirds legal and one-third illegal is a reasonable expectation for after the market has stabilized a few years after state-licensed supply opens and before national legalization. That ballpark estimate comes with several elaborations and two warnings.”

On social equity:  Although “Most discussion focuses on” “[e]nsuring equitable access to cannabis licenses,” “[t]hat is a mistake.” 

And there’s a warning that regulating the marijuana industry won’t be easy.


#CBD #Hemp

Caulkins on Cannabis: Illicit Market Share and Social Equity


November 8, 2023 1:16 pm

FDA Roundup: November 3, 2023

FDA: FDA Roundup: November 3, 2023 FDA Roundup: November 3, 2023 Anonymous (not verified) Fri, 11/03/2023 – 13:13

Short Title
FDA Roundup: November 3, 2023

FDA Statement
No

Press Release Date
November 03, 2023

Detailed Description
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Short Description
FDA Roundup: November 3, 2023

Body

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

  • On Thursday, the FDA announced that its Center for Devices and Radiological Health (CDRH) is seeking input from the public on advancing health equity and facilitating access to digital health technologies for detecting prediabetes and type 2 diabetes, particularly in racial and ethnic minorities. CDRH is uniquely positioned to advance the development of high-quality, safe, and effective technologies to meet the needs of all patients and consumers, including diverse populations. 
  • On Thursday, the FDA proposed to revoke the regulation authorizing the use of brominated vegetable oil (BVO) in food. This action is part of our regulatory authority over ingredients added to food, which includes reassessing previously evaluated food ingredients and addressing safety concerns. Brominated vegetable oil (BVO) is a vegetable oil that is modified with bromine. As authorized, it is used in small amounts to keep the citrus flavoring from floating to the top in some beverages. The FDA is issuing a proposed rule now because the agency has recent data from studies it conducted that demonstrate adverse health effects in animals at levels more closely approximating real-world human exposure. Based on these data and remaining unresolved safety questions, the FDA can no longer conclude that the use of BVO in food is safe.
  • On Thursday, the FDA issued a guidance, which is being implemented immediately, titled: Enforcement Policy for Certain Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions. The guidance provides recommendations for limited modifications affecting the safety or effectiveness of a device approved through the FDA’s PMA or HDE program, where the modification is necessary to address current manufacturing limitations, potential shortages, or supply chain issues.
  • On Wednesday, the FDA revised the EUA for Paxlovid to facilitate the transition from the U.S. government’s distribution of Paxlovid labeled for use under the EUA to Pfizer’s distribution of the commercial (NDA-labeled) Paxlovid. The FDA has updated the frequently asked questions about Paxlovid during this transition period and encourages people to visit the HHS Paxlovid landing page for additional information.
  • On Wednesday, the FDA released a CDER From Our Perspective summarizing a recently published article in Open Exploration titled, “A U.S. FDA Perspective on Cannabis Research and Drug Development.” In the article, the FDA presents a breakdown of cannabis and cannabis-derived product (CCDP) applications the agency has received over the past 50 years, summarizes our experiences and challenges in reviewing CCDP research applications, and provides recommendations and resources for those interested in studying CCDPs in human clinical trials. For more information, please visit FDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development
  • On Tuesday, the FDA approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). View full prescribing information for Keytruda.
  • On Tuesday, the FDA issued a Safety Alert advising restaurants and food retailers not to sell and to dispose of oysters and consumers not to eat oysters from Fanny Bay Oysters based in British Columbia, Canada harvested on 10/17/2023 from harvest area 14-8 Landfile #278757 and shipped to distributors in California and Washington due to Vibrio parahaemolyticus test results.
Content Owner

Contributing Office

Publish Date
Fri, 11/03/2023 – 15:05

Review Date
Sun, 11/03/2024 – 00:00

Last Reviewed Date
Fri, 11/03/2023 – 00:00

Site Structure

Next Review Date
1 Year

Source Organization

Bulk Approved
Off

Hide main image
hide

Display Short Description
Off

Regulated Product*

Language

Media Contact
Media Contact Name
FDA Office of Media Affairs

Media Contact Phone
888-INFO-FDA

Media Contact Email

First Publish Date
Fri, 11/03/2023 – 15:05

Add Subscription Box
Off

Boilerplate
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Quote Attribution

Announcement Type
FDA News Release

#CBD #Hemp http://www.fda.gov/news-events/press-announcements/fda-roundup-november-3-2023 November 3, 2023 5:13 pm

From Our Perspective

FDA: From Our Perspective From Our Perspective

Site Structure

Anonymous (not verified) Thu, 11/02/2023 – 15:05

Navigational Page
On

Last Reviewed Date
Thu, 11/02/2023 – 00:00

Next Review Date
1 Year

Short Description
Insights from CDER leadership and experts on public health actions

Short Title
From Our Perspective

Detailed Description
Insights from CDER leadership and experts on public health actions

Body

FDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development

By: Cassandra L. Taylor, public health advisor, Office of the Center Director, Center for Drug Evaluation and Research (CDER) and Schuyler Pruyn, project manager, Office of Executive Programs, CDER

FDA has a long history of reviewing clinical research for cannabis (such as marijuana and hemp) and cannabis-derived products (such as cannabidiol or CBD). Since the early 1970s, FDA has received more than 800 investigational new drug applications (INDs) for, and pre-investigational new drug applications (pre-INDs) related to cannabis and cannabis-derived products (CCDP). Over the last 10 years, there has been increased interest in studying CCDPs as medical treatment options. We have received double the number of IND and pre-IND applications during this time. We also have seen increased clinical research of new types of cannabis products and routes of administration (ROA), which is the way the drug is administered in the body.

More with Cassandra L. Taylor and Schuyler Pruyn

 

Previous From Our Perspectives

2023

2022

2021

2020

Source Organization

Bulk Approved
Off

Hide main image
hide

Display Short Description
Off

Regulated Product*

Sorting Order
10

Language

Place Paragraphs below the Datatable
Off

Add Subscription Box
Off

Display Short Title
On

#CBD #Hemp http://www.fda.gov/drugs/news-events-human-drugs/our-perspective November 2, 2023 7:05 pm

Guide to the Global Regulation of Hemp

The Library of Congress released a compendium of many nations’ hemp laws. 137 pages.

Regulation of Hemp
Australia • Brazil • Canada • China • Colombia • Ecuador • European Union • Great Britain • India • Israel • Italy • Japan • Mexico • New Zealand • Russian Federation
Appendix: Table on Legalization of Hemp Production November 2022
LL File No. 2022-021696 LRA-D-PUB-002598

Download it free at: https://tile.loc.gov/storage-services/service/ll/llglrd/2022666115/2022666115.pdf

August 2023 510(K) Clearances

August 2023 510(K) Clearances August 2023 510(K) Clearances Anonymous (not verified) Wed, 09/06/2023 – 10:00

Detailed Description
August 2023 510(K) Clearances

 510(K) SUMMARIES OR 510(K) STATEMENTS FOR FINAL DECISIONS RENDERED DURING THE PERIOD August 2023   DEVICE: Maxiocel Chitosan Wound Dressing Advamedica Inc.                   510(k) NO: K212766(Traditional) ATTN: Leo  Mavely                 PHONE NO : 1 973 7187575  Harvard Square, 1 Mifflin Place, SSE DECISION MADE: 24-AUG-23 Cambridge MA  02138               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Accu-Chek Guide Solo diabetes manager blood glucose monitoring system Roche Diabetes Care GmbH          510(k) NO: K213131(Traditional) ATTN: Wolfgang  Handel            PHONE NO : 49 621 7598331  Sandhofer Strasse 116             SE DECISION MADE: 10-AUG-23 Mannheim  DE 68305                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Accu-Chek Solo micropump system with interoperable technology Roche Diabetes Care GmbH          510(k) NO: K213134(Traditional) ATTN: Wolfgang  Handel            PHONE NO : 49 621 7598331  Sandhofer Strasse 116             SE DECISION MADE: 10-AUG-23 Mannheim  DE 68305                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: MedicloseTM System Health Value Creation BV, trading 510(k) NO: K213271(Traditional) ATTN: Kim  Sondeijker             PHONE NO : 31 43 3882948  Oxfordlaan 55                     SE DECISION MADE: 31-AUG-23 Maastricht  NL 6229 EV            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: MONTAGE Settable, Resorbable Hemostatic Bone Putty Orthocon, Inc.                    510(k) NO: K213418(Traditional) ATTN: Howard  Schrayer            PHONE NO : 914 3572600  1 Bridge Street, Suite 121        SE DECISION MADE: 30-AUG-23 Irvington NY  10533               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: BD Vacutainer K2EDTA Blood Collection Tubes, BD Vacutainer K3EDTA Blood Collection Tubes Becton Dickinson and Company      510(k) NO: K213670(Traditional) ATTN: Katherine Kenner Lemus      PHONE NO : 801 5419274  1 Becton Drive                    SE DECISION MADE: 25-AUG-23 Franklin Lakes NJ  07417          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Alinity h-series System Abbott Laboratories               510(k) NO: K220031(Traditional) ATTN: Neha  Vatsyayan             PHONE NO : 408 3134401  4551 Great America Pkwy           SE DECISION MADE: 04-AUG-23 Santa Clara CA  95054             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit KRONUS, Inc.                      510(k) NO: K220085(Traditional) ATTN: Delaney  Sauer              PHONE NO : 208 3774800  170 S. Seneca Springs Way Suite 10SE DECISION MADE: 24-AUG-23 Star ID  83669                    510(k) STATEMENT                                                       DEVICE: Monaghan medical filtered mouthpiece kit Monaghan Medical Corporation      510(k) NO: K220145(Traditional) ATTN: Cari J Reil                 PHONE NO : 518 5617330  153 Industrial Boulevard          SE DECISION MADE: 24-AUG-23 Plattsburgh NY  12901             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Eco Abutment, Multiunit Abutment DIO Corporation                   510(k) NO: K220253(Traditional) ATTN: Cho  Hye-won                PHONE NO : 82 51 7457836  66, Centumseo-ro                  SE DECISION MADE: 18-AUG-23 Busan  KR 48058                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SQA-iO Sperm Quality Analyzer Medical Electronic Systems LTD    510(k) NO: K220828(Traditional) ATTN: Marcia  Deutsch             PHONE NO : 972 54 7708618  Alon Hatavor 20, Zone 6, Caesarea SE DECISION MADE: 07-AUG-23 Caesarea  IL 3088900              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Nova HD+ Aura Wellness, LLC                510(k) NO: K220938(Traditional) ATTN: Scott  Blomberg             PHONE NO : 502 7141993  11530 Electron Drive              SE DECISION MADE: 22-AUG-23 Louisville KY  40299              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Immunoglobulin G (IgG) Beckman Coulter Laboratory Systems510(k) NO: K221114(Traditional) ATTN: Tracy  Jin                  PHONE NO : 86 512 68955129  No. 181 West Su Hong Road, Suzhou SE DECISION MADE: 02-AUG-23 Suzhou  CN 215021                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Titus Titanium Cervical by SAGICO SAGICO VA USA, LLC                510(k) NO: K221138(Traditional) ATTN: James  Gibson               PHONE NO : 813 8150613  2189 W.Busch Blvd                 SE DECISION MADE: 04-AUG-23 Tampa FL  33612                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: circul™ pro Ring BodiMetrics, LLC                  510(k) NO: K221361(Traditional) ATTN: Mark  Goettling             PHONE NO : 818 2686828  1601 N. Sepulveda Blvd, Suite 839 SE DECISION MADE: 29-AUG-23 Manhattan Beach CA  90266         510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Lumbar Expandable lnterbody Spacers -Additional Indications/Implants Globus Medical Inc.               510(k) NO: K221894(Traditional) ATTN: Kelly  Baker                PHONE NO : 610 9301800  2560 General Armistead Ave.       SE DECISION MADE: 03-AUG-23 Audubon PA  19403                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ID NOW COVID-19 2.0 Abbott Diagnostics Scarborough, In510(k) NO: K221925(Dual Track) ATTN: Jessica E. Stahle           PHONE NO : 207 7306353  10 Southgate Road                 SE DECISION MADE: 10-AUG-23 Scarborough ME  04074             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Q21 NeuroField Inc.                   510(k) NO: K221959(Traditional) ATTN: Nicholas J. Dogris          PHONE NO : 760 8724200  386 West Lane                     SE DECISION MADE: 31-AUG-23 Bishop CA  93514                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Nitrile Patient Examination Gloves, Powder Free, Pink Color Shandong YINGHNG Medical Products 510(k) NO: K222103(Traditional) ATTN: Emily  Dong                 PHONE NO : 86 53 66136888  No.15 East Road, Hongrun Industry SE DECISION MADE: 24-AUG-23 Qingzhou  CN 262500               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Protective Gown AAMI Level 4 Kenpax International Limited      510(k) NO: K222128(Traditional) ATTN: Solomon  Chen               PHONE NO : 909 4387898  Flat 5, 5/F, Wing On Plaza, 62 ModSE DECISION MADE: 08-AUG-23 Hong Kong  CN 999077              510(k) STATEMENT                                                       DEVICE: HemoScreen Hematology Analyzer PixCell Medical Technologies, Ltd.510(k) NO: K222148(Traditional) ATTN: Yaara Ben Yosef             PHONE NO : 972 4 9593516  6 Hayezira St.                    SE DECISION MADE: 16-AUG-23 Yoknaem Ilit  IL 2069202          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ACR Screw System BioMaterials Korea, Inc           510(k) NO: K222245(Traditional) ATTN: Young-yeop  Kim             PHONE NO : 82 31 7904511  #329, #331, #413 150, Jojeong-daerSE DECISION MADE: 21-AUG-23 Hanam-si  KR 12930                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Atellica® CH Phencyclidine (Pcp), Atellica® CH Vancomycin (Vanc) Siemens Healthcare Diagnostics Inc510(k) NO: K222439(Traditional) ATTN: Joy  Anoop                  PHONE NO : 516 2323307___  511 Benedict Avenue               SE DECISION MADE: 08-AUG-23 Tarrytown NY  10591               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Air Smart Extra Spirometer FeelLife Health Inc.              510(k) NO: K222443(Traditional) ATTN: May  Xiao                   PHONE NO : 0755 66867080  Room 1903, Building A, No.9 FurongSE DECISION MADE: 09-AUG-23 Shenzhen  CN 518104               510(k) STATEMENT                                                       DEVICE: Alveoair Digital Spirometer Roundworks Technologies Private Li510(k) NO: K222525(Traditional) ATTN: Prashant  Patel             PHONE NO : 91 750 7776273  Office No. B 302, Building No. B, SE DECISION MADE: 28-AUG-23 Wakad, Pune  IN 411047            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: BD Kiestra IdentifA Becton, Dickinson and Company     510(k) NO: K222563(Traditional) ATTN: Laura  Stewart              PHONE NO : 410___ 5044252  7 Loveton Circle Mail Code 694    SE DECISION MADE: 31-AUG-23 Sparks MD  21152                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Premier Resolution System Trinity Biotech (Primus Corporatio510(k) NO: K222635(Traditional) ATTN: Kaitlyn  Eastman            PHONE NO : 716 4837423  4231 E. 75th Terrace              SE DECISION MADE: 04-AUG-23 Kansas City MO  64132             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Oral/Enteral Syringe with ENFit connector Anhui Tiankang Medical Technology 510(k) NO: K222772(Traditional) ATTN: Zhang  Yong                 PHONE NO : 86 1370 5505106  No. 228, Weiyi Road, Economic DeveSE DECISION MADE: 17-AUG-23 Tianchang  CN 239300              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Feeding Tube Anhui Tiankang Medical Technology 510(k) NO: K222773(Traditional) ATTN: Zhang  Yong                 PHONE NO : 86 1370 5505106  No. 228, Weiyi Road, Economic DeveSE DECISION MADE: 17-AUG-23 Tianchang  CN 239300              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: 072 Aspiration System Q’Apel Medical, Inc.              510(k) NO: K222786(Traditional) ATTN: Kim  Ky                     PHONE NO : 510 8284757  4245 Technology Drive             SE DECISION MADE: 25-AUG-23 Fremont CA  94538                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: HAVAb IgG II ABBOTT LABORATORIES               510(k) NO: K222850(Traditional) ATTN: Dominic  Tunzi              PHONE NO : 224 6683644  100 Abbott Park Road              SE DECISION MADE: 10-AUG-23 Abbott Park IL  60064             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: BlueStar CGM insulin dose calculator Welldoc, Inc.                     510(k) NO: K222888(Traditional) ATTN: Ian  Cadieux                PHONE NO : 619 8940873  10221 Wincopin Circle, Ste #150   SE DECISION MADE: 11-AUG-23 Columbia MD  21044                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Oneday Mini Implant System Oneday Biotech Co., Ltd.          510(k) NO: K222946(Traditional) ATTN: Jae Hyun Song               PHONE NO : 82 53 5812835  135 C Seongseodongro Dalseogu     SE DECISION MADE: 23-AUG-23 Daegu  KR 42721                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: BioProtect Balloon Implant™ System BioProtect, Ltd.                  510(k) NO: K222972(Traditional) ATTN: Itay  Barnea                PHONE NO : 97 52 8677373  8 Tsor st                         SE DECISION MADE: 25-AUG-23 Tzur Yigal  IL 4486200            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Flexylon Surgical Powder Free Gloves with Low Dermatitis Potential Claim, Green Tested For Use with 13 Chemotherapy Drugs; Flexylon Surgical Powder Free Gloves with Low Dermatitis Potential Claim, White Tested For Use with 32 Chemotherapy Drugs Sentienx Sdn Bhd                  510(k) NO: K222993(Traditional) ATTN: Sahrudin Shah Bin Abu Bakar PHONE NO : 60 378 903338  Lot 7, Jalan Hi-Tech 12, Zon IndusSE DECISION MADE: 18-AUG-23 Kulim  MY 09090                   510(k) STATEMENT                                                       DEVICE: Suture Anchors - HTA Headless Titanium Anchor and Zip Anchors Gm Dos Reis Industria E Comerico L510(k) NO: K223114(Traditional) ATTN: Iara  Guimaraes             PHONE NO : 55 19 37659900  Avenida Pierre Simon De La Place 6SE DECISION MADE: 02-AUG-23 Campinas  BR 13069320             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: MENIX®; MENIX® DUO S.B.M. SAS (Science & Bio Material510(k) NO: K223122(Traditional) ATTN: Anne  Cospin-Latapie        PHONE NO : 33 562 422101  ZI du Monge                       SE DECISION MADE: 03-AUG-23 Lourdes  FR 65100                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Shiley™ Pediatric Oral/Nasal Endotracheal Tube with TaperGuard™ Cuff, Non DEHP (86125, 86130, 86135, 86140, 86145, 86150, 86155, 86160) Covidien                          510(k) NO: K223130(Traditional) ATTN: Anila  Tarte                PHONE NO : 978 4966694  6135 Gunbarrel Avenue             SE DECISION MADE: 30-AUG-23 Boulder CO  80301                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: VisiRad XR Imidex Inc.                       510(k) NO: K223133(Traditional) ATTN: Kris  Zeschin               PHONE NO : 303 9022171___  3513 Brighton Blvd., Suites 456 7 SE DECISION MADE: 03-AUG-23 Denver CO  80216                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: APS Metal Plate & Screw System A Plus Biotechnology Co., Ltd     510(k) NO: K223150(Traditional) ATTN: Frank  Hsu                  PHONE NO : 886 2 22499222 710 2F-2, No. 120, Qiaohe Rd., ZhongheSE DECISION MADE: 24-AUG-23 New Taipei City  TW 23584         510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sleepiz One+ Sleepiz AG                        510(k) NO: K223163(Third Party - Traditional) ATTN: Marta  Stepien              PHONE NO : 41 76 7837350___  Hornbachstrasse 23                SE DECISION MADE: 18-AUG-23 Zurich  CH 8008                   510(k) SUMMARY AVAILABLE FROM FDA                                   THIRD PARTY REVIEW  DEVICE: Spirair Nasal Septal Strap Spirair, Inc.                     510(k) NO: K223167(Traditional) ATTN: James  Kintzing             PHONE NO : 703 9999462  6084 Monterey Hwy, 108            SE DECISION MADE: 17-AUG-23 San Jose CA  95138                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: AIRAscore AIRAmed GmbH                      510(k) NO: K223180(Traditional) ATTN: Maximilian  Stalter         PHONE NO : 49 7071 5393366  Konrad-Adenauer-Str. 13           SE DECISION MADE: 25-AUG-23 Tübingen  DE 72072                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Spinery™ RF Ablation System Axon Spine Medical System         510(k) NO: K223303(Traditional) ATTN: Salvatore  Accardo          PHONE NO : 39 335 5300347  Via Lepanto 84                    SE DECISION MADE: 30-AUG-23 Pompei  IT 80045                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Ochsner Connected Inhaler Sensor Ochsner Clinic Foundation         510(k) NO: K223367(Traditional) ATTN: Hakm  Murad                 PHONE NO : 504 8427785  1514 Jefferson Hwy                SE DECISION MADE: 30-AUG-23 New Orleans LA  70121             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Citric Complete Liquid Citric Acid Concentrate Nipro Renal Solutions USA, Corp.  510(k) NO: K223431(Traditional) ATTN: Vincent  DeGrandchamp       PHONE NO : 267 6784390  509 Fishing Creek Road            SE DECISION MADE: 04-AUG-23 Lewisberry PA  17339              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ArtiFascia Nurami Medical Ltd.               510(k) NO: K223445(Traditional) ATTN: Hannoch  Marksheid          PHONE NO : 972 74 7408822  Ha'Namal 36                       SE DECISION MADE: 10-AUG-23 Haifa  IL 3303203                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Otsuka Digital Feedback Device-RW Otsuka America Pharmaceutical, Inc510(k) NO: K223463(Traditional) ATTN: Nancy  Teague               PHONE NO : 240 6833560___  2440 Research Boulevard           SE DECISION MADE: 11-AUG-23 Rockville MD  20850               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Nexis® compressive screws Novastep                          510(k) NO: K223468(Abbreviated) ATTN: Gilles  Audic               PHONE NO : 33 29 9338650  2, allée Jacques Frimot           SE DECISION MADE: 30-AUG-23 Rennes  FR 350000                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: V-PRO maX 2 Low Temperature Sterilization System Steris Corporation                510(k) NO: K223476(Traditional) ATTN: Anthony  Piotrkowski        PHONE NO : 440 3927437___  5960 Heisley Rd                   SE DECISION MADE: 07-AUG-23 Mentor OH  44060                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: AQUAbase nX, AQUAbase nX HT B. Braun Medical Inc.             510(k) NO: K223479(Traditional) ATTN: Rushtin  Chaklader          PHONE NO : 610 5962789  901 Marcon Blvd                   SE DECISION MADE: 16-AUG-23 Allentown PA  18109               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SuperBall Meniscal Repair System Arcuro Medical Ltd.               510(k) NO: K223500(Traditional) ATTN: Lee  Ranon                  PHONE NO : 972 72 2607000  17 Tchelet St.                    SE DECISION MADE: 10-AUG-23 Misgav  IL 2017400                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: CL-DP40 (Dr’s Light PRIME), CL-DP40 (Dr’s Light CHOICE) Good Doctors Co., Ltd.            510(k) NO: K223507(Traditional) ATTN: Heeseop  Lim                PHONE NO : 714 2025789  #208, B-Dong, 283 Bupyeong-Daero, SE DECISION MADE: 04-AUG-23 Incheon  KR 21315                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Carex Hybrid Personal Lubricant Karex Industries Sdn. Bhd.        510(k) NO: K223519(Abbreviated) ATTN: Lai Peng Lim                PHONE NO : 60 7 6881996  PTD 7906 & 7907, Taman Pontian JaySE DECISION MADE: 11-AUG-23 Pontian  MY 82000                 510(k) STATEMENT                                                       DEVICE: ALLEVYN Ag+ Border Antimicrobial Silicone Gel Adhesive Composite Hydrocellular Foam Dressing, ALLEVYN Ag+ Border Sacrum Antimicrobial Silicone Gel Adhesive Composite Hydrocellular Foam Dressing, ALLEVYN Ag+ Surgical Antimicrobial Silicone Gel Adhesive Composite Hydrocellular Foam Dressing Smith & Nephew Medical Limited    510(k) NO: K223526(Traditional) ATTN: Hannah  Sharp               PHONE NO : 44 077 40531714  101 Hessle Road                   SE DECISION MADE: 18-AUG-23 Hull  GB HU3 2BN                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Little Wave Clik, Rogue XP, Little Wave XP, Spark Ki Mobility LLC                   510(k) NO: K223527(Traditional) ATTN: Mark  Murphy                PHONE NO : 715 3036447  5201 Woodward Drive               SE DECISION MADE: 31-AUG-23 Stevens Point WI  54481           510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Little Wave Arc; Little Wave Flip Ki Mobility LLC                   510(k) NO: K223533(Traditional) ATTN: Mark  Murphy                PHONE NO : 715 3036447 ______ 5201 Woodward Drive               SE DECISION MADE: 31-AUG-23 Stevens Point WI  54481           510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Integrity Implant Anika Therapeutics, Inc.          510(k) NO: K223538(Traditional) ATTN: Wei  Zhao                   PHONE NO : 978 8885948  32 Wiggins Ave.                   SE DECISION MADE: 17-AUG-23 Bedford MA  01730                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Dreem 3S Beacon Biosignals, Inc.           510(k) NO: K223539(Traditional) ATTN: Delphine  Lemoine           PHONE NO : 33 6 32047992  22 Boston Wharf Rd., 7th Floor, unSE DECISION MADE: 18-AUG-23 Boston MA  02210                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: TubaVent Balloon Dilatation System Spiggle & Theis Medizintechnik Gmb510(k) NO: K223542(Traditional) ATTN: Claudia  Winterschladen     PHONE NO : 49 2206 908165  Burghof 4                         SE DECISION MADE: 03-AUG-23 Overath  DE 51491                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sterile Water for Inhalation in 1L Flexoval ® bottles. Hometa Inc                        510(k) NO: K223551(Traditional) ATTN: Raza  Mohammed              PHONE NO : 443 5545486  300 Great Oaks Blvd, Suite 325    SE DECISION MADE: 03-AUG-23 Albany NY  12203                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Spine Planning (2.0), Elements Spine Planning, Elements Planning Spine Brainlab AG                       510(k) NO: K223553(Traditional) ATTN: Sadwini  Suresh             PHONE NO : 49 8999 15680  Olof-Palme-Str.9                  SE DECISION MADE: 02-AUG-23 Munich  DE 81829                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Plato 17 Microcatheter Scientia Vascular Inc             510(k) NO: K223560(Traditional) ATTN: Max  Alfonso                PHONE NO : 888 3859016  3487 West 2100 South Suite 100    SE DECISION MADE: 21-AUG-23 West Valley City UT  84119        510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Onera Sleep Test System (Onera STS) Onera B.V.                        510(k) NO: K223573(Traditional) ATTN: Ruben de Francisco Martin   PHONE NO : 31 0 403082177  Torenallee 42-54                  SE DECISION MADE: 18-AUG-23 Eindhoven  NL 5617BD              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: IntelliVue Patient Monitor MX400 (866060), IntelliVue Patient Monitor MX450 (866062), IntelliVue Patient Monitor MX500 (866064), IntelliVue Patient Monitor MX550 (866066) Philips Medizin Systeme Boeblingen510(k) NO: K223574(Traditional) ATTN: Siegfried  Breitling        PHONE NO : 49 151 20044377  Hewlett-Packard-Strasse 2         SE DECISION MADE: 22-AUG-23 Boeblingen  DE 71034              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Pre-Filled Normal Saline Flush Syringe Anhui Tianyang Pharmaceutical Co.,510(k) NO: K223584(Traditional) ATTN: Zhang  Shunlin              PHONE NO : 86 158 05509075  46 Tiantong Road, Tianchang City, SE DECISION MADE: 12-AUG-23 Tianchang  CN                     510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Access Folate Assay Beckman Coulter, Inc.             510(k) NO: K223590(Traditional) ATTN: Dr. Kuljeet  Kaur           PHONE NO : 1 952 4651914___  1000 Lake Hazeline Drive          SE DECISION MADE: 23-AUG-23 Chaska MN  55318                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: 23andMe® Personal Genome Service® (PGS®) Cancer Predisposition Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) 23andMe, Inc.                     510(k) NO: K223597(Traditional) ATTN: Marianna  Frendo            PHONE NO : 650 6869288  349 Oyster Point Blvd             SE DECISION MADE: 31-AUG-23 South San Francisco CA  94080     510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sterilization Wrap Wuhan Zonsen Medical Products Co.,510(k) NO: K223600(Traditional) ATTN: Linna  Ye                   PHONE NO :  No 8 Jinchao Rd, Zhucheng Street  SE DECISION MADE: 25-AUG-23 Wuhan  CN                         510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: LifeShield™ Infusion Safety Software Suite ICU Medical, Inc.                 510(k) NO: K223606(Traditional) ATTN: Pernell  Abrantes           PHONE NO : 224 7062229  600 N. Field Drive                SE DECISION MADE: 24-AUG-23 Lake Forest IL  60045             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Plum Duo™ Infusion System ICU Medical, Inc.                 510(k) NO: K223607(Traditional) ATTN: Yuliya  Matlin              PHONE NO : 224 7062419  600 N. Field Drive                SE DECISION MADE: 24-AUG-23 Lake Forest IL  60045             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: GEM Premier 7000 with IQM3 Instrumentation Laboratory Company510(k) NO: K223608(Traditional) ATTN: Gabriella  Erdosy           PHONE NO : 781 8614571  180 Hartwell Road                 SE DECISION MADE: 10-AUG-23 Bedford MA  01730                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Rubicon™ Control Support Catheter (H749394323506A1) Boston Scientific Corporation     510(k) NO: K223633(Traditional) ATTN: Mary-Jo  Foley              PHONE NO : 353 0915 17427  One Scimed Place Maple Grove      SE DECISION MADE: 08-AUG-23 Maple Grove MN  55311-1566        510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: VisAble.IO TechsoMed                         510(k) NO: K223639(Traditional) ATTN: Dalia  Dickman, PhD         PHONE NO : 972 54 5595951  Meir Weisgal 2                    SE DECISION MADE: 28-AUG-23 Rehovot  IL 7654055               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SaintView Inviz Corporation                 510(k) NO: K223660(Traditional) ATTN: Priscilla  Chung            PHONE NO : 714 2025789  307, Biomedical Components Center,SE DECISION MADE: 14-AUG-23 Gwangju  KR                       510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Surgeon Controlled Arm Levita Magnetics International Cor510(k) NO: K223673(Traditional) ATTN: Alberto  Rodriguez-Navarro, PHONE NO : 650 2410320  4055-A Campbell Avenue            SE DECISION MADE: 04-AUG-23 Menlo Park CA  94025              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Disposable Needle Guides and Grids Advance Medical Designs, Inc.     510(k) NO: K223689(Traditional) ATTN: David  Mackie               PHONE NO : 1 770 4223125 244 1241 Atlanta Industrial Drive     SE DECISION MADE: 02-AUG-23 Marietta GA  30066                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Kyphoplasty Balloon Catheter Jiangsu Changmei Medtech Co., Ltd.510(k) NO: K223709(Traditional) ATTN: Yang  Lifan                 PHONE NO : 86 186 51969542  No.27, Xinke West Road, Luoyang ToSE DECISION MADE: 16-AUG-23 Changzhou  CN 213104              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ANNE One Sibel Health Inc.                 510(k) NO: K223711(Traditional) ATTN: Sarah  Coughlin             PHONE NO : 224 2518859  6650 W Touhy Ave.                 SE DECISION MADE: 10-AUG-23 Niles IL  60714                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Powder Free Nitrile Examination Glove (Grey) Tested for Use with Chemotherapy Drugs and Fentanyl Citrate Better Care Plastic Technology Co.510(k) NO: K223713(Traditional) ATTN: Zhu  Chunyan                PHONE NO : 86 311 66766067  Fuqian Xi Road, West district of SSE DECISION MADE: 07-AUG-23 Shenze County  CN 050000          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Lavieen Won Tech Co., Ltd.                510(k) NO: K223727(Traditional) ATTN: Hyun Sik Yoon               PHONE NO : 82 10 67505346  64 Techno 8-ro                    SE DECISION MADE: 25-AUG-23 Yuseong-gu  KR 34028              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ECGenius System Cath Vision ApS                   510(k) NO: K223787(Traditional) ATTN: Mads  Matthiesen            PHONE NO : 45 31 470730  Titangade 11                      SE DECISION MADE: 04-AUG-23 Copenhagen N  DK 2200             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Reusable Temperature Probe, Disposable Temperature Probe Shenzhen SINO-K Medical Technology510(k) NO: K223807(Traditional) ATTN: Lao  Chengxin               PHONE NO : 86 137 15333326  Room401,Bldg2, Veteran Ind.City,GoSE DECISION MADE: 25-AUG-23 Shenzhen  CN 518115               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Aveta System 2.0 Meditrina, Inc.                   510(k) NO: K223813(Traditional) ATTN: Csaba  Truckai              PHONE NO : 408 4714877  1190 Saratoga Avenue, Suite 180   SE DECISION MADE: 21-AUG-23 San Jose CA  95129                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Self-Cath Closed System Coloplast                         510(k) NO: K223821(Traditional) ATTN: Preeti  Jain                PHONE NO : 612 4135614___  1601 West River Road North        SE DECISION MADE: 02-AUG-23 Minneapolis MN  55411             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: eRapid Nebulizer System PARI Respiratory Equipment, Inc.  510(k) NO: K223840(Traditional) ATTN: Michael  Judge              PHONE NO : 804 2537274  2412 Pari Way                     SE DECISION MADE: 11-AUG-23 Midlothian VA  23112              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: NuEra Tight RF Family BIOS s.r.l.                       510(k) NO: K223856(Traditional) ATTN: Manuela  Brambilla          PHONE NO : 0039 02 27304275  Via Guido Rossa 10/12             SE DECISION MADE: 11-AUG-23 Vimodrone  IT 20055               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: IDS ACTH II Immunodiagnostic Systems Limited  510(k) NO: K223867(Traditional) ATTN: Mick  Henderson             PHONE NO : 44 191___ 5190660  10 Didcot Way,  Boldon Business PaSE DECISION MADE: 18-AUG-23 Boldon  GB NE35 9PD               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: BAROguard Paragonix Technologies            510(k) NO: K223874(Traditional) ATTN: Nathan  Yetton              PHONE NO : 1 617 8177790  Suite 408, 639 Granite St.        SE DECISION MADE: 15-AUG-23 Braintree MA  02184               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Daye Tampon Annes Daye Ltd                    510(k) NO: K223883(Traditional) ATTN: Valentina  Milanova         PHONE NO : 447 366 456294  The Biscuit Factory, 100 Drummond SE DECISION MADE: 18-AUG-23 London  GB SE16 4DG               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: VitalFlowTM Centrifugal Pump Michigan Critical Care Consultants510(k) NO: K223898(Traditional) ATTN: Martha  Rumford             PHONE NO : 734 9959089  2555 Bishop Circle West           SE DECISION MADE: 25-AUG-23 Dexter MI  48130                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: InterCollagen® Guide SigmaGraft Inc.                   510(k) NO: K223912(Traditional) ATTN: Elcin  Chang                PHONE NO : 1 714 5250112  575 Sally Place                   SE DECISION MADE: 17-AUG-23 Fullerton CA  92831               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SOMNUM (V.1.1.2.) Honeynaps Co., Ltd                510(k) NO: K223922(Traditional) ATTN: Tony  Lee                   PHONE NO : 82 108 9220937  4F, Marine Tech B/D, 529, NonhyeonSE DECISION MADE: 16-AUG-23 Seoul  KR 06126                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: LW Implant System Ossvis Co., Ltd.                  510(k) NO: K223924(Traditional) ATTN: Young Jae Kim               PHONE NO : 82 31 3600082  7F and B1, 38, Burim-ro 170beon-giSE DECISION MADE: 08-AUG-23 Anyang-si  KR 14055               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Silk'n Titan Allways Silk'n Beauty Ltd.                510(k) NO: K230013(Traditional) ATTN: Amit  Goren                 PHONE NO : 972 4 9097470  Tabor Building, Shaar Yokneam     SE DECISION MADE: 30-AUG-23 Yoqneam Illit  IL 2069200         510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: MagVenture Pain Therapy: MagPro R30, MagPro R30 with MagOption, MagPro X100, MagPro X100 with MagOption Tonica Elektronik A/S             510(k) NO: K230014(Traditional) ATTN: Jan  Kjøller                PHONE NO : 45 2 4899976  Lucernemarken 15                  SE DECISION MADE: 25-AUG-23 Farum  DK DK-3520                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Polyisoprene Surgical Gloves Tested for Use with Chemotherapy Drugs and Low Dermatitis Potential Ansell Healthcare Products, LLC.  510(k) NO: K230079(Traditional) ATTN: Don  Cronk                  PHONE NO : 775 4707106  2301 Robb Drive                   SE DECISION MADE: 23-AUG-23 Reno NV  89523                    510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Responsive Arthroscopy Stealth and Mini Stealth All-Suture Anchors Responsive Arthroscopy LLC        510(k) NO: K230094(Traditional) ATTN: Garrett  Ahlborg            PHONE NO : 612 5326800  701 N. 3rd Street, Suite 208      SE DECISION MADE: 25-AUG-23 Minneapolis MN  55401             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Dentis s-Clean Regular Abutment Dentis Co., Ltd                   510(k) NO: K230126(Traditional) ATTN: Gyu Ri Kim                  PHONE NO : 82 53 5893541  99, Seongseoseo-ro, Dalseo-gu     SE DECISION MADE: 04-AUG-23 Daegu  KR 42718                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Mick Valencia Applicator Set Mick Radio-Nuclear Instruments, In510(k) NO: K230155(Traditional) ATTN: James  Hurlman              PHONE NO : 914 6670291  521 Homestead Avenue              SE DECISION MADE: 30-AUG-23 Mount Vernon NY  10550            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SoundBite® Crossing System XS Peripheral Soundbite Medical Solutions, Inc. 510(k) NO: K230159(Traditional) ATTN: Diane  Marceau              PHONE NO : 514 9562525 3352 2300 Alfred Nobel, Suite 230      SE DECISION MADE: 28-AUG-23 Montreal  CA H4S 2A4              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: uCT 760 with uWS-CT-Dual Energy Analysis, uCT 780 with uWS-CT-Dual Energy Analysis Shanghai United Imaging Healthcare510(k) NO: K230162(Traditional) ATTN: Xin  Gao                    PHONE NO : 86 21670 768885386  No. 2258 Chengbei Rd., Jiading IndSE DECISION MADE: 01-AUG-23 Shanghai  CN 201807               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Luja Coudé (20118 Male CH8 - small packaging (Pocket size)), Luja Coudé (20111 Male CH10 - small packaging (Pocket size)), Luja Coudé (20112 Male CH12 - small packaging (Pocket size)), Luja Coudé (20114 Male CH14 - small packaging (Pocket size)), Luja Coudé  (20101 Male CH10 - large packaging), Luja Coudé  (20102 Male CH12 - large packaging), Luja Coudé  (20104 Male CH14 - large packaging), Luja Coudé  (20106 Male CH16 - large packaging) Coloplast                         510(k) NO: K230165(Traditional) ATTN: Troy  Thome                 PHONE NO : 612 3569917  1601 West River Road North        SE DECISION MADE: 25-AUG-23 Minneapolis MN  55411             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Pulse Oximeter Beijing Choice Electronic Technolo510(k) NO: K230172(Traditional) ATTN: Haiying  Zhao               PHONE NO : 86 10 88794631  No. 9 Shuangyuan road, Badachu Hi-SE DECISION MADE: 12-AUG-23 Beijing  CN 100041                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: QDOSE® Multi-purpose Voxel Dosimetry (Personalized Dosimetry in Molecular Radiotherapy) Versant Medical Physics and Radiat510(k) NO: K230221(Traditional) ATTN: Darrell R. Fisher           PHONE NO : 509 5393223___  119 N. Church Street              SE DECISION MADE: 28-AUG-23 Kalamazoo MI  49007               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ZenPro 40 Bluecore Company Co Ltd           510(k) NO: K230268(Traditional) ATTN: Bill  Choi                  PHONE NO : 82 517 474318  Ace Hightech 21 #1203 48, Centurm SE DECISION MADE: 10-AUG-23 Busan  KR 48059                   510(k) STATEMENT                                                       DEVICE: PMT Expandable Cage (PMT EXP) Providence Medical Technology, Inc510(k) NO: K230297(Traditional) ATTN: Edward  Liou                PHONE NO : 415 9239376  4234 Hacienda Drive, Suite 150    SE DECISION MADE: 11-AUG-23 Pleasanton CA  94588              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Celsi Monitor Hadleigh Health Technologies      510(k) NO: K230298(Traditional) ATTN: Molly  McCabe               PHONE NO : 510 6733653  30 Castro Avenue                  SE DECISION MADE: 16-AUG-23 San Rafael CA  94901              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Polyisoprene Surgical Gloves Puyang Linshi Medical Supplies Co.510(k) NO: K230304(Traditional) ATTN: Catherine  Liu              PHONE NO : 86 198 39327898  East of Panjin Road and North of FSE DECISION MADE: 09-AUG-23 Puyang  CN 457001                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sterile Powder Free Nitrile Examination Gloves (Blue, Black &White Colors) New Era Medicare Sdn. Bhd.        510(k) NO: K230314(Traditional) ATTN: Fatin Nor Irdina binti AhmadPHONE NO : 60 149 072860  Plot 2621-2624                    SE DECISION MADE: 16-AUG-23 Teluk Intan  MY 36000             510(k) STATEMENT                                                       DEVICE: Phototherapy System  (OL-PDT950) Shanghai Omni Laser Skinology Co.,510(k) NO: K230342(Traditional) ATTN: Avril  Ouyang               PHONE NO : 86 021 54847192  Floor 3, Building 3, NO.227, MingqSE DECISION MADE: 16-AUG-23 Shanghai  CN 201612               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Vantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit for MR Canon Medical Systems Corporation 510(k) NO: K230355(Traditional) ATTN: Janine F Reyes              PHONE NO : 714 6697853  1385 Shimoshigami                 SE DECISION MADE: 30-AUG-23 Otawara-shi  JP 324-8550          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: VitalFlow™ Console Michigan Critical Care Consultants510(k) NO: K230364(Traditional) ATTN: Martha  Rumford             PHONE NO : 734 9959089  2555 Bishop Circle West           SE DECISION MADE: 25-AUG-23 Dexter MI  48130                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Reprocessed Agilis NxT Steerable Introducer Innovative Health, LLC.           510(k) NO: K230376(Traditional) ATTN: Rick  Ferreira              PHONE NO : 877 4003740  1435 North Hayden Road, Suite 100 SE DECISION MADE: 07-AUG-23 Scottsdale AZ  85257              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Surgical Face Masks, Model: EFMDS-L50Pn BLU Iris USA                          510(k) NO: K230380(Traditional) ATTN: Michael  Cruz               PHONE NO : 602 7071770  11111 80th Ave.                   SE DECISION MADE: 03-AUG-23 Pleasant Prairie WI  53158        510(k) STATEMENT                                                       DEVICE: PolyWear® Personal Protective Level 3 Gown Polyconversions, INC              510(k) NO: K230384(Traditional) ATTN: William  Smith              PHONE NO : 309 6623614  3202 Apollo Drive                 SE DECISION MADE: 11-AUG-23 Champaign IL  61822               510(k) STATEMENT                                                       DEVICE: Wrist Type Blood Pressure Monitor (W05,W1101L) Shenzhen Jamr Technology Co., Ltd.510(k) NO: K230409(Traditional) ATTN: Haiyu  Zhang                PHONE NO : 86 186 75539961  A101-301, D101-201, Jamr Science &SE DECISION MADE: 25-AUG-23 Shenzhen  CN 518100               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Cadwell Guardian Cadwell Industries, Inc.          510(k) NO: K230415(Traditional) ATTN: Jason  Ford                 PHONE NO : 509 7356481  909 North Kellogg Street          SE DECISION MADE: 17-AUG-23 Kennewick WA  99336               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sequel Tampon with Plastic Applicator Tampro Inc                        510(k) NO: K230419(Traditional) ATTN: Greta  Meyer                PHONE NO : 215 2609081  3749 Buchanan Street #316         SE DECISION MADE: 03-AUG-23 San Fransisco CA  94123           510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Dr. pen Microneedling System Guangzhou Ekai Electronic Technolo510(k) NO: K230420(Traditional) ATTN: Guihua  Chen                PHONE NO : 86 020 81177539  3/F Building E No.81 Zijing Road, SE DECISION MADE: 11-AUG-23 Guangzhou  CN 510000              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Ambu® aScope™ 5 Broncho 2.7/1.2, Ambu® aScope™ 5 Broncho 4.2/2.2, Ambu® aBox™ 2 Ambu A/S                          510(k) NO: K230428(Traditional) ATTN: Karina  Matthiesen          PHONE NO : 45 7225 2094  Baltorpbakken 13                  SE DECISION MADE: 10-AUG-23 Ballerup  DK 2750                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sterile Syringe Bulk Tray Shanghai Kindly Enterprise Develop510(k) NO: K230447(Traditional) ATTN: Hualong  Liu                PHONE NO : 86 02169 118232  No.658 Gaochao Road               SE DECISION MADE: 16-AUG-23 Shanghai  CN 201803               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Cove Strip SeaSpine Orthopedics Corporation  510(k) NO: K230486(Traditional) ATTN: Cindy  Toyama               PHONE NO : 949 8557175  2 Goodyear                        SE DECISION MADE: 21-AUG-23 Irvine CA  92618                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: EL27-Compact; Sterile EHL-Probes Walz Elektronik GmbH              510(k) NO: K230488(Traditional) ATTN: Bernd  Vollmer              PHONE NO : 49 745 22020  Walddorfer Strasse 40             SE DECISION MADE: 31-AUG-23 Rohrdorf  DE 72229                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Visual-ICE Cryoablation System Boston Scientific Corporation     510(k) NO: K230551(Traditional) ATTN: Amy  McKinney               PHONE NO : 651 2875096  One Scimed Place                  SE DECISION MADE: 08-AUG-23 Maple Grove MN  55311-1566        510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Arm-type Fully Automatic Digital Blood Pressure Monitor, Wrist-type Fully Automatic Digital Blood Pressure Monitor Joytech Healthcare Co.,Ltd        510(k) NO: K230566(Traditional) ATTN: Ren  Yunhua                 PHONE NO : 86 571 81957767  No.365, Wuzhou Road Yuhang EconomiSE DECISION MADE: 25-AUG-23 Hangzhou  CN 311100               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sterile Triplex Surgical Gown (S, M, L, XL, XXL, XXXL) Medcare Saglik Urunleri Sanayi Ve 510(k) NO: K230577(Traditional) ATTN: Muge  Ersahin               PHONE NO : 90 232 28116  Fatih Mah. Camlik Cad No 54       SE DECISION MADE: 16-AUG-23 Izmir  TR 35410                   510(k) STATEMENT                                                       DEVICE: Polyisoprene Surgical Glove (Unified Double Layer), Sterile, Tested for Use with Chemotherapy Drugs and Fentanyl WRP Asia Pacific Sdn. Bhd.        510(k) NO: K230578(Traditional) ATTN: Saravanan  Ramasamy         PHONE NO : 60 387 061486  Lot 1, Jalan 3, Kawasan PerusahaanSE DECISION MADE: 31-AUG-23 Sepang  MY 43900                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Smart Wedge algorithm Edwards Lifesciences, LLC         510(k) NO: K230579(Traditional) ATTN: Jennifer  Wilbur            PHONE NO : 949 7564436  1 Edwards Way                     SE DECISION MADE: 18-AUG-23 Irvine CA  92614                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: TOPA12 Portable X-ray Unit NEUF Inc.                         510(k) NO: K230581(Traditional) ATTN: Woo Sang Lee                PHONE NO : 82 61 7402830  #103 Production Bldg. 13, YulchonsSE DECISION MADE: 16-AUG-23 Suncheon-si  KR 58034             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Aer-O-Scope Colonoscope System GI View Ltd.                      510(k) NO: K230588(Traditional) ATTN: Sharon  Goldfarb            PHONE NO : 972 54 6454034  5 Shoham St.                      SE DECISION MADE: 17-AUG-23 Ramat Gan  IL 5251001             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Arrow Non-Stimulating SnapLock Adapter (K-05520-005C); Arrow Non-Stimulating Next Gen SnapLock Adapter (Luer Connection) (CA-000010-19); Arrow Non-Stimulating Next Gen SnapLock Adapter (Neuraxial Connection) (CA-000014-19); Arrow Stimulating SnapLock Adapter (with cable) (TZ-02060-001); Arrow Stimulating SnapLock Adapter (with tab) (TZ-05000-002) Teleflex Medical                  510(k) NO: K230603(Traditional) ATTN: Kristen  Bisanz             PHONE NO : 404 2909807  3015 Carrington Mill Blvd.        SE DECISION MADE: 30-AUG-23 Morrisville NC  27560             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SPICCA Cervical Fusion Cages Southern Medical (Pty) Ltd        510(k) NO: K230607(Traditional) ATTN: Nathan  Wright              PHONE NO : 719 3510248  Building 10, Southern Implants OffSE DECISION MADE: 14-AUG-23 Irene  ZA 0062                    510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SPICCA Stand-Alone Cervical Fusion Cages Southern Medical (Pty) Ltd        510(k) NO: K230608(Traditional) ATTN: Dalene  Styger              PHONE NO : 27 12 6676243  55 Regency Drive Route 21 CorporatSE DECISION MADE: 14-AUG-23 Irene  ZA 0178                    510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Disposable Surgical Gown (Level 3, MF2103 Series), Disposable Surgical Gown (Level 3, MF2104 Series), Disposable Surgical Gown (Level 4, MF2105 Series) Dongguan Shin Yi Healthcare Produc510(k) NO: K230610(Traditional) ATTN: Shuge  Zhao                 PHONE NO : 86 769 8336138  No. 17 Ban Hu Road, Huang Jiang ToSE DECISION MADE: 23-AUG-23 Dong Guan  CN 523750              510(k) STATEMENT                                                       DEVICE: SKEEPER Smartsound Corporation            510(k) NO: K230613(Traditional) ATTN: Jungho  Lee                 PHONE NO : 82 257 52252  171, Yangjaecheon-ro, Gangnam-gu  SE DECISION MADE: 02-AUG-23 Seoul  KR 06302                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Gentuity® HF-OCT Imaging System with Vis-Rx® Micro-Imaging Catheter Gentuity, LLC                     510(k) NO: K230620(Traditional) ATTN: Padmini  Gagnon             PHONE NO : 508 4251560  142 North Road, Suite G           SE DECISION MADE: 08-AUG-23 Sudbury MA  01776                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ReliOn Premier BLU Blood Glucose Monitoring System i-SENS, Inc.                      510(k) NO: K230625(Special) ATTN: H.S.  Yoo                   PHONE NO : 82 29 100516  43, Banpo-Daero 28 Gil Seocho-Gu  SE DECISION MADE: 10-AUG-23 Seoul  KR 06646                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Portrait™ Central Viewer Application (Portrait CV A01), Portrait ™ Core Services (Portrait CSS01), Portrait™ Clinical Alarming Unit (Portrait CAU01); Portrait™ Mobile Patient Monitor (Portrait HUB01), Portrait™ Sensor Battery (Portrait SBT01), Portrait™ Bedside Charger (Portrait BCH01); Portrait™ Wearable Pulse Oximetry Sensor (Portrait SpO2 P-SA01, Portrait SpO2 P-SP01, Portrait SpO2 P-W01 and Portrait SpO2 P-SE01); Portrait™ SpO2 Attachment Accessory Band (Portrait AAB01), Portrait™ Mobile Patient Monitor Pouch (Portrait MMP01); Portrait™ Wearable Respiration Rate Sensor (Portrait RR P-RR01), Portrait™ RR Electrode Patch (Portrait RRP01) GE Medical Systems Information Tec510(k) NO: K230626(Traditional) ATTN: Joel  Kent                  PHONE NO : 617 8510943  9900 Innovation Drive             SE DECISION MADE: 11-AUG-23 Wauwatosa WI  53226               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: VersiHD with GuideMe software NxStage Medical, Inc.             510(k) NO: K230632(Traditional) ATTN: Denise  Oppermann           PHONE NO : 781 9969103  350 Merrimack St.                 SE DECISION MADE: 11-AUG-23 Lawrence MA  01843                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Electronic Blood Pressure Monitor Dongguan kangweile Electronic Tech510(k) NO: K230642(Traditional) ATTN: Zhixin  Gao                 PHONE NO : 86 769 82677482  4th floor, building D, Yizhong SciSE DECISION MADE: 11-AUG-23 Dongguan  CN 523770               510(k) STATEMENT                                                       DEVICE: Density Jeisys Medical Inc.               510(k) NO: K230663(Traditional) ATTN: Bora  Kim                   PHONE NO : 82 10 30197221  307 Daeryung Techno Town 8th      SE DECISION MADE: 14-AUG-23 Seoul  KR 08501                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Annabella Breast Pump Annabella Ltd.                    510(k) NO: K230672(Traditional) ATTN: Uri  Yaffe                  PHONE NO : 97 254 5555484  23/5 Hataas                       SE DECISION MADE: 04-AUG-23 KFAR SABA  IL 4442525             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Tandry Locking Plate System Microware Precision Co., Ltd.     510(k) NO: K230690(Traditional) ATTN: Harrison  Du                PHONE NO : 886 4 24636275 100 No. 12, Keyuan 2nd Rd., Situn DistSE DECISION MADE: 17-AUG-23 Taichung  TW 40763                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Stryker Resorbable Fixation System Stryker Leibinger GmbH & Co. KG   510(k) NO: K230733(Traditional) ATTN: Gregory  Gohl               PHONE NO : 269 3701476  Boetzinger Strasse 41             SE DECISION MADE: 05-AUG-23 Freiburg  DE D-79111              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Disposable Ureteral Access Sheath YouCare Technology Co., Ltd. (Wuha510(k) NO: K230748(Traditional) ATTN: Bing  Hu                    PHONE NO : 86 27 87926396 830___ Tangxunhu North Street            SE DECISION MADE: 02-AUG-23 Wuhan  CN 430000                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: TK Pre-Filled Normal Saline Flush Syringe Anhui Tiankang Medical Technology 510(k) NO: K230756(Traditional) ATTN: Bai  Baodong                PHONE NO : 86 1350 5557811  No. 228 Weiyi Road, Economic DevelSE DECISION MADE: 12-AUG-23 Tianchang  CN                     510(k) STATEMENT                                                       DEVICE: Precice Ankle Salvage System NuVasive Specialized Orthopedics, 510(k) NO: K230765(Traditional) ATTN: Miriam  Cervantes           PHONE NO : 909 2297836  101 Enterprise, Suite 100         SE DECISION MADE: 29-AUG-23 Aliso Viejo CA  92656             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Withings Scan Monitor 2.0 Withings                          510(k) NO: K230812(Traditional) ATTN: Khushboo  Surendran         PHONE NO : 857 2052072  2 rue Maurice Hartmann            SE DECISION MADE: 23-AUG-23 Issy-Les-Moulineaux  FR 92130     510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Powdered Free Sterile Natural Rubber Latex Surgical Gloves The Egyptian Company For Medical &510(k) NO: K230832(Traditional) ATTN: Alaa  Elsayed               PHONE NO : 201 0000 80163  Industrial Zone 7. Part 7062A&B   SE DECISION MADE: 16-AUG-23 Sadat City  EG                    510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: EXTRON 5; EXTRON 7 DRTECH Corporation                510(k) NO: K230871(Traditional) ATTN: Kim  Minjeong               PHONE NO : 82 031 7797783  Suite No. 1, 2 Floor/Suite No. 2, SE DECISION MADE: 17-AUG-23 Seongnam-si  KR 13216             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Angulated Screw Channel (ASC) Solution Abutments & SI-BASE Abutments Southern Implants (Pty) Ltd       510(k) NO: K230873(Traditional) ATTN: Colin  Saffy                PHONE NO : 27 12 6671046  1 Albert Road                     SE DECISION MADE: 01-AUG-23 Irene  ZA 0062                    510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: qXR-PTX-PE Qure.ai Technologies              510(k) NO: K230899(Traditional) ATTN: Ayushi  Mahendra            PHONE NO : 91 22 68505800  Level 7, Commerz II, InternationalSE DECISION MADE: 22-AUG-23 Mumbai  IN 400063                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Vein360 Reprocessed Visions PV.018 Digital IVUS Catheter Vein 360 LLC                      510(k) NO: K230928(Traditional) ATTN: Suzanne  Meyer              PHONE NO : 513 5541300  4460 Lake Forest Dr Suite 230     SE DECISION MADE: 25-AUG-23 Blue Ash OH  452423741            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Arthrex Radiopaque FiberTape Cerclage sutures Arthrex, Inc                      510(k) NO: K230976(Traditional) ATTN: Stacy  Valdez               PHONE NO : 1 239 6435553 72010 1370 Creekside Boulevard          SE DECISION MADE: 24-AUG-23 Naples FL  34108-1945             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Yomi Robotic System Neocis Inc.                       510(k) NO: K231018(Traditional) ATTN: Joshua  Davis               PHONE NO : 508 2940749  2800 Biscayne Blvd Suite 600      SE DECISION MADE: 14-AUG-23 Miami FL  33137                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: AquaBeam Robotic System PROCEPT BioRobotics Corporation   510(k) NO: K231024(Traditional) ATTN: Sara  Muddell               PHONE NO : 650 2327217  900 Island Drive, Suite 101       SE DECISION MADE: 30-AUG-23 Redwood City CA  94065            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: 12MP Color LCD Monitor C1216W, C12*** ("*" = 0 to 9, A to Z or blank, and the difference among models means the product is named according to different appearance colors and customer models) Shenzhen Beacon Display Technology510(k) NO: K231026(Traditional) ATTN: Li  Yafei                   PHONE NO : 86 248 8087610  15F, Building 6, Hengda Shishang HSE DECISION MADE: 18-AUG-23 Shenzhen  CN 518109               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Unicare (K-UNICARE-USA) TensCare Ltd                      510(k) NO: K231053(Traditional) ATTN: Saskia  Eldridge-Hinmers    PHONE NO : 44 137 2723434  9 Blenheim Road                   SE DECISION MADE: 18-AUG-23 Epsom  GB KT199BE                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: V-Laser WON TECH Co., Ltd.                510(k) NO: K231054(Special) ATTN: Hyun Sik Yoon               PHONE NO : 82 10 67505346  64 Techno 8-ro, Yuseong-gu        SE DECISION MADE: 14-AUG-23 Daejeon  KR 34028                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: 1.5T HD T/R Knee Array (10-F34127) Shenzhen RF Tech Co., Ltd.        510(k) NO: K231085(Traditional) ATTN: Wang  Gary                  PHONE NO : 0086__ 7552 6641989  2-F,BLD4 Juhui Industrial Park,TiaSE DECISION MADE: 18-AUG-23 Shenzhen  CN 518132               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Guided Surgery Kit Implant Direct Sybron Manufacturin510(k) NO: K231087(Traditional) ATTN: Reina  Choi                 PHONE NO : 1 818 3073132  3050 East Hillcrest Drive         SE DECISION MADE: 16-AUG-23 Thousand Oaks CA  91362           510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: AlphaVent Suture Anchors Stryker Endoscopy                 510(k) NO: K231093(Traditional) ATTN: Katie  Farraro              PHONE NO : 408___ 4647396  5900 Optical Ct.                  SE DECISION MADE: 30-AUG-23 San Jose CA  95138                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Annalise Enterprise CTB Triage-OH Annalise-AI Pty Ltd               510(k) NO: K231094(Traditional) ATTN: Haylee  Bosshard            PHONE NO : 61 4932 66602  Level P, 24 Campbell St.          SE DECISION MADE: 15-AUG-23 Sydney  AU 2000                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Automatic Continuous Effusion Shunt (ACES) System ACES System Pleural Dynamics, Inc.            510(k) NO: K231096(Traditional) ATTN: Martin  Mayse               PHONE NO : 314 5181786  952 Medina Road                   SE DECISION MADE: 18-AUG-23 Wayzata MN  55391                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: LineSider® Spinal System Integrity Implants Inc.           510(k) NO: K231098(Traditional) ATTN: Alexa  Kamer                PHONE NO : 561 5293861  354 Hiatt Drive                   SE DECISION MADE: 07-AUG-23 Palm Beach Gardens FL  33418      510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Zimmer® Natural Nail® System Cephalomedullary Nails; Affixus® Natural Nail® Humeral Nail System Zimmer Switzerland Manufacturing G510(k) NO: K231114(Traditional) ATTN: Annemie Kausch Rehor        PHONE NO : 41 795 615986  Sulzerallee 8                     SE DECISION MADE: 09-AUG-23 Winterthur  CH 8404               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Phoenix Contact Lens Case - dome top flat pack (CL-01); Phoenix Contact Lens Case - classic flat pack (CL-02); Phoenix Contact Lens Case - sunglass shape flat pack (CL-03) Phoenix Innovative Healthcare Manu510(k) NO: K231123(Traditional) ATTN: Michael  Stuart             PHONE NO : 954 8804274  EL-209, Shil Mahape Road ElectroniSE DECISION MADE: 30-AUG-23 Navi Mumbai  IN 400710            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Eblator Device E Surgical, LLC                   510(k) NO: K231126(Traditional) ATTN: Michael  Blomeyer           PHONE NO : 775___ 4331808___  150 Isidor Court Unit 203         SE DECISION MADE: 02-AUG-23 Sparks NV  89441                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Enzyme Packed Cartridge - RELiZORB Alcresta Therapeutics, Inc.       510(k) NO: K231156(Traditional) ATTN: Matthew  King               PHONE NO : 603 4599755  130 Turner Street, Building 3, SuiSE DECISION MADE: 30-AUG-23 Waltham MA  02453                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Conductive carbon film electrode Guangzhou Xinbo Electronic Co., Lt510(k) NO: K231164(Traditional) ATTN: Sammy  Li                   PHONE NO : 86 020 34822409  No.23 Building, The Second Phase, SE DECISION MADE: 09-AUG-23 Guangzhou  CN 511450              510(k) STATEMENT                                                       DEVICE: Conductive Silicone Rubber Electrode Guangzhou Xinbo Electronic Co., Lt510(k) NO: K231167(Traditional) ATTN: Sammy  Li                   PHONE NO : 86 020 34822409  No.23 Building, The Second Phase HSE DECISION MADE: 09-AUG-23 Guangzhou  CN 511450              510(k) STATEMENT                                                       DEVICE: BPBIO750 InBody Co, Ltd.                   510(k) NO: K231174(Traditional) ATTN: Kichul  Cha                 PHONE NO : 82 02 5013939  15, Heugam-Gil , Ipjang-Myueon, SeSE DECISION MADE: 02-AUG-23 Cheonan-Si  KR 31025              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Non absorbable Surgical Polyester Suture Shandong Haidike Medical Products 510(k) NO: K231183(Traditional) ATTN: Yan  Wang                   PHONE NO : 86 530 4660062  Tianfu Road, Dongcheng District, SSE DECISION MADE: 25-AUG-23 Heze  CN 274300                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Cochlear™ Osia® System; Cochlear™ Osia® OSI300 Implant; Cochlear™ Magnet Cassette; Cochlear™ Non-Magnetic Cassette; Cochlear™ Osia® 2(I) Sound Processor; Cochlear™ Osia® Fitting Software 2; Cochlear™ Osia® Smart App Cochlear                          510(k) NO: K231204(Traditional) ATTN: Denis  DiMartino            PHONE NO : 508 3044356  10350 Park Meadows Drive          SE DECISION MADE: 18-AUG-23 Lone Tree CO  80124               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: GuruNanda Dry Mouth Oral Rinse and GuruNanda Dry Mouth Oral Spray GuruNanda LLC                     510(k) NO: K231205(Traditional) ATTN: Puneet  Nanda               PHONE NO : 714 4100466  6645 Caballero Blvd.              SE DECISION MADE: 22-AUG-23 Buena Park CA  90620              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Stryker Resorbable Fixation System Stryker Leibinger GmbH & Co. KG   510(k) NO: K231208(Traditional) ATTN: Gregory  Gohl               PHONE NO : 269 3701476  Boetzinger Strasse 41 D-79111     SE DECISION MADE: 14-AUG-23 Freiburg  DE                      510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Ventrax™ Delivery System  (VTR851) Merit Medical Systems, Inc.       510(k) NO: K231246(Traditional) ATTN: Jenny  Soderquist           PHONE NO : 801 2084579  1600 West Merit Parkway           SE DECISION MADE: 30-AUG-23 South Jordan UT  84095            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: NovoFine® Plus Novo Nordisk Inc.                 510(k) NO: K231255(Special) ATTN: Hiral Palkhiwala Shah       PHONE NO : 609 7877603  P.O Box 846                       SE DECISION MADE: 25-AUG-23 Plainsboro NJ  08536              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Pangea Utility Plating System, Pangea Platform Stryker GmbH                      510(k) NO: K231257(Traditional) ATTN: Danese  Joiner-Fox          PHONE NO : 475 3334452  325 Corporate Drive               SE DECISION MADE: 18-AUG-23 Mahwah NJ  07430                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Pangea Femur Plating System, Pangea Fibula Plating System, Pangea Tibia Plating System, Pangea Humerus Plating System Stryker GmbH                      510(k) NO: K231262(Traditional) ATTN: Danese  Joiner-Fox          PHONE NO : 475 3334452  325 Corporate Drive               SE DECISION MADE: 18-AUG-23 Mahwah NJ  07430                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Pediatric Nailing Platform | Tibia OrthoPediatrics Corp.             510(k) NO: K231266(Traditional) ATTN: Yan  Li                     PHONE NO : 574 2670864  2850 Frontier Drive               SE DECISION MADE: 21-AUG-23 Warsaw IN  46582                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Natural Cycles Natural Cycles Nordic AB          510(k) NO: K231274(Traditional) ATTN: Raoul  Scherwitzl, PhD      PHONE NO : 46 707 174866____  St Eriksgatan 63b                 SE DECISION MADE: 24-AUG-23 Stockholm  SE 112 34              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SmartCardia 7L Platform SmartCardia SA                    510(k) NO: K231276(Traditional) ATTN: Srinivasan  Murali          PHONE NO : 41 788 750864  EPFL Innovation Park Building C   SE DECISION MADE: 30-AUG-23 Lausanne  CH 1015                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Knotless Suture Anchor Riverpoint Medical, LLC           510(k) NO: K231278(Traditional) ATTN: Bianca Silva de Sousa       PHONE NO : 503 5178001  815 NE 25th Ave                   SE DECISION MADE: 01-AUG-23 Portland OR  97232                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Chemfort® Catheter Adaptor Simplivia Healthcare LTD.         510(k) NO: K231286(Traditional) ATTN: Shay  Shaham                PHONE NO : 97 246 908826  North Industrial Zone             SE DECISION MADE: 02-AUG-23 Kiryat Shmona  IL 1101801         510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: S-Patch Ex Wearable ECG Patch Wellysis Corp.                    510(k) NO: K231289(Traditional) ATTN: DoGyun  Im                  PHONE NO : 82 109 1408475  8F, 425 Teheran-ro, Gangnam-gu    SE DECISION MADE: 30-AUG-23 Seoul  KR 06159                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Vscan Air GE Medical Systems Ultrasound and 510(k) NO: K231301(Traditional) ATTN: Bush  Lee                   PHONE NO : 262 3099429  9900 W. Innovation Drive          SE DECISION MADE: 15-AUG-23 Wauwatosa WI  53226               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Ancora-SB Aspero Medical, Inc.              510(k) NO: K231323(Traditional) ATTN: Mark  Rentschler            PHONE NO : 303 8347885  320 E. Vine Drive, Suite 101      SE DECISION MADE: 31-AUG-23 Fort Collins CO  80524            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: LUX-Dx II (M302); LUX-Dx II+ (M312) Boston Scientific Corp            510(k) NO: K231328(Traditional) ATTN: Melissa  Klamerus           PHONE NO : 651 5826771  4100 Hamline Ave North            SE DECISION MADE: 19-AUG-23 St. Paul MN  55112                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: STRETTO™ Cable System Globus Medical Inc.               510(k) NO: K231333(Traditional) ATTN: Jennifer  Antonacci         PHONE NO : 610 9301800  2560 General Armistead Ave.       SE DECISION MADE: 04-AUG-23 Audubon PA  19403                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Organic cotton tampon, Viscose tampon Zhejiang Tianqing Manufacturing Te510(k) NO: K231341(Traditional) ATTN: Roy  Du                     PHONE NO : 86 138 17862379  Lianshi Industrial Park, Nanxun DiSE DECISION MADE: 14-AUG-23 Huzhou  CN 313013                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ActivSight Intraoperative Imaging System Activ Surgical Inc.               510(k) NO: K231344(Traditional) ATTN: Nicholas  Child             PHONE NO : 857 4494840  30 Thomson Place                  SE DECISION MADE: 02-AUG-23 Boston MA  02110                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Dewin Blastocyst Medium (with HSA and without HSA) DonneVie Medical Technology (Shang510(k) NO: K231370(Traditional) ATTN: Hannah Hang Yin             PHONE NO :  Suite 201, Bld 1, 138 Xinjun Ring SE DECISION MADE: 04-AUG-23 Shanghai  CN 201114               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Q-FIX With Needles (Q-FIX With Needles, #0 Suture & Q-FIX With Needles, Minitape) Smith & Nephew Inc.               510(k) NO: K231376(Traditional) ATTN: Pragnya  Bakka              PHONE NO : 512 3913900  150 Minuteman Road                SE DECISION MADE: 09-AUG-23 Andover MA  01810                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: AirLife DuoTherm™ Humidification System Vyaire Medical, Inc.              510(k) NO: K231380(Traditional) ATTN: Megan  Walsh                PHONE NO : 872 2063142  26125 N. Riverwoods Blvd.         SE DECISION MADE: 10-AUG-23 Mettawa IL  60045                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Harvest Dental HD Gum Strip Harvest Dental Products, LLC      510(k) NO: K231389(Traditional) ATTN: Colleen  Boswell            PHONE NO : 714 5853431  905 Columbia Street               SE DECISION MADE: 16-AUG-23 Brea CA  92821                    510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Intense Pulsed Light System Smedtrum Medical Technology Co., L510(k) NO: K231394(Traditional) ATTN: Crimson  Wu                 PHONE NO : 88 622 2989578 301 1F., No. 8, Ln. 97, Wugong Rd.,   SE DECISION MADE: 09-AUG-23 New Taipei City  TW 248016        510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Bladeless Trocar – Artemis Lap Cannula T.A.G. Medical Products Corporatio510(k) NO: K231400(Special) ATTN: Shlomi  Dines               PHONE NO : 972 4 9858400  T.A.G. Medical Products CorporatioSE DECISION MADE: 04-AUG-23 Gaaton  IL 2513000                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: T-Button® A Adjustable Loop UHMWPE Suture PEEK Button, Close Button, T-Button® S Adjustable Loop UHMWPE Suture PEEK Button, Open Button Healthium Medtech Limited         510(k) NO: K231404(Traditional) ATTN: Pankaj  Dawar               PHONE NO : 91 988 6529934  472-D, 13th Cross, 4th Phase, PeenSE DECISION MADE: 04-AUG-23 Bangalore  IN 560058              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: StarFin Premium Medical Technology LLC    510(k) NO: K231407(Traditional) ATTN: Kuowei  Chang               PHONE NO : 781 8914201  1377 Main Street 2nd Floor        SE DECISION MADE: 29-AUG-23 Waltham MA  02451                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Basic Synguard Nitrile Exam Gloves, Powder Free, Blue Colored, Non-Sterile Shandong Intco Medical Products Co510(k) NO: K231408(Traditional) ATTN: Max  Li                     PHONE NO : 86 189 18364816  No. 9888 Qiwang Road, Naoshan InduSE DECISION MADE: 11-AUG-23 Qingzhou  CN 2625000              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Erchonia FX-405 Erchonia Corporation              510(k) NO: K231409(Traditional) ATTN: Travis  Sammons             PHONE NO : 888 2420571  650 Atlantis Road                 SE DECISION MADE: 11-AUG-23 Melbourne FL  32904               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: EnSite™ X EP System Abbott Medical                    510(k) NO: K231415(Traditional) ATTN: Alyssa  Timmers             PHONE NO : 651 7563706  One St. Jude Medical Drive        SE DECISION MADE: 10-AUG-23 St. Paul MN  55117                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ENDOGATOR™ Hybrid Irrigation Tubing Medivators                        510(k) NO: K231418(Traditional) ATTN: Disha  Kabrawala            PHONE NO : 732 3197766  14605 28th Avenue North           SE DECISION MADE: 14-AUG-23 Minneapolis MN  55447             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Aura 10 PET/CT XEOS Medical                      510(k) NO: K231420(Traditional) ATTN: Bjorn  Delbeecke            PHONE NO : 0032 09 2777794  Ottergemsesteenweg-Zuid 808 Bus 35SE DECISION MADE: 10-AUG-23 Gent  BE 9000                     510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Precision GI Limaca Medical Ltd                510(k) NO: K231422(Traditional) ATTN: Assaf  Klein                PHONE NO : 972 54 2299572  3 Ha'Rimon street Mevo-Carmel ScieSE DECISION MADE: 28-AUG-23 En Ha'Emeq  IL 1925000            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: The Sensititre YeastOne Susceptibility System with Rezafungin in the dilution range of 0.008-8ug/mL Thermo Fisher Scientific          510(k) NO: K231433(Traditional) ATTN: Cynthia  Knapp              PHONE NO : 800 87189093 224117 1 Thermo Fisher Way               SE DECISION MADE: 31-AUG-23 Oakwood Village OH  44146         510(k) STATEMENT                                                       DEVICE: DESS Dental Smart Solutions Terrats Medical SL                510(k) NO: K231434(Traditional) ATTN: Roger  Terrats              PHONE NO : 34 935 646006  Carrer Mogoda 75-99               SE DECISION MADE: 14-AUG-23 Barbera del Valles  ES 08210      510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: KIMTECH™ Polaris™ Xtra Nitrile Powder-Free Exam Gloves Tested for Use with Chemotherapy Drugs, Opioid Fentanyl Citrate, Simulated Gastric Acid and Fentanyl in Simulated Gastric Acid Kimberly-Clark Corporation        510(k) NO: K231435(Traditional) ATTN: Kimberly  Tempas            PHONE NO : 920 7214084  1400 Holcomb Bridge Road          SE DECISION MADE: 28-AUG-23 Roswell GA  30076                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Powder Free White, Black, and Purple Nitrile Examination Glove S&S Glove Corporation             510(k) NO: K231439(Traditional) ATTN: Poppy Farrah Rossa          PHONE NO : 84 283 8725999  Lot 4, D6 Road, Dat Do I IndustriaSE DECISION MADE: 11-AUG-23 Ba Ria-Vung Tau  VN VN790000      510(k) STATEMENT                                                       DEVICE: Implant-One System Implant Logistics, Inc.           510(k) NO: K231455(Traditional) ATTN: Thomas  Arendt              PHONE NO : 1 608 4984855  711 Spartan Drive                 SE DECISION MADE: 15-AUG-23 Sparta WI  54656                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SPARK Scan SPARK Neuro Inc.                  510(k) NO: K231457(Traditional) ATTN: Marinela  Gombosev          PHONE NO : 949 5847331  212 West 18th Street, Unit 17A    SE DECISION MADE: 18-AUG-23 New York NY  10011                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Extremity Staple restor3d                          510(k) NO: K231458(Traditional) ATTN: Anika  Moorjani             PHONE NO : 501 2403476  311 West Corporation Street       SE DECISION MADE: 03-AUG-23 Durham NC  27701                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Xpert Xpress CoV-2/Flu/RSV plus Cepheid®                          510(k) NO: K231481(Traditional) ATTN: Suzette  Chance             PHONE NO : 262 6231775  904 Caribbean Drive               SE DECISION MADE: 17-AUG-23 Sunnyvale CA  94089               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Celerity™ HP Chemical Indicator;  Celerity™ HP Multivariable Chemical Indicator; VERIFY HPU Chemical Indicator; VERIFY VH2O2 Indicator Tape STERIS                            510(k) NO: K231488(Traditional) ATTN: Anthony  Piotrkowski        PHONE NO : 440 3927437  5960 Heisley Rd                   SE DECISION MADE: 07-AUG-23 Mentor OH  44060                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Celerity 20 HP Biological Indicator; VERIFY V24 Self-Contained Biological Indicator STERIS Corporation                510(k) NO: K231490(Traditional) ATTN: Gregory  Land               PHONE NO : 440 3927424  5960 Heisley Rd                   SE DECISION MADE: 07-AUG-23 Mentor OH  44060                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: TA™ Stapler and Loading Unit with DST Series™ Technology Covidien                          510(k) NO: K231491(Traditional) ATTN: Emily  Jacobs               PHONE NO : 860 9336557  60 Middletown Ave.                SE DECISION MADE: 16-AUG-23 North Haven CT  06473             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: NITINEX Memory Compression Staple Vilex, LLC                        510(k) NO: K231493(Traditional) ATTN: Brock  Johnson              PHONE NO : 801 9164157  111 Moffitt Street                SE DECISION MADE: 11-AUG-23 McMinnville TN  37110             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: TITAN 3-D Wedge System Paragon 28 Inc                    510(k) NO: K231496(Traditional) ATTN: Haylie  Hertz               PHONE NO : 303 7200017  14445 Grasslands Drive            SE DECISION MADE: 22-AUG-23 Englewood CO  80112               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Vis-U-All Low Temperature Sterilization Pouches Steris Corporation                510(k) NO: K231500(Traditional) ATTN: Jennifer  Nalepka           PHONE NO : 440 3927458  5960 Heisley Road                 SE DECISION MADE: 07-AUG-23 Mentor OH  44060                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: PRO-LITE Sterilization Tray STERIS Corporation                510(k) NO: K231501(Traditional) ATTN: Jennifer  Nalepka           PHONE NO : 440 3927458  5960 Heisley Road                 SE DECISION MADE: 07-AUG-23 Mentor OH  44060                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: CUPTIMIZE™ Advanced DePuy Orthopaedics, Inc           510(k) NO: K231503(Traditional) ATTN: Sierra  Robinson            PHONE NO : 850 2519921  700 Orthopaedic Dr                SE DECISION MADE: 22-AUG-23 Warsaw IN  46582                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Current Health System Current Health Ltd                510(k) NO: K231506(Special) ATTN: Giovanni  Maggi             PHONE NO : 44 131 2858101  The Stamp Office, Level 3, 10 WateSE DECISION MADE: 24-AUG-23 Edinburgh  GB EH1 3EG             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Surgical Gown (S,M,L,XL,XXL,XXXL); Reinforced Surgical Gown (S,M,L,XL,XXL,XXXL) Xiantao Zhibo Non-Woven Products C510(k) NO: K231510(Traditional) ATTN: Fen  Peng                   PHONE NO : 86 188 72609993  No. 8 Hefeng Industrial Park, PengSE DECISION MADE: 22-AUG-23 Xiantao  CN                       510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: VITROS Immunodiagnostic Products CEA Reagent Pack Ortho Clinical Diagnostics        510(k) NO: K231517(Traditional) ATTN: Rebecca  Lewis              PHONE NO : 440 7917 427649  Felindre Meadows Pencoed          SE DECISION MADE: 23-AUG-23 Bridgend  GB CF35 5PZ             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: VITROS Immunodiagnostic Products CA 19-9TM Reagent Pack Ortho Clinical Diagnostics        510(k) NO: K231525(Traditional) ATTN: Declan  Hynes               PHONE NO : 44 0750 5370257  Felindre Meadows Pencoed          SE DECISION MADE: 09-AUG-23 Bridgend  GB CF35 5PZ             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SofWave System Sofwave Medical Ltd.              510(k) NO: K231537(Traditional) ATTN: Ruthie  Amir, MD            PHONE NO : 97 254 3003164  1 Ha-Otsma St.                    SE DECISION MADE: 28-AUG-23 Yokneam Ilit  IL 2069200          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Meical Diode Laser, Model S1Pro Wuhan Pioon Technology Co., Ltd.  510(k) NO: K231548(Traditional) ATTN: Feng  Zhang                 PHONE NO : 86 180 62448535  7th Floor, A21 of Sino Pharm BuildSE DECISION MADE: 03-AUG-23 Wuhan  CN 430075                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ZENEX FreeMilling & CCM Cast Abutment Izenimplant Co., Ltd.             510(k) NO: K231557(Traditional) ATTN: Ji-Hwan  Jeong              PHONE NO : 82 31 6620657  1, 2Dong, 26-32, Suworam 4-Gil, SeSE DECISION MADE: 24-AUG-23 Pyeongtaek-Si  KR 17703           510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: NIM™ 35cm long Surgeon Control Probe, 1mm Ball-Tip (NIMDTP35) Medtronic Xomed, Inc.             510(k) NO: K231580(Traditional) ATTN: Alexandra  Oliver           PHONE NO : 904 3328936  6743 Southpoint Drive North       SE DECISION MADE: 30-AUG-23 Jacksonville FL  32216            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Route 92 Medical Full Length 054 Access System Route 92 Medical, Inc.            510(k) NO: K231583(Special) ATTN: Kirsten  Valley             PHONE NO : 650 2798427  155 Bovet Road, Suite 100         SE DECISION MADE: 15-AUG-23 San Mateo CA  94402               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sapphire X3 Anterior Cervical Plate System Spinal Elements, Inc              510(k) NO: K231593(Traditional) ATTN: Julie  Lamothe              PHONE NO : 760 6071816  3115 Melrose Dr., Suite 200       SE DECISION MADE: 02-AUG-23 Carlsbad CA  92010                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Stryker MP, Mandible, HMMF and MMF AXS Screws Stryker Leibinger GmbH & Co. KG   510(k) NO: K231599(Traditional) ATTN: Amelia  Kesti               PHONE NO : 269 3305919  Boetzinger Strasse 41             SE DECISION MADE: 24-AUG-23 Freiburg  DE D-79111              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Protego Air Water Connector; Protego Air Water Bottle Tubing; Protego Hybrid Tubing GA Health Company Limited         510(k) NO: K231602(Traditional) ATTN: Cindy  Ye                   PHONE NO : 852 28339010  Unit 18, 21/F, Metropole Square, 2SE DECISION MADE: 01-AUG-23 Hong Kong  HK                     510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Instrument Case Cochlear Americas                 510(k) NO: K231604(Special) ATTN: Whitney  Alexander          PHONE NO : 719 3378620  10350 Park Meadows Drive          SE DECISION MADE: 24-AUG-23 Lone Tree CO  80124               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: HOLO Portal™ Surgical Guidance System Surgalign Spine Technologies      510(k) NO: K231611(Traditional) ATTN: Jeremy  Markovich           PHONE NO : 760 5224378  520 Lake Cook Road Suite 315      SE DECISION MADE: 31-AUG-23 Deerfield IL  60015               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ZEUS IFA(TM) nDNA Test System, ZEUS dIFine ZEUS Scientific                   510(k) NO: K231616(Traditional) ATTN: Mark  Kopnitsky             PHONE NO : 908 5263744  200 Evans Way                     SE DECISION MADE: 31-AUG-23 Branchburg NJ  08876              510(k) STATEMENT                                                       DEVICE: Nuubo Smart Smart Solutions Technologies SL   510(k) NO: K231620(Traditional) ATTN: Borja Gonzal Vez            PHONE NO :  Paseo de la Castellena 200        SE DECISION MADE: 01-AUG-23 Madrid  ES 28046                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Distal Elbow Plating System Skeletal Dynamics Inc             510(k) NO: K231623(Traditional) ATTN: Alexandra  Rodriguez Rojas  PHONE NO : 305 5967585  7300 North Kendall Drive          SE DECISION MADE: 28-AUG-23 Miami FL  33156                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: OSPREY Closed IV Catheter System (OspreyV2) SkyDance Vascular, Inc.           510(k) NO: K231626(Traditional) ATTN: Scott  Pease                PHONE NO : 678 6898010  3058 Millcreek Road               SE DECISION MADE: 31-AUG-23 Pleasant Grove UT  84062          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: NorthStar OCT System SeaSpine Inc.                     510(k) NO: K231654(Traditional) ATTN: Jesse  Albright             PHONE NO : 815 3422428  5770 Armada Dr.                   SE DECISION MADE: 03-AUG-23 Carlsbad CA  92008                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Brainomix 360 e-MRI Brainomix Limited                 510(k) NO: K231656(Traditional) ATTN: Zsolt  Szrnka               PHONE NO : 0044 79 49013914  First Floor Seacourt Tower West WaSE DECISION MADE: 30-AUG-23 Oxford  GB OX2 0JJ                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: P200TE (A10700) Optos Plc                         510(k) NO: K231673(Traditional) ATTN: Rachel  Reay                PHONE NO : 00 441 383843300  Queensferry House, Carnegie CampusSE DECISION MADE: 18-AUG-23 Dunfermline  GB KY11 8GR          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: CALLISTO eye Carl Zeiss Meditec AG             510(k) NO: K231676(Traditional) ATTN: Hans-Joachim  Miesner       PHONE NO : 49 3641 220362  Goeschwitzer Strasse 51-52        SE DECISION MADE: 28-AUG-23 Jena  DE 07745                    510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: AccelFix Lumbar Expandable Cage System L&K BioMed Co., Ltd.              510(k) NO: K231680(Special) ATTN: Katherine  Kim              PHONE NO : 82 10 54770325  #101, 201, 202 16-25, DongbaekjungSE DECISION MADE: 24-AUG-23 Yongin-si  KR 17015               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Fusion Bond 5, Fusion Bond 7, Fusion Bond DC, Renew MDP, Renew Universal Prevest Denpro Limited            510(k) NO: K231696(Traditional) ATTN: Atul  Modi                  PHONE NO : 941___ 9194280  Unit II, Export Promotion IndustriSE DECISION MADE: 11-AUG-23 Bari Brahmana  IN 181133          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Holmium Medical Laser Allengers Global Healthcare Privat510(k) NO: K231718(Traditional) ATTN: Harpreet  Singh             PHONE NO : 91 1762 272600  Room No.5, Khasra no. 79, BhankarpSE DECISION MADE: 18-AUG-23 Derabassi, District- Mohali  IN 14510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Optional Screen Displays for HeartSee Cardiac P.E.T. Processing Software - HeartSee version 4 McGovern Medical School           510(k) NO: K231731(Traditional) ATTN: K. Lance  Gould             PHONE NO : 713 5006611  6431 Fannin Street, MSB 4.256     SE DECISION MADE: 21-AUG-23 Houston TX  77030                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: MA012 Aluminum wheelchair, MS019 steel wheelchair Sichuan AST Medical Equipment Co.,510(k) NO: K231750(Traditional) ATTN: Mae  Tse                    PHONE NO : 86 830 8130333  No.58 JinPeng Road, Area C, West ISE DECISION MADE: 15-AUG-23 Luzhou City  CN 646100            510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Stable-C Interbody System Nexus Spine, LLC                  510(k) NO: K231763(Traditional) ATTN: Jared  Crocker              PHONE NO : 801 7028592  2825 East Cottonwood Parkway SuiteSE DECISION MADE: 21-AUG-23 Salt Lake City UT  84121          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Electrosurgical Generator ESG-410 and Accessories (WA91327U, WA91327W), Accessories: Foot switches (WA91311W, WA91321W) Olympus Winter & Ibe GmbH         510(k) NO: K231777(Traditional) ATTN: Ian  Pericevic              PHONE NO : 49 40 669660  Kuehnstrasse 61                   SE DECISION MADE: 18-AUG-23 Hamburg  DE 22045                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: primaLOK™ SP Interspinous Fusion System Wenzel Spine, Inc.                510(k) NO: K231807(Traditional) ATTN: William  Wilson             PHONE NO : 512 4690600  1130 Rutherford Lane, Suite 200   SE DECISION MADE: 15-AUG-23 Austin TX  78753                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Zavation Connector System Zavation Medical Products, LLC    510(k) NO: K231811(Traditional) ATTN: Noah  Slack                 PHONE NO : 601 9191119  3670 Flowood Dr.                  SE DECISION MADE: 22-AUG-23 Flowood MS  39232                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: NOxBOXi Nitric Oxide Delivery System Linde Gas & Equipment Inc.        510(k) NO: K231823(Special) ATTN: Dave  Loflin                PHONE NO : 412 8743315  208 W Main St.                    SE DECISION MADE: 11-AUG-23 Livingston TN  38570              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Xenix Medical Sacroiliac Fixation System HT Medical d.b.a. Xenix Medical   510(k) NO: K231829(Traditional) ATTN: Teresa  Cherry              PHONE NO : 888 5948633  111 W Jefferson St., Suite 100    SE DECISION MADE: 15-AUG-23 Orlando FL  32801                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: TiLink-L Joint Fusion System SurGenTec                         510(k) NO: K231831(Special) ATTN: Andrew  Shoup               PHONE NO : 561 9907882  911 Clint Moore Rd                SE DECISION MADE: 03-AUG-23 Boca Raton FL  33487              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: RxSight® Insertion Device (63002) RxSight, Inc.                     510(k) NO: K231838(Traditional) ATTN: Maureen  OConnell           PHONE NO : 978 2071245___  100 Columbia                      SE DECISION MADE: 15-AUG-23 Aliso Viejo CA  92656             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Arthrex TightRope II Arthrex Inc.                      510(k) NO: K231857(Traditional) ATTN: Kristi  Frisch              PHONE NO : 1 239 5984302 73849 1370 Creekside Boulevard          SE DECISION MADE: 08-AUG-23 Naples FL  34108-1945             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Grappler Suture Anchor System Paragon 28, Inc.                  510(k) NO: K231867(Traditional) ATTN: Edward  Wells-Spicer        PHONE NO : 585 4552810  14445 Grasslands Dr               SE DECISION MADE: 21-AUG-23 Englewood CO  80112               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Polaris Bipolar Electrosurgical Generator (29-1000); Polaris Irrigation Module (29-1600); Polaris Light Source Module (29-1900); Dual Footswitch (29-1020) Kirwan Surgical Products LLC      510(k) NO: K231872(Traditional) ATTN: Matthew  Prario             PHONE NO : 781 8349500  180 Enterprise Drive              SE DECISION MADE: 25-AUG-23 Marshfield MA  02050              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Medline UNITE® REFLEX® Nitinol Staple System Medline Industries, LP            510(k) NO: K231885(Traditional) ATTN: Jennifer  Mason             PHONE NO : 847 6433652  Three Lakes Drive                 SE DECISION MADE: 09-AUG-23 Northfield IL  60093              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Montage-QS Settable, Resorbable Bone Putty Orthocon, Inc.                    510(k) NO: K231903(Traditional) ATTN: Aniq  Darr                  PHONE NO : 855 4759175  700 Fairfield Avenue- Suite 1     SE DECISION MADE: 25-AUG-23 Stamford CT  06902                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Electro-Spec Steri-Caps Electro-Spec, Inc                 510(k) NO: K231905(Traditional) ATTN: Jeff  Smith                 PHONE NO : 1 317 7390924  1800 Commerce Parkway             SE DECISION MADE: 14-AUG-23 Franklin IN  46131                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Mineral Collagen Composite Bioactive Extra Moldable Collagen Matrix, Inc.             510(k) NO: K231942(Special) ATTN: Victoria  Augustine         PHONE NO : 646 2229564  15 Thornton Rd.                   SE DECISION MADE: 02-AUG-23 Oakland NJ  07436                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: CATAMARAN SI Joint Fusion System Tenon Medical, Inc.               510(k) NO: K231944(Traditional) ATTN: Susan  Noreiga              PHONE NO : 650 7931966  104 Cooper Court                  SE DECISION MADE: 24-AUG-23 Los Gatos CA  95032               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Aristotle 18 Guidewire; Aristotle 24 Guidewire Scientia Vascular, Inc.           510(k) NO: K231954(Special) ATTN: Bailey  Johannsen           PHONE NO : 888 3859016  2460 S 3270 W                     SE DECISION MADE: 01-AUG-23 West Valley City UT  84119        510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: EXPD 4357; EXPD 4357P DRTECH Corporation                510(k) NO: K231959(Special) ATTN: Lee  Youna                  PHONE NO : 82 31 7797710  Suite No.1, 2 Floor/Suite No. 2, 3SE DECISION MADE: 01-AUG-23 Seongnam-si  KR 13216             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: NIBPCuff Shenzhen SINO-K Medical Technology510(k) NO: K231961(Traditional) ATTN: Lao  Chengxin               PHONE NO : 86 137 15333326  Room401,Bldg2,Veteran Ind.city,GonSE DECISION MADE: 30-AUG-23 Shenzhen  CN 518115               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: REAL INTELLIGENCE™ CORI™ Blue Belt Technologies, Inc.      510(k) NO: K231963(Special) ATTN: Corrine  Herlinger          PHONE NO : 412 5526428  2875 Railroad Street              SE DECISION MADE: 01-AUG-23 Pittsburgh PA  15222              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: BioSieve™ Marijuana Test Panel 50; BioSieve™ Marijuana Test Strip 50; BioSieve™ Dx Marijuana Test Strip 20; BioSieve™ Dx Marijuana Test Strip 50; BioSieve™ Dx Marijuana Test Panel 20; BioSieve™ Dx Marijuana Test Panel 50 VivaChek Biotech (Hangzhou) Co., L510(k) NO: K231978(Traditional) ATTN: Jessica  Chen               PHONE NO : 86 182 57349413  Floor 2, Block 2, 146 East ChaofenSE DECISION MADE: 31-AUG-23 Hangzhou  CN 311100               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sensititre 20-24-hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System with Dalbavancin in the dilution range of 0.0005-2µg/ml Thermo Fisher Scientific          510(k) NO: K231988(Traditional) ATTN: Joel  Mathew                PHONE NO : 978 9074417  One Thermo Fisher Way             SE DECISION MADE: 30-AUG-23 Oakwood Village OH  44146         510(k) STATEMENT                                                       DEVICE: Sensititre 18-24 hour MIC or Breakpoint Susceptibility System with Sulbactam-durlobactam in the dilution range of 0.015/4-32/4 ug/mL Thermo Fisher Scientific          510(k) NO: K231994(Traditional) ATTN: Cynthia  Knapp              PHONE NO : 1 216 2122844  One Thermo Fisher Way             SE DECISION MADE: 25-AUG-23 Oakwood Village OH  44146         510(k) STATEMENT                                                       DEVICE: HEALICOIL PK Suture Anchor with Needles, ULTRATAPE (Blue); HEALICOIL PK Suture Anchor with Needles, ULTRATAPE (Blue Cobraid) Smith & Nephew, Inc.              510(k) NO: K232005(Special) ATTN: Camille  Fleischer          PHONE NO : 978 7491057  150 Minuteman Road                SE DECISION MADE: 04-AUG-23 Andover MA  01810                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: LEGACY®  IPC IG Technology Ltd                 510(k) NO: K232006(Third Party - Traditional) ATTN: Ivan  Green                 PHONE NO : 440 7770 386797  Wylcut House, 316 Petre St        SE DECISION MADE: 04-AUG-23 Sheffield  GB S33 0AW             510(k) STATEMENT                                   THIRD PARTY REVIEW  DEVICE: Disposable Medical Examination Nitrile Gloves Raxwell Industrial LLC            510(k) NO: K232008(Third Party - Traditional) ATTN: Xianda  Yao                 PHONE NO : 1 765 4300178___  20323 Bristol Bluff Ln            SE DECISION MADE: 08-AUG-23 Richmond TX  77407                510(k) SUMMARY AVAILABLE FROM FDA                                   THIRD PARTY REVIEW  DEVICE: iTEMPSHIELD AION Biosystems Inc.              510(k) NO: K232010(Third Party - Traditional) ATTN: Joseph  Azary               PHONE NO : 203 2426670  12 Plymouth Road                  SE DECISION MADE: 04-AUG-23 Darien CT  06820                  510(k) SUMMARY AVAILABLE FROM FDA                                   THIRD PARTY REVIEW  DEVICE: ATMOS Scope (507.7000.0); ATMOS Scope Pro (507.7050.0); ATMOS Scope iPrime (507.7060.0) ATMOS MedizinTechnik GmbH & Co. KG510(k) NO: K232015(Traditional) ATTN: Reinhold  Storch            PHONE NO : 49 7653 689647  Ludwig-Kegel-Str. 16              SE DECISION MADE: 03-AUG-23 Lenzkirch  DE 79853               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Ingenia Elition R5.7.1 SP4 MR Systems Philips Medical Systems Nederland 510(k) NO: K232030(Special) ATTN: Ioana  Ulea                 PHONE NO : 31 618 345875  Veenpluis 6                       SE DECISION MADE: 02-AUG-23 Best  NL 5684PC                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sterile Powder Free Nitrile Examination Gloves (Blue), Tested for Use with Chemotherapy Drugs and Fentanyl Citrate Grand Work Plastic Products Co., L510(k) NO: K232039(Special) ATTN: Wu  Yuli                    PHONE NO : 86 311 66179668  Donggao Industrial Zone           SE DECISION MADE: 09-AUG-23 Zanhuang  CN 050000               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Ceribell Instant EEG Headband Ceribell, Inc.                    510(k) NO: K232052(Special) ATTN: Raymond  Woo                PHONE NO : 650 5564349  360 North Pastoria Avenue         SE DECISION MADE: 08-AUG-23 Sunnyvale CA  94085               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: YosemiteView 4343W/YosemiteView 3643W CareRay Digital Medical Technology510(k) NO: K232058(Special) ATTN: Xu  Wei                     PHONE NO : 86 512 86860288  A2-201/B3-501, Biobay,218 Xinghu SSE DECISION MADE: 03-AUG-23 Suzhou  CN 215123                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Efai Pacs Picture Archiving and Communication System Pro Ever Fortune.AI Co., Ltd.         510(k) NO: K232100(Special) ATTN: Joseph  Chang               PHONE NO : 866 4 23226363  8 F., No. 573, Sec. 2, Taiwan BlvdSE DECISION MADE: 08-AUG-23 Taichung City  TW 403020          510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: CoreLink Navigation Instruments CoreLink, LLC                     510(k) NO: K232116(Special) ATTN: Steven  Mounts              PHONE NO : 888 3497808___  2072 Fenton Logistics Park        SE DECISION MADE: 16-AUG-23 St. Louis MO  63026               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: EEA™Circular Stapler with Tri-Staple™ Technology and OrVil™ Transoral Circular Stapler Anvil Covidien                          510(k) NO: K232126(Special) ATTN: Helen  Chen                 PHONE NO : 86 21 33230135  Room 501, 502, 601, 602, No. 3 BuiSE DECISION MADE: 16-AUG-23 Min Hang District, Shanghai  CN 20510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: 21HQ513D, 32HL512D, 31HN713D, 32HQ713D LG Electronics Inc.               510(k) NO: K232127(Special) ATTN: Daseul  An                  PHONE NO : 82 31 80665641  168, Suchul-daero                 SE DECISION MADE: 15-AUG-23 Gumi-si  KR 39368                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: LifeSPARC System CardiacAssist, Inc.               510(k) NO: K232132(Special) ATTN: Arielle  Drummond           PHONE NO : 412 8899021  620 Alpha Drive                   SE DECISION MADE: 03-AUG-23 Pittsburgh PA  15238              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: CD Horizon ModuLeX FNS Screw Set (Fenestrated Screw); CD Horizon ModuLeX Spinal System (Modular Extended Tab Head) Medtronic Sofamor Danek USA, Inc. 510(k) NO: K232141(Special) ATTN: Kelly  McDonnell            PHONE NO : 1 651 2699806  1800 Pyramid Place                SE DECISION MADE: 16-AUG-23 Memphis TN  38132                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Sterile Products of the APTUS System Medartis AG                       510(k) NO: K232144(Special) ATTN: Claudia  De Santis          PHONE NO : 41 61 6333434  Hochbergerstrasse 60E             SE DECISION MADE: 18-AUG-23 Basel  CH 4057                    510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ZSFab Cervical Interbody System ZSFab Inc.                        510(k) NO: K232150(Special) ATTN: Xuewei  Ma                  PHONE NO : 617 4688665  96 Clematis Ave, Suite 2F         SE DECISION MADE: 18-AUG-23 Walthan MA  02453                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Avéli Revelle Aesthetics, Inc.          510(k) NO: K232153(Special) ATTN: Melissa  Viotti             PHONE NO : 650 3365985  2570 W El Camino Real, Suite 310  SE DECISION MADE: 18-AUG-23 Mountain View CA  94040           510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Connected OR Hub with Device and Voice Control, SDC4K Information Management System with Device and Voice Control Stryker Corporation               510(k) NO: K232157(Special) ATTN: Janki  Bhatt                PHONE NO : 669 2153045  5900 Optical Ct                   SE DECISION MADE: 18-AUG-23 San Jose CA  95138                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Autotome Pro RX 39 Sphincterotome; Autotome Pro RX 44 Sphincterotome; Jagtome Pro RX 44 Sphincterotome; Jagtome Pro RX 39 Sphincterotome; Dreamtome Pro RX 44 Sphincterotome; Hydratome Pro RX 44 Sphincterotome; Jagtome Revolution Pro RX 39 Sphincterotome Boston Scientific Corporation     510(k) NO: K232162(Special) ATTN: Stephanie  Gorman           PHONE NO : 508 3820441  100 Boston Scientific Way         SE DECISION MADE: 14-AUG-23 Marlborough MA  01752             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: SM-IV Sedecal SA                        510(k) NO: K232185(Special) ATTN: Mª Luisa Gómez  de Agüero   PHONE NO : 34 91 6280544  C/ Pelaya, 9 - 13 Pol. Ind. Río DeSE DECISION MADE: 21-AUG-23 Algete  ES 28110                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: 6F Sherpa NX Balanced Guide Catheter, 7F Sherpa NX Balanced Guide Catheter Medtronic Vascular                510(k) NO: K232190(Special) ATTN: Colleen  Gentile            PHONE NO : 1 508 8436178  37A Cherry Hill Drive             SE DECISION MADE: 22-AUG-23 Danvers MA  01923                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: OMNI Surgical System Sight Sciences Inc.,              510(k) NO: K232214(Special) ATTN: Ranjani  Madhavan           PHONE NO : 737 2470998  4040 Campbell Ave, Suite 100      SE DECISION MADE: 25-AUG-23 Menlo Park CA  94025              510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Quantra Hemostasis Analyzer HemoSonics, LLC                   510(k) NO: K232215(Special) ATTN: Debbie  Winegar             PHONE NO : 919 2446990  4020 Stirrup Creek Drive, Suite 10SE DECISION MADE: 24-AUG-23 Durham NC  27703                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Zenius™ Spinal System Medyssey USA, Inc.                510(k) NO: K232218(Special) ATTN: Youngsu  Jang               PHONE NO : 847 4270200  43176 Business Park Dr Ste 107    SE DECISION MADE: 24-AUG-23 Temecula CA  92590                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: ARROW Off-Centred Humeral Insert FH Industrie                      510(k) NO: K232226(Special) ATTN: Naoual  Rahimi              PHONE NO : 33 02 56102046  6 rue Nobel, Zi De Kernevez       SE DECISION MADE: 29-AUG-23 Quimper  FR 29000                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: EVO 700 series high speed handpiece Ttbio Corp.                       510(k) NO: K232243(Special) ATTN: Sheng-Chieh  Su             PHONE NO : 886 4 23595958  2F., No.7, 6th Road Industry Park SE DECISION MADE: 23-AUG-23 Taichung  CN 40755                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: RAYSCAN a-Expert3D Ray Co., Ltd.                     510(k) NO: K232287(Special) ATTN: Sooji  Huh                  PHONE NO : 82 605 1000  1F~3F, 4F(Part), 5F, 265, Daeji-RoSE DECISION MADE: 31-AUG-23 Yongin-si  KR 16882               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Essenz HLM, Essenz ILBM LivaNova Deutschland GmbH         510(k) NO: K232291(Special) ATTN: Florian  Goetz              PHONE NO : 49 89 32301236  Lindberghstr. 25                  SE DECISION MADE: 24-AUG-23 Munich  DE 80939                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: LAA Exclusion System Syntheon, LLC                     510(k) NO: K232295(Special) ATTN: Toygar  Unal                PHONE NO : 973 9978532  13755 SW 119 Avenue               SE DECISION MADE: 30-AUG-23 Miami FL  33186                   510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: LnK Spinal Fixation System /OpenLoc-L Spinal Fixation System, AccelFix Spinal Fixation System L&K Biomed Co., Ltd.              510(k) NO: K232311(Special) ATTN: Katherine  Kim              PHONE NO : 82 10 54770325  #101, 201, 202 16-25, DongbaekjungSE DECISION MADE: 14-AUG-23 Yongin-si  KR 17015               510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: LIGACLIP Endoscopic Rotating Multiple Clip Applier 12mm L (ER420); LIGACLIP Endoscopic Rotating Multiple Clip Applier 10mm M/L (ER320) Ethicon Endo Surgery, LLC.        510(k) NO: K232313(Special) ATTN: Lakrisha  Tinner            PHONE NO : 517 3377475  475 Calle C                       SE DECISION MADE: 29-AUG-23 Guaynabo  PR 00969                510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: StealthFix Intraosseous Fixation System Medartis Inc.                     510(k) NO: K232324(Special) ATTN: Chelsea  Kozior             PHONE NO : 610 7318650  1195 Polk Drive                   SE DECISION MADE: 30-AUG-23 Warsaw IN  46582                  510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: AC3™ Series IABP Arrow International, LLC          510(k) NO: K232343(Special) ATTN: Sheila  Payzant             PHONE NO : 763 6564290  3015 Carrington Mill Blvd         SE DECISION MADE: 30-AUG-23 Morrisville NC  27560             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Powder Free Nitrile Examination Gloves (Black) Shanxi Hongjin Plastic Technology 510(k) NO: K232353(Special) ATTN: Wu  Zhigang                 PHONE NO : 86 311 66179668  Coal Bed Gas Industrial Zone, Qu'eSE DECISION MADE: 31-AUG-23 Linfen  CN 042300                 510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: Treace Medical Concepts (TMC) Compression Implant System Treace Medical Concepts           510(k) NO: K232387(Special) ATTN: Brittany  Grochala          PHONE NO : 515 8650494  100 Palmetto Park Place           SE DECISION MADE: 28-AUG-23 Ponte Vedra FL  32081             510(k) SUMMARY AVAILABLE FROM FDA                                                       DEVICE: UltraSeal XT plus - Bioprotection by Nobio, UltraSeal XT hydro - Bioprotection by Nobio Ultradent Product, Inc.           510(k) NO: K232498(Third Party - Traditional) ATTN: Ruth  Gardner               PHONE NO : 801 5534431  505 West Ultradent Drive (10200 SoSE DECISION MADE: 18-AUG-23 South Jordan UT  84095            510(k) SUMMARY AVAILABLE FROM FDA                                   THIRD PARTY REVIEW                 TOTAL 510(k)s THIS PERIOD   310                                                     TOTAL WITH SUMMARIES        289                                                     TOTAL WITH STATEMENTS        21                                        

Short Title
August 2023 510(K) Clearances

Source Organization

Short Description
August 2023 510(K) Clearances

Publish Date
Wed, 09/06/2023 – 10:58

Review Date
Fri, 09/06/2024 – 00:00

Last Reviewed Date
Wed, 09/06/2023 – 00:00

Site Structure

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Wed, 09/06/2023 – 10:00

Generic Boolean
Off

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/medical-devices/510k-clearances/august-2023-510k-clearances September 6, 2023 2:00 pm

Marijuana or Cannabis

Marijuana or Cannabis

What do we call the drug?

Here’s the first jurisdiction to tax our subject:

British Indian colonizers used “hemp drugs” generally, ganja and bhang and more for different products, cannabis rarely, and only for the plant (marijuana not at all): 

https://digital.nls.uk/indiapapers/browse/archive/74574106

https://nida.nih.gov/publications/drugfacts/cannabis-marijuana:

Marijuana refers to the dried leaves, flowers, stems, and seeds from the Cannabis sativa or Cannabis indica plant.

https://www.dea.gov/sites/default/files/2020-06/Marijuana-Cannabis-2020_0.pdf:

Marijuana is a mind-altering (psychoactive)
drug, produced by the Cannabis sativa plant. 

Beyond official federal sources, there are lots of opinions.  I googled marijuana or cannabis – and I may slant what I found toward marijuana.

https://www.theguardian.com/society/2018/jan/29/marijuana-name-cannabis-racism:

Harborside, which is among the oldest and largest dispensaries in California, says on its website: “‘Marijuana’ has come to be associated with the idea that cannabis is a dangerous and addictive intoxicant, not a holistic, herbal medicine … This stigma has played a big part in stymying cannabis legalization efforts throughout the US.”

It’s clear why a business like Harborside would prefer the more scientific word for branding purposes, but does that mean everyone should follow along?

https://www.leafly.com/news/politics/is-the-word-marijuana-racist:

(I know the author, who is at the top of hemp drug journalism — I recommend the whold article)

Queen Adesuyi, senior national policy manager for the Drug Policy Alliance, brought up another aspect of marijuana usage. That is: Labeling marijuana as racist or offensive may alienate many of the people most connected to the plant—and those disproportionately targeted by the War on Drugs.

“The word cannabis is very disconnected to most communities,” she said. “Your average person does not refer to the plant as cannabis.”

“As we’re working to advance legalization across the country, what we don’t want is a complete whitewashing of the history of marijuana criminalization and the impact that’s had on people of color,” Adesuyi added. “This is something we’re seeing the industry do. There’s an active attempt to revamp what the plant means, and who it represents.”

“When you think about ‘the new face of cannabis’” presented by some companies, she said, “it oftentimes is not in alignment with [those most affected by] the stigmatized and criminalized history of the plant.”

There’s also the question of political focus and wasted resources. “It’s important to lead the public discussion about the terms we use,” said Calvin Stovall, Leafly’s East Coast editor, “but I don’t think it’s productive to police how consumers or other members of the industry use the word marijuana.

“I’d rather see us direct our collective energy at the institutional level—to change the laws that are racist and offensive. Forcing people to take a political stance by only saying cannabis and never marijuana creates a dynamic where the legalization community gets caught up arguing among ourselves about terminology.”

Decision time in Word Court

After weeks of conversation and rumination, I find myself disagreeing with Rep. Melanie Morgan.

Let me say it clearly: Marijuana is not pejorative or racist.

The impulse that drove Morgan to change the language of Washington State law wasn’t unfounded, though. It’s time to update the legal conversation to cannabis. But Morgan’s diagnosis was imprecise and too simplistic. Marijuana is a problematic, complicated word with a problematic, complicated history. In the year 2022 it exists in a state of flux, loathed by some while used without malice by many.

Thriving in the cannabis world requires flexibility and quick adaptive reflexes. The language we use reflects that. We’re constantly reading the room to determine the appropriate verbiage. Mostly it’s cannabis or marijuana, but now and then it’s weed and sometimes it’s pot. Sometimes it can feel like living in a Key & Peele code-switch sketch.

That’s my answer today. Stay tuned. It’ll probably change, because language never stops evolving and neither should we.

https://www.kuow.org/stories/stop-using-the-word-marijuana-some-lawmakers-think-so:

Stop saying ‘marijuana’? Lawmakers say it’s racist

David Hyde

March 31, 2022 / 11:55 am

caption: Chelsea Stenson trims marijuana buds before packaging  on Wednesday, July 18, 2018, at House of Cultivar in Seattle.

Chelsea Stenson trims marijuana buds before packaging on Wednesday, July 18, 2018, at House of Cultivar in Seattle. 

KUOW Photo/Megan Farmer

PLAYING5 MINS LEFT

Gov. Jay Inslee recently signed a bill striking the word “marijuana” from the text of all state law. The measure says to use the word “cannabis” instead.

The effort in Washington is part of a national movement to retire the word.

Washington Democrat Melanie Morgan, who sponsored the bill in the state House, calls the word marijuana “pejorative and racist.” Morgan said replacing it is merely one way to create change.

Some cannabis retailers and industry trade groups have stopped using the word. Earlier this year, Maine and Virginia also introduced bills about striking the word marijuana from their laws.

Recreational weed is now legal in these states. But lawmakers are seeking to address the ways that decades of anti-drug policies continue to affect communities of color. For instance, arrests and incarceration for drug crimes have hit Black and Latino communities hardest. Arrests can make it harder to find a job, buy a home and build generational wealth.

“This is just another layer, of peeling off the systemic racism that’s built in our system,” Morgan said of the effort to retire the word marijuana.

But some historians are raising concerns about this effort. They say those who support it are leaning too heavily on a version of cannabis history that’s seeped into popular culture. They say that Morgan and other reformers who point to racist usage of the word have based that assessment on an incomplete reading of cannabis history.

The marijuana story

Historians note that “marijuana” was the word most people in Mexico used for the drug cannabis by the 19th century. Here in the U.S., by the 1920s and ’30s, anti-drug crusaders spread false claims about the effects of smoking marijuana. The 1936 movie “Reefer Madness” famously repeated this misinformation, claiming weed-smoking led to murder, suicide and insanity.

 Anti-drug activists often used the word marijuana in a negative way, and the media and government officials also turned it against people of color, including Mexican immigrants and jazz musicians. Then, in 1937, the federal government outlawed the drug.

That popularized narrative is part of why many now say the word marijuana should be retired. But historians KUOW spoke with believe the popular version of cannabis history is incomplete, and ultimately inaccurate.

“The idea that the word marijuana is racist, I just think it’s nonsense. Marijuana is just the Mexican word for drug cannabis,” said Isaac Campos, a professor of Latin American history who has studied the story of weed.

The making of a myth

Campos said stories about smoking marijuana leading to madness and violence didn’t originate in the U.S. They were first printed in Mexican newspapers, and it was the Mexican government that ended up outlawing the drug first — nearly 20 years before the U.S. did.

U.S. media reprinted anti-weed stories from the Mexican press. And as immigrants moved north, many carried negative stories about marijuana with them.

According to Campos, the more complete story of the word marijuana is a story about the influence of Mexican culture. He believes banning the word would erase that history.

Campos doesn’t deny that racists have sometimes used the word marijuana in a pejorative way. But he argues many other words, such as “salsa,” have also been used in racist ways without anyone calling for their retirement.

“The way we use the word marijuana in the United States is not unlike the way we use the word salsa in the United States. Salsa in Mexico just means ‘sauce.’ It’s any kind of sauce — it could be a Hollandaise sauce — it’s not necessarily what we call salsa in this country. 

“But the fact that we use it for a certain kind of Mexican sauce that goes on tacos just shows that Mexican cuisine has had a huge influence in this country,” Campos said.

Another cannabis historian, Adam Rathge, said something else is missing from pop-culture histories of weed. Long before anyone in the U.S. linked Mexican immigrants with the word marijuana, doctors and lawmakers in America were raising concerns about consuming cannabis.

“If you read 19th century medical journals or if you go look at laws that are passed in the 19th century, at the state level, there’s immediate concern by American physicians about the potential negative effects of cannabis,” Rathge said.

But that story was forgotten. In its place, by the 1980s, the cannabis legalization movement instead preferred a partially made-up narrative, based largely on an influential book written by a pot legalization activist named Jack Herer, who claimed America had a simple love affair with hemp and cannabis before racist prohibition began.

The film “Dazed and Confused” satirized this version of history, with tales of George Washington smoking weed with Martha Washington’s assistance, back when the “whole country” was supposedly “getting high.”

 For her part, Rep. Melanie Morgan stands by the new measure nixing the word marijuana from state law. But she also said she welcomes more information and debate about the linguistic history of the word.

“I’m glad that this is causing conversations, because what this is doing is actually opening the door to bigger issues,” Morgan said.

Morgan pointed to other bills to address structural racism that did not pass this legislative session, including an attempt to increase the number of cannabis businesses licenses that go to communities most affected by the war on drugs, and a bill she sponsored to address racial, economic and social disparities.

The measure striking the word marijuana from Washington state law starts to go into effect this coming June.


#CBD #Hemp

Marijuana or Cannabis


August 28, 2023 10:58 pm

Who should get a license to sell cannabis? 

Who should get a license to sell cannabis? 

Here’s a list of cannabis supply architecture models that say what private sellers can get licenses.  Maybe others have been used.  (Jurisdictions listed are just examples, not exhaustive.)

All comers (Oklahoma with $2,500 fee)

All comers with significant fees (Doesn’t some state do that?)

All comers at the state level with local license needed (Colorado, California)

First-come first-served (Los Angeles for retail; no state starts with this, but moratoria in Oklahoma and Oregon transmute “All comers” into FCFS when licensing stops)

Grandfather existing medical marijuana sellers (lots of states)

Lottery for all applicants who meet certain criteria (Washington, https://www.pbs.org/newshour/health/medical-marijuana-licensing-states))

Lottery for all comers (“Arizona doesn’t analyze business proposals the way other states do.  https://www.pbs.org/newshour/health/medical-marijuana-licensing-states)

Lottery for social equity applicants with post-drawing verification of status (Illinois, https://www.illinois.gov/news/press-release.26715.html; Connecticut, https://portal.ct.gov/cannabis/knowledge-base/articles/how-does-the-lottery-work?language=en_US)

Lottery for social equity applicants with pre-drawing verification of status (Maryland, I think, https://www.cannabisindustrylawyer.com/maryland-social-equity-cannabis-lottery-licenses/)

On the merits – competitive licensing (Georgia, Florida)

On the merits — social equity licensing (New York)

Auctions (British India) 


#CBD #Hemp

Who should get a license to sell cannabis? 


August 20, 2023 9:42 pm

In North Carolina, the Left and the Right oppose casinos and medical marijuana cartels.

In North Carolina, the Left and the Right oppose casinos and medical marijuana cartels.

They also oppose having some state body in charge of somehow choosing a handful of medical marijuana sellers that will cartelize the market.

https://reason.org/commentary/north-carolina-house-medical-marijuana-bill/


#CBD #Hemp

In North Carolina, the Left and the Right oppose casinos and medical marijuana cartels.


August 11, 2023 3:05 pm

Cannabis Legalization at UVA Law School

Cannabis Legalization at UVA Law School

University of Virginia Law School Professor Kim Krawiec, who had me talk to her class at when she taught at Duke, asked me to help her teach a class on cannabis legalization this fall.  I was delighted to sign up to in person in Charlottesville for four Fridays.

https://www.law.virginia.edu/courses/cannabis-legalization-sc-123820664

Cannabis Legalization (SC)

LAW7724

Section 1, Fall 23

Krawiec, Kimberly D. 

Oglesby, Pat 

SCHEDULE INFORMATION

Enrollment: 16/16

Credits: 1

Days Date Time Room
Fri 09/08/2023 0900-1200 WB127
Fri 09/29/2023 0900-1200 WB127
Fri 10/20/2023 0900-1200 WB127
Fri 11/10/2023 0900-1200 WB127

COURSE DESCRIPTION

This short course will examine various cannabis legalization regimes, both domestically and internationally, with a focus on the market and financial aspects of legalization. Specifically, we will consider license allocation methods, taxation, racial equity, reparative justice for casualties of the war on drugs, and the continuing existence of illegal transactions after commercial legalization.

COURSE REQUIREMENTS

WRITTEN WORK PRODUCT

Students will be required to upload a final paper to EXPO by noon on Nov 24th. 2500 words maximum. That’s about five single-spaced or ten double-spaced pages. You’ll be able to choose among a variety of topics on implementation and regulation of cannabis commerce

OTHER COURSE DETAILS

Prerequisites: None Concurrencies: None

Exclusive With: None

Laptops Allowed: Yes

First Day Attendance Required: Yes

Course Resources: To be announced.

GRADUATION REQUIREMENTS

Satisfies Understanding Bias/Racism/Cross-Cultural Competency requirement: Yes

Satisfies Writing Requirement: No

Credits For Prof. Skills Requirement: No

Satisfies Professional Ethics: No

ADDITIONAL COURSE INFORMATION

Schedule No.: 123820664

Modified Type: ABA Seminar

Cross Listed: No

Concentrations: Health Law  , Public Policy and Regulation  , Tax Law

Evaluation Portal Via LawWeb Opens: Thursday, November 02, 08:01 PM

Evaluation Portal Via LawWeb Closes: Sunday, November 12, 11:59 PM


#CBD #Hemp

Cannabis Legalization at UVA Law School


August 8, 2023 2:38 pm

La FDA y la FTC advierten a seis compañías por vender ilegalmente imitaciones de productos alimenticios que contienen Delta-8 THC

La FDA y la FTC advierten a seis compañías por vender ilegalmente imitaciones de productos alimenticios que contienen Delta-8 THC La FDA y la FTC advierten a seis compañías por vender ilegalmente imitaciones de productos alimenticios que contienen Delta-8 THC Anonymous (not verified) Thu, 07/06/2023 – 10:08

Short Title
La FDA y la FTC advierten a las compañías por vender ilegalmente imita

FDA Statement
No

Press Release Date
July 05, 2023

Detailed Description
La FDA y la FTC emitieron cartas de advertencia a seis compañías por vender ilegalmente imitaciones de productos alimenticios que contienen Delta-8 THC en violación de la Ley Federal de Alimentos, Medicamentos y Cosméticos (FD&C Act, por sus siglas en inglés).

Short Description
La FDA y la FTC emitieron cartas de advertencia a seis compañías por vender ilegalmente imitaciones de productos alimenticios

Body

English

Hoy, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) y la Comisión Federal de Comercio (FTC, por sus siglas en inglés) emitieron cartas de advertencia a seis compañías por vender ilegalmente imitaciones de productos alimenticios que contienen tetrahidrocannabinol Delta-8, también conocido como Delta-8 THC. Estos productos pueden confundirse fácilmente con alimentos tradicionales como papas fritas, galletas, dulces, gomitas u otros refrigerios. A la FDA le preocupa que los consumidores, incluidos los niños, puedan ingerir accidentalmente estos productos o que los tomen en dosis superiores a las previstas. Las cartas de advertencia se emitieron a: Delta Munchies, Dr. Smoke LLC (también conocida como Dr. S LLC), Exclusive Hemp Farms/Oshipt, Nikte’s Wholesale LLC, North Carolina Hemp Exchange LLC y The Haunted Vapor Room.

“Los niños son más vulnerables que los adultos a los efectos del THC, y muchos de ellos se han enfermo e incluso han sido hospitalizados después de comer “productos comestibles” que lo contienen. Es por eso que emitimos advertencias a varias compañías que venden imitaciones de productos alimenticios que contienen Delta-8 THC, que pueden confundirse fácilmente con alimentos populares que son atractivos para los niños y pueden hacer que un niño pequeño lo ingiera en dosis muy altas sin darse cuenta”, declaró la Comisionada Principal Adjunta de la FDA, Dra. Janet Woodcock, “Los productos contra los que advertimos imitan de manera intencional marcas conocidas de refrigerios al usar nombres de marcas, logotipos o imágenes similares en el envase, que los consumidores, especialmente los niños, pueden confundir con refrigerios tradicionales. También nos preocupa que los adultos puedan consumirlos de manera involuntaria o consumir una dosis más alta de la prevista y sufrir consecuencias graves. Este riesgo es especialmente peligroso para aquellas personas que conducen, trabajan o tienen otras responsabilidades. La FDA mantiene su compromiso de tomar medidas contra cualquier compañía que venda de manera ilegal productos regulados que puedan representar un riesgo para la salud pública”.

Delta-8 THC es una sustancia que se encuentra en la planta de Cannabis sativa, de la cual la marihuana y el cáñamo son dos variedades. Tiene efectos psicoactivos e intoxicantes que pueden ser peligrosos para los consumidores y no ha sido evaluado ni aprobado por la FDA para su uso seguro en ningún contexto, incluso cuando se agrega a los alimentos. La FDA ha recibido informes de efectos adversos graves experimentados por personas que han consumido estos productos, como alucinaciones, vómitos, temblores, ansiedad, mareos, confusión y pérdida del conocimiento. A la FDA también le preocupa que las compañías estén produciendo Delta-8 THC de maneras que podrían resultar en productos con contaminantes dañinos. 

“La comercialización de productos comestibles con THC que los niños pueden confundir fácilmente con alimentos regulares es imprudente e ilegal”, declaró Samuel Levine, Director de la Oficina de Protección al Consumidor de la FTC. “Las compañías deben asegurarse de que sus productos se comercialicen de manera segura y responsable, especialmente cuando se trata de proteger el bienestar de los niños”.

En junio de 2022, la FDA advirtió a los consumidores sobre el consumo de productos alimenticios que contenían Delta-8 THC. Como se indicó en la advertencia, la agencia recibió más de 125 reportes sobre efectos adversos desde el 1 de enero de 2021 hasta el 31 de mayo de 2022, relacionados con niños y adultos que consumieron productos comestibles que contenían Delta-8 THC. Diez de los informes mencionan específicamente que el producto comestible es una imitación de los refrigerios populares.

Si un consumidor cree que un producto podría haber provocado una reacción o una enfermedad, debe dejar de usar el producto de inmediato y comunicarse con su proveedor de atención médica. La FDA también alienta a los proveedores de atención médica y a los consumidores a informar las reacciones adversas asociadas con los productos regulados por la FDA a la agencia mediante MedWatch o el Portal de informes de seguridad.

Estas cartas de advertencia describen violaciones de la Ley Federal de Alimentos, Medicamentos y Cosméticos relacionadas con la adición de Delta-8 THC a los alimentos convencionales. La FDA ha solicitado respuestas por escrito de las seis compañías que recibieron cartas de advertencia en un plazo de 15 días hábiles en las que se indica cómo abordarán estas violaciones y evitarán que vuelvan a ocurrir. Si no se abordan de inmediato las violaciones, se pueden iniciar acciones legales, incluidas incautaciones de productos y/o medidas cautelares.

Content Owner

Publish Date
Thu, 07/06/2023 – 10:20

Review Date
Sat, 07/06/2024 – 10:00

Last Reviewed Date
Thu, 07/06/2023 – 10:00

Site Structure

Next Review Date
1 Year

Source Organization

Bulk Approved
Off

Hide main image
hide

Display Short Description
Off

Regulated Product*

Language

Media Contact
Media Contact Name
Gloria Sánchez-Contreras

Media Contact Phone
301-796-7686

Media Contact Email

First Publish Date
Thu, 07/06/2023 – 10:10

Add Subscription Box
Off

Boilerplate
La FDA, una dependencia del Departamento de Salud y Servicios Sociales de los Estados Unidos, protege la salud pública asegurando la protección, eficacia y seguridad de los medicamentos tanto veterinarios como para los seres humanos, las vacunas y otros productos biológicos destinados al uso en seres humanos, así como de los dispositivos médicos. La dependencia también es responsable de la protección y seguridad de nuestro suministro nacional de alimentos, los cosméticos, los suplementos dietéticos, los productos que emiten radiación electrónica, así como de la regulación de los productos de tabaco.

Quote Attribution

Announcement Type
FDA News Release

#CBD #Hemp http://www.fda.gov/news-events/press-announcements/la-fda-y-la-ftc-advierten-seis-companias-por-vender-ilegalmente-imitaciones-de-productos July 6, 2023 2:08 pm

Medical marijuana in North Carolina op-ed

Medical marijuana in North Carolina op-ed

The Raleigh, Durham, and Charlotte papers put this op-ed below in online and print editions, https://www.newsobserver.com/opinion/article272626684.html#storylink=hpdigest_opinion; it’s been mentioned favorably by Thomas Mills’s PoliticsNC, https://www.politicsnc.com/a-week-of-bipartisan-progress-for-nc/, and featured in depth by a NC Policy Watch, https://ncpolicywatch.com/2023/03/21/north-carolina-should-learn-from-other-places-and-try-to-do-marijuana-right/ (no paywalls).

Excerpts:

The Compassionate Care Act (Senate Bill 3) would unleash the profit motive on millions of dollars’ worth of medical marijuana commerce in our state. But it’s likely to let well-funded out-of-state corporations grab the lion’s share of that money. They would then want to legalize lucrative recreational use quickly and be first in line to sell it.

While state commerce violates free market principles, SB 3’s 10 permanent licenses make for oligopoly, not market freedom. Sure, state delivery and eventually stores would take time and money to set up, but awarding licenses to private sellers “on the merits” or by lottery, SB-3-style, is a recipe for delays and litigation. Four years elapsed between the passage of a medical marijuana law and the first legal sale of medicine in West Virginia and Delaware.


#CBD #Hemp
Medical marijuana in North Carolina op-ed
March 22, 2023 2:04 pm

Social equity and state cannabis sales

Social equity and state cannabis sales

Excerpts from panel appearance of Shaleen Title of the Parabola Center for the North Carolina Department of Justice webinar in 2022.  https://www.youtube.com/watch?v=ehlLi6hlWRE, 21-minute mark:

We need to make “evidence-based decisions that are not based on fear or stigma but rather the reality of data that we have in front of us.  I also want to say you don’t have to use the same models that other states have used. You can think about fairness and equity and one thing that’s brought up a lot is the idea of potentially state regulated storesI think we are long overdue for a state to try that model. I think from a public health perspective and equity perspective it makes sense to see if they try that so I hope that is considered strongly.”

25-minute mark:

“I hope you’ll consider being the first state potentially to look at a state-run model . . . especially because we don’t have a state yet that has a successful equitable for profit model.  Maybe we will soon.  I think New York is an exciting one to look at, but we don’t have that yet.”

Here’s the Parabola Center’s story:

“Our team was the first in the nation to devise a clear path for small businesses and historically disenfranchised groups to enter the market. We are here to help create polices that reflect the needs of the millions of people who continue to form the legal cannabis movement.”


#CBD #Hemp
Social equity and state cannabis sales
March 15, 2023 4:48 pm

Excretion and residue depletion of cannabinoids in beef cattle fed hempseed cake for 111 days

Abstract
Thirty-two crossbred heifers were fed either a control diet or 20% (dry matter basis) hempseed cake in a complete ration for 111 days; of the cattle fed hempseed cake, four each were harvested with 0, 1, 4, and 8-day withdrawal periods. Urine and plasma were collected during the feeding and withdrawal periods and liver, kidney, skeletal muscle, and adipose tissue were collected at harvest. Total cannabinoid (n = 10) concentration of hempseed cake averaged 11.3 ± 11.7 mg kg−1 across the feeding period with total cannabidiol and tetrahydrocannabinol (CBD/THC) concentrations of 1.3 ± 0.8 mg kg−1. Neutral cannabinoids (cannabinol [CBN], CBD/THC, and cannabidivarin [CBDV]) were not detected in plasma or urine, but CBD/THC was measured in adipose tissue at all withdrawal periods (6.3 ± 2.1 to 10.1 ± 2.5 ng g−1). In contrast, cannabinoid acids (cannabinolic acid [CBNA], cannabidiolic acid [CBDA]/tetrahydrocannabinolic acid [THCA], cannabichromenic acid [CBCA], and cannabidivarinic acid [CBDVA]) were sporadically detected (<15 ng mL−1) in plasma and urine of cattle fed hempseed cake. Cannabinoid acids were depleted from liver by withdrawal day 4, but could still be measured (<1 ng g−1) in kidney of some animals harvested on withdrawal day 8. Assessment of human exposures to CBD/THC residues through the consumption of beef fat from animals fed hempseed cake suggests that the probability of consuming the equivalent of an acute reference dose (ARfD) is remote, even with the use of a conservative reference dose ARfD (1 μg kg−1 body weight) [60 micrograms consumed per day for a 60 kg person; 2,500 micrograms is the minimum psychoactive dose. “Hempseed cake” typically means the de-fatted presscake from oil pressing, ~40-50% protein but lower in fatty acids than the seed. THC would tend to accumulate in the oil, not so much the presscake. RR].”

See the study at: https://doi.org/10.1080/19440049.2023.2187645

CTP-Supported Tobacco Regulatory Research Projects (3-1-23 TEST)

CTP-Supported Tobacco Regulatory Research Projects (3-1-23 TEST) CTP-Supported Tobacco Regulatory Research Projects (3-1-23 TEST) Anonymous (not verified) Wed, 03/01/2023 – 10:17

Detailed Description
CTP-Supported Tobacco Regulatory Research Projects (3-1-23 TEST)

Research supported by FDA’s Center for Tobacco Products (CTP) informs regulatory and public education efforts aimed at improving the overall health of the public and may also provide data about the impact of these efforts.

Award
Date
Title /
Description
Principal
Investigator(s)
Info
04/15/2022

Systematic Identification of Cardiotoxic E-Cigarette Flavorants

The goal of this study is to examine how individual flavorants in e-cigarettes modify the effects of e-cigarette aerosol exposures on the electrical activities of the heart (i.e., cardiac electrophysiology), leading to heart arrhythmias and functional remodeling. Researchers will identify short-term and long-term effects of flavorant exposure on cardiac electrophysiology in mice by using various state-of-the-art analytical approaches. Study aims are: (1) to identify the short-term effects of flavored e-cigarette aerosol inhalation on cardiac electrophysiology; (2) to examine the direct impact of flavorants on cardiac electrophysiology by examining cardiac myocyte function; and (3) to clarify the impacts of individual flavorants on the short- and long-term impacts of e-cigarette aerosol exposures on cardiac electrophysiology, structure, and function. This study will provide new data on the cardiac toxicity of e-cigarette flavorants.

Alex Carll and Matthew Nystoriak Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01HL163818-01
Institution: University of Louisville
03/30/2022

Evaluating the Potential Impact of a Menthol Ban in Cigarettes and E-Cigarettes Among Current Menthol Smokers

The goal of this study is to model the impact of different menthol regulatory scenarios on real-world smoking behavior. Study aims are: (1) to examine the impact of banning menthol flavor in cigarettes and e-cigarettes on smoking behavior and (2) to investigate whether outcomes differ by race to understand the impact of menthol ban policies on Black (vs. non-Black) individuals, given high rates of menthol cigarette use in this population. Researchers will recruit 150 adults (ages 21+) who currently smoke menthol cigarettes and will provide them with cigarette and e-cigarette products to use for 8 weeks; subjects will be randomized to one of three study conditions in which they will receive products as follows: (1) no menthol ban (menthol cigarettes and menthol flavored e-cigarettes), (2) menthol ban on cigarettes only (non-menthol cigarettes and menthol flavored e-cigarettes), or (3) menthol ban on both cigarettes and e-cigarettes (non-menthol cigarettes and tobacco flavored e-cigarettes). A follow-up survey at 12 weeks will assess changes in the number of cigarettes smoked per day (the primary study outcome) as well as percent days smoke-free, changes in nicotine dependence, and motivation, confidence, and intention to quit smoking. Findings may inform regulatory activities related to menthol.

Krysten Bold Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01DA054993-01A1
Institution: Yale University
03/28/2022

Novel “Tobacco-Free” Oral Nicotine Pouches: The Impact of Product Features and Marketing Influences on Abuse Liability, Perceptions, and Use Behavior in Smokers and Non-Nicotine Users

A novel class of oral nicotine pouches that contain a nicotine powder instead of tobacco leaves has recently emerged; these pouches often contain non-tobacco flavors (e.g., fruit) with known appeal to youth. The goal of this study is to describe nicotine pouch product features and marketing tactics that may drive initiation and continued use among smokers and non-nicotine users, including youth. Study aims are: (1) to examine how pouch flavors and nicotine doses impact pharmacokinetics (PK), or how nicotine moves through the body, and pharmacodynamics (PD), or the effects a person feels after using a drug, in cigarette smokers; (2) to characterize nicotine pouch marketing tactics in advertisements and examine the influence of these tactics on cigarette smokers’ and youth non-nicotine users’ product perceptions; and (3) to examine how a common marketing tactic (e.g., “tobacco-free” descriptors) impacts use behaviors and PK/PD effects in cigarette smokers and non-nicotine users. To achieve Aim 1, 28 smokers (ages 21+) will use pouches of different flavors (tobacco, mint, fruit) and nicotine doses (low, high), and their own brand of cigarettes over seven laboratory sessions, and PK and PD effects (e.g., subjective abuse liability, tobacco withdrawal) will be assessed. In Aim 2, researchers will review nicotine pouch advertisements over 5 years to identify/monitor marketing tactics and examine, via web-based experiments, how common tactics influence product perceptions (i.e., perceived harm, addictiveness, appeal) and use intentions among 2,500 adult (ages 21+) cigarette smokers and 2,500 youth (ages 13-20) non-nicotine users. In Aim 3, researchers will conduct a second laboratory study with 60 smokers and 60 non-nicotine users (ages 21+) to determine how a common marketing tactic identified from the Aim 2 marketing analysis (“tobacco-free” descriptors) impacts pouch use behaviors and PK/PD effects. Findings may inform future regulatory activities related to novel oral nicotine pouches.

Tory Spindle and Meghan Moran Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01DA055962-01
Institution: Johns Hopkins University
03/22/2022

The Effect of Menthol on ENDS Users’ Dependence, Respiratory, and Toxicants Emission Outcomes

The goal of this study is to clarify how menthol affects electronic nicotine delivery system (ENDS) users’ experience and puffing patterns, which in turn affect dependence, exposure to toxicants, and clinical outcomes. In this study, 200 current/past month closed-system ENDS users (ages 21-35) will attend two laboratory sessions and use their ENDS once with menthol flavor and once with tobacco flavor. Study aims are: (1) to test the effects of menthol vs. tobacco flavor on subjective, puffing, and respiratory outcomes including pre-post-use assessment of craving, withdrawal, satisfaction, harm perception, intention to quit or use, respiratory functions, and symptoms (e.g., dry mouth, irritation, cough, palpitation, nausea); and (2) to use a smoking robot to measure the effects of menthol vs. tobacco flavor on ENDS emissions of 14 aldehydes. Findings may inform future regulatory activities related to the use of menthol flavor in ENDS.

Wasim Maziak Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01DA055937-01
Institution: Florida International University
03/18/2022

The Impact of Menthol Flavoring on Switching in Adult Menthol Smokers

More information about the impact of menthol-flavored e-cigarettes in enabling menthol cigarette smokers to switch to e-cigarettes would be useful. The goal of this study is to compare the efficacy of menthol-flavored versus tobacco-flavored e-cigarettes in facilitating switching from combustible cigarettes to e-cigarettes among adult menthol smokers. Researchers will randomize 800 menthol smokers (≥ age 21) into a 12-week trial comparing menthol-flavored and tobacco-flavored e-cigarettes, with follow-up at week 26. Study aims are: (1) to compare the effectiveness of menthol versus tobacco e-cigarettes at facilitating switching (measured by cigarette and e-cigarette use patterns) at week 12; (2) to compare tobacco harm reduction of menthol versus tobacco e-cigarettes (measured by self-reported health-related quality of life, expired carbon monoxide, respiratory measures, and blood pressure) at week 12; (3) to compare the acceptability of menthol versus tobacco e-cigarettes (measured by product use; effects on withdrawal, craving, and dependence; and subjective and sensory effects) at week 12; and (4) to examine the long-term use of menthol versus tobacco e-cigarettes at week 26. Findings may inform future regulatory activities related to menthol flavoring in e-cigarettes.

Nicole Nollen Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01DA055999-01
Institution: University of Kansas Medical Center
10/31/2021

Nicotine Flux, A Potentially Powerful Tool for Regulating Nicotine Delivery from Electronic Cigarettes: Significance of Nicotine Flux to the Rate of Nicotine Delivery and Subjective Effects

The rate at which electronic nicotine delivery systems (ENDS) emit nicotine (“nicotine flux”) can be predicted based on knowledge of a few device design and operating variables. The goal of this study is to provide empirical evidence demonstrating the relationship between nicotine flux and nicotine delivery and between nicotine flux and the physiological and subjective effects that support nicotine dependence. Study aims are: (1) to examine the relationship between nicotine flux, nicotine form, and the rate and dose of nicotine delivery, and (2) to assess the relationship between nicotine flux, nicotine form, and subjective effects. To achieve Aim 1, participants will puff on ENDS devices under conditions that differ by flux and form while arterial blood is sampled for nicotine levels; the outcome will indicate the degree to which nicotine flux and form determine the speed and dose of ENDS nicotine delivery, and thus, abuse liability. To achieve Aim 2, participants will use ENDS devices with varying nicotine fluxes and forms, and dependency measures such as urge to smoke, craving, and abstinence will be assessed; the outcome will indicate the degree to which nicotine flux/form influence subjective effects related to dependency, puffing intensity, and toxicant exposure. Findings may provide evidence for using nicotine flux to inform possible regulatory activities.

Soha Talih Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01DA052565-01A1
Institution: American University of Beirut
10/15/2021

CTP Supplement to Parent Grant: Chronic Hookah (Waterpipe) Smoking, Vascular Dysfunction, Inflammation and Oxidative Stress

As a supplement to a parent grant, this study will further examine the long-term health effects of hookah smoking by evaluating autonomic nervous system regulations of the heart and identifying additional biomarkers of harm that could be used to evaluate and monitor the effects of chronic hookah smoking on cardiovascular health. In a group of generally 34 healthy chronic hookah smokers ages 21-49 who do not smoke cigarettes — matched with 34 cigarette smokers and 34 nonsmokers — researchers will examine: (1) cardiac sympathetic nerve activity measured by heart rate variability; and (2) biological markers of inflammation and oxidative stress, including: (a) interleukin-6 and tumor necrosis factor-a; (b) free polyunsaturated fatty acids and oxidized metabolites, assessed by mass spectrometry; and (c) concentrations of glutathione, bilirubin, heme oxygenase-1, and functional activity of paraoxonase1, determined by colorimetric and enzymatic assays. Findings will provide new information about the cardiovascular effects of hookah smoking.

Mary Rezk-Hanna Funding Mechanism: National Institutes of Health – Grant
ID Number: 3R01HL152435-02S1
Institution: University of California, Los Angeles
10/12/2021

Determinants and Health Effects of Dynamic Changes in E-Cigarette use Before, During, and After Pregnancy

The goal of this secondary data analysis is to examine changes in maternal e-cigarette use before, during, and after pregnancy, determinants of these changes, and their effects on maternal and infant health. Study aims are: (1) to examine determinants of changes in e-cigarette use before, during, and after pregnancy; and (2) to assess health outcomes associated with changes in e-cigarette use (discontinuing, switching, and relapsing) before, during, and after pregnancy. Researchers will analyze data from two large U.S. national studies: the Pregnancy Risk Assessment Monitoring System (PRAMS) with N=153,336 existing mothers during 2016-2019 plus new mothers in 2020-2021, and the Population Assessment of Tobacco and Health (PATH) Study with N=4,392 existing pregnancies in waves 1-4 during 2013-2017 plus new pregnancies in wave 5 during 2018-2019 and the adult telephone survey in 2020. Potential determinants of e-cigarette use changes to be evaluated will include socio-demographics, pregnancy intention and characteristics, baseline e-cigarette use and product features, risk perception of e-cigarette use, concurrent substance use, and time of survey. Prenatal outcomes will include gestational weight gain and gestational duration. Neonatal outcomes will include small-for-gestational-age birth, mode of delivery, and length of infant hospital stay. Postpartum outcomes will include breastfeeding and postpartum depression. Findings will provide new information about changes in e-cigarette use and its effects on maternal and child health.

Xiaozhong Wen Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21DA053638-01A1
Institution: State University of New York at Buffalo
09/30/2021

Can Machine Generated Nicotine Yield Predict Human Nicotine Exposure from ENDS?

The goal of this study is to examine whether machine-generated nicotine yield from electronic nicotine delivery systems (ENDS) can predict human exposure to nicotine. Study aims are: (1) to determine whether nicotine yields generated from machine-vaped ENDS are associated with human nicotine exposure following prescribed or ad libitum ENDS use, and (2) to determine which machine-vaping regimes (e.g., CORESTA, intense, playback of human puff topography), if any, are most effective for estimating human exposure to nicotine. Researchers will also investigate how changes in ENDS nicotine yield may affect nicotine pharmacokinetics, pharmacodynamics, non-nicotine HPHC exposure, subjective effects, and puff topography. In this randomized study, 32 current ENDS users (ages 21-65) will complete four experimental visits during which they will use an ENDS containing one of four e-liquid nicotine concentrations (i.e., very low, low, medium, high) under prescribed and ad libitum use conditions; researchers will then measure nicotine pharmacokinetic parameters (e.g., maximum plasma nicotine concentration) to determine nicotine exposure and compare it to machine-generated yields. Results will help determine whether nicotine yield data can be used to estimate human exposure to nicotine from ENDS, whether these data can be used to draw inferences regarding ENDS abuse liability, and whether certain machine-puffing regimens are most suitable for estimating human nicotine exposure from ENDS.

Wallace Pickworth (CTP Contact: Marzena Hiler and Arit Harvanko) Funding Mechanism: Research Contract
ID Number: HHSF22320170040I
Institution: Battelle
09/23/2021

Strengthening Cigar Warnings to Prevent Adolescent Use

In 2016, the Food and Drug Administration (FDA) mandated six rotating text-only warning statements to be placed on little cigar and cigarillo (LCC) packaging. The goal of this study is to advance the science on LCC warnings that are effective for youth ages 15-20 who currently use, have ever used, or are susceptible to using LCCs, especially Black/African American youth. Study aims are: (1) to identify the most effective images to pair with FDA-mandated LCC text-only warning statements using a youth advisory board and a quantitative online survey delivered to 500 youth; (2) to examine whether LCC warning size (30% vs 50% on the LCC package principle display panels) and type (text-only vs. text+image) affect perceived message effectiveness of LCC warnings among an online sample of 500 youth; and (3) to conduct a randomized controlled trial with 900 youth to test whether the most effective LCC warnings from Aim 2 reduce willingness to use LCCs (compared to the text-only 30% size FDA-mandated LCC warnings and a control condition). Findings may inform regulatory activities related to LCC warnings.

Leah Ranney and Jennifer Cornacchione Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01CA260822-01A1
Institution: University of North Carolina at Chapel Hill
09/23/2021

Effect of Tobacco Use Patterns on Toxicant Exposure and Successful Cessation: A Longitudinal Study among US Adult Cigarette Smokers

Researchers will analyze data from Waves 1-5 of the Population Assessment of Tobacco and Health (PATH) Study to identify groups of adult smokers defined by their toxicant exposure and investigate how levels of nicotine dependence and patterns of tobacco use could impact adults’ ability to achieve successful smoking cessation (smoking abstinence ≥3 months). Study aims are: (1) to analyze data on biomarkers of exposure to tobacco chemicals (i.e., nicotine, tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, volatile organic compounds) in 8,000 adult current cigarette smokers and group those smokers based on toxicant concentrations detected in urine; researchers will examine whether groups differ by personal characteristics, smoking behaviors (e.g., menthol vs. non-menthol smoking; cigarette smoking only or polytobacco use), and level of nicotine dependence; and (2) to describe trends in nicotine dependence and smoking behaviors to identify characteristics and behaviors of adults who achieved successful smoking cessation. Findings may inform regulatory and research activities that address tobacco-related toxicant exposure and will shed light on barriers and facilitators to achieving successful smoking cessation in adults.

Ban Majeed Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21CA267932-01
Institution: Augusta University
09/23/2021

Development of Biomarkers of Exposure and Effects for Electronic Cigarette vs. Combustible Cigarette Use

E-cigarette use has been associated with a variety of diseases, including cancer. The goal of this study is to detect genetic and epigenetic (i.e., behavioral, environmental) alterations in key genes in the oral and blood cells of 45 healthy adult vapers and 45 healthy adult smokers in comparison to a control group (45 nonsmokers/non-vapers) matched for age, sex, and race. Study aims are: (1) to screen for the deregulation (i.e., functional impairment) of disease-related genes in oral and blood cells of vapers and smokers as compared to controls; (2) after identifying the deregulated genes, to employ targeted next-generation sequencing (a method of analyzing DNA) to detect genetic changes in the deregulated genes; and (3) to employ targeted next-generation sequencing to detect epigenetic modifications to the deregulated genes. As a secondary goal, researchers will identify correlations between the identified genetic changes and subjects’ tobacco product use patterns and product characteristics (e.g., e-cigarette device features; e-liquid content; cigarette brand, type, and chemical constituents); this will clarify the impact of vaping/smoking dose and product characteristics on the biological effects of e-cigarette use vs. cigarette smoking. Study findings will identify gene changes that can serve as biomarkers to differentiate among vapers, smokers, and nonsmokers/non-vapers, thereby indicating the health risks and/or potential benefits of e-cigarette use relative to smoking.

Ahmad Besaratinia Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21CA268197-01
Institution: University of Southern California
09/21/2021

Pulmonary Toxicological Evaluation and Chemical Interactions of Menthol, Mint, and Tobacco Flavored E-Cigarette Products

Menthol/mint and tobacco flavors contain harmful chemicals that can cause adverse cellular and molecular changes in lung tissue. The goal of this study is to identify constituents of menthol/cooling and tobacco flavors and their pulmonary toxicity and to determine potential biomarkers of disease. Study aims are: (1) to identify the chemistry of menthol, menthol-like (cooling), and tobacco flavors, including flavoring chemicals and secondary products formed upon aerosolization; (2) to determine the in vitro and in vivo toxicity and health effects of menthol, menthol-like, and tobacco-flavored electronic nicotine delivery systems (ENDS) in EpiAirway 3D tissues (tissues constructed of human tracheal/bronchial epithelial cells) and in mice under normal and pre-existing respiratory conditions (chronic obstructive pulmonary disease and asthma) (3) to determine in vitro and in vivo toxicity and health effects of exposure to responsible flavoring chemicals identified in Aim1 using EpiAirway 3D tissues and mice under normal and pre-existing respiratory conditions. Findings will provide new information about lung toxicity caused by menthol and tobacco flavored e-cigs, identify disease processes of asthma and COPD upon switching to menthol and tobacco flavors from combustible cigarettes, and identify the culprits in these flavored e-cigs causing lung disease and exacerbations, thus, providing critical information for regulation of constituents of these ENDS.

Thivanka Muthumalage Funding Mechanism: National Institutes of Health – Grant
ID Number: 1K99ES033835-01
Institution: University of Rochester
09/21/2021

Impact Analysis of Flavor Restrictions and Tobacco 21 Policies on Youth Tobacco Use

Sixteen states and the District of Columbia enacted state-wide tobacco 21 (T21) policies prior to passage of the federal T21 law in December 2019, and seven states have recently enacted bans on flavored tobacco products. The goal of this study is to examine the impact of state flavor restrictions and state and federal T21 policies on disparities in tobacco use among youth and young adults aged 14-24 years. Researchers will analyze data from two surveys: the Behavior Risk Factor Surveillance System (BRFSS), an annual national phone-based survey of health-related behaviors among adults aged 18+; and the Youth Risk Behavior Survey (YRBS), a biennial school-based survey of health-related behaviors in 44 states. Study aims are: (1) to evaluate the impact of flavor restrictions and T21 policies on tobacco use (cigarettes, ENDS, smokeless tobacco) across age (18-20 vs. 21-24) and examine the impact of both policies on tobacco use across socio-demographic strata, using BRFSS data; (2) to evaluate the impact of flavor restrictions and T21 policies on tobacco use (cigarettes, ENDS, smokeless tobacco, cigars) across age (14-17 vs. 18) and examine the impact of both policies on tobacco use across socio-demographic strata, using YRBS data; and (3) to examine the impact of Covid-19 state closures and re-openings on tobacco use overall, by age, and across sociodemographic strata, using data from both surveys. Findings may inform future regulatory activities related to youth and young adult tobacco use.

Summer Hawkins Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21CA268199-01
Institution: Boston College
09/21/2021

Countering E-cigarette Marketing in the Retail Environment among Adolescents and Young Adults

Many adolescents and young adults directly purchase e-cigarettes from brick-and mortar retail stores. The goal of this study is to identify appealing and influential characteristics of e-cigarette marketing in the retail environment that impact adolescent (ages 11-18) and young adult (ages 19-21) e-cigarette purchase and use. Study aims are: (1) to examine adolescent and young adult descriptions of e-cigarette marketing in the retail environment and its influence on their e-cigarette purchase and use behavior; (2) to identify the most appealing characteristics of e-cigarette retail marketing that influence purchase and use; and (3) to develop and evaluate the effectiveness of an e-cigarette counter-marketing lesson to reduce adolescents’ intent to use and actual use of e-cigarettes. To achieve Aim 1, researchers will conduct focus group discussions with adolescents and young adults who have either never used e-cigarettes or have ever used or currently use e-cigarettes; the study will include a separate focus group for youth peer advocates working on e-cigarette prevention (total participants = 72). To achieve Aim 2, researchers will survey 2,250 adolescents and young adults to identify how and which e-cigarette marketing characteristics influence e-cigarette purchase and use; the survey will include a discrete choice experiment. Aim 3 will involve a randomized controlled trial that will assign 950 adolescents to one of two conditions: (1) a newly-developed online counter-marketing lesson about e-cigarette marketing in the retail environment, or (2) an existing online e-cigarette overview lesson to assess influence on intent to use and actual use of e-cigarettes. Findings may inform future educational and regulatory activities related to e-cigarette retail marketing.

Shivani Gaiha Funding Mechanism: National Institutes of Health – Grant
ID Number: 1K99CA267477-01
Institution: Stanford University
09/20/2021

Personal Factors, Product Characteristics, and Changes in Biomarkers of Exposure among Cigarette Smokers Who Switch to Noncombustible Tobacco Products

The goal of this study is to evaluate the factors associated with transitioning from cigarettes to noncombustible tobacco products (e.g., smokeless tobacco, e-cigarettes) and assess the potential of noncombustibles as a harm reduction strategy. Researchers will evaluate four possible trajectories — continued smoking (least optimal outcome), complete cessation (most optimal outcome), exclusive noncombustible use (possible harm reduction) or dual/poly tobacco use (unlikely harm reduction) — through an analysis of Population Assessment of Tobacco and Health Study data. Study aims are: (1) to identify personal characteristics (e.g., sociodemographic characteristics, smoking history, harm perceptions, exposure to messaging) associated with switching from cigarettes to noncombustibles; (2) to describe product characteristics (e.g., cigarette characteristics, noncombustible characteristics such as flavor and nicotine content) associated with switching; and (3) to examine health outcomes and exposure biomarkers in smokers who have switched. Findings will provide new information related to switching from cigarettes to noncombustible tobacco products.

Nicholas Felicione Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21CA268198-01
Institution: Roswell Park Cancer Institute Corporation
09/14/2021

Modeling the Impact of Tobacco Regulations on US Future Trends of Chronic Obstructive Pulmonary Disease

The objective of this research project is to build a chronic obstructive pulmonary disease (COPD) model based on individual cigarette smoking histories that will be used to predict the long-term population impact of two FDA tobacco regulatory scenarios on COPD disease burden. Study aims are: (1) to analyze data from a database of US adults with COPD (the COPDGene Study) to determine the impact of smoking behavior changes on lung function decline and COPD mortality; (2) to develop a COPD simulation that estimates future COPD incidence, prevalence and COPD-associated respiratory and lung cancer deaths based on individual smoking histories; and (3) to predict possible future trends in COPD morbidity and mortality under two FDA tobacco regulatory scenarios: cigarette pack and advertisement graphic health warnings (implementation of a Final Rule) and a menthol cigarette ban (planned). Findings will provide new information about the impact of tobacco control policies on COPD trends.

Luz Maria Sanchez-Romero Funding Mechanism: National Institutes of Health – Grant
ID Number: 1K01CA260378-01A1
Institution: Georgetown University
08/20/2021

CTP Supplement to Parent Grant: Impact of Flavor on Youth & Young Adults Use Intention, Abuse Liability and Perceptions of Cigarillos

The goal of this project supplement to the parent grant is to determine how the removal of flavors from cigarillos could impact co-use of cigarillos and cannabis, and whether that impact is related to perceptions of appeal or harm. Specific aims are: (1) to analyze parent study data on 361 young adult (ages 21-28) cigarillo users to determine the relationship between use of flavored cigarillos and co-use with cannabis (including blunts), and (2) to conduct one-on-one interviews with a subset of 38 participants to expand findings from the parent study, including understanding flavor appeal, perceived harm, and product substitution, and to assess these factors in the context of co-use with cannabis. Findings will provide new information about the influence of flavor on young adult co-use of cannabis and cigarillos.

Erika Trapl Funding Mechanism: National Institutes of Health – Grant
ID Number: 3R01DA048529-03S1
Institution: Case Western Reserve University
08/18/2021

Evaluation and Comparison of Impacts of Flavored Waterpipe Tobacco and Electronic Waterpipe E-Liquid Formulation Variations on Toxicant Yields and Particle Size Distribution in Mainstream Emissions

The popularity of flavored waterpipe (WP) smoking has expanded in recent years to flavored tobacco-free alternatives, including electronic WP (EWP). EWP replaces the traditional WP bowl and heat source with an electronic head filled with flavored, nicotine-containing liquid (e-liquid), turning the WP into an electronic nicotine delivery system (ENDS). The goal of this study is to compare the impact of variations in flavor profiles, humectants, sugar levels, and heating temperature in a variety of commercially available WP tobaccos and EWP e-liquids on hazardous and potentially hazardous constituents (HPHCs) and other toxicant yields as well as particle size distribution in mainstream WP emissions. Specific aims are: (1) to characterize variations in formulations of a variety of commercially available WP tobaccos and EWP e-liquids by determining the flavor profiles and humectant and sugar content; (2) to determine HPHC and other toxicant yields and particle size distribution in mainstream emissions generated by machine-smoking the WPTs using a research-grade electric heater operating at a high and low temperature; and (3) to determine HPHC and other toxicant yields and particle size distribution in mainstream emissions generated by machine smoking the e-liquids at a high and low EWP power setting. To achieve Aim 1, nine WP tobaccos and nine e-liquid flavors within popular flavor categories will be selected and chemically analyzed using established methods. To achieve Aim 2, WP tobaccos selected in Aim 1 will be machine-smoked using a human-derived smoking regimen; mainstream emissions will be analyzed for volatile and semivolatile HPHCs, particle size distribution, and other toxicants. The heater and tobacco temperature will be monitored and recorded. To achieve Aim 3, EWP e-liquids selected in Aim 1 will be machine-smoked as in Aim 2 but using an EWP head with variable power. Findings may inform future regulatory actions related to WP and EWP.

Stephanie Buehler Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01ES033016-01
Institution: Battelle Centers Public Health Research and Evaluation
07/22/2021

Survey of Risk Factors of Lithium Ion Batteries Used in ENDS

Electronic nicotine delivery system (ENDS) lithium-ion battery-related overheat, fire, and explosion (O/F/E) incidents have increased in recent years, but limited information is available about ENDS-related O/F/E risk factors. Efforts to understand causes of ENDS-related O/F/E incidents suggest that specific products and certain user practices may increase the risk of ENDS-related O/F/E incidents. The goals of this project are to collect data from a representative sample of 6,000 U.S. adult ENDS users via an online survey to identify user practices, ENDS devices, and batteries that may increase the risk of ENDS-related O/F/E incidents, and to estimate the prevalence of O/F/E incidents. Findings may inform future regulatory activities related to ENDS.

Jessica Pepper (CTP Contact: Azieb Kidanu) Funding Mechanism: Research Contract
ID Number: 75F40120A00017
Institution: Research Triangle Institute (RTI) International
06/30/2021

Multi-Parameter Investigation of Factors Controlling Carbonyl Emissions from Electronic Cigarettes

Carbonyl compounds, such as formaldehyde, a known human carcinogen, are among the hazardous and potentially hazardous constituents (HPHCs) found in e-cigarette aerosols. Researchers have reported numerous factors that influence e-cigarette carbonyl production (e.g., e-cigarette type, power, coil material, e-cigarette liquid (e-liquid) composition, topography), but differences in sampling methodology and testing protocols and a limited number of parameters investigated in individual studies have contributed to controversy regarding carbonyl levels in e-cigarette aerosols and the role individual factors play in their production. The goal of this study is to resolve some of the outstanding questions regarding e-cigarette carbonyl emissions by performing comprehensive testing of popular devices that are representative of three e-cigarette types (a cig-a-like, a sub-Ohm “mod”, and a “pod” type) under a variety of use patterns. Study aims are: (1) to test different carbonyl collection methods using a NIST-traceable formaldehyde standard and e-cigarette aerosols containing different amounts of liquid particulates, and select the best method for subsequent tests; (2) to investigate interactions between the main flavoring compound classes with e-cigarettes that have fresh and aged coils at different temperatures and e-liquid formulations; and (3) to investigate how different combinations of power, puff topography, and e-liquid viscosity affect carbonyl emissions of the e-cigarette types. Findings will help determine the optimal sampling methodology for carbonyls in e-cigarette aerosols and may inform future regulatory activities related to e-cigarettes.

Andrey Khylstov Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01ES033390-01
Institution: Desert Research Institute
06/15/2021

Receipt and Use of Prohibited Free Samples of Tobacco Products Among Adult Cigarette, Cigar, and/or Smokeless Tobacco Users, 2020

On March 19, 2010, FDA finalized regulations restricting the distribution of free samples of cigarettes, roll-your-own cigarette products, and smokeless tobacco in the U.S. (excepting free samples of smokeless tobacco distributed in “qualified adult-only facilities”). This ban was extended to cover all tobacco products, including e-cigarettes and cigars, when the Deeming Rule went into effect on August 8, 2016. More information about tobacco product free samples distribution since the regulations went into effect would be useful. Using data from the National Panel of Tobacco Consumer Studies (TCS Panel), which includes approximately 4,000 U.S. adult current cigarette, cigar, and/or smokeless tobacco users, this study will report on free samples receipt and use behavior for cigarettes, cigars, smokeless, and e-cigarette products; locations where free samples are received; top brands received; and demographic and behavioral characteristics of recipients. If sample sizes are large enough, the following may also be examined: how and/or where tobacco users receive free samples, including vouchers to exchange for free samples; types of products and top brands received; how often tobacco users received free samples; whether recipients used the free samples; whether users of the free samples like and consider purchasing products that they received as free samples; and significant predictors or factors associated with receipt. Findings will provide new information on outcomes related to the tobacco free samples ban.

Brett Loomis (CTP Contact: Naa Inyang) Funding Mechanism: Research Contract
ID Number: HHSF223201510002B-HHSF22317005
Institution: Research Triangle Institute (RTI) International
06/15/2021

Predicting Effects of ENDS Flavor Regulations on Tobacco Behavior, Toxicity, and Abuse Liability among African American Menthol Smokers

More research would be useful regarding how electronic nicotine delivery system (ENDS) uptake affects tobacco use and associated toxicity among African American (AA) cigarette smokers, particularly those who smoke menthol cigarettes. The goal of this study is to evaluate how future ENDS flavor regulations may impact African American menthol smokers. The study will evaluate whether ENDS menthol flavor availability affects measures of tobacco use, biomarkers of cigarette/ENDS exposure, and addiction among AA menthol smokers (N=210, ages ≥21) by performing a six-week clinical trial of ENDS provision with follow-up to 30 days. Specific aims are: (1) to compare the effect of ENDS flavor availability on patterns of tobacco use behavior; (2) to quantify the effect of ENDS flavor availability on biomarkers of cigarette/ENDS exposure (expired air carbon monoxide, urine cotinine/NNAL, and urine propylene glycol; and (3) to test the effect of ENDS flavor availability on addiction/abuse liability using validated behavioral economic instruments at multiple time points during the trial. Researchers will provide subjects with JUUL devices with compatible cartridges at 5% nicotine and will randomize them to one of three groups that differ by potential FDA regulations related to ENDS flavor availability: (1) the current market where only menthol- and tobacco-flavored ENDS cartridges are available; (2) a market where only tobacco-flavored ENDS are available, and (3) a market where only unflavored cartridges are available. Study visits will occur weekly beginning one week prior to randomization with daily tobacco use monitoring throughout and biomarker/self-report data collection at each in-person visit. Study results may clarify the impact on AA menthol smokers of moving from the current regulatory market where menthol/tobacco-flavored ENDS cartridges are available, to one where only tobacco or unflavored cartridges are available.

Andrew Barnes and Caroline Cobb Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01DA050996-01A1
Institution: Virginia Commonwealth University
05/28/2021

The Effect of Sweet Flavoring on the Rewarding and Reinforcing Value of Cigarillo Use Among Young Adults

Data on the impact of sweet flavoring on combustible cigarillo use is important for understanding their health impact among young adults. The study aim is to determine whether the subjective rewarding value, the relative reinforcing value, and the absolute reinforcing value of sweet-flavored cigarillos are greater than that of non-flavored cigarillos among young adults. Researchers will investigate these aims in three separate laboratory visits among 86 young adults (ages 18-24 years) who have smoked at least 10 cigarillos in their lifetime. Participants will complete various validated scale measurements, a behavioral choice task, and an ad-libitum smoking procedure. Researchers will examine whether indices of abuse liability remain significant while controlling for other factors that may underlie the preference for flavoring. Results may inform future regulatory activities related to cigarillos.

Janet Audrain-McGovern Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21DA050789-01A1
Institution: University of Pennsylvania
05/27/2021

The Effects of IQOS Use on Cigarette Smoking Behavior

In 2019, the Food and Drug Administration (FDA) authorized the sale of IQOS, and more data on the impact of IQOS use on cigarette smoking behaviors would be useful. This study addresses two aims: (1) to evaluate the effects of IQOS use on cigarette smoking behaviors; and (2) to examine which subjective and objective effects of IQOS predict cigarette smoking. Researchers will recruit 100 combustible cigarette smokers ages (18-65) to a 21-day study. Baseline smoking rate will be established during days 1-5. After overnight cigarette smoking abstinence, laboratory visits on days 6 and 7 will assess IQOS-associated craving relief, withdrawal relief, risk perceptions, subjective reward, and the reinforcing value of IQOS relative to combustible cigarettes. Participants will switch from cigarette smoking to IQOS use for the following 14 days (days 8-21). Participants will collect their spent cigarette filters and their used IQOS HeatSticks daily to enable researchers to assess consumption of cigarettes and tobacco sticks per day. The primary outcome is the daily count of cigarettes from baseline to day 21, and the secondary outcome is changes in motivation to quit smoking from baseline to day 21. Findings may inform future regulatory activities related to heated tobacco products.

Janet Audrain-McGovern Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01CA260448-01
Institution: University of Pennsylvania
05/24/2021

The Impact of Cigarillo Warnings on Purchasing and Smoking Behaviors Among Young Adult Cigarillo Users

This study will assess the effectiveness of cigarillo warnings by extending previous research in which the researchers developed pictorial warnings for cigarillos. Study aims are: (1) to examine the impact of a pictorial cigarillo warning policy on young adult cigarillo smokers’ purchasing behaviors using a behavioral economics framework; and (2) to examine the impact of repeated exposure to pictorial versus text cigarillo warnings on cigarillo smoking intentions and behaviors. Participants will be young adult frequent cigarillo users ages 21-34. An estimated 1,282 subjects (635 Black/African American and 647 White) will complete an online shopping task using the Experimental Tobacco Marketplace; researchers will then examine the impact of different cigarillo warning manipulations (pictorial, FDA text-only, Surgeon General text-only) on cigarillo purchasing, cigarillo demand, and substitution of other tobacco products. Researchers will then recruit another sample of 600 young adult frequent cigarillo users (300 Black/African American and 300 White) to participate in a 6-week randomized control trial where they will be exposed to cigarillo warnings weekly to examine the impact of the warnings on intentions to continue cigarillo smoking and cigarillo smoking behaviors. Study results may reveal how to effectively communicate the risks of cigarillo smoking to young adults, including Black/African Americans, and may inform regulatory decision-making related to cigarillo warnings.

Jennifer Cornacchione (Ross) Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01CA260460-01
Institution: Wake Forest University Health Sciences
05/18/2021

Exosomal Epigenetic Biomarkers Associated with Flavored Electronic Cigarette Use in Adults

More information about the health risks, especially long-term health risks, of flavored e-cigarette use would be useful. The goal of this study is to identify exosomal epigenetic biomarkers (including microRNAs and long non-coding RNAs) associated with flavored e-cigarettes. Study aims are: (1) to examine blood and urinary exosomal epigenetic biomarkers and associated biological pathways related to flavored (such as fruit-flavored) e-cigarette use; and (2) to evaluate within-subject alterations in exosomal epigenetic biomarkers and associated biological pathways during e-cigarette initiation and cessation. Researchers will analyze blood and urine specimens from the Population Assessment of Tobacco and Health (PATH) Study biorepositories. After identifying key biomarkers, researchers will expose them to primary human bronchial epithelial cells and small airway epithelial cells from non-smoker adults to determine their toxicity/inflammatory response. Findings may inform future regulatory activities related to flavored e-cigarettes.

Dongmei Li and Ifran Rahman Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21ES032159-01A1
Institution: University of Rochester
05/10/2021

Impact of E-Cigarette Characteristics and Marketing on Tobacco Use and Health: A Longitudinal Study Among U.S. Youth and Adults

More information about the impact of e-cigarette characteristics and marketing on tobacco use among youth and adults would be useful. Researchers will analyze longitudinal data (Waves 1-4) from the Population Assessment of Tobacco and Health (PATH) Study to accomplish three study aims: (1) to identify the impact of e-cigarette flavors (non-tobacco and non-menthol flavors vs. tobacco and menthol flavors) and types (open vs. closed system) on e-cigarette use among youth (12-17 years), young adults (18-34 years), and older adults (35 years and older); (2) to determine the impact of e-cigarette advertising exposure on e-cigarette initiation, use frequency, and susceptibility, as well as the mediating effect of harm and addiction perceptions; and (3) to identify the effect of e-cigarette use on cardiovascular, respiratory, and periodontal health, and compare the effects among different types of tobacco users (e.g., exclusive e-cigarette users, never cigarette smokers, exclusive e-cigarette users, former cigarette smokers, dual users, cigarette-only smokers). Findings may impact future regulatory activities related to e-cigarettes.

Nan Jiang Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21CA260423-01
Institution: New York University School of Medicine
04/28/2021

The Effects of Branded and Influencer Social Media Promotion of Flavored Tobacco Products (FTP) on FTP Use Among Youth and Young Adults

This study will examine the impact of exposure to social media marketing of flavored tobacco products (FTPs). Study aims are: (1) to identify and characterize social media message content related to FTPs by source (e.g., brand, influencer/community, regular consumer) and major themes (e.g., new-user targeting, health risks, flavor-type); (2) to examine the impact of exposure to commercial and influencer FTP content on product sales and on youth and young adult awareness, risk perceptions, intentions to use, initiation, and patterns of use of FTP products; and (3) to study whether/to what extent FTP regulatory policies modify the impact of exposure to social media content on FTP product sales and youth and young adult awareness, risk perceptions, intentions to use, initiation, and patterns of use of FTP products. These aims will be accomplished by analyzing social media data from Twitter and Instagram; individual-level data on exposure to tobacco marketing, tobacco attitudes, and tobacco use from the Population Assessment of Tobacco and Health (PATH) Study; FTP sales volume data from Nielsen store scanner data; and state/local FTP policy data collected by the National Opinion Research Center. Findings from this study may inform future regulatory activities related to social media marketing of FTPs.

Sherry Emery and Ganna Kostygina Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01DA051000-01A1
Institution: National Opinion Research Center
04/20/2021

Racial Disparities in Biomarkers, Tobacco Cessation, and Smoking Relapse in Association with Electronic Cigarette Use

Biomarkers can play an important role in assessing the potential health effects of tobacco products. However, evidence on the racial disparities related to biomarker outcomes of e-cigarette use is scarce. The goal of this study is to examine the racial disparities in biomarkers of exposure and toxicants in association with e-cigarette use by analyzing Population Assessment of Tobacco and Health (PATH) Wave 1-4 biomarker data. Study aims are: (1) to assess racial disparities in biomarkers of tobacco exposure and toxicants; and (2) to develop a bio-socio-psycho risk score in prediction of cessation, relapse, and health outcomes. To achieve Aim 1, researchers will link the biomarker data with the PATH adult surveys to identify the between-person and within-person differences in biomarkers by use of different vaping products, flavors, and transitions between e-cigarettes and combustible cigarettes across different waves. To achieve Aim 2, researchers will then use machine learning algorithms to develop a composite bio(biomarker)-socio(socio-demographics)-psycho(psychosocial factors) risk index score for each racial/ethnic group to predict subsequent abstinence from cigarette smoking and relapse to cigarette smoking. Study findings will provide new information related to racial disparities in e-cigarette health effects.

Hongying Dai Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21DA054818-01
Institution: University of Nebraska Medical Center
04/20/2021

Electronic Cigarette Use During Pregnancy and the Impact on Newborn Metabolic Profile and Perinatal Health Outcomes

More information about the effects of e-cigarette use by pregnant women would be useful. The goal of this study is to evaluate the potential adverse effects of e-cigarettes on pregnant women and their developing fetuses. Specific study aims are: (1) to determine the pattern of women’s smoking from preconception to the perinatal period; (2) to determine the pattern of women’s smoking from 2016 to 2018; (3) to determine whether pregnancy e-cigarette use is associated with pregnancy, perinatal, and infant-related adverse outcomes; and (4) to determine whether pregnancy e-cigarette use is associated with an imbalanced metabolic profile in infants measured at birth. Researchers will conduct a surveillance study of women who had live births between 2016-2018 and participated in the Pregnancy Risk Assessment Monitoring System (PRAMS) survey. Data analyzed will include detailed smoking information, including conventional cigarette and e-cigarette use during preconception, third trimester of pregnancy, and post-delivery; researchers will also link PRAMS subjects from Tennessee and Iowa to newborn metabolic screening data to identify and validate metabolic profiles measured at birth that are associated with secondhand in utero e-cigarette and conventional cigarette exposure. Study findings may inform future regulatory activities that impact pregnant e-cigarette users.

Pingsheng Wu Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21DA052026-01A1
Institution: Vanderbilt University Medical Center
04/20/2021

Assessing the Impacts of the Four 2019/2020 US Federal-Level Tobacco Control Actions: Flavors, Youth Marketing, Youth Access, and Tobacco 21

Four key federal-level tobacco control actions were taken in the U.S. in December 2019/January 2020 to reduce electronic nicotine delivery system (ENDS)/tobacco use appeal and access, particularly among young people. These four actions were: (1) ENDS Flavors/Device Guidance, in which FDA prioritized enforcement against “any flavored, cartridge-based ENDS product (other than a tobacco- or menthol-flavored ENDS product),” (2) ENDS Marketing Guidance, in which FDA prioritized enforcement against “any ENDS product that is targeted to minors or whose marketing is likely to promote use of ENDS by minors,” (3) ENDS Access Guidance, in which FDA prioritized enforcement against “all other ENDS products for which the manufacturer has failed to take (or is failing to take) adequate measures to prevent minors’ access,” and (4) Federal T21, in which the federal minimum age of sale of tobacco products was raised from 18 to 21 years. Around the same time, two national public health events occurred that likely also contributed to population-level changes in ENDS/tobacco use behaviors: an outbreak of ENDS/vaping-associated lung injury (EVALI) was identified by CDC in August 2019, and the spread of a novel coronavirus in the US in January 2020 (COVID19). The shared historical timing of these actions and events requires innovative methods to assess the specific impacts of each federal action. Researchers will use a theoretically grounded mediational model to disentangle overall impacts into action-specific impacts. They will conduct secondary data analyses using the following sources: two complementary nationally-representative data sources, which each assess key measures of appeal and access and together include over 61,000 participants; the Population Assessment of Tobacco and Health (PATH) Study youth and adult surveys (2017-2021); and the U.S. arm of the International Tobacco Control (ITC) Project youth and adult surveys (2018-2021). Study findings will contribute to an understanding of the impacts of each action on Americans’ ENDS/tobacco use behaviors.

Karin Kasza Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R21DA053614-01
Institution: Roswell Park Cancer Institute Corporation
04/16/2021

Testing the Effect of Anti-Tobacco Message Framing on Polytobacco Use in Lesbian, Gay, Bisexual, and Transgender Young Adults

Polytobacco use, defined as concurrent use of more than one tobacco product including electronic nicotine delivery systems (ENDS), is rising in lesbian, gay, bisexual, and transgender (LGBT) young adults. More information about how to effectively frame polytobacco risk communications for this population would be useful. The goal of this study is to test the effect of polytobacco message framing on risk perceptions and polytobacco use in LGBT young adults. Study aims are: (1) to identify polytobacco risk messages that effectively communicate absolute and relative risks to young adults; (2) to determine the effects of cultural targeting on LGBT young adult polytobacco users’ attention to messages and perceived effectiveness; (3a) to assess the feasibility of polytobacco risk messages developed in Aims 1 and 2 to LGBT young adults via text; and (3b) to estimate the effect sizes of exposure to messages on risk perceptions and tobacco use over time. Researchers will develop 48 messages and will conduct an online survey study with 2400 young adults (ages 18-35, estimated 50% LGBT) in which each participant will view and rate eight polytobacco education messages. Researchers will also conduct an in-laboratory study and focus groups (108 and 24-32 participants, respectively) and a Phase I randomized controlled trial (300 participants) to determine the message framing and targeting most effective for LGBT young adults. Findings may inform future tobacco education campaigns targeted to LGBT young adults.

Joanne G. Patterson Funding Mechanism: National Institutes of Health – Grant
ID Number: 1K99CA260718-01
Institution: The Ohio State University
01/26/2021

Pharmacokinetic Bridging Study for the Inhalation of Nicotine in Saline in Male Sprague-Dawley Rats

Additional information on nicotine pharmacokinetics (PK) following inhalation will be useful in accurately predicting its PK across species (i.e., rodents, non-human primates, and humans). The CTP-NCTR InhaleCore Group has recently completed studies evaluating nicotine PK profiles in rats following a single dose administration by inhalation, oral gavage, and intravenous injection (E07607.01 and E07716.01). In these studies, the dose formulations for inhalation exposure consisted of nicotine in propylene glycol and water. Due to possible unknown inhalation toxicities of propylene glycol and its potential to impact the lungs, propylene glycol is probably not an appropriate vehicle for investigating nicotine inhalation toxicity in planned subacute and subchronic inhalation toxicology studies. In this study, the InhaleCore Group will assess the applicability of the previously collected PK data (nicotine in propylene glycol and water) to the PK profiles for new nicotine formulations (nicotine in saline) that will be used in the planned studies. Results from these studies will provide useful information for the development of physiologically-based pharmacokinetic (PBPK) modeling to characterize the PK of nicotine and its metabolites (cotinine and 3-hydroxycotinine) in rodents across different routes of exposure.

Qiangen Wu (CTP Contact: Prabha Kc) Funding Mechanism: FDA Internal
ID Number: E07763.01
Institution: National Center for Toxicological Research (NCTR)
12/22/2020

Uptake and Patterns of Use of the IQOS Heated Tobacco System by US Smokers

More information about the U.S. population health impact of IQOS, a heated tobacco system, would be useful. The goal of this project is to provide postmarket data evaluating the sociodemographic and tobacco use patterns of IQOS initiators, including the extent to which adult smokers are completely stopping use of all tobacco products, switching to exclusive IQOS use, dual-using cigarettes and IQOS, or rejecting IQOS and continuing smoking, as well as differing perceptions and use of IQOS by sociodemographic variables relevant to tobacco disparities. Study aims are: (1) to examine the sociodemographic and tobacco use characteristics, decision-making processes, and marketing exposure among adult initiators of IQOS; and (2) to examine the longitudinal determinants of long-term tobacco use outcomes among adult cigarette smokers who purchased and initiated use of IQOS. The study will involve an initial survey of 1000 adult (ages ≥18) IQOS initial purchasers and follow-up surveys of 600 cigarette smokers initially surveyed; follow-up will occur at 1 month, 6 months, and 12 months. A subsequent focus group study of 20 survey participants who had either switched to exclusive IQOS use or were dual-using IQOS and cigarettes will be conducted to obtain a deeper understanding of the quantitative findings. Findings will reveal important information about heated tobacco product use in the U.S.

Scott Weaver Funding Mechanism: National Institutes of Health – Grant
ID Number: 1R01DA051002-01A1
Institution: Georgia State University
12/01/2020

Smoking Machine Adaptor Design Project for ENDS, Cigars, and Heated Tobacco Product

A single standardized smoking machine adaptor for cigars, ENDS, and heated tobacco products does not exist, making it difficult to accurately quantify the aerosol and smoke physical properties and hazardous and potentially hazardous constituent (HPHC) levels produced by these products. This design project has four aims: (1) to develop a single universal adaptor, or standardized family of adaptors, for the attachment of ENDS, cigars, and heated tobacco products to existing smoking machines originally designed for use with cigarettes; (2) to ensure that the adaptor(s) have high repeatability and reproducibility; (3) to coordinate and administer a study that tests repeatability and device validation while comparing the newly designed adaptor(s) to currently available adaptors; and (4) to provide tobacco product stakeholders with continued adaptor product support and improvement. A well-validated standardized smoking machine adaptor will ensure that accurate data are being used by stakeholders in their efforts to protect the public from tobacco-related death and disease.

Marielle Brinkman (CTP Contact: Raymond Williamson) Funding Mechanism: Research Contract
ID Number: 1UC2FD007229-01
Institution: The Ohio State University
09/15/2020

Waterpipe Tobacco Additives and Their Effect on Human Puffing Behavior, Toxicant Exposures, Pulmonary Function and Appeal

Sweetened waterpipe (WP) tobacco may increase WP smoking appeal for first-time users; furthermore, high levels of sweet additives produce harmful and potentially harmful constituents (HPHCs) in WP smoke. The goal of this study is to define the effects of WP tobacco’s primary chemical additives with respect to sweet perception, appeal, toxicant exposure, addictiveness, harm and health risk perceptions, and lung function. Study aims are: (1) to characterize the HPHC and sugar content of four WP tobaccos (one brand prepared four different ways to vary glycerol and sugars); (2) to characterize the HPHC and sugar yields in mainstream smoke generated from machine smoking the four WP tobacco preparations using a research-grade waterpipe and a standardized WP puffing regimen; (3) to determine how WP tobacco content impacts puffing behaviors, a carbon monoxide biomarker, pulmonary function, nicotine uptake, and perceived sensory attributes and appeal of WP smoking, based on data gathered from 50 experienced WP smokers (ages 21-50) who will smoke the four different WP tobacco preparations in four different laboratory sessions; and (4) to determine the HPHC exposure ranges from the average puffing behaviors measured under Aim 2 for each WP tobacco preparation. Findings will provide new information about the impact of chemical additives in WP tobacco.

Marielle Brinkman and Theodore Lee Wagener Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01CA255563-01
Institution: Ohio State University
09/10/2020

Understanding Uncontrolled Vaping Among Vulnerable Populations

E-cigarettes differ from combustible cigarettes in ways that may make it harder to control vaping. For example, e-cigarettes lack many of the same stopping cues as cigarettes, indoor bans are less common, and discreet use is easy. The goal of this study is to understand uncontrolled vaping and vaping restraint strategies. Study aims are: (1) to develop measures of uncontrolled vaping and restraint strategies; (2) to assess prevalence of and factors related to both uncontrolled vaping and restraint strategies; and (3) to establish the long-term impact of vaping restraint on uncontrolled vaping. To achieve Aim 1, researchers will conduct phone interviews with 8 adolescent (ages 13-17), 8 young adult (ages 18-25), and 8 adult (ages 26 and older) current e-cigarette users to understand how they describe uncontrolled use and vaping restraint and will then develop survey measures. To achieve Aim 2, researchers will survey 1,050 current e-cigarette users (300 adolescents, 300 young adults, and 450 adults) and evaluate the usefulness of the new measures. Researchers will then estimate uncontrolled use and vaping restraint strategies for the nation and examine whether these outcomes are more common among vulnerable populations, certain device type users, and dual users. To achieve Aim 3, researchers will conduct a follow-up online survey with approximately 700 e-cigarette users from the Aim 2 sample to examine how baseline vaping restraint related to uncontrolled vaping and smoking behavior one year later. Findings may inform regulatory activities related to e-cigarettes.

Noel Todd Brewer Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01CA246606-01A1
Institution: University of North Carolina
09/10/2020

The Impact of Cigar Pack Quantity on Tobacco Use Behaviors

The goal of the proposed analyses is to clarify the relationship between cigar pack quantity and tobacco use behaviors. Study aims are: (1) to determine whether cigar pack quantity is associated with between- or within-person changes in cigar use and assess whether changes vary by sociodemographic characteristics (age, sex, race, ethnicity, income, and educational attainment); (2) to evaluate the impact of minimum cigar pack quantity laws on tobacco use and assess whether the impact of these laws varies by sociodemographic characteristics; (3) to evaluate the impact of minimum cigar pack quantity laws on cigar sales and assess whether the impact of these laws varies by county characteristics; and (4) to characterize differences in implementation and enforcement of minimum cigar pack quantity laws through qualitative interviews with key implementation personnel. The researcher will analyze data from national datasets, including the Population Assessment of Tobacco and Health (PATH) Study, the Tobacco Use Supplement to the Current Population Survey (TUS-CPS), the Youth Risk Behavior Surveillance System (YRBSS), and Nielsen retail scanner data. Study findings may inform future regulatory activities related to cigar pack quantity.

Jessica Lynn King Funding Mechanism: National Institutes of Health – Grant
ID number: 1K01CA253235-01
Institution: University of Utah
09/09/2020

Designing and Evaluating Communication for Dual Users of E-cigarettes and Combustible Cigarettes

People who use both cigarettes and e-cigarettes (“dual users”) may not be adequately informed of their continued risk from smoking combustible cigarettes as well as the known harms of e-cigarettes. The goal of this project is to develop communication campaign messages for dual users that increase their knowledge of the high health risk of dual use and increase their intent to quit combustible cigarettes and ultimately e-cigarettes. Study aims are: (1) to develop effective campaign messages by investigating how dual users think about their identity, motivations for tobacco product use, and the barriers to quitting combustible cigarettes; (2) to determine whether campaign ads are more engaging if they focus on quitting combustible cigarettes only, sequentially quitting cigarettes and e-cigarettes, or simultaneously quitting cigarettes and e-cigarettes; and (3) to pilot test the effectiveness of texted campaign ads in changing real-world combustible cigarette and e-cigarette quit intention among dual users. To achieve Aim 1, the research team will conduct six focus groups (8-10 adult dual users ages 18+ per group) to better understand dual use and gather concepts for messages, draft 50-75 potential campaign messages for dual users to encourage them to quit, and conduct a national survey with 1,008 adult dual users to select the most promising campaign message themes. To achieve Aim 2, the team will create visual ads for the messages from Aim 1 and use an eye-tracking experiment to determine how the different conditions affect attention among dual users. To achieve Aim 3, the team will conduct a five-week experiment with 90 adult dual users randomized to receive the most effective ads from Aim 2 or control ads in order to determine subsequent quit intentions and behaviors. Study findings may inform the development of communication campaign messages specifically for dual cigarette and e-cigarette users.

M. Justin Byron Funding Mechanism: National Institutes of Health – Grant
ID number: 1K01CA253234-01
Institution: University of North Carolina
09/16/2020

Patterns of Use and Health Effects of “Premium Cigars” and Priority Research

Patterns of use can vary widely across cigar subtypes both by frequency of use and the population subgroups most likely to use them. Some research indicates that “premium” cigar smokers (versus smokers of other cigar subtypes) are significantly less likely to use cigars regularly (daily or monthly) or report current cigarette smoking. Still, all cigars pose serious negative health risks and premium cigars are used by youth and young adults. The goal of this study is to conduct an in-depth evaluation of the public health issues related to premium cigars (defined in this study as large cigars that contain tightly rolled tobacco wrapped in a tobacco leaf) as well as the health effects of premium cigars compared to other cigars and other tobacco products. This study will involve a comprehensive and systematic review and assessment of the scientific literature related to premium cigars. Topics evaluated will include patterns of use of premium cigars; how use patterns differ among cigar subtypes and other tobacco products and among different populations (types of tobacco users, age groups, and other demographics); and the short- and long-term health effects of premium cigar use. Findings may inform future regulatory activities related to premium cigars.

Stuart Nightingale and Caroline Hagedorn (CTP Contact: Lisa Lagasse) Funding Mechanism: Research Contract
ID Number: 75F40120S90019
Institution: National Academics of Sciences, Engineering, and Medicine (NASEM)
09/14/2020

Chronic Hookah (Waterpipe) Smoking, Vascular Dysfunction, Inflammation and Oxidative Stress

The goal of this research is to clarify the long-term health effects of hookah (waterpipe) smoking on endothelial (artery lining) and vascular (blood vessel) function and identify biomarkers of harm that are associated with the effects of chronic hookah smoking on vascular health. Study aims are: (1) to evaluate the chronic effects of hookah smoking on peripheral endothelial function; (2) to study the chronic effects of hookah smoking on central artery stiffness; and (3) to evaluate the chronic effects of hookah smoking on biological markers of oxidative stress and inflammation. In 34 healthy chronic hookah smokers (ages 21-49 years) who never smoked cigarettes, matched for age and sex with 34 cigarette smokers and 34 non/never-smokers, researchers will measure: (a) endothelial function (measured by brachial artery flow-mediated dilation); and (b) vascular stiffness (measured by carotid-femoral pulse wave velocity and aortic augmentation index). Biological markers of inflammation (high sensitivity C-reactive protein, 8-iso-prostaglandin F2a, fibrinogen) and oxidative stress (pro-oxidant high density lipoprotein oxidant index and total antioxidant capacity) will be collected. Findings will provide new information about the chronic effects of hookah smoking and provide a foundation for future long-term studies of the effects of hookah smoking.

Mary Rezk-Hanna Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01HL152435-01A1
Institution: UCLA
09/10/2020

The Effect of Switching on or off Menthol Use on Cigarette Consumption, Dependence, Nicotine Exposure and Quitting Success

More information about menthol use among subpopulations would be useful. Researchers will analyze data from the adult (ages 18+) sample of cigarette smokers in Waves 1-4 of the Population Assessment of Tobacco and Health (PATH) Study using a technique called propensity score matching. They will study two groups of adult smokers: smokers who switched from menthol to non-menthol cigarettes and later attempted to quit smoking, and smokers who switched from non-menthol to menthol cigarettes and later attempted to quit smoking. Study aims are: (1) to compare quitting success between quit attempters who switched from menthol to non-menthol cigarettes and those who switched from non-menthol to menthol cigarettes; (2) to compare consumption, nicotine exposure, and dependence between adult smokers who did not successfully quit after either switching from menthol to non-menthol cigarettes or switching from non-menthol to menthol cigarettes; and (3) to assess whether race, sex or age modify the effect of switching from menthol to non-menthol cigarettes or from non-menthol to menthol cigarettes on 30-day cigarette abstinence, 12-month cigarette abstinence, consumption, dependence, and nicotine exposure. Study findings may inform future regulatory activities related to menthol.

Eric Leas Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21DA051356-01
Institution: University of California, San Diego
09/01/2020

Distinguishing Exposure to Secondhand and Thirdhand Tobacco Smoke and Electronic Cigarettes among U.S. Children Based on Multiple Biomarker Profiles

Currently, tobacco smoke exposure biomarkers that differentiate exposure to thirdhand smoke (THS) from exposure to secondhand smoke (SHS) or e-cigarette aerosol exposure are lacking. The goal of this project is to examine existing tobacco-specific and nonspecific biomarkers to assess children’s exposure to diverse tobacco/nicotine products. Researchers will analyze National Health and Nutrition Examination Survey (NHANES) 2013-2016 data to examine the prevalence and health risks of exposure to SHS and THS among children presumed to be unexposed to any tobacco smoke and among children exposed to e-cigarette aerosol only. This project has three study aims. Aim 1 is to compare tobacco-specific biomarkers of exposure (e.g., cotinine, total nicotine equivalents, tobacco-specific nitrosamines) with self-reported smoking and tobacco smoke exposure to categorize children into one of four groups: (a) mixed SHS and THS group (MEG): lives with nonsmokers or smokers of combustible products only, reported SHS; (b) THS group (TEG): lives with nonsmokers or smokers, no reported SHS; (c) e-cigarette group (ECG): lives with e-cigarette only users, reported e-cigarette aerosol exposure; and (d) no/minimal exposure group (NEG): lives with nonsmokers, no reported SHS. Aim 2 is to examine multiple tobacco-nonspecific (i.e., polyaromatic hydrocarbons, volatile organic compounds) and tobacco-specific biomarkers and biomarker ratios (e.g., NNAL/cotinine, 2-hydroxyfluorene/cotinine) to assess which combination of biomarker profiles further differentiates children by exposure type. Aim 3 is to examine the associations between exposure type and demographics, exposure-related symptoms, diagnoses, and healthcare utilization patterns in the MEG, TEG, and ECG compared with the NEG. Study findings will provide insight into the different health effects children experience depending on type of tobacco product exposure.

Ashley Merianos Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21ES032161-01
Institution: University of Cincinnati
08/24/2020

CTP Supplement to Parent Grant: Yale Center for the Study of Tobacco Product Use and Addiction: Flavors, Nicotine, and Other Constituents (YCSTP) (TCORS 2.0)

This supplement project will measure the effects of e-cigarette use and abstinence on the adolescent brain and behavior by testing biomarkers to assess short- and long-term e-cigarette effects. This project will add neuroimaging and neurocognitive testing to an existing clinical trial of an e-cigarette cessation intervention in adolescents (Yale’s Adolescent Brain Cognitive Development [ABCD] study); it will use ABCD neuroimaging and neurocognitive testing protocols to investigate how critical domains of function (i.e., reward processing, impulsivity and impulse control, working memory, emotion regulation) differ among adolescent e-cigarette users and change with abstinence. All youth in the trial (N=100; ages 13-20) will complete the ABCD neurocognitive battery, and 30 youth in the trial and 30 age/sex-matched controls will complete the ABCD neuroimaging protocol. Specific aims are: (1) to test for baseline brain and behavioral differences in critical domains of function between youth e-cigarette users and non-users; (2) to compare changes in brain and behavioral measures of critical domains of function between youth e-cigarette users and non-users; and (3) to test the relationship between changes in critical domains of function and e-cigarette abstinence among youth users. Findings will provide some of the first measures of the impact of e-cigarette use and abstinence on brain and behavior biomarkers of addiction among adolescents.

Stephanie O’Malley and Suchitra Krishnan-Sarin Principal Investigator:
Funding Mechanism: National Institutes of Health – Grant
ID Number: 3U54DA036151-08S3
Institution: Yale University
08/21/2020

Center for the Study of Tobacco Products: Respiratory Effects of THC and Nicotine E-Cigarettes: A Prospective Study

E-cigarette/vaping-associated lung injury (EVALI) is a new disease that is not well-understood, in part because of the differences among e-cigarette devices and liquids used; however, it has been linked to tetrahydrocannabinol (THC) liquid use and vitamin E acetate inhalation. Importantly, computed tomography (CT) scans of the lungs of EVALI patients uniformly reveal “ground-glass opacities” (GGOs), which indicates partial displacement of air within the lung; the appearance of GGOs in e-cigarette users is a potential EVALI biomarker. Researchers at the Center for the Study of Tobacco Products (CSTP) will perform CT scans and pulmonary function tests and analyze the devices and liquids from healthy e-cigarette users aged 18-45 years. They will track participants’ respiratory health for two years and then conduct a second set of CTs and pulmonary function tests. Study aims are: (1) to perform CT scans and pulmonary function tests at baseline and after two years on 45 exclusive nicotine e-cigarette users, 45 exclusive THC e-cigarette users, and 45 nicotine+THC e-cigarette users, as well as an additional 45 non-e-cigarette users as controls; (2) to identify e-cigarette devices and analyze e-cigarette liquids used by each participant; and (3) to track respiratory health over two years using quarterly online surveys assessing respiratory and gastrointestinal symptoms. Study findings may provide more information about EVALI and may inform future regulatory activities related to e-cigarettes.

Thomas Eissenberg Funding Mechanism: National Institutes of Health – Grant
ID number: 3U54DA036105-08S1
Institution: Virginia Commonwealth University
08/20/2020

Pilot Study to Determine Health Effects of E-cigarettes in Healthy Young Adults

In this CTP supplement to a parent grant (Integrated Translational Health Research Institute of Virginia (iThriv): Using Data to Improve Health), researchers will conduct studies to assess early changes in human lungs due to e-cigarette use. This study will use a new magnetic resonance imaging technique called 3-dimensional hyperpolarized xenon-129 MRI. It is anticipated that this new MRI technique will help detect possible early changes in the lungs of healthy young people who use e-cigarettes. Study aims are: (1) to determine effects of e-cigarette use on healthy young adults (ages 21-30) who have never smoked cigarettes, and (2) to develop research methods to perform a larger clinical trial to determine whether e-cigarettes cause lung disease, and if so, what kind. To achieve the first aim, researchers will study ten e-cigarette users with normal lung function tests and ten healthy non-users. Researchers will perform MRI tests and collect exhaled breath, blood, and urine for testing. To achieve the second aim, researchers will develop study methods for performing MRIs at two locations, the University of Virginia and Duke University, in preparation for a multi-center clinical trial to conclusively determine if there are harmful health effects of e-cigarettes. Study results will provide new knowledge on the impact of e-cigarettes on human lung health.

Karen Johnston Funding Mechanism: National Institutes of Health – Grant
ID number: 5UL1TR003015-02S4
Institution: University of Virginia
08/19/2020

Yale Center for the Study of Tobacco Product Use and Addiction: Flavors, Nicotine and Other Constituents

To reduce the risk of e-cigarette/vaping acute lung injury (EVALI), several states have banned flavored e-cigarette sales and one temporarily banned all vaping product sales. In this CTP supplement to a parent grant (Yale Center for the Study of Tobacco Product Use and Addiction), researchers will use new data from e-cigarette/vaping acute lung injury (EVALI) case reports by state and by month to estimate how smoking and vaping rates shifted in response to these policies as well as to the EVALI outbreak itself. Study aims are: (1) to clarify how state variation in behaviors and policies may have contributed to EVALI’s geographic distribution; (2) to quantify changes in vaping and smoking rates in response to the EVALI outbreak; and (3) to estimate how states’ policy responses to EVALI affected vaping and smoking. To address Aim 1, researchers will conduct analyses to characterize states’ 2019 EVALI prevalence by their pre-outbreak rates of vaping and marijuana use as well as marijuana legalization policies. To address Aim 2, researchers will analyze how adults’ smoking and vaping behavior shifted following changes in their state’s reported EVALI prevalence. To address Aim 3, researchers will estimate how banning flavored e-cigarette sales and all vaping product sales affected smoking and vaping rates (before and after policy implementation and compared to states that did not adopt policies). Study findings may inform state regulatory activities related to e-cigarettes.

Suchitra Krishnan-Sarin Funding Mechanism: National Institutes of Health – Grant
ID number: 3U54DA036151-08S2
Institution: Yale University
08/14/2020

Secondhand E-cigarette Exposure and Lung Function in Children

In this CTP Supplement to a parent grant about how lifetime environmental exposures impact health (the HERCULES Exposome Research Center), researchers will describe secondhand e-cigarette aerosol exposure and measures of lung function in children (ages 6-12) who reside with daily vapers. Study aims are: (1) to examine associations between secondhand e-cigarette aerosol chemical exposures and salivary metabolic profiles and pathways, and (2) to examine associations of secondhand e-cigarette chemical exposure and salivary metabolic profiles with markers of lung function. To achieve Aim 1, researchers will measure nicotine, benzene, and toluene exposure in 30 children of daily vapers and 30 children of non-vapers/non-smokers who will wear wristband air samplers for 120 hours (5 days). Researchers will collect saliva samples and analyze them to identify altered metabolic profiles and pathways; they will also examine associations of nicotine, benzene, and toluene with salivary metabolic profiles. To achieve Aim 2, researchers will examine associations between nicotine, benzene, and toluene exposure data and metabolomics data (from Aim 1) and lung function measures including fractional exhaled nitric oxide (FeNO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC), mid-expiration forced expiratory flow rate (FEF 25-75%), and parent report of recurrent/chronic respiratory symptoms. Study findings may inform future regulatory activities related to e-cigarettes.

Carmen Marsit Funding Mechanism: National Institutes of Health – Grant
ID number: 3P30ES019776-08S1
Institution: Emory University
08/11/2020

Understanding the Influence of E-cigarette Advertisement Features

The goal of this study is to examine the influence of four e-cigarette advertisement features (flavors, models, marketing claims, and price promotions) on young adult (ages 18-29) non-tobacco users who are susceptible to e-cigarette use. Study aims are: (1) to identify key features of e-cigarette advertisements that lead to greater attention; (2) to examine the associations between key features of e-cigarette advertisements and positive neurocognitive responses; and (3) to determine whether edited advertisements without key features lead to reduced positive e-cigarette perceptions and behavioral intentions compared to original advertisements. To address Aim 1, researchers will use eye-tracking technology to identify key e-cigarette advertisement features that receive attention (gaze duration and fixation frequency) in 70 young adults. To address Aim 2, researchers will use electroencephalogram (EEG) technology to evaluate the associations between key e-cigarette advertisement features and sustained cognitive processing and emotional arousal in 120 young adults. To address Aim 3, researchers will conduct a randomized comparative study among 900 young adults to determine whether an intervention group that receives e-cigarette advertisements without key features has lower levels of positive e-cigarette perceptions and behavioral intentions than a control group that receives original unaltered advertisements. Findings will provide information about the potential impact of specific e-cigarette advertising characteristics on the initiation and progression of e-cigarette use among young adults.

Julia Cen Chen-Sankey Funding Mechanism: National Institutes of Health – Grant
ID number: 1K99CA242589-01A1
Institution: National Institute on Minority Health and Health Disparities
08/07/2020

The Relationship Between Nicotine Metabolism and Nicotine Concentrations in E-cigarettes on Smoking Behavior and Toxicant Exposure in African American and White Smokers

African Americans are particularly vulnerable to smoking-related diseases and are less successful at smoking cessation. The goal of this study is to investigate the use of e-cigarettes for smoking reduction in African American and White smokers. Study aims are: (1) to investigate the impact of nicotine metabolism on nicotine pharmacokinetics and the subjective effects of nicotine concentrations in e-cigarettes, and (2) to elucidate the relationship between nicotine metabolism and nicotine concentrations in e-cigarettes and the impact on smoking behavior and toxicant exposure. To address Aim 1, 56 smokers (28 African American subjects and 28 White subjects ages 18 and older) will receive e-cigarettes with their preferred flavor (menthol or tobacco) and 10mg/ml and 50mg/ml of nicotine during two sessions (one concentration per session). To address Aim 2, one week after the completion of Aim 1, subjects will receive preferred-flavor e-cigarettes with 10mg/ml or 50mg/ml of nicotine to take home for two weeks. Outcomes (and associated race differences) for these study aims will include nicotine metabolite rate, plasma nicotine levels, carbon monoxide, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), cigarette craving, nicotine withdrawal, nicotine dependence, cardiovascular and lung function, volatile organic compounds, self-reports of combustible tobacco product use, e-cigarette use, and amount of e-liquid used. Study findings will help elucidate the relationship between nicotine metabolism and e-cigarette nicotine concentration and its impact on smoking behavior and toxicant exposure in African American and White smokers.

Asti Jackson Funding Mechanism: National Institutes of Health – Grant
ID number: 1K01DA051882-01
Institution: Yale University
08/05/2020

Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Use Escalation Among Young Adult Electronic Nicotine Delivery Systems Users

The goal of this study is to identify neurobehavioral markers of nicotine use escalation and cigarette smoking initiation among young adult electronic nicotine delivery systems (ENDS) users. Study aims are: (1) to identify neural and behavioral markers of ENDS escalation and smoking initiation; (2) to determine whether neural markers add predictive utility beyond traditional measures; and (3) to determine the efficacy of public service announcements (PSAs) and identify neural predictors of PSA efficacy. At baseline, the researcher will measure traditional behavioral and novel brain responses using functional MRI in 180 non-smoking young adult (age 18-20) ENDS users to identify salient predictors of nicotine use escalation and smoking initiation; the researcher will quantify responses to smoking stimuli, vaping stimuli, and associated food stimuli in brain systems associated with cognitive control, emotion, and salience. Responses in the same brain networks will be assessed in response to existing tobacco control education PSAs and PSAs addressing ENDS flavors. Over the following six months, participants will receive weekly PSAs and bi-weekly PSA evaluations via emails and texts. In addition to evaluating the PSAs, participants will report all tobacco product use during the past two weeks. In-person visits at 3, 6, 9 and 12 months will include breath carbon monoxide and urine cotinine tests. Outcomes will include cigarettes smoked, exhaled carbon monoxide levels, urine cotinine levels, and ENDS and tobacco use outcomes. Study findings may inform future regulatory activities related to ENDS.

Jiaying Liu Funding Mechanism: National Institutes of Health – Grant
ID number: 1K01DA049292-01A1
Institution: University of Georgia
08/01/2020

Novel Methods for Evaluating the Association of Electronic Cigarette Use with Cardiovascular Health

The goal of this study is to provide population-based evidence on the cardiovascular (CV) effects of e-cigarette use, including particular e-cigarette aerosol components that may be responsible for CV harm. Study aims are: (1) to examine the effects of e-cigarette use and cigarette/e-cigarette transitions on CV events; (2) to estimate associations of e-cigarette use with risk factors and preclinical biomarkers of CV injury, and to analyze biomarkers of exposure as potential mediators; and (3) to identify unique biomarker signatures of e-cigarette exposure and to associate clusters with preclinical biomarkers of CV injury. To achieve Aim 1, the researcher will use data from the Population Assessment of Tobacco and Health (PATH) Study Waves 1-4 (2013-2017) to investigate to what extent e-cigarette use is associated with CV events including myocardial infarction, stroke, and heart failure. To achieve Aim 2, the researcher will assess the effects of e-cigarette use on CV risk factors (blood pressure, triglycerides, and cholesterol) using data from the National Health and Nutrition Examination Survey (NHANES, 2013-2016) and on preclinical biomarkers of CV injury (inflammation, thrombosis, and oxidative stress) using data from PATH Wave 1 (2013-2014). To identify specific e-cigarette aerosol components that mediate CV risk, the researcher will analyze urinary exposure biomarkers for product constituents (nicotine, tobacco-specific nitrosamines [TSNAs], volatile organic compounds [VOCs], polycyclic aromatic hydrocarbons [PAHs], and metals). To achieve Aim 3, the researcher will use data from PATH Wave 1 to define clusters of e-cigarette use based on shared urinary exposure biomarker profiles related to use behaviors (frequency, other tobacco products, and reasons for use) and product characteristics (type and flavors), and associate each with preclinical biomarkers of CV injury. Study findings may inform regulatory activities related to e-cigarettes.

Andrew Stokes Funding Mechanism: National Institutes of Health – Grant
ID number: 1K01HL154130-01
Institution: Boston University Medical Campus
07/30/2020

Development of Early Warning System for Toxins Related to EVALI and Vaping

In this CTP supplement to a parent grant (Co-Abuse of Cannabis and Tobacco), researchers will lay the foundation for developing an early warning system that identifies and evaluates emerging chemical threats posed by e-liquids that may lead to acute illnesses such as e-cigarette/vaping-associated acute lung injury (EVALI). The goal is to detect emerging trends in the composition of vaping liquids and would allow identification and evaluation of possible hazards before their use becomes widespread. Study aims are: (1) to mine social media data to identify emerging vaping products and potential hazardous constituents used in vape liquids; and (2) to analyze the aerosol properties and chemical composition of aerosolized vitamin E acetate (i.e., a chemical already suspected to be hazardous) and other potential hazardous constituents identified from social media monitoring in Aim 1 to determine their effects in lung tissue. Findings may inform future regulatory activities related to e-cigarettes.

Jenny Wiley Funding Mechanism: National Institutes of Health – Grant
ID number: 3R33DA044377-04S1
Institution: Research Triangle Institute (RTI) International
07/27/2020

Hispanic and Latino Youth and Tobacco Use: Foundational Research

The goal of this research effort is to guide CTP audience segmentation and communications strategies to inform evidence-based decisions about communications activities designed to prevent initiation of tobacco use among Hispanic/Latino youth and young adults. The research includes three tasks: (1) a comprehensive literature review and environmental scan, (2) secondary data analysis and audience segmentation, and (3) primary data collection among high-risk audiences. The scope and approach of the primary data collection will be informed by the first two phases and will include at least one round of qualitative data collection (e.g., focus group discussions) and may also include quantitative data collection/survey research; the number of subjects and age ranges have yet to be determined. This research will inform future CTP communications activities that are targeted toward Hispanic/Latino youth.

Everly Marcario and Emily Sanders Funding Mechanism: Contract
ID number: 75F40120A00002
Institution: IQ Solutions
07/27/2020

Respiratory Health and Cigar and Pipe Use in the NHLBI Pooled Cohorts Study

Cigarette smoking is the major risk factor for chronic lower respiratory disease (CLRD), which includes chronic obstructive pulmonary disease (COPD) and asthma. The goal of this study is to test whether cigar and pipe use is associated with accelerated lung function decline and CLRD-related hospitalizations and mortality. Researchers will analyze data from the National Heart, Lung, and Blood Institute (NHLBI) Pooled Cohorts Study, which collected lung function data (including spirometry exam data) from nine US general population-based cohorts that included 65,251 American Indian, Asian, Black, Hispanic and White adult men and women. Study aims are: (1) to harmonize self-reported interview questions on cigar and pipe use across the study cohorts in order to characterize cigar/pipe use; (2) to assess associations between cigar/pipe use and lung function changes over time, including rates of forced expiratory volume in one second (FEV1) decline, forced vital capacity (FVC) decline, FEV1/FVC, and airflow obstruction; and (3) to assess the association between cigar/pipe use and CLRD-related hospitalizations and mortality. Study findings may inform future regulatory activities related to cigar and pipe tobacco products.

Elizabeth Oelsner Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21HL153700-01
Institution: Columbia University Health Sciences
07/25/2020

Respiratory Effects of Exposure to Metals from Electronic Cigarettes (RE-EMIT)

Several metals, including lead and nickel, are known lung toxicants and have been found in e-cigarette aerosols. In this CTP supplement to a parent grant (The Exposure to Metals from E-Cigarettes (EMIT) Study), researchers will study how patterns of “pod” e-cigarette device use impact exposure to metals among young adults (ages 18-24) and how these metal exposures may be associated with pulmonary health effects. Study aims are: (1) to evaluate the contribution of pod devices to metal exposure; (2) to measure pod users’ pulmonary health outcomes and evaluate their association with pod use; and (3) to assess the role of metals in pod-related pulmonary health outcomes. To achieve Aim 1, researchers will assess metal concentrations in pod aerosol (collected from each participant’s device) and assess their association with use patterns (from a questionnaire) as well as established biomarkers of metal exposure in blood (lead, cadmium, manganese and zinc) and urine (nickel, arsenic, chromium, antimony, and tungsten); they will also measure chromium and arsenic in the aerosol. To achieve Aim 2, researchers will characterize differences in pulmonary outcomes between pod users and non-users at 0 and 6 months; among users, researchers will evaluate differences by age, sex, and pod type. To achieve Aim 3, researchers will assess the association of metals in pods and in biomarkers of exposure (e.g., urine nickel) with measures of lung effects by evaluating which patients fall below the lower limit of normal for pulmonary function tests. Researchers will add pulmonary outcome measures to 25 pod users and 25 control participants from the parent study, and will recruit an additional 25 pod users and 25 non-users (ages 18-24) to characterize pulmonary outcomes (reductions in the forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing capacity of carbon monoxide (DLCO)), measures of metals in device aerosols, and measures of exposure to metals in urine and blood at 0 and 6 months. Study findings may inform future regulatory activities related to e-cigarettes.

Ana Maria Rule Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01ES030025-03S1
Institution: Johns Hopkins University
07/22/2020

Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs

Additional information about the pulmonary health effects of e-cigarettes would be useful, particularly given the growing number of e-cigarette or vaping use-associated lung injury (EVALI) cases. In this CTP Supplement to a parent grant (Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs), researchers will use a human induced pluripotent stem cell (iPSC)-based in vitro pulmonary toxicity screen to investigate the cellular, molecular, and genomic effects of six common e-cigarette components on lung tissue. Study aims are: (1) to generate iPSC-derived lung cells (i.e., alveolar epithelial cells, fibroblasts, smooth muscle cells, endothelial cells) from 12 existing healthy iPSC lines (6 male/6 female); and (2) to investigate the effects of e-cigarette components implicated in EVALI, including vitamin E acetate, tetrahydrocannabinol (THC), nicotine, propylene glycol, vegetable glycerin, and cannabidiol (CBD). Study findings may lead to new biomarkers and may inform future regulatory activities related to e-cigarettes.

Joseph Wu and Thomas Quertermous Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01HL141851-02S1
Institution: Stanford University
07/20/2020

Cigarette Smoking as a Risk Factor for Greater Psychiatric Symptom Severity Across Serious Mental Illnesses: A Secondary Analysis of Three Nationally-Representative NIH Datasets

People with serious mental illnesses (SMIs) such as bipolar disorder (BD), schizophrenia (SCZ), and major depressive disorder (MDD) comprise a population that is especially vulnerable to tobacco use; people with SMIs are twice as likely to smoke as people without SMIs. However, a federal tobacco education campaign targeted to the SMI subpopulation has not yet been developed. The goal of this study is to provide scientific evidence that could be used to develop such a campaign. Specific aims are: (1) to determine whether smoking is a risk factor for increased time in illness episodes (mood episodes in BD smokers; psychotic episodes in SCZ smokers; and depressive episodes in MDD smokers) in people with SMIs; (2) to determine whether smoking is a risk factor for increased time in depression across SMIs; and (3) to determine predictors of within-person changes in smoking behavior (initiating, quitting, relapsing). To achieve these aims, researchers will analyze data from three large National Institutes of Health datasets (BD: STEP-BD study, N=4361; SCZ: CATIE study, N=1460; and MDD: STAR*D study, N=2248). Study findings will provide scientific evidence that may be used to inform the development of a tobacco education campaign targeted to people with SMIs.

David Bond Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21DA051538-01
Institution: University of Minnesota
07/20/2020

Predicting Longitudinal Patterns of Change in Adolescent Polytobacco Use: A Socio-Ecological Framework

More information about how patterns of single and polytobacco use change from early adolescence into emerging adulthood would be useful. The goal of this project is to examine patterns of change and associated predictive factors over an extended time period. Study aims are: (1) to examine trajectories and related predictors of single tobacco product use from early adolescence (age 12) to emerging adulthood (age 23); (2) to examine transitions into and out of polytobacco use classes, as well as predictors of these classes, from early adolescence (age 12) to emerging adulthood (age 23), and (3) to examine interactions among individual (e.g., motives for use, sensation seeking), interpersonal (e.g., parent modeling, rules), and contextual (e.g., geographic location) factors in predicting trajectories of single tobacco product use and transitions in polytobacco use. Researchers will analyze Population Assessment of Tobacco and Health (PATH) Study data (total of 52,731 respondents) from study waves 1 (2013-2014), 2 (2014-2015), 3 (2015-2016) and 4 (2016-2018) to examine the changes over time in use of tobacco products (cigarettes, cigars, waterpipes, smokeless tobacco, electronic cigarettes) individually and in combination. Study findings may inform regulatory activities related to youth and young adult use of tobacco products.

Melissa Blank Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21DA051628-01
Institution: West Virginia University
07/20/2020

Measuring Anatalline and Nicotelline to Differentiate Non-combusted Tobacco Use Using the PATH Study

Biomarkers that can distinguish between types of tobacco product use can be used to help track associated health effects. The goal of this study is to measure nicotelline, a minor tobacco alkaloid associated with tobacco smoke particulate matter, in urine biospecimens gathered during Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study. Previous research has shown that, when expressed as a ratio with its parent compound (anatalline), nicotelline may distinguish smokeless tobacco use from combusted tobacco use. Study Aim 1 will validate the anatalline/nicotelline ratio cut-points (as well as nicotelline in combination with other tobacco exposure biomarkers) that distinguish exclusive cigarette use, exclusive smokeless tobacco use, and dual smokeless plus cigarette use (140 adults each). In Study Aim 2, researchers will use the same participant groups defined in Study Aim 1 to explore whether nicotelline and ratios of nicotelline-to-traditional tobacco biomarkers (i.e., 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL]) can differentiate e-cigarette use from exclusive cigarette use using data from exclusive e-cigarette users and dual e-cigarette plus cigarette users. Study findings may confirm nicotelline’s usefulness as a biomarker to discriminate among tobacco products and to identify patterns of polytobacco use.

Kathryn Edwards and Gideon St. Helen Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21DA051491-01
Institution: Westat
07/20/2020

Tobacco Use Trajectories and Disparities Among Sexual Minorities in U.S Adolescents and Adults

Sexual minority individuals comprise a population that is particularly vulnerable to tobacco use. The goal of this project is to analyze tobacco use across time in sexual minorities and resulting tobacco-related health disparities using Population Assessment of Tobacco and Health (PATH) Study data. Of PATH respondents with valid self-reported sexual identity (gay/lesbian, bisexual, something else, or straight) at all four study waves (N=26,696, ages 12+years), 2,520 reported sexual minority identity at one wave or more; 1,474 reported sexual minority identify at wave 1; and 905 reported sexual minority identity at all four waves. Study aims are: (1) to examine tobacco product initiation and use trajectories by sexual orientation and their associations with regular tobacco use and tobacco use disorder symptoms; (2) to identify tobacco use trajectories by sexual orientation and different associations with self-reported and biological health outcomes; and (3) to examine the role of biological and psychological stress on tobacco use trajectories, tobacco cessation, and tobacco-related health outcomes among adults and how these measures differ by sexual orientation. Researchers will assess tobacco use trajectories, including tobacco use initiation; progression in the number of products used, with a focus on e-cigarette use/non-use; and increase and decrease in use frequency. Aims 2 and 3 will involve analysis of survey self-report measures of stress (psychological distress) and health outcomes (respiratory illness, cancer, cardiovascular disease) alongside biological markers of stress (e.g. C-reactive protein, interleukin-6) and tobacco-specific markers linked to cancer risk (NNAL, NNN, TNE2). Researchers will also examine important moderators including age, sex, race and ethnicity throughout in all analyses. This project will provide new data that may inform regulatory activities to address the health burden of tobacco use among sexual minorities.

Rebecca Evans-Polce Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21DA051388-01
Institution: University of Michigan
07/20/2020

Do E-Cigarette Users Airways Have an Altered Lipid Content?

In this study, researchers will use previously-collected serum, saliva, sputum, and bronchoalveolar lavage fluid (BALF) from healthy never-smokers, tobacco smokers or vapers to determine whether the airways of e-cigarette users have an altered lipid (fat) content that may cause acute lung injury. Study aims are: (1) to determine the concentrations of lipid-associated surfactant proteins in samples of BALF, sputum and saliva from non-smokers, smokers and vapers; (2) to measure lung cell lipid content and stain alveolar macrophages (a type of white blood cell in the lung) with Oil Red O to look for altered lipid content in vapers’ alveolar macrophages and airway secretions; and (3) to study metabolites on samples of BALF, sputum and saliva from non-smokers, smokers and vapers. To achieve Aim 1, researchers will use western blotting techniques to determine the amounts of lipid-associated surfactant proteins in vapers’ airway secretions. To achieve Aim 2, researchers will use mass spectrometry as well as standard histological techniques to better understand the impact of lipid accumulation on vapers’ lungs. To achieve Aim 3, researchers will use mass spectrometry to determine levels of nicotine, cotinine, tetrahydrocannabinol (THC), and metabolites that are associated with lung injury in vapers’, non-smokers’, and smokers’ lungs. Findings may inform future regulatory activities related to e-cigarettes.

Robert Tarran Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21HL153698-01
Institution: University of North Carolina, Chapel Hill
07/20/2020

Do E-cigarette Design Features Impact Cigarette Initiation, Cessation & Relapse?

More information about how e-cigarette characteristics impact transitions to and from cigarette smoking would be useful. This project will evaluate the independent effects of four e-cigarette design features (flavors, device type, nicotine content, and nicotine formulation) on later cigarette smoking initiation, cessation, and relapse among youth (ages 12-17), young adults (ages 18-24) and adults (ages 25 and older) in the U.S. Researchers will analyze data from the Population Assessment of Tobacco and Health (PATH) Study, the U.S. arm of the International Tobacco Control (ITC) Youth Tobacco and E-cigarette Survey, and the U.S. arm of the ITC Four Country Smoking and Vaping Survey. Study aims are: (1) to examine e-cigarette use and cigarette initiation among non-smoking youth and young adults, particularly whether and how e-cigarette design features predict future cigarette smoking initiation, including progression to regular cigarette smoking; (2) to examine e-cigarette use and cigarette cessation among youth and adult cigarette smokers, specifically whether and how e-cigarette design features impact later cigarette smoking cessation, considering both the potential reach and effectiveness of design features; and (3) to examine e-cigarette use and cigarette relapse among adult former cigarette smokers, specifically whether and how e-cigarette design features impact later cigarette smoking relapse. These findings may inform FDA regulatory activities related to e-cigarettes.

Karin Kasza Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21DA051446-01
Institution: Roswell Park Cancer Institute Corporation
07/17/2020

Derivation of Lung Epithelia from iPS cells for Advanced Disease Modeling

The goal of this CTP supplement to a parent grant (which funds the study of alveolar epithelial type 2 cells [AEC2s], a type of lung cell) is to determine the effects of e-cigarette vapor exposure on the human alveolar epithelium (the internal surface area of the lung). Researchers will use newly-developed protocols to generate human AEC2s from induced pluripotent stem cells (iPSCs). They will culture the AEC2s using an air-liquid interface method and then expose them to (1) e-cigarette vapor containing nicotine, (2) e-cigarette vapor containing vitamin E-acetate (implicated in e-cigarette/vaping acute lung injury, or EVALI), (3) cigarette smoke, or (4) air (a control condition). Researchers will then measure the effects of these exposures on the RNA molecules, proteins, and metabolites in the AEC2s and generate a dataset. Study findings will describe e-cigarette vapor injury to this key lung cell type.

Darrell Kotton Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01HL095993-11S1
Institution: Boston University Medical Campus
07/17/2020

CTP Supplement to Parent Grant: The Role of Histone Deacetylase 9 in Vascular Calcification

In this CTP Supplement to a parent grant studying the role of histone deacetylase 9 (HDAC9, an essential regulator of vascular function), researchers will investigate whether toxic metals from vaping products prompt HDAC9-dependent dysregulation of vascular cell function and increased inflammation. Study aims are: (1) to analyze the heavy metal profiles of aerosol vapor generated by different open-system vaping devices, and (2) to determine the effects of toxic heavy metals in vaping aerosols and e-fluids on vascular cell function in vitro and cardiovascular and pulmonary function in vivo. To achieve Aim 1, researchers will use mass spectrometry to profile metals (by element and concentration) in aerosol vapor from six different open-system vaping devices (three refillable cartridges and three tank devices) and identify the origin (e-fluid, reservoir, heating coil) of each metal. To achieve Aim 2, researchers will use cell culture-based assays to determine how vaping aerosols, e-fluids, and metal constituents identified in Aim 1 affect gene and protein expression patterns and cellular function. They will also use wild-type and HDAC9-deficient mice to study the effects of chronic (1 month) vaping aerosol exposure on cardiovascular function (echocardiography), blood pressure, endothelial function, vascular reactivity, pulmonary function, and inflammation profile. Study findings may inform regulatory activities related to e-cigarettes.

Rajeev Malhotra Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01HL142809-03S1
Institution: Massachusetts General Hospital
07/17/2020

A Mouse Model of Vaping Vitamin E Acetate: Effects on Lung Function and Pathology

In this CTP supplement to a parent grant (Effects of E-cigarette Exposure during Pregnancy on Offspring Lung Function and Disease: Characterization of Pulmonary, Intergenerational, and Epigenetic Effects), researchers will study the effects of inhaling vitamin E acetate (VEA) compared to aerosolized nicotine in propylene glycol/vegetable glycerol (PG/VG), which is linked to e-cigarette/vaping-associated lung injury (EVALI), on lung function and pathology in a mouse model. Study aims are: (1) to characterize the acute effects of vaping with increasing e-liquid percentage of VEA; and (2) to characterize the chronic effects of vaping VEA on lung function and pathology. To achieve Aim 1, researchers will expose mice that have not previously been exposed to vaping (naïve mice) and mice that have been exposed to house dust mite antigen (sensitized mice) or to aerosolized nicotine in PG/VG to increasing percentages (0, 10, 20, 40, or 80%) of VEA in PG/VG (1:1) e-liquid; researchers will determine VEA effects on pulse oximetry, bronchial lavage composition, and lung pathology compared to nicotine. At the optimal condition found to induce EVALI-like changes, researchers will determine the effects of modifying voltage. To achieve Aim 2, researchers will determine the chronic pulmonary effects of vaping (measured at 2 and 4 weeks) using a complete battery of pulmonary function tests, pulse oximetry, heart rate, bronchial lavage and lung pathology on naïve and sensitized mice. Study findings may inform the understanding of the link of pre-disposing factors, such as prior ENDS use, and pre-existing respiratory conditions, such as asthma, on the incidence of EVALI.

Eliot Spindel Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01HL144384-02S1
Institution: Oregon Health & Science University
07/09/2020

Impact of E-cigarette Prevention Messages on Adolescents

Additional research to inform effective communications related to e-cigarette prevention among adolescents would be useful. The goal of this project is to identify e-cigarette prevention messages that will reduce adolescents’ (ages 13-17) willingness to use e-cigarettes. Study aims are: (1) to identify promising ways to communicate with adolescents to prevent e-cigarette use; (2) to develop a set of e-cigarette prevention messages that discourage adolescents from wanting to use e-cigarettes; and (3) to evaluate whether prevention messages reduce at-risk adolescents’ willingness to use e-cigarettes and e-cigarette use behavior in a randomized controlled trial (RCT). To achieve Aim 1, researchers will: identify promising prevention message themes (e.g., health effects, social norms, addiction) targeted to adolescents based on the empirical literature; vet these themes with the study team, expert consultants, and a teen advisory panel; work with an advertising agency to develop creative concepts for the most prominent themes; and conduct six focus groups with about 60 adolescents to examine their responses to the creative concepts. To achieve Aim 2, researchers will: develop 10 e-cigarette prevention messages based on the chosen concepts from Aim 1; conduct 30 cognitive interviews with 10 tobacco-using, 10 tobacco-susceptible, and 10 non-susceptible non-user adolescents to refine the messages; and conduct an online study of 1,600 adolescents to examine the perceived effectiveness of the messages in discouraging e-cigarette use. To achieve Aim 3, researchers will select a set of the most promising messages from Aim 2 to test in an RCT with 506 adolescents who will receive daily text messages for 20 days; one group will receive one of the five e-cigarette prevention messages in a randomized order, while the other group will receive a control message such as “This study will help others in the future. Thanks for taking part!”. Researchers will examine the impact of messages on willingness to use e-cigarettes (primary outcome) and e-cigarette use, cognitive elaboration, negative affect, e-cigarette beliefs, and social interactions (secondary outcomes) with a brief daily assessment, 3 weekly surveys, and a survey at 3 months. Study findings may inform e-cigarette prevention messages and campaigns for adolescents.

Seth M. Noar Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA049155-01A1
Institution: University of North Carolina at Chapel Hill
06/12/2020

Translational Studies on Electronic Cigarette-Derived Oxidants and Their Long-term Pulmonary Effects

Oxidative stress and damage resulting from exposure to oxidants such as free radicals and aldehydes play critical roles in the development and progression of most tobacco-caused diseases, including chronic obstructive pulmonary disease (COPD). The goal of this project is to evaluate toxicities caused by exposure to e-cigarette-derived free radicals and aldehydes and their role in the development of COPD. Study aims are: (1) to investigate the long-term pulmonary effects of e-cigarette exposure from products delivering high vs. low oxidant levels in a COPD mouse model; (2) to determine the impact of switching from cigarettes to e-cigarettes; and (3) to conduct a pilot single arm trial to determine the impact of switching from cigarettes to e-cigarettes on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting COPD. To address Aim 1, researchers will conduct 3-month exposure studies to compare high vs. low oxidant e-cigarette products (Mod vs. Juul, respectively). To address Aim 2, researchers will pre-expose mice for 1.5 months to cigarette smoke prior to switching them to filtered air, e-cigarette aerosol, or 50/50 e-cigarette aerosol/cigarette smoke for the remaining 1.5 months to mimic the harm from “real world” e-cigarette use patterns in smokers (smoking cessation, switching to e-cigarettes, and dual use). The primary outcomes of Aims 1 and 2 will be development of a COPD phenotype (including changes in lung function and histology) and assessment of systemic and lung-specific biomarkers of oxidative stress/damage and inflammation. To address Aim 3, researchers will provide e-cigarettes to 30 smokers (ages 18-65) with mild/moderate COPD and ask them to use these products exclusively for a year; e-cigarette and cigarette usage will be monitored along with assessments of COPD-related clinical symptoms, spirometric lung function, and biomarkers of oxidative stress and inflammation. These studies will provide new information about the toxicological impact of oxidant exposure from specific e-cigarette devices.

John P. Richie Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01HL152436-01
Institution: Pennsylvania State University
05/22/2020

Impact of Nicotine Messaging on Nicotine Beliefs and Tobacco Use Behavior

The public health impact of FDA’s proposed nicotine reduction policy hinges on the extent to which tobacco users and non-users understand the harms of nicotine in specific products (e.g., e-cigarettes, nicotine replacement therapy (NRT), reduced nicotine content (RNC) cigarettes) and how this understanding influences decisions made by non-users to try a product and by users regarding cessation, product switching, or continued use. Research has highlighted widespread public misperceptions of the health risks of nicotine. A brief nicotine corrective messaging intervention may correct misperceptions of nicotine, NRT, e-cigarettes, and RNC cigarettes. The goal of this study is to examine the effect of multiple exposures to a nicotine corrective messaging (NCM) intervention (compared to a delayed intervention control) on nicotine beliefs and intention/use of tobacco and nicotine products in U.S. adults (age 18 and older). Study aims are: (1) to test the impact of NCM on nicotine beliefs and the subsequent impact on intention and use of tobacco and nicotine products in a national sample of 715 adult smokers and non-smokers followed for 12 weeks; and (2) to test the impact of NCM (messaging vs. control) and nicotine content of study cigarettes (normal vs. reduced) on nicotine beliefs and subsequent use of tobacco and nicotine products using a 2 x 2 factorial design in a sample of 160 adult current smokers followed for 4 weeks (participants will be explicitly told which product they have been given). In both studies, participants will complete online surveys at scheduled intervals throughout the study period in which they will be exposed to up to six corrective messages and subsequently complete survey questions. Study findings will provide information about the potential of NCM communication efforts on tobacco use behavior in the general population and in adult smokers affected by a reduced nicotine content standard in combustible cigarettes.

Andrea Villanti and Andrew Strasser Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA051001-01
Institution: University of Vermont and State Agricultural College
05/22/2020

Modified Use of E-Cigarettes and Marketing on YouTube

The goal of this study is to understand ways in which youth modify e-cigarettes, their motivations for doing so, and marketing sources. Study aims are: (1) to identify and characterize modified uses of e-cigarettes and associated marketing sources on youth-accessible YouTube videos, and (2) to examine modified uses and marketing exposure among an online sample of 500 adolescent (ages 13-17) and 500 young adult (ages 18-25) e-cigarette users. To address Aim 1, researchers will identify modified uses of e-cigarettes and marketing using fictitious youth YouTube viewer profiles to search for e-cigarettes using a browser plug-in and custom scripted web-crawling; then they will use machine-learning to automatically code the videos to identify e-cigarette modifications, motivations for modification, marketing sources, and appeal (number of views, number of likes). Subject matter experts in tobacco regulatory science, social media, youth tobacco use, toxicology, communications, and tobacco marketing will assess the potential impact of identified modified uses on e-cigarette appeal, addiction, and health effects. To address Aim 2, researchers will conduct an online survey with 1000 adolescent and young adult e-cigarette users to examine the prevalence, appeal, motivations, risk perceptions, and marketing exposure related to these modified uses and their predictors (i.e., demographic variables, past-month e-cigarette use frequency, e-cigarette dependence, other tobacco/substance use, interpersonal and intrapersonal risk factors). Findings may inform regulatory activities related to e-cigarettes.

Grace Kong Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA049878-01A1
Institution: Yale University
05/22/2020

Greenwashing Cigarettes: Perceptual and Behavioral Evidence of Inaccurate Modified Risk Advertising

“Greenwashing” is an increasingly common tobacco marketing strategy in which products are portrayed as eco-friendly and/or natural. Greenwashing tactics may inaccurately convey modified product risk to consumers. The goal of this project is to describe how cigarette companies use greenwashing to market their products and test the effect of these tactics on young adult (ages 18-29) risk perceptions in an online sample and actual smoking behavior in a controlled laboratory study. Study aims are: (1) to identify specific greenwashing tactics used in cigarette ads, determine their prevalence across brands and sub-brands, and determine changes in these tactics over time; (2) to test the extent to which the greenwashing tactics identified in Aim 1 contribute to inaccurate modified risk perception in 1,500 young adults using an online survey; and (3) to test the effect of greenwashing on behavioral economic demand and smoking topography in a laboratory-controlled cigarette self-administration study of 35 young adults. Findings will provide new information about the connection of greenwashing strategies to product risk perceptions and actual smoking behavior and may inform future regulatory activities.

Meghan B. Moran and Matthew Johnson Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA049814-01A1
Institution: Johns Hopkins University
05/21/2020

Shrinking the Size of the Tobacco Powerwall and Restricting the Number of Tobacco Products Displayed to Reduce Adolescent Tobacco Use

The most prominent source of retail point-of-sale (POS) tobacco advertising comes from the tobacco power wall, the large, expansive display of hundreds of different tobacco products typically located behind the cashier in full view of consumers. Adolescents are frequent visitors to retail stores and thus are at significant risk for having repeated exposures to the tobacco power wall. The goal of this project is to experimentally evaluate the extent to which reducing the size of the tobacco power wall and the number of tobacco product units displayed influences tobacco use risk in adolescents. Study aims are: (1) to evaluate the extent to which reducing the size of the power wall and number of units of each tobacco product displayed on the power wall influences tobacco use risk; (2) to model the mediational pathways through which these reductions initiatives have their effects; and (3) to examine whether gender and/or tobacco use experience moderate adolescents’ reactions to the power wall regulatory options under investigation. This study will take place in the RAND StoreLab (RSL), a life-sized replica of a convenience store developed to evaluate how altering aspects of POS promotion influences tobacco use risk during simulated shopping experiences. A total of 750 adolescents (ages 11-20) will be randomly assigned to shop in the RSL under one of three conditions (250 per condition): (1) large power wall/ multiple product units displayed; (2) small power wall/multiple product units displayed; and (3) small power wall/single product units displayed. Researchers will consider the effect of these power wall alterations on risk of use of four classes of tobacco products: cigarettes, electronic nicotine delivery devices, cigarillos, and smokeless tobacco. Tobacco use risk will be indexed by: attention to the tobacco power wall, perceived tobacco use norms, perceived availability of tobacco products, and tobacco use intentions. Findings may inform future regulatory activities related to POS tobacco advertising.

William G. Shadel Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA050972-01
Institution: RAND Corporation
05/19/2020

Assessing Toxicant Properties and Health Effects of Cigarillo and Hookah Tobacco Aerosols in Rats

The goal of this project is to evaluate whether cigarillo and hookah tobacco aerosols exhibit differences in toxicants associated with five health outcomes (cancer, transcriptional reprogramming, lung function and inflammation, cardiovascular effects and serum circulatory inflammation) compared to cigarette smoke using a rat model. Study aims are: (1) to evaluate 14-day nose-only dose response exposures to aerosols generated from cigarettes, cigarillos, and hookah products; and (2) to evaluate the effect of these exposures on biomarkers of cardiopulmonary health effects. To address Aim 1, researchers will expose a total of 360 rats (10/sex/group) for one hour per day for 14 days to one of three exposure groups (250, 500, or 750 mg total particulate matter (TPM)/m3) and one of six tobacco products (two major consumer brands each of cigarettes, cigarillos, or hookah tobacco, selected based on their in vitro toxicant properties); an air exposure group of 20 rats will be included as a control group. The exposure atmosphere will be characterized for hazardous chemical substances including (but not limited to) carbon monoxide, tobacco-specific nitrosamines, nicotine, volatile carbonyls, and tar. To address Aim 2, researchers will use biospecimens collected following the exposures to assess and compare effects across the five health outcomes listed above. Researchers will obtain quantitative readouts of cardiopulmonary biomarkers to enable comparisons across products and to evaluate dose effects; biomarkers will include specific DNA adducts, lipid peroxidation, cytokine panels, global assessment of lung transcriptional reprogramming, gene expression changes in the heart and aorta, and gene expression changes predictive of circulatory inflammation. Findings may inform regulatory activities related to cigarillos and hookah tobacco.

Steven A. Belinsky and Carmen Tellez Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01ES031787-01
Institution: Lovelace Biomedical and Environmental Research Institute (LBERI)
05/15/2020

Impact of Sugars on Tobacco Product Toxicity and Abuse Liability

Sugars are present naturally in some tobacco types and are also added to cigarette tobacco filler. Data suggest that sugars in tobacco filler may contribute to the harmful properties of cigarettes by enhancing smoke palatability and appeal and, as precursors to aldehydes and furans in smoke, by increasing smoke toxicity and carcinogenicity and potentially addictiveness. The goal of this study is to provide additional quantitative data on the relationship between tobacco sugar content and relevant toxicant yields in U.S. commercial cigarettes, and associated user exposures, behaviors, and cigarette appeal. Study aims are: (1) to characterize the impact of sugars in the filler of U.S. cigarettes on the chemical profile of cigarette smoke; (2) to investigate the impact of sugar content in cigarette tobacco on toxicant and carcinogen intake in U.S. smokers; and (3) to investigate the impact of sugar content in cigarette tobacco on cigarette abuse liability and appeal. To address Aim 1, researchers will add stable isotope-labeled sugars to a commercial cigarette that is low in sugars and will analyze the dose-dependent formation of corresponding pyrolysis products in the smoke of this cigarette; they will also analyze the impact of sugar content on the levels of nicotine and tobacco-specific nitrosamines (TSNAs) in the smoke. To address Aim 2, researchers will analyze sugars in U.S. commercial cigarettes and use Population Assessment of Tobacco and Heath (PATH) Study biomarker data to investigate the impact of sugar content in cigarette tobacco on toxicant and carcinogen intake in U.S. smokers. To address Aim 3, researchers will investigate the impact of sugar content on cigarette abuse liability and appeal by conducting a laboratory study in which 30 smokers (aged 18 and older) will assess study cigarettes with different sugar levels. Findings may inform future regulatory measures related to sugar levels in tobacco products.

Irina Stepanov and Dorothy Hatsukami Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA051005-01
Institution: University of Minnesota
04/28/2020

Impact of a Reduced Nicotine Standard on Young Adult Appeal for Menthol and Non-Menthol Cigarettes

The goal of this study is to examine response to smoking menthol and non-menthol very low nicotine cigarettes (VLNCs) in 100 young adult (ages 18-24) menthol smokers. Study aims are: (1) to determine the influence of menthol flavoring on smoking reinforcement in the context of a reduced nicotine standard in the laboratory; (2) to determine the influence of menthol flavoring on smoking reinforcement in the context of a reduced nicotine standard in the natural environment; and (3) to examine the impact reinforcement on tobacco product purchasing. To achieve Aim 1, abstinent smokers (>12 hours) will attend three laboratory visits where they will smoke a cigarette. During Visit 1, smokers will smoke their usual brand cigarette ad libitum; researchers will measure subjective response (satisfaction, craving reduction, psychological reward, sensory effects like throat hit), smoking exposure (carbon monoxide [CO] boost), and behavior (number of puffs, puff volume). Next, after 7 days of usual brand smoking, participants will undergo two experimental conditions at home: (1) 7 days smoking menthol VLNCs; and (2) 7 days smoking non-menthol VLNCs. For each condition, participants will be instructed to switch their usual cigarette for the assigned research cigarette but may use other tobacco products. (Each experimental condition will be separated by a 7-day wash-out period.) On the last day of each condition, participants will smoke the assigned research cigarette in the laboratory, and researchers will collect data on subjective response, smoking exposure, and behavior to compare craving reduction, positive subjective response, and CO boost among menthol VLNCs, non-menthol VLNCs, and usual brand. To address Aim 2, during each 7-day period, participants will complete twice-daily assessments of cigarette and other tobacco use, withdrawal, and subjective response; data will allow researchers to compare cigarettes per day, craving reduction, and positive subjective response for menthol VLNCs, non-menthol VLNCs, and usual brand. To address Aim 3, in a fourth visit participants will complete two tasks in the laboratory to indicate the impact of menthol and nicotine content on cigarette purchasing behavior in the context of all tobacco products currently on the market. Findings will provide new information about the abuse liability of menthol VLNCs.

Amy M. Cohn Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA050990-01
Institution: University of Oklahoma Health Sciences Center
03/31/2020

A Measurement Burst Study of Vaping in a National Sample of Young Adults

In this supplement to the Monitoring the Future (MTF) parent grant (Monitoring the Future: Drug Use and Lifestyles of American Youth), researchers will conduct a new longitudinal study of approximately 1100 individuals who participated in MTF as 12th graders in 2019 and will be modal age 19 in 2020, with an oversample of those who reported vaping and other substance use in high school. Approximately 570 respondents who report current vaping at age 19 will be invited to complete a one-time web-based survey (30 minutes) followed by 14 consecutive daily web-based surveys (5-7 minutes) to capture real-time fluctuation in vaping use patterns, consequences, and co-use with other substances. Study aims are to examine: (1) vaping frequency, products, devices, patterns, and contexts with daily data over two weeks, (2) signs of vaping addiction, craving, quit attempts, and physical consequences in real time, (3) co-use of vaping and other substances including alcohol, cigarettes, marijuana, and non-prescription drugs, and (4) recent exposure to nicotine through collection of biometric samples. Findings will provide new information about vaping behaviors and consequences among young adults that may inform future regulatory activities.

Richard Miech and Megan Patrick Funding Mechanism: National Institutes of Health – Grant
ID number: 5R01DA001411-46S1
Institution: University of Michigan
03/26/2020

Identification of Free Radical Induced Biomarkers of Exposure to Electronic Cigarette Aerosol

E-cigarette aerosol contains highly reactive free radicals that can cause oxidative damage, which can contribute to the progression of cancers and other diseases. The goal of this study is to identify these free radicals and use their unique structures to develop an e-cigarette-specific biomarker of exposure. Study aims are: (1) to determine the structures of the free radicals produced by propylene glycol and glycerin in e-cigarettes; and (2) to determine the primary targets of radical adduct formation in the tissue of e-cigarette-exposed mice and identify metabolites formed from radical adducts in the serum. To address Aim 1, researchers will use free radical spin trapping, electron paramagnetic resonance spectroscopy techniques, and mass spectroscopy to identify and analyze the unique structural features of free radicals in e-cigarette aerosol produced from a popular temperature-controlled e-cigarette device. To address Aim 2, 120 mice will be exposed to e-cigarette aerosols and either pre- or post-exposed to 5,5-dimethyl-1-pyrroline noxide (DMPO) spin traps via nose-only exposures. Using an anti-DMPO antibody, the areas of free radical exposure will be observed in the pre-DMPO exposures and targets of radical damage will be observed in the post-DMPO exposures. Radical adducts formed in the post-DMPO exposures will be identified via mass spectroscopy and metabolites of these adducts will be identified in the serum to find viable e-cigarette-specific biomarkers of exposure. Findings may inform future regulatory activities related to e-cigarettes.

Zachary T. Bitzer Funding Mechanism: National Institutes of Health – Grant
ID number: 1K99HL147346-01A1
Institution: Pennsylvania State University
03/12/2020

Cardiopulmonary Effects Induced by Electronic Cigarette and JUUL Aerosols in Both In Vivo and In Vitro Models

Although clinical evidence demonstrates declines in lung function and increases in heart attack risk in healthy dual-users of e-cigarettes and cigarettes, more evidence regarding the cardiopulmonary effects of chronic inhalation of electronic nicotine delivery system (ENDS) aerosols would be useful. The goal of this study is to evaluate how two ENDS products — open system e-cigarette devices and closed system JUUL-type devices — impact individual or combinations of aerosol constituents and their toxicity using innovative cell culture systems and mouse models. Study aims are: (1) to examine the roles that e-liquid constituents (i.e., propylene glycol/vegetable glycerin, flavors, nicotine) play in the chemical profiles and lung toxicity of ENDS aerosols using in vitro models; (2) to define a panel of biomarkers for cardiopulmonary effects following exposures to e-cigarette aerosols, JUUL aerosols, and dual use of cigarettes and e-cigarettes in juvenile mice; and (3) to compare pulmonary toxicity induced by e-cigarette or JUUL aerosols in mice. Findings may clarify the cardiopulmonary effects caused by prolonged use of ENDS and inform regulatory activities.

Alexandra Noël Funding Mechanism: NIH Grant
ID number: 1K01HL149053-01
Institution: Louisiana State University A&M College Baton Rouge
03/06/2020

Yale Center for the Study of Tobacco Product Use and Addiction: Flavors, Nicotine and Other Constituents (YCSTP) (TCORS 2.0)

Systematic data collection can provide more information about e-cigarette or vaping product use-associated lung injury (EVALI), particularly regarding number of cases and specific products involved. In this supplement to the Yale University TCORS 2.0 parent grant, researchers will develop a robust surveillance system that will prospectively identify hospitalized patients with acute lung injury who vape or smoke. Study aims are: (1) to develop a robust surveillance system to prospectively identify admitted patients with acute lung injury who vape or smoke; (2) to perform toxicology analyses of e-liquids and device contents that are associated with EVALI; and (3) to build a biorepository of patient blood and urine samples among patients with acute lung injury who vape or smoke to investigate disease mechanisms. This project will enable research into disease mechanisms and elucidate risk factors associated with EVALI.

Suchitra Krishnan-Sarin and Stephanie O’Malley Funding Mechanism: National Institutes of Health – Grant
ID number: 3U54DA036151-07S1
Institution: Yale University
03/02/2020

Center for the Study of Tobacco Products – Electronic Cigarette Use and Alveolar Macrophages: A Preliminary Study

Data from animal studies suggest that e-cigarette users may be at risk for a potentially debilitating condition called lipoid pneumonia. In this supplement to the Virginia Commonwealth University TCORS 2.0 parent grant, this supplement will collect pilot data relevant to the generalizability of lipoid pneumonia-related animal study data to humans. Study aims are: (1) to investigate lipid-laden macrophages in e-cigarette users, and (2) to characterize other disease biomarkers in e-cigarette users’ bronchoalveolar lavage (BAL) fluid. To address Aim 1, researchers will recruit 10 high-wattage (i.e., >20 W) e-cigarette users (ages 21-55) with over one year of experience exclusively using nicotine-containing e-cigarettes as well as an additional 10 never-e-cigarette-using, never-smoking controls. Using well-established methods, all 20 participants will undergo bronchoscopy and BAL to enable the collection of alveolar macrophages. Researchers will then compare the incidence of lipid-laden macrophages between groups. To satisfy Aim 2, researchers will determine the alveolar fluid composition differences in miRNA expression, extra-vesicle-miRNA, and microbiome profiles between the e-cigarette users and the control group. Findings may inform regulatory activities related to e-cigarette liquid constituents that have the potential to cause lung disease.

Thomas Eissenberg and Alison Breland Funding Mechanism: National Institutes of Health – Grant
ID number: 3U54DA036105-07S1
Institution: Virginia Commonwealth University
01/31/2020

FDA CTP This is Our Watch Retailer Feedback Study

FDA’s Center for Tobacco Products (CTP) Office of Health Communication and Education has created and maintains retailer education materials, referred to as This Is Our Watch (TIOW), designed to give retailers the tools they need to comply with tobacco regulations. As a result of the Tobacco 21 legislation raising the federal minimum age for the sale of tobacco products from 18 to 21, FDA CTP is required to update TIOW retailer education materials. The goal of this study is to obtain feedback from retailers about their awareness, preferences and experiences related to the TIOW materials. Researchers will conduct 32 in-depth interviews (22 English, 10 Spanish) that will each last up to 60 minutes. Participants will include clerks, managers, and owners of tobacco retail establishments identified through government contacts, such as the State Synar Program managed by the Substance Abuse and Mental Health Services Administration (SAMHSA). Study aims are: (1) to identify T21 knowledge gaps and educational opportunities among tobacco retailers, and (2) to understand retailers’ sentiments, needs and challenges related to minimum legal purchase age compliance. Findings will allow FDA to understand what additional messages, information, and material format would complement the current TIOW education materials.

Alessandra Raimondi (CTP Contacts: Megan Wall, Matthew Walker, Emily Sanders) Funding Mechanism: Research Contract
ID Number: 75F40120A00002-75F40120F19001
Institution: Fors Marsh Group
09/30/2019

The Human Dose-Response Effects of Methyl Salicylate in Smokeless Tobacco

The goals of this project are to determine how changes in the methyl salicylate content of smokeless tobacco may affect HPHC exposure and nicotine pharmacokinetics (the body’s effects on nicotine), as well as to determine how changes in methyl salicylate content affect nicotine pharmacodynamics (nicotine’s effects on the body) and abuse liability. First, researchers will amend commercially available smokeless tobacco to create four investigational smokeless tobacco products (no methyl salicylate and low, medium, and high methyl salicylate content ranging from 0.3-30 mg/g). Next, researchers will administer each of the four products to 56 adult smokeless tobacco users (aged 21-65) under specific use conditions. Researchers will measure heart rate, blood pressure, pharmacokinetics, exposure to harmful and potentially harmfully constituents (HPHCs), and abuse liability (measures of liking, craving, and withdrawal) before and after product use. Findings may inform future regulatory activities related to smokeless tobacco products.

Bortosz Koszowski and Mollie Miller Funding Mechanism: Research Contract
ID number: HHSF223201710040I
Institution: Battelle
09/27/2019

Study of E-Cigarette Aerosol Toxicity in In Vivo Nonclinical Models

Few peer-reviewed studies have compared the toxicity associated with inhaling aerosol from different types of e-cigarettes; therefore, a thorough comparison of the chemical constituent levels, pharmacokinetics (PK), and toxicity from different e-cigarettes would be informative for future toxicological assessments. Researchers will perform a 28-day study with PK assessment, a 90-day nose-only inhalation study with 45-day recovery groups, and a 6-month nose-only inhalation study; all studies will be conducted in male and female Sprague Dawley rats. The 28-day study will evaluate the toxicity of two e-cigarettes and will provide PK data (results will be used to inform dose selection in the 90-day and 6-month studies). The objective of the 90-day and 6-month studies is to perform longer-term comprehensive studies of four top-market-share e-cigarette products in the U.S. Researchers will gather data including e-liquid and aerosol concentration measurements; measurements in animals such as body weight and food/water consumption; clinical observations; and biomarkers of exposure. Findings will provide new information about the potential toxicological effects of e-cigarette use.

Jake McDonald, Gladys V. Erives, and Cissy Li Funding Mechanism: Research Contract
ID number: 75F40119C10161
Institution: Lovelace Biomedical and Environmental Research Institute (LBERI)
09/19/2019

Smokers’ Decision-Making about Tobacco Use: The Interplay of Affective and Cognitive Factors with Product Characteristics

Misperceptions about the health risks and benefits of electronic nicotine delivery systems (ENDS) and heated tobacco products (HTP), as well as consumer dissatisfaction with product characteristics, may limit initiation and complete substitution for cigarettes. This project will investigate how price, indoor-air policies, and ENDS and HTP product characteristics (type/design, flavors, ability to reduce cravings to smoke) interact with risk/benefit perceptions to affect smokers’ decisions to reject ENDS, to substitute them for only a few cigarettes, to switch exclusively to ENDS, or to use ENDS to completely quit using tobacco products. Study aims are: (1) to examine how cognitive, affective, and contextual factors (e.g., whether products can be used where smoking is prohibited) moderate the influence of ENDS/HTP product characteristics on product choice and tobacco use patterns and trajectories; and (2) to examine how the effects of specific ENDS/HTP product characteristics on product use patterns are moderated by risk/benefit perceptions. Aim 1 will involve qualitative focus group interviews with 120 current and former adult smokers (aged 18+) and an intensive one-year (12 weekly, then 3 quarterly) assessment with 300 current smokers who recently initiated ENDS use to examine how ENDS/HTP product characteristics influence smokers’ decisions to initiate, dual use with, or substitute for combustible product use. Aim 2 involves two experiments and a randomized clinical trial. A discrete-choice experiment (DCE) will be embedded in a survey of 300 current adult smokers to examine the relative importance of ENDS/HTP product characteristics on risk/benefit perceptions, product preferences, and use intentions, and evaluate the predictive validity of these preferences on future tobacco use. A second DCE will examine the interaction of product characteristics, risk/benefit perceptions, and contextual factors on product preferences among 2,400 adult current smokers who currently, formerly, or never used ENDS/HTP products. These results will inform the design of a randomized clinical trial with 1,800 adult smokers involving a hypothetical purchase task that will manipulate risk/benefit perceptions of ENDS/HTP products to estimate the effect on smokers’ consumption of cigarettes, ENDS, and HTP, including the substitutability or complementarity of ENDS and HTP for each other and for cigarettes. Findings may inform regulatory activities related to cigarettes, ENDS and HTP products.

Terry Frank Pechacek and Scott R. Weaver Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01CA235719-01A1
Institution: Georgia State University
09/18/2019

Assessing IQOS Marketing Influences and Consumer Behavior in Israel: Implications for the US

Developing an understanding of how heated tobacco products (HTPs) are marketed would be useful. IQOS, the global HTP leader, has a presence in several markets, including Israel. Israel is unique in that it represents three distinct regulatory contexts for IQOS: (1) during IQOS’s initial emergence in Israel, it was not categorized as a tobacco product (Dec 2016-Apr 2017); (2) IQOS was classified as a tobacco product in a relatively weak regulatory context (Apr 2017- December 2019); and (3) IQOS will be regulated as a tobacco product within new progressive legislation (study period starting January 2020). The goal of this study is to examine IQOS marketing strategies used in Israel during these three regulatory periods and assess their impact on segments of the Israeli and U.S. populations. Study aims are: (1) to examine IQOS marketing strategies in Israel from its emergence in the Israeli market and begin surveillance as IQOS is launched in the US; and (2) to examine market segments of Israeli and U.S. adults (users and nonusers aged 18-45) in relation to IQOS use and/or likelihood of future use. The researchers will study marketing content and consumer reactions in both Israel and the U.S. via examination of marketing channels (including point-of-sale audits), content analysis of advertising messaging strategies, interviews with IQOS retailers, online surveys of 1,000 Israeli and 1,000 U.S. adults, and interviews with 40 Israeli and 40 U.S. adults. Among the panel of Israeli and U.S. adults, the researchers will conduct market segmentation research on consumer characteristics; four specific market segments defined by the IQOS website will be examined: business and current events; art, culture and fashion; nature and hiking; and innovation and technology. By examining IQOS marketing strategies used in the three different regulatory periods in Israel and understanding the impact of these strategies on different consumer segments and the extent to which they generalize to U.S. consumers, findings will provide information to better estimate the potential impact of IQOS and its marketing in the U.S.

Carla J. Berg and Hagai Levine Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01CA239178-01A1
Institution: Emory University
09/18/2019

Assessing the Effects of Smokeless Tobacco Influencer Marketing in the Rapidly Changing Media Environment

Social media marketing remains an understudied area in tobacco control, particularly related to smokeless tobacco. The goal of this project is to examine the effects of exposure to smokeless tobacco-related social media content. Study aims are: (1) to conduct a content analysis to identify and characterize social media messages related to smokeless tobacco by source and major themes (e.g., new user targeting, health risks, flavors); (2) to assess the impact of social media content exposure on smokeless tobacco use, attitudes, harm perceptions, perceived prevalence of use, initiation, and use intentions) using data from the Truth Longitudinal Cohort Survey on Tobacco-Related Attitudes, Beliefs and Behavior (13,892 youth and young adults aged 15-21 at baseline [April 2014]); and (3) to study whether/to what extent tobacco control policies moderate the relationship between exposure to smokeless tobacco-related social media content and smokeless tobacco use. Investigators will apply various research and analytic methods to a unique combination of data sets, including social media data from Twitter, Instagram and Facebook and survey data on tobacco-related outcomes. Findings will provide policy-relevant scientific evidence on the impact of social media marketing of smokeless tobacco products.

Ganna Kostygina Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01CA234082-01A1
Institution: National Opinion Research Center
09/18/2019

The E-Cigarette Population Paradox: Testing Effects of Youth-Targeted Population Warnings for E-Cigarettes among Two Key Populations

Warnings on e-cigarette advertisements and packaging should communicate the risks of e-cigarettes to youth and non-smokers while also protecting perceptions of the potential benefits of switching completely to e-cigarettes among combustible cigarette smokers. The goal of this study is to identify effective e-cigarette ad warnings given this complex population paradox. Study aims are: (1) to develop and test a set of proposed warning messages to maximize desirable outcomes among both nonsmoking youth and adult smokers; (2) to evaluate e-cigarette ad warnings that maximize favorable effects on youth as the critical at-risk population; and (3) to test for unintended effects of e-cigarette ad warnings among adult cigarette smokers who may be discouraged from switching to e-cigarettes when exposed to some types of warnings. To address Aim 1, researchers will conduct a series of 16 focus groups (30 youth aged 14-18 and 30 adults aged 19+) to identify warnings that are likely to discourage non-smoking youth from using the product but do not discourage cigarette smokers from wanting to switch completely. To address Aim 2, researchers will use a mobile lab outfitted with computing and eye-tracking technology to test the effects of promising warnings from Aim 1 in a randomized experiment with 400 youth aged 14-18 to identify warnings that increase visual attention to the warnings, decrease attention to ad appeals, increase risk beliefs, and reduce use intentions. To address Aim 3, using the same mobile lab, researchers will randomize 400 adults aged 19+ to test whether the most effective warnings among youth that emerge in Aim 2 have any unintended consequences among adult smokers; specifically, they will test whether youth-effective warnings influence visual attention, comparative risks between combustible and e-cigarettes, and intentions to use both products (switching completely to e-cigarettes, dual use, or continued smoking of combustible cigarettes) among adults. Findings may inform regulatory activities related to e-cigarette ad warnings.

Sahara Byrne and Jeff Niederdeppe Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01CA246605-01
Institution: Cornell University
09/17/2019

Advancing Perceived Message Effectiveness: A New Measure for Youth Prevention Media Campaigns

Among other tools, the FDA uses the perceived message effectiveness (PME) scale to select ads for The Real Cost campaign. However, this scale has some limitations, including: (1) it was developed with adult smokers; (2) it was developed before the advent of e-cigarettes and vaping; and (3) it assesses message PME (beliefs about the message; i.e., “This ad is informative”), while a growing body of literature suggests that effects PME (beliefs about the message’s impact; i.e., “This ad gives me good reasons not to smoke”) better predicts the impact of ads on intention and behavior change. The goals of this project are to develop and validate an effects PME scale for adolescent (aged 13-17) tobacco prevention and to compare the performance of this new scale to the FDA’s current message PME scale. Study aims are: (1) to develop a youth effects PME scale for vetting cigarette and e-cigarette prevention ads; (2) to establish whether effects and message PME prospectively predict the impact of smoking prevention ads on intentions to smoke cigarettes; and (3) to examine whether effects and message PME predict the impact of vaping prevention ads on intentions to vape. To achieve Aim 1, researchers will develop a youth effects PME scale for vetting cigarette and e-cigarette prevention ads. They will develop and refine an item pool, cognitively test items with 48 adolescents, and conduct a scale development study with a national sample of 800 adolescents. To achieve Aim 2, researchers will randomize 1,280 adolescents at risk of cigarette smoking to one of three The Real Cost cigarette prevention ad conditions or to a control ad condition; participants will view a set of ads each week and complete a final assessment at week 3, and the researchers will examine whether PME predicts the impact of ads on intentions to smoke, risk beliefs about smoking, and smoking behavior. To achieve Aim 3, researchers will randomize 1,024 adolescents to view three The Real Cost e-cigarette ads or to a control ad condition and examine whether PME predicts the impact of e-cigarette ads on intentions to vape and risk beliefs. Findings may help campaign designers select more effective ads, thereby increasing the impact of tobacco education campaigns targeted to youth.

Seth Michael Noar Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01CA246600-01
Institution: University of North Carolina at Chapel Hill
09/16/2019

Communicating about Nicotine and Differential Risks of Tobacco Products

The goal of this project is to study a communication strategy that combines messages about reduced nicotine in combusted cigarettes with messages about relative risks of other tobacco products (i.e., potential “modified risk claims”). Study aims are: (1) to develop preliminary messages about reduced nicotine in combusted tobacco products; (2) to quantify the relative importance of different types of information in communications about reduced nicotine; and (3) to test the impact of messages about reduced nicotine in combusted tobacco products in the context of potential modified risk statements for novel tobacco products in a randomized clinical trial. To achieve Aim 1, researchers will conduct focus groups with 36 adult (aged 18+) current exclusive smokers, 36 adult dual users of cigarettes and ENDS, 36 adult former smokers, and 36 young adult non-smokers (aged 18-29). To achieve Aim 2, researchers will assess the relative effects of various message attributes (e.g., specific numbers for reduction, mention of addiction and health effects, source) on affect, perceived risk, and intentions to quit (for smokers) or to try reduced nicotine cigarettes (for non-smokers) in a discrete choice experiment; participants will be adult current exclusive smokers, adult dual users, adult former smokers, and young adult non-smokers (450 from each group). To achieve Aim 3, researchers will conduct a randomized clinical trial with 900 adult current exclusive smokers, 450 adult dual users, and 450 young adult non-smokers to compare effects of reduced nicotine and potential modified risk messages (executed as full-color ads) alone and in combination; outcomes will include risk perceptions, affect, behavioral intentions and recall and behavioral outcomes. Findings may inform regulatory activities related to communication strategies involving low nicotine tobacco products.

Lyudmila Popova and James Thrasher Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01CA239308-01A1
Institution: Georgia State University
09/16/2019

Impact of Adding Tobacco Constituents Nornicotine and Anatabine on Self-Administered Nicotine

Because most electronic cigarettes contain nicotine, users may be at greater risk of transitioning to other tobacco products given the addictive nature of nicotine. More information about the interactions between nicotine and other tobacco constituent compounds in the context of this addictive risk would be useful. The objective of this research is to assess the impact of the addition of other tobacco constituent compounds to nicotine in an intravenous self-administration model in male and female adult and adolescent rats. Study aims are: (1) to assess the impact of adding nornicotine and anatabine to self-administered nicotine on the motivational value of nicotine in rats that began their nicotine consumption as adults; and (2) to assess the impact of adding those constituents to self-administered nicotine on the motivational value of nicotine in rats that began their nicotine consumption as adolescents. Findings on the impact of adding tobacco constituent compounds to ongoing nicotine self-administration may inform future regulatory activities.

Jennifer E. Murray Funding Mechanism: NIH Grant
ID number: 1R03DA045740-01A1
Institution: University of Guelph
09/16/2019

The Role of Humectants and Flavor on Microbial Growth in Waterpipe Tobacco

More information regarding how additives like humectants and flavors alter microorganisms in waterpipe tobacco would be useful. The goal of this study is to assess the impact of humectants (humidifying ingredients) and flavor additives on microbial growth in waterpipe tobacco. Study aims are: (1) to evaluate the effect of flavor and humectant content on microbial growth in waterpipe tobacco; and (2) to assess the relationship between tobacco-specific nitrosamine (TSNA) production and microbial activity in waterpipe tobacco. To address Aim 1, researchers will use an unflavored, low-humectant commercially available waterpipe tobacco as a control and prepare it several different ways to determine the individual and cumulative effects of additives (glycerin, propylene glycol, and vanillin) on microbial growth; flavor and humectants will be added at quantities comparable to those in commercially available waterpipe tobacco. Researchers will quantify microbial composition using whole genome sequencing analysis, and will use shotgun proteomic analysis to characterize proteins expressed by organisms colonizing tobacco. To achieve Aim 2, two TSNAs (Nʹ-nitrosonornicotine [NNN] and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [NNK]) will be quantified in each tobacco preparation after 1 and 6 months of incubation and compared to levels found in the control. Study findings will provide new information about how humectants and flavors influence toxic exposures associated with waterpipe tobacco.

Anna Marie Adetona Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R21CA244305-01
Institution: Battelle Centers/Public Health Research & Evaluation
09/16/2019

E-Cigarettes and Youth: Tests of Strategies to Prevent Recreational Use

Use of e-cigarettes by non-smoking youth has increased dramatically in recent years. The goal of this study is to test how variations in modified risk statements, novelty flavors, and flavor representation (pictorial images vs. plain-text flavor names) influence middle school youth (aged 11-14) e-cigarette perceptions and use susceptibility. Study aims are: (1) to determine how modified risk statements and the specificity of the health risks addressed by them influence middle school students’ perceptions of e-cigarettes and the FDA’s warning label; (2) to determine how flavor category influences middle school students’ perceptions of e-cigarettes and the FDA’s warning label; and (3) to determine how flavor representation influences middle school students’ perceptions of e-cigarettes and the FDA’s warning label. Two randomized experiments will be conducted on a sample of middle school students. The first, with 150 participants, will vary whether participants view a modified risk statement alongside the FDA warning on e-cigarette packages, as well as the type of modified risk statement (abstract health consequence vs. specific health consequence). The second experiment, with 550 participants, will vary whether participants view e-liquid vials with tobacco flavor or a novelty flavor (menthol, fruit, candy, goth). Outcome measures include risk perceptions, message comprehension, harm minimizing beliefs, susceptibility, and behavioral intentions toward e-cigarette uptake. Findings may inform communication strategies that minimize uptake of e-cigarettes by middle school youth.

Sherri Jean Katz Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R21CA246602-01
Institution: University of Minnesota
09/16/2019

Evaluating the Impact of Waterpipe Tobacco Marketing Claims on Young Adults

Specific evidence related to waterpipe tobacco packaging and marketing to identify claims and determine their influence on consumer harm misperceptions would be useful. The goal of this study is to document claims on waterpipe tobacco packaging and in digital marketing (websites and social media) and evaluate how such claims influence consumer perceptions and willingness to try waterpipe tobacco. Study aims are: (1) to identify waterpipe tobacco product packaging and digital marketing; (2) to analyze waterpipe tobacco product packaging and digital marketing to determine whether they contain health claims; and (3) to evaluate the impact of health claims on young adults’ willingness to try the product, product appeal, and perceptions of harm. To achieve Aim 1, researchers will we will select a random sample of 30 waterpipe tobacco manufacturers and purchase five flavors from each manufacturer to document claims made on product packaging (150 packages). Researchers will also randomly select 30 U.S. retailers (i.e., waterpipe cafés, bars, lounges). For each of the 30 manufacturers and 30 retailers identified, researchers will capture content from their websites, as well as capture the 20 most recent Instagram (n=1,200) and Facebook (n=1,200) posts. To achieve Aim 2, researchers will content analyze all the packaging and digital marketing content captured in Aim 1. They will then use an expert panel to determine whether claims found on packaging and in digital marketing are health claims. To achieve Aim 3, researchers will conduct a randomized online experiment with 1,500 young adults (aged 18-29), including waterpipe users or those susceptible to future use, to evaluate the impact of the health claims on willingness to try the product, perceptions of harm, and product appeal. Findings will provide new information about which claims consumers perceive as health claims and may inform related regulatory activities.

Erin L. Sutfin Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01CA239192-01A1
Institution: Wake Forest University Health Sciences
09/16/2019

Analysis of ENDS Products

The goal of this project is to identify which of the 93 harmful and potentially harmful constituents (HPHCs) identified by the FDA are present in electronic nicotine delivery system (ENDS) products. Using validated testing methods, researchers will analyze ENDS e-liquids (33 e-liquids and four disposable devices containing e-liquid cartridges) and ENDS aerosols (aerosols of the 33 e-liquids produced from 21 different ENDS devices). In addition, researchers will provide relevant information (when available) about the products’ physical attributes and design characteristics, including e-liquid volume or weight, labelled nicotine concentration, power output, resistance, heating coil temperature, and battery capacity.

Karen Carter and Tianrong Cheng Funding Mechanism: Research Contract
ID number: 75F40119D10003
Institution: Enthalpy Analytical
09/13/2019

CTP Supplement to Parent Grant: Center for the Assessment of the Public Health Impact of Tobacco Regulations – Diversity Supplement for Project 3 (TCORS 2.0)

This is a supplement to an existing study titled “Modeling the Impact of Tobacco Control Policies on Polytobacco Use and Associated Health Disparities.” The aims of the supplemental research study are: (1) to evaluate the relationship between perceived discrimination and individual tobacco product use by race/ethnicity and gender; and (2) to evaluate the relationship between perceived discrimination and polytobacco use by race/ethnicity and gender. Using nationally representative data of adults aged 18 years and older, the study will examine the role of perceived discrimination on the use of cigarettes, cigars, pipe, smokeless tobacco, and e-cigarettes, individually and in combination. Importantly, differences by race/ethnicity (i.e., non-Hispanic White, non-Hispanic Black, Hispanic, and other races) and gender will be examined. Findings may lead to a better understanding of the complex interplay between social determinants and tobacco-related health disparities of polytobacco use among racial/ethnic minorities.

Rafael Meza and David Levy Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 3U54CA229974-02S1
Institution: University of Michigan at Ann Arbor
09/13/2019

Modeling the Public Health Impact of a National Menthol Cigarette Ban

The goal of this project is to use microsimulation modeling to estimate the impact of a national menthol cigarette ban on tobacco use and tobacco-related disease, specifically cardiovascular disease (CVD) and tobacco-related cancers. Study aims are: (1) to identify trajectories of cigarette use over time among youth and adults using longitudinal, nationally representative survey data; (2) to conduct a review of studies examining the effects of a menthol cigarette ban on product use; and (3) to build a model of smoking and tobacco-related disease to estimate the impact of a national menthol cigarette ban on smoking, CVD, and tobacco-related cancers. To achieve Aim 1, the researcher will compute transition probabilities of tobacco use behavior (frequency, intensity, flavor preference) over time using Population Assessment on Tobacco and Health (PATH) Study data. To achieve Aim 2, the researcher will synthesize the literature on the impact of a menthol cigarette ban and conduct a meta-analysis to pool data from individual studies, generating critical information for simulation modeling. To achieve Aim 3, the researcher will build a microsimulation model of tobacco use and tobacco-related diseases, incorporate the effect of a national menthol cigarette ban on cigarette use, and estimate changes in smoking, CVD, and tobacco-related cancers that would occur in the total population and in specific socioeconomic and racial/ethnic groups if a ban were implemented. Findings may inform potential regulatory activities on menthol cigarettes.

Sarah D. Mills Funding Mechanism: NIH Grant
ID number: 1K01CA242530-01
Institution: University of North Carolina, Chapel Hill
09/13/2019

Prospective Health Outcomes and Inflammatory Biomarkers Associated with e-Cigarette Use

The goal of this project is to identify validated biomarkers for use in the assessment of electronic nicotine delivery systems (ENDS). By analyzing data from two studies (the COPDGene and UCSD ENDS studies), researchers propose to identify ENDS-related inflammatory biomarkers in ENDS-only and dual (ENDS + cigarette) users and relate these biomarkers to five-year lung health outcomes. COPDGene is an ongoing longitudinal study of >6,000 current and former cigarette smokers; the study is identifying factors that increase chronic obstructive pulmonary disease (COPD) risk and includes detailed longitudinal lung phenotyping data (including chest computed tomography [CT]), genome-wide blood RNA-sequencing, and proteomic data. The UCSD ENDS Study is a study of young ENDS-only users and controls involving detailed assessment of inflammatory biomarkers in the oropharynx, airways and blood. Study aims are: (1) to identify and validate inflammatory transcriptomic and proteomic biomarkers of ENDS exposure in ENDS-only and dual users from the COPDGene five-year study visit; biomarkers will be validated in two independent sets of subjects from the COPDGene ten-year visit and the UCSD ENDS Study; (2) to identify antibody-specific adaptive immune response biomarkers of ENDS exposure in ENDS-only and dual users using adaptive immune receptor repertoire sequencing; and (3) to relate ENDS use and biomarker panels to five-year lung health outcomes using spirometry, chest CT, and questionnaire data from COPDGene. Findings may inform future regulatory activities related to ENDS.

Peter Castaldi Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01HL147326-01A1
Institution: Brigham and Women’s Hospital
09/13/2019

Using PET to Measure Pulmonary Oxidative Stress in E-cigarette Users

Inducible nitric oxide synthase (iNOS) is an enzyme that is expressed in lung epithelium and causes inflammation, a common pathway for many types of lung disease. Researchers will measure lung inflammation using positron emission tomography (PET) imaging with [18F]-6-(1/2)(2-fluoro-propyl)-4-methylpyridin-2-amine ([18F]NOS), a new PET radiotracer that targets iNOS. The goal of the study is to use this technique to compare lung inflammation in adult (aged 18+) electronic nicotine delivery system (ENDS) users, cigarette smokers, and nonsmokers. Study aims are: (1) to quantify and localize the effects of ENDS use, cigarette smoking, and nonsmoking on lung inflammation, and (2) to examine the effect of ENDS use, cigarette smoking, and nonsmoking on biomarkers of airway and lung inflammation and lung function. To accomplish these aims, 60 subjects (three groups of 20: ENDS users, traditional cigarette smokers who report having smoked ≥10 cigarettes per day for the past year with no history of ENDS use or cannabis smoking, and nonsmoking controls) will complete self-report measures, undergo a one-hour [18F]NOS PET/CT (computed tomography) scan of the chest, provide a breath and blood sample for measurement of biomarkers of airway and lung inflammation, and complete lung function tests using spirometry. Researchers will compare biomarkers of airway (fractional exhaled nitric oxide (FeNO)) and lung inflammation (proinflammatory cytokines TNF-α, IL-1β, and IL-8) and lung function (forced expiratory volume (FEV), forced vital capacity (FVC)). Findings may inform regulatory activities related to ENDS.

Reagan R. Wetherill Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R21HL144673-01A1
Institution: University of Pennsylvania
09/13/2019

The Impact of E-cigarette Marketing Features on Youths’ E-cigarette Perceptions and Use Intentions

The goal of this study is to determine the impact of branded e-cigarette marketing features – such as color, use of people in images, and language specifically targeting smokers – on e-cigarette perceptions and use intentions among youth. Study aims are: (1) to examine the e-cigarette marketing context surrounding youth over time; (2) to assess the impact of e-cigarette marketing features on youth’s e-cigarette perceptions and use intentions; and (3) to explore the impact of branded e-cigarette marketing features on youths’ attention using eye tracking. Studies will be conducted with non-current users of e-cigarettes who are aged 13-17. To achieve Aim 1, the researcher will conduct a longitudinal content analysis over five years, as well as yearly, of print, online, and point-of-sale marketing materials for five brands of e-cigarettes to monitor the potential for youth exposure and to identify e-cigarette marketing trends. To achieve Aim 2, the researcher will first conduct four online focus groups (each with 8-12 youth) to understand their perceptions about e-cigarettes and e-cigarette marketing; the researcher will then conduct an online survey experiment with 600 youth to test the effects of use of color, use of people in images, and language specifically targeting smokers on e-cigarette perceptions and use intentions. To achieve Aim 3, the researcher will use eye tracking technology to objectively measure attention (e.g., dwell time, gaze patterns) among 60 youth exposed to e-cigarette marketing materials. Findings may inform future regulatory activities related to e-cigarette marketing, packaging, and labeling.

Michelle Jeong Funding Mechanism: NIH Grant
ID number: 1K01CA242591-01
Institution: Rutgers University, RBHS-School of Public Health
09/12/2019

CTP Supplement to Parent Grant: Graphic and Text-Based Waterpipe Warning Labels to Combat Harm Misperceptions

This study is a supplement to a parent study that investigated the impact of the placement of text-only or graphic-and-text health warning labels on waterpipes on smoking behavior and toxicant exposure. The supplemental study will investigate warning label placement and whether changes in participants’ waterpipe smoking behavior due to warning labels result in measurable changes in biomarkers of potential harm and puffing behavior. The parent study aims are: (1) to determine the optimal message and placement of the health warning label on a waterpipe to attract user attention; (2) determine the effect of the presence of the optimal text vs. text/graphic vs. no health warning label on a carbon monoxide biomarker, waterpipe puffing behavior, and other behaviors, including perceptions of risk as measured by the social interaction among participants during the waterpipe smoking session; and (3) to explore the impact of the presence of a health warning label (text vs. text/graphic) on smoking behavior at 3 and 6 months post-experiment. For Aim 1, researchers will determine the optimal placement of heath warning labels on different waterpipes using focus group methods (n = up to 36) and eye tracking research (n=72) in samples of young adults ages 18-29 years. For Aim 2, researchers will randomize 246 young adults (ages 21-29 years) to view text-only labels, text/graphic labels, or no health warning label on waterpipes that they smoke ad libitum in a controlled laboratory setting; outcomes will include waterpipe puffing topography measures; subjective ratings of nicotine dependence, craving, and liking/disliking; exhaled carbon monoxide; and conversation topics related to fear, health risks, and the health warning label. For Aim 3, researchers will measure changes in smoking behavior at 3 and 6 months after the experiment. The supplement will add spirometry and genotoxicity measures to the laboratory experiment and the 3-month assessment in order to study lung function and biomarkers of harm, respectively. This study will provide new information about waterpipe health warning labels that may inform regulatory activities.

Amy K. Ferketich and Marielle C. Brinkman Funding Mechanism: NIH Grant
ID number: 3R01CA229306-02S2(Suppl)
Institution: Ohio State University
09/12/2019

A State-of-Art NMR Technique to Investigate Biologicals Effects of Electronic Nicotine Delivery Systems

More information regarding the molecular structures of electronic nicotine delivery system (ENDS) aerosols and their biological consequences would be useful. The goal of this study is to determine whether ENDS use at different temperatures alters aerosol constituents and/or molecular structure and toxicity by identifying and using metabolic signatures. Specific aims are: (1) to investigate the formation of ENDS aerosols at different temperatures using a magic angle spinning (MAS) technique, and (2) to apply a non-destructive slow-MAS nuclear magnetic resonance (NMR) metabolomics platform to define the dynamic response of lung organotypic cultures to ENDS aerosols. To address Aim 1, researchers will use their recently developed in situ MAS technique, which generates high resolution NMR spectra on samples containing a mixture of gases, liquids, and solids at significantly elevated temperature and pressure. To address Aim 2, researchers will use their lung organotypic culture platform, which enables the investigation of single cell populations (e.g., normal vs. cancer cells) as well as mixed cell populations (e.g., normal/cancer cell co-cultures) to define the baseline metabolome of normal human lung epithelial cells, lung cancer cells, and their mixture as cultures, as well as changes induced by ENDS aerosols generated at different temperatures. Findings may inform regulatory activities related to ENDS.

Jian Zhi Hu Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R21ES029778-01A1
Institution: Battelle Pacific Northwest Laboratories
09/11/2019

Early Phase Pharmacokinetic Analysis of Nicotine in Sprague-Dawley Rats

Nicotine is a naturally occurring alkaloid that is found in many nightshade plants, with most human exposure occurring through exposure to tobacco. The CTP-NCTR InhaleCore Group has recently completed studies evaluating nicotine pharmacokinetics (PK) profiles in rats following a single dose administration by inhalation, oral gavage, and intravenous injection (E07607.01). In these studies, the dose formulations for inhalation exposure consisted of nicotine in propylene glycol and water. PK samples were collected at 10 different timepoints ranging from 3 minutes to 48 hours post-dose exposure. Early PK timepoints (< 15 minutes post-dose) were collected using venous blood via the tail vein (i.e., peripheral source), whereas later PK timepoints were collected using arterial blood via terminal cardiac puncture (i.e., systemic source). For the venous blood to reflect the PK sample of the arterial blood, a minimum of 15 minutes is needed post-dose exposure. In this study, early PK timepoints will be collected using arterial blood via cardiac puncture to obtain a more accurate assessment of nicotine levels post-dose exposure. Two timepoints (5 and 10 minutes) to replace the timepoints from the previous study data collection via the tail vein and one additional 30-minute timepoint will be included, to provide an overlapping datapoint with the previous study data collection via cardiac puncture. Results will provide useful information to characterize nicotine kinetics across different routes of exposure, which is critical for the development of the physiologically-based PK model for nicotine and its metabolites (cotinine and 3-hydroxycotinine) in rodents across different routes of exposure. This scientific data may be used to identify and assess potential public health concerns related to nicotine inhalation exposure and may inform potential nicotine product standards.

Yunan Tang (CTP Contact: Prabha Kc) Funding Mechanism: FDA Internal
ID Number: E07716.01
Institution: National Center for Toxicological Research (NCTR)
09/02/2019

Little Cigar and Cigarillo Warnings to Reduce Tobacco-Related Cancers and Disease

Few studies have examined the effectiveness of currently mandated little cigar and cigarillo (LCC) warnings. The goal of this study is to clarify which LCC warning characteristics (i.e., content, format, size) are most influential in reducing LCC use and how an additional LCC policy, the removal of flavor descriptors on packaging, could influence LCC warning impact. Study aims are: (1) to develop a comprehensive set of effective LCC warning statements and images; (2) to determine whether effective LCC warnings increase LCC quit intentions; and (3) to determine how removal of LCC flavor descriptors on packaging further impacts attention and affective responses to LCC warnings. To address Aim 1, researchers will use existing research and expert review to develop new LCC warnings (text plus images) and test them using online experiments with 500 adult (aged 18-65) LCC users to identify warnings that subjects perceive to be the most effective. To address Aim 2, researchers will conduct a national, web-based randomized controlled trial with 900 adult LCC users to examine whether the most effective warnings identified in Aim 1 encourage quitting compared to the currently mandated warnings and a control condition. To address Aim 3, researchers will conduct an in-person laboratory study with 100 adult LCC users using objective measures of attention (eye tracking), affect (facial electromyography), and arousal (electrodermal activity) to determine how flavor descriptors influence the effectiveness of new warnings compared to currently mandated warnings. Findings may inform regulatory activities related to LCC warnings.

Adam O. Goldstein Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01CA240732-01
Institution: University of North Carolina at Chapel Hill
09/01/2019

Using Social Media for Tobacco Regulatory Intelligence

This research involves two projects that will use artificial intelligence (Al) methods to analyze social media posts and comments. Researchers will apply Al models to messages collected from Twitter and Reddit; these models will enable the timely identification, organization, and analysis of millions of social media posts and comments. Separate models will be developed for Twitter and Reddit, which will allow researchers to compare and contrast findings from the two social media platforms. Project 1 will detect and identify tobacco brands and products from a list of previously established brands and products. Project 2 will identify the mentions of tobacco product-related adverse events (e.g., burns from e-cigarettes, vaping lung illnesses) and the perceived health benefits and harms of tobacco products. Project findings will provide new information that may inform FDA regulatory activities and communications.

Mark Dredze (CTP contact: Mario Navarro) Funding Mechanism: Centers of Excellence in Regulatory Science and Innovation Grant (CERSI)
ID number: 3U01FD005942-04S1
Institution: Johns Hopkins University
09/01/2019

Understanding How Flavors and Nicotine are Used in Electronic Nicotine Delivery Systems Advertising (Phase 2)

This work represents an extension of earlier CERSI-funded analysis of the content of electronic nicotine delivery systems (ENDS) advertising. The goal of Phase 2 of this research is to understand how ENDS design features including flavors are presented in advertising content, as well as how nicotine and its concentration/volume/mass and type (nicotine or nicotine salts, for example) are depicted/communicated in ads. Researchers will purchase ENDS advertisements and their associated spend data (i.e., cost per ad) for 2018-2020 from a media tracking service. The sample will include ENDS ads from magazines (consumer and business-to-business), newspapers, radio, television, out-of-home (e.g., billboards, point-of-sale), and electronic media (e.g., direct-to-consumer emails, online displays, banner ads). Researchers will then content-code the ads for features, focusing on how flavors and nicotine are presented, including written and visual content; ads will also be coded for the prevalence and content of health warnings. Results across all ad years of the Phase 1 and Phase 2 study periods (2015-2020) will be combined. Researchers will analyze the depiction of flavor and nicotine content by advertisement medium over time, the depiction of flavor and nicotine content by medium audience, and marketing investments by manufacturer, brand, advertising medium, and products (including flavor and nicotine features). Researchers will also assess the presence and content of health warnings now required in ENDS advertisements. Findings of this study may be used to inform future regulatory activities related to ENDS marketing.

Ryan Kennedy (CTP contact: Dannielle Kelley) Funding Mechanism: Centers of Excellence in Regulatory Science and Innovation Grant (CERSI)
ID number: 3U01FD005942-03S1
Institution: Johns Hopkins University
08/30/2019

CTP Supplement to Parent Grant: Assessing the Intended and Unintended Consequences of E-cigarette TV Advertising

This proposed administrative supplement will build upon the parent project, titled “Assessing the Intended and Unintended Consequences of E-cigarette TV Advertising”, to leverage resources and infrastructure to investigate how a newly authorized heated tobacco product, IQOS, will be marketed in Atlanta, GA, the first test market for IQOS in the U.S. Study aims are: (1) to monitor and conduct surveillance of IQOS marketing in retail stores and public events in Atlanta, and IQOS marketing on social media, print media, and via direct mail/email; and (2) to analyze the content of IQOS marketing to determine whether it may target or appeal to tobacco disparity populations defined by gender, age, race/ethnicity, sexual orientation and socioeconomic status. Findings may inform regulatory activities related to heated tobacco products, particularly those related to youth and other priority populations.

Jidong Huang Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 3R01CA194681-05S1
Institution: Georgia State University
08/29/2019

CTP Supplement to Parent Grant: The Impact of Design Characteristics on the Modification Potential of Electronic Nicotine Delivery Systems

The goal of this project is to study early adopters of the IQOS heated tobacco product in Atlanta, Georgia by assessing their knowledge, risk perceptions, exposure to marketing, tobacco use history, and reasons for using IQOS; studying their IQOS use experience and behaviors, including dual or poly use with other tobacco products; and investigating their sociodemographics to understand the characteristics of early IQOS adopters. Study aims are: (1) to examine reasons for purchase, use intentions, risk/harm and benefit perceptions, knowledge about tobacco products, marketing exposure, tobacco use history, and sociodemographics among early adopters of IQOS in the greater Atlanta area, and (2) to conduct an in-depth examination of the IQOS retail experience, marketing exposure, and product use behaviors among IQOS early adopters, including experience with using IQOS, patterns of use, and dual or poly use with other tobacco products. To achieve Aim 1, researchers will conduct 400 intercept surveys within the first six months of product release among a convenience sample of adult (aged 18+) consumers who purchase IQOS at the IQOS store at Lenox Square and other Atlanta area retail stores that sell lQOS products. To achieve Aim 2, researchers will conduct six focus groups among IQOS early adopters (three among 20 young adults aged 18-29 and three among 20 adults aged 30+). Findings will provide information about early IQOS adopters.

Lyudmila Popova Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 3R01DA047397-02S1
Institution: Georgia State University
08/23/2019

CTP Supplement to Parent Grant: Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes Among Daily and Non-Daily Smokers on Abuse Liability

In this supplement to an existing study titled “Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E­cigarettes Among Daily and Non-Daily Smokers on Abuse Liability,” researchers will add a third arm to the study: one that exposes 80 adult daily cigarette smokers (aged 21 and older) to high and low nicotine dose JUUL e-cigarettes, along with very low nicotine content cigarettes (VLNCCs). Parent study aims are: (1) to characterize the effects of dual use of VLNCC and e-cigarettes on abuse liability, nicotine compensation, and product use, liking, and relative reinforcing efficacy among 80 adult daily smokers; (2) to characterize the effects of dual use of VLNCC and e-cigarettes on abuse liability, nicotine compensation, and product use, liking, and relative reinforcing efficacy among 80 adult intermittent smokers; and (3) to characterize the effects of dual product use on abuse liability as measured by retrospective measures, smartphone daily diary, and real-time measures captured via smartphone ecological momentary assessment. The study is obtaining information about the effects of dual use of VLNCCs and e-cigarettes with differing levels of nicotine on nicotine abuse liability, as measured by nicotine compensation, product use and liking, relative reinforcing efficacy, and assessments of withdrawal, craving, affect and satisfaction. In the parent study, smokers are provided with eGo-T e-cigarettes, which are second-generation devices; given the growth in market share of JUUL, researchers will add a third study arm that will use the same design and measures as existing study arms but will expose smokers to JUUL e-cigarettes rather than the eGo-T product. Findings may inform regulatory activities related to JUUL products.

Paul Cinciripini and Jason Robinson Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 3R01DA042526-03S1
Institution: University of Texas, M.D. Anderson Cancer Center
08/19/2019

Tobacco Longitudinal Mortality Study

The Tobacco Longitudinal Mortality Study (TLMS) will examine tobacco use and associated mortality in a large national sample of American households. Researchers will create a TUMS database using data from the Current Population Survey (CPS) Tobacco Use Supplements (TUS) (which includes 3 million individuals), the National Death Index (NDI), the Centers for Medicare and Medicaid Services (CMS), and other health agencies and researchers. Researchers will then link and analyze this data to estimate all-cause and cause-specific mortality outcomes including cardiovascular disease, stroke, heart attack, and respiratory disease (including chronic obstructive pulmonary disease (COPD)) associated with the use of cigarettes, cigars, pipes, hookah, and smokeless tobacco products. Finally, researchers will incorporate data from the National Cancer Institute to assess risks of lung, colorectal and breast cancer. Researchers will assess the mortality and cancer risk of common dual and poly-use patterns and may also examine the influence of tobacco cessation on total mortality, cause-specific mortality and cancer incidence. Findings will provide new information about the link between tobacco use and mortality.

Norman Johnson and Carol Christensen Funding Mechanism: Research Contract
ID number: 75F40119S90002
Institution: US Census Bureau
08/15/2019

Impact of Flavor on Youth & Young Adults use Intention, Abuse Liability and Perceptions of Cigarillos

The goal of this study is to examine the impact of characterizing flavors in cigarillos on product appeal, attention to marketing, product perceptions, abuse liability, and subsequent use behavior among youth (ages 14-20) and young adults (ages 21-28). Study aims are: (1) to evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users; (2) to examine differences in visual attention and risk perceptions of flavored and unflavored cigarillo advertisements among young adult cigarillo users and nonusers; and (3) to evaluate, in an experimental tobacco marketplace, the abuse liability/addictive potential of flavored versus unflavored cigarillos while simultaneously evaluating the substitutability of flavored versus unflavored JUUL e-cigarettes. To achieve Aim 1, researchers will ask 392 youth and young adult cigarillo smokers to quantitatively rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions; participants will also complete purchase and substitution tasks. To achieve Aim 2, researchers will use eye tracking equipment to compare visual attention across a set of flavored only, unflavored only, or mixed advertisements for cigarillo products and JUUL in a randomized experiment involving 150 young adult and adolescent users and non-users; participants will provide absolute and relative risk perception ratings immediately and one week after advertisement exposure. To achieve Aim 3, researchers will randomly assign 162 young adult cigarillo users to one of four conditions in an experimental online store with different products available: (1) flavored cigarillos and fruit-flavored JUUL devices, (2) unflavored cigarillos and fruit-flavored JUUL devices, (3) flavored cigarillos and tobacco-flavored JUUL devices, or (4) unflavored cigarillos and tobacco-flavored JUUL devices; researchers will then evaluate purchasing behavior, price sensitivity, product substitutability, and motivation to quit. Findings may inform regulatory activities related to cigarillos.

Erika Trapl Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01DA048529-01A1
Institution: Case Western Reserve University
08/15/2019

Blood and Brain Based Biomarkers of Injury to Assess the Cerebrovascular Impact of Emerging Alternatives to Classic Cigarette Products

While traditional measures exist for assessing cardiovascular and respiratory health in response to the short- and long-term effects of tobacco smoking and, to a lesser extent, e-cigarette use, more data concerning the cerebrovascular toxicity of these products would be useful. The goals of this study are to investigate the impact of cigarette smoking vs. e-cigarette use on the brain microvascular environment; validate selected biomarkers associated with pro-thrombotic alteration of blood hemostasis (increased risk of stroke) and severity of post-ischemic brain injury in response to chronic exposure to tobacco smoking and/or e-cigarette use; and evaluate the relevance of selected biomarkers in assessing e-cigarette vs. tobacco smoking harm with respect to blood-brain barrier viability, neurovascular inflammation, onset of stroke, and stroke outcome. Study aims are: (1) to assess the cerebrovascular impact of e-cigarette vaping and JUULing vs. tobacco smoking in mice and develop potential biomarkers to determine harm/toxicity; and (2) to evaluate and validate the impact of chronic exposure to e-cigarettes and JUUL vs. tobacco smoking on the risk of stroke, secondary brain damage, and post-ischemic neurological impairments in mice. To address Aim 1, researchers will compare the harm/toxicity of vaping/JUULing vs. tobacco smoking on the blood-brain barrier and will evaluate potential biomarkers of harm. To address Aim 2, researchers will compare the impact of tobacco smoking and vaping/JUULing on brain vascular damage, focusing specifically on the impact on stroke risk and outcomes using brain and blood-based biomarkers specific to inflammation, hemostasis and antioxidative response that were evaluated in Aim 1. Findings may inform regulatory activities related to cigarettes, e-cigarettes, and JUUL.

Luca Cucullo and Thomas Abbruscato Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R01DA049737-01
Institution: Texas Tech University Health Science Center
08/14/2019

Physical and Chemical Characterization of Aerosols Produced by Nicotine Salt Based E-Liquids

E-liquids containing nicotine salts of volatile organic acids can deliver nicotine more rapidly and efficiently than traditional free-base nicotine formulations. Manufacturers have incorporated this formulation into electronic nicotine delivery systems (ENDS) production, and nicotine salt-based products (led by JUUL) now have a major share of the U.S. ENDS market. More information regarding the chemical and physical characteristics of nicotine salt-based ENDS would be useful, specifically related to how nicotine salt aerosols differ from those produced by other nicotine formulations, which characteristics may influence nicotine delivery, and whether nicotine salt aerosols have a different profile of harmful and potentially harmful constituents (HPHCs). The goal of this project is to provide comparative data on the aerosol characteristics and HPHC profiles of nicotine salt and free-base nicotine ENDS. Researchers will develop and validate a set of analytical methods that will physically and chemically characterize nicotine salt e-liquids and the aerosols produced by both nicotine salt and free-base nicotine e-liquids. Findings will provide information about how nicotine formulation affects nicotine delivery and HPHC emissions.

Karen Carter and Margaret Schmierer Funding Mechanism: Research Contract
ID number: 75F40119D10003
Institution: Enthalpy Analytical
08/13/2019

Respiratory Effects of E-Cigarette Use Among Youth: A Prospective, Longitudinal Investigation

More information about the acute and chronic pulmonary and respiratory effects of e-cigarettes would be useful. The goal of this study is to investigate pulmonary functioning and respiratory effects among 150 youth aged 15-17 years, 100 of whom are exclusive-e-cigarette users and 50 of whom are never-users. Study aims are: (1) to compare changes over one year in pulmonary functioning and respiratory health between exclusive e-cigarette users and never-users in repeated laboratory sessions; and (2) to identify a dose-response relationship between quantity/frequency of e-cigarette use (via daily self-monitoring on a mobile phone app) and acute changes in pulmonary functioning (via same-day, home-based spirometry measurements). To achieve Aim 1, subjects will complete one baseline and four subsequent laboratory assessments over one year to provide a comprehensive assessment of respiratory health (e.g., airway reactivity, airway inflammation, pulmonary functioning). To achieve Aim 2, subjects will track their e-cigarette use by using a mobile phone app and take home-based spirometry measurements daily for four two-week periods (one prior to each laboratory assessment) so that the immediate acute effects of e-cigarette use on respiratory markers can be tracked. Findings may inform regulatory activities related to e-cigarettes.

Alayna Pauline Tackett Funding Mechanism: NIH Grant
ID number: 1K01HL148907-01
Institution: University of Oklahoma, Health Sciences Center
08/09/2019

Modeling the Impact of Flavor Bans Among Young Adult Tobacco Users Using Discrete Choice Experiments and Agent-Based Modeling

The goal of this study is to examine the impact of two flavor ban alternatives on young adults (aged 18-34) who are recent (past 30-day) users of tobacco products including electronic nicotine delivery systems (ENDS). Products studied will include menthol cigarettes; flavored cigars, cigarillos, and little cigars; and menthol and non-menthol flavored ENDS. Study aims are: (1) to assess product switching after implementation of a flavor ban and examine related determinants; (2) to estimate consumer response to hypothetical flavor bans using discrete choice experiments; and (3) to examine the impact of flavor ban policies using agent-based models. To address Aim 1, researchers will conduct an online survey among 600 young adult tobacco/ENDS users to assess product switching behavior after implementation of a flavor ban in San Francisco; researchers will evaluate flavor ban compliance enforcement, examine switching patterns, and analyze the determinants of changes in product use. To address Aim 2, researchers will conduct online discrete choice experiments with 600 young adults to estimate the impact of hypothetical flavor bans on product demand. They will examine multiple flavor ban policies related to menthol cigarette and flavored ENDS and will estimate the effects of product, flavor, price, nicotine content, and perceived harmfulness on smoker/user behavior. To address Aim 3, researchers will develop simulation models that capture the key determinants of switching behaviors and use the models to examine the impact of various flavor ban policies on switching behaviors as well as conversations between tobacco retailers and consumers. Researchers will also examine additional intervention strategies (price/tax policy, mass media campaign, smoking cessation program) that may work in concert with flavor ban policies. Findings will provide new information about the effects of tobacco product flavor bans on young adult use behavior.

Yong Yang Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 1R03DA048460-01A1
Institution: University of Memphis
07/30/2019

Randomized Trial of Low Nicotine Cigarettes Plus Electronic Cigarettes in Smokers with a Mental Health Condition

Individuals with mental health conditions are particularly vulnerable to tobacco use. The goal of this project is to determine the likely health effects of use of very low nicotine content (VLNC) cigarettes, in conjunction with availability of nicotine-containing e-cigarettes, in adult smokers (aged 18-65) with mental health conditions. Study aims are: (1) to determine whether smokers with mental health conditions have lower levels of markers of harm (e.g. urine NNAL, carbon monoxide [CO]), measures of mental health, and cigarette addiction when switched to VLNC cigarettes for 16 weeks, as compared with normal nicotine content cigarettes (NNCs); (2) to determine whether smokers with mental health conditions have lower levels of markers of harm and cigarette addiction when provided with nicotine-containing (15mg/ml) versus zero nicotine e-cigarettes in order to switch to e-cigarettes or lower their cigarette consumption; and (3) to determine whether use of VLNCs increases the proportion of smokers who completely switch away from combustible tobacco use, as assessed four weeks after the end of the randomized phase of the trial. Researchers will randomize 240 smokers with mental health conditions to one of four groups: (1) NNCs (11mg nicotine/cigarette) and 15 mg/mL nicotine e-cigarettes; (2) NNCs and zero mg/mL nicotine e-cigarettes; (3) VLNCs (0.2 mg nicotine/cigarette) and 15mg/mL nicotine e-cigarettes; and (4) VLNCs and zero mg/mL nicotine e-cigarettes. Subjects will be followed for 16 weeks on study products and then another four weeks thereafter. At the end of the 16-week phase, participants will attend their last visit, receive encouragement to quit all tobacco products, and notified of community resources where they can receive smoking cessation counseling. Participants will be asked to provide information about their intentions for ongoing tobacco product use or cessation and will be followed for four weeks to assess these outcomes; those claiming to be no longer using combustible tobacco products will be visited to verify with a measure of exhaled CO. Study findings may inform regulatory activities related to VLNCs.

Jonathan Foulds Funding Mechanism: NIH Grant
ID number: 1R01DA048428-01
Institution: Pennsylvania State University
06/28/2019

SmartVape: Real-Time Assessment of ECIG Device Characteristics using a Smartphone App

Most e-cigarettes use an electrically-powered heater to aerosolize a liquid that usually contains nicotine, a solvent (i.e., propylene glycol and/or vegetable glycerin), and flavorants. The power of the e-cigarette device, which is based on the device’s operating voltage and heater resistance, varies across devices and is a major determinant of how much nicotine and other toxicants are aerosolized. The goal of this study is to develop a tool to assess e-cigarette power objectively in real-world settings. Study aims are: (1) to standardize methods for e-cigarette and e-liquid image capture; (2) to develop the SmartVape app and supporting software; and (3) to test the app’s usability and data quality in real-world conditions. Researchers will develop a smartphone app (SmartVape) designed for e-cigarette users to capture images of their devices and e-liquid. On a back-end server, an operator will be able to compare these images to an image-based product registry with known data on device characteristics and e-liquid nicotine content. The result will be the ability to assess accurately the device used and the amount of liquids consumed over a discrete time period. With this information, researchers will be able to estimate nicotine intake from e-cigarettes more accurately in real-world settings. To address Aim 1, researchers will recruit 200 adult (aged 18+) e-cigarette users who will bring all of their e-cigarette devices and e-liquids to a laboratory, where the devices will be measured and photographed. To address Aim 2, researchers will develop the app and the image-based product registry. To address Aim 3, 50 adult e-cigarette users will use the app to record the devices and liquids they use over a 14-day period. The tool will provide a feasible and objective method for assessing e-cigarette device and e-liquid characteristics in surveillance research.

Bernard Fuemmeler and Thomas Eissenberg Funding Mechanism: NIH Grant
ID number: 1R21CA239188-01
Institution: Virginia Commonwealth University
06/26/2019

Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes

In July 2017, FDA announced a comprehensive approach to tobacco and nicotine regulation that includes moving toward a very low nicotine content (VLNC) standard for cigarettes. The goal of this study is to reduce unintended consequences of a VLNC policy by developing campaign messages that address the common public misperception that VLNC cigarettes are safer to smoke than normal nicotine content cigarettes (a misperception that could potentially lead to lower quit rates). Study aims are: (1) to develop communication campaign messages that address the misperception that VLNC cigarettes are less likely to cause cancer than current cigarettes; and (2) to determine whether selected campaign messages reduce this misperception. Researchers will first develop 24 potential campaign messages and will obtain feedback from a panel of communication experts to refine the messages. Next, they will conduct an online experiment in 1,000 adult (ages 18 and older) smokers to identify the six most effective messages; conduct six focus groups, each with 8-10 adult smokers, to obtain feedback about the six messages; and work with the expert panel to select three messages for evaluation. They will then conduct an online experiment with a nationally representative sample of 1,096 adult smokers to understand the extent to which the three campaign messages reduce VLNC misperceptions and increase motivation to quit if a VLNC standard is enacted. Study findings may inform communication campaigns about VLNC cigarettes.

M. Justin Byron Funding Mechanism: NIH Grant
ID number: 1R21CA234968-01A1
Institution: University of North Carolina at Chapel Hill
06/21/2019

Investigation into Waterpipe Physical Design Parameters’ Effects on HPHC yields in Smoke and Charcoal Emissions (Phase II)

The goal of this project is to investigate the relationship between waterpipe physical parameters and harmful and potentially harmful constituent (HPHC) yields. Researchers will methodically isolate and alter individual waterpipe physical parameters (e.g., hose length; stem length, stem depth in water) and determine how these parameters affect yields of HPHCs such as quantities of aldehydes, metals, nicotine, tobacco-specific nitrosamines (TSNAs), and volatile organic compound (VOC) levels in waterpipe tobacco smoke. Phase II of this project seeks to determine how waterpipe dimensions affect waterpipe tobacco smoke chemistry and explores the need for a standardized testing waterpipe. Findings may provide new information about a standard waterpipe design for waterpipe tobacco product testing.

Timothy Fennell and Megan Mekoli Funding Mechanism: Contract
ID number: 75F40119P10251
Institution: RTI
06/15/2019

Impact of Flavors on Nicotine Perception and Self-Administration via E-cigarettes

Mechanisms by which flavors impact the initiation and maintenance of tobacco use are not well understood. Existing evidence suggests that flavors may enhance the appeal of and facilitate the development of addiction to tobacco products by influencing nicotine’s reinforcing or aversive actions. The goal of this study is to examine whether menthol and fruit flavors impact e-cigarette use through specific behavioral mechanisms and exert different effects across nicotine concentrations. Study aims are to assess the impacts of nicotine and flavor (and their interactions) on participants’ subjective ratings of different e-liquids and the cumulative amounts of self-administered e-liquids. Fifty young adults (ages 18-30 years) will be asked to attend four test sessions each. Each test session will consist of two components. During the first component, subjects will use five different e-cigarettes and will be directed to take two 4-second puffs at 15-second intervals for each e-cigarette, with a 5-minute break between each e-cigarette. Subjects will be asked to self-administer a total of 12 puffs of the e-cigarette across approximately half an hour. They will be asked to report subjective effects for each e-cigarette during the 5-minute breaks using the Drug Effects Questionnaire (DEQ). In the second component, subjects will be given access to the same five e-cigarettes and be allowed to use them as they choose for 45 minutes in total; researchers will track number of puffs. The sessions will be identical except that the e-liquids in the e-cigarettes will differ between sessions. The subjects will use 20 e-liquid types across the entire study (4 test sessions x 5 e-liquid conditions per session) and the e-liquids will vary by flavor (unflavored, menthol, menthol mint, green apple, watermelon) and nicotine level (0, 6, 12, 24 mg/ml nicotine). The order of flavors and nicotine levels will be randomly assigned to each subject and neither the subject nor the researcher will be told the order. This study will provide new information about the impact of flavors on e-cigarette use.

Elise DeVito Funding Mechanism: NIH Grant
ID number: 1R01DA046360-01A1
Institution: Yale University
06/12/2019

Impact of Cigar Flavor on Tobacco Use Behaviors and Addiction in Dual Users

The rapid increase in dual use of flavored little cigars/cigarillos (LCCs) with cigarettes among U.S. young adults has significant implications for their health, addiction, and cessation. The goal of this study is to determine the addiction potential of flavored and unflavored LCCs compared with cigarettes, and if addiction potential varies by flavor and sex, among young adult (ages 18-34) dual users. Study aims are: (1) to characterize the addiction potential of LCCs compared with cigarettes; (2) to determine the extent to which the addiction potential of LCCs varies by flavor and sex of user; and (3) to determine the extent to which flavoring affects LCC use in the natural environment. The study will be conducted over three weeks with 145 young adult dual users of cigarettes and LCCs. Participants will be asked to substitute preferred flavor LCCs for one week and unflavored LCCs for one week in place of their normal LCCs. The study will include survey-based measures and ecological momentary assessments (EMAs) of addiction potential, dependence, and tobacco use, and biomarkers of exposure (exhaled carbon monoxide and urinary cotinine). Addiction potential of cigarettes and LCCs will be characterized by behavioral economic indices of demand (such as hypothetical consumption at escalating prices) and other standardized measures to address Aims 1 and 2. Participants will record their tobacco use, craving, mood, and setting using EMA on their mobile phones to address Aim 3. This study will provide new information about LCCs that may inform regulatory activities.

Erin Mead Funding Mechanism: NIH Grant
ID number: 1K01DA048494-01
Institution: University of Connecticut School of Medicine
05/24/2019

Understanding the Association Between Electronic Cigarette Aerosol Emissions, Tobacco Product Characteristics and User Topography and Consumption Behavior

There is a lack of consensus regarding appropriate metrics for reporting e-cigarette emissions. The total particulate mass concentration, CTPM, of whole aerosol emissions is dependent upon both user topography behavior and e-cigarette/e-liquid product characteristics; the mass ratio of harmful and potentially harmful constituents (HPHC) (fHPHC) and nicotine (fNic) present in aerosol emissions are different functions of topography behavior and product characteristics. The researchers propose a theoretical framework that defines the product of the two terms as HPHC mass concentration: CHPHC [mg/mL] = fHPHC [mg/mg] x CTPM [mg/mL]; similarly, for nicotine, CNic [mg/mL] = fNic [mg/mg] x CTPM [mg/mL];. The goals of this study are to use this framework to develop a standardized test protocol for e-cigarettes and e-liquids, propose standardized emissions outcome measures, and inform the development of criteria to distinguish low- and high-dose ENDS. Study aims are: (1) to conduct screening studies of 24 e-cigarette products and 8 e-liquid compositions to inform the creation of a formal, standardized e-cigarette emissions test protocol; (2) to evaluate total particulate mass concentration as a function of product characteristics and user topography behavior; and (3) to evaluate HPHC and nicotine mass ratio of emissions present in whole aerosol as a function of product characteristics and user behavior characteristics. Findings may inform standardized testing processes for e-cigarette emissions.

Edward Hensel Funding Mechanism: NIH Grant
ID number: 1R21ES029984-01A1
Institution: Rochester Institute of Technology
05/21/2019

Differences in Inflammation, Cardiovascular Risk Factors and Respiratory Health with Use of Menthol Cigarettes: Informing the Regulation of Tobacco Flavorings to Protect Public Health

There is limited information regarding potential differences in cardiovascular risk factors or respiratory health with menthol cigarette use. The goal of this project is to evaluate differences in systemic inflammation, cardiovascular risk factors, and respiratory health with use of menthol cigarettes among US smokers. Researchers will use interview, physical examination, and biological specimen data from 9,880 adult current smokers who participated in the National Health and Nutrition Examination Survey (NHANES), a series of nationally-representative surveys of the US population, from 1999 through 2016. Study aims are to evaluate the associations between menthol compared to nonmenthol cigarette use by analyzing: (1) markers of systemic inflammation (C-reactive protein, fibrinogen, white blood cell count, and homocysteine); (2) cardiovascular risk factors (hypertension, diabetes, and reduced kidney function); and (3) respiratory health outcomes (fractional exhaled nitric oxide levels, spirometry-defined pulmonary impairment, past year wheeze, and frequent cough and frequent phlegm). Findings may inform regulatory activities related to menthol cigarettes.

Miranda Jones Funding Mechanism: NIH Grant
ID number: 1R03HL147318-01
Institution: Johns Hopkins University
05/21/2019

Mitochondrial Genetic Alterations: A Clinical Trial of a Standardized Research E-cigarette

E-cigarettes may have the potential to reduce harm for current smokers, but additional research on target organ toxicity (e.g., the respiratory tract) would be useful. This study will focus on the effects of e-cigarette use on mitochondrial DNA (mtDNA) in the lung and nasal tract. Researchers will use bronchoscopy to evaluate the lungs of smokers who are switched to e-cigarettes, namely the National Institute on Drug Abuse (NIDA) Standardized Research E-cigarette (SREC). In this study, 96 smokers aged 21-45, following baseline bronchial and nasal brushings, will be randomized to continue smoking their usual brand (control group), completely switch to the SREC, or receive nicotine replacement therapy (NRT). A follow-up bronchial and nasal brushing will be done after two months of use. Study aims are: (1) to assess changes in mtDNA genetic features (mutations and copy numbers) in the bronchial and nasal epithelium of smokers randomized to continued smoking, exclusive e-cigarette, or NRT use; (2) to investigate whether changes in mtDNA alterations are associated with lung inflammation and gene expression; and (3) to compare mtDNA alterations between bronchial and nasal samples. This study will determine the extent to which mtDNA alterations as a biomarker of harm are reduced following the use of e-cigarettes and provide evidence for the use of nasal epithelium for noninvasive biomarkers of harm.

Min-Ae Song Funding Mechanism: NIH Grant
ID number: 1R21HL147401-01
Institution: The Ohio State University
05/21/2019

Electronic Cigarette Cardiotoxicity Varies by Flavorings: What Can We Learn from Mice?

More information about the potential pulmonary toxicity of e-cigarette flavorings would be useful. The goal of this study is to evaluate whether long-term (three-month) inhalation exposure of adolescent mice to flavored e-cigarette aerosols leads to changes in pulmonary blood vessels (vasculature) — such as inflammation, pulmonary remodeling, artery thickening, and increase in right ventricular systolic pressure — that predispose adult male and female mice to pulmonary hypertension. Researchers selected flavors (vanilla, cinnamon, menthol, double apple hookah, and peach schnapps) based on human usage and published diacetyl levels. The study aim (with multiple sub-aims) is: (1A) to determine whether three-month inhalation exposure of adolescent mice to e-cigarette aerosols (with or without flavorings) produces changes in pulmonary vasculature; (1B) to investigate the time course of effects by examining changes associated with the development of pulmonary hypertension and/or emphysema on days 30, 60, and 90; and (1C) to determine persistent effects 90 days after cessation of the three-month exposure. Study findings may inform regulatory activities related to flavored e-cigarettes.

Judith Zelikoff Funding Mechanism: NIH Grant
ID number: 1R21HL142507-01A1
Institution: New York University School of Medicine
05/21/2019

Oxidant Exposure and Related Harm from Tobacco Smoke

Oxidants are a major class of toxicant in tobacco smoke and likely play a critical role in the development of tobacco-related diseases including chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD), and cancer by causing oxidative stress/damage and inflammation. However, the specific oxidants most responsible remain unclear. The goals of this project are to identify specific oxidants responsible for tobacco-related harm and determine the impact of oxidant reduction on tobacco-related toxicity endpoints. Study aims are: (1): to determine the levels and identity of free radicals and other oxidants delivered by different combustible tobacco products/brands using advanced electron paramagnetic resonance (EPR) spectroscopy and liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies; (2) to determine the impact of tobacco smoke oxidants on lung damage and inflammation, comparing effects of high vs. low oxidant brands and tobacco varieties, in mice; and (3) to determine the impact of charcoal filtration of cigarette smoke on oxidant-induced lung damage in mice. Findings will reveal new information on the toxicological importance of oxidant exposure.

John Richie Funding Mechanism: NIH Grant
ID number: 1R01HL147344-01
Institution: Pennsylvania State University
05/20/2019

Impact of New Standards for Tobacco Products among Dual E-cigarette/Combusted Cigarette Users

Dual users of e-cigarettes and combusted cigarettes comprise 40% of multiple tobacco product users. The goal of this research is to evaluate the potential effects of limiting e-cigarette/e-liquid flavors to tobacco-only on preference for combusted cigarettes. In this study, 280 adult dual users (aged 18 and older) will undergo preference sessions during which they will make choices between an e-cigarette and a combusted cigarette. Study aims are to evaluate users’ self-reported anticipated choices if e-liquid flavors would be limited to tobacco only on: (1) choices for usual brand cigarettes; (2) choices for menthol and non-menthol cigarettes (among menthol-preferring participants); and (3) choices for cigarettes with normal nicotine content versus very low nicotine content. Findings may inform regulatory activities related to product standards.

Francis McClernon Funding Mechanism: NIH Grant
ID number: 1R01DA048454-01
Institution: Duke University
05/20/2019

The Role of E-cigarette Characteristics and Constituents in Cardiac Dysfunction

The acute and chronic health effects of e-cigarettes are mostly unknown. The goal of this project is to identify specific e-cigarette device characteristics and constituents associated with cardiac toxicity. Researchers will conduct electrocardiogram (ECG) and programmed stimulus electrophysiology (EP) studies in mice to test the hypothesis that e-cigarettes induce electrical disturbances in the heart that are related to e-cigarette characteristics and constituents. Study aims are: (1) to determine how device characteristics influence the acute electrophysiologic effects of e-cigarettes in mice, and (2) to assess the impacts of chronic e-cigarette exposure on cardiac electrophysiology and hemodynamics. Real-time cardiac physiology will be monitored during and after acute exposures to aerosols of e-cigarettes with various characteristics (device type, user settings, nicotine levels) to determine how they affect both harmful and potentially harmful constituent (HPHC) production and ECG measures of cardiac dysfunction. The device characteristics with the greatest and smallest acute cardiac effects will be selected for chronic exposure studies that will comprehensively assess cardiac EP and hemodynamics. E-cigarette exposure groups will be simultaneously compared to cigarette smoke and filtered-air exposure groups. This study will present new data regarding the relative cardiac toxicity of different e-cigarette devices, constituents, and settings, particularly with regard to their potential to cause cardiac arrhythmia.

Alex Carll Funding Mechanism: NIH Grant
ID number: 1R01HL147343-01
Institution: University of Louisville
05/17/2019

Impact of Novel Heat-not-Burn Cigarettes on Pulmonary Inflammation and Immunity

More information about the impact of heat-not-burn (HnB) aerosols generated from a product called IQOS on pulmonary inflammation and immunity to pathogens that cause respiratory diseases would be useful. The goal of this project is to determine whether HnB aerosol inhalation results in pulmonary damage and suppresses the immune response to respiratory infection and vaccination. Researchers will compare the potential effects of HnB aerosol inhalation exposure to effects caused by cigarette smoke and e-cigarette aerosols in both male and female mice. Study aims are: (1) to evaluate whether chronic inhalation exposure to HnB aerosol has the potential to cause lung inflammation and prompt changes in inflammatory cell numbers and cytokine levels in the lung, thereby altering the innate immune response; (2) to evaluate whether chronic inhalation of HnB aerosol creates an environment in the lungs that has the potential to impair adaptive immune responses to a vaccine and reduce the ability to overcome infection in the lung; and (3) to evaluate whether transition to HnB use following tobacco smoke exposure hinders the reduction in pulmonary inflammation and immune suppression that could be achieved by true cessation. Findings will provide new insights on the health risks of HnB products.

Yasmin Thanavala Funding Mechanism: NIH Grant
ID number: 1R01HL142511-01A1
Institution: Roswell Park Cancer Institute Corp
05/17/2019

The Impact of E-Cigarette Advertising and Warning Labels on E-Cigarette Use Behavior in Adolescents

Images of sweet/fruit flavors on e-cigarette advertisements may distract youth from health warnings. To better understand how these factors impact youth e-cigarette use, researchers will use functional magnetic resonance imaging (fMRI) and eye tracking to link neural responses to e-cigarette advertising and health warnings to future e-cigarette use in 80 adolescents aged 14-17 years. Participants will view e-cigarette advertisements and health warnings and complete quarterly follow-up surveys for one year. Medial prefrontal cortex (MPFC) and nucleus accumbens (NAc) activity will be measured and tested for relationships with future e-cigarette attitudes, intentions and use. Researchers will also test the specific impact of different categories of health warnings and different flavors and the interactions between these factors, including impact on memory of health warnings. Study aims are: (1) to test the hypothesis that greater MPFC activity as adolescents view e-cigarette health warnings will be related to more negative e-cigarette attitudes and intentions and lower use of e-cigarettes in the next year; (2) to test the hypothesis that greater NAc activity as adolescents view e-cigarette advertisements will be related to more positive e-cigarette attitudes and intentions and greater use of e-cigarettes in the next year; and (3) to compare the relative value of multiple measures –fMRI, eye tracking and surveys — to predict future e-cigarette use in the next year. This project will generate evidence on the impact of e-cigarette advertising and health warnings on youth e-cigarette use and may inform regulatory activities related to flavors, labeling and marketing.

Kathleen Garrison Funding Mechanism: NIH Grant
ID number: 1R01DA046334-01A1
Institution: Yale University
05/09/2019

Age of Initiation of Tobacco Products Among USA Youth and Young Adults

Estimating the age of onset of tobacco product initiation, transition or trajectories of patterns of use, and correlates of use among U.S. youth and young adults could be informative. This study involves a prospective secondary analysis of the first three waves of the Population Assessment of Tobacco and Health (PATH) Study among U.S. youth (aged 12-17 years) and young adults (aged 18-24 years) who reported never use at Wave 1. Use of the following tobacco products will be analyzed: cigarettes, e-cigarettes, cigars (traditional cigars, cigarillo, filtered cigars), hookah, and smokeless tobacco. Seven outcomes will be evaluated for each product: age to first report ever or past 30-day use, age to become susceptible to use, age to be an established user (i.e. ever use fairly regularly), age to first report dual/poly use, age to report first use of a flavored product, and age of ever combustible use. Study aims are: (1) among youth who were never users at Wave 1, to estimate their age of initiation of tobacco products and to identify the risk factors associated with age of initiation of each product; (2) among young adults who were never users at Wave 1, to estimate their age of initiation of tobacco products and to identify the risk factors associated with age of initiation of each product; and (3) among all participants, to identify trajectories and transitions in the onset of tobacco product use across time and to identify associated risk factors. Researchers will explore socio-demographic, interpersonal, intrapersonal, social, and environmental factors potentially associated with the age of initiation of the different products. This study will provide new data regarding tobacco product use trajectories among youth and young adults.

Adriana Perez Funding Mechanism: NIH Grant
ID number: 1R01CA234205-01A1
Institution: The University of Texas
05/08/2019

Understanding the Real-World Impact of the Use of Three Alternate Nicotine-Delivery Products on Combustible Cigarette Use

In this study, researchers will examine how well e-cigarettes and very low nicotine content cigarettes (VLNCs) substitute for combustible cigarettes in real-world settings and whether this is influenced by nicotine patch use. Study aims are: (1) to examine the ability of VLNCs, e-cigarettes, and no alternative product to substitute for smokers’ usual cigarettes in real-world settings and whether these effects are influenced by nicotine replacement; and (2) to examine the effects of VLNC, e-cigarette, and no alternative product use on the use of study products and the underlying mechanisms that drive such use and whether these effects are influenced by nicotine replacement. Researchers will randomly assign 180 daily smokers aged 18 and older who are not planning to quit smoking to one of three study conditions: VLNCs, Juul e-cigarettes, or no alternative product. Participants will have access to these products for four weeks. During two different weeks, participants will be asked to switch from their usual cigarettes and use only their assigned study product. They will also be asked to use either a nicotine or placebo patch. Participants will record each time they use their own cigarettes or the alternative product in real time via a smartphone, and, for some use events, answer questions about the use context (e.g., affect, smoking permitted) and possible mechanisms driving use behavior (e.g., withdrawal alleviation, taste, satisfaction). Researchers will also examine the impact of factors such as sex, dependence, psychiatric comorbidity, and risk perceptions on use behavior. Findings may inform regulatory activities regarding e-cigarettes and VLNCs.

Megan Piper Funding Mechanism: NIH Grant
ID number: 1R01CA239309-01
Institution: University of Wisconsin-Madison
02/26/2019

Investigation into Waterpipe Regimen Effects on HPHC Yields in Smoke and Project Title Charcoal Emissions (Phase l)

The goal of this project is to investigate the relationship between waterpipe smoking regimen parameters and harmful and potentially harmful constituent (HPHC) yields. Researchers will methodically isolate and alter waterpipe smoking regimen parameters (e.g., puff duration, puff volume, interpuff interval) and determine how these parameters affect yields of HPHCs such as quantities of aldehydes, metals, nicotine, tobacco-specific nitrosamines (TSNAs), and volatile organic compound (VOC) levels in waterpipe tobacco smoke. Phase I of this project focuses on the way waterpipes and waterpipe tobaccos are smoked and seeks to determine how these parameters affect waterpipe tobacco smoke chemistry. Findings may provide new information about intense and non-intense smoking regimens for waterpipe tobacco product testing.

Timothy Fennell and Megan Mekoli Funding Mechanism: Contract
ID number: HHSF223201910059P
Institution: RTI
02/14/2019

Analysis of Tobacco Filler/Matrix-Specific HPHCs

The goal of this study is to identify which of the 93 harmful and potentially harmful constituents (HPHCs) identified by the FDA are present in tobacco products currently marketed in the U.S. Researchers will use validated analytical testing methods to conduct qualitative and quantitative analyses on 27 brands of cigarette tobacco fillers, 24 brands of roll-your-own tobacco fillers, 27 brands of smokeless tobacco fillers, and 21 brands of waterpipe tobacco fillers. Findings may inform regulatory activities regarding HPHCs.

Karen Carter and Tianrong Cheng Funding Mechanism: Research Contract
ID number: HHSF2232013100381
Institution: Enthalpy Analytical
11/01/2018

Identification and Validation of a Biomarker of Electronic Cigarette Exposure

The goal of this study is to identify and confirm a biomarker specific to e-cigarette use and secondhand exposure. Study aims are: (1) to confirm that the exact oligomer compounds formed by the thermal degradation of propylene glycol (PG) and vegetable glycerin (VG) are unique to e-cigarettes and not common in other tobacco products; and (2) to determine whether these chemicals or their metabolites are found in urine and/or blood specimens of e-cigarette users and bystanders who experience secondhand exposure. Researchers will confirm the chemical structure of the VG and PG oligomers formed during e-cigarette use. This information will guide a review of the literature to identify metabolites and metabolic pathways in urine and adducts in blood specimens and to inform the selection of the most appropriate biospecimen analytical approach. Researchers will then collect and analyze blood (serum and plasma) and urine from 63 e-cigarette users, conventional cigarette smokers, and non-users (ages 18 and older) to determine whether the biomarker is unique to e-cigarette users and present at measurable concentrations in the aerosol produced from 20 e-liquids. Upon agreement from FDA that a biomarker unique to e-cigarette aerosol has been identified, researchers will proceed with additional experiments to develop an empirical model that predicts the mass of the biomarker produced per puff. This model will correlate e-cigarette use with biomarker intensity in the biospecimens collected as part of a later study of e-cigarette user exposure and secondhand exposure. Study findings may provide the identification of a unique biomarker of e-cigarette use to be used in epidemiological and clinical studies that evaluate the acute and chronic health effects from e-cigarette use and secondhand exposure.

Jonathan Thornburg (CTP Contact: Marcella Ferlito) Funding Mechanism: Research Contract
ID Number: HHSF223201810194C
Institution: Research Triangle Institute (RTI), International
10/01/2018

Developing Brand and Creative Concepts Designed to Prevent AI/AN Youth Tobacco Use

FDA Center for Tobacco Products (CTP) will conduct formative research to inform the development of messaging and creative concepts for a tobacco prevention campaign targeting American Indian/Alaska Native (AI/AN) youth. Researchers will conduct 12 focus groups with up to 16 AI/AN youth ages 13-17 per group who are either experimental cigarette users or at-risk non-triers. Participants will be recruited through community-intercept recruitment. Focus group activities will include individual surveys and discussions to gain insight into youth perceptions related to local teen culture, tobacco use trends, tobacco-related facts, and campaign brands and creative concepts to inform campaign development. Findings will inform the development of an AI/AN tobacco public education campaign.

Dana Wagner and Mario Navarro Funding Mechanism: Research Contract
ID number: HHSF223201710001G
Institution: Rescue Agency
10/01/2018

Development of a Multi-pathway Physiologically Based Pharmacokinetic (PBPK) Model for Nicotine in Humans

In this study, researchers will build a computational tool to characterize nicotine pharmacokinetics in humans. This tool will include databases, referenced literature, and a multi-pathway physiologically-based pharmacokinetic (PBPK) model. In addition, the Population Assessment of Tobacco and Health (PATH) Study human nicotine and metabolite biomarker data, and potentially behavioral and physiological response profiles established in animal models, will be included. Overall, this model will be used to evaluate the nicotine exposure-response relationship across tobacco product types and user populations. The model will also be incorporated with other existing software to predict lung deposition of nicotine via inhalation exposure from tobacco product use. This computational tool may be used to inform regulatory science efforts.

Ying Bryant Funding Mechanism: Research Contract
ID number: E07682.01
Institution: National Center for Toxicological Research
09/30/2018

Experimental Study to Test Acute Nicotine Toxicity Warnings for E-Liquids on Consumer Knowledge and Perceptions

The goal of this study is to assess the effectiveness of draft acute nicotine toxicity warnings for e-liquids in promoting consumer awareness and understanding of nicotine toxicity due to exposure to electronic nicotine delivery systems (ENDS). Specific aims of this study are to evaluate the effect of acute nicotine toxicity warnings for e-liquids on: (a) consumer knowledge of the health effects of acute toxicity from e-liquid exposure; (b) consumer knowledge of precautionary storage and handling practices for products that contain e-liquids; and (c) consumer knowledge of what to do in case of accidental contact with e-liquids. The final study sample will include approximately 5,000 current ENDS users. This study will include both young adult (aged 18-24) and adult (aged 25-65) participants from an Internet panel. Findings may inform regulatory activities related to ENDS warnings.

Anh “Bao” Zarndt Funding Mechanism: Research Contract
ID number: HHSF223201510003B
Institution: Fors Marsh Group
09/21/2018

E-Cigarettes – Relationship between Wicking Rate and Other ENDS Design Parameters

As e-cigarettes have evolved, new models have increased user control of device settings, including a variety of choices in atomizers, atomizer coils, wicks, and airflow settings. If the wicking rate is insufficient, all of these parameters combined can cause a “dry puff,” essentially burning the wick and leading to an increase in carcinogenic carbonyls and other harmful and potentially harmful constituents (HPHCs). Currently, no published studies directly measure wicking rate and isolate the effects of other ENDS design parameters (e.g., puff topography, wattage, coil configuration, preheat time, wicking material and amount) on wicking rate. The goal of this study is to understand the impact of each of these design parameters on wicking rate and eventual production of HPHCs. Findings may inform future regulatory activities related to e-cigarettes.

Karen Coyne Funding Mechanism: Research Contract
ID number: HHSF223201810047I
Institution: Research Triangle Institute International
09/19/2018

Toxicity and Carcinogenicity Profiling of Tobacco Products via Organ Microengineering and Systems Biology

The goal of this study is to advance our recently developed “Breathing-Smoking Human Lung-on-a-Chip” technology to determine the toxic effects of hookah tobacco smoke and e-cigarette emissions. In Phase 1 (18 months) of this project, we will develop a three-dimensional (3D) functional organomimetic human lung airway by combining organ-on-a-chip and 3D bioprinting technologies. The synthetic living human lung will then be validated for recreating physiological responses in vitro. In Phase 2 (6 months), we will enhance a smoking robot prototype by creating add-on modules that will generate fresh whole smoke/vapors from a diverse range of hookah tobacco and e-cigarette products; we will also use tubing with minimal adsorption properties to transfer gases and aerosols and upgrade the control software to execute e-smoking and waterpipe tobacco smoking topographies. In Phase 3 (18 months), we will integrate the lung airway with the smoking robot for system- and organ-level evaluation of tobacco products. We will expose the synthetic living human lung to freshly produced emissions of two different e-cigarette products and hookah tobacco from two commercial sources and examine pathological responses, including oxidative stress, inflammation, matrix remodeling, pH changes, nicotine absorption, and pre-neoplastic transformation at molecular, cellular, tissue and organ levels. Findings may inform future regulatory activities related to hookah and e-cigarette products.

Erica Clark Funding Mechanism: Research Contract
ID number: HHSF223201810127C
Institution: University of Colorado Denver
09/19/2018

Tracking Metals from E-cigarettes: From the Coil into Lung Tissue

E-cigarette devices may release nickel, chromium, lead, and other metals into the heated aerosol that may accumulate in lung tissue and blood. The goals of this study are to analyze the metal content of e-cigarette aerosol and to measure metal concentrations in lung tissue and blood using a mouse model of exposure. Study aims are: (1) to use Neutron Activation Analysis (NAA) to radiolabel various disassembled e-cigarette hardware components, followed by reassembly and measurement of the radiation energy spectrum of collected aerosol to identify specific sources of metal contamination; and (2) to conduct mouse exposure experiments to measure and analyze time- and dose-response relationships for nickel, chromium, and lead concentrations in lungs and blood following four-week exposure to e-cigarette aerosol. Findings will provide information about toxic metal exposures arising from e-cigarette use.

Markus Hilpert Funding Mechanism: NIH Grant
ID number: 1R21ES029777-01
Institution: Columbia University Health Sciences
09/19/2018

Emerging Chemicals of Concern in Evolving Electronic Nicotine Delivery Systems

Because electronic nicotine delivery systems (ENDS) contain plastic, glass and metal parts as well as e-liquids, they may contain a number of emerging chemicals of concern (ECCs), including phthalates, phenolic compounds, and flame retardants, that have been associated with adverse health outcomes such as asthma, endocrine disruption, reproductive and developmental abnormalities, and carcinogenic activity. The goal of this study is to characterize the types and levels of these chemicals in ENDS products, using various rigorous and reproducible analytical methods. Study aims are: (1) to characterize the contamination of e-liquids with ECCs by identifying the types and levels of ECCs in e-liquids; (2) to identify and measure the types and levels of ECCs in certain parts of ENDS, including refillable cartridge/tanks, as well as mouthpieces, which are potential ECC exposure sources; (3) to characterize thes types and levels of ECCs in ENDS aerosols; and (4) to examine and characterize the similarities and differences in types and levels of ECCs in e-liquids, extracted samples, and ENDS aerosols. Findings may inform future regulatory activities related to ENDS products.

Binnian Wei Funding Mechanism: NIH Grant
ID number: 1R21ES030028-01
Institution: Roswell Park Cancer Institute Corp
09/19/2018

The Exposure to Metals from E-Cigarettes (EMIT) Study

E-cigarettes expose users to metals, since a metal coil is used to generate aerosol and most coils are composed of nickel and chromium, which are known inhalation carcinogens. A new e-cigarette type called POD is growing in popularity with unknown potential for exposure. The goal of this study is to evaluate how e-cigarette use patterns impact exposure to toxic metals. Study aims are: (1) to understand the role of metal heating components on the transfer of metals into the aerosol, by analyzing metal concentrations in e-liquid before it is in contact with the heating coil, and in the aerosol generated; (2) to characterize patterns of e-cigarette use and other potential sources of metal exposures; and (3) to measure metals in blood, urine, saliva, and exhaled breath condensate of e-cigarette users, non-users, smokers and dual users, to evaluate how different patterns of e-cigarette and smoking use impact metal exposure. Researchers will assign 250 adults ages 18 and older to one of five groups: (1) 50 MOD e-cigarette users, (2) 50 POD users, (3) 50 cigarette smokers, (4) 50 dual users of e-cigarettes and combustible tobacco products, and (5) 50 non-users/non-smokers. All participants will answer a questionnaire on smoking history, e-cigarette use patterns, and work/hobbies that may involve metal use. Researchers will collect samples of blood, urine, saliva, and exhaled breath to measure and compare metal levels; samples of e-liquid and vapor will also be collected from e-cigarette users. Researchers will then use linear regression models to estimate the association of metals in biomarkers with e-cigarette use patterns, cotinine biomarkers, and metal concentrations in e-liquid and aerosol. Findings will provide new information about e-cigarette user exposure to metals and may inform regulatory activities related to e-cigarettes.

Ana Maria Rule Funding Mechanism: Intra-Departmental Delegation of Authority (IDDA)
ID number: 1R01ES030025-01
Institution: Johns Hopkins University
09/19/2018

Assessing Toxicant Properties of Cigarillo and Hookah Aerosols in Lung Epithelial and Cardiac Cells Through Aerosol Exposure

The goal of this study is to evaluate the toxicant properties and predicted health effects of cigarillo and hookah tobacco products compared to cigarettes. Study aims are: (1) to characterize the hazardous chemicals linked to cancer and cardiopulmonary diseases in aerosols from eight common hookah tobacco products using standardized cytotoxicity, mutagenicity, and genotoxicity assays; (2) to evaluate complete and fractionated (particles and gas only) aerosols generated from cigarettes, cigarillos, and hookah products in lung epithelial cells, cardiac cells, and endothelial cells using short-term assays and biomarkers (cytokines, DNA adducts); and (3) to evaluate the adaptive responses of lung epithelial cells in response to treatment of cells for four weeks with aerosols from one of each type of tobacco product. Findings will indicate new information about the potential respiratory and cardiac health effects associated with cigarillo and hookah use.

Stephen A. Belinsky Funding Mechanism: NIH Grant
ID number: 1R01ES029448-01A1
Institution: Lovelace Biomedical & Environmental Research Institute
09/18/2018

Characterization of Potential Harm Caused by Electronic Cigarette Flavor Chemicals and their Reaction Products

The flavor chemicals and their degradation reaction products (generated by heating) in e-cigarette aerosols may cause cell toxicity. The goals of this project are to analyze commercial e-liquids to identify and quantify flavor chemicals and their degradation reaction products and to evaluate cellular responses. The researchers will test 550 popular refill and cartomizer fluids and 100 fluids that have been anecdotally reported to cause sickness in users using gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry, and other analytical methods. Study aims are: (1) to understand the identities and concentrations of dominant flavor chemicals in e-cigarette refill fluids and heat-generated reaction products in aerosols; (2) to analyze 3D lung epithelial cells at the air liquid interface to identify and characterize their response to heat-generated aerosols containing high potency flavor chemicals; and (3) to evaluate the potency and biological effects of individual flavor chemicals and reaction products in aerosols generated without heating. Study findings may inform future regulatory activities related to e-cigarettes.

Prudence Talbot Funding Mechanism: NIH Grant
ID number: 1R01ES029741-01
Institution: University of California Riverside
09/17/2018

Studies Using the Tobacco Consumer Studies Panel – Topical Study B

This study is part of a larger contract to conduct a series of studies using the Tobacco Consumer Studies (TCS) Panel to research consumer reactions to tobacco-related information/communications and perceptions of tobacco products and their association with product use, intention, and behaviors; and consumer reactions (such as purchasing behaviors) to anticipated or actual changes in tobacco product availability and in tobacco product constituents. This study focuses specifically on free samples of tobacco products and tobacco product coupons participants may have received, how they received them, and where they redeemed them for tobacco products. The full TCS panel of approximately 4,000 tobacco users will be invited to take part in this study via web or mail. Researchers will conduct analyses to assess the prevalence of coupon and free sample receipt and use as well as details surrounding the receipt and use context (e.g., demographics, product type/brands, locations). Further analyses may explore the relationships between receipt of free samples/coupons and use behaviors, quit intentions, and harm perceptions.

Caryn Nagler Funding Mechanism: Research Contract
ID number: HHSF223201510002B
Institution: Research Triangle Institute International
09/14/2018

Linking E-Cigarette Aerosol Characteristics to Mechanisms of Pulmonary Toxicity

The goal of this study is to understand how atomizer parameters and key ingredients in e-liquids contribute to undesirable aerosol characteristics and pulmonary toxicity. Study aims are: (1) to systematically vary e-cigarette device parameters (e.g., coil composition, coil resistance, applied voltage) and e-liquid components (propylene glycol, vegetable glycerin, nicotine, flavoring) to determine their impacts on aerosol physiochemical characteristics and in vitro toxicity; (2) to expose human airway epithelial cells to e-cigarette aerosols and determine toxicity signatures resulting from specific physiochemical features; and (3) to determine acute and sub-chronic lung toxicity profiles resulting from exposures to e-cigarette aerosols in mice. Findings may inform future regulatory activities related to e-cigarettes.

Yifang Zhu Funding Mechanism: NIH Grant
ID number: 1R01HL139379-01A1
Institution: University of California Los Angeles
09/14/2018

Implied Modified Risk Statements as Predictors of Flavored Little Cigar and Cigarillo Use

Several brands of flavored little cigar and cigarillos (LCCs) come in packages that use potential modified risk descriptors (e.g., “additive-free”). The goal of this study is to examine how young adults’ receptivity to flavored LCC product packaging features (e.g., text, colors, images, pack size) and price influences their smoking behavior. Study aims are: (1) to assess the impact of flavored LCC packaging descriptors in risk perceptions and future LCC smoking behaviors among young adult LCC current users and non-users; and (2) to assess the influence of flavored LCC package features on young adults’ preferences for LCCs. Researchers will conduct a 12- and 24- month online survey (1,120 young adults ages 18-34 in each wave) to examine transitions in risk perceptions and subsequent LCC smoking behavior that occur due to receptivity to flavored LCC packaging descriptions. Also, six focus groups (with 6-8 participants per group), stratified by race/ethnicity and smoking status, will be conducted after each survey wave to understand what factors influenced transitions in receptivity, risk perceptions, and LCC smoking profiles. Next, researchers will conduct a discrete choice experiment to assess the impact of packaging features such as text, color, images, and pack size, as well as price, on the product preferences on 250 ever and 250 never LCC users ages 18-34. Findings may inform future regulatory activities related to LCC packaging.

Kymberle L. Sterling Funding Mechanism: NIH Grant
ID number: 1R01CA228906-01A1
Institution: University of Texas Health Sciences Center School of Public Health
09/14/2018

Investigating the Cardiovascular Toxicity of Exposure to Electronic Hookah Smoking

Electronic hookah (e-hookah) bowls, which contain flavored e-liquid that is heated electrically but inhaled through traditional waterpipes, are increasing in popularity in the United States. The goals of this study are to compare the effects of traditional hookah smoking with e-hookah inhalation on human vascular and endothelial function, and to examine the role of inflammation and oxidative stress in hookah-related cardiovascular disease development. Study aims are: (1) to determine the acute effects of e-hookah bowl inhalation on endothelial function; (2) to determine the acute effects of e-hookah bowl inhalation on arterial stiffness; and (3) to determine the acute effects of e-hookah bowl inhalation on biomarkers of oxidative stress and inflammation. Researchers will conduct cross-over studies in 18 young adult hookah smokers (ages 21-39). Findings will provide new information about the effects of e-hookah use on human health and may inform regulatory activities related to e-hookah.

Mary Rezk-Hanna Funding Mechanism: NIH Grant
ID number: 1R21HL145002-01
Institution: University of California-Los Angeles
09/14/2018

Effects of E-Cigarette Exposure During Pregnancy on Offspring Lung Function and Disease: Characterization of Pulmonary, Intergenerational, and Epigenetic Effects

Nearly all the effects of maternal smoking during pregnancy on fetal lung development are caused by nicotine crossing the placenta to interact with nicotinic receptors in the developing lung. The goal of this study is to use a mouse model to describe the effects of perinatal e-cigarette exposure on offspring pulmonary function and disease. Study aims are: (1) to characterize the direct effect of maternal in-utero e-cigarette exposure on first-generation offspring pulmonary function, respiratory disease and epigenetic changes; (2) to characterize the intergenerational effect of grand-maternal in-utero e-cigarette exposure on second-generation offspring pulmonary function, respiratory disease and epigenetic changes; and (3) to characterize the additive, multigenerational effect of both grand-maternal and maternal in-utero e-cigarette exposure on offspring pulmonary function, respiratory disease and epigenetic changes. Researchers will expose pregnant mice to filtered air, e-cigarettes without nicotine, and e-cigarettes with nicotine from gestation day 1 to postnatal day 7 and will analyze effects on lungs at age 8 weeks; in addition, they will analyze the effects of in-utero exposures on asthma susceptibility based on sensitivity to house dust mite antigen. Researchers will conduct similar analyses on the second-generation mice to determine intergenerational effects. Findings will provide new information about the effects of e-cigarette use by pregnant women.

Eliot R. Spindel and Kent Pinkerton Funding Mechanism: NIH Grant
ID number: 1R01HL144384-01
Institution(s): Oregon Health & Science University and University of California, Davis
09/14/2018

Airway Protein Modifications caused by New and Emerging Tobacco Products as Markers of Exposure and Potential Health Risks

The use of new and emerging tobacco products (NETPs) such as hookah and e-cigarettes is increasing, particularly by the younger population in the US. The goal of this study is to examine airway protein modifications that result from NETP use. Study aims are: (1) to identify NETP-induced protein modifications in vitro of smoke/vapor-exposed human bronchial epithelial cell (HBEC) surfaces (airway epithelial cells for analysis are routinely received and subsequently maintained by the institution); and (2) to establish protein modifications as markers of NETP use and effects in vivo by conducting mass spectrometry analysis of tobacco product user sputum samples (previously collected from healthy cigarette, e-cigarette and hookah users ages 18-50). Findings will provide new information about the airway toxicity effects of tobacco product use.

Boris Reidel Funding Mechanism: NIH Grant
ID number: 1R03HL140402-01A1
Institution: University of North Carolina – Chapel Hill
09/14/2018

CRoFT TCORS: WNY Center for Research on Flavored Tobacco Products (CRoFT)

Many tobacco flavoring ingredients are labeled Generally Recognized as Safe (GRAS) as they are intended for ingestion; however, they have not been evaluated for inhalation toxicity. More data can provide understanding regarding how consumers perceive and use flavored tobacco products and whether these have implications for health. The goal of the Western New York (WNY) Center for Research on Flavored Tobacco Products (CRoFT) is to develop a novel framework and approaches for assessing the impact of tobacco product flavors and flavorings on consumer behavior, exposures, and health. Four projects will provide useful information about the toxicological, health, and behavioral implications of flavors and flavoring chemicals. Project 1 will apply state-of-the art methods to assess the chronic toxicity of specific flavorings used in tobacco products using chemical reactivity, in vitro models, and in vivo research studies. Project 2 will apply consumer sensory and behavioral laboratory approaches to examine the behavioral impacts of flavors, including sensory thresholds for single and combined flavorings, and the impact of flavoring concentration on use patterns (puffing topography, inhalation). Project 3 will apply longitudinal cohort and product-switching designs to examine the chronic respiratory health effects of flavorings in tobacco products among current users. Project 4 will apply qualitative, quantitative, and experimental approaches to examine the effects of information on flavor choice and flavored product use.

Richard J. O’Connor and Maciej Goniewicz Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA228110-01
Institution: Roswell Park Cancer Institute and University of Rochester
09/14/2018

CRoFT TCORS Project 1: In Vitro and In Vivo Assessment of Flavorant Toxicity

Commonly-marketed flavors in emerging tobacco products such as e-cigarettes, cigarillos, and waterpipe tobacco include tobacco, mint/menthol, fruits/candy, coffee/tea, chocolate, berries, crème/butter, clove/cinnamon, and alcoholic beverages. Underlying these flavors are chemical flavorings, some of which have known respiratory toxicity (e.g., diacetyl, cinnamaldehyde). Comparative toxicity data would be useful to clarify the health effects of these tobacco products. The goal of this Center for Research on Flavored Tobacco Products (CRoFT) project is to determine and compare the effects of various flavorings in e-cigarettes, cigarillos, and waterpipe tobacco on toxicological and immune-inflammatory responses. Study aims are: (1) to determine comparative in vitro toxicity of selected tobacco product flavorings using (a) the aerosol exposure system for cell-free reactive oxygen species reactivity, and (b) exposure to human lung epithelial cells via air-liquid interface and 3D culture; (2) to determine comparative oxidative, DNA damage and immune-inflammatory responses to tobacco product flavorings in a mouse model to determine the link between flavoring toxicity and adverse respiratory health outcomes; and (3) to identify comparative biomarkers in response to tobacco product flavorings. Assessment of toxicity within the same class of flavorings across different types of tobacco products will allow a toxicity/hazard ranking and information related to flavoring-specific adverse health outcomes.

Irfan Rahman Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA228110-01
Institution: University of Rochester
09/14/2018

CRoFT TCORS Project 2: Human Thresholds for Characterizing Flavors and Impact on Behavior

Flavors are common in electronic nicotine delivery systems (ENDS) and are often named as a primary reason for their use. The goal of this Center for Research on Flavored Tobacco Products (CRoFT) study is to evaluate whether flavors might have “indirect” toxicity: that is, regardless of whether flavorings show biological evidence of toxicity, they may increase harm by other means, such as increasing appeal, decreasing risk perceptions, or masking harshness or irritation that might lead users to discontinue use. Study aims are: (1) to develop expert (trained per industry best practices) and consumer (untrained) sensory panels to identify and assess characterizing flavors in e-liquids; and (2) to examine the effects of flavorings on use topography, subjective effects of vaping, and sensory experience among current ENDS users. For Aim 1, researchers will compare the ability of trained and untrained individuals to identify and characterize flavors, determine threshold detection levels for individual and mixed flavors, and identify the dominant flavor of mixtures; four panels (expert user, expert nonuser, consumer user, consumer nonuser) of 35 individuals each (ages 18-55) will be convened. For Aim 2, researchers will examine whether flavor concentration affects use topography (puff volume, puff duration, inhalation volume, breathhold duration), subjective effects, and detection of “dry puff” under high power conditions in 120 daily e-cigarette users (ages 18-49). Findings may inform future regulatory activities related to flavors.

Richard J. O’Connor Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA228110-01
Institution: Roswell Park Cancer Institute
09/14/2018

CRoFT TCORS Project 3: Respiratory Health Effects of Flavors

More information about the respiratory health hazards of the flavorings used in tobacco products would be useful. The goal of this Center for Research on Flavored Tobacco Products (CRoFT) project is to characterize the respiratory health effects — including inflammation, biomarkers of exposure, and clinical markers with relevance to disease endpoints — attributable to the use of flavored tobacco products. Two studies will evaluate daily ENDS users as they switch among various flavors. Study aims are: (1) to assess changes in respiratory symptoms and biomarker levels in ENDS users during spontaneous switching between flavors (Study 1); (2) to evaluate respiratory symptoms in ENDS users switching from flavors of potentially high toxicity to flavors of potentially low toxicity (Study 2); and (3) to characterize ENDS users’ preferences, selection, patterns of use and switching between various flavors (Studies 1&2). In Study 1, researchers will establish a cohort of 176 ENDS users (ages 18-54) to assess changes in respiratory symptoms during spontaneous switching among flavors over one year. In Study 2, researchers will conduct a randomized, parallel-group open-label trial to evaluate respiratory symptoms in 216 ENDS users (ages 18-54) switching from higher-toxicity to lower-toxicity flavors (as identified by Project 1). Endpoints will include clinically relevant biomarkers of inflammation and oxidative stress, changes in respiratory function, subjective respiratory symptoms and side-effects, and expression of immune and inflammatory response genes in nasal epithelial cells. Results may inform future regulatory activities related to flavors.

Maciej Lukasz Goniewicz Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA228110-01
Institution: Roswell Park Cancer Institute
09/14/2018

CRoFT TCORS Project 4: Evaluating Effects of Packaging and Market Availability of Flavored Tobacco Products on Consumer Perception and Behavior

Flavored tobacco products influence appeal, use, and perceptions of reduced harm. This project will investigate how descriptor terms such as “natural”, “cherry gummy bear”, “Neapolitan ice cream”, and “chocolate milk shake” and pictures illustrating those terms influence perceptions of appeal, harm, and intention to use, among both current and susceptible non-users of electronic nicotine delivery systems (ENDS). The goal of this Center for Research on Flavored Tobacco Products (CRoFT) project is to evaluate perceptions of flavored tobacco products and relevant messages as conveyed by package design characteristics (i.e., colors, design, descriptor terms), as well as the potential impact on demand and behavior, for cigarettes, cigarillos/little cigars, and ENDS. Study aims are: (1) to evaluate how to communicate messages about flavors and potential harms associated with specific flavors to consumers of combustible tobacco products and ENDS; and (2) to evaluate the potential effects on tobacco use behavior of flavored tobacco products with varied risk messaging and changes in market availability (e.g., restricted range of flavors, changes in descriptors). Researchers will conduct three studies in adults (ages 18 and older) to achieve these aims. In Study 1, researchers will conduct eight focus groups with 100 participants and 20 in-depth one-on-one interviews to examine beliefs and behaviors related to flavored e-cigarette use. In Study 2, researchers will conduct a mall-intercept survey experiment with 192 e-cigarette users and susceptible non-users to obtain reactions to e-cigarettes/e-liquids with fictitious packaging/brand names. In Study 3, researchers will conduct an experimental auction in which 384 participants bid on five unflavored and flavored products (four types of e-cigarettes and one pack of cigarettes or little cigars) to examine the influence of changes in market availability of flavored tobacco products on willingness to pay. Findings may inform future regulatory activities related to flavors.

Maansi Bansal-Travers Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA228110-01
Institution: Roswell Park Cancer Institute
09/14/2018

USC TCORS: Tobacco Regulatory Science Investigating the Intersections of Products with Diverse Populations

The University of Southern California Tobacco Center of Regulatory Science (USC-TCORS) will conduct research on the use and health effects of specific e-cigarette products across populations. Researchers will study e-cigarette product characteristics and marketing approaches hypothesized to increase tobacco product attraction, use, and addiction in youth and young adult non-smokers and have little impact on tobacco product use in older smokers. These characteristics and marketing approaches include: (a) non-tobacco flavorings; (b) constituents and devices that produce large vapor clouds and the user experience; (c) modifiable devices; (d) device designs not resembling cigarettes; (e) cartoons in packaging and advertising; and (f) candy flavors or other youth-oriented marketing themes. The TCORS will include four projects. Project 1 will characterize publicly available social media postings of e-cigarette product characteristics and marketing themes and will study links with tobacco product use behavior in youth and young adults. Project 2 will involve vape shop customer interviews to assess the impact different e-cigarette regulation scenarios on tobacco product use. Project 3 will study associations of e-cigarette product characteristics and marketing exposures with tobacco product use and dependence across 10 years (ages 14-25). Project 4 will involve laboratory tests of the impact of e-cigarette product characteristics and marketing exposure manipulations on product appeal, abuse liability, and other outcomes.

Mary Ann Pentz and Adam Matthew Leventhal Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 CA180905-06
Institution: University of Southern California
09/14/2018

USC TCORS Project 1: Effects of Social Media Marketing and Messages on Tobacco Transitions

More information about e-cigarette product diversity portrayed on social media and how social media exposure impacts tobacco product use would be useful. The goal of this project is to examine how social media portrays e-cigarette product diversity and how this portrayal may affect tobacco product transitions. Study aims are: (1) to analyze continuously collected social media posts that include e-cigarette and other tobacco product-related keywords to determine trends in product marketing and conversations about e-cigarette products and their diverse product characteristics; and (2) to determine whether participation (e.g., posting, liking, sharing) in e-cigarette-related social media, especially posts that contain youth-oriented themes, is associated with tobacco product susceptibility and use among youth and young adults. To address Aim 1, researchers will collect, code, and analyze messages posted on popular social media sites using existing tobacco-related keywords and identifying new keywords; they will identify types of tobacco messages (e.g., youth-oriented messages, health-oriented messages aimed at current smokers) and the characteristics of messages about e-cigarettes that generate the most user engagement and dissemination. To address Aim 2, researchers will analyze publicly-available and accessible e-cigarette-related social media postings generated by participants in a cohort of adolescents and young adults (ages 14-25) in Southern California to determine links between posting and transitions across six stages of tobacco use (non-susceptible never-user, susceptible never-user, single product experimenter, poly-tobacco experimenter, single-product regular user, poly-tobacco regular user). Findings will provide new information about the links between exposure to products and marketing via social media and tobacco product use and transitions.

Jennifer Beth Unger and Tess Boley Cruz Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 CA180905-06
Institution: University of Southern California
09/14/2018

USC TCORS Project 2: Influence of Tobacco Product Characteristics and Marketing on Diverse Populations of Vape Shop Customers

Vape shops, which specialize in selling a variety of e-cigarette products, are a key channel of exposure to these products. The goal of this project is to examine how different segments of the vape shop customer population would likely react to hypothetical e-cigarette regulations. The project will contrast three groups of vape shop customers — e-cigarette-only users (who never smoked cigarettes extensively); switchers (who quit smoking and now only use e-cigarettes); and dual users (who currently use both e-cigarettes and cigarettes) —regarding perceived appeal and anticipated purchase/use of e-cigarettes and combustible products currently and after hypothetical regulatory changes. Study aims are: (1) to test the hypothesis that hypothetical regulations related to sweet flavors, e-liquid propylene glycol/vegetable glycerin ratios, and ability to calibrate a device will be associated with lower e-cigarette appeal and lower anticipated future purchase/use in e-cigarette-only users (vs. switchers and dual users); (2) to test hypothetical marketing practices that may be associated with lower e-cigarette appeal and lower anticipated future purchase/use in e-cigarette-only users (vs. switchers and dual users); (3) to test the hypothesis that these hypothetical product regulations and marketing practices will be associated with lower e-cigarette appeal and lower anticipated purchase/use among young adults (age 21-29) vs. middle/older adults (30+); and (4) to examine the above associations as a function of (a) current product(s) used, (b) race/ethnicity, (c) gender, (d) socioeconomic status, and (e) shop location. Researchers will conduct interviews with customers (ages 21 and older) exiting vape shops in a racially/ethnically diverse set of neighborhoods. Findings may inform future regulatory activities related to e-cigarettes.

Steven Yale Sussman and Lourdes Baezconde-Garbanati Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 CA180905-06
Institution: University of Southern California
09/14/2018

USC TCORS Project 3: Product Characteristics, Marketing, and E-cigarette and Cigarette Use Across Adolescence and Young Adults

E-cigarette product diversity (i.e., product characteristics and associated marketing strategies) can affect product appeal and use, especially among adolescents and young adults. The goal of this project is to test hypothesized e-cigarette product characteristics and marketing strategies that may attract never-smokers and put them at risk for tobacco product use but do not affect the likelihood that young smokers will adopt and switch to e-cigarettes. Examples of product features that may disproportionately attract never smokers (vs. smokers) include sweet flavors (vs. tobacco or other flavors), devices and e-liquid compositions used to generate large aerosol clouds for “vape tricks” (vs. devices that look and feel like cigarettes), and youth-oriented marketing strategies for e-liquid naming (such as “Kustard Killer”) and packaging with cartoon images. Study aims are: (1) to evaluate the associations of: (a) product characteristics and marketing exposure with e-cigarette interest, (b) e-cigarette interest with subsequent initiation, and (c) marketing exposure with subsequent initiation; (2) to evaluate the association of (a) e-cigarette initiation with cigarette initiation and progression, or discontinuation of tobacco product use, and (b) e-cigarette product characteristics and marketing exposure with dual use, nicotine dependence, or discontinuation of tobacco product use; and (3) to evaluate whether associations of product characteristics and marketing with outcomes observed in Aims 1 and 2 differ between baseline never-smokers and smokers. Researchers will survey participants in a cohort of adolescents and young adults (ages 14-25) in Southern California. Findings may inform future regulatory activities related to e-cigarettes.

Rob Scot McConnell and Jessica Barrington-Trimis Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 CA180905-06
Institution: University of Southern California
09/14/2018

USC TCORS Project 4: Human Laboratory Research to Inform Precision Regulation of E-cigarettes Across Populations

E-cigarettes may adversely impact the health of some populations (e.g., young never-smokers), but also may reduce health risk in others (e.g., middle-aged/older smokers who completely switch to e-cigarettes). The goal of this project is to identify dimensions of e-cigarette product diversity that put young adult never-smokers at risk of using e-cigarettes, yet do not deter middle/older adult smokers from adopting and potentially switching to e-cigarettes. Study aims are: (1) to determine which dimensions of e-cigarette product diversity differentially affect product appeal in never-smoking young adult e-cigarette users and middle-aged/older adult smokers with an interest in, but no significant experience with, e-cigarettes; (2) to determine which dimensions of e-cigarette product diversity differentially affect abuse liability in never-smoking young adult e-cigarette users and ability to resist smoking in middle-aged/older adult smokers with an interest in, but no significant experience with, e-cigarettes; and (3) to examine sex differences in the effects of product diversity on appeal, abuse liability, and ability to resist smoking by testing sex and product dimension interactions. In two studies, subjects will self-administer e-cigarette products varied according to three dimensions: flavor (e.g., sweet vs. menthol vs. tobacco); propylene glycol/vegetable glycerin ratio (e.g., 20:80 vs. 40:60 vs. 60:40 vs. 80:20); and packaging design (e-liquid characterizing flavor label [e.g., “peach”] vs. youth-oriented non-characterizing flavor [e.g., “gummy heaven”] vs. non-characterizing flavor + cartoon). The Aim 1 study will test product exposure effects on subjective ratings of appeal (e.g., liking, desire to use again). The Aim 2 study will test product exposure effects on choice to use (vs. earn money) the previously-exposed e-cigarette product (an abuse liability test; never-smoking young adults only), or own brand cigarettes (test of ability to resist smoking; middle-age/older adult smokers only). Findings may inform future regulatory activities related to e-cigarettes.

Adam Matthew Leventhal Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 CA180905-06
Institution: University of Southern California
09/14/2018

UPenn/Rutgers TCORS: Examining the Effects of Advertising, Packaging and Labeling on Perceptions, Use and Exposure of Combustible Tobacco Products

Tobacco advertisements are an important marketing vehicle that allows companies to prominently and creatively feature brand imagery and benefit claims, including those that might suggest modified risk. In addition, tobacco packaging uniquely provides repeated opportunities to express brand image and implicitly convey brand attractiveness, quality and health appeals to consumers every time the product is used. The goal of the University of Pennsylvania – Rutgers University TCORS is to accumulate a comprehensive and rigorous body of knowledge on the effects of tobacco communication, including advertising, marketing, packaging and labeling, on regulatory-relevant outcomes of risk perceptions, use, behavior and exposure for combustible tobacco products, given their disproportional burden on public health. The UPenn & Rutgers TCORS includes four projects. Project 1 will study the effects of cigarette package color on smoking behavior, exposure and risk perception when using low nicotine content cigarettes. Project 2 will examine the effects of advertising and correctives for reduced harm tobacco products. Project 3 will study the influence of cigarillo packaging and labeling on young adults. Project 4 will examine products that have descriptors that may imply modified risk.

Andrew A. Strasser and Cristine Delnevo Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA229973-01
Institution: University of Pennsylvania and Rutgers University
09/14/2018

UPenn/Rutgers TCORS Project 1: The Effects of Cigarette Package Color on Smoking Behavior, Exposure and Risk Perception when using Low Nicotine Content Cigarettes

Cigarettes with reduced nicotine content decrease dependence and toxicant exposure, suggesting potential public health benefits of mandating a low nicotine product standard. These findings, however, come primarily from studies using investigational low nicotine content (LNC) cigarettes in basic packaging with no accompanying marketing campaign. Thus, there is no data currently available to clarify the impact of product marketing. The goal of this project seeks to evaluate the effects of LNC cigarette packaging on two primary outcomes: smoking behavior and biological toxicant exposure. Study aims are: (1) to examine the effect of cigarette packaging on smoking behavior during LNC use; and (2) to examine the effect of cigarette packaging on biological exposure during LNC use. Researchers will recruit 500 currently daily cigarette smokers (ages 21-65) to a 35-day randomized controlled trial; after a five-day period of smoking their own cigarettes, participants will be randomized to continue smoking their own brand (control group) or to smoke investigational LNC cigarettes in one of four types of packaging (red/blue/gray/plain) for 30 days. Outcomes will include smoking behavior (daily cigarette consumption, total puff volume), biological exposure (total nicotine equivalents, NNAL, carbon monoxide), subjective ratings (taste, smoking satisfaction, perceived nicotine strength, harshness), and risk and harm perceptions. Findings will provide important information about low nicotine content cigarettes in the context of cigarette packaging.

Andrew A. Strasser Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA229973-01
Institution: University of Pennsylvania
09/14/2018

UPenn/Rutgers TCORS Project 2: The Effects of Advertising and Correctives for Reduced Harm Tobacco Products

Misperceptions of the risks of potential modified risk tobacco products (MRTPs) can be exacerbated by product marketing. The goal of this project is to develop scientifically rigorous protocols to establish the magnitude and strength of inaccurate beliefs created by advertising and marketing practices for potential MRTPs in target audiences. The studies proposed in this project focus on advertising claims about combustible MRTPs and identifying the associated beliefs – both harms and benefits – in the minds of both likely users (smokers) and former smokers. Study aims are: (1) to understand the effects of advertising about potential MRTPs on product beliefs; (2) to assess the impact of potential MRTP ad content on beliefs about and attitudes and intentions toward MRTPs and examine whether false beliefs mediate the link between ad claims and attitudes/intentions; and (3) to design simple correctives to modify inaccurate inferences about potential MRTPs and assess their ability to change inaccurate (but not accurate) beliefs, redirect attention to corrective information, and affect MRTP use behavior. Eight studies will address these three aims. To address Aim 1, researchers will monitor past and current requests to FDA for MRTP approval of combustible tobacco products (Study 1), track beliefs about MRTPs derived from online comments by members of the public (Study 2), conduct a descriptive pilot study with 1000 current and 1000 former smokers (ages 18 and older) to derive a set of targeted beliefs (Studies 3 and 4), and conduct a study to determine whether ad content can encourage beliefs in one direction or another (Study 5). To address Aim 2, researchers will evaluate beliefs of 1500 participants (ages 18 and older) using standardized assessment tools to determine whether beliefs mediate between advertising claims and attitudes and use intentions (Study 6). To address Aim 3, researchers will conduct two studies in current daily smokers (ages 21-60); an eye tracking study (Study 7) as well as behavioral tests of MRTP use in the presence and absence of corrective statements (Study 8). Findings may inform future regulatory activities related to potential MRTP advertising.

Joseph Nicholas Cappella Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA229973-01
Institution: University of Pennsylvania
09/14/2018

UPenn/Rutgers TCORS Project 3: Influence of Cigarillo Packaging and Labeling on Young Adults

The use of cigarillos is growing among young adults. Therefore, more information about the influence of cigarillo packaging and labeling on young adults would be useful. The goal of this project is to understand how cigar and cigarillo packaging and labeling may both facilitate and dissuade cigar among young adults (ages 18-24). Using a series of complementary mixed methods studies (i.e., online exposure experiments, observational secondary data analyses, smoking lab study), researchers will study the effects of exposure to cigar/cigarillo packaging with varying warning labels (text and pictorial) and descriptors (flavors and potentially modified-risk claims) on perceptions, use intentions, and use. Study aims are: (1) to test the effect of different cigarillo packaging features (descriptors, colors, presence of current warning labels) on perceptions and use intentions among 2400 young adult past-year cigarillo smokers using a between-subjects online experiment; (2) to compare the effect of different text and pictorial warnings on cigarillo perceptions and use intentions among 1,800 young adults using an online experiment; and (3) to evaluate exposure to cigar warnings (and associations with cigar harm perceptions and use) over time through an analysis of Population Assessment of Tobacco and Health (PATH) survey data. In addition, in an exploratory smoking experiment, 100 young adult past 30-day cigarillo smokers will smoke non-flavored cigarillos placed in packaging with flavor descriptors, allowing researchers independently examine the potential impact of packaging and descriptors on cigar ratings. Study findings may inform future regulatory activities related to cigar and cigarillo flavoring, packaging descriptors, packaging, and pictorial warnings.

Cristine D. Delnevo & Olivia Wackowski Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA229973-01
Institution: Rutgers University
09/14/2018

UPenn/Rutgers TCORS Project 4: Examining Product Descriptors in Natural American Spirit Cigarette Marketing

Extensive research has confirmed that cigarettes marketed as “light,” “low tar,” and “mild” were misperceived as having lower risks. In recognition of this, the 2009 Tobacco Control Act (TCA) banned the use of these descriptors in one of its earliest regulatory actions but did not address other misleading terms that studies have shown also suggest reduced harm for products utilizing them. One of these products is Natural American Spirit, a heavily-advertised and top-selling premium cigarette brand popular among young adults that promoted itself using the terms “additive free,” “natural,” and “organic.” The goal of this project is to provide additional scientific evidence on product descriptors that may imply a health claim, such as the terms “natural,” “additive-free,” and “organic.” Study aims are: (1) to understand consumer perceptions of brand name, descriptors (e.g., “organic”, “Tobacco Ingredients: Tobacco and Water”), and imagery advertising by conducting 12 focus groups each with 6-8 young adult (ages 18-24) smokers and nonsmokers; (2) to assess the effect of potentially misleading descriptors in print advertising on cigarette risk perceptions and use intentions among 2400 young adult (ages 18-24) smokers and non-smokers using a between-subjects online experiment; and (3) to examine population differences in tobacco perceptions, use intentions, and use between products that may imply a modified risk or health claim and other brand smokers, comparing them over time through analysis of Population Assessment of Tobacco and Health (PATH) study data. A secondary aim will be to monitor claims and images used in cigarette advertising with a longitudinal content analysis of print and direct mail advertising. Findings will advance the evidence base on the impact of misleading terms implying reduced risk.

Jane Lewis Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA229973-01
Institution: Rutgers University
09/14/2018

U of M TCORS: Center for the Assessment of the Public Health Impact of Tobacco Regulations

The University of Michigan Center for the Assessment of the Public Health Impact of Tobacco Regulations aims to provide evidence-based and expert-informed modeling of the behavioral and public health impacts of tobacco regulations. The Center will have three projects based on detailed analysis of historical tobacco use patterns in the U.S. and will use four established tobacco simulation models. Project 1 will involve comparative modeling analyses of the impact of tobacco regulations and policies on smoking and e-cigarette use and related long-term health outcomes, including heart, pulmonary disease and maternal and child health. Project 2 will extend two well-established models to examine the possible consequences of regulating nicotine in combusted tobacco products. Project 3 will model tobacco-related health disparities associated with single- and multi-product tobacco use and will investigate how potential policy options may impact tobacco use and tobacco-related health disparities.

Rafael Meza and David T. Levy Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA229974-01
Institution: University of Michigan and Georgetown University
09/14/2018

U of M TCORS Project 1: Comparative Modeling of the Impact of E-cigarettes use on Smoking and Long-Term Health Outcomes

The goal of this project is to use four established tobacco control simulation models to examine the impact of different possible FDA regulatory actions on future trends in cigarette and e-cigarette use and associated health outcomes. Study aims are: (1) to characterize differences in cigarette and e-cigarette use patterns and to monitor changes in use patterns over time; (2) to extend well-established simulation models so that they consider mortality from specific health outcomes, including lung cancer, chronic obstructive pulmonary disease (COPD), cardiovascular disease, and maternal and child health outcomes; (3) to project mortality from lung cancer, COPD, cardiovascular disease, and low birth weight births under current cigarette and e-cigarette use patterns (status quo); (4) to estimate the impact of past and potential new tobacco control policies on patterns of cigarette and e-cigarette use; and (5) to model the impact of past and potential new policies on all-cause mortality and health outcomes associated with cigarettes and e-cigarettes. Researchers will use a generalized decision analysis framework and statistical approaches to develop initial prevalence rates for the models, a range of plausible future status quo transitions by age and gender for initiation and cessation of cigarettes and e-cigarettes, and a range of plausible switching rates between cigarettes and e-cigarettes. Using literature reviews and expert elicitation panels, researchers will develop relative risk estimates for specific health outcomes, and then will project tobacco-related mortality due to cardiovascular disease, COPD, and adverse maternal and child health outcomes. Researchers will extend the models to project how specific potential regulatory activities (e.g., health warnings on cigarette packages; public education campaign) individually and in combination will likely impact cigarette and e-cigarette use rates and associated health outcomes over a 50-year future period. The models may be extended to consider other nicotine delivery products, including cigars, smokeless tobacco and heat-not-burn products. Results will provide evidence-based, expert-informed estimates of tobacco use prevalence, health outcomes, and policy impacts.

David T. Levy, Theodore R. Holford, David Mendez and Rafael Meza Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA229974-01
Institution: Georgetown University, Yale University, and University of Michigan
09/14/2018

U of M TCORS Project 2: Modeling the Impact of Nicotine Regulation on Smoking and Smoking-Related Mortality

The Food and Drug Administration (FDA) has the authority to regulate nicotine levels on all tobacco products. The focus has been primarily on lowering nicotine to minimally or non-addictive levels in cigarettes. While lowering nicotine levels in cigarettes might lead to declining smoking rates, such policies could generate unintended consequences that would undermine their effectiveness. The goal of this project is to examine how nicotine regulation may impact public health, including possible unintended consequences from compensation behaviors and the emergence of a black market. Study aims are: (1) to modify two existing U.S. population-based dynamic smoking prevalence and mortality models to account for the effects of policies that reduce nicotine to non-addictive levels in all combusted tobacco products; (2) to model the number of new smokers, smoking prevalence trajectory, and smoking-related mortality in the U.S. population from 2018-2100 in the absence of nicotine regulation; and (3) to conduct policy simulation exercises on the impact of nicotine regulations on smoking prevalence and associated mortality. Researchers will focus on the impact of potential nicotine policy-related changes on smoking prevalence and overall mortality; however, other health outcomes may be incorporated as they become available from Project 1 of this TCORS. While the focus of this project will be on nicotine reduction, the models will be flexible enough to examine the effect of other FDA regulations to alter cigarette content, such as limits on specific toxic ingredients, as well as the influence of other tobacco control policies. Results may inform potential regulatory activities related to nicotine.

David Mendez and Rafael Meza Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA229974-01
Institution: University of Michigan
09/14/2018

U of M TCORS Project 3: Modeling the Impact of Tobacco Control Policies on Polytobacco Use and Associated Health Disparities

More information about how the evolving tobacco marketplace will shape the patterns of tobacco use, their subsequent long-term health effects, and potential disparities by socioeconomic status (SES) and race/ethnicity would be useful. Simulation modeling can predict future health outcomes and provide insights into how different policies and regulations may affect disparities in tobacco use and downstream health outcomes. The goal of this project is to estimate tobacco-related health disparities associated with tobacco use and to investigate the impact of specific tobacco control policy options on these disparities. Study aims are: (1) to estimate current disparities in single- and multi-product tobacco use by SES and race/ethnicity and monitor changes in consumption patterns over time; (2) to estimate the impact of past tobacco control policies on patterns of tobacco and nicotine product use by SES and race/ethnicity; (3) to estimate tobacco-related health disparities in all-cause mortality, cardiovascular mortality, and other health outcomes associated with single- and multi-product tobacco use and the role of past policies in influencing these outcomes; and (4) to model the impact of potential new policies on tobacco use and on tobacco-related health disparities associated with single- and multi-product tobacco use. To address Aim 1, researchers will use five datasets to characterize single- and multi-product tobacco use, including initiation, cessation, relapse, and switching, across demographic groups. To address Aim 2, researchers will use literature reviews, data analyses, and expert panels to determine a range of plausible values for the effect of different potential policies on initiation, cessation, relapse, and single- and multi-product use for key sociodemographic subgroups. Using results from Aims 1 and 2, Aims 3 and 4 will expand simulation models to project the consequences of tobacco use on tobacco-related health disparities. Results will indicate which potential tobacco control policies may be most effective in reducing tobacco-related health disparities due to tobacco use over time.

Nancy Fleischer and David T. Levy Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1 U54 CA229974-01
Institution: University of Michigan and Georgetown University
09/13/2018

The Effects of E-liquid Nicotine Concentration on the Abuse Liability of ENDS in Current Users

Studies reveal that large differences (>100%) in nicotine content affect the abuse liability of e-liquids, but more information demonstrating how smaller differences in nicotine affect abuse liability of electronic nicotine delivery systems (ENDS) would be useful. The goal of this study is to determine how modest differences (e.g., ±20%) in e-liquid nicotine concentration affect the abuse liability of ENDS. Following an initial laboratory phase where study e-liquids/aerosol and participants’ own brands of e-liquids will be chemically characterized, 30 adult current ENDS users will participate in five ad libitum vaping sessions where they will use five e-liquids, each containing a different nicotine concentration. Measures of abuse liability will include pharmacokinetic and pharmacodynamic data, biomarkers of nicotine exposure, puff topography, and subjective measures of craving, withdrawal, liking, and reinforcement. Findings may inform regulatory standards for tobacco products.

Babita Das and Olga Rass Funding Mechanism: Research Contract
ID number: HHSF223201710040I
Institution: Battelle
09/13/2018

E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease Risk

The goal of this study is to relate the acute and long-term use of e-cigarettes and conventional cigarettes to cardiovascular and pulmonary disease biomarkers. Researchers will enroll four different “use-groups” of adults ages 18 and older (n=440): exclusive e-cigarette users (n=110), exclusive cigarette smokers (n=110), dual product users (who both smoke and vape; n=110), and never smokers (n=110). These groups reflect the primary decisions that individuals can make regarding their future tobacco use: to continue to smoke cigarettes, to switch to e-cigarettes, to use both cigarettes and e-cigarettes, or not to use these products. Product use will be related to biomarkers that accurately and reproducibly reflect mechanisms, injury, and future risks related to cardiovascular or pulmonary disease. Primary cardiovascular biomarkers measured will include brachial artery flow-mediated dilation (a measure of endothelial function) and carotid intima-media thickness, a measure of subclinical arterial injury and atherosclerosis. Primary pulmonary disease biomarkers will be measures of lung volumes and flow rates (predicted FEV1, FVC, FEV1/FVC) obtained by spirometry. Researchers will also conduct treadmill exercise stress testing (to assess aerobic fitness), perform electrocardiography (to measure heart rate and its variability), and measure blood pressure, lipids, HgbA1c, inflammation/oxidation markers (leukocyte count, C-reactive protein, urinary F2 isoprostanes) and exhaled nitric oxide. Study findings will yield new data regarding product use, subclinical arterial injury, atherosclerosis burden, arterial and pulmonary function, cardiac and aerobic fitness, cardiac autonomic dysregulation, systemic and pulmonary inflammation, and oxidative stress, as well as other key outcomes.

Timothy Baker and James Stein Funding Mechanism: NIH Grant
ID number: 1R01HL139331-01A1
Institution: University of Wisconsin-Madison
09/13/2018

Integrated Risk Assessment and Molecular Characterization of Pulmonary Response to E-cigarette Exposure

E-cigarette aerosol is a complex mixture of e-liquid components (propylene glycol, vegetable glycerol, nicotine, water, and flavoring additives) and other constituents (such as aldehydes, metals, nanoparticles, and some unknown compounds) produced during e-cigarette heating. The goals of this study are to evaluate the oxidative stress and inflammation resulting from e-cigarette aerosol, identify aerosol constituents’ distinct “signatures” of early oxidative/nitrative damage in cells and tissue, and use these findings to evaluate the relative hazards of constituents. Researchers will use the Research Grade E-cigarette (REC) device developed at Battelle to generate and characterize aerosol from individual e-liquid components with and without the use of a heated coil. Study aims are: (1) to characterize e-cigarette aerosol generated at moderate and high heating temperatures; (2) to characterize pulmonary response to e-cigarette aerosol constituents in mice; and (3) to predict airway deposition and site-specific tissue dose and translation to humans using computational fluid dynamic-physiologically-based pharmacokinetic (CFD/PBPK) models. Study findings will provide new information about the oxidative and inflammatory effects of e-cigarette use.

Charles K. Ansong Funding Mechanism: NIH Grant
ID number: 1R01HL139335-01A1
Institution: Battelle Pacific Northwest Laboratories
09/13/2018

Exploring Cardiovascular and Other Health Associations of Electronic Cigarette Use in US Persons of Hispanic Heritage: The Hispanic Community Health Study / Study of Latinos (HCHS/SOL)

Information on the effects of electronic nicotine delivery system (ENDS) use on cardiovascular disease (CVD) and other health risks in minority populations would be useful. The goal of this study is to examine associations between ENDS use and CVD and other health risks in the Hispanic/Latino population. Researchers will analyze existing data from a large community-based sample of more than 12,000 individuals of Hispanic/Latino origin (ages 18-74 at baseline) who participated in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) at both baseline (2008-2011) and follow-up (2015-2017). Study aims are: (1) to determine the prevalence of ENDS use and assess demographic, socio-economic, and cultural factors associated with use; (2) to study associations of ENDS use with levels of CVD risk factors, other health measures, assessments of subclinical atherosclerosis, and markers of inflammation, including heart rate, blood pressure, high-density lipoproteins (HDL), low-density lipoproteins (LDL), triglycerides, fasting glucose, body mass index, and white blood count, taking into account history and current use of tobacco products; (3) to study changes between baseline and follow-up in associations of ENDS use with CVD risk factors, other health measures, and markers of inflammation, taking into account history and current use of tobacco products; and (4) to obtain new data to examine ENDS use as it relates to motivations, dose, flavors, and duration by mailing a questionnaire to users who participated in the HCHS/SOL follow-up. Findings will provide new information about the cardiovascular impact of ENDS use in the Hispanic/Latino population.

Thanh Huyen and Thiv Vu Funding Mechanism: NIH Grant
ID number: 1R03HL144902-01
Institution: Northwestern University at Chicago
09/11/2018

Evaluation Support: Rapid Assessments of State and Local Tobacco Control Policies

This project involves maintaining and evaluating an ongoing systematic approach for identifying relevant state and local tobacco control policies for potential evaluation. This approach includes conducting environmental scans, performing evaluability assessments, conducting pilot evaluations, conducting data analyses for evaluation purposes, and reporting key findings to FDA-CTP on an ongoing basis.

Tarsha McCrae Funding Mechanism: Research Contract
ID number: HHSF223201310007B
Institution: Research Triangle Institute International
09/11/2018

The Role of ENDS Use in Changing Rates of Escalation and Quitting of Cigarette Smoking in Those Under Age 35 Years in US Population

Electronic nicotine delivery systems (ENDS) have the potential to reduce the proportion of young adults who are addicted to cigarette smoking, either by reducing escalation to daily cigarette smoking or increasing cessation before age 35. The goal of this study is to determine whether ENDS use changes the pattern of escalation and early cessation among those younger than age 35 using data from the first four waves of the Population Assessment of Tobacco and Health (PATH) Study. Study aims are: (1) to examine the contribution of early use of ENDS and other tobacco products in differentiating early cigarette smoking escalators from those who do not escalate before age 20; (2) to examine the contribution of ENDS use to late escalation of tobacco use; and (3) to identify whether ENDS use is associated with long-term discontinuation of cigarette smoking in people under age 35. Researchers will conduct separate analyses for early escalators, late escalators, and quitters before age 35, and will use various analytical methods including propensity score matching, marginal structural models, and targeted maximum likelihood estimation techniques. Findings may provide new information related to the potential long-term impact of ENDS use.

John P. Pierce and Tarik Benmarhnia Funding Mechanism: NIH Grant
ID number: 1R01CA234539-01
Institution: University of California, San Diego
09/07/2018

The Impact of Design Characteristics on the Modification Potential of Electronic Nicotine Delivery Systems

Different designs of electronic nicotine delivery systems (ENDS) make them more or less likely to be modified by users, which may impact the public health effect of their use. The goal of this study is to evaluate who is most likely to modify ENDS, how and why consumers modify ENDS, how much modification is occurring, and what design characteristics lead to modification. Study aims are: (1) to identify ways that consumers modify ENDS; (2) to determine the extent to which ENDS modification occurs in the U.S. population; and (3) to evaluate the ENDS product characteristics that lead to modification and what motivates modification. To address Aim 1, researchers will conduct interviews with 12 ENDS enthusiasts, analyze social media websites, conduct three focus groups with 20 young adult ENDS users (ages 18-29) and three focus groups with 20 adult ends users (ages 30+); and individual interviews with 20 adolescent ENDS users (ages 12-17). To address Aim 2, researchers will conduct a population-level quantitative survey of current ENDS users (750 adults, 750 young adults, and 750 adolescents) to estimate the prevalence of modification activities and differences by user profile (e.g., dual ENDS/cigarette users vs. exclusive ENDS users). To address Aim 3, researchers will use the data from the quantitative survey to evaluate the association of ENDS characteristics with different types of product modifications. Findings will provide new information about ENDS modification activities and may inform regulatory activities related to ENDS design.

Lyudmila (Lucy) Popova and David L. Ashley Funding Mechanism: NIH Grant
ID number: 1R01DA047397-01
Institution: Georgia State University
09/07/2018

Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm from Tobacco

Youth who use multiple tobacco products differ from youth who solely smoke cigarettes in ways that may affect their responses to a nicotine reduction regulatory policy, which would mandate a reduction of nicotine in all commercially available cigarettes. The goal of this study is to examine the effects of very low nicotine content (VLNC) cigarettes on multiple tobacco product use and toxicant exposure in youth. Following a one-week baseline period, researchers will randomize adolescent cigarette smokers (ages 15-19, n=120) who report past-month alternative tobacco product use to a four-week trial during which they will switch from their usual brand cigarettes to either VLNC or normal-nicotine content (15.8 mg/g nicotine) study cigarettes. This study will use laboratory-based assessments to investigate the effects of cigarette nicotine reduction on: cigarette and multiple tobacco product use; the harms associated with tobacco use, including nicotine and toxicant exposure; and effects on respiratory symptoms, perceived health risk, and nicotine dependence. Using real-time smartphone-based assessments in the natural environment, researchers will also examine the role of nicotine withdrawal and craving in understanding how cigarette nicotine reduction may affect other tobacco use. Findings will provide new information about the effects of VLNC cigarettes on real-world tobacco use and indices of tobacco-related harm in adolescents.

Rachel N. Cassidy and Suzanne Colby Funding Mechanism: NIH Grant
ID number: 1R01DA047356-01
Institution: Brown University
09/01/2018

How Consumers Use Flavors to Make Inferences about Electronic Nicotine Delivery System (ENDS) Product Qualities and Intentions to Use (Phase 2)

This project (Phase 2) will test how different features used to advertise electronic nicotine delivery system (ENDS) flavors are associated with product appeal and intentions to use the product. Specifically, researchers will examine three features identified previously (Phase 1): the use of flavor-related imagery (e.g., picture of a cherry), the use of flavor name modifiers (e.g., Cherry Crush), and the use of flavor descriptors (e.g., “cool”, “fresh”). In Phase 2, researchers will collect data and conduct six analyses, each with four outcomes: (a) product appeal, (b) curiosity about the product, (c) interest in using the product, and (d) increased positive product perceptions (e.g., likeliness to switch from cigarettes, good taste, health effects). Analyses 1 and 2 will investigate whether absence of a flavor-representing image is associated with decreased outcomes compared to an identical ad with a flavor-representing image, and whether presence of the image is associated with increased outcomes compared to an identical ad without any flavor feature. Analyses 3 and 4 will investigate whether absence of a flavor name modifier is associated with decreased outcomes compared to an identical ad with the modifier, and whether presence of the modifier is associated with increased outcomes compared to an identical ad without any flavor features. Finally, analyses 5 and 6 will investigate whether absence of a flavor descriptor is associated with decreased outcomes compared to an identical ad with the descriptor, and whether presence of a descriptor is associated with increased outcomes compared to an identical ad without any flavor features. Secondary analyses will explore sub-group differences among flavors and brands, as well as effects on broader product perceptions, including relative risk and harm. Findings may inform future regulatory activities related to ENDS flavors and marketing.

Meghan Moran (CTP contact: Lexie Perreras) Funding Mechanism: Centers of Excellence in Regulatory Science and Innovation Grant (CERSI)
ID number: 3U01FD005942-03S1
Institution: Johns Hopkins University
09/01/2018

Evaluation of Canada’s Menthol Ban

Menthol cigarettes comprise a substantial portion of the American cigarette market, with prevalence estimates reaching about 25%. A US ban on menthol cigarettes would likely elicit changes in the behavior of menthol cigarette smokers and the tobacco industry. On January 1, 2017, the Province of Ontario implemented one of the first bans on menthol products worldwide; a full Canadian ban followed on October 1, 2017. The goal of this study is to conduct a long-term assessment of the menthol ban in Ontario to provide information about its potential impact. Study aims are: (1) to understand tobacco use behavior changes by pre-ban menthol smokers; (2) to characterize industry and sales changes subsequent to the ban; and (3) to explore how menthol cigarette smokers transition from menthol cigarettes to either smoking cessation/reduction or replacement tobacco products. To address these aims, researchers will follow up with of a cohort of 1,738 smokers aged 16 and older surveyed pre-ban to examine smoking behaviors and attitudes two years post-ban. Researchers will also conduct an analysis of administrative tobacco product sales data reported to Health Canada to examine changes in sales and changes in characteristics of products sold post-pan in Ontario and nationally. Finally, researchers will conduct a concept mapping study to supplement the self-reported data and administrative data with an in-depth understanding of user behavior. Findings will reveal menthol smoker and tobacco industry responses to a real-world menthol-flavored tobacco ban, which may inform future regulation and associated public education messaging.

Michael Chaiton Funding Mechanism: NIH Grant
ID number: 1R21DA047358-01
Institution: University of Toronto
09/01/2018

Assessing Physiological, Neural, and Self-Reported Response to Tobacco Education Messages

This project uses neuroimaging, physiological, and self-report measures to assess responses to FDA tobacco education messages from “The Fresh Empire”, “The Real Cost” and “This Free Life” campaigns. To align with FDA campaign target audiences, the project will recruit 100 adolescents (ages 12-17, stratified by race/ethnicity), 50 young adults (ages 18-24, stratified by LGBT status), and 50 adult smokers (ages 25-54, stratified by past-year quit attempt). Physiological measures will assess indicators of arousal (such as heart rate variability) and affective response (such as facial muscle activity). Functional near-infrared spectroscopy (fNIRS), a brain monitoring technique, will measure activation of different brain areas to assess message processing and acceptance. Eye tracking methods will be used to assess attention to messages and message features. Self-report measures will assess message efficacy (e.g., perceived effectiveness, recall, comprehension, agreement with the message main point) and indicators of persuasive processes (e.g., identification with characters, transportation into the message, emotional response, counterarguing). Outcome measures will include changes from baseline in knowledge, attitudes and behavioral intent. Findings will enhance the understanding of effective tobacco education messaging tactics and may inform future tobacco education campaigns.

Meghan Moran (CTP contacts: Matthew Walker and Mario Navarro) Funding Mechanism: Centers of Excellence in Regulatory Science and Innovation Grant (CERSI)
ID number: 3U01FD005942-03S1
Institution: Johns Hopkins University
09/01/2018

Measurement of Metal Ions and HPHCs in Electronic Nicotine Delivery Systems (ENDS) and Their Physio-pathological Impact on Cells of the Oral Cavity and Upper Respiratory Tract

This project will use the electronic nicotine delivery systems (ENDS) aerosolization machine previously developed by the research team to expose normal human cells to complex ENDS aerosol mixtures and determine the physiological and pathological effects from exposure. Study aims are: (1) to determine the effects of ENDS aerosol on cells of the oral cavity and upper respiratory tract, and (2) to identify the constituents of e-liquids, hardware and aerosol to which ENDS users are exposed. In this study, five pre-filled ENDS and two cartomizers and their associated e-liquid formulations will be aerosolized and effects on cells will be assessed (via proteomics and in vitro cell biology assays of specific biological pathways by immunoblotting, cytokine quantitation and metallomics) against appropriate controls. Researchers will also analyze ENDS hardware, e-liquids (including color and ingredients), and the constituents of the complex aerosol for each ENDS category evaluated. All data collected will be compiled into a database that may help to inform the regulatory decision-making process. Project findings may inform future regulatory activities related to ENDS.

Sarah Michel (CTP contact: Vyomesh Patel) Funding Mechanism: Centers of Excellence in Regulatory Science and Innovation Grant (CERSI)
ID number: 3U01FD005946-03W1
Institution: University of Maryland School of Pharmacy
08/31/2018

Addiction and Behavior Related to Menthol Cigarette Substitutes

Several products in the tobacco marketplace – including mentholated pipe tobacco (for roll-your-own cigarettes, mRYO), menthol filtered little cigars (mFLC), and non-menthol cigarettes (nmC) — could serve as substitutes for menthol cigarettes. The goal of this study is to examine the abuse liability and substitutability of these potential menthol cigarette alternatives. Specific aims are: (1) to assess the abuse liability of menthol cigarette alternatives; (2) to assess the substitutability of menthol cigarette alternatives; and (3) to evaluate which product characteristics and perceived effects influence greater substitution. Eighty current menthol cigarette smokers (40 smokers ages 18-24 and 40 smokers ages 25+) will complete a three-phase study. In Phase 1, participants will complete four smoking sessions, smoking a different product in each session to examine each product’s abuse liability, demand, and topography. Products will include participants’ usual brand menthol cigarette (UBMC) and three commercially-available alternatives, including mFLC, an mRYO product, and nmC. In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and completely substitute the product for their UBMC for one week. Participants will complete ecological momentary assessments (EMA) during this period to more accurately assess substitution and perceived effects in real time. In Phase 3, participants will complete a final laboratory visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated menthol cigarette ban conditions using a progressive ratio task. In all phases, multiple domains of abuse liability will be assessed, including product administration, product liking/craving, and withdrawal suppression. Findings will provide new information regarding the substitutability of potential menthol cigarette substitutes in adult smokers and may inform future regulatory activities related to menthol cigarettes.

Theodore Lee Wagener and Andrea Villanti Funding Mechanism: NIH Grant
ID number: 1R21DA046333-01A1
Institution: University of Oklahoma Health Sciences Center
08/31/2018

UVM TCORS: University of Vermont Tobacco Center of Regulatory Science

Building upon research in the previous TCORS, the University of Vermont TCORS will conduct research projects on the impact of low nicotine content cigarette use in four vulnerable populations: socioeconomically disadvantaged women of reproductive age (Project 1), individuals with comorbid opioid use disorders (Project 2), individuals with comorbid affective disorders (Project 3), and pregnant women (Project 4). Each of these populations is at increased risk for tobacco use, dependence, and/or tobacco-related adverse health outcomes. Despite their increased risk, these populations are often excluded from tobacco regulatory studies, leaving a significant knowledge gap. The overall goal of the UVM TCORS is to provide sound scientific evidence on the impacts of tobacco products in vulnerable populations. The projects will examine the extent to which the availability and appeal of alternative non-combusted sources of nicotine (i.e., e-cigarettes) may moderate the impact of reduced nicotine standards on reducing cigarette smoking. That topic will be investigated in each of the primary vulnerable populations of interest, using common study protocols to the extent possible, as well as protocols that facilitate comparisons with studies in healthier populations as noted above.

Stephen T. Higgins Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036114-06
Institution: University of Vermont and State Agricultural College
08/31/2018

UVM TCORS Project 1: Low Nicotine Content Cigarettes in Vulnerable Populations: Economically Disadvantaged Women (Non-Pregnant)

Despite marked reductions in cigarette smoking in the general population, smoking rates among economically disadvantaged women have increased. Smoking among women of reproductive age is a concern because in addition to the usual health risks, they face additional risks should they become pregnant. Research indicates that economically disadvantaged women respond to low nicotine content cigarettes (VLNCCs) with reductions in smoking rates, cigarette demand, dependence severity, and other measures of addiction. The goal of this project is to evaluate whether increased availability and appeal of an alternative non-combusted nicotine source (e-cigarettes) will enhance the effectiveness of a reduced-nicotine standard for cigarettes in socioeconomically disadvantaged female smokers of reproductive age. Study aims are: (1) to compare the effects of normal nicotine content cigarettes (NNCCs) alone, VLNCCs alone, VLNCCs + tobacco-flavored e-cigarettes, and VLNCCs + preferred-flavor e-cigarettes on total number of cigarettes per day; (2) to compare the effects of the four study conditions on cigarette demand, smoke exposure (breath carbon monoxide), and tobacco carcinogen biomarkers (NNAL, PAH metabolites); (3) to explore the effects of the four study conditions on cerebral blood flow, other measures of brain function and structure, and airway inflammation; and (4) to explore the effects of the four study conditions on abstinence-induced cigarette demand, craving, and withdrawal. In this study, 212 disadvantaged female smokers (ages 18-44) will be randomized to 16 weeks of: (1) NNCCs alone (the control condition); (2) VLNCCs alone; (3) VLNCCs + nicotinized tobacco-flavored e-cigarettes; or (4) VLNCCs + nicotinized preferred-flavor e-cigarettes. Participants will complete two in-person assessments (involving baseline health and smoking assessments, a variety of questionnaires, biomarker assessments, cognitive functioning tests, and functional MRI) and use an interactive voice response system to report daily product use and nicotine withdrawal symptoms. After 16 weeks of use, participants will undergo an abstinence assessment in which researchers will examine the effects of the study conditions on participants’ ability to abstain from cigarettes and their responses to abstinence. Findings may inform regulatory activities related to reduced-nicotine cigarettes.

Stephen T. Higgins Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036114-06
Institution: University of Vermont and State Agricultural College
08/31/2018

UVM TCORS Project 3: Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders

Affective disorders (ADs; mood and anxiety disorders) are the most common mental health conditions in the US. Over 40% of people with ADs are current smokers, and they experience disproportionately high rates of tobacco-related disease and death. Research indicates that smokers with ADs respond to very low nicotine content cigarettes (VLNCCs) with reductions in cigarette demand and other measures of addiction. The goal of this project is to evaluate whether increased availability and appeal of an alternative non-combusted nicotine source (e-cigarettes) will enhance the effectiveness of a reduced-nicotine standard for cigarettes in smokers with ADs. Study aims are: (1) to compare the effects of normal nicotine content cigarettes (NNCCs) alone, VLNCCs alone, VLNCCs + tobacco-flavored e-cigarettes, and VLNCCs + preferred-flavor e-cigarettes on total number of cigarettes per day; (2) to compare the effects of the four study conditions on cigarette demand, psychiatric symptoms, smoke exposure (breath carbon monoxide), and tobacco carcinogen biomarkers (NNAL, PAH metabolites); (3) to explore the effects of the four study conditions on cerebral blood flow, other measures of brain function and structure, and airway inflammation; and (4) to explore the effects of the four study conditions on abstinence-induced cigarette demand, craving, and withdrawal. In this study, 236 adults with ADs (ages 18-70) will be randomized to 16 weeks of exposure to (1) normal nicotine content cigarettes alone, which will serve as the control condition, (2) VLNC cigarettes alone, (3) VLNCs + tobacco-flavored nicotinized e-cigarettes, or (4) VLNCs + nicotinized e-cigarette with preferred flavoring. Participants will complete two in-person assessments (involving baseline health and smoking assessments, a variety of questionnaires, biomarker assessments, cognitive functioning tests, and functional MRI) and use an interactive voice response system to report daily product use and nicotine withdrawal symptoms. After 16 weeks of use, participants will undergo an abstinence assessment in which researchers will examine the effects of the study conditions on participants’ ability to abstain from cigarettes and their responses to abstinence. Findings may inform regulatory activities related to reduced-nicotine cigarettes.

Jennifer W. Tidey Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036114-06
Institution: Brown University
08/31/2018

UVM TCORS Project 4: Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women

Approximately 11% of U.S. women (~17 million women) are smokers when they become pregnant, with prevalence as high as 40% among socioeconomically disadvantaged women. Smoking during pregnancy can cause catastrophic pregnancy complications and adverse effects on fetal development that a growing body of evidence suggests can compromise health throughout the lifespan. Researchers are currently conducting a multi-site study examining the acute effects of very low nicotine content cigarettes (VLNCCs) on the addiction potential of smoking in pregnant women; the goal of this project is to further this line of research by examining extended exposure. Study aims are: (1) to compare extended exposure to either usual brand cigarettes or VLNCCs on number of cigarettes smoked per day; (2) to quantify the effects of extended exposure to VLNCCs on measures of biomarkers of exposure (total cotinine, NNAL, PAH) and sonographic assessments of fetal growth and body composition; and (3) to compare the effects of VLNCCs on abstinence-induced cigarette demand, craving, and withdrawal. It should be noted that a recommendation to all women screened for this study will be that they should quit, consistent with ethical guidelines about smoking during pregnancy. All potential participants will be asked at screening about their intentions to quit smoking during pregnancy. Those with intentions to quit in the next 12 weeks will be referred to our ongoing studies on smoking cessation in pregnant women. Those who do not will be randomized to smoke either usual brand cigarettes or VLNCCs for 12 weeks. Ninety participants (ages 18-44) will complete two in-person baseline assessments (involving baseline health and smoking assessments, a variety of questionnaires, biomarker assessments, and fetal measurements) and will be seen weekly throughout the study. Findings may inform regulatory activities related to reduced-nicotine cigarettes.

Sarah H. Heil Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036114-06
Institution: University of Vermont and State Agricultural College
08/31/2018

A-TRAC TCORS: American Heart Association Tobacco Center for Regulatory Science (A-TRAC) 2.0

The overall goal of the American Heart Association (AHA) Tobacco Regulation Center (A-TRAC) is to provide scientific data relevant to the cardiovascular effects of tobacco products by evaluating the cardiovascular effects of tobacco products and their constituents. A-TRAC will support three projects. Project 1 will assess the toxicity of tobacco products and their constituents in in vitro assays and animal models. Project 2 will evaluate short- and long-term cardiovascular health effects of tobacco products. Project 3 will assess the cardiovascular disease risk associated with the use of non-cigarette tobacco products in multiple large NIH-supported cardiovascular cohorts. Research supported by the A-TRAC will develop new understanding of the cardiovascular effects of current, new and emerging tobacco products; and build and deploy capacity and expertise to respond to new developments.

Rose Marie Robertson and Aruni Bhatnagar Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 HL120163-06
Institution: American Heart Association and University of Louisville
08/31/2018

A-TRAC TCORS Project 1: Cardiovascular Toxicity of Tobacco Products

Cardiovascular disease (CVD), including coronary heart disease and stroke, is the leading causes of death and disability associated with tobacco use. However, more information would be useful regarding specific tobacco product constituents that affect cardiovascular toxicity. The goal of this American Heart Association Tobacco Center for Regulatory Science (A-TRAC) project is to test the hypothesis that cardiovascular injury due to tobacco product use could be attributed mostly to volatile organic compounds (VOCs; e.g., formaldehyde, acetaldehyde, acrolein, benzene, xylene) generated in a variety of tobacco products. Study aims are: (1) to quantify the cardiovascular toxicity of tobacco product-derived VOCs in human cells in vitro; (2) to assess short-term and chronic toxicity of tobacco products (i.e., combustible cigarettes, smokeless tobacco, electronic nicotine delivery systems, electronic and conventional hookah) using a mouse model; and, (3) to identify individual VOCs that mediate the cardiovascular toxicity of tobacco products. To test this hypothesis, researchers will define the contribution of VOCs to the cardiovascular toxicity of tobacco products using sensitive and informative in vitro assays and well-controlled animal exposures. Findings will provide new information related to the cardiovascular toxicity of tobacco products and their constituents to inform future regulatory activities.

Daniel Joseph Conklin Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 HL120163-06
Institution: University of Louisville
08/31/2018

A-TRAC TCORS Project 2: Cardiovascular Injury Due to Tobacco Use

The goal of this American Heart Association Tobacco Center for Regulatory Science (A-TRAC) project is to assess and evaluate the cardiovascular effects of non-cigarette tobacco products and to determine whether cardiovascular injury due to tobacco product use is mediated, in part, by exposure to volatile organic chemicals (VOCs) present in or generated by tobacco products. To describe the contribution of VOCs to cardiovascular injury and dysfunction induced by tobacco products, researchers will evaluate the short- and long-term cardiovascular health and disease risk in 555 adult (ages 18-45) users of cigarettes, e-cigarettes, and cigarillos. Study aims are: (1) to identify cardiovascular harm associated with the use of e-cigarettes and cigarillos; (2) to examine the acute cardiovascular effects of e-cigarettes and cigarillos; and (3) to identify cardiovascular disease risk associated with chronic use of e-cigarettes and cigarillos. To accomplish these aims, researchers will examine baseline differences in biomarkers of endothelial injury, inflammation and thrombosis and indices of vascular function and cardiac excitability in e-cigarette and cigarillo users and compare results with cigarette smokers and individuals who do not use tobacco products. To examine long-term effects of tobacco products, researchers will identify progressive changes in cardiovascular disease risk due to continued use of tobacco products over two to six years. Findings will provide new information related to the cardiovascular toxicity of tobacco products and may inform future regulatory activities.

Aruni Bhatnagar Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 HL120163-06
Institution: University of Louisville
08/31/2018

A-TRAC TCORS Project 3: Cardiovascular Effects of Tobacco Products in Community-based Cohorts

Although overwhelming evidence supports the association between cigarette smoking and cardiovascular disease, the cardiovascular effects of other tobacco products such as cigars, pipes, smokeless tobacco, and e-cigarettes remain unclear. The goal of this American Heart Association Tobacco Center for Regulatory Science (A-TRAC) project is to assess the cardiovascular health impact of these less frequently used tobacco products. Study aims are: (1) to use the Cross Cohort Collaboration (CCC) dataset to harmonize tobacco data across 18 cohort studies and to create the largest cardiovascular study of cigar, pipe, and smokeless tobacco users yet undertaken (among 200,000 total cohort participants, there are 65,000 former smokers, 24,000 current smokers, 2,900 cigar users, 3,300 pipe users, and 1,900 smokeless tobacco users); (2) to use the CCC dataset to examine whether the use of cigars, pipes, and smokeless tobacco is associated with volatile organic compound (VOC) exposure, biomarkers of subclinical inflammation, vascular injury, and cardiovascular events; and (3) to develop e-cigarette use data from existing cardiovascular cohort studies to undertake first-of-its-kind study of the cardiovascular health effects of e-cigarettes in a large geographically dispersed, community-based sample (~1500-2000 ever e-cigarette users, ~600 current e-cigarette users). Aggregate data from these aims will be used to test the hypothesis that non-cigarette tobacco product use is associated with significant cardiovascular injury, which is attributable, in part, to VOCs generated by or present in these products. Findings will provide new information related to the cardiovascular impact of tobacco product use and may inform future regulatory activities.

Michael J. Blaha Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 HL120163-06
Institution: Johns Hopkins University
08/29/2018

UCSF TCORS: Integrated Health, Behavioral and Economic Research on Current and Emerging Tobacco Products

The goal of this TCORS is to examine health effects, behavior, and impact related to current and emerging tobacco products, including e-cigarettes, smokeless tobacco, and new “heated tobacco products (HTPs). Specific aims are: (1) to evaluate the short-term health effects, including respiratory and cardiovascular effects, of e-cigarettes, HTPs, and other tobacco products and how specific tobacco product characteristics influence health effects and behavior; (2) to further add to the science base to inform product standards and marketing regulations for these tobacco products, integrating the health and behavioral dimensions of tobacco use with economic models, with particular emphasis on specific product characteristics and short-term effects; and (3) to build the tobacco regulatory science research community through mentoring, developmental grants, and other support. The TCORS will accomplish these aims through five projects; topics are as follows: (1) the impact of different e-cigarette characteristics on acute lung injury; (2) the short-term cardiovascular effects of e-cigarettes, including the influence of device power and e-liquid pH, and how e-cigarettes compare with HTPs; (3) the cardiovascular health effects of emerging HTPs; (4) the influences of product characteristics on perceptions, behaviors, and biologic exposures in rural adolescents; and (5) the impact of changing tobacco product use on healthcare costs for general and vulnerable populations. Project findings may provide information that may inform future regulatory activities.

Pamela Ling Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 9-U54HL147127-06
Institution: University of California, San Francisco
08/29/2018

UCSF TCORS Project 1: Impact of Different E-Cigarette Characteristics on Acute Lung Injury

Variation in e-cigarette characteristics may have a significant impact on pulmonary health. Changes in e-cigarette device and liquid characteristics may influence acute pulmonary effects, both under healthy conditions and in the setting of acute respiratory infection and/or inflammation. This project proposes a comprehensive assessment of the impact of e-cigarette characteristics on acute lung injury, combining data from cell culture, mouse models, and human subjects. Study aims are: (1) to test how different device characteristics (applied power and metal coil components) impact the acute pulmonary effects of e-cigarettes; and (2) to test how different e-liquid characteristics (nicotine concentration and flavorings) impact the acute pulmonary effects of e-cigarettes. Both aims begin with an evaluation of the impact of varying e-cigarette characteristics on susceptibility to viral or bacterial lung injury in cell culture and mouse models. This evaluation will be conducted with and without infectious and inflammatory stimuli, including viral (influenza) and bacterial (pneumococcal) infection. The e-cigarette characteristics that appear to be most important in these models will then be tested in a human model of lung inflammation, in which 60 healthy adult (age >21) e-cigarette users and dual cigarette/e-cigarette users inhale endotoxin, followed by bronchoscopy with bronchoalveolar lavage. Findings will yield new information regarding how specific e-cigarette device and e-liquid characteristics impact their potential to cause acute lung injury and may inform future regulatory activities.

Carolyn Calfee Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 9-U54HL147127-06
Institution: University of California, San Francisco
08/29/2018

UCSF TCORS Project 2: Short-Term Cardiovascular Effects of E-Cigarettes: Influence of Device Power and E-Liquid pH and How E-Cigarettes Compare with Heat-Not-Burn Products

This project will provide more information about how specific aspects of e-cigarettes influence their overall health effects, including short-term cardiovascular effects. The goal of this project is to evaluate the impact of e-cigarette power on cardiovascular effects; the influence of e-liquid pH on rate of systemic nicotine absorption, nicotine-induced sympathetic nervous system stimulation, and heart rate increase (a risk factor for cardiovascular disease); and the health effects of heated tobacco products (HTPs), which heat tobacco without combustion. Study aims are: (1) to determine the impact of e-cigarette power on nicotine pharmacology, systemic exposure to toxic volatile organic compounds (VOCs), and short-term cardiovascular effects; (2) to determine the impact of changes in e-liquid pH on nicotine pharmacokinetics, cardiovascular, and subjective effects of e-cigarettes; and (3) to compare differences in nicotine pharmacology, systemic exposure to toxic VOCs, and short-term cardiovascular effects of e-cigarettes and an HTP (iQOS). These aims will be achieved through three studies, one study for each aim. Each study will be conducted on an inpatient research ward and will include 21 healthy users (age >21) of e-cigarettes and/or an HTP. Studies 1 and 2 will test different electrical power and e-liquid pH levels, respectively. Study 3 will be a within-subject comparison of toxicant exposure and the cardiovascular effects of e-cigarettes compared to iQOS. Study endpoints will include markers of cardiovascular disease risk, such as heart rate and blood pressure changes, hormonal release, biomarkers of endothelial function, platelet activation, inflammation, and oxidative stress. Findings will contribute to knowledge of the influence of e-cigarette characteristics on short-term cardiovascular effects and may inform future regulatory activities.

Gideon St. Helen Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 9-U54HL147127-06
Institution: University of California, San Francisco
08/29/2018

UCSF TCORS Project 3: Cardiovascular Health Effects of Emerging Heat-Not-Burn Tobacco Products

Heated tobacco products (HTPs), which heat a mixture of tobacco and other compounds to temperatures below those at which combustion occurs, deliver an inhalable aerosol containing nicotine and other chemicals. Despite harm reduction claims, the health effects of HTPs are poorly understood. The goal of this project is to evaluate the cardiovascular effects of an HTP (iQOS), including effects on cardiac and peripheral vascular function and cardiac tissue preservation after acute myocardial infarction, relative to tobacco smoke and e-cigarette aerosol. Study aims are: (1) to understand the chemical properties of HTP aerosol and chemical changes during its generation; (2) to evaluate and understand cardiovascular health effects of both acute and repeated exposure to HTP aerosol in rats; and (3) to determine whether acute and chronic exposure to HTP aerosol prior to acute myocardial infarction increases the extent of the resulting cardiac tissue death. To satisfy aim 1, researchers will perform chemical analyses of HTP aerosol and compare results to the chemical composition of unused HTP tobacco and to residual HTP tobacco after use. To satisfy aim 2, researchers will collect functional measurements in rats following HTP aerosol exposure and will evaluate the effects of single acute exposures and repeated exposures over 14 days. To satisfy aim 3, researchers will induce myocardial infarction in rats after a single brief exposure or multiple exposures to HTP aerosol or cigarette smoke and measure the extent of cardiac tissue damage. Results may inform future regulatory activities related to HTPs.

Matthew Lawrence Springer Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 9-U54HL147127-06
Institution: University of California, San Francisco
08/29/2018

UCSF TCORS Project 4: Current and Emerging Tobacco Products in a Rural Context: Influences of Product Characteristics on Perceptions, Behaviors, and Biologic Exposures

In recent decades, smokeless tobacco (ST) use has shifted from an older to a younger demographic, along with increasing industry marketing and expanding diversity in ST product characteristics. New ST products include different types, brands, flavors, and levels of nicotine and cancer-causing nitrosamines. More information about how different characteristics of ST products and other tobacco products contribute to youth perceptions, initiation, established use, poly-use, and exposure to nicotine and carcinogens would be useful. Study aims are: (1) to identify the impact of ST and other tobacco product characteristics, including packaging, characterizing flavors, and product design, on rural adolescents’ perceived harm, acceptability, and appeal of current and emerging smokeless, combustible, and alternative tobacco products; (2) to characterize tobacco use behaviors over time (e.g., initiation, cessation, changes in intensity, product switching, and poly-use) and how family and social factors and specific product characteristics predict transitions in behavior; and (3) to evaluate the impact of tobacco product use on rural adolescents’ exposure to nicotine and tobacco-specific nitrosamines. This study will include 1500 adolescents (aged 14-16) attending seven rural high schools in California, followed for five survey waves over 24 months. Qualitative studies (focus groups and one-on-one interviews) with adolescents and their parents/guardians will be conducted to provide information about how product characteristics and socio-contextual factors influence perceptions and behavioral decisions regarding tobacco products. Collected biomarkers (saliva specimens to measure cotinine levels; urine specimens to measure levels of the nitrosamines NNN and NNAL) will reveal how exposure to nicotine and nitrosamines varies with differences in product use and use patterns. Study findings will improve understanding of how different characteristics of ST and emerging tobacco products impact behavior and health effects in rural adolescents.

Benjamin Wilk Chaffee Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 9-U54HL147127-06
Institution: University of California, San Francisco
08/29/2018

UCSF TCORS Project 5: Impact of Changing Tobacco Product Use on Healthcare Costs for General and Vulnerable Populations

Many factors contribute to tobacco-attributable healthcare costs, including changing tobacco product use patterns, sociodemographic characteristics, health status, and socioeconomic status (SES). The goal of this project is to develop economic models that analyze the impact of new patterns of tobacco product use on healthcare costs for different populations, including vulnerable populations. Study aims are: (1) to develop microeconomic models to estimate the healthcare costs attributable to e-cigarette use; (2) to estimate healthcare costs attributable to cigarette smoking and e-cigarette use for vulnerable populations (people with low SES, rural populations, people with medical co-morbidities, and youth); (3) to develop microeconomic models to estimate the healthcare costs attributable to the most common combinations of tobacco product use (i.e., dual use of cigarettes and e-cigarettes; dual use of cigarettes and cigars; and poly-use of cigarettes, e-cigarettes, and other tobacco products); and (4) to analyze potential scenarios to determine the likely impact of regulatory changes on healthcare costs. Tobacco-attributable healthcare costs will be estimated using econometric models and an approach in which costs among product users are compared with costs among people assumed to be never tobacco users or sole cigarette smokers (depending on the relevant comparison group). The healthcare cost estimates from this project will be useful metrics for measuring the impact of tobacco use on public health, allowing a comparison of the relative magnitude of health effects of different tobacco products on specific populations.

Wendy B. Max Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 9-U54HL147127-06
Institution: University of California, San Francisco
08/28/2018

VCU TCORS: Center for the Study of Tobacco Products

Methods exist for assessing a regulation’s effects once it is in place, but few models predict impact beforehand. The VCU Center for the Study of Tobacco Projects (CSTP) will explore a model that may allow the prediction of regulatory impact. The model assesses how a potential regulation might change product toxicity, user behavior, and addiction/abuse liability. To verify the model, the CSTP will also examine the extent to which its predictions about potential regulatory effects describe actual population-level outcomes. This TCORS includes four projects. Projects 1, 2 and 3 will test hypotheses and generate predictions regarding the impact of three potential e-cigarette regulations (i.e., limit e-cigarette liquid nicotine concentration, constrain rate of e-cigarette nicotine emission or “flux”, reduce e-cigarette liquid flavor availability); specifically, researchers will assess how each potential regulation might influence product toxicity (Project 1), user behavior (Project 2), and addiction/abuse liability (Project 3). Project 4 will evaluate the predictions generated by Projects 1,2, and 3 at the population level by surveying current exclusive e-cigarette users and e-cigarette/cigarette dual users (ages 18 and older) every three months for four years. VCU CSTP’s goal is to provide tools to guide regulation development so that, by the time a regulation goes into effect, validated methods have tested it, refined it, and generated data showing that its health-promoting effects are maximized and unintended consequences are minimized. The model and associated tools may be used to shape, refine, and predict the effects of many potential regulatory actions in the future.

Thomas Eissenberg and Alison Breland Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036105-06
Institution: Virginia Commonwealth University
08/28/2018

VCU TCORS Project 1: Using Toxicity Testing Data to Test Hypotheses about Advanced-Generation ECIGs and Generate Population-level Predictions Regarding Potential Regulatory Action

The goal of this project is to examine how e-cigarette toxicant emissions are influenced by several potential regulatory actions. This project’s three study aims will use established aerosol research and analytical chemistry methods to evaluate how three potential regulatory actions — (1) limits on e-cigarette nicotine concentration, (2) constraints on e-cigarette nicotine flux, and (3) reduction in e-cigarette flavor availability – might influence e-cigarette emissions. For Aim 1, researchers will use our previously published mathematical model that predicts e-cigarette nicotine flux to explore conditions under which e-cigarette liquids containing <20 mg/ml nicotine might exceed tobacco cigarette nicotine yield, and then measure actual nicotine and non-nicotine toxicant yields for these conditions. For Aim 2, researchers will manipulate nicotine flux and then examine how flux manipulation influences the toxicity of the resulting e-cigarette aerosols. For Aim 3, researchers will explore the non-nicotine toxicant emissions produced by do-it-yourself e-cigarette liquids. This project will provide new data regarding the role of nicotine concentration, flux, and liquid flavor availability on e-cigarette toxicity, while informing predictions regarding the consequences of potential regulatory action.

Alan Shihadeh Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036105-06
Institution: American University of Beirut
08/28/2018

VCU TCORS Project 2: Using User Behavior Data Collected in the Clinical Lab to Test Hypotheses about Advanced-generation ECIGs and Generate Population-level Predictions Regarding Potential Regulatory Action

E-cigarette nicotine delivery, user subjective response, and user behavior measures (such as puff topography) can be assessed using rigorously-controlled, well-established clinical laboratory methods. The goal of this project is to use these established clinical laboratory methods to examine the extent to which e-cigarette nicotine delivery, e-cigarette liquid consumption, subjective response, and puff topography are influenced by manipulations of e-cigarette liquid nicotine concentration and device power, nicotine flux, and flavor availability. Study aims are: (1) to manipulate e-cigarette liquid nicotine concentration and device power to evaluate how nicotine delivery, abstinence suppression, and e-cigarette liquid consumption change as nicotine concentration is lowered, and whether these changes are offset by higher power; (2) to manipulate nicotine flux to determine whether nicotine delivery and abstinence suppression are related directly to flux; and (3) to manipulate e-cigarette liquid flavors to determine whether nicotine delivery, abstinence suppression, and e-cigarette liquid consumption vary by flavor for e-cigarette users and for smokers. The three aims correspond to three independent studies, each involving exclusive e-cigarette users and non-e-cigarette-using cigarette smokers (ages 18-55). This project will assess the nicotine delivery and subjective response profile of e-cigarettes, will generate new data regarding the effects of advanced-generation e-cigarettes on user behavior, and will contribute to population-level predictions.

Alison Breland Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036105-06
Institution: Virginia Commonwealth University
08/28/2018

VCU TCORS Project 3: Using Abuse Liability Data to Test Hypotheses about Advanced-Generation ECIGs and Generate Population-level Predictions Regarding Potential Regulatory Action

Behavioral economic tasks reveal how much people are willing to pay for nicotine delivery, how hard they will work to earn nicotine delivery, and how price sensitive their product choices are. This project will use standard abuse liability assessments to examine the extent to which response to behavioral economic tasks is influenced by three potential regulatory actions: limits on e-cigarette liquid nicotine concentration, constraints on nicotine flux, and reduction in flavor availability. Study aims are: (1) to manipulate e-cigarette liquid nicotine concentration and device power to evaluate whether abuse liability is altered as nicotine concentration is lowered, and whether this effect is offset by higher power; (2) to manipulate nicotine flux to determine the extent to which willingness to pay/work and price sensitivity are directly related to nicotine flux; and (3) to manipulate e-cigarette liquid flavors to determine whether predictors of abuse liability vary with flavor differently for e-cigarette exclusive users than for dual users. The three aims correspond to three independent studies, each involving exclusive e-cigarette users and dual e-cigarette and tobacco cigarette users (ages 18-55). Findings will provide new data regarding e-cigarette abuse liability in two populations that will likely be impacted by regulatory actions, and will generate predictions regarding the consequences of three potential regulatory actions.

Caroline O. Cobb Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036105-06
Institution: Virginia Commonwealth University
08/28/2018

VCU TCORS Project 4: Using a Prospective Cohort Survey to Test Population-level Predictions Generated by Projects 1-3

Examining how potential regulatory actions influence product toxicity, user behavior, and product abuse liability in controlled settings can help generate predictions regarding regulatory consequences at the population level. However, the extent to which these predictions reflect real-world behavior should be tested. The goal of this project is to survey current exclusive e-cigarette users and e-cigarette/cigarette dual users (ages 18 and older) to test population-level predictions that arise from the studies conducted in Projects 1-3 of the VCU TCORS. Specifically, the study will assess the population-level effects of three potential regulatory actions: limits on e-cigarette liquid nicotine concentration, constraints on e-cigarette nicotine flux, and reduction in e-cigarette flavor availability. Study aims are: (1) to assess relationships among nicotine concentration, amount of e-cigarette liquid consumed, and device power; (2) to assess relationships among nicotine flux and e-cigarette use, dependence and transitions; and (3) to examine associations between availability of e-cigarette liquid flavors and e-cigarette use behavior. After an initial survey, follow-up survey waves will occur regularly for four years. Survey questions will be designed to monitor e-cigarette use behaviors and e-cigarette liquid and device characteristics. Measures will include frequency of use; current device type, wattage, voltage, and resistance; presence of nicotine; nicotine concentration, propylene glycol/vegetable glycerin ratio; flavor preference; frequency of do-it-yourself e-cigarette liquid mixing; method, location and price of purchase; length of e-cigarette/tobacco cigarette cessation (if any); abstinence effects; tobacco cravings; dependence; and respiratory symptoms. A subgroup of participants will undergo puff topography measurement so that nicotine flux can be calculated.

Joanna E. Cohen Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036105-06
Institution: Johns Hopkins University
08/27/2018

Animal Models to Inform FDA Tobacco Regulation: Assessing the Relative Abuse Liability of Different Classes of Tobacco Products

Although nicotine is the main addictive chemical in tobacco, other chemicals may also contribute to tobacco addiction. The goal is to understand whether non-nicotine constituents unique to cigarette smoke contribute to differences in abuse liability between conventional combusted cigarettes and non-combusted products like e-cigarettes, smokeless tobacco, and nicotine replacement therapy (NRT), using rat models of abuse liability including self-administration. Researchers will measure levels of non-nicotine constituents (e.g., monoamine oxidase [MAO] inhibitors, volatile organic compounds [VOCs]) and identify the specific constituents that may be responsible for observed differences in abuse liability. Study aims are: (1) to compare demand for cigarette smoke extract to nicotine dose-equivalent concentrations of smokeless tobacco extract, e-cigarette extract, and nicotine alone when each is available in isolation or under choice procedures to determine relative reinforcing efficacy and substitutability of the extracts and nicotine alone; (2) to compare reinforcement-enhancing and aversive effects between extracts and nicotine alone; and (3) to evaluate the reinforcement-enhancing and aversive effects of isolated MAO inhibitors and VOCs when administered alone or in combination with nicotine. Findings will provide information about how chemicals other than nicotine contribute to tobacco addiction and may inform regulatory activities.

Andrew Charles Harris and Mark G. LeSage Funding Mechanism: NIH Grant
ID number: 1R01DA046318-01A1
Institution: Minneapolis Medical Research Foundation, Inc.
08/17/2018

Dissolution of Smokeless Tobacco Products

The purpose of this study is to characterize the nicotine release profiles of smokeless tobacco products available in the US to investigate the effects of tobacco blend changes, formulation changes, pH changes, and differences in physical parameters on nicotine release and to create a baseline for product comparison. Study aims are: (1) to develop and validate a method for nicotine quantification using high performance liquid chromatography/ultra-performance liquid chromatography-mass spectrometry (HPLC/UPLC-MS) to measure nicotine in the selected dissolution medium; and (2) to develop and validate dissolution methods (USP 4 and Chewing gum tester) for different categories of smokeless tobacco products and to analyze their nicotine release profiles. Findings will provide new information about the effects that different tobacco blends, pouch materials, pH buffers and buffering capacity, and other additives have on nicotine release from smokeless products.

Mimy Young Funding Mechanism: Research Contract
ID number: HHSF223201810173P
Institution: Texas A&M
08/15/2018

Yale TCORS Project 1: Effects of Sweet and Coolant Flavors on Nicotine Choice, Consumption and Seeking

The proportion of users of sweet-flavored and mentholated tobacco products has increased dramatically, especially among adolescents, raising concerns that flavors may facilitate tobacco product initiation and promote nicotine addiction. An additional concern is the recent introduction of synthetic cooling agents that may have effects similar to menthol. Children and adolescents are conditioned, through prior experience, to associate sweet and cooling flavors (fruit, candy, mints, etc.) with high sweetener content (sugar or artificial sweeteners). However, the role of flavors in the initiation of tobacco product use is difficult to study in humans, especially in adolescents and never-users. The goal of this project is to use adolescent and adult rodent models of inhaled and smokeless tobacco product use, and of oral flavor-paired nicotine self-administration, to examine whether sweet and cooling flavors in tobacco products enhance nicotine use behavior and addiction. Researchers will determine whether early flavor exposure and early flavorant associations with sweeteners influence subsequent nicotine choice and initiation, maintenance, and relapse. Study aims are: (1) to examine sweet and cooling flavor exposure and conditioning effects on nicotine choice and use using the two-bottle choice test in mice and nicotine self-administration in rats; and (2) to examine the effects of synthetic cooling agents on respiratory irritation caused by e-cigarette vapors. Study findings will provide new information about sweet and cooling flavor effects on the initiation and persistence of tobacco use.

Nii A. Addy Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036151-06
Institution: Yale University
08/15/2018

Yale TCORS Project 2: Sweet and Cooling Flavors and Nicotine: Examinations in New and Established Tobacco Product Users

Evidence suggests that younger tobacco users have a greater preference for flavors compared with older tobacco users. Furthermore, youth who are initiating tobacco use often report the availability of appealing flavors as one of the primary reasons for trying and using certain tobacco/nicotine products, like e-cigarettes, cigars and hookahs. Flavors could alter the appeal and abuse potential of nicotine/tobacco either through offering appealing aroma or taste or by ameliorating aversive characteristics of tobacco/nicotine. The goal of this project is to conduct two studies to determine the influence of the “aroma and taste” and “ameliorating” attributes of popular sweet and menthol flavors on the appeal and use of e-cigarettes. Study 1 will examine the influence of brief exposures to sweet, cool and tobacco flavors (and combinations) on the appeal and abuse potential of e-cigarettes containing nicotine concentrations varying in harshness (3 and 12 mg/ml), among 60 youth (aged 16-20), who have tried e-cigarettes, do not use regularly, but plan to continue use in the future. This study will provide useful information about the influence of sensory responses to flavors on the appeal of e-cigarettes among new users. This study will also explore whether sensory responses to flavors predict emergence of e-cigarette and other tobacco use behaviors at six-month and one-year follow-ups. Study 2 will examine whether different classes of flavors (i.e., sweet, cool, tobacco), when combined with nicotine concentrations differing in harshness (6 and 18 mg/ml) alter appeal and nicotine reward among 60 young adult (aged 18-24) and 60 older adult (aged 35-50) cigarette/cigar smokers; this study will also explore the differential influence of sweet, cool, and tobacco flavors on switching from combustible tobacco product use to e-cigarettes. Findings may inform future regulatory activities related to flavors in tobacco/nicotine products.

Suchitra Krishnan-Sarin Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036151-06
Institution: Yale University
08/15/2018

Yale TCORS Project 3: Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol

Rapid delivery to the brain enhances the abuse potential of drugs of abuse, including nicotine. As proposed by Shihadeh and Eissenberg, nicotine flux, or the rate at which an e-cigarette delivers nicotine, is the most critical factor for evaluating its abuse potential. In this model, when an e-cigarette delivers nicotine at rates above a certain (undetermined) threshold, it can have high abuse potential and may initiate or maintain tobacco addiction. In contrast, when the nicotine flux is optimal, the e-cigarette may have low addiction potential while providing sufficient nicotine delivery to help smokers quit smoking by alleviating urges to smoke. This proposed “optimal nicotine flux” concept has yet to be assessed in human studies. In addition, flavors and other e-cigarette ingredients may affect nicotine flux; notably, menthol may have such an effect through inhibition of nicotinic receptors and slowing of nicotine metabolism. The goal of this project is to examine the impact of nicotine delivery rate on nicotine’s abuse potential and its potentially beneficial effects of alleviating smoking urges and withdrawal. Researchers will also determine whether switching from menthol to non-menthol cigarettes changes the impact of nicotine delivery rate on the study outcomes. To achieve these goals, researchers will conduct two studies in adult (aged 18-30) smokers. Study 1 will recruit equal numbers of menthol (n=35) and non-menthol (n=35) smokers for five experimental sessions, which will be at least 24 hours apart. Each session will include one randomly-assigned infusion that will be either saline or a single dose of nicotine (1 mg per 70 kg body weight) delivered at four different infusion rates (0.24, 0.096, 0.048 or 0.024 μg per kg body weight per second). In Study 2, menthol-preferring smokers (n=38) will be randomized to a menthol or non-menthol cigarette smoking condition for two weeks and will then be crossed over to the alternative smoking condition for two weeks. For both studies, the main outcome measures will be measures of abuse potential (subjective drug effects and reinforcement) smoking urges, tobacco withdrawal, plasma nicotine concentrations, nicotine metabolite ratio, heart rate, and blood pressure. Study findings may inform standards for nicotine delivery rates that minimize the addictive risks of e-cigarettes and other electronic nicotine delivery systems.

Mehmet Sofuoglu Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036151-06
Institution: Yale University
08/15/2018

Yale TCORS: Yale Center for the Study of Tobacco Product Use and Addiction: Flavors, Nicotine and Other Constituents (YCSTP)

The Family Smoking Prevention and Tobacco Control Act prohibits adding characterizing artificial or natural flavors to tobacco cigarettes other than tobacco flavor and menthol. Menthol and a wide variety of flavors, however, are in other tobacco products. Research addressing the influence of flavors on the appeal of tobacco/nicotine and the initiation, progression and maintenance of tobacco use can inform further regulation of flavors. Toward this end, the Yale Center for the Study of Tobacco Product Use and Addiction (YCSTP) will examine the role of different classes of sweet and cool flavors, including sweeteners. on initiation, continued use and addiction to nicotine/tobacco, and their relevance to harm reduction. Researchers will integrate biological and behavioral testing in animal models and in humans to generate a firm scientific foundation for potential future regulation of flavors in tobacco products. Project 1 will examine whether preconditioning to flavors and sweeteners influences nicotine use behaviors and addiction and will evaluate the influence of novel cooling agents, which may ultimately replace menthol in tobacco products. Project 2 will examine the influence of sweet and cool flavors on initiation behaviors in youth who are susceptible to future use; it will also evaluate whether sweet and cool flavors have different impacts on nicotine reward and switching behaviors in both younger and older combustible tobacco users. Project 3 will determine the optimal delivery rate needed by tobacco users to relieve nicotine withdrawal while producing minimal positive effects, and whether the influence of this delivery rate is altered if combustible tobacco users switch from using mentholated to non-mentholated products. This TCORS may inform future regulatory activities related to flavors in tobacco products.

Suchitra Krishnan-Sarin and Stephanie O’Malley Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 2 U54 DA036151-06
Institution: Yale University
08/14/2018

Leachables and Extractables in E-liquid Bottles and Closed ENDS Products

Electronic nicotine delivery system (ENDS) products can be defined as having a closed-ENDS or open-ENDS design. In closed-ENDS products, e-liquid is contained in a non-refillable reservoir; in open-ENDS products, e-liquid is contained in a refillable reservoir, and may include e-liquid drip tip devices designed to allow individual drops of liquids, waxes, or tobacco to be placed on the atomizing element. E-liquids are commonly packaged in plastic containers manufactured from a variety of polymers, co-polymers, plasticizers, colors, and other additives that may migrate or leach into the e-liquid. The goal of this study is to develop and validate a controlled extraction method to measure extractable compounds from low density polyethylene (LDPE) and polyethylene terephthalate (PET) plastic bottles with a plastic dropper and/or rubber stopper, closed ENDS devices, and e-liquid drip tips. If any of the extractables exceed the determined safety threshold, researchers will conduct a study to identify leachable compounds using the e-liquid constituents solvents propylene glycol and vegetable glycerin at various ratios, and a long-term (shelf-life) study of final packaging. Findings will provide new information about the harmful compounds that may leach into e-liquid.

Jenna DuMond and Margaret Schmerier Funding Mechanism: Research Contract
ID number: HHSF223201820229A
Institution: EAG
08/06/2018

CTP Supplement to Parent Grant: Monitoring the Future: Drug Use and Lifestyles of American Youth

Anecdotal reports indicate rampant youth use of JUUL; however, quantitative information about use among youth and information on use patterns, beliefs and perceptions would be useful. Researchers will add questions about JUUL and other pod-mods to the Monitoring the Future (MTF) survey, an annual nationally-representative in-school survey of 45,000 8th, 10th, and 12th grade US students. Study aims are: (1) to estimate past-month, past-year, and lifetime use prevalence of JUUL and other pod-mods among US 8th, 10th, and 12th grade students in 2019, 2020, and 2021; (2) to develop state-of-the-science survey questions on vaping frequency and topography; (3) to collect information related to JUUL and other pod-mod nicotine beliefs, methods of access, use and appeal perceptions about flavors, advertising, and abuse liability and addiction symptoms; (4) to document perception and use of JUULs in vulnerable populations by analyzing demographic and age differences in pod-mod use, attitudes, and terminology, as well as co-use of pod-mods with the 50+ other drugs and drug classes that MTF surveys; and (5) to assess trends over the next three years in pod-mod use, attitudes, and terminology with analysis of survey results from 2019 to 2021. Results will provide new information about JUUL use and related issues.

Richard A. Miech Funding Mechanism: NIH Grant
ID number: 3R01DA001411-44S1
Institution: University of Michigan at Ann Arbor
08/06/2018

CTP Supplement to Parent Grant: Reactions to Reduced Nicotine Cigarettes in Young Adult Low- Frequency Smokers-Supplement

The goal of the parent study was to evaluate reactions to and choices of cigarettes with varying nicotine content among low-frequency, non-dependent smokers aged 18-25 years; this supplement extends the age range of the sample by recruiting and collecting data from adolescents aged 15-17 years. (Note: The research plan was developed in consultation with an expert in adolescent smoking research; all participants will be given information about smoking cessation resources.) As in the parent study, participants will undergo three sessions in which they will receive fixed doses of smoke from investigational cigarettes with three different nicotine content levels (15.8 mg/g, 2.5 mg/g, and 0.4 mg/g of tobacco). Following the third fixed-dose session, participants will return to the lab to choose one of the cigarettes to self-administer. Study aims are: (1) to combine the 15-17-year old sample with the parent grant sample and evaluates initial reactions to, and choices of, cigarettes with varying nicotine content; and (2) to identify correlates of reactions to, and choices of, cigarettes with varying nicotine content in the entire sample of low-frequency smokers. Findings will present an evaluation of the amount of nicotine in cigarette smoke that produces reactions associated with progression from initial smoking to nicotine dependence in a sample representative of individuals experimenting with cigarette use.

Francis Joseph McClernon Funding Mechanism: NIH Grant
ID number: 3R01DA042532-03S1
Institution: Duke University
07/24/2018

Support Services for Evaluating Minnesota Tobacco Policies Restricting the Sale of Flavored Tobacco Products

From 2015 to 2017, three cities in Minnesota (i.e., Minneapolis, St. Paul and Duluth) passed ordinances that restricted the sale of flavored and/or menthol tobacco products. These city ordinances provide a unique opportunity to evaluate the potential impacts of flavor restrictions. This study will employ various methods to evaluate these ordinances. Researchers will develop questions to evaluate process, outcomes, and potential unintended consequences and will use these questions to design a data collection and analysis plan. Key study components will be as follows: conducting stakeholder interviews (n=9 per interview protocol); compiling and analyzing retail scanner data; obtaining data about the implementation activities of area tobacco and liquor stores; reviewing archival data regarding enforcement and licensure; analyzing existing population survey data regarding behavior; and purchasing and visually assessing actual tobacco products in retail settings. This evaluation study will allow CTP to learn from policy development and implementation experiences; explore barriers and facilitators to policy implementation and enforcement; document policy effects on outcomes such as product availability and sales and consumer behavior; and uncover potentially unintended consequences of the policies.

Ashley Ross Funding Mechanism: Research Contract
ID number: HHSF223201310007B
Institution: Research Triangle Institute International
06/14/2018

User Exposure to Toxicants from Vaporized Nicotine Products

This study supplements the research objectives of a parent grant entitled, “Evaluating How Tobacco Control Policies are Shaping the Nicotine Delivery Market (P01CA200512).” In this supplemental study, researchers will evaluate the relative exposure profile of nicotine metabolites and tobacco-related carcinogens in ex-smokers using heated tobacco products (HTPs) products compared with ex-smokers using e-cigarettes, cigarette-only smokers, and never nicotine users. Using a web panel recruitment and mail-based urine sample collection strategy, researchers will examine attitudes, behaviors, and exposures in users and nonusers of HTPs and other tobacco products, including dual users of cigarettes and HTPs and/or e-cigarettes in Japan and Canada. Findings may inform future regulatory activities related to HTPs and other tobacco products.

K. Michael Cummings, Geoffrey T. Fong Funding Mechanism: Intra-Departmental Delegation of Authority
ID number: 3P01CA200512-03S1
Institution: Medical University of South Carolina
05/25/2018

CTP Supplement to Parent Grant: Informing Tobacco Regulatory Policy Through Laboratory Assessment of Appeal and Demand for Flavored Tobacco Products Among Young Adults

This supplement to the parent grant will address the impact of flavored tobacco product (FTP) packaging on young adult (ages 18-24) perceptions of harm, addictiveness, curiosity, and intentions to use. Specific aims are: (1) to augment the parent grant sample size from 30 to 60 to enhance the power of the parent grant’s experimental paradigm, and (2) to investigate the link between tobacco marketing techniques (i.e., packaging) with susceptibility and use of flavored e-cigarettes and little cigars/cigarillos (LCCs); this will be accomplished via two separate randomized controlled trials in which 5,600 young adults will be randomized to view one of seven pack images of an e-cigarette (n =2,800) or LCC (n = 2,800) that vary by color and flavor descriptor. Findings will provide a comprehensive assessment of factors related to FTP use and appeal.

Amy Cohn Funding Mechanism: National Institutes of Health – Grant
ID Number: 3R03DA042010-02S1
Institution: Battelle Centers Public Health Research and Evaluation
05/01/2018

Smokeless Tobacco Variability Lab Analysis Testing

The goal of this project is to determine the minimal number of testing replicates that provides acceptable variability in the measurement of harmful and potentially harmful constituents (HPHCs) and physical product characteristics data for smokeless tobacco products in the US. The project has two phases. Phase 1 will measure HPHCs and physical characteristics for a variety of smokeless tobacco products by systematically varying the number of test measurements and will determine the changes in analytical variability to give an optimal number of replicates. Phase 2 will use the optimum number of replicates, determined from Phase 1, and will evaluate inter-batch variability of smokeless tobacco products. Various products will be tested from common smokeless tobacco subcategories. Researchers will use published testing methods for benzo[a]pyrene, nicotine, NNN and NNK, pH, and water. A laboratory-validated method will be used to test acetaldehyde, crotonaldehyde, and formaldehyde levels. Findings will provide data regarding the number of replicates needed for reliable smokeless tobacco HPHC testing and may inform future regulatory activities.

Kenneth Taylor Funding Mechanism: Research Contract
ID number: HHSF223201310038I
Institution: Enthalpy Analytical
12/04/2017

Role of Menthol vs. Non-menthol Cigarette Smoking in Progression to Regular Tobacco Use Among Youth: Analysis of the ExPECTT Longitudinal Survey Data

The goal of this study is to investigate the role of menthol in progression to regular smoking among youth. Researchers will analyze FDA’s Public Education Campaign on Teen Tobacco (ExPECTT) longitudinal survey data to evaluate differences between menthol and non-menthol cigarette smokers in the likelihood of progression and rates of progression from never or experimental use to established smoking. Youth aged 11-16 years were enrolled in the ExPECTT study (n=6,743), and 4,210 completed all five surveys. Findings will provide new information about the use of menthol cigarettes by youth and young adults and may inform regulatory activities related to menthol.

Olga Rass Funding Mechanism: Research Contract
ID number: HHSF223201510002B
Institution: Research Triangle Institute International
09/29/2017

Tobacco Consumer Studies (TCS) Panel: Brands and Purchasing Behaviors

FDA-CTP has established the National Panel of Tobacco Consumer Studies (TCS), a high-quality national panel of approximately 4,000 adult tobacco users. Panel members have the opportunity to participate in up to eight studies over a three-year period that will assess consumers’ responses to tobacco marketing, warning statements, product labels, and other communications about tobacco products. The purpose of this study, “Brands and Purchasing Behaviors,” is to describe brand preferences of cigarette, cigar, and smokeless tobacco users; examine factors associated with brand loyalty; and assess purchasing patterns and consumption. Panel members will be invited to participate in the study by completing a questionnaire on the Web using their personal devices or a loaned tablet or via mail. The questionnaire includes questions about the frequency and intensity of cigarette, cigar, and smokeless tobacco use. Current users of cigarette, cigar, and/or smokeless tobacco are asked about their usual brand; reasons for using their usual brand or for trying other brands; use of promotions such as coupons and in-store promotions; where they purchase tobacco products; and how many they purchased in the past 30 days. Study findings will provide new information about tobacco product purchasing behavior.

Susan Kinsey and Sherry Liu Funding Mechanism: Research Contract
ID number: HHSF223201510002B
Institution: Research Triangle Institute, International
09/29/2017

Hookah Purchase Journey

This study will provide information about (1) the supply chain for waterpipe tobacco and charcoal; (2) the U.S. market size for waterpipe tobacco and charcoal, with growth trends over time; (3) the costs of smoking hookah tobacco in waterpipe establishments; and (4) annual hookah unit sales. Researchers will gather qualitative and quantitative data to identify waterpipe tobacco and charcoal supply chains in waterpipe bars. For tasks involving waterpipe bars, researchers will gather information from establishments in 6-8 U.S. cities; sales data for waterpipe tobacco, charcoal, and hookah units will be determined by analyzing sales data from at least two sources, with assumptions validated by qualitative interviews. This study will provide information about the business of selling waterpipe tobacco and waterpipe-related components, and may yield insights on supply chain segments.

Robin Gasloli and Sandra Retzky Funding Mechanism: Research Contract
ID number: HHSF223201710169C
Institution: SmartAnalyst
09/21/2017

Consumer Perceptions of Health Claims in Vape Shops

More information about consumer perceptions of health claims related to advertising for electronic nicotine delivery systems (ENDS) would be useful, particularly advertising claims made in vape shops, which are the fastest growing segment of ENDS retailers. This study will build upon a pilot study that developed the methodology to photographically document ENDS claims in vape shops using wearable imaging technology. In this study, researchers will use this methodology to collect data related to advertising claims in vape shops. The claims from both the pilot and the new wave of data collection will be combined to create a comprehensive list of unsubstantiated claims for use in a survey that will investigate consumer perceptions of these claims. This study will provide new information about how consumers interpret real-world ENDS health claims made by retailers.

Kimberly G. Wagoner Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03CA223600-01
Institution: Wake Forest University Health Sciences
09/21/2017

A Regulatory Impact Analysis of the FDA Warning Statement on Youth Preferences for Electronic Nicotine Delivery Systems

Since the U.S. Food & Drug Administration announced its final Deeming Rule, electronic nicotine delivery systems (ENDS) have been deemed a tobacco product and are now subject to several regulations, including a new warning statement requirement for ENDS products and advertisements that will take effect in August 2018. The goal of this project is to inform a regulatory impact analysis by evaluating the effects of the required warning statement on the likelihood that youth and young adults will purchase ENDS, and whether this effect depends on ENDS flavor. Researchers will conduct an experiment with 900 youth and young adults aged 16-25 years to address three aims: (1) to examine the effects of the ENDS warning statement on willingness to purchase and intentions to use ENDS; (2) to determine whether the effect of the warning statement on willingness to purchase is mediated by risk perceptions of ENDS; and (3) to determine whether product flavors and individual factors (e.g., demographics, tobacco use) modify the warning statement’s effect on risk perceptions, intentions to use, and willingness to purchase. In this online experiment, researchers will randomize participants into conditions varying according to the warning statement and ENDS flavor, and will be asked to complete a hypothetical purchase task. Study findings will provide new information regarding the impact of the ENDS warning statement and flavors on ENDS use, purchase intentions, and risk perceptions.

Scott R. Weaver Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03CA216834-01A1
Institution: Georgia State University Research Foundation
09/21/2017

The Influence of Vaper and Smoker Identities on Young Adult Smokers Who Use Electronic Cigarettes

Smoking behavior is generally viewed negatively by others. However, identifying as a “vaper” (e-cigarette user) provides a more positive social image and allows young adult dual users to distance themselves from having a smoker identity. More information on vaper identity, how smoker and vaper identities influence each other, and how these identities influence smoking and vaping behaviors over time would be useful. Researchers will recruit 500 young adult smokers (aged 18-29 years) who initiated e-cigarette use in the past six months to complete two online surveys administered six months apart; the surveys will examine how smoking and vaping behaviors and identities change over time. Researchers will then conduct on-line individual interviews with fifty participants who complete the second survey to explore the influence of social identity and social stigma on smoking and vaping behaviors, and if/how vaping and smoking identities changed over six months. Researchers will also validate measures of vaper identity and vaping stigma scales in young adult dual users. Study findings may inform regulatory activities related to e-cigarette marketing messages and practices.

Marshall Cheney Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03CA216832-01A1
Institution: University of Oklahoma-Norman
09/20/2017

Investigating Subjective Effects and Nicotine Pharmacokinetics of Mentholated Smokeless Tobacco Products in Current Users

More information about the effects of smokeless tobacco (ST) product menthol content on the absorption of nicotine in the human body and the effect of nicotine on physiological outcomes (e.g., heart rate) would be useful. This project will examine nicotine absorption as well as the subjective and physiological effects of mentholated ST products in current users. A non-mentholated commercial ST product will be amended to produce ST products with varying levels of menthol. Adult ST users will attend five laboratory sessions and receive a prescribed amount of ST at each session under the following conditions: (1) usual brand ST, (2) non-mentholated ST, (3) ST with low menthol content, (4) ST with medium menthol content, and (5) ST with high menthol content. Physiological measures (e.g., heart rate, blood pressure) and subjective measures (e.g., self-reports of how much participants like the product) will be assessed before, during, and after prescribed use. Researchers will also collect blood and urine samples at each session to assess plasma nicotine concentration and other biomarkers of exposure. Study findings will provide new information that may help inform regulatory activities.

Eric Claus, Steven Meredith, and Kia Jackson Funding Mechanism: Research Contract
ID number: HHSF2232013100331
Institution: Lovelace Biomedical and Environmental Research Institute
09/15/2017

Assessment of Genotoxic Potential of Serially Diluted Whole Tobacco Smoke using Ames, Micronucleus, and Pig-A Assays

Information about the genotoxic (gene toxicity) potential of whole smoke generated from commercial cigarettes is useful in evaluating health risk. The goal of this study is to test the genotoxicity of diluted whole smoke generated from research and commercial cigarettes using three standard genotoxicity assays (the Ames test, the micronucleus assay, and the Pig A assay). The top eight cigarettes in the U.S. will be selected based on their market volume. Researchers will use an air-liquid interface cell exposure system to expose human bronchial epithelial cells and cardiac cells to diluted whole smoke generated using the International Standards Organization (ISO) and Health Canada Intense (HCI) smoking regimens. Researchers will measure levels of tar/nicotine/carbon monoxide (TNCO), acrolein, acetaldehyde, tobacco-specific nitrosamines (NNN and NNK), formaldehyde, and benzo[a]pyrene. Total particulate matter and gas-vapor phase from the mainstream smoke will also be tested separately using both smoking regimens for comparison purposes. Study findings will provide new information regarding the genotoxic effects of cigarette smoke.

Steven Belinsky and Eric Beier Funding Mechanism: Research Contract
ID number: HHSF223201510001I
Institution: Lovelace Biomedical and Environmental Research Institute
09/14/2017

Inhalation Study of the In Vivo Toxicity of Essential Oils

Some essential oils used in tobacco products – including cinnamon bark oil, cinnamon leaf oil, and sage oil — have been shown in in vitro studies to be toxic or are believed to possess toxic properties based on scientific literature. The aim of this study is to determine the inhalation toxicity of these three essential oils in rats and use these data to estimate potential inhalation toxicity in humans. In three 14-day dose-ranging studies (one per oil), researchers will expose rats to aerosol generated from the oil and determine the threshold concentration that can cause non-lethal/non-painful/non-stressful effects and the maximum tolerable dose (or maximum feasible dose). In three sub-acute 28-day studies (one per oil), researchers will characterize the dose response of each oil and determine the no observed adverse effect level (NOAEL), no observed effect level (NOEL), lowest observed adverse effect level (LOAEL), and lowest observed effect level (LOEL). The objective of the 14-day studies is to determine the starting dosages for the 28-day studies based on clinical signs, whereas the objective of the sub-acute studies is to observe and quantify toxicity in all organs, especially the nasopharyngeal tissue, respiratory tract and lungs. Study findings will help determine the potential for human health effects from exposure to inhaled essential oils and may inform regulatory activities related to tobacco product additives/ingredients.

Narayanan Rajendran and Lynn Crosby Funding Mechanism: Research Contract
ID number: HHSF223201510033I
Institution: Illinois Institute of Technology Research Institute
09/14/2017

In Vitro Detection and Characterization of DNA Adducts Generated by Tobacco Flavorants in Aerosol Using ALI

Tobacco products contain flavor chemicals that have been determined to be “generally recognized as safe” (GRAS) for food products, but for tobacco products, flavor chemicals may be harmful when the flavors themselves or flavor combustion products are inhaled. Researchers will identify DNA adducts for selected tobacco flavors in five different lung or respiratory tract cell types. DNA adducts are formed by chemicals that bind to pieces of DNA, which causes modifications of the DNA. If these modifications are not repaired, cancer may develop. Over two years, five lung or respiratory cell lines that express specific P450 or sulfurtaransferase enzymes will be used to detect DNA adducts from the selected flavors. The researchers will conduct dose-response experiments to develop and confirm the methods for quantifying specific DNA adducts. Based on these dose-response experiments, researchers will then investigate in vitro air-liquid interface (ALI) aerosol exposures of the cell lines by adding a flavoring to a propylene glycol/vegetable glycerin solution and measuring the formation of adducts. Study results will provide new information about the health risks associated with tobacco flavorings.

Steven Belinsky, Carmine Leggett, Jueichuan (Connie) Kang, and Luis G. Valerio, Jr. Funding Mechanism: Research Contract
ID number: HHSF223201510001I
Institution: Lovelace Biomedical and Environmental Research Institute
09/11/2017

Genotoxicity Assessments of Flavoring Ingredients in ENDS Product

More information about the potential of flavoring ingredients to cause genotoxicity (gene toxicity) would be useful. The primary objective of this study is to conduct a high throughput mammalian cell genotoxicity study using commercially-available validated genotoxicity screening assays. The results from the screening assays will indicate whether a flavor ingredient is potentially genotoxic and, for those that are positive, describe the mechanism of action of the genotoxic effects. The secondary objective is to conduct statistical quantitative structure-activity relationship (QSAR) and structure-activity relationship (SAR) analyses for predicting the genotoxicity of the flavoring agents tested in the screening assay. Comparing the results of the QSAR and SAR analyses with the findings of the in vitro screening assays will help in the creation of a predictive model for genotoxicity assessment of the flavoring ingredients in tobacco products.

Carol Swartz and Mamata De Funding Mechanism: Research Contract
ID number: HHSF223201510009I
Institution: Integrated Laboratory System
09/07/2017

Cytotoxicity of Common Solvents used in Liquid Nicotine Formulations

This study aims to establish the baseline toxicity of propylene glycol (PG) and vegetable glycerin (VG), the primary solvents in e-liquid, as well as the effect of temperature and heating element composition on solvent-induced cytotoxicity (cell toxicity) with and without nicotine co-exposure. The first part of the study will involve measurement of in vitro cellular toxicity using human bronchial epithelial cells. The cells will be exposed to e-cigarette aerosol produced with e-liquid mixtures with varying ratios of PG and VG. The second part of the study will involve separately changing two parameters: (1) the power output of the device relative to the setting used in the first part of the study, and (2) the constituent materials used in the heating element. The heating element materials tested will include Kanthal, nichrome, stainless steel and ceramic; the solvent formulations used will be the three formulations that showed the greatest cytotoxicity in the first part of the study. Chemical characterization of the aerosol will include identification and quantification of chemical constituents, total particulate matter (TPM), pH, and particle size distribution. Study findings may inform the development of a potential in vitro toxicity screening protocol for e-cigarettes.

Jake McDonald and Wanyoike Kang’ethe Funding Mechanism: Research Contract
ID number: HHSF223201510001I
Institution: Lovelace Biomedical and Environmental Research Institute
09/01/2017

Understanding How Flavors are Used in Advertisements for Electronic Nicotine Delivery Systems (ENDS)

More information about the marketing of flavored electronic nicotine delivery system (ENDS) products would be useful. Researchers will analyze U.S. advertisement content and associated audiences for e-cigarette products to understand how flavors are portrayed and which sub-populations are seeing which flavored product advertisements. The ads will be purchased through media tracking services and coded by researchers for descriptive content, including how flavors are portrayed in the physical composition/ad format (e.g., size, image, setting) and the content of the ad (e.g., descriptors, themes). For example, e-liquids (e.g., berry, mint) may be described in ads as smooth or fresh (descriptors traditionally used for cigarette or other tobacco products), as delicious or satiating (suggesting the product could be used as a hunger suppressant), or as fun and novel. The media tracking services provide information about the media platform the ads appeared in and the general audience meant for each platform, allowing the ad content to be associated with an audience. Study findings may inform regulatory activities related to flavored e-cigarette product marketing and advertising.

Ryan Kennedy Funding Mechanism: Centers of Excellence in Regulatory Science and Innovation
ID Number: 5U01FD005942-02
Institution: Johns Hopkins University
08/31/2017

Qualitative Study on Nicotine Exposure Risk: Knowledge, Beliefs, Perceptions, and Behaviors

Researchers will conduct a qualitative study to gain insight on consumer knowledge and perceptions surrounding risk of acute toxicity due to nicotine exposure. In addition, consumers will be asked to view a variety of draft electronic nicotine delivery systems (ENDS) warnings for e-liquid nicotine toxicity. A total of twelve focus groups will be conducted with 104 participants. Of these, eight focus groups will be conducted with young adult (aged 18-24) and adult (aged 25-65) ENDS users. In addition, four focus groups will be conducted with youth (aged 13-17) who have used or currently use ENDS. Focus groups will discuss what adults and youth know about acute toxicity due to exposure to e-liquids, the best ways to present information about e-liquid nicotine toxicity to consumers, and reactions to draft ENDS warnings for acute nicotine toxicity.

Anh “Bao” Zarndt Funding Mechanism: Research Contract
ID number: HHSF223201510002B
Institution: Research Triangle Institute International
08/30/2017

Evaluation of Metal Ions in Electronic Cigarette Aerosol Condensates and Determination of their Effects on Oral Keratinocytes

Several reports suggest that toxic metal ions and harmful and potentially harmful constituents (HPHCs) are present in e-cigarette aerosol condensates. It is unknown whether metal ions or the potential presence of HPHCs in e-cigarette aerosol condensates can trigger adverse biological responses in oral keratinocytes, the primary oral cavity cells targeted by potential toxicants. In this study, researchers will develop an integrated approach that will (1) generate and collect e-cigarette aerosols in a manner that mimics user inhalation and (2) uses inductively coupled plasma mass spectrometry to identify metal ions (e.g., lead, tin, cadmium, iron, copper, zinc) and HPHCs present in aerosol condensates. This approach will include exposing normal oral keratinocytes to aerosol condensates and then assessing their ability to divide and identifying signs of toxicity. Researchers will assess several e-cigarette brands and tobacco- and menthol-flavored e-liquids. This approach will provide a quantitative analysis of the metal ions present in e-cigarette aerosol condensates and oral cavity cells.

Sarah Michel and Vyomesh Patel Funding Mechanism: Centers of Excellence in Regulatory Science and Innovation
ID number: 5U01FD005946-02
Institution: University of Maryland School of Pharmacy
08/27/2017

Cognitive Interviews with Adult E-cigarette Users Designed to Inform CTP Infographic and Website Content

Some of the adverse experiences associated with electronic nicotine delivery systems (ENDS) that have been reported to FDA include burns and injuries resulting from battery explosions. CTP has developed a set of materials (an infographic, shareable images, and website content) to educate consumers about the risks of battery explosions when using e-cigarettes. Researchers will conduct a qualitative study to gather information about the utility of these materials in helping consumers avoid an e-cigarette battery explosion. Qualitative and in-depth interviews will be conducted with nine participants, including four young adults (aged 18-25) and five adults (aged 26-65) who are current established and experimental e-cigarette users. The interviews will be conducted at professional focus group and interviewing facilities in Arlington, VA. Potential participants will be recruited and screened by the interviewing facilities. One-on-one interviews will be facilitated by a professional moderator using a structured moderator guide. Study findings will be used to refine the existing content and inform the development of future materials.

Atanaska Dineva Funding Mechanism: Research Contract
ID number: HHSF223201510003B
Institution: Fors Marsh Group
08/24/2017

Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking

Clinical trials evaluating reduced nicotine content cigarettes generally have not found evidence of compensatory smoking behaviors among participants; however, most participants in low nicotine groups use non-study cigarettes, despite explicit instructions to use only the study cigarettes provided to them. The aim of this study is to test the impact of nicotine reduction on smoking behavior and toxicant exposure when participants do not have access to normal nicotine content cigarettes. Twenty adult smokers (aged 18 years and older) will be confined to a hotel setting for two four-night stays during which they will only have access to research cigarettes. During one hotel stay they will have access to normal nicotine content cigarettes, and during the second hotel stay they will only have access to very low nicotine content cigarettes. Participants will purchase all of their cigarettes using a study bank, and will be able to purchase up to three packs of cigarettes per day. To assess whether smokers engage in compensatory smoking (e.g., smoking more cigarettes, taking longer puffs) as a result of nicotine reduction, biomarkers of smoke and toxicant exposure (e.g., expired carbon monoxide) and behavioral measures of smoking (e.g., cigarettes smoked per day, puff topography) will be compared between the two conditions. This study will provide new information about the effects of reduced nicotine content cigarettes.

Tracy Smith Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03DA045197-01
Institution: University of Pittsburgh at Pittsburgh
08/18/2017

Effect of Banning Menthol Flavorant on Cigarette and e-Cigarette Use

More information about how menthol flavoring in e-cigarettes affects overall tobacco use would be useful. This study will obtain preliminary information regarding how a menthol ban that either exempts or includes e-cigarettes is likely to affect overall tobacco use. In this six-week study, researchers will assign menthol cigarette smokers to one of three conditions: (1) a condition simulating a ban on menthol cigarettes but not menthol e-cigarettes; (2) a condition simulating a ban on both menthol cigarettes and menthol e-cigarettes; and (3) a condition in which menthol is not banned for either product (the control condition). Tobacco product use, motivation to quit, number of quit attempts, and support for a menthol ban will be assessed. Data from this study will be used to plan larger studies examining how menthol flavoring in e-cigarettes affects tobacco product use patterns and toxicant exposure.

Michael Kotlyar Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03DA045150-01
Institution: University of Minnesota
08/17/2017

Using Concept Mapping to Inform the Measurement of Flavor Outcome Expectancies among Young Adults; CTP Supplement to Parent Grant: Center for the Study of Tobacco Products

Flavor additives in e-cigarettes may play a role in e-cigarette initiation, dual use, and switching among young adult combustible tobacco product (cigarette/little cigar/cigarillo) smokers, but gaps remain in the availability of measurement tools that can assess how flavors influence e-cigarette use behaviors. The goal of this study is to develop a flavor outcome expectancies scale that can help quantify the role of flavors in e-cigarette trajectories among young adult cigarette and/or little cigar/cigarillo smokers. This study builds on five previously-completed concept mapping studies that yielded more than 100 user-generated statements that describe positive and negative flavor experiences. Study aims are: (1) to use the statements to develop items for the flavor outcome expectancies scale; (2) to establish the content validity of the scale and test the scale items using cognitive interviews; and (3) to pilot test the scale, examine the internal consistency and factor structure, and investigate the concurrent and construct validity of the scale. First, researchers will reduce and revise relevant concept mapping statements and obtain feedback from an expert panel on the content validity and structure of the items. Next, researchers will conduct cognitive interviews (n=10) and focus groups (n=24) among young adult cigarette and/or little cigar/cigarillo smokers ages 18-35 to examine their understanding of the items. Finally, researchers will recruit smokers who have never used e-cigarettes (n=140) and smokers who currently use e-cigarettes (n=140) to complete an online survey that will allow the researchers to examine the structure of the scale and test its validity. This project will provide new information about the role of flavors in e-cigarette initiation, dual use, and switching by young adult smokers.

Thomas Eissenberg Funding Mechanism: National Institutes of Health – Grant
ID number: 3P50DA036105-05S1
Institution: Virginia Commonwealth University
08/15/2017

CTP Supplement to Parent Grant: Metals in Electronic Cigarette Aerosol

This study is a supplement to a parent study that sought to identify and quantify the metal content of e-cigarette aerosols from various products and designs, to examine the cell and gene toxicity of aerosols with metal content, and to examine biomarkers of metal exposure and health effects in e-cigarette users. E-liquids often contain high concentrations of the flavor chemicals menthol (M-ol) and/or menthone (M-one) and cinnamaldehyde (CAD). This supplemental project will: (1) identify and quantify flavor chemical degradation products formed by vaping e-liquids containing M-ol, M-one, and CAD; and (2) determine which in vitro assays best assess the toxicity of e-cigarette aerosols and which reaction products cause toxicity. This study will provide new information about e-cigarette aerosol toxicity.

Prudence Talbot Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01DA036493-04S1
Institution: University of California, Riverside
08/14/2017

Evaluation of E-Cigarette Aerosol in In Vivo Nonclinical Models

Additional information about inhaled e-cigarette aerosol toxicity would be useful. In this study, researchers will first conduct a seven-day pharmacokinetic nose-only inhalation study in female rats exposed to e-cigarette aerosol generated by three commercially-available devices. Researchers will test low, medium, and high nicotine doses based on potential human exposure with e-cigarette use. Blood and urine nicotine biomarkers will be collected to determine e-cigarette aerosol nicotine dose exposure levels. Researchers will also conduct a 90-day nose-only inhalation sub-chronic study in female rats to examine in vivo aerosol toxicity using three e-cigarette devices; exposure concentrations will be based on the data from seven-day study. Data gathered will include aerosol concentration measurements; measurements such as food consumption, body weight and food/water consumption; clinical observations; and urinary biomarkers of exposure. Study findings will inform characterization of the dose-response relationship and potentially identify a maximum tolerated dose without substantial toxicity.

Jake McDonald and Gladys V. Erives Funding Mechanism: Research Contract
ID number: HHS223201510032I
Institution: Lovelace Biomedical and Environmental Research Institute
07/24/2017

Perceptions of Nicotine and Relative Harm of Tobacco Products in U.S. Young Adults

Existing studies on tobacco harm perceptions have largely focused on the tobacco products themselves without addressing perceptions of nicotine separately. This study seeks to provide new information about the interplay between nicotine harm perceptions and tobacco product harm perceptions and how these perceptions affect tobacco use susceptibility and population-level tobacco use patterns. Researchers will conduct secondary analyses of longitudinal data from a large, national sample of U.S. young adults (4,100 young adults aged 18-34 years) using new measures of nicotine harm perceptions to examine the perceived harm of nicotine, the relative harm of tobacco products, and the impact of these perceptions on tobacco-related intentions and behavior. Study aims are: (1) to examine perceptions of nicotine and relative harm of tobacco products in a national sample of U.S. young adults and identify correlates of these perceptions (e.g., sociodemographics, tobacco use); (2) to characterize young adult subgroups based on their perceptions of nicotine and relative harm of tobacco products using latent class analysis; and (3) to describe the impact of nicotine and tobacco harm perception “class” on longitudinal patterns in susceptibility and curiosity to use tobacco and tobacco use behavior. Study findings will provide new information related to tobacco product and nicotine harm perceptions, and may inform regulatory activities related to tobacco product warning labels and other public education efforts.

Andrea Villanti Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03CA212694-01A1
Institution: Truth Initiative Foundation
07/12/2017

Evaluation of Micronuclei and DNA Damage in B6C3F1 Male Mice Administered 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone by Intraperitoneal Injection

The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is on FDA’s published list of harmful and potentially harmful constituents (HPHCs) in smokeless tobacco products and tobacco product smoke. NNK is a strong lung carcinogen, causing lung tumors in a variety of laboratory animals, including mice. This study will evaluate the gene toxicity potential of NNK in live animals using a micronucleus and comet assay study. Researchers will treat mice with NNK or a positive control chemical and evaluate the animals for genetic toxicity. Researchers will assign five male mice to each one of three experimental groups (NNK, positive control, and negative control) and will administer the respective treatments for three consecutive days. After exposure, they will collect blood and bone marrow cells for micronuclei frequency assessment (chromosomal abnormalities that serve as surrogates for carcinogenic potential) and liver, lung, and bone marrow for DNA damage assessment. Study findings will provide information regarding the genotoxic and chromosomal damage profile of NNK and the carcinogenicity mode of action for NNK.

Jeffrey Davis and Juan Crespo-Barreto Funding Mechanism: Research Contract
ID number: HHSF223201510034I
Institution: Integrated Laboratory System
07/03/2017

CTP Supplement to Parent Grant: Interactions between Tobacco Smoke Constituents in Rodent Tumor Models

This study is a supplement to a parent project that sought to characterize the potential interactions between known human carcinogens (e.g., NNK, NNN, BaP) and volatile components of tobacco smoke (e.g., acetaldehyde, acrolein, formaldehyde) in established rodent tumor models. This study will add a histopathological analysis (an analysis of tissue changes) to the previous study analyses; histopathological analysis will provide additional useful information for the detection of the interaction between acetaldehyde or formaldehyde (two tobacco-associated lung carcinogens) and NNK. Taken together, these analyses will provide important information about the ability of volatile compounds to influence the tumor-generating activity of established tobacco carcinogens.

Lisa Peterson Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01CA184987-04S1
Institution: University of Minnesota
05/31/2017

CTP Supplement to Parent Grant: Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes Among Daily and Non-Daily Smokers on Abuse Liability

This study is a supplement to a parent study that modeled abuse liability in a market in which the combustible cigarette nicotine level was lowered to meet a potential regulatory standard, but an alternate source of nicotine in the form of e-cigarettes was also available. The coexistence of these products raises questions about whether the potential public health benefit of reducing abuse liability with low nicotine cigarettes might be offset by the concurrent use of e-cigarettes. In this supplemental study, researchers will quantify the formaldehyde DNA adduct N6-hydroxymethyldeoxyadenosine in leukocyte DNA samples collected via cheek swabs of 160 adult e-cigarette users aged 18-65. This will provide a measure of exposure to a potential toxicant specific to e-cigarettes, and will complement the biomarkers of combustible tobacco and nicotine exposure included as part of the parent study.

Paul Cinciripini Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01DA042526-02S1
Institution: University of Texas MD Anderson Cancer Center
05/31/2017

Chemical Analysis of Mainstream Smoke from Cigarillos, Large Cigars and Reference Cigarettes to Determine the Amount of Carbonyls

This task order is a continuation of a project to measure specific harmful and potentially harmful constituent (HPHC) quantities in a variety of currently-marketed cigarillos, large cigars and reference cigarettes using a validated testing method. Acrolein is a chemical compound that has been identified as a significant contributor to tobacco products’ non-cancer respiratory effects (such as chronic obstructive pulmonary disease, or COPD). This study will measure the acrolein yields of commercial cigar tobacco products (10 cigarillos and five large cigars) using the CORESTA No. 74 recommended method under the ISO and Canadian Intense smoking regimens. Additional analysis using reference cigarettes may help identify sources of variability (i.e., whether variability is due to the smoking regimen or the cigar products themselves) in the data generated for the cigarillo and cigar products. This study may help identify a recommended method to determine acrolein levels in cigars and cigarillos.

Andrew Mooney and Todd Cecil Funding Mechanism: Research Contract
ID number: HHSF223201310037I7T
Institution: Labstat International ULC
05/31/2017

Establishing Matrix-Specific Harmful and Potentially Harmful Constituents Lists (Phase 2, Task Order 1)

More information about which harmful and potentially harmful constituents (HPHCs) are present in specific types of tobacco samples – particularly the newly deemed tobacco products — would be useful. The primary goal of this study is to establish product/sample type-specific HPHC lists through laboratory testing. A second goal is to establish baseline values for the HPHCs present in each product/sample type. Products will be selected for testing based on market volumes, product features, and types/subcategories. Because of its broad scope, this study includes three phases, with one or two task orders under each phase. In Phase 2-Task Order 1, testing will focus on roll-your-own tobacco, pipe tobacco, cigar tobacco, and cigar smoke. HPHCs to be investigated will include aflatoxin, amide, metals, non-tobacco specific nitrosamines, PAHs, phenols, tobacco specific alkaloids, dioxins, heterocyclic aromatic amines, and hydrazine. Study findings may inform regulatory activities related to product testing, reporting, and evaluation.

Andrew Mooney and Shixia Feng Funding Mechanism: Research Contract
ID number: HHSF22301008T
Institution: Labstat International ULC
05/23/2017

Reduction in Carbonyl Yields from Sheet-Wrapped Cigars by Charcoal Filtration

Carbonyl compounds, including formaldehyde, acetaldehyde, and acrolein, are harmful and potentially harmful constituents (HPHCs) present in the gas and particulate phases of the mainstream smoke of combusted tobacco products. Carbon-based materials like charcoal, which have a large surface area and are porous, have been incorporated into cigarette filters to capture HPHCs, including carbonyls, from mainstream cigarette smoke with varying degrees of effectiveness. However, more information about charcoal filtration in sheet-wrapped cigars would be useful. The goal of this project is to evaluate the effect of charcoal filtration on carbonyl reduction in the mainstream smoke of sheet-wrapped cigars. Researchers will modify currently marketed sheet-wrapped cigars with an adapted filter design that incorporates charcoal into the filter at varying quantities, and will measure carbonyl levels in the resulting mainstream smoke. Study findings may inform the development of technologies that could reduce levels of carbonyl and other HPHCs in the smoke of sheet-wrapped cigars.

Clifford Watson and Julie Morabito Funding Mechanism: Interagency Agreement (Non-PATH)
ID number: 224-11-9022
Institution: Centers for Disease Control and Prevention
05/23/2017

Menthol Use in Roll-Your Own Tobacco and Little Cigars and Migration

Menthol is a common flavor additive that masks harshness and makes smoking tobacco more appealing. To better understand menthol application and migration in combusted tobacco products, menthol will be quantitatively determined in select cigarette, little cigar, and roll-your-own tobacco (RYO) tobacco products. Additionally, researchers will apply defined quantities of menthol to either the filter, tobacco rod, or packaging of various commercial non-menthol cigarettes and little cigars and measure the menthol in these components at different storage times. Researchers will also measure the menthol in the mainstream smoke from these products. Information from this study will expand upon our previous research activities related to menthol in combusted tobacco products and how its application and physical properties may influence its transfer to mainstream smoke.

Clifford Watson and Kenneth Taylor Funding Mechanism: Interagency Agreement (Non-PATH)
ID number: 224-11-9022
Institution: Centers for Disease Control and Prevention (CDC)
05/17/2017

Establishing Matrix-Specific Harmful and Potentially Harmful Constituents Lists (Phase 2, Task Order 2)

More information about which harmful and potentially harmful constituents (HPHCs) are present in specific types of tobacco samples – particularly the newly deemed tobacco products — would be useful. The primary goal of this study is to establish product/sample type-specific HPHC lists through laboratory testing. A second goal is to establish baseline values for the HPHCs present in each product/sample type. Products will be selected for testing based on market volumes, product features, and types/subcategories. Because of its broad scope, this study includes three phases, with one or two task orders under each phase. In Phase 2-Task Order 2, testing will focus on pipe tobacco, cigar tobacco, and cigar smoke. HPHCs to be investigated will include coumarin, hydrogen cyanide, PAHs, non-tobacco specific nitrosamines, caffeic acid, ethyl carbamate, and tobacco specific alkaloids. Study findings may inform regulatory activities related to product testing, reporting, and evaluation.

Karen Carter and Shixia Feng Funding Mechanism: Research Contract
ID number: HHSF22301004T
Institution: Enthalpy Analytical, Inc.
05/12/2017

Establishing Matrix-Specific Harmful and Potentially Harmful Constituents Lists (Phase 3, Task Order 2)

More information about which harmful and potentially harmful constituents (HPHCs) are present in specific types of tobacco samples – particularly the newly deemed tobacco products — would be useful. The primary goal of this study is to establish product/sample type-specific HPHC lists through laboratory testing. A second goal is to establish baseline values for the HPHCs present in each product/sample type. Products will be selected for testing based on market volumes, product features, and types/subcategories. Because of its broad scope, this study includes three phases, with one or two task orders under each phase. In Phase 3-Task Order 2, testing will focus on hookah tobacco and smokeless tobacco products. HPHCs to be investigated will include amide, caffeic acid, coumarin, ethyl carbamate, hydrogen cyanide, non-tobacco specific nitrosamines, polycyclic aromatic hydrocarbons, and volatiles. Study findings may inform regulatory activities related to product testing, reporting, and evaluation.

Karen Carter and Shixia Feng Funding Mechanism: Research Contract
ID number: HHSF22301003T
Institution: Enthalpy Analytical, Inc.
04/26/2017

Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function

Because hookah tobacco is heated with burning charcoal, hookah smoke contains charcoal combustion products including carbon monoxide (CO) and oxidants that can clog coronary arteries. The CO level associated with hookah use decreases oxygen delivery to the heart unless it is offset by increased blood flow. The goals of this study are: (1) in young healthy hookah smokers, to test if CO dilates the heart’s arteries, thereby masking a tobacco-induced impairment; and (2) in long-term middle-aged hookah smokers, to test: (a) whether the coronary endothelium (the tissue lining the heart’s arteries) has become too dysfunctional to respond to CO in hookah smoke, thereby indicating impaired blood flow to the heart; and (b) whether the reduced blood flow is large enough to stress the heart. Heart function will be measured as the increase in heart blood flow caused by handgrip exercise. Blood flow in the heart will be measured by ultrasound. The handgrip-induced increase in blood flow will be measured in younger and older hookah smokers before and after smoking charcoal-heated or electrically-heated hookah tobacco, and, for comparison, in age-matched cigarette smokers before and after smoking two cigarettes. Specific aims are: (1) to determine the acute effect of hookah smoking on blood flow to the heart in 24 healthy young adult hookah smokers (aged 21-25 years), compared to 12 young adult cigarette smokers; 2) to determine the acute effect of inhaled CO gas alone (to mimic the hookah-induced CO level of 25 ppm, generally considered to be non-toxic) on blood flow to the heart in a subset of 16 young adult hookah smokers; and (3) to determine the acute effect of hookah smoking on blood flow and heart function in 12 long-term middle-aged hookah smokers (aged 35-49 years), compared to 12 middle-aged cigarette smokers. Study findings may provide new understanding of how hookah smoking impacts the regulation of blood flow to the heart in both young and middle-aged adults.

Ronald G. Victor Funding Mechanism: National Institutes of Health – Grant
ID Number: 1 R21 DA041596-01A1
Institution: Cedars-Sinai Medical Center
04/17/2017

Establishing Matrix-Specific Harmful and Potentially Harmful Constituents Lists (Phase 1, Task Order 1)

More information about which harmful and potentially harmful constituents (HPHCs) are present in specific types of tobacco samples – particularly the newly deemed tobacco products — would be useful. The primary goal of this study is to establish product/sample type-specific HPHC lists through laboratory testing. A second goal is to establish baseline values for the HPHCs present in each product/sample type. Products will be selected for testing based on market volumes, product features, and types/subcategories. Because of its broad scope, this study includes three phases, with one or two task orders under each phase. In Phase 1-Task Order 1, testing will focus on cigarette smoke, cigar smoke, and smokeless tobacco products. HPHCs to be investigated will include metals, amides, aromatic amines, carbonyls, polycyclic aromatic hydrocarbons, non-tobacco specific nitrosamines, and phenols. Study findings may inform regulatory activities related to product testing, reporting, and evaluation.

Andrew Mooney and Shixia Feng Funding Mechanism: Research Contract
ID number: HHSF22301009T
Institution: Labstat International ULC
04/17/2017

Refilling Addiction: Investigating Marketing for E-liquid on Instagram

E-cigarette use has been steadily increasing in the U.S. over the past decade, particularly among adolescents and young adults. The liquids used in refillable e-cigarette devices (e-liquids) often contain nicotine and are sold in a range of appealing flavors and colors. At present, there is little understanding of how e-liquids are marketed on social media or which social media marketing elements are most appealing and persuasive to young adults. Instagram, a social media platform in which each post contains an image or short video, is used by over half of all U.S. adolescents and young adults who use the Internet; exploratory research suggests that Instagram is home to a large volume of e-liquid posts. The goal of this study is to investigate e-liquid marketing on Instagram. Study aims are: (1) to document the ways in which e-liquid manufacturers and retailers market their products on Instagram, and (2) to discern how young adults interpret and respond to e-liquid marketing on Instagram. Investigators will perform a content analysis of 2,000 Instagram posts with the hashtags #eliquid and/or #ejuice to identify marketing themes and claims, promotional strategies, and products promoted. They will analyze health, harm reduction, and cessation claims, as well as products and marketing strategies known to appeal to youth. Investigators will draw posts from four time periods in 2017 and 2018 in order to capture changes in content over time. Additionally, they will track the total number of posts with each hashtag to determine trends in the volume of e-liquid activity. In addition to the content analysis, investigators will hold 12 focus groups with a total of approximately 72 18-24 year olds in Milwaukee, WI who use Instagram. Focus groups will identify participant interpretations and responses to actual Instagram marketing posts.

Linnea Laestadius Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03CA216528-01
Institution: University of Wisconsin Milwaukee
04/13/2017

E-Cigarette Vaping in Advertising Portrayals and Behavioral Outcomes Research (E-VAPOR Study)

Young adults have the highest prevalence of dual use of cigarettes and e-cigarettes (current smokers who also use e-cigarettes). Little is known about the causal links among young adult exposure to vaping images in e-cigarette advertisements, urge to smoke conventional cigarettes, and objective measures of conventional cigarette smoking intensity. The goal of this study is to identify key factors in tobacco advertising that influence young adult smoking. Investigators will conduct a randomized controlled experiment among 210 young adult dual users aged 21-30 years. Specific aims are: (1) to demonstrate the causal link between vaping portrayals in e-cigarette ads and subjective measures of urge to smoke among dual-users, and (2) to demonstrate the causal link between vaping portrayals in e-cigarette ads and objective measures of smoking intensity based on puffing topography measures. Participants will be randomly assigned to one of three video conditions: e-cigarette ads containing vaping portrayals, e-cigarette ads edited to remove vaping portrayals, or neutral videos. Each participant will view eight 30-second ads within each condition for a total of four minutes of ads, and ads will appear in random order. After viewing the ads, participants will complete the Questionnaire on Smoking Urges-Brief (QSU-Brief) instrument and will smoke their own brand of cigarettes so that investigators can measure puffing topography (puff number, volume, duration, interpuff interval, and flow rate).

Andy S. L. Tan Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03CA212544-01A1
Institution: Harvard T. H. Chan School of Public Health
04/10/2017

The Real Cost General Market: Wave 4 Creative Concept Testing Designed to Prevent Youth ENDS Use

Researchers will conduct a qualitative research study to inform the development of appropriate messaging to prevent the use of electronic nicotine delivery systems (ENDS) among youth (aged 12-17). Specifically, this study will use focus groups to explore the target audience’s reactions to various creative advertisement concepts and messaging probes intended to prevent youth ENDS use. Approximately 24 focus groups with up to 8 participants each will be conducted in various locations across the U.S. for a total sample of up to 192 youth. Participants will be youth who: (1) are at-risk of initiating ENDS use; (2) are ENDS-only experimenters (do not use or experiment with combustibles); and (3) have experimented with cigarettes and ENDS (dual experimenters). Participants will be diverse in terms of race/ethnicity, gender, and geographical location. Findings will inform public education campaign messaging about ENDS.

Kristen Holtz and Maria Roditis Funding Mechanism: Research Contract
ID number: HHSF223201750007A
Institution: KDH Research & Communication?
04/10/2017

The Real Cost Smokeless: Wave 2 In-depth Interviews Designed to Prevent Rural Youth Tobacco Use

In support of FDA’s efforts to refresh youth tobacco prevention campaign messaging, researchers will conduct a qualitative research study to gain a richer understanding of the target audience, including their home life, values, and exposure to smokeless tobacco. In-depth interviews will be conducted in three geographically distinct rural regions with 22 male adolescents aged 12-17 years who are at risk for smokeless tobacco use, experimenting with smokeless tobacco, or established users of smokeless tobacco. Interviews will be conducted in schools and will include a mix of races and ethnicities. This study will inform the development of appropriate messaging for subsequent waves of FDA’s The Real Cost Smokeless campaign.

Brian Griepentrog and Maria Roditis Funding Mechanism: Research Contract
ID number: HHSF223201750007A
Institution: Fors Marsh Group
04/10/2017

TRC Smokeless Wave 2 Creative Concept Testing – Focus Groups With Rural Youth

Researchers will conduct a qualitative research study to inform the development of a new set of messages for Wave 2 of FDA’s The Real Cost Smokeless campaign. Focus groups will be conducted in four rural regions with male youth aged 12-17 years who are at risk for smokeless tobacco use or who are experimenting with smokeless tobacco. Researchers will conduct 18-24 focus groups with four to eight students each (for a maximum of 144 participants). Focus groups will be segmented by school level (middle or high school), smokeless tobacco status (at risk or experimenter) and race/ethnicity (Non-Hispanic White or all other races and ethnicities besides Non-Hispanic White). Focus groups will explore reactions to various creative concepts intended to prevent youth smokeless tobacco use. Findings will contribute to the development of appropriate educational campaign messaging.

Brian Griepentrog and Maria Roditis Funding Mechanism: Research Contract
ID number: HHSF223201750007A
Institution: Fors Marsh Group
04/10/2017

Developing Strategic Concepts Designed to Prevent AI/AN Youth Tobacco Use

This study will involve qualitative research to inform the development of a public education campaign to discourage use of cigarettes by American Indian/Alaska Native (AI/AN) youth. Researchers will conduct focus groups with up to 168 U.S. AI/AN youth aged 12-17 who are experimental tobacco users and susceptible non-triers. Participants will be recruited using a community-intercept approach, and groups will be conducted in both community and commercial focus group facilities. Focus group activities will include individual surveys, facilitator-led activities, and group discussions. The activities are designed to provide insight into youth perceptions related to local teen cultures and tobacco use attitudes, beliefs, and perceptions. Findings will provide information to inform campaign development.

Chaunetta Jones Funding Mechanism: Research Contract
ID number: HHSF223201750007A
Institution: Rescue Agency
04/06/2017

Creative Concept Testing Designed to Prevent Youth and Young Adult Smoking

In 2014, FDA launched its first youth tobacco education campaign, called The Real Cost, targeting at-risk youth aged 12-17. In 2018, the FDA expanded its public education campaigns to focus on the prevention of youth electronic nicotine delivery systems (ENDS) use. To support these efforts, the FDA’s Center for Tobacco Products (CTP) will conduct a qualitative research study to inform the development of appropriate campaign messaging to prevent combustible cigarette smoking and other nicotine use among youth and young adults. Focus groups will explore participants’ reactions to various creative advertisement concepts. Approximately 30 focus groups with up to eight participants each will be conducted remotely across the U.S. with a total sample of up to 240 youth (ages 13-17) and young adults (ages 18-20) who are at risk of initiating cigarettes (susceptible) or have experimented with cigarettes (experimenter). Discussion groups will include a diversity of participants and will be segmented by cigarette usage (i.e., experimenter/susceptible) and by age. Findings will inform messaging included in future tobacco education campaigns.

Kristen Holtz (CTP Contact: Andrea Malterud) Funding Mechanism: Research Contract
ID Number: HHSF2232017500007A
Institution: Rescue Agency, KDH Research & Communication, FCB
03/17/2017

Establishing Matrix-Specific Harmful and Potentially Harmful Constituents Lists (Phase 1, Task Order 2)

More information about which harmful and potentially harmful constituents (HPHCs) are present in specific types of tobacco samples – particularly the newly deemed tobacco products — would be useful. The primary goal of this study is to establish product/sample type-specific HPHC lists through laboratory testing. A second goal is to establish baseline values for the HPHCs present in each product/sample type. Products will be selected for testing based on market volumes, product features, and types/subcategories. Because of its broad scope, this study includes three phases, with one or two task orders under each phase. In Phase 1-Task Order 2, testing will focus on cigarette smoke, cigar smoke, and smokeless tobacco products. HPHCs to be investigated will include aflatoxin, coumarin, non-tobacco specific nitrosamines, volatiles, heterocyclic aromatic amines, and hydrogen cyanides. Study findings may inform regulatory activities related to product testing, reporting, and evaluation.

Karen Carter and Shixia Feng Funding Mechanism: Research Contract
ID number: HHSF22301002T
Institution: Enthalpy Analytical, Inc.
03/13/2017

Associations of Youth E-Cig and Tobacco Use: Ecological Momentary Assessment

Research suggests that socio-ecological factors, such as e-cigarette access, perceptions, marketing, and use by others, may increase youth susceptibility to future use of combustible tobacco products. This study will use a longitudinal ecological momentary assessment (EMA) approach and a computer-assisted self-interview survey to examine both within-person and between-person associations of factors related to e-cigarette and tobacco use, use intentions, willingness to use, and the role of environment and situational factors on adolescent use of e-cigarettes and tobacco. Data will be collected from 50 adolescents (ages 13-17) who are e-cigarette only users or dual users of e-cigarettes and tobacco and who live in Kentucky, a state where e-cigarette use rates are three times higher than the national average for middle schoolers and two times higher than the national average for high schoolers. Specific aims are: (1) to investigate within-person associations among e-cigarette and tobacco access, motivations, exposure, context, intentions, willingness, and behaviors; (2) to investigate between-person associations among e-cigarette and tobacco beliefs, norms, access, motivations, exposure, context, intentions, willingness, and behaviors; and (3) to explore differences between e-cigarette only users and dual users regarding e-cigarette and tobacco beliefs, access, motivations, exposure, context, intentions, willingness, behaviors, and personal risk factors. Study results may provide preliminary data to guide the design of the larger, more rigorous studies about e-cigarette initiation, use, perceptions, and transition to other tobacco products.

Melissa H. Abadi Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03DA041899-01A1
Institution: Pacific Institute for Research and Evaluation
03/10/2017

E-Cigarette Warning Labels: Tests of Messages to Reduce Recreational Use among Adolescents

Recreational use of e-cigarettes by non-smoking youth has increased dramatically in recent years. This study tests warning label alternatives in the context of other product information to identify communication strategies that minimize youth recreational uptake of e-cigarettes. Specific aims are: (1) to determine the impact of three different e-cigarette warning labels on adolescents’ perceptions of the product; (2) to determine whether a modified risk statement near the warning label changes how adolescents perceive the product; and (3) to determine whether the mention of a novelty flavor near the warning label changes how adolescents perceive the product. Investigators will present 650 ninth and tenth graders with a randomly assigned warning label that varies by the type of consequence mentioned in the warning label (3 variables) as well as whether or not the package features a modified risk statement (“This product presents a lower risk of tobacco-related disease than traditional cigarettes”; 2 variables) and/or the mention of any one of three sweet novelty flavors to be determined (2 variables); the 3x2x2 study design, plus one control condition, will yield 13 possible experimental labels. The three warning labels are: (a) one specific consequence (FDA text: WARNING: This product contains nicotine. Nicotine is an addictive chemical.); (b) multiple specific consequences (a 117-word warning that was proposed by the MarkTen manufacturer); or (c) an abstract consequence (WARNING: The long-term health risks associated with this product are unknown.). Participants will then complete an iPad survey that includes both newly-developed questions and questions from previously-validated surveys such as the Youth Tobacco Study and the Population Assessment of Tobacco and Health Study; outcomes measured will include risk perceptions, message comprehension, harm-minimizing beliefs, susceptibility, and behavioral intentions toward e-cigarette uptake. Participants will be debriefed and advised against using e-cigarettes.

Sherri Jean Katz Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03DA043022-01A1
Institution: University of Minnesota
02/28/2017

Evaluating New Nicotine Standards for Cigarettes – Renewal

This research study will examine the impact of reducing nicotine in cigarettes in the context of alternative tobacco product availability. The study includes three projects. Project 1 is a 12-week clinical trial that examines the use of very low nicotine content (VLNC) vs. normal nicotine content (NNC) cigarettes when 700 adult smokers are given vouchers to exchange for cigarettes in an experimental marketplace that contains a wide range of non-combusted products. Project 2 is a seven-week clinical trial comparing VLNC and NNC cigarettes when 480 adult smokers have access to e-cigarettes that vary in nicotine concentration (high vs. low) and available flavors (tobacco only vs. tobacco and other flavors). Project 3 is a laboratory-based study that will assess the choice to smoke, vape, or abstain when 120 adolescent smokers (ages 18-24 are provided cigarettes with VLNC vs. NNC and e-cigarettes that vary in nicotine concentrations and flavors. Other study activities will include the analysis of biomarkers associated with exposure to nicotine and tobacco-related toxicants and the development of novel ways to analyze data.

Eric C. Donny and Dorothy K. Hatsukami Funding Mechanism: National Institutes of Health – Grant
ID number: 2U54DA031659-06
Institution: University of Pittsburgh at Pittsburgh
02/21/2017

E-Cigarettes: Formaldehyde DNA Adducts, Oxidative Damage, and Potential Toxicity and Carcinogenesis

Recent reports indicate that e-cigarettes may generate unacceptable levels of the human carcinogen formaldehyde, and preliminary data indicate that levels of urinary biomarkers of oxidative damage and inflammation are the same in e-cigarette users as in cigarette smokers. The goal of this study is to test whether e-cigarette use leads to formaldehyde-DNA adducts and elevated exposure to other carbonyls, and to similar levels of oxidative damage and inflammation as in smokers; the study will also assess toxicant and carcinogen exposure in e-cigarette users, smokers, and non-smokers. Specific aims are: (1) to quantify formaldehyde-DNA adducts in tissues of rats exposed to vapor generated from e-liquids containing propylene glycol; (2) to analyze samples from a prior study in which smokers stopped smoking for 12 weeks to determine the time course of decreases in formaldehyde-DNA adducts in leukocytes and 8-iso-PGF-2α and prostaglandin E2 metabolite (PGEM) in urine; and (3) to recruit 134 e-cigarette tank system users, 134 smokers, and 134 non-users of any e-cigarette or tobacco product and compare levels of (a) formaldehyde, diacetyl, and other carbonyl compounds in saliva (before and after puffing in the e-cigarette users and smokers), (b) formaldehyde-DNA adducts in oral cells and leukocytes, (c) 8-iso-PGF-2α and PGEM in urine, (d) C-reactive protein, the serum biomarker of inflammation, and (3) a panel of urinary toxicant and carcinogen biomarkers.

Stephen S. Hecht Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01CA203851-01A1
Institution: University of Minnesota
02/03/2017

Impact of Prenatal Waterpipe Use on Infant Biomarkers and Neurodevelopment

Waterpipe tobacco (hookah, narghile) use has serious health risks similar to those associated with cigarette smoking. Waterpipe use is especially problematic among reproductive-age women because it increases the risk of obstetrical complications, low birth weight, and respiratory problems in newborns. However, although cigarette tobacco and nicotine are known to harm the developing brain, data regarding the effects of waterpipe tobacco use during pregnancy on infant toxic chemical exposure and neurodevelopmental outcomes is lacking. A prospective, observational, longitudinal study is investigating the impact of flavors and design features on waterpipe use patterns and toxic chemical exposure in pregnant and postpartum current waterpipe users; participants are being provided with information about the health risks of hookah and other tobacco use following assessments. In this supplement, investigators will analyze data from 115 infants of mothers participating in the longitudinal study. Study aims are: (1) to determine the impact of prenatal waterpipe tobacco use, flavors, and design features on biomarkers of infant nicotine and toxic chemical exposure (cotinine, volatile organic compounds [VOCs]), and (2) to determine the impact of prenatal waterpipe tobacco use, flavors, and design features on infant neurodevelopment. Investigators will collect infants’ urine and saliva to measure nicotine and markers of VOCs, respectively, and will assess neurodevelopment using the NICU Network Neurobehavioral Scale (NNNS), a standardized assessment designed to reveal deficits in substance-exposed infants.

Laura R. Stroud and Lori A.J. Scott-Sheldon Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01DA042484-01S1
Institution: Miriam Hospital
01/12/2017

Development of an In Vitro Porcine Buccal Model to Determine Permeability of Tobacco HPHCs

Measuring the absorption of harmful and potentially harmful constituents (HPHCs) in tobacco products through mouth exposure is important for understanding the toxic effects of these constituents. The goal of this study is to develop a measure of HPHC absorption (a “permeability constant”) that will allow investigators to predict how a given dose of a constituent absorbed through the mouth contributes to the relative risk of that constituent. In Phase 1 of the study, investigators will conduct a literature search on the physical and chemical properties of each constituent as well as their absorption through other membranes (i.e., skin, mucus membranes). In Phase 2, investigators will use an in vitro buccal (mouth) membrane absorption pig model to determine the permeability constants for five HPHCs found in smokeless tobacco: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), nicotine, benzo[a]pyrene, crotonaldehyde, and arsenic. In Phase 3, investigators will use the model to evaluate HPHC properties in three to five different types of three smokeless tobacco products (moist snuff [including a reference product], dissolvables, and snus), and will measure the absorption percentage of each constituent. These results will be compared to the results generated in Phase 2. Study findings will provide new information about buccal absorption of HPHCs.

Jeffrey Yourick, Juan Crespo-Barreto and Dana Lauterstein Funding Mechanism: Performance Agreement
ID number: PA-DNCS-001-16
Institution: Center for Food Safety and Applied Nutrition (CFSAN)
10/01/2016

Creative Concept Testing to Prevent Youth ENDS Use in General & Hip Hop Audiences

FDA’s Center for Tobacco Products (CTP) will conduct a qualitative research study to inform the development of appropriate messaging to prevent electronic nicotine delivery system (ENDS) use among youth. Specifically, this study will use focus group discussions to explore the target audience’s reactions to various creative advertisement concepts and messaging probes intended to prevent youth ENDS use. Approximately 30 focus groups with up to nine participants each will be conducted in various locations across the U.S. with a total of up to 270 youth aged 12-17 who: (1) are at risk of initiating ENDS use; (2) have experimented with ENDS only (do not use or experiment with combustibles); or (3) have experimented with cigarettes and ENDS (dual experimenters). Additionally, up to six of the 30 focus groups will have an added recruitment criterion for participants to self-report as part of the multicultural Hip-Hop peer crowd. Participants will be diverse in terms of race/ethnicity, gender, and geographical location. Findings will inform the development of future public education campaigns targeting youth and ENDS use.

Kristen Holtz and Maria Roditis Funding Mechanism: Research Contract
ID number: HHSF223201710001G
Institution: KDH Research & Communication
10/01/2016

Nicotine Education Project: Qualitative Study to Gain Insights from Adult Current and Former Smokers to Educate the General Public

In order to inform potential communications to the public, FDA’s Center for Tobacco Products (CTP) will conduct a qualitative research study consisting of up to 30 focus groups to gain insights around tobacco perceptions and nicotine addiction messaging. Specifically, researchers will explore the target audience’s thoughts about nicotine and tobacco products as well as potential regulatory actions. Approximately 30 focus groups with up to eight participants each will be conducted in various locations across the U.S. with a total sample of up to 240 adults ages 19-54 who are: (1) current cigarette smokers, 2) former smokers who currently use a non-combustible tobacco product or nicotine replacement therapy, or (3) former smokers who do not currently use any nicotine products. Individuals will be diverse in terms of race/ethnicity, gender, and geographical location. Findings may inform future public education efforts related to nicotine.

Dana Wagner and Maria Roditis Funding Mechanism: Research Contract
ID number: HHSF223201710001G
Institution: Rescue Agency
10/01/2016

Quantitative Study of Tobacco Facts Designed to Inform Youth Tobacco Prevention Messaging (TFR II)

The goal of this study is to evaluate scientific tobacco facts with regard to their applicability to special populations. Specifically, study results will inform the American Indian/American Native (AI/AN), Fresh Empire (multicultural youth) and The Real Cost: Smokeless (rural youth) campaigns. Youth reactions to the facts will be assessed on a range of reaction measures, including Perceived Argument Strength (PAS), trust, likelihood of sharing, understandability, likelihood of outcome, and desirability of outcome. Researchers will identify top-performing facts that can help inform the development of messages for FDA’s youth tobacco prevention campaigns. This study extends previous research that assessed the utility of cigarette and e-cigarette facts for use in future messaging with The Real Cost general market target audience (youth aged 13-17) who experimented with cigarette smoking or were susceptible to smoking.

Shane Mannis and Atanaska Dineva Funding Mechanism: Research Contract
ID number: HHSF223201510003B
Institution: Fors Marsh Group
10/01/2016

2019 Electronic Nicotine Delivery Systems Formative Data Collection to Inform Experimenter and Established User Definitions

The goal of this study is to develop a working definition for youth ENDS experimentation as contrasted with established ENDS use. Researchers will conduct a study to explore youth use of electronic nicotine delivery systems (ENDS) to assess what measures of use or the user’s knowledge, attitudes and behaviors best differentiate experimenters from established users. Study subjects will include up to 1,600 youth aged 13-17 who have ever used an ENDS device such as an e-cigarette. Participants will be recruited online and will complete an online screening survey to determine eligibility. Qualified youth will participate in a survey that addresses the participant’s ENDS use and its social context; measures of tobacco product-related knowledge, attitudes, and behaviors; advertising and counter-marketing exposure; sensation-seeking; measures of other tobacco product use; and demographics. After analyzing the survey data, researchers will construct definitions of experimental and established ENDS use and test which definitions are effective at discriminating between experimental and established youth ENDS users using various measures, such as harm perceptions.

Annice Kim and Mario Navarro Funding Mechanism: Research Contract
ID number: HHSF223201510002B
Institution: Research Triangle Institute (RTI), International
10/01/2016

HPHC Level Monitoring of Tobacco Products

The identities and quantities of harmful and potentially harmful constituents (HPHCs) in different tobacco products, including newly deemed tobacco products commercially available in 2016-2017, is critical information that can be used to protect the public health. This study involves analyzing 30 brands of each type of tobacco product (e.g., cigarettes, smokeless tobacco, roll-your-own tobacco, pipe tobacco, waterpipe tobacco, e-cigarettes) representing the top, middle, middle-low, and low quartiles of market share for each tobacco type in and around the Atlanta metropolitan area. Researchers will analyze 33 HPHCs using various methods, including high performance liquid chromatography-mass spectrometry (HPLC-MS). Data on moisture, pH, tar, and engineering parameters will also be collected on the different tobacco products. The project is expected to be performed in three six-month phases. Phase 1 will include testing cigarette filler, roll-your-own tobacco filler, pipe tobacco, waterpipe tobacco and smokeless tobacco. Phase 2 will include testing cigarette smoke under intense and non-intense smoking regimens. Phase 3 will include testing e-cigarette liquids and aerosols. Study findings will provide a better understanding of the constituent yields for 33 HPHCs across tobacco product types and may inform regulatory activities related to HPHCs.

Clifford Watson and Matthew Walters Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention (CDC)
09/30/2016

Effect of Menthol on Pharmacokinetic Profiles of Nicotine and Tobacco Specific Nitrosamines (TSNAs) in Rats

Animal studies using various routes of administration have been performed to investigate the pharmacokinetics of harmful and potentially harmful constituents (HPHCs); however, more information on the effects of menthol on the pharmacokinetics of HPHCs would be useful. The objectives of this study are to investigate the pharmacokinetics of nicotine and tobacco-specific nitrosamines (TSNAs) in 60 Sprague Dawley rats exposed to cigarette smoke, and to evaluate the effects of menthol on those pharmacokinetic profiles. Nicotine and TSNAs will be measured in blood, urine and tissue collected from the respiratory tract. The analyses will involve thorough evaluation of the pharmacokinetics of nicotine and TSNAs in rats exposed to low or high doses of cigarette smoke in the presence or absence of menthol.

June Liu, Roxana Weil and Juan Crespo-Barreto Funding Mechanism: Research Contract
ID number: HHSF223201510032I
Institution: Lovelace
09/29/2016

Evaluation of the FDAs Public Education Campaign on Teen Tobacco (ExPECTT II)

To assess the effectiveness of the FDA’s efforts to reduce or prevent tobacco use by youth, researchers will conduct an evaluation of The Real Cost public education campaign targeting youth aged 12-17 years who are at risk for smoking cigarettes and e-cigarettes. The specific aims of the study are to gauge campaign awareness and examine the statistical relationships between exposure to the campaigns and changes in outcome variables of interest, which include changes in beliefs and attitudes regarding cigarette smoking and e-cigarette use. Data are being collected through in-person and online surveys of adults and youth in the United States. Approximately 6,000 at-risk youth and their parents will complete questionnaires at four time points (baseline and three follow-up surveys) at eight-month intervals. The results of the study will inform the development of this and future youth-oriented tobacco education campaigns.

Alexandria Smith Funding Mechanism: Research Contract
ID number: HHSF223201610032I
Institution: Research Triangle Institute International
09/29/2016

Point of Sale Evaluation Intervention Evaluation (POSITEv)

The Center for Tobacco Products (CTP) launched a public education campaign, “Every Try Counts,” aimed at encouraging adult cigarette smokers to quit through messages of support that underscore the health benefits of quitting. The “Every Try Counts” campaign targets smokers aged 25-54 who have attempted to quit smoking in the last year but were unsuccessful. The campaign features motivational, positive messages that are displayed in and around gas stations or convenience stores – retail locations that typically feature cigarette advertisements and where smokers face multiple triggers. The campaign is being evaluated through a multi-year outcome evaluation study to determine the campaign’s effectiveness in affecting targeted tobacco-related knowledge, attitudes and beliefs, and changes in motivation to quit smoking among the target audience. The longitudinal study will follow a group of approximately 2500 individuals across up to four rounds of data collection conducted at approximately seven-month intervals. Data will be collected in person and online in 15 campaign-targeted media markets and 15 control markets across the U.S. Results from this study will be used to improve the current campaign and inform the development of future adult cessation public education initiatives.

Chaunetta Jones Funding Mechanism: Research Contract
ID number: HHSF223201610032I
Institution: Research Triangle Institute International
09/22/2016

Cigarette Packaging: Design, Cognition, and Consumer Choices

As part of its regulation of tobacco products, the Food and Drug Administration (FDA) can assess tobacco product packaging and labeling. Additional scientific evidence regarding what types of pack labeling changes matter to perceptions of “newness” would be informative. Study aims are: (1) to determine how adult smokers perceive cigarette product newness and identify design characteristics related to perceptions of newness; (2) to determine which cigarette pack design characteristics, when changed, are most important to adult smokers’ perception of product newness; and (3) to link changes in pack design identified in Aim 2 to adult smokers’ perceptions of taste, quality, and harm. Researchers will first investigate smoker perceptions of cigarette packaging changes by conducting five online focus groups including 6-8 adult smokers each; two groups will be diverse groups of low-income smokers, two will be diverse groups of LGBT smokers, and one will include diverse smokers in the general population. Researchers will then use focus group findings to inform two online surveys conducted with separate groups of 250 adult smokers each. The first experiment will assess which changes to pack labeling identified by the focus groups are most associated with the product being perceived as a new, distinct product. The second experiment will assess the influence of these labeling changes on the thoughts and feelings that drive smoker behavior. In these experiments, one-third of the subjects will be lower-income and one-third will be LGBT.

Joseph G. L. Lee Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03CA212542-01
Institution: East Carolina University
09/20/2016

Perceptions, Initiation, and Use of E-cigarettes among Middle School Students: A New Generation of Tobacco Users?

E-cigarette use is growing among youth. Additional scientific knowledge regarding why e-cigarettes appeal to youth, the effects of e-cigarette use, and how e-cigarette marketing influences adolescents’ beliefs, intentions, and willingness to use these products would be useful. The goal of this study is to generate scientific data on e-cigarette marketing impact, access to products, and initiation and use among youth. Study aims are: (1) to examine the prevalence of lifetime e-cigarette use and current use patterns among 1,150 middle school students (ages 11-14; half Hispanic) across a school year; (2) to assess concurrent and prospective factors related to e-cigarette initiation and use, including perceptions of risk, social images of users, motives for using, intentions and willingness to use, access to products, and exposure to marketing; and (3) to explore associations between e-cigarette initiation and poly-use or willingness and intentions to use other tobacco products, as well as nicotine dependence symptoms resulting from e-cigarette use. Researchers will conduct two school-based surveys across a school year (Fall and Spring) in two middle schools. Based on information obtained in the school surveys, researchers will select 60 e-cigarette users for in-depth interviews in order to gather additional information on the contexts surrounding e-cigarette use, to obtain sequential details of co-use with other tobacco products, and to delve more deeply into the appeal and motivations to use e-cigarettes. Study findings will contribute to the body of research on e-cigarettes and youth.

Erika Westling Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03CA206551-01A1
Institution: Oregon Research Institute
09/20/2016

Comparing Graphic to Text-Only Warning Labels to Discourage Cigarillo Smoking by Young Adults

Significant knowledge gaps exist regarding how to effectively communicate the risks of cigarillo smoking. The goal of this study is to test the effectiveness of possible warning labels that communicate cigarillo smoking risks. Study aims are: (1) to develop graphic cigarillo warning labels that effectively communicate the risks of cigarillo smoking by pairing existing images with the six FDA-required text warnings; and (2) to compare the relative effectiveness of text-only versus graphic cigarillo warning labels to discourage cigarillo smoking by young adult cigarillo users and at-risk nonusers. In Year 1, researchers will convene four focus groups, each with 7-10 young adults (ages 18-29) who are current users of or at risk of using cigarillos; focus groups will inform the development of the graphic warning labels by choosing images that represent the six text warnings in FDA’s Final Deeming Rule, which extends the agency’s regulatory authority over a variety of tobacco products, including cigarillos. Subsequently, researchers will conduct an experiment using a nationally-representative panel of 660 young adult cigarillo users and at-risk nonusers to assess the relative effectiveness of text-only versus graphic warnings in discouraging them from cigarillo smoking.

Jennifer Jane Cornacchione Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03CA206487-01A1
Institution: Wake Forest University Health Sciences
09/19/2016

The Effect of Nicotine Delivery Rate on Reinforcement

If e-cigarettes deliver nicotine at rates above a certain threshold, they can be addictive and potentially harmful, especially in nicotine-naïve users. In contrast, if the nicotine delivery rate of an e-cigarette falls below a critical threshold, it may have low addiction liability yet still provide sufficient nicotine to help smokers quit by reducing smoking urges and nicotine tobacco withdrawal symptoms. However, the critical rate of delivery that underlies the addictive effects of nicotine has yet to be empirically validated by controlled human studies. To close this knowledge gap, researchers will test nicotine reinforcement in 18 adult male and female smokers who will participate in a total of four experimental sessions involving different rates of nicotine administration. During experimental sessions, subjects will be given an intravenous (IV) nicotine infusion of either saline (as placebo) or 1 mg nicotine at rapid, moderate or slow infusion rates (nicotine at 0.24, 0.05 or 0.02 μg per kg body weight per second). The infusion conditions for each experimental session will be determined in a random order. Study aims are: (1) to establish a dose-effect curve for nicotine reinforcement as a function of nicotine delivery rate; (2) to establish a dose-effect curve for nicotine’s positive and negative subjective effects as a function of nicotine delivery rate; (3) to establish a dose-effect curve for nicotine’s ability to alleviate nicotine withdrawal symptoms in abstinent smokers as a function of nicotine delivery rate; and (4) to establish a dose-effect curve for nicotine’s acute cardiovascular health effects. Data from this project may help to establish benchmark values for nicotine’s threshold effects.

Kevin Jensen Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03DA043004-01
Institution: Yale University
09/15/2016

Analysis of Chemical Constituents and HPHCs in Waterpipe Tobacco, Charcoal, Wastewater

The goal of this study is to characterize and quantify chemical constituents in unheated waterpipe (WP) tobacco, unburned WP charcoal, heated WP tobacco, burned WP charcoal, and WP wastewater, specifically related to the use of quick light charcoal. Study aims are: (1) to conduct a lab analysis of ten different WP tobacco products, five different WP charcoal products, and WP wastewater; (2) to characterize and quantify the different chemical constituents and harmful and potentially harmful constituents (HPHCs) for both unheated and heated WP tobacco; (3) to characterize and quantify the different chemical constituents and HPHCs for both unburned and burned WP charcoal; (4) to understand the filtering effect of WP wastewater for WP tobacco and charcoal chemical constituents and HPHCs; and (5) to determine whether these constituents and HPHCs affect public health and/or the environment. Study findings will provide data about the constituents of WP tobacco, charcoal, and wastewater, and may provide new information about potential environmental harm.

Quintella Bester and Ronald Edwards Funding Mechanism: Research Contract
ID number: HHSF223201600607A
Institution: Battelle Memorial Institute
09/15/2016

In Vivo Biomarker that Identifies Waterpipe Smoking-Related Lung Health

Waterpipe smoking is increasing in the US, particularly among young adults. The goal of this study is to develop an in vivo respiratory tract epithelium-based assay sensitive to waterpipe smoke toxicity, in order to predict the impact of waterpipe smoking on lung health. Researchers will analyze data from a cohort young adults (ages 18-35) that includes 200 waterpipe-only smokers and 100 never smokers. Researchers will gather a wide variety of data from the participants, including: (1) responses to questionnaires that assess tobacco use, other exposures, lung health, and cough and sputum scores; (2) urine cotinine and blood carboxyhemoglobin levels; (3) full lung function tests; (4) chest imaging; and (5) the respiratory tract epithelial transcriptome (i.e., the set of all messenger RNA molecules in a population of cells) from small airway epithelium (SAE) and nasal epithelium. The study aims are: (1) to identify abnormalities in the SAE transcriptome; (2) to identify abnormalities in the nasal epithelial transcriptome; and (3) to determine whether these biologic abnormalities correlate with abnormalities in lung function, and if so, whether the nasal epithelial transcriptome can be a surrogate for the SAE transcriptome in predicting lung toxicity. This research may provide an in vivo biomarker that can be used in future studies to assess waterpipe smoking-associated risk to lung health.

Ronald Crystal Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01HL134163-01
Institution: Weill Medical College of Cornell University
09/12/2016

Assessment of Inhalation Toxicity of Essential Oils and Flavors in Tobacco Products

Essential oils and flavors are complex chemicals that may have the potential to worsen the risks associated with tobacco product use. The inhalation toxicity of these ingredients is often poorly characterized. To better understand the potential respiratory toxicity of essential oils and flavors used in e-cigarettes, researchers will expose normal human bronchial epithelial cells to the aerosols of nine essential oils and nine flavors generated under conditions simulating typical e-cigarette use, with and without co-exposure to nicotine, to evaluate the dose-response of cell toxicity. The 18 essential oils and flavors are buchu leaf oil, cinnamon bark oil, cinnamon leaf oil, lavender oil, orange oil, peppermint oil, sage oil (Spanish), spearmint oil, yiang ylang oil, 4-(p-Hyrdoxyphenyl)-2-butanone, benzaldehyde, benzyl alcohol, piperonal, diacetyl, ethyl maltol, ethyl vanillin, eugenol, and licorice extract. In addition, researchers will investigate the impact of 10 of these ingredients on oxidative stress, cellular morphology, inflammatory biomarker expression, and potential gene toxicity. The ingredients in the tested aerosols will be characterized using analytical methods such as gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry, and tandem mass spectrometry. This study will identify the respiratory toxicity associated with essential oils and flavors.

Jacob McDonald and Lynn Crosby Funding Mechanism: Research Contract
ID number: HHSF223201510032I
Institution: Lovelace Biomedical and Environmental Research Institute
09/12/2016

Investigation of the Effects of Electronic Cigarettes on Vascular Health

Although e-cigarettes do not produce smoke and users are not exposed to tar and carbon monoxide, they deliver nicotine, which is the primary addictive component of tobacco. Nicotine has been shown to promote atherosclerosis by generating systemic oxidative stress, which leads to various adverse cardiovascular effects (i.e., lipid peroxidation, atherosclerotic plaque formation, endothelial dysfunction, vascular endothelial cell damage). The goal of this study is to establish the acute and chronic effects of e-cigarette use on inflammation, systemic oxidative stress, and endothelial toxicity in 60 subjects (20 nonsmokers, 20 established e-cigarette users, and 20 cigarette smokers; ages 18-35). Study aims are: (1) to characterize the effects of chronic e-cigarette smoking on systemic oxidative stress; (2) to determine the acute effects of e-cigarette smoking on endothelial cell integrity; and (3) to identify the effects of chronic e-cigarette usage on endothelial function. To achieve Aim 1, researchers will measure markers of oxidative stress (plasma and urinary levels of F2-isoprostanes) in nonsmokers, chronic e-cigarette users, and cigarette smokers. To achieve Aim 2, researchers will measure levels of endothelial progenitor cells (which increase as a result of endothelial injury) in e-cigarette users and cigarette smokers immediately before and after using an e-cigarette or smoking a cigarette, and compare these levels to those in nonsmokers. To achieve Aim 3, researchers will compare brachial artery flow-mediated dilatation measurements, expression of NFkB (a marker of vascular inflammation), and reduction in eNOS (an enzyme that is essential for cardiovascular health) in e-cigarette users, cigarette smokers, and nonsmokers.

Roman Shingarev Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03HL132570-01A1
Institution: Sloan-Kettering Institute Cancer Research
09/09/2016

Effects of Cigar Flavors on Measures of Abuse Liability among Young Adults

The availability of cigar flavors, among other characteristics, has been linked to increased sales and consumption, with the largest increases among youth/young adults and certain racial/ethnic minorities. No studies exist quantifying the effect of cigar flavors on abuse liability (the potential for dependence and addiction). Researchers will examine the effect of four flavors of Black & Mild (B&M), the most popular cigar brand, on different measures of abuse liability. In this study, 25 young adults (ages 18-25 years) who are current cigarette smokers but inexperienced cigar smokers (≤5 times) will complete five smoking sessions that differ by product smoked: own brand cigarette and B&M cigars in original, apple, cream, and wine flavor. Researchers will then evaluate three measures of abuse liability: (1) exposure to nicotine via saliva concentrations; (2) breakpoint from behavioral tasks where individuals choose between money or cigar puffs; and (3) subjective measures of cigar effects.

Andrew J. Barnes Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03DA043005-01
Institution: Virginia Commonwealth University
09/08/2016

Analysis of Chemical Constituents in Cigarette Butt Leachate

A major environmental consequence of cigarette use is the disposal of discarded cigarette filters: each year, an estimated 4.5 trillion cigarette butts (1.69 billion pounds of cigarette butts) are thrown away worldwide. The National Environmental Policy Act requires an environmental impact analysis with human health impact scenarios for federal actions such as tobacco product marketing authorizations; thus, more information about the identities and amounts of constituents that leach from cigarette butts would be useful. Investigators will conduct a preliminary study to identify leachable constituents, including harmful and potentially harmful constituents (HPHCs), from cigarette butts. The objectives of this study are (1) to conduct laboratory analyses of three replicates from a single cigarette butt leachate; and (2) to characterize and quantify the different chemical constituents and HPHCs for the leachate. This study will provide new information about the leachable constituents in cigarette butts.

Diane Waldschmidt and Gregory Gagliano Funding Mechanism: Research Contract
ID number: HHSF223201610575P
Institution: Environmental Data Services
09/07/2016

Examine the Impact of Ontario’s Bans on Flavored and Menthol Tobacco Products on Consumer and Industry Behavior in the Tobacco Retail Environment

In 2015, Ontario, Canada enacted the Making Healthier Choices Act, which banned flavored and menthol tobacco products, including e-cigarettes. The goal of this study is to evaluate the impact of that law on consumer purchase behavior and retail marketing. Study activities will primarily entail analyses of secondary data such as enforcement agency records, retail sales (i.e., scanner data), and tobacco manufacturer data on sales to wholesalers. An in-store purchase study to explore product availability will also be conducted. Findings will provide evidence on the implementation, effectiveness, impact, and any potential unintended consequences of Ontario’s Making Healthier Choices Act of 2015, which may inform FDA’s tobacco regulatory activities.

Todd Rogers and Ashley Ross Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: Research Triangle Institute
09/07/2016

Intentions, Perceptions, Patterns, and Toxicant Exposure

Waterpipe smoking is a growing trend among young adults. A potential reason for the appeal of waterpipe tobacco is that it is nearly always flavored with sweeteners and additional fruit, candy, savory and dessert flavorings. The goal of this study is to investigate the impact of waterpipe tobacco flavors on waterpipe initiation, smoking behaviors, abuse liability, and exposure to tobacco-related toxicants. Study aims are: (1) to understand how flavorings impact waterpipe initiation, smoking behaviors, abuse liability, and exposure to tobacco-related toxicants; and (2) to understand whether level of waterpipe dependence influences the impact of waterpipe tobacco flavoring on smoking behaviors, intentions for continued use, abuse liability, and exposure to tobacco-related toxicants. Sixty current waterpipe smokers (ages 18-50; 30 rated “low” and 30 rated “high” on the Lebanese Waterpipe Dependence Scale) will all complete four waterpipe smoking sessions using four different tobacco flavors (i.e., preferred flavor/sweetened, preferred flavor/very low sweetened, unflavored/sweetened, unflavored/very low sweetened). Sessions will be preceded by 12 hours of tobacco/nicotine abstinence and separated by 48 hours, and waterpipe tobacco nicotine levels will be held constant across sessions. Researchers will collect measures of smoking behavior (puff topography), acute toxicant exposure (carbon monoxide boost and plasma nicotine), and self-report measures of abuse liability, intentions for continued use, and importance of flavors in using waterpipe. Findings will indicate whether flavorings influence users use behavior, intention to use, perceptions and subjective effects, and exposure to tobacco-related toxicants.

Theodore Lee Wagener Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03DA041928-01A1
Institution: University of Oklahoma Health Sciences Center
09/06/2016

Comparative Pharmacokinetics and in Vivo Genetic Toxicology of the Tobacco Specific Nitrosamine NNN in Rats

A study that compares the pharmacokinetic effects of N-nitrosonornicotine (NNN), a carcinogenic tobacco specific nitrosamine (TSNA), by different administration routes would be informative. The purpose of this study is to compare the pharmacokinetics of NNN via three routes of administration (inhalation, oral, and intravenous) in order to understand NNN’s in vivo genotoxic effects. Investigators will expose six groups of rats (15 per group) to different NNN concentrations (low, medium, and high doses) via nose only inhalation (one hour exposure), intravenous injection, or oral gavage. Blood and urine samples will be collected over 48 hours and analyzed for NNN and its metabolites (R,S)-nornicotine and N´-nitrosonornicotine-1-N-oxide. Investigators will evaluate pharmacokinetic parameters including observed maximum serum concentration (Cmax), the time at which Cmax is observed (Tmax), apparent volume of distribution and clearance, area under the curve (AUC: last and infinity), elimination rate constant and its corresponding half-life, renal clearance, urinary excretion, and relative bioavailability. At 24 or 48 hour time points, investigators will analyze tissues for genotoxic endpoints using the Comet assay, micronucleus assay, and DNA adduct formation. Study findings may inform the development of pharmacokinetic models for NNN.

Jacob Nofsinger, Mamata De and Arianne Motter Funding Mechanism: Research Contract
ID number: HHSF223201510031I
Institution: Battelle Memorial Institute
09/06/2016

Development of a Standard Guideline Protocol for Rodent Tobacco Smoke Inhalation Studies

This study will measure the dose of cigarette smoke that represents the maximum tolerated dose (MTD), dose limiting toxicity, NOAEL (no observable effect level), and LOAEL (lowest observable effect level), as well as smoke’s effects on clinical symptoms and tissue changes at these levels. Researchers will expose groups of 10 male and female rats for 14 days to increasing amounts of smoke from the leading brand of cigarette until the MTD is reached. Next, researchers will expose control, low, mid- and high-dose exposure groups of 10 male and female rats each to commercial cigarette smoke generated under the ISO or Canadian intense regimen for 13 weeks at the MTD, the NOAEL or LOAEL, and an intermediate dosage. Researchers will measure clinical, blood, chemistry, toxicological, and respiratory effects. This study will serve as a guideline study against which other previously-published studies can be compared in the future and will provide new data about tobacco smoke toxicity in rats.

Jacob McDonald and Lynn Crosby Funding Mechanism: Research Contract
ID number: HHSF223201510032I / HHSF22301002T
Institution: Lovelace Biomedical and Environmental Research Institute
09/05/2016

Informing Tobacco Regulatory Policy through Laboratory Assessment of Appeal and Demand for Flavored Tobacco Products among Young Adults

Young adults are particularly susceptible to the use of flavored tobacco products; additional research could help clarify the specific reasons underlying their appeal. The goal of this study is to develop new methods for quantifying flavored tobacco product appeal. Study aims are: (1) to validate indices of implicit (below conscious awareness) appeal across flavored and non-flavored products; (2) to examine differences in implicit appeal for flavored and non-flavored products in both susceptible (never) and current tobacco users, controlling for factors related to tobacco use (e.g., social influences, harm perceptions); and (3) to examine the impact of baseline implicit flavored product appeal on changes in flavored/non-flavored harm perceptions, intentions and curiosity to use, and tobacco use. Researchers will recruit 60 young adult current tobacco users and 60 susceptible never users (ages 18-24) and measure baseline implicit appeal for flavored and non-flavored tobacco products. Then, using monthly web-based assessments, researchers will evaluate the impact of appeal on changes in tobacco use behavior and attitudes over six months. Implicit appeal will be assessed via two laboratory tasks: (1) an Implicit Association Task that measures the speed with which participants accurately pair pictures of flavored versus non-flavored products with words related to “attractive” or “unattractive,” and (2) a behavioral economic purchase task designed to assess demand for flavored versus non-flavored products under escalating price conditions. The goal is to determine whether implicit flavored product appeal is higher than non-flavored product appeal, especially among susceptible never users, and whether flavored product appeal negatively influences tobacco use outcomes and attitudes.

Amy M. Cohn Funding Mechanism: National Institutes of Health – Grant
ID number: 1R03DA042010-01A1
Institution: Truth Initiative Foundation
09/01/2016

PATH Questionnaire Reliability and Validity Study

The Population Assessment of Tobacco and Health (PATH) Study is a national longitudinal study of tobacco use and health that is following approximately 46,000 U.S. household residents ages 12 and older. The goal of this study is to evaluate the reliability and validity of the PATH Study adult and youth Round Four assessment instruments. Researchers will interview 875 PATH Study respondents who represent a subsample of the PATH Study sample areas. Respondents will be interviewed twice, with the re-interview completed within 10-17 days after the initial interview. For a subset of the items where discrepancies are found, the questionnaire will include probes designed to shed light on the nature of the discrepancy. At the end of the re-interview, the interviewer will photograph the products used by the participant so that they can be compared to the brands self-reported in the questionnaire. To assess the validity of answers to key items on tobacco use, researchers will analyze saliva specimens for biomarkers of exposure. Researchers will conduct additional analyses to identify person-level variables associated with different levels of reliability, identify question characteristics that affect answer reliability, and examine different methods for estimating reliability. Study findings will be incorporated in new tools to predict the reliability of study questions in order to advance measurement practices in future studies.

Roger Tourangeau Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA040736-01A1
Institution: Westat
08/25/2016

Impact of Ontario Menthol Cigarette Ban

In May 2015, Ontario, Canada passed legislation banning menthol cigarettes as of January 2017. This legislation presents an opportunity to understand the impacts of a menthol ban on individual and industry behavior. To goal of this study supplement is to use large-scale survey and mixed quantitative/qualitative methods to evaluate the effects of Ontario’s menthol ban on smoker and industry behavior. Study aims are: (1) to understand user behavior changes subsequent to a menthol ban by quantifying changes in tobacco use among recent menthol smokers (defined as having smoked a menthol cigarette in the past year), and (2) to characterize industry behavior changes subsequent to the menthol ban by analyzing pack and advertising signs and symbols. The project involves three studies. The first involves telephone surveys of cigarette smokers; the surveys include questions about tobacco use behaviors, demographics, and knowledge of and support for a menthol cigarette ban in Ontario. A total of 1,041 smokers (ages 16 and older) completed a baseline survey before the menthol cigarette ban went into effect; 27% reported smoking a menthol cigarette in the past year. These menthol cigarette smokers will complete two additional follow-up surveys to track changes over time following the ban implementation. The second study involves visiting retail stores in Ontario to identify menthol cigarette availability and attempting to purchase menthol cigarettes before and after the menthol cigarette ban; packaging will be analyzed for content and the cigarettes themselves will be analyzed for the presence and amount of menthol. A final study involves an approach called concept mapping. In this study, 50-100 menthol smokers from the first study will identify specific behavior changes they have made and other ways the menthol cigarette ban has affected them. This project will be the first rigorous evaluation of a real-world ban on menthol flavored tobacco in a large market. Results will reveal how recent menthol smokers respond to the ban and how the tobacco industry adapts to it, and may inform regulatory activities related to menthol.

Thomas Eissenberg Funding Mechanism: National Institutes of Health – Grant
ID number: 3P50DA036105-04S1
Institution: Virginia Commonwealth University
08/23/2016

The Effects of Flavors on Nicotine PK/PD and Use Topography in E-Cigarette Users

Clinical studies investigating the effects of e-liquid flavors on nicotine exposure, pharmacokinetics (the body’s effects on the absorption, distribution, metabolism, and elimination of nicotine), pharmacodynamics (the effects of nicotine on the body), and use behaviors may increase knowledge regarding the health effects of e-cigarettes. The goal of this study is to investigate the effects of e-liquid flavors on topography (use behaviors) and nicotine pharmacokinetics and pharmacodynamics, and to begin to establish the effects of flavors on biomarkers of exposure in experienced e-cigarette users. Researchers will conduct a clinical study where experienced adult e-cigarette users will complete four sessions where they will use e-liquids of different flavors (e.g., tobacco, menthol, fruit) in nicotine and nicotine-free conditions. During these sessions, researchers will collect blood and urine samples, vital signs, topography, abuse liability measures, subjective effects, and other self-report measures. The study will yield information on the effects of e-liquid flavors on nicotine pharmacokinetics and pharmacodynamics, biomarkers of exposure, and topography, and may provide useful information on the impact of these tobacco products on public health.

Michael McGuire, Olga Rass, and Lingling Guan Funding Mechanism: Research Contract
ID number: HHSF223201310033I
Institution: Lovelace Scientific Resources, Inc.
08/22/2016

Dose Effects of Nicotine: Behavioral Economics of Cigarette Abuse Liability

Reduced nicotine cigarettes may result in decreased nicotine intake and dependence. However, the addictive effects and abuse liability of reduced-nicotine cigarettes are less well understood. The goal of this study is to determine the abuse liability of reduced-nicotine cigarettes compared to standard full-nicotine cigarettes. Study aims are: (1) to determine if six weeks of exposure to reduced nicotine cigarettes reduces demand for reduced nicotine cigarettes; (2) to determine if six weeks of exposure to reduced nicotine cigarettes reduces the abuse liability of full-nicotine cigarettes; (3) to determine the degree to which various levels of nicotine in fixed-price reduced-nicotine cigarettes may substitute for full-nicotine cigarettes when full-nicotine cigarette price increases, both before and after six weeks of exposure to reduced-nicotine cigarettes; (4) to determine the “addictiveness threshold” by examining the above aims with varying levels of reduced nicotine cigarettes across participants; and (5) to determine the relationship between behavioral economic assessments and traditional subject-rated abuse liability assessment (i.e., ratings of “liking”). The study will include 100 non-treatment seeking dependent adult smokers (50 men, 50 women) who will smoke either full nicotine cigarettes (15.8 mg nicotine/g tobacco) or reduced nicotine cigarettes (5.2, 2.4, or 1.3 mg/g) at home for six weeks. Researchers will assess abuse liability using two measures of demand — lower demand intensity and increased demand elasticity — as well as other demand measures and subjective ratings of “liking,” and will evaluate the degree to which reduced-nicotine cigarettes may substitute for full-nicotine cigarettes.

Matthew W. Johnson Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042527-01
Institution: Johns Hopkins University
08/22/2016

Vapor and Particulate Phase Smoke Components and Cardiovascular Dysfunction

The health risks of waterpipe (hookah) smoking include harmful cardiovascular and pulmonary effects. The goals of this study are: (1) to clarify the role of toxic constituents in waterpipe smoke in the development of cardiopulmonary diseases, and (2) to evaluate the role of inflammation and oxidative stress. After describing the chemical composition of waterpipe smoke, researchers will measure changes in respiration, electrocardiographic patterns, and cardiac function during and after acute and chronic waterpipe smoke exposure in mice that are genetically susceptible to atherosclerosis using implanted telemetry devices. Study aims are: (1) to use state-of-the-art analytical methods to identify potentially harmful constituents in waterpipe smoke; (2) to assess the redox and electrophilic properties of gas- and particle-phase components present in waterpipe smoke extracts using in vitro systems that explore various mechanisms of action; and (3) to assess the cardiopulmonary toxicity of waterpipe smoke in mice experiencing acute and chronic exposures in order to assess the impact of inflammation and oxidative stress on the lungs, brain, and cardiovascular system. This study will be among the first to evaluate the cardiopulmonary toxicity of waterpipe smoke by in vitro and in vivo assays.

Michael T. Kleinman Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01ES027232-01
Institution: University of California, Irvine
08/15/2016

Adolescent ENDS Use, Nicotine Metabolism and Toxicant Exposure

Use of electronic nicotine delivery systems (ENDS), such as e-cigarettes, is increasing among adolescents. The goal of this study is to investigate e-cigarette toxicant levels and the influence of nicotine metabolism rate on use behaviors and nicotine dependence in adolescents. Study aims are: (1) to investigate the level of toxicants including propylene oxide, acrolein, ethylene oxide, benzene, acrylamide, formaldehyde, and 1,3, butadiene found in adolescent ENDS-only users; and (2) to examine the association between nicotine metabolism rate (measured by the salivary 3’hydroxycotinine/cotinine ratio) and the frequency of ENDS use and reported dependence in adolescent ENDS-only users. Researchers will enroll 180 adolescent ENDS-only users (aged 13-17 years) and a control group of 20 similarly-aged non-smokers/non-ENDS users. Researchers will analyze urine to determine toxicant levels and saliva to determine the nicotine metabolism rate. ENDS behavior questionnaires and nicotine dependence scales will be administered.

Mark Rubinstein Funding Mechanism: National Institutes of Health – Grant
ID number: 1R21DA040718-01
Institution: University of California, San Francisco
08/15/2016

Assessing Toxicity of Waterpipe Tobacco Smoking in Laboratory and Naturalistic Settings

Waterpipe users are exposed to toxicants classified by FDA as harmful and potentially harmful constituents (HPHCs). As part of this study, researchers will conduct two projects. Project 1 is a machine-smoking study designed to determine the effects of different use behaviors (topography) on the toxicity of waterpipe tobacco smoke inhaled by users. Researchers will use a machine to “smoke” a popular U.S. manufactured waterpipe tobacco (Starbuzz) using two variables — quick-light charcoal vs. charcoal-free electrically heated waterpipe head, and room temperature water vs. adding ice cubes in the waterpipe jar – to create four waterpipe configurations. They will then quantify and compare levels of mainstream carbon monoxide (CO), nicotine, select volatile and semi-volatile organic compounds including furan. Project 2 is a real-world study of the effects of these smoking practices on biomarkers of toxicants and carcinogens. Researchers will recruit a sample of 50 adult male and female exclusive waterpipe smokers and a control sample of 25 adult male and female non-smokers. Waterpipe smokers will smoke one waterpipe tobacco head (10g) of Starbuzz during three separate sessions: Session 1: smoking waterpipe tobacco using quick-light charcoal and room temperature water in the waterpipe jar; Session 2: smoking waterpipe tobacco using quick-light charcoal and adding ice cubes to the water in the waterpipe jar; and Session 3: smoking waterpipe tobacco without charcoal using a charcoal-free electrically-heated waterpipe head and room temperature water in the waterpipe jar. Researchers will collect the following data from participants: (1) tobacco use history; (2) a four-week tobacco exposure diary; (3) a waterpipe use session form; (4) CO exposure (measured using a Micro+ Smokerlyzer® CO monitor) and (5) six first-morning urine samples, in order to measure nicotine metabolites and other biomarkers of tobacco exposure.

Nada O. Kassem Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042471-01
Institution: San Diego State University Research Foundation
08/15/2016

Nicotine Reinforcement and Aversion in Young Adult Light Smokers

The critical threshold for nicotine reinforcement that underlies the addictive effects of nicotine has yet to be empirically validated by controlled human studies. The goal of this study is to use a novel intravenous (IV) nicotine self-administration model to estimate threshold reinforcing doses of nicotine and to generate dose-effect curves for low doses of nicotine in smokers. Study aims are: (1) to assess the threshold reinforcing dose and dose-effect curve for IV nicotine self-administration at low doses in young adult light and intermittent smokers (“chippers”); and (2) to assess the threshold and dose-effect curve for the positive and negative/aversive subjective effects of IV nicotine at low doses and its relationship to nicotine reinforcement. Researchers will enroll 72 young adult (ages 18-30) male and female light and intermittent smokers who show few or no signs of addiction. Smokers will participate in five experimental sessions. In each session, they will first be exposed to the assigned nicotine dose and the placebo (saline) dose followed by the opportunity to choose between nicotine and placebo administrations.

Mehmet Sofuoglu Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042528-01
Institution: Yale University
08/15/2016

Targeted Tobacco Regulatory Science: Nicotine Dose Effects in Animal Models of Smoking Initiation in Vulnerable Adolescent Subpopulations

Adolescents with depression and/or Attention Deficit Hyperactivity Disorder (ADHD) have a higher incidence of smoking, start smoking at a younger age, exhibit a faster progression to daily smoking and dependence, and are less successful at quitting than adolescents without depression and/or ADHD. The goal of this study is to determine whether depression and ADHD predispose adolescents to nicotine addiction by lowering their nicotine reinforcement threshold. Experiments involving smoking initiation in adolescents cannot be accomplished in human studies, but can be addressed with animal models. Study aims are to test the hypothesis that the nicotine reinforcement threshold is lower in adolescent rat models of depression (Aim 1) and ADHD (Aim 2) compared to control animals. Researchers will determine the threshold-reinforcing nicotine dose for acquisition of nicotine self-administration, and will assess self-administration persistence during increases in the “price” of nicotine (i.e., difficulty reducing intake), nicotine pharmacokinetics (how quickly the body eliminates nicotine), and sex differences. These data will provide insight into the relative risk of nicotine reinforcement in adolescents, and how the reinforcement threshold is modified by depression and ADHD.

Mark LeSage Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042525-01
Institution: Minneapolis Medical Research Foundation, Inc.
08/15/2016

Understanding Tobacco Flavor Effects on Waterpipe Smokers’ Experiences and Exposures

Waterpipe tobacco smoking is increasing rapidly in the U.S., particularly among youth and young adults. Evidence suggests that waterpipe smoking can lead to addiction, cigarette smoking, and known smoking-related diseases including cancer, cardiovascular disease and adverse pregnancy outcomes. The goal of this study is to evaluate the impact of flavorings on nicotine delivery, toxicant exposure, dependence, and smoking behavior. This will be evaluated in a clinical laboratory study including beginning as well as established waterpipe smokers. The study will compare how smoking unflavored waterpipe tobacco compares to preferred flavored brand in terms of smokers’ exposure to nicotine, puffing behaviors, subjective measures of satisfaction, and suppression of withdrawal and craving. Researchers will recruit two groups of waterpipe smokers aged 18-30) based on their use frequency: 72 low frequency smokers (beginners) and 72 high frequency (experienced) smokers. All subjects will participate in two waterpipe smoking sessions that differ by flavor (preferred flavor; unflavored). Study aims are: (1) to examine the influence of flavor manipulation on subjective/dependence responses among beginning and experienced waterpipe smokers: (2) to examine the influence of flavor manipulation on nicotine delivery among beginning and experienced waterpipe smokers; and (3) to examine the effect of flavor on smoking behavior (puff topography) and toxicant exposure among beginning and experienced waterpipe smokers.

Wasim Maziak Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042477-01
Institution: Florida International University
08/15/2016

Reactions to Reduced Nicotine Cigarettes in Young Adult Low-Frequency Smokers

Evidence suggests that reducing nicotine content in cigarettes reduces smoking behavior and toxicant exposure among dependent adult daily smokers, but more research is needed regarding the effects of nicotine reduction on experimentation with cigarettes among adolescents and young adults at risk for progression to regular use and dependence. The goal of this study is to evaluate reactions to, and choices to self-administer, cigarette smoke with varying nicotine content among 90 low-frequency (i.e., smoke less than 15 days per month), non-dependent adolescent/young adult smokers (ages 18-25 years). Study aims are: (1) to evaluate the effects of nicotine content on subjective reactions to fixed doses of cigarette smoke at three nicotine content levels in adolescent/young adult, low-frequency smokers; (2) to evaluate choice of study cigarette to self-administer following sampling the three nicotine content cigarettes; and (3) to evaluate moderators of reactions to, and choices for, cigarette smoke with varying nicotine content. Participants will undergo three sessions in which their reactions to fixed doses of smoke from investigational cigarettes with three different nicotine contents (15.8, 2.5, and 0.4 mg/gram of tobacco) will be measured. Following the third fixed-dose session, participants will return to the lab to choose one of the cigarettes to self-administer. This will provide an evaluation of the amount of nicotine in cigarette smoke that produces reactions and choices associated with progression from initial smoking to nicotine dependence.

Francis J. McClernon Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042532-01
Institution: Duke University
08/15/2016

Topography, Constituents, and Toxicity of Waterpipe Tobacco Smoke Under Realistic Conditions

The goal of this study is to measure waterpipe smoke emissions and levels of inhaled constituents associated with different smoking topographies (use behaviors) and assess effects on pulmonary toxicity. Study aims are: (1) to compare waterpipe smoking topography and toxicity based on real-life use; (2) to identify harmful and potentially harmful constituents (HPHCs) inhaled by users under realistic use conditions based on waterpipe smoking topography; and (3) to determine the impact of waterpipe smoke on pulmonary and gene toxicity. Researchers will measure waterpipe and conventional cigarette smoking topographies (including frequency and exposure duration) in 25 waterpipe smokers, 25 cigarette smokers, and 25 dual users aged 21-65 who will use a wireless personal use monitor for three weeks; these participants and 25 nonsmokers will provide urine and blood samples to allow researchers to compare changes in biological indicators of oxidative stress and inflammatory responses. Next, waterpipe smoke emissions will be machine-generated using the subjects’ puffing topographies, and researchers will measure the chemical constituents in inhaled emissions. Finally, investigators will compare the effect of waterpipe tobacco and cigarette smoke exposures on pulmonary toxic responses (e.g., oxidative stress, inflammatory markers including lipid mediators and C-reactive protein) and gene toxicity (DNA damage/repair) in mice. Findings may inform regulatory activities related to waterpipe use.

Irfan Rahman and Risa Robinson Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042470-01
Institution: University of Rochester
08/15/2016

Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use

Information regarding the impact of reducing the nicotine content of cigarettes on tobacco product use behavior would be helpful in understanding the potential consequences of possible nicotine regulation. Researchers will randomize 320 smokers (both heavy, long-time smokers and lighter, younger smokers) to switch from their usual brands of cigarettes to research cigarettes with similar tar yields but five different nicotine contents. All participants will have access to concurrent use of e-cigarettes during the 12-week exposure period. Study aims are: (1) to assess the effects of cigarette nicotine content on abuse liability among smokers who also use e-cigarettes; (2) to measure nicotine discrimination thresholds and how they are affected by exposure to reduced nicotine content cigarettes; and (3) to determine the relationship between abuse liability of low nicotine cigarettes and extent of e-cigarette use. Researchers will assess the effects of cigarette nicotine content on measures of abuse liability including daily cigarette consumption, smoking reward and measures of dependence such as nicotine withdrawal symptoms. In laboratory sessions, researchers will measure nicotine thresholds for detecting and recognizing the rewarding effects of smoking.

Jed Rose Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042541-01
Institution: Rose Research Center, LLC
08/15/2016

Impact of Flavors and Design Features on Patterns of Waterpipe Use and Toxicity in Pregnant Mothers

Studies have reported an association between waterpipe tobacco use during pregnancy and increased risks of infertility, obstetrical complications, low birth weight, and respiratory problems. Sweetened flavored waterpipe tobacco and novel design features have contributed to the growth in waterpipe use. However, data are lacking regarding rates and patterns of waterpipe tobacco use, the impact of flavors and design features on use patterns, and biomarkers of nicotine and toxicant exposure in pregnant women in the U.S. The goal of this prospective longitudinal study is to investigate the impact of flavors and design features on use patterns, dependence, and biomarkers of toxicant exposure in 100 pregnant current waterpipe users. Study participants will complete detailed interviews regarding (a) use, perceptions, and preferences for waterpipe flavors and design features, and (b) patterns of waterpipe and dual/poly waterpipe tobacco use and dependence at three assessment points (first and third trimesters, and three months postpartum). Design features will be investigated through personal photographs of waterpipes and waterpipe tobacco use (e.g., owned waterpipes, waterpipe smoking in bar settings) throughout pregnancy and postpartum. Urine, breath, and saliva samples will be collected to assess maternal/fetal exposure to nicotine, carbon monoxide, and state-of-the-art markers of volatile organic compounds. Participants will be provided with information about the health risks of waterpipe and other tobacco use following assessments.

Laura Stroud and Lori Scott-Sheldon Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042484-01
Institution: Miriam Hospital
08/15/2016

Abuse Liability of Reduced Nicotine Content Cigarettes within a Complex Tobacco Marketplace

Research regarding how reduced nicotine cigarettes are valued by smokers may provide information about their abuse liability. The goal of this study is to use behavioral economic methods to examine consumption of reduced-nicotine cigarettes within the context of the larger tobacco marketplace. Study aims are: (1) to examine the effect of nicotine concentration in tobacco and resulting plasma nicotine on laboratory behavioral economic measures of demand intensity and elasticity, and (2) to assess behavioral economic measures of demand intensity and elasticity of cigarettes and substitution by dose in the Experimental Tobacco Marketplace under four conditions that mimic two different potential regulatory environments and two control conditions. To achieve Aim 1, researchers will ask daily cigarette smokers to consume, on separate sessions, controlled puffs of a cigarette containing a blinded concentration of nicotine and then complete a cigarette purchase task while plasma nicotine is measured. To achieve Aim 2, researchers will use the Experimental Tobacco Marketplace, a method that allows experimental price manipulation while simulating real-world markets featuring different tobacco products; two different regulatory environments will be studied. Experiments will determine how valued reduced-nicotine cigarettes are, whether reduced-nicotine cigarettes are preferred and substitute for conventional cigarettes in a complex tobacco marketplace, and whether the introduction of reduced-nicotine cigarettes into the marketplace influences the consumption of other combustible and non-combustible nicotine products.

Warren K. Bickel and Mikhail N. Koffarnus Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042535-01
Institution: Virginia Polytechnic Institute and State University
08/15/2016

Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes among Daily and Non-Daily Smokers on Abuse Liability

It is unknown whether the potential of very low nicotine content cigarettes (VLNCCs) to reduce abuse liability might be offset by the concurrent use of e-cigarettes. The goal of this study is to model abuse liability in a market in which VLNCCs and e-cigarettes (an alternate source of nicotine) are both available. Study aims are: (1) to characterize the effects of dual use of VLNCC and e-cigarettes on abuse liability, nicotine compensation, and product use, liking, and relative reinforcing efficacy among 80 adult daily smokers; (2) to characterize the effects of dual use of VLNCC and e-cigarettes on abuse liability, nicotine compensation, and product use, liking, and relative reinforcing efficacy among 80 adult intermittent smokers; and (3) to characterize the effects of dual product use on abuse liability as measured by retrospective measures, smartphone daily diary, and real-time measures captured via smartphone ecological momentary assessment. Participants will smoke their usual brand during week 1 and will exclusively smoke VLNCCs during weeks 2-4. During weeks 5-7 and weeks 8-10, participants will be instructed to freely use any combination of VLNCCs and e-cigarettes with either high or low nicotine content (36 mg/ml or 8 mg/ml; three weeks each). The study will obtain information about the effects of dual use of VLNCCs and e-cigarettes with differing levels of nicotine on nicotine abuse liability, as measured by nicotine compensation, product use and liking, relative reinforcing efficacy, and assessments of withdrawal, craving, affect and satisfaction. Study findings may provide additional information on the impact of reducing combustible cigarette nicotine to a non-reinforcing level in a dual product use environment.

Paul M. Cinciripini Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042526-01
Institution: University of Texas MD Anderson Cancer Center
08/10/2016

Effect of Waterpipe Tobacco Ingredients on Human Puffing, Exposures and Appeal

Increases in waterpipe use may be due, in part, to the availability of sweet, fruit- and candy-flavored tobaccos that make inhaling tobacco smoke more appealing. Flavorings and high levels of sweet humectants produce harmful and potentially harmful constituents in the smoke, and are thought to contribute to the direct and indirect harm experienced by users. To define the effects of specific chemical content with respect to sweet perception and likability among users, researchers must use waterpipe tobacco that differs only in the variables of interest; however, there is no set of commercially-available tobacco brands for which this is true. In this study, researchers will manipulate commercial products to systematically investigate the effects of sweet humectant concentration and flavorings on the appeal, puffing behavior, and toxicity of waterpipe tobacco smoking. Study aims are: (1) to characterize the content of four waterpipe tobaccos (one brand prepared four different ways to vary flavoring, humectant, and sweetness levels); (2) to characterize the mainstream smoke generated from the four waterpipe tobaccos; (3) to determine how waterpipe tobacco content impacts puffing behaviors, perceived sweetness and appeal of waterpipe smoking; and (4) to determine HPHC and particle exposure ranges from the average puffing behaviors measured under Aim 3 for each tobacco preparation. Researchers will conduct mainstream smoke analyses and then conduct four laboratory smoking sessions with 40-48 adult waterpipe smokers (ages 18 and older) to collect data related to puffing topography and perceptions.

Marielle Brinkman Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01CA209961-01
Institution: Battelle Centers Public Health Research and Evaluation
08/09/2016

Harmful Constituents and Respiratory Effects of Waterpipe Smoke

The social culture of waterpipe use, the perception that waterpipe smoking is less harmful than cigarettes, and wide availability of flavored tobacco products influences waterpipe popularity among younger adults. The goal of this study is test whether different waterpipe products and puffing regimens generate unique profiles of harmful and potentially harmful constituents (HPHCs) that will yield a continuum of toxic health effects in in vivo and in vitro models. Study aims are: (1) to define the constituents of mainstream and secondhand waterpipe smoke using different puffing regimens and several different popular shisha products/flavors; (2) to conduct comparative in vitro and in vivo exposures to different waterpipe products and assess multiple effect endpoints of toxicity in lungs and in vitro airway epithelia; and (3) to identify biomarkers of exposure from studies in Aim 2 and examine human urine samples from individuals with recent mainstream/secondhand exposure to waterpipe smoke. Researchers will then use bioinformatics approaches to integrate human in vivo and in vitro data from the three study aims to develop an overall hazard index.

Shyam Biswal Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01HL134149-01
Institution: Johns Hopkins University
08/09/2016

Impact of Waterpipe Configuration on the Size Distribution and Number Density of Smoke Particles and Targeted Chemical Analysis of Particle Profiles that Diminish Alveolar Cell Health

Both new and long-time waterpipe smokers have misconceptions regarding the filtration ability of the waterpipe’s bowl liquid and the toxicity of components drawn into the lungs. However, waterpipe tobacco smoke includes many of the same harmful components found in cigarette smoke, and is even more complex because it includes charcoal heat source combustion products and pyrolysis products from the waterpipe tobacco’s humectants and flavorants. Air quality research can provide important data about waterpipe smoke hazards. The goal of this study is to examine the physical and toxicological characteristics of waterpipe smoke particles that affect air quality. Because particulate formation is affected by waterpipe configuration, researchers will analyze the physical properties of particles generated when pipe height, heat source (charcoal vs. non-charcoal), tobacco, and hose length/material are varied (Study Aim 1). Researchers will also determine the relative cell toxicity of waterpipe tobacco smoke generated by different waterpipe configurations and smoking regimes (Study Aim 2). These investigations will use whole smoke (not re-suspended condensate or vapor) and lung cells grown and exposed to smoke at the air-liquid interface.

Cindy Hauser Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01HL134169-01
Institution: Davidson College
08/09/2016

Tobacco Use Outcome Equalities and Tobacco Marketing Features

Certain tobacco marketing features (e.g., colors, descriptors, branding, marketing claims) may appeal to specific ethnic groups and thus may result in tobacco use outcome inequalities. The aims of this study supplement are: (1) to describe key features of tobacco marketing that could contribute to these inequalities, and (2) to identify the features associated with liking and recall of advertisements. Researchers will content code tobacco marketing images and show those images to an ethnically diverse sample of 2,000 youths (12-17 years old) and 2,000 young adults (18-24 years old) who will be recruited using Facebook and Instagram. To achieve Aim 1, tobacco ads from 2016 will be content coded for key marketing tactics. To achieve Aim 2, participants will take an online survey in which they will be shown a random sample of 20 ads and asked whether they recalled seeing the ad in the past 12 months and whether they liked the ad. Researchers will use these data to calculate “recalled” and “liked” ratings for each ad, and will compare features to the ad features coded in the content analysis. Ultimately, the marketing features identified through this project will be integrated into future experimental studies to assess how they affect consumers’ cognitive and affective responses. This work will allow the key features of the ads most recalled and most liked by different ethnic groups to be identified.

Meghan B. Moran Funding Mechanism: National Institutes of Health – Grant
ID number: 3K01DA037903-03S1
Institution: Johns Hopkins University
08/09/2016

Biomarkers for Dependence and Menthol in ENDS

Chronic exposure to menthol changes the level of nicotinic acetylcholine receptors (nAChRs) in the brain, which may help to explain the observation that menthol smokers find it harder to quit. This study supplements a parent grant that established a biomarker for nicotine dependence in mice and then used that biomarker to study the impact of menthol on nAChRs. This supplemental study will develop and use a set of three live-cell assays suitable for assessing tobacco product additives such as menthol and electronic nicotine delivery system (ENDS) liquid flavorings. Supplemental study aims are: (1) to select human neuroblastoma cell lines expressing human nicotine-sensitive nAChRs; (2) to develop and standardize three assays for assessing the effects of menthol on nAChRs; and (3) to use the assays to assess whether chronic exposure to menthol isomers added to tobacco cigarettes and ENDS has specific effects on the brain.

Henry A. Lester Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01DA036061-03S1
Institution: California Institute of Technology
08/04/2016

The Effects of Modest Changes in Cigarette Menthol Content on Nicotine Pharmacology and Smoking Topography

Recent research on cigarettes and other tobacco products indicates that flavors, including menthol, may play an important role in user liking and sensation, and may directly or indirectly influence the pharmacology of nicotine and its associated abuse liability. In this study, researchers will investigate the impact of smoking cigarettes with four menthol concentrations on nicotine exposure, pharmacokinetics (the movement of nicotine in the body), metabolism, pharmacodynamics (the effects of nicotine on the body), and topography (use behavior). Forty-eight experienced adult (aged 18-65) menthol smokers will complete a screening visit and four clinical laboratory sessions where they will smoke one of four products: either a non-mentholated research 0.8 mg nicotine yield cigarette or the same research cigarettes that have been modified to achieve concentrations of low, medium, and high menthol levels (3, 6, and 12 mg, respectively) that bracket the menthol content of most commercially-available cigarettes. All laboratory sessions will include prescribed use and ad libitum use sessions. Researchers will measure the impact of menthol on smoking topography, nicotine pharmacokinetics, pharmacodynamics, and subjective assessments of abuse liability, risk perceptions, and product characteristics (e.g., strength, harshness). The study will provide a comprehensive assessment of menthol level on the acute effects of cigarette smoking, including effects on exposure, behavior and subjective effects.

Wallace Pickworth, Kia Jackson, and Megan Schroeder Funding Mechanism: Research Contract
ID number: HHSF223201310030I
Institution: Battelle Memorial Institute
08/02/2016

ITO Chemical Analysis of Mainstream Smoke from Little Cigars, Cigarillos and Large Cigars to Determine Quantities of Carbonyls

Carbonyls (including acetaldehyde, acrolein, 2-butanone, crotonaldehyde, and formaldehyde) are strong, toxic irritants of the skin, eyes and nasal passage. Human exposure to these chemical constituents is introduced through tobacco smoke. The goal of this project is to conduct chemical analyses on little cigars, cigarillos, and large cigars to determine mainstream smoke quantities of acrolein (the main contributor to non-cancer respiratory effects from cigarette smoke) and other carbonyls (all of which have shown to cause cancer). Investigators will measure carbonyl quantities in a variety of little cigar (10), cigarillo (10) and large cigar (5) tobacco products currently marketed in the United States, under ISO and Canadian intense smoking regimens and using CORESTA recommended methods for carbonyl analysis.

Andrew Mooney and Todd Cecil Funding Mechanism: Research Contract
ID number: HHSF223201310037I7T
Institution: Labstat International
07/29/2016

Quantitative Study of Tobacco Facts Designed to Inform Youth Tobacco Prevention

The goal of this study is to assess the impact of different tobacco-related facts that may be used to inform messaging strategies used in FDA’s youth tobacco prevention campaigns. The study will include pre-test cognitive interviews followed by an online survey that will solicit opinions on a set of facts about a variety of tobacco products, including cigarettes, cigars, e-cigarettes, hookah (waterpipe), and smokeless tobacco; the online survey will ask respondents to rate approximately 10 randomly-selected tobacco-related facts and then answer questions about their knowledge, attitudes and beliefs about these facts. Pretest interviews will be conducted with 22 youth ages 13-17 in order to: (1) assess technical aspects and functionality of the survey instrument, and (2) identify areas of the survey that may be unclear or difficult to understand. Participants will complete the survey and will then be interviewed individually or with one or two other participants about the survey. The survey will be refined based on feedback, and then will be administered to approximately 1500 youth ages 13-17. The results of the survey will be used to inform messaging for future tobacco prevention campaigns.

Annice Kim and Tesfa Alexander Funding Mechanism: Research Contract
ID number: HHSF223201510002B
Institution: RTI International
07/25/2016

Assessment of Tobacco Product Pharmacology and Behavior using Nonclinical Models

Nicotine is as the primary constituent in tobacco that promotes addiction; however, studies indicate that minor tobacco alkaloids contribute to the reinforcing effects of nicotine. Researchers will conduct behavioral studies in adult rats to compare the addictive potential of whole tobacco extracts from various tobacco products. A smoking machine will generate whole tobacco smoke or aerosol condensate from up to 15 commercially-available U.S. brands of each of the following four tobacco products (including flavored products): cigarettes, little cigars, e-cigarettes, and waterpipe tobacco. Researchers will analyze amounts of nicotine and minor tobacco alkaloids (nornicotine, acetaldehyde, anabasine, anatabine, myosmine, cotinine, harmane, and norharmane) in the different tobacco products. After analysis, researchers will select a representative brand for each tobacco product and generate an aqueous solution for use in rodent self-administration studies. Adult male rats (4 groups with 10 rats per group) will be trained in a self-administration model designed to compare the reinforcing effects of nicotine alone (in a control solution that contains none of the minor tobacco alkaloids) and the aqueous smoke or aerosol solutions generated from each of the four products. Study results will provide information on the levels and associated abuse liability of non-nicotine tobacco constituents in several brands of different tobacco products.

Jenny Wiley, Kia Jackson, and Steven Meredith Funding Mechanism: Research Contract
ID number: HHSF223201310034I
Institution: RTI International
07/08/2016

Chemistry and Design of Cigars and Related Products

Cigars are combusted tobacco products with filler, binder and wrapper all made from tobacco. Compared to cigarettes, less information exists on the chemistry of cigar filler and smoke. Cigars differ from cigarettes in tobacco type, tobacco processing and curing, product design, and manufacturing, all of which may cause them to have different chemical properties than cigarettes. The goal of this research project is to survey the chemical and physical characteristics of cigars of different types and compare them with cigarettes. Laboratory analyses will include the measurement of specific harmful and potentially harmful constituents (HPHCs) and other tobacco-related compounds in cigar tobacco filler, cigar smoke, cigarette tobacco filler, and cigarette smoke, using quantitative analytical methods and appropriate smoking regimens. Findings will help inform how cigars may be distinguished from cigarettes and whether they present different public health impact concerns.

Clifford Watson and Kenneth Taylor Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention (CDC)
07/08/2016

Tobacco: Relationship between Reduced Nicotine Content and Reinforcement in Rats

Despite increasing awareness about the adverse health effects of smoking, adolescents continue to experiment with cigarettes and about two-thirds of them transition from occasional to daily smoking. The goal of this study is to determine whether positive and negative reinforcing properties of low-nicotine cigarettes are diminished compared to those of high-nicotine cigarettes in a rat model; the positive reinforcing effects of nicotine are critical for the initiation of smoking and the negative reinforcing effects of withdrawal prevent people from maintaining abstinence. Study aims are: (1) to determine if the nicotine content of tobacco affects the rewarding properties of smoke in adolescent rats; (2) to determine if exposure to tobacco smoke with various nicotine levels during early-mid adolescence affects the acquisition of nicotine intake and the motivation to self-administer nicotine during late adolescence; and (3) to determine if tobacco nicotine content affects the development of nicotine dependence during adolescence and early adulthood in rats. Study findings may inform regulatory activities related to reducing the nicotine content in tobacco as a measure to prevent the transition to daily smoking and nicotine addiction.

Adriaan W. Bruijnzeel Funding Mechanism: National Institutes of Health – Grant
ID number: 1R01DA042530-01
Institution: University of Florida
05/09/2016

Ventilation and Pulmonary Endothelium Toxicities (VaPE-Tox) of E-cigarettes: A Randomized Crossover Pilot Study

E-cigarette vapor contains toxicants that may damage lungs and airways, eventually causing chronic lung disease. Magnetic resonance imaging (MRI) measures may be used to detect and characterize the possible acute lung toxicities of e-cigarettes. Two promising approaches — hyperpolarized helium (3He)-enhanced MRI and an innovative measure of pulmonary microvascular blood flow on gadolinium (Gd)-enhanced MRI developed by the researchers — have never been used to assess e-cigarette lung toxicities. The goal of this 11-day pilot study is to test the acute effects of e-cigarette exposure on the lungs and airways using these MRI approaches in 10 healthy, young adult (ages 21-35) e-cigarette users. After a three-day pre-study period during which participants will abstain from e-cigarette use, participants will be randomized to use a standardized refillable e-cigarette with nicotine on either days 2 and 3 or days 6 and 7 of the study period; participants will then undergo both 3He-enhanced and Gd-enhanced MRI to determine the effects of e-cigarette use on the airways and blood vessels in the lungs. Study findings may provide new information regarding the effects of e-cigarettes on the lungs.

Elizabeth Oelsner Funding Mechanism: National Institutes of Health-Grant
ID number: 1R03HL132590-01
Institution: Columbia University Health Sciences
04/06/2016

Systematic Review of Perceived Message Effectiveness Measures for Anti-Tobacco Communication

The development and evaluation of tobacco education campaign messages are often based on participants’ perceived message effectiveness (PME). However, PME conceptualization and measurement vary greatly across research studies. The goal of this study is to conduct a systematic literature review and meta-analysis of PME measures for tobacco control. Study aims are: (1) to conduct a systematic literature review to identify the conceptual and methodological characteristics of PME measures used in studies of video and print advertisements, and (2) to identify investigators’ purpose in using PME and synthesize the outcomes and predictive findings from PME studies. To achieve Aim 1, investigators will search research databases, unpublished literature, and references in review and primary articles; code all relevant articles on participant and study characteristics as well as PME conceptualization and measurement; and summarize various aspects of PME measures. To achieve Aim 2, investigators will code investigators’ purpose in using PME; summarize study findings; identify studies that use PME as a predictor of advertisement effectiveness; and conduct a meta-analysis of the association between PME and advertisement effectiveness (e.g., tobacco quit intentions). Research findings will help optimize and enhance PME measures for future research so that optimal tobacco education messages can be developed.

Seth Michael Noar Funding Mechanism: National Institutes of Health-Grant
ID number: 1R03DA041869-01
Institution: University of North Carolina at Chapel Hill
04/01/2016

Psychometric Validation of an E-Cigarette Purchase Task in Users of Advanced Generation

The use of e-cigarettes, particularly advanced-generation refillable e-cigarettes, is rapidly growing. However, little is understood about the strength of users’ motivation to continue using e-cigarettes, known as reinforcing efficacy. One tool for assessing reinforcing efficacy is a behavioral economic purchase task, in which participants estimate their daily consumption of a product at escalating prices; if demand for the product remands strong even as prices rise, then the product’s reinforcing efficacy is strong. To date, a purchase task specifically designed for e-cigarettes has not been validated. In preliminary work, the investigator developed two versions of an e-cigarette purchase task (E-CPT) in which daily consumption was measured either in puffs or in mLs of nicotine liquid. The goal of this study is examine the validity of both versions of the E-CPT to determine which one is a better measure of use behavior and reinforcing efficacy. Study aims are: (1) to validate indices of demand derived from an E-CPT against laboratory measures of e-cigarette use behavior and dependence in refillable e-cigarette users, and (2) to determine which daily unit of consumption (puffs or mLs of nicotine liquid) more accurately reflects actual use behavior. In this study, 120 refillable e-cigarette users (ages 18-60) will complete both versions of the E-CPT as well as other self-report measures of e-cigarette use and dependence. Then, participants will be videotaped using their own refillable e-cigarette for one hour. Measures of demand derived from the E-CPT will be compared with puffs taken, inter-puff interval, and other measures of use and dependence in order to determine which version of the E-CPT better characterizes the actual use of these products. Additional analyses using the validated version of the E-CPT will examine whether demand indices predict current cigarette use, traditional cigarette quit status, and other variables. This project will result in a validated measure of the reinforcing efficacy of refillable e-cigarettes that can be used to describe user behavior and provide insight into how behavior might change as a function of e-cigarette price changes.

Rachel Cassidy Funding Mechanism: National Institutes of Health-Grant
ID number: 1R03DA041820-01
Institution: Brown University
03/24/2016

Vape Tricks on Social Media: Implications for Electronic Cigarette Regulation for Youth

Many adolescents are exposed to nicotine and other potentially harmful constituents through the use of e-cigarettes. Identifying appealing e-cigarette components and marketing strategies can inform strategies to reduce youth e-cigarette use. In previous research, investigators determined that adolescent e-cigarette users found the ability to perform “smoke tricks” using e-cigarettes to be highly appealing. However, no information is available about how vaping images in advertisements entice youth and how social media communications teach youth how to modify e-cigarettes to produce “smoke tricks.” The goals of this project are to analyze social media sites popular among youth to obtain user and industry perspectives on e-cigarette characteristics and use patterns related to “smoke tricks,” as well as to identify marketing strategies that use vapor-related themes to increase the appeal of e-cigarettes to youth. Study aims are: (1) to analyze the content of YouTube videos on how e-cigarettes are manipulated and used to emit visible aerosol to produce “smoke tricks,” and (2) to assess the appeal of vaping images on the Facebook marketing pages of e-cigarette companies. Study findings may inform strategies such as product standards, advertising standards, and social media communication strategies that could reduce the appeal of e-cigarettes to youth.

Grace Kong Funding Mechanism: National Institutes of Health-Grant
ID number: 1R03DA041853-01
Institution: Yale University
03/23/2016

Innovative Statistical Methods for Detecting and Accounting for Non-Compliance in Randomized Trials of Very Low Nicotine Content Cigarettes

Recent clinical trials on very low nicotine content (VLNC) cigarettes have examined whether reducing the nicotine content of cigarettes changes product use behavior (e.g., reducing cigarette consumption) by making cigarettes less reinforcing. However, these studies reported substantial non-compliance (i.e., smoking cigarettes other than those provided by the study). This is problematic because measures of product use behavior for these subjects are likely to be different than if they had only smoked the VLNC cigarettes assigned by the study. The goal of this project is to develop statistical methods for identifying and accounting for non-compliance in randomized trials of VLNC cigarettes and apply them to data collected by the Center for the Evaluation of Nicotine in Cigarettes (CENIC). Study aims are: (1) to develop statistical methods for estimating the probability that a subject was compliant based on his/her levels of nicotine exposure biomarkers, and (2) to develop a statistical framework for estimating the causal effect of VLNC use when noncompliance is not measured precisely. The development of these methods will result in estimates of the effects of VLNC cigarettes while accounting for the error associated with using biomarkers to identify non-compliance.

Joseph Koopmeiners and David Vock Funding Mechanism: National Institutes of Health-Grant
ID number: 1R03DA041870-01
Institution: University of Minnesota
03/11/2016

Animal Models for Evaluating the Relative Abuse Liability of Electronic Cigarettes

The goal of this study is to develop a methodology for testing the relative abuse liability of electronic cigarettes (e-cigarettes) in adolescents and to determine whether non-nicotine constituents contribute to e-cigarette abuse liability in this population. Current animal models of tobacco abuse that only examine nicotine may not be sufficient because compounds other than nicotine may contribute to tobacco abuse and the interaction or sum of all compounds in a tobacco product may determine its actual abuse liability. Therefore, new animal models involving exposure to a mixture of nicotine and other constituents derived directly from e-cigarettes would be useful to more accurately assess e-cigarette abuse liability. The goal of this project is to compare the abuse-related effects of nicotine alone versus e-cigarette aerosol extracts (which include non-nicotine constituents such as minor alkaloids) in adolescent rats. Study aims are: (1) to compare the reinforcing effects of nicotine alone and extracts as measured by intravenous self-administration, and (2) to compare formulations in terms of their aversive effects as measured by conditioned taste aversion. The methodology established in these studies will more comprehensively assess e-cigarette abuse liability and may inform future human research studies as well as regulatory activities related to nicotine or other constituents in e-cigarettes.

Andrew Charles Harris Funding Mechanism: National Institutes of Health-Grant
ID number: 1R03DA042009-01
Institution: Minneapolis Medical Research Foundation
03/02/2016

Effects of Menthol on Acrolein, Smoke-Induced Lung Inflammation

Acrolein, one of the most toxic aldehydes in cigarette smoke, is a respiratory irritant that contributes to the inflammation and lung disease caused by cigarette smoke. While menthol reduces the irritation response to acrolein, how menthol influences the effects of cigarette smoke and acrolein on lung inflammation is currently unknown. The goal of this in vitro cell-based study is to determine how menthol influences the effects of acrolein on lung inflammation. Study aims are: (1) to characterize and identify dose ranges of acrolein and cigarette smoke on inflammation markers in lung epithelial cells, and (2) to understand the effects of menthol on acrolein- and smoke-induced lung inflammation in lung epithelial cells. Findings will contribute new information regarding the dose ranges and mechanisms of acrolein and cigarette smoke actions related to inflammation and cell death.

N. Rajendran and Alex Tu Funding Mechanism: Research Contract
ID number: HHSF223201510000I
Institution: Illinois Institute of Technology (IIT) Research Institute
03/02/2016

Evaluation of Toxic Profiles of Tobacco Additives in a Systemic, Tiered Approach

The goal of this study is to investigate the effects of cigarette additives on in vitro mutagenicity and cytotoxicity using respiratory tract and heart cells. Investigators will first conduct a comprehensive systematic literature review to identify information on the selected additives (in unburnt and burnt form). Next, investigators will expose human airway epithelial and cardiac cell lines to freshly-generated whole cigarette smoke (using the ISO and Health Canada Intensive smoking regimens) for various assays at the air-liquid interface. Study objectives are: (1) to determine the cytotoxic potential of ingredients and/or their pyrolysis products using the neutral red assay, the lactate dehydrogenase leakage assay, and the methyl tetrazolium assay; and (2) to determine the genotoxic potential of ingredients and/or their pyrolysis products using the comet assay, Ames test, and micronucleus test.

Nicole Sawyer and Berran Yucesoy Funding Mechanism: Research Contract
ID number: HHSF223201510001I
Institution: Lovelace
03/02/2016

Development of Standard Guideline Protocol for Rodent Sub-chronic Tobacco Smoke Inhalation Study

Historically, methodologies used in rodent inhalation studies have not adequately described toxicological differences between test cigarettes. This study addresses four key issues observed in the tobacco literature. The first issue is the normalization of tobacco smoke emitted from test cigarettes to 150 mg/m3 total particulate matter (TPM). One problem with this approach is that it normalizes the levels of toxic components present as particulates in tobacco smoke, potentially minimizing differences in toxicity that might arise from differences in particulate matter. A second problem with this approach is that it dilutes the smoke from different test cigarettes with different amounts of air, which results in the uneven dilution of the gas vapor phase. Importantly, the smoke mixture resulting from TPM normalization is very different from the smoke mixture to which smokers might be exposed. The second issue is that there are little available data that allow for a direct toxicological comparison between smoke mixtures generated under the ISO and Canadian Intense (CI) smoking regimens. Third, the vast majority of publicly-available data pertaining to cigarette toxicology has been generated using experimental “reference” cigarettes, which differ greatly in composition from the commercial cigarettes that smokers actually consume. Fourth, most available rodent toxicology studies in the tobacco literature do not address systemic toxicity, but rather focus only on respiratory tract endpoints. The goal of this study is to relate critical toxicological endpoints (e.g., no-observed-adverse-effect level [NOAEL], lowest-observed-adverse-effect level [LOAEL], dose-limiting toxicity) to serially diluted whole smoke from a commercial cigarette generated under the ISO and CI machine smoking regimens. In an initial range-finding study, researchers will expose Sprague-Dawley rats to mainstream smoke generated using a commercial cigarette brand following the CI smoke regimen. Researchers will measure various endpoints, including blood carboxyhemoglobin level, to monitor the rats’ health status. After establishing a reasonably high dose as a top dose, researchers will expose the rats to cigarette smoke for one hour per day for thirteen weeks under different serial dilutions of whole smoke generated under the ISO and CI regimens. Researchers will evaluate end-organ toxicity and conduct in vitro assays to identify different aspects of lung disease. The information obtained will provide: (1) the first publicly-available information on the dose-response curve of serially diluted whole smoke without manipulation of the gas-vapor phase in favor of the particulate phase, (2) a toxicological comparison of the smoke mixtures generated under the ISO and CI machine smoking regimens, and (3) the first publicly-available dose-response information using smoke from an actual cigarette consumed by U.S. smokers. This study is not meant to be the beginning of a series of in vivo toxicology studies using commercial cigarettes; rather, it is meant to provide an empirical basis for evaluation of the toxicology data presently available in the tobacco literature.

Jacob McDonald and Lynn Crosby Funding Mechanism: Research Contract
ID number: HHSF223201510032I
Institution: Lovelace
02/11/2016

Measuring Consumer Comprehension of Displays of Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke

Section 904(d) of the Tobacco Control Act requires FDA to publish its list of harmful and potentially harmful constituents (HPHCs) in tobacco products (including quantity of each HPHC by brand and sub-brand) in a format that is understandable and not misleading to the public. The goal of the study is to gain insight on consumer comprehension of and preferences regarding presentation of information about HPHCs. Researchers will conduct a series of 50 individual in-depth interviews with adults and youth ages 14-17 years to gather information about different ways of presenting HPHC information for cigarettes, smokeless tobacco and roll-your-own tobacco. Participants will be asked questions regarding different ways of presenting HPHC information by brand and by quantity in each brand and subbrand. Interviews will be designed to answer the following questions about consumer knowledge, attitudes, and behavior: (1) What do adults and youth know and what do they perceive about HPHCs in tobacco products? (2) How, and in what formats, do adults and youth prefer to receive information regarding HPHCs? and (3) How do adults and youth understand and perceive the information about HPHCs provided in sample formats?

Jonathan Blitstein and Katherine Margolis Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: FDA/CTP
01/01/2016

Effects of Atomizer Temperature on Electronic Cigarette Aerosol

There is little consensus in the scientific community on the overall toxicity of e-cigarette aerosols based on their chemical constituents, physical characteristics of the aerosols, and design parameters. There is also little published data on the accuracy of emerging temperature control technologies and how they work. The goal of this project, a joint project between FDA/CTP and FDA/Center for Devices and Radiological Health (CDRH) is to develop a methodology to correlate e-cigarette design parameters to chemical and physical aerosol characteristics. The primary study aim is to develop a methodology to correlate coil temperature and other design parameters with the resulting chemical and physical characteristics of e-cigarette aerosol. Study findings will contribute to knowledge about e-cigarette aerosol toxicity.

Matthew Myers, Samanthi Wickramasekara and Gloria Kulesa Funding Mechanism: Performance Agreement with FDA/CDRH
ID number: PA-DPS001-16
Institution: FDA
11/20/2015

VCU TCORS: Comparison of Methods for Measurement of Electronic Cigarette Topography

The ability of electronic cigarettes (e-cigarettes) to deliver nicotine depends not only on their product characteristics but also on user behavior. Estimating the impact of user behavior on nicotine delivery involves measuring puffing behavior (i.e., puff topography), including puff number, volume, duration, inter-puff-interval, and flow rate. Puff topography measurement is accomplished with direct observation (e.g., video recordings of actual use) or computerized device methods. Previously, the researchers developed a computerized e-cigarette topography device, the eTop, and used it to demonstrate topography differences between users with and without e-cigarette experience. However, the eTop uses a mouthpiece that is compatible only with e-cigarette models that a have a cylindrical mouthpiece shape (i.e., “ciga-like” models). Researchers subsequently developed the mouthpiece-free eTop 2.0 for use with e-cigarette models of nearly any design and mouthpiece style, including tank models. The specific aim of this proof-of-concept study is to compare the sensitivity, reliability, and validity of the eTop, the eTop 2.0, and direct observation. Thirty experienced e-cigarette users and 30 cigarette users with no e-cigarette experience will participate in three experimental conditions that differ by these three measurement methods. Within each condition, participants will complete three e-cigarette puffing bouts, answer subjective questionnaires before and after each bout, and have their heart rate and blood pressure tested. Results will be used to determine whether the eTop 2.0 provides an accurate estimate of e-cigarette puff topography.

Thomas Eissenberg Funding Mechanism: National Institutes of Health – Grant
ID number:  3P50DA036105-03S1
Institution: Virginia Commonwealth University
10/22/2015

Detection of NNK-Induced DNA Adduct Formation in Human Air-Liquid-Interface Airway Tissue Models

The tobacco specific nitrosamine 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK) is one of the major carcinogens found in tobacco smoke; it causes gene mutations in vivo and in vitro and cancer in rodents. The aims of this six-month pilot study are: (1) to develop a liquid chromatography-mass spectrometry method to detect NNK-induced DNA adducts, and (2) to establish procedures to measure DNA damage using the Comet assay in in vitro human respiratory tract tissue models. An air-liquid-interface (ALI) model using well-differentiated primary human bronchial epithelial cells will be compared with single-layer human lung cancer cells and normal human bronchial epithelial cells. These data will be compared to in vivo adduct formation and DNA damage in rats and humans. This pilot study may guide future studies that compare NNK-induced toxicity outcomes in vitro with the findings from existing in vivo studies involving different NNK doses. Pilot study results may provide methodology to develop new in vitro respiratory tissue models in evaluations of the cancer-causing and gene mutation-related effects of inhaled carcinogens, which will be a new approach in the toxicological evaluation of tobacco products.

Xuefei Cao and Xin Fu Funding Mechanism: Internal FDA
ID number: E07604.01
Institution: National Center for Toxicological Research (NCTR)
10/22/2015

In Vitro-In Vivo Extrapolation of the Mutagenic Potential of NNK

Standard gene toxicity assays conducted to inform regulatory decision-making, such as the Ames’ bacterial gene mutation assay, provide only qualitative (i.e., positive, negative, equivocal) estimates of gene mutation. These estimates are difficult to translate into relevant human doses and responses, and potency in in vitro assays may or may not reflect potency in animal or human responses. In this study, researchers will “calibrate” responses in the Ames’ assay and the in vitro Pig-a assay to in vivo mutagenicity in the rat Pig-a assay. Researchers will develop mutation dose responses for a tobacco-specific mutagen (nicotine-derived nitrosamine ketone, or NNK) in the in vitro Ames’ and Pig-a assays and in the in vivo rat Pig-a assay. The goal is to assess whether or not animal and human mutagenic responses can be estimated from the Ames’ assay and in vitro Pig-a responses. This study may provide a new methodology for assessing human gene toxicity associated with tobacco products.

Robert Heflich and Berran Yucesoy Funding Mechanism: Internal FDA
ID number: E07606.01
Institution: National Center for Toxicological Research (NCTR)
10/22/2015

Extrapolation of In Vitro Acrolein Dose-Response Derived in Air-Liquid-Interface Airway Epithelial Models to In Vivo Lung Toxicity

New methods for conducting risk assessments that could reduce or replace animal testing would be valuable for assessing the human health effects of tobacco product use. Advancements in in vitro tissue models and physiologically-based computational modeling provide a potential means for better using in vitro mammalian cell assays to make quantitative assessments of human risk. This study will combine an in vitro human testing model with a chemical-specific strategy to use in vitro results to predict human responses. In this study, researchers will evaluate acrolein toxicity in human lung cell culture and air-liquid-interface (ALI) airway tissue models derived from both rat and human bronchial epithelial cells using toxicity endpoints relevant to human respiratory disease. Dose-response relationships derived from in vitro rat ALI toxicity data will then be compared with corresponding in vivo rat dose-response relationships to derive an in vitro-to-in vivo extrapolation factor for each toxicity endpoint. This extrapolation factor, along with human in vitro toxicity data, will then be input into mathematical models to predict in vivo human responses. The methodology developed in this study may allow scientists to evaluate claims of equivalent or modified health risks of tobacco products without animal testing.

Xuefei Cao and Sheila Healy Funding Mechanism: Internal FDA
ID number: E07603.01
Institution: National Center for Toxicological Research (NCTR)
09/21/2015

OSU TCORS: Tailoring and Interactivity Website Features and their Impacts on Smokers’ Knowledge

Information about harmful and potentially harmful constituents (HPHCs) in tobacco products must be provided to the public in a way that efficiency conveys important details without causing cognitive “overload”. The specific aim of this project is to test the impact of different formats for web-based HPHC information delivery on smokers’ knowledge about HPHCs. To accomplish this, researchers will recruit 270 adult smokers and dual users (ages 18 and older) to view one of two experimental websites that vary in the depth of HPHC information and interactive features; researchers will then examine the influence of these attributes on smokers’ knowledge about HPHCs. Eye tracking technology will be used to capture detailed information about attention paid to website elements, and a “think aloud” protocol will be used to note subjects’ impressions of barriers to website usability. Study findings may provide a foundation for determining key web design attributes that can optimize consumer learning about HPHCs.

Mary Ellen Wewers Funding Mechanism: National Institutes of Health – Grant
ID number: 5 P50 CA180908-03
Institution: The Ohio State University
09/21/2015

Emission Aerosol Constituents and Comparative Toxicology of Electronic Cigarettes with Flavorings

Data on the potentially toxic impact of exposure to flavors in e-cigarettes is needed. The goal of this study is to evaluate the aerosol constituents and cellular toxicity of flavored e-cigarettes. Researchers’ preliminary data indicate that flavored e-cigarette aerosols cause varying levels of oxidative stress and inflammatory cytokine release in human lung cells. In this study, researchers will use gas chromatography-mass spectrometry (GCMS) and in vitro cell-based assays to identify the chemicals formed in flavored e-cigarette liquids and vapors and compare their effects on oxidative stress, DNA damage, and inflammation. Specific aims are: (1) to identify and compare the chemical constituents (including some on FDA’s harmful and potentially harmful constituent [HPHC] list) present in e-liquids and aerosols in selected e-cigarettes with flavorings; and (2) to compare oxidative stress, DNA damage, and inflammatory responses to flavored e-cigarette aerosols in human and mouse lung epithelial cells. Assessment of flavored e-cigarette chemical constituents and toxicity may inform regulatory activities related to e-cigarettes.

Irfan Rahman Funding Mechanism: National Institutes of Health – Grant
ID number:  3R01HL085613-07S2
Institution: University of Rochester
09/18/2015

Measure Development for Prediction of E-cigarette Initiation

Given the growth in e-cigarette use among young adults, developing an understanding of why cigarette smokers and non-smokers choose to use or not use e-cigarettes is critical. Assessing e-cigarette outcome expectancies (i.e., beliefs about the results of e-cigarette use) could be a key tool in predicting initiation. In this project, researchers will develop an e-cigarette expectancy questionnaire. Specific aims are: (1) to systematically assess young adult attitudes and experts’ opinions in order to develop an initial item pool for an “Electronic Cigarette Outcomes” measure; and (2) to refine the initial item pool via field testing. In the first phase of survey development (Aim 1), researchers will conduct focus groups with 80 young adults aged 18-24 years (including equal numbers of e-cigarette users, non-users, smokers, and non-smokers) and consult with an expert panel of researchers in order to develop a preliminary list of possible survey items. In the second phase, this preliminary list will be tested in 500 young adults aged 18-24 years (including e-cigarette users, non-users, smokers, and non-smokers). Researchers will then analyze the findings and use the results from these analyses to narrow down the items. The final survey will be a well-informed assessment of e-cigarette expectancies. This outcome expectancy measure for e-cigarettes will facilitate future research and may inform the development and evaluation of public health interventions.

Paul Harrell Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R03 CA195124-01
Institution: Eastern Virginia Medical School
09/15/2015

CTP Supplement to Parent Grant: The Impact of Tobacco Exposure on the Lungs Innate Defense System

The heating of e-cigarette liquids can generate new and potentially toxic chemicals, and temperature is a major factor in causing e-liquid ingredient decomposition. The goal of this project is to determine the effect of temperature-dependent heating on e-liquid aerosol composition, and to evaluate the biological effects of the resulting aerosols on lung function. Specific aims are: (1) to determine the aerosol composition of e-liquids subjected to different temperatures; and (2) to determine the biologic effects of aerosols resulting from different temperatures on airway epithelial and macrophage function. To address Aim 1, researchers will generate vapors from four e-cigarette liquids (i.e., two e-cigarette liquids [menthol tobacco and vanilla tobacco] with and without nicotine) at different temperatures and will analyze the resulting aerosols using mass spectrometry techniques. To address Aim 2, researchers will measure the effects of the aerosols on cell growth, signaling, viability, oxidative stress and inflammatory responses on human airway epithelial cells. Study findings may inform regulatory activities related to e-cigarettes.

Robert Tarran Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 HL120100-03S1
Institution: The University of North Carolina at Chapel Hill
09/15/2015

A-TRAC TCORS: Toxicity of Flavors

Many tobacco products – including cigars, cigarettes, cigarillos, and e-cigarettes – contain artificial flavors to enhance palatability and appeal. However, the toxicity of many of these flavors, especially when inhaled after heating or burning, is unknown. Specific aims of this project are: (1) to identify and quantify the chemical products generated due to the thermal degradation that occurs when tobacco product flavorings are heated or burned; and (2) to compare the relative toxicity of different flavorings commonly used in tobacco products before and after burning or heating. To address Aim 1, researchers will heat or burn major classes of common tobacco product flavor chemicals (i.e., alcohols, phenols, aldehydes, esters, ethers, hydrocarbons, ketones, lactones, organic acids, pyrazines, pyridines, pyrones) to determine the extent of degradation. To address Aim 2, researchers will use in vitro assays to measure whether chemicals from each major class of common flavor chemicals cause human platelet adhesion, human endothelial cell activation, and myocardial excitability; researchers will then compare results from these assays to discern the cardiac harm potential of different tobacco product flavorings and their thermal degradation products. This project may inform regulation related to flavored tobacco products.

Aruni Bhatnagar and Rose Robertson Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 HL120163-03S1
Institution: American Heart Association
09/15/2015

Effect of Temperature-Dependent Heating On E-Liquid Aerosol Composition and of the Resulting Aerosols on Lung Function

The heating of e-cigarette liquids can generate new and potentially toxic chemicals, and temperature is a major factor in causing e-liquid ingredient decomposition. The goal of this project is to determine the effect of temperature-dependent heating on e-liquid aerosol composition, and to evaluate the biological effects of the resulting aerosols on lung function. Specific aims are: (1) to determine the aerosol composition of e-liquids subjected to different temperatures; and (2) to determine the biologic effects of aerosols resulting from different temperatures on airway epithelial and macrophage function. To address Aim 1, researchers will generate vapors from four e-cigarette liquids (i.e., two e-cigarette liquids [menthol tobacco and vanilla tobacco] with and without nicotine) at different temperatures and will analyze the resulting aerosols using mass spectrometry techniques. To address Aim 2, researchers will measure the effects of the aerosols on cell growth, signaling, viability, oxidative stress and inflammatory responses on human airway epithelial cells. Study findings may inform regulatory activities related to e-cigarettes.

Robert Tarran Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 HL120100-03S1
Institution: The University of North Carolina at Chapel Hill
09/15/2015

Investigation of Consumer Perceptions of Implied Modified Risk Claims

Section 911 of the Tobacco Control Act prohibits tobacco labels, labeling, or advertisements that include the descriptors “light,” “mild,” “low,” or other descriptors that imply lower risk or harm. The goal of this project is to identify modified risk tobacco product (MRTP) claims that act as similar descriptors on labels, labeling, and advertising. Study aims are: (1) to determine whether hypothesized implied MRTP claims convey modified risk to consumers, (2) to determine whether implied MRTP claims affect consumer perceptions of risk, harm, and exposure to harmful chemicals, (3) to determine whether and how consumer perceptions of risk, harm, and exposure vary among different populations exposed to implied MRTP claims, and (4) to determine the similarities and differences when implied MRTP claims are viewed on labeling versus in advertisements. Approximately 6,300 adolescent, young adult, and adult tobacco users and non-users will participate in an online experimental study of three hypothesized implied MRTP claims on tobacco labeling and advertising for three tobacco products (cigarettes, smokeless tobacco, and e-cigarettes). Participants will be randomly assigned to view one of three claims or a control claim with no MRTP information. Participants will also be randomly assigned to the types of products and media they will view. Participants will be asked to provide their assessments of risk, harm, and exposure to harmful chemicals for the product label or advertisement viewed. This project will provide insights about how consumer perceptions of the risks and harms of tobacco products are influenced by implied MRTP claims on packaging and labeling.

Jane Allen and Amber Koblitz Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: Research Triangle Institute
09/09/2015

Does Abstinence from E-cigarettes Produce Withdrawal Symptoms?

Many e-cigarette users achieve nicotine blood levels from e-cigarettes that are much higher than those from nicotine replacement products and, in some studies, similar to those of cigarette users. Accordingly, abrupt cessation of e-cigarettes could be expected to produce withdrawal symptoms, an important feature of addiction; however, this hypothesis has not been tested. The specific aim of this study is to determine whether abruptly stopping e-cigarette use causes withdrawal symptoms. Researchers will recruit 80 adult (ages 18 and older) long-term e-cigarette-only users and instruct them to use their own e-cigarettes for five days and then abruptly stop using them for five days.  Participants will monitor symptoms of nicotine withdrawal daily by calling an interactive voice response system each night.  Abstinence from e-cigarettes will be supported by payments contingent on breath and saliva samples. Participants will attend three laboratory visits each week to provide carbon monoxide and cotinine samples to verify abstinence, complete longer surveys, and complete a task to measure whether their motivation to use e-cigarettes has increased. Study results will help determine the addiction potential of e-cigarettes.

John Hughes Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 CA192940-01
Institution: University of Vermont & State Agricultural College
09/01/2015

Focus Groups on ENDS: Device Types, User Experiences, and Product Appeal

Electronic nicotine delivery systems (ENDS), including e-cigarettes, are growing in popularity. The goal of this study is to understand how ENDS device characteristics influence users’ experiences, and how these experiences shape ENDS use behavior, beliefs, and attitudes. Researchers will conduct 23 focus groups with a total of 156 participants who are users of “cigalikes” (non-customizable devices that look similar to cigarettes) or “tank systems” (advanced-generation, customizable devices). Focus groups will be conducted in four locations — New York, NY; Chicago, IL; Memphis, TN; and Denver, CO – and will be segmented by type of device used. Groups will be conducted with young adults (ages 18-29 years) and adults (ages 30+ years); and will include a mix of ages, sex, races/ethnicities, education levels, and rural/urban geography.

Jennifer Alexander, Blair Coleman, and Sarah Johnson Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: RTI International
08/31/2015

UNC TCORS: Optimizing Public Display of Information on Tobacco Product Constituents

As directed by the Tobacco Control Act, the FDA Center for Tobacco Products is required to disclose information about harmful and potentially harmful constituents (HPHCs) in tobacco products to the public in a format that is “understandable” and “not misleading to a lay person.” The specific aim of this study is to identify website formats and content that increase comprehension of HPHC information, especially among people with lower health literacy. To investigate this aim, researchers will meet with legal scholars to better conceptualize the Tobacco Control Act’s language regarding comprehension of HPHC information (i.e., “understandable,” “not misleading”). They will also design and pilot test website variations for presenting information about HPHCs in ways that are “understandable” and “not misleading” to the public. After this developmental work, researchers will conduct an online study involving 1,400 adolescents (ages 13-17), young adults (ages 18-25), and adults (ages 26 and older). The study will identify website characteristics that lead to higher comprehension and may inform regulatory activities related to the communication of HPHCs.

Kurt Ribisl Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 CA180907-03S1
Institution: The University of North Carolina at Chapel Hill
08/28/2015

Yale TCORS: Irritant Flavor Products in Heated E-Cigarette Liquids and Vapors

While many of the flavorings used in e-cigarette liquids are generally recognized as safe in food, the safety of inhaling flavorings when using e-cigarettes has not been established. Popular e-liquid flavor mixes contain aldehydes such as cinnamaldehyde (cinnamon), carvone (spearmint), and terpenoids such as menthol (mint) and limonene (citrus). Notably, aldehydes and other chemicals are known to activate the transient receptor potential (TRP) ion channels in respiratory cells, thereby causing irritation in the respiratory system. The goal of the project is to study the impact of flavor chemicals on the TRP ion channels. Specific aims are: (1) to identify the chemical reaction products of e-liquid flavorings produced during heating and aerosolization; (2) to compare responses of TRP ion channels to e-liquids and their aerosols; and (3) to examine the sensitivity of newly-identified chemosensory receptors to flavorings and their products. To investigate these aims, researchers will use a variety of analytical techniques, including high performance liquid chromatography-mass spectrometry (HPLC-MS), gas chromatography-mass spectrometry (GC-MS), gas chromatography-flame ionization detector (GC-FID), and other screening approaches. The study will provide new data that may inform regulatory activities related to toxic and potentially toxic constituents in e-cigarette liquids.

Suchitra Krishnan-Sarin and Stephanie O’Malley Funding Mechanism: National Institutes of Health – Grant
ID number:  3 P50 DA036151-03S1
Institution: Yale University
08/28/2015

Assessing the Intended and Unintended Consequences of E-cigarette TV Advertising

To date, no studies have examined the population level impact of televised e-cigarette advertising. The goal of this project is to examine the effects of televised e-cigarette advertising. Specific aims are: (1) to examine the impact of e-cigarette television advertising on awareness, risk perceptions, intentions to use, initiation, and patterns of use of e-cigarettes and conventional cigarettes; (2) to assess the potential consequences of e-cigarette television advertising, examining impact on attitudes, beliefs, and behaviors related to electronic nicotine delivery systems (ENDS) and e-liquid as well as the use of e-cigarettes as substitutes for smoking cessation methods; and (3) to study whether and to what extent state and local tobacco control policies and policies restricting e-cigarette use modify the effects of e-cigarette television advertising. Researchers will conduct two nationally representative longitudinal surveys of youth and young adults (ages 15-24) and adults (ages 25-60) to measure individual attitudes, beliefs and behaviors. They will also use data from their other studies—including e-cigarette and nicotine replacement therapy sales data from commercial store scanner databases, Nielsen television ratings data for e-cigarettes and pharmaceutical cessation products, and state and local policy data related to tobacco, and e-cigarettes—to measure key contextual and policy influences on individuals’ attitudes, beliefs and behaviors. Project findings may inform future regulatory activities related to e-cigarette advertising and promotion.

Jidong Huang Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 CA194681-01
Institution: University of Illinois at Chicago
08/27/2015

Assessment of Tobacco Products and Tobacco Product Constituents’ Genetic Toxicology in In Vitro Assays: Comparative In Vitro Toxicity of Conventional Cigarettes Versus Electronic Cigarettes – Mutagenicity, Cytotoxicity, and Genotoxicity

More information about the toxicity differences between cigarette smoke and e-cigarette aerosol would be useful. The goals of this study are to compare the in vitro mutagenicity, cytotoxicity, and genotoxicity of total particulate matter (TPM) generated from conventional cigarettes to that of e-cigarettes, and to characterize the qualitative and quantitative profiles of conventional cigarette smoke and e-cigarette aerosols. Researchers will select 15 cigarettes of different brands and six e-cigarettes representative of first, second and third generation devices based on market share. Researchers will generate TPM from conventional cigarettes using the Canadian Intense (CI) and the International Organization for Standardization (ISO) regimens, and generate TPM from e-cigarettes using a modified puffing protocol described by Behar et al. (PLoS One 2015;10(2):e0117222). They will then quantify nicotine in TPM from each of the samples collected and measure nicotine and cotinine levels using the gas chromatography-mass spectrometry (GC-MS) method. Cytotoxicity will be assessed using the Neutral Red Uptake assay; genotoxicity will be assessed using the micronucleus assay; and mutagenic potency will be assessed using the bacterial Ames test and the thymidine kinase gene mutation assay. Study findings will provide new information about the differences in toxicity profiles between cigarette smoke and e-cigarette aerosol.

Kelly Brant (CTP Contact: Gladys Erives) Funding Mechanism: Research Contract
ID Number: HHSF22320151001I
Institution: Lovelace Biomedical and Environmental Research Institute (LBERI)
08/25/2015

Flavoring Compounds in Tobacco Products

Although the popularity and use of flavored e-cigarettes and other flavored tobacco products continues to increase, particularly among youth, data on the potential human health effects of these products are limited. In the early 2000s, concerns were raised about chemicals used in flavorings after workers at a microwave popcorn factory were diagnosed with the respiratory disease bronchiolitis obliterans; the disease was attributed to their inhalation of diacetyl, a butter flavoring compound. Diacetyl and its replacements (2, 3-pentanedione and acetoin) are used in the manufacture of many foods to create a wide range of flavors (e.g., caramel, cream, pina colada, strawberry). Many of these flavors are common in e-cigarette flavor cartridges, and users of e-cigarettes are directly inhaling these flavoring compounds. The goals of this study are: to quantify the concentrations of these flavoring compounds in e-cigarette liquids and aerosols; to estimate exposures for users of e-cigarettes; to profile airway epithelial cells; and to conduct in vitro assays for inflammation, cell proliferation and apoptosis. . Researchers will conduct a market survey to identify the top brands of flavored e-cigarettes and other categories of flavored tobacco products (i.e., flavored cigarettes and cigars, including little cigars and cigarillos) available for purchase in U.S. retail outlets, and then test samples of 51 products. Results may inform regulatory activities related to flavoring compounds used in e-cigarettes and other combusted tobacco products.

Douglas Dockery Funding Mechanism: National Institutes of Health – Grant
ID number:  3 P30 ES000002-52S1
Institution: Harvard School of Public Health
08/20/2015

Nicotine Self-Administration with Flavor Cues

Flavor additives in tobacco products and e-cigarettes may increase their appeal and encourage experimentation, repeated use, and dependence, even when only small amounts of nicotine are available. Many of the flavors in tobacco products are “incentives” – stimuli that have become rewards because of their inclusion in foods and beverages. For example, strawberry and licorice flavors become incentives because they are consumed in sweet foods that are high in calories before people use tobacco or vapor products. The goal of this study is to evaluate whether the psychological value of flavor additives interacts with nicotine to increase motivation to self-administer the drug in a rat model. Specific aims are: (1) to investigate which specific flavors (menthol, licorice, strawberry, or cocoa) promote the most nicotine self-administration; (2) to investigate whether these flavor incentives increase dependence-like behavior when they are self-administered with nicotine; and (3) to investigate whether the combination of incentive flavors and nicotine will increase the release of dopamine, a brain chemical that contributes to compulsive substance use and dependence. Researchers will give one flavor (e.g., menthol) psychological appeal by pairing it with sugar (e.g., incentive flavor); a second “unsweetened” flavor will serve as a control (e.g., neutral flavor). During testing, rats will be tethered to a leash that can deliver nicotine intravenously. One of four nicotine doses (0, 3, 10, or 60 ug/kg/infusion) will be delivered when rats lick a sipper tube with the flavors. Each time the rat receives a nicotine infusion, a few drips of a flavor (incentive or neutral) will be released into the sipper tube. This procedure mimics the fast delivery of nicotine to the brain in conjunction with the oral perception of flavor additives during vaping and smoking. To more closely model smoking and vaping, the flavors will be presented “unsweetened” during these tests. Based on past research and preliminary data, the investigators have hypothesized that an interaction between nicotine and the incentive flavors will promote drug-taking at low doses, increase the motivation for nicotine, increase levels of dopamine in the brain, and increase dependence-like behavior. Findings may inform regulatory activities related to flavors.

Matthew Palmatier Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R15 DA038843-01A1
Institution: East Tennessee State University
08/13/2015

Golestan Tobacco Biomarkers Study

Epidemiologic studies that link tobacco exposure biomarkers (measurable indicators of exposure) to adverse health effects are valuable for complementing existing toxicological information about harmful and potentially harmful constituents (HPHCs) present in tobacco products. The goal of this study is to examine associations between tobacco exposure biomarkers and tobacco-related diseases using the Golestan Cohort Study, a study that includes more than 50,000 adults (ages 40-75 years) in Northern Iran; subjects have provided urine specimens and tobacco use data and have been followed since 2004 for disease and mortality outcomes. Study aims are: (1) to characterize mean levels and distribution of tobacco constituents in users’ urine by type of tobacco used (e.g., cigarettes, hookah); (2) to compare the stability of biomarker levels over time in current smokers; and (3) to estimate associations between individual biomarkers of polyaromatic hydrocarbons (PAHs), volatile organic compounds (VOCs), and tobacco-specific nitrosamines (TSNAs) and the risk of disease and death. To accomplish these aims, investigators will first conduct a pilot study to assess biomarker levels in tobacco users and non-users and compare biomarker levels at two different time points. Second, investigators will conduct a full study in which they will define groups based on disease (i.e., cancer, heart disease, stroke, respiratory disease) as well as a control group. They will then examine the association between pre-diagnostic levels of urinary biomarkers of nicotine, PAHs, VOCs, and TSNAs and the risk of each disease. The results of this study will provide information on the associations between biomarkers of exposure and adverse health effects and may help to inform regulatory actions regarding HPHCs.

Neal Freedman, Ben Blount, and Cindy Chang Funding Mechanism: Interagency Agreements
ID numbers: 224-10-9022 and 224-15-9011
Institution: Centers for Disease Control and Prevention (CDC) and National Cancer Institute
08/13/2015

Investigation of Consumer Perceptions of Expressed Modified Risk Claims

Modified risk tobacco products (MRTPs) are products whose packaging or advertising states the products are less risky than other tobacco products. The goal of this project is to understand more about how MRTPs are perceived. Study aims are: (1) to develop and validate measures of risk beliefs and knowledge about tobacco products; (2) to identify groups who may be more likely than others to misunderstand product risk information or who may be particularly affected by the marketing of MRTPs; and (3) to test debriefing procedures to reduce the lingering effects of viewing (hypothetical) risk information. Two experiments will be conducted on a total of 6,000 adult tobacco users and non-users participating in an Internet survey panel. One experiment will focus on smokeless tobacco and the other on e-cigarettes. Participants will view an image of a package or advertisement for a smokeless tobacco or e-cigarette product. The product will be presented with or without hypothetical statements about the risks of using the product compared to smoking cigarettes. Participants will then be asked about their perceptions of the risks associated with using the product, and their intention to use the product. The debriefing will explain that the statements about the product’s risks may not be true and were created for the purposes of the experiment. The debriefing will differ in terms of format (a standard block of text format vs. a more visually pleasing ‘bubble’ format) and content (standard vs. expanded content). The information collected by this study may inform regulatory activities related to the marketing of MRTPs.

Jane Allen and Alexander Persoskie Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: Research Triangle Institute
08/13/2015

Investigation of Consumer Perceptions of Expressed Modified Risk Claims

Modified risk tobacco products (MRTPs) are products whose packaging or advertising states the products are less risky than other tobacco products. The goal of this project is to understand more about how MRTPs are perceived. Study aims are: (1) to develop and validate measures of risk beliefs and knowledge about tobacco products; (2) to identify groups who may be more likely than others to misunderstand product risk information or who may be particularly affected by the marketing of MRTPs; and (3) to test debriefing procedures to reduce the lingering effects of viewing (hypothetical) risk information. Two experiments will be conducted on a total of 6,000 adult tobacco users and non-users participating in an Internet survey panel. One experiment will focus on smokeless tobacco and the other on e-cigarettes. Participants will view an image of a package or advertisement for a smokeless tobacco or e-cigarette product. The product will be presented with or without hypothetical statements about the risks of using the product compared to smoking cigarettes. Participants will then be asked about their perceptions of the risks associated with using the product, and their intention to use the product. The debriefing will explain that the statements about the product’s risks may not be true and were created for the purposes of the experiment. The debriefing will differ in terms of format (a standard block of text format vs. a more visually pleasing ‘bubble’ format) and content (standard vs. expanded content). The information collected by this study may inform regulatory activities related to the marketing of MRTPs.

Jane Allen and Alexander Persoskie Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: Research Triangle Institute
08/13/2015

Heating Flavor Chemicals in E-cigarette Liquids – Supplement to Metals in Electronic Cigarettes Aerosol

The effects of heating flavor chemicals in e-cigarette liquids on human health are largely unknown. The goals of this project are to identify and quantify the reaction products formed during heating of flavored e-cigarette liquids and to determine which tests can best identify the flavor chemicals and reaction products that are harmful to the human respiratory system. Specific aims are: (1) to identify and quantify the primary flavor chemicals and major flavor-derived pyrolysis/oxidation products formed during use of approximately 100 e-cigarette refill fluids and disposable e-cigarettes; (2) to screen individual chemicals identified in Aim 1 in unheated e-cigarette fluids and aerosol condensates for toxic effects in human respiratory system cells; and (3) to test the most toxic chemicals identified in Aim 2 using air-liquid interface (ALI) technology.  Researchers will conduct the experiments using a variety of methods, including gas chromatography/mass spectrometry (GC/MS), two-dimensional GC with MS, liquid chromatography/MS/MS, a moderate throughput (MTT) assay, and an ALI system that resembles a human lung. Study findings may inform regulatory activities related to flavorings in e-cigarettes.

Prudence Talbot Funding Mechanism: National Institutes of Health – Grant
ID number: 3 R01 DA036493-02S1
Institution: University of California Riverside
08/12/2015

CTP Supplement to Parent Grant: Nicotine Delivery from Novel Non-Tobacco Electronic Systems

Data on the inhalation toxicity of flavorings used in electronic nicotine delivery systems (ENDS) are limited. The goal of this study is to evaluate the potential toxicity of several of the most popular flavorings in ENDS and ENDS liquids sold in the U.S. This study will assess the concentration, emission, and potential degradation of flavorings from storage or heating as well as the cellular toxicity of different flavorings in ENDS aerosols. Specific aims are: (1) to determine flavoring type and amounts in 32 disposable ENDS products, cartridges and refill solutions, as well as inter-brand and intra-brand variability in flavorings; (2) to determine the stability of flavorings under various storage conditions; (3) to determine flavoring yields in vapors from various types of ENDS; (4) to determine the effect of various product characteristics on flavoring levels in aerosols; (5) to compare the cellular effects of flavored ENDS aerosols versus tobacco smoke; and (6) to establish an evidence base for evaluating potential harm to users. One study, which will address Aims 1 and 2, will involve laboratory analytical chemistry testing of multiple brands and batches of flavored ENDS in order to characterize flavored ENDS products. A second study, which will address Aims 3 and 4, will involve laboratory analytical chemistry testing to determine flavoring yields in aerosols from various types of ENDS. A third study, which will address Aims 5 and 6, will test the cellular toxicity of aerosol generated from flavored ENDS using an air-liquid interface (ALI) model to measure the effects of aerosol on non-cancerous bronchial epithelial cells and mutated lung cancer cell lines. Study findings may inform the development and implementation of standard quality assessment procedures and testing methods for flavored ENDS.

Maciej Lukasz Goniewicz Funding Mechanism: National Institutes of Health – Grant
ID number: 3 R01 DA037446-02S1
Institution: Roswell Park Cancer Institute
08/10/2015

Evaluation of the NYC Cigar Packaging and Pricing Law

In 2014, New York City (NYC) implemented a cigar pricing and packaging law that mandates that cigars sold for $3 or less must be sold in a package of at least four cigars and that little cigars must be sold in packs of at least 20 and for at least $10.50 per pack. The NYC cigar law is part of a law with multiple tobacco control measures that aim to reduce tobacco use by decreasing the availability of low-priced tobacco products in NYC. The NYC cigar law provides an opportunity to evaluate the implementation and outcomes associated with this type of change in the retail environment. This evaluation will focus on whether the cigar pricing and packaging law was implemented as planned, whether it achieved its intended impacts on tobacco product sales and use, and whether it had any unintended consequences.  As part of the evaluation, investigators will collect and analyze retailer scanner data to study product pricing, sales volume and product characteristics pre- and post-policy implementation within New York City and comparison areas; conduct population health surveys to collect quantitative data on tobacco use and identify cigar-related outcomes; collect social media data to monitor the content and reach of social media activity related to cigar pricing and packaging; and gather tobacco retailer observations in New York City and surrounding areas to assess packaging and pricing in the retail environment. Study findings will provide new information on a number of topics, including trajectories of cigar consumption by product type; comparisons of cigars with other combustible and non‐combustible tobacco products with regard to consumer use, sales, and availability; and expected outcomes of a cigar product pricing and packaging policy within a specified jurisdiction.

Todd Rogers and Tarsha McCrae Funding Mechanism: Research Contract
ID number: HHSF223201310007B
Institution: Research Triangle Institute, International
08/10/2015

Context and Subjective Experience Surrounding Dual Cigarette and E-Cigarette Use

More information is needed about e-cigarette use and its association with other factors, such as continued use of conventional cigarettes, nicotine dependence, and changes in tobacco use patterns.  This project will use Ecological Momentary Assessment (EMA), a research methodology that gathers information about real-world experiences in real time, to collect reports of dual product (cigarette and e-cigarette) users’ daily tobacco use. Researchers will examine how the immediate context of tobacco use and individuals’ subjective reactions vary by product and individual characteristics and influence future use patterns. Researchers will recruit 450 adult cigarette smokers (ages 18 and older) who also use or report that they are likely to use e-cigarettes and conduct two one-week waves of EMA using smartphone interview “apps” and biweekly email surveys for one year. Specific aims are: (1) to examine the contexts of tobacco use (e.g., mood, alcohol use) and how they vary by product and individual differences (e.g., demographics, tobacco history, dependence) in order to understand the functional value of e-cigarettes; (2) to examine real-time withdrawal, cravings, and satisfaction with tobacco products and how these affect transitions in tobacco use; and (3) to examine how tobacco cues relate to tobacco use experiences, contexts, and patterns of use. This information may inform regulatory activities related to e-cigarettes.

Robin Mermelstein Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 CA184681-01A1 
Institution: University of Illinois at Chicago
08/04/2015

CTP Supplement to Parent Grant: Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure

The Tobacco Control Act requires that the amounts of harmful and potentially harmful constituents (HPHCs) reported by tobacco manufacturers to the FDA be disclosed to the public in a format that is understandable and not misleading. Previous research, which was largely focused on cigarette smoke constituents, showed that consumers generally have inadequate awareness and understanding of the chemicals in tobacco products, and may be misled into believing that lower amounts of specific constituents in cigarette smoke directly translate into reduced health risks. However, research on consumer perceptions of constituent levels in smokeless tobacco products is extremely limited. The goal of this project is to investigate the comprehension of different presentations of smokeless tobacco product HPHC lists by conducting an online survey of 1,500 individuals ages 18 and older. Specific aims are: (1) to investigate differences in consumer understanding of information about smokeless tobacco product HPHCs displayed in two formats (graphic and numerical), as well as differences in health risk perceptions and search behaviors as a function of the display format; and (2) to investigate which consumer characteristics moderate knowledge levels, inferences, and search behavior in the context of the two different display formats. Study findings will provide important information on effective communication of smokeless tobacco constituent levels to lay persons in general and to smokeless tobacco users specifically.

Irina Stepanov Funding Mechanism: National Institutes of Health – Grant
ID number: 5 R01 CA180880-02
Institution: University of Minnesota
07/14/2015

Nicotine Pharmaockinetics and Salivary pH of Large and Small Cigar Smokers

Cigar products are diverse, varying in tobacco weight, nicotine concentration, and tobacco pH. Despite rapid increases in cigar smoking prevalence, the risks of nicotine exposure and addiction have not been systematically studied. For example, although tobacco pH is an important factor in nicotine absorption, there is little evidence of how cigar tobacco pH affects nicotine bioavailability and nicotine absorption, two fundamental aspects in understanding a product’s addictive potential. The goal of this study is to evaluate the nicotine pharmacokinetics and salivary pH of cigar smokers. Specific aims are: (1) to chemically characterize 20 cigars for nicotine content and tobacco pH; and (2) to evaluate the relationship among tobacco pH, salivary pH, and nicotine exposure in non-inhaling large (n=24) and small (n=24) cigar smokers. In three separate sessions designed to equate nicotine consumption, participants will smoke their own brand cigar and two cigars with similar nicotine content but different tobacco pH. Nicotine exposure, subjective effects, and salivary pH will be measured and compared. Study findings will provide new information about the impact of cigar tobacco pH and its relationship with oral nicotine absorption resulting from cigar use. 

Wallace Pickworth, Megan Schroeder, and Lynn Hull Funding Mechanism: Research Contract
ID number: HHSF223201310030I
Institution: Battelle Memorial Institute
07/14/2015

Effect of pH of Smokeless Tobacco Products on the Pharmacokinetics of Nicotine in Current Users

The absorption of nicotine from smokeless tobacco (ST) may be affected by the pH of the product. Increasing the pH of an ST product increases the amount of free base nicotine (the most potent and easily-absorbed form of nicotine) and may increase absorption through the mouth. Although ST products are typically buffered with an alkaline pH (presumably) to facilitate oral absorption of nicotine, clinical data examining this phenomenon are sparse. The goal of this study is to determine whether increasing the pH of an ST product correlates with free base nicotine exposures measured clinically. Study aims are: (1) to evaluate the effect of pH values on the nicotine pharmacokinetics of ST products; and (2) to evaluate the pharmacodynamic effects (e.g., subjective and physiological effects) of ST products with prospectively adjusted pH values. Investigators will ask 40 adult ST users to test one of four ST products (with an adjusted pH of 5, 7.7, 8.2, and 8.6) or a placebo product. Participants will use each product for 30 minutes during a laboratory session. During each session, a series of blood samples will be obtained to determine the time course and nicotine levels resulting from ST product use. In addition, subjective assessments will be administered to determine the qualitative effects of ST product use (e.g., questions about “liking”). Study findings may inform regulatory activities related to smokeless tobacco.

Wallace Pickworth and Elena Mishina Funding Mechanism: Research Contract
ID number: HHSF223201310030I
Institution: Battelle Memorial Institute
07/13/2015

Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers

Compared to the general population, individuals with attention deficit hyperactivity disorder (ADHD) are more likely to smoke, start smoking at a younger age, smoke more, become more dependent, and have a harder time quitting. Reducing the nicotine content of cigarettes has shown promising beneficial effects in the general population, but individuals with ADHD may respond with compensatory increases in smoking, potentially increasing exposure and adverse health effects. The goal of this project is to examine the effects of very low nicotine content (VLNC) cigarettes on smoking behavior and clinical functioning in 200 young adult smokers (ages 18-40) with ADHD. Researchers will randomly assign participants to smoke experimental cigarettes with very low (0.05 mg/cigarette) or conventional (0.8 mg/cigarette) nicotine yield for six weeks, during which participants will provide daily feedback using a telephone-based interactive voice response system and attend weekly visits during which researchers will measure a range of smoking and ADHD-related outcomes. Specific aims are: (1) to assess how VLNC cigarettes impact cigarette smoking and related biomarkers (i.e., expired air carbon monoxide, urine cotinine) and nicotine dependence; (2) to assess how reduced nicotine content influences ADHD symptoms and related measures of cognition (i.e., inhibitory control, working memory) and overall clinical functioning; and (3) to evaluate outcomes associated with acceptability (i.e., withdrawal, study dropout, compliance) and safety/adverse outcomes (i.e., changes in physical health, alcohol/drug use, use of other tobacco products). Data from this study may inform regulatory activities regarding reduced-nicotine tobacco products.

Scott H. Kollins and Frances J. McClernon Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 HD083404-01
Institution: Duke University
07/13/2015

New, Emerging, and Traditional Tobacco Use in the Military

U.S. military personnel are highly vulnerable to tobacco use; currently, more than 30% of active duty military personnel use some type of tobacco product. Researchers will investigate military personnel perceptions, use of traditional, new and emerging tobacco products, and risk factors for use. Specifically, researchers will collect data on 30,000 Airmen, Air National Guard members, and reservists by administering a 97-item written survey at three timepoints (baseline, one year, two years) at the five largest U.S. Technical Training Air Forces Bases. Specific aims are: (1) to determine the prevalence and incidence of traditional, new and emerging, and multiple tobacco product use; (2) to determine social-cognitive (e.g., self-efficacy) and affective (e.g., perceptions, attitudes, beliefs) factors associated with the use of new and emerging tobacco products (such as e-cigarettes, hookah, cigars, and snus) and traditional tobacco products (e.g., smokeless tobacco, little cigars); (3) to evaluate perceptions and beliefs about risks and harms of tobacco product use; (4) to assess the association among awareness of tobacco marketing strategies (e.g., free samples of non-regulated products such as e-cigarettes, price promotions), receipt of information about tobacco products, and tobacco use behaviors; and (5) to directly compare tobacco initiation, resumption, and predictors of tobacco use between Airmen (who remain in active duty) and National Guard/reservists (who train and then return to civilian life). Findings will clarify the prevalence, incidence and diversity of tobacco product use in this highly-vulnerable population and may inform future regulatory activities.

Robert C. Klesges Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 DA037273-01A1
Institution: University of Tennessee Health Science Center
07/07/2015

Toxicant Production and Mitigation in the Electronic-Cigarette Reaction Vessel

E-cigarettes are growing in popularity; however, their health effects are unknown. The goal of this project is to clarify the origins and levels of toxins produced during e-cigarette use as well as the properties of the particles inhaled by users and those exposed to secondhand aerosol. Specific aims are: (1) to define the effect of use on glycerol and propylene glycol, the primary aerosol-forming molecules; (2) to define the effect of use on nicotine and related alkaloids likely to be present in some e-cigarette liquids; (3) to define the effect of flavorings and environmental contaminants on electronic nicotine delivery systems; and (4) to determine the ability of formaldehyde to be released from carrier product molecules and to examine the toxicities of e-cigarette aerosols using various bioassays. Using laboratory analysis techniques such as gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance, researchers will generate predictive models that estimate the products of use and particle size distributions. Study findings may inform regulatory activities related to e-cigarettes.

Robert Strongin Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 ES025257-01
Institution: Portland State University
07/06/2015

Literature Review of the Impact of Tobacco Quantity on Consumer Perceptions, Intentions, and Use Behavior

Research is limited on how different elements of tobacco packaging (e.g., package dimensions, package volume, portion size, portion count per package) affect consumer perceptions, use intentions, and use patterns. The goal of this project is to provide a systematic review of the scientific literature to identify and summarize how the amount of tobacco product in a package affects customer perceptions (e.g., risk/harm perceptions, curiosity, attitudes, beliefs), use intentions (e.g., purchase intentions, use intentions, quit intentions), and use patterns (e.g., product uptake, product re-uptake, increased/decreased product use) of consumer products, with a specific focus on tobacco products. A secondary objective is to identify public health, marketing/sales, and other sources of data related to the effect of these variables on consumer perceptions, use intentions, and use patterns. Study findings may inform regulatory activities related to tobacco packaging.

Raydel Valdes Salgado and David Portnoy Funding Mechanism: Research Contract
ID number: HHSF223201310024I
Institution: SciMetrika
07/06/2015

Cardiovascular Toxicity of Tobacco Products and Constituents

Tobacco product use is associated with increased risk of cardiovascular disease. The goals of this project are to quantify and evaluate the cardiovascular toxicity of the major aldehydes in tobacco products and to validate the association between exposure to these aldehydes and cardiovascular toxicity in humans. Specific aims are: (1) to assess the contribution of aldehydes to the cardiovascular toxicity of tobacco products in mice; (2) to evaluate the cardiovascular toxicity of individual aldehydes and the toxicity modification by nicotine in mice; and (3) to identify aldehyde-induced cardiovascular toxicity in humans. To address Aim 1, researchers will conduct acute and chronic inhalation studies to expose adult male mice to cigarette smoke containing variable levels of acetaldehyde, acrolein, and formaldehyde (which are classified by the FDA as harmful and potentially harmful constituents [HPHCs]) within the range of commercially-available cigarettes or e-cigarette aerosols and evaluate cardiovascular risk factors, including changes in thrombosis, insulin resistance, and plasma lipids. To address Aim 2, researchers will expose adult male mice to different levels of individual aldehydes to determine the dose-response relationship between aldehyde exposure and cardiovascular injury; they will also examine how the presence of nicotine affects aldehyde toxicity and metabolism, and whether dual exposure to tobacco smoke and e-cigarette aerosol results in increased cardiovascular toxicity. To address Aim 3, researchers will use banked blood and urine samples from 350 high-risk cardiovascular disease patients (adult smokers and nonsmokers over age 21 already enrolled in the Louisville Healthy Heart Study) to evaluate whether the cardiovascular toxicity profiles in human smokers are comparable to patterns of aldehyde-induced toxicity in mice. Study findings will provide information about how major aldehydes present in cigarette smoke and e-cigarette aerosols contribute to cardiovascular toxicity.

Daniel J. Conklin Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 HL122676-01A1
Institution: University of Louisville
05/19/2015

Stability Study for Reference Cigarette Tobacco Filler

Little publicly-available information exists regarding the short- and long-term stability of cigarette tobacco filler. Depending on storage conditions and packaging, the characteristics of the tobacco filler may change over time. This project will determine the stability of cigarette tobacco filler at three-month intervals over a 12-month period of time for the certified reference material (SRM 3222) developed at the National Institute of Standards and Technology (NIST). Stability testing will include monitoring the effects of storage temperature and time on levels of three harmful and potentially harmful constituents (HPHCs) — nicotine, N-nitrosonornicotine (NNN), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) — as well as on moisture and pH in cigarette tobacco filler. Stability testing will be conducted using validated, analytical methods.

Andrew Mooney and Matthew Walters Funding Mechanism: Research Contract
ID number: HHSF223201310037I
Institution: Labstat International
05/15/2015

PATH Study Analysis Assays of Multiple Analytes

The Population Assessment of Tobacco and Health (PATH) Study is a longitudinal, nationally representative study of tobacco use and health in the U.S. population.  A cohort of approximately 46,000 adults and youth ages 12 years and older are followed annually for three years to assess use of conventional and emerging tobacco products, attitudes and perceptions related to the use of different tobacco products, and near- and longer-term health outcomes associated with tobacco product use.  The study includes the collection of biospecimens (urine, whole blood, and buccal cells) from adults (ages 18 and older) to examine biomarkers of tobacco exposure and tobacco-related disease processes.  The goal of this project is to measure biomarkers of tobacco exposure and harm in PATH Study participant samples. Levels of interleukin 6 (Il-6) and soluble intercellular adhesion molecule-associated inflammation (sICAM) will be measured in plasma using standard enzyme-linked immunosorbent (ELISA) assays. Fibrinogen activity will be measured in serum using the Clauss assay. These data will be sent to the PATH Study data repository and merged with the main study instrument for future analyses. Results from this project may inform FDA on behaviors and exposures related to tobacco use.

Alim Seit-Nebi and Dana van Bemmel Funding Mechanism: Research Contract
ID Number: HHSF223201510013C
Institution: GenWay Biotech Incorporated, Inc
05/06/2015

Manipulating Cigarette Constituents in Male Menthol Smokers

FDA has the regulatory authority to reduce nicotine levels and ban menthol in cigarettes, but has not yet taken action in either area. In a parent study, researchers are examining the impact of these two potential regulatory actions alone and in combination on smoking behavior in 320 female menthol smokers. In this study supplement, researchers will study 57 male menthol smokers (aged 18-45) in order to examine whether there are gender differences in smoking behavior in response to reduced nicotine levels and menthol content. Specific aims are: (1) to examine gender differences in smoking rates in response to nicotine and menthol content manipulations in menthol smokers; (2) to examine gender differences in smoking motivation in response to nicotine and menthol content manipulations in menthol smokers; and (3) to explore the effect of “supertaster” status (i.e., individuals who experience taste with greater intensity than average) on tolerability of experimental cigarettes, smoking satisfaction, and smoking behavior. Researchers will randomize the male smokers to one of three alternatives – reduced nicotine content (0.07 mg) non-menthol cigarettes, reduced nicotine content (0.07 mg) menthol cigarettes, or conventional nicotine cigarettes (0.8 mg) – for six weeks with an additional six-week follow-up period. Researchers will then compare male and female data related to cigarette usage, exhaled carbon monoxide, and other measures in order to determine differences in use of, dependence on, and craving associated with experimental cigarettes. This study will provide insight into gender-based differences in the impact of menthol and reduced nicotine content cigarettes in menthol smokers.

Cheryl Oncken Funding Mechanism: National Institutes of Health – Grant
ID number: 3 R01 DA036486-02S1
Institution: University of Connecticut School of Medicine
05/05/2015

Clinical Pharmacology of Electronic Cigarettes

Electronic cigarettes (e-cigarettes) are growing in popularity. However, their potential addictiveness and safety of use are unknown. The goal of this study is to evaluate e-cigarettes by assessing key factors associated with nicotine addiction and possible health effects. Specific aims are: (1) to characterize nicotine delivery, systemic exposure and effects following e-cigarette use; (2) to assess the possible health effects of e-cigarette use; and (3) to validate biomarkers to distinguish e-cigarette use from traditional cigarette use.  In this two-week study, 36 dual e-cigarette/traditional cigarette users (ages 18 and older) will switch between the two product types, each to be used exclusively for one week. During each week, subjects’ use and subjective assessments will be tracked for four days as outpatients followed by three days on a research ward. To address Aim 1, researchers will gather information related to the fraction of nicotine inhaled from e-cigarettes that is retained in the body and how retention is influenced by device type, e-liquid nicotine, propylene glycol and glycerin concentrations, e-liquid pH, e-liquid flavor, and battery voltage. Researchers will also evaluate users’ systemic exposure to nicotine and the amount of nicotine exhaled, and how these relate to e-cigarette product characteristics. Finally, researchers will compare e-cigarette and traditional cigarette use with regard to time to peak nicotine concentration; daily intake of nicotine; satisfaction, reward, craving and withdrawal symptoms; and puff patterns.  To address Aim 2, researchers will compare dual use, e-cigarette use alone, traditional cigarette use alone, and no product use with regard to levels of exposure to tobacco smoke toxicants (particularly volatile organic compounds) and cardiovascular effects. To address Aim 3, researchers will evaluate whether the ratio of nicotelline to nicotine metabolites (cotinine or total nicotine equivalents) in urine distinguishes e-cigarette use from traditional cigarette use.  Findings may inform regulatory activities related to e-cigarettes. 

Neal Benowitz Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 DA039264-01
Institution: University of California, San Francisco
04/24/2015

Composition and Biologic Effects of Flavored E-Liquids

E-cigarettes are sold in many flavors, yet little is known about the impact of inhaling their chemical constituents or biological and psychophysiological effects and psychosocial influences contributing to their addictive properties. Both the tongue and the lung express taste receptors that elicit biological responses when savory, sweet and bitter compounds are detected. The goal of this supplement to an ongoing study is to determine the reinforcing properties of different e-liquid flavorings, determine the biological effects of flavored/sweet e-cigarette on taste receptors, and further determine the chemical constituents of e-liquids. Study aims are: (1) to determine the composition of flavored e-liquids by using mass spectrometry; (2) to determine the biologic effects of e-liquids by measuring the in vitro response of bitter and sweet taste receptors following exposure to common brands of e-liquids; and (3) to perform a psychophysical and psychosocial evaluation of the reinforcing properties of e-cigarette flavors, including menthol, to determine which flavors are associated with varying reinforcing and analgesic properties and how psychosocial stress affects the reinforcing properties of e-cigarettes. As part of Study Aim 3, researchers will test 75 adults (ages 18-45). Study findings may inform regulatory activities related to e-cigarette flavorings.

Robert Tarran Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 HL120100-02S2
Institution: The University of North Carolina at Chapel Hill
04/24/2015

CTP Supplement to Parent Grant: The Impact of Tobacco Exposure on the Lung’s Innate Defense System

E-cigarettes are sold in many flavors, yet little is known about the impact of inhaling their chemical constituents or biological and psychophysiological effects and psychosocial influences contributing to their addictive properties. Both the tongue and the lung express taste receptors that elicit biological responses when savory, sweet and bitter compounds are detected. The goal of this supplement to an ongoing study is to determine the reinforcing properties of different e-liquid flavorings, determine the biological effects of flavored/sweet e-cigarette on taste receptors, and further determine the chemical constituents of e-liquids. Study aims are: (1) to determine the composition of flavored e-liquids by using mass spectrometry; (2) to determine the biologic effects of e-liquids by measuring the in vitro response of bitter and sweet taste receptors following exposure to common brands of e-liquids; and (3) to perform a psychophysical and psychosocial evaluation of the reinforcing properties of e-cigarette flavors, including menthol, to determine which flavors are associated with varying reinforcing and analgesic properties and how psychosocial stress affects the reinforcing properties of e-cigarettes. As part of Study Aim 3, researchers will test 75 adults (ages 18-45). Study findings may inform regulatory activities related to e-cigarette flavorings.

Robert Tarran Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 HL120100-02S2
Institution: The University of North Carolina at Chapel Hill
04/20/2015

GSU TCORS: Testing Displays and Understanding of HPHCs

FDA is required by law to establish and make publicly available a list of harmful and potentially harmful constituents (HPHCs) in tobacco that is understandable and not misleading to the public. This study has two aims: (1) to determine how to best present information on HPHCs to consumers in a way that is understandable and not misleading, and (2) to test the relative effectiveness of different HPHC information formats by education level. In Aim 1, investigators will develop four visual formats to communicate information about the quantity of HPHCs in tobacco products. Each format will present information on the quantity of constituents selected from the list of HPHCs for which testing methods are established and widely available. The most simplistic of these formats will provide only numerical information listing the yields of constituents; the remaining formats will convey this information using visual or graphical presentations. Information about the health effects associated with each constituent will also be included. In Aim 2, investigators will evaluate the effectiveness of the four formats by testing them in a sample of 2,000 adult smokers (ages 18 and older), evenly split between low and high education level. Participants will be randomly assigned to receive one of the four formats or no information; participants will then complete a short survey about verbatim and gist knowledge of HPHCs, understandability of the information presented, and the extent to which the information presented might be misleading. Study findings may inform regulatory activities related to the development and public dissemination of an HPHC list.

Michael Eriksen Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 DA036128-02S1
Institution: Georgia State University Research Foundation
03/30/2015

Measurement of Nicotine Dependence among Adolescent and Young Adult Cigarillo Users

Cigar, cigarillo, and little cigar (CCLC) use increased 124% between 2000 and 2012. Adolescents and young adults are the most prevalent users; in some geographic areas, CCLC use now exceeds cigarette use among adolescents. Recent evidence shows that CCLC users inhale when smoking and that CCLC products contain as much or more nicotine than cigarettes. Therefore, assessing nicotine dependence among CCLC users is critical to understanding use behavior. Product-specific measures are needed to more precisely assess nicotine dependence, but no CCLC-specific nicotine dependence measures exist. The goal of this study is to establish a CCLC nicotine dependence symptom measurement tool that is relevant, valid, and reliable for use in adolescents (ages 13-17) and young adults (ages 18-38). Using an array of rigorous methods (including qualitative in-depth interviews with 40-60 participants, Rasch modeling for measure development, and survey and biomarker data), investigators will create and validate a measurement tool. The tool will then be administered to 1,000 adolescents using the National Youth Risk Behavior Survey to assess the prevalence of nicotine dependence symptoms among CCLC users. Study findings may inform regulatory activities related to CCLC products.

Susan A. Flocke Funding Mechanism:  National Institutes of Health – Grant
ID number:  1 R01 CA190130-01
Institution: Case Western Reserve University
03/26/2015

Effect of Packaging on Smoking Perceptions and Behavior: A Randomized Trial

The impact of cigarette packaging and labeling on consumer perceptions and smoking behavior and the effectiveness of graphic warning labels for communicating tobacco product risks are two critical topics warranting further study. In a randomized controlled trial, investigators will enroll 450 committed smokers (ages 21-50 years) who currently smoke at least five cigarettes per day and who have no intention of quitting in the next six months. Study aims are: (1) to test how standard tobacco industry imagery from U.S. cigarette packs influences consumer perceptions of their cigarettes; (2) to test whether adding large graphic warning labels increases perceptions of the harm of tobacco products; and (3) to test whether the Australian model packs result in a change in cigarette pack handling, consumption patterns, and quitting cognitions. For four months, participants will order their cigarettes on a secure study website and have them delivered within two days. Participants will be randomized to receive one of three types of cigarette packs: a) cigarettes repackaged in a plain pack, with the Surgeon-General’s warning labels but no tobacco marketing; b) cigarettes repackaged into the Australian-type pack (large graphic warning label, highlighted warning labels but no tobacco marketing) and c) a standard U.S. pack. During the course of the study, participants will: a) complete a web-based questionnaire; b) provide a saliva sample for cotinine analysis; c) undergo a laboratory-based motion sensor technology assessment that will measure pack handling and time interacting with warning labels; and d) participate in interactive messaging. Research findings may inform regulatory activities related to cigarette packaging and labeling.

David Strong and John P. Pierce Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 CA190347-01
Institution: University of California San Diego
03/12/2015

Microbial Populations and the Development of Tobacco Specific Nitrosamines in Moist Snuff Products

Certain bacteria and fungi in tobacco may contribute to the development of tobacco-specific nitrosamines (TSNAs), which are cancer-causing substances in smokeless tobacco and other tobacco products. The goal of this study is to evaluate potential additional ways that TSNAs can be limited in smokeless tobacco products. Study aims are: (1) to determine whether there is a difference in the types of bacteria and fungi found in products purchased at different times of the year; (2) to compare the TSNA levels with the types of microorganisms present; and (3) to examine the impact of storage time and temperature on microbial populations and TSNA levels. Researchers will count cultured bacteria and fungi from moist snuff, identify unique strains using DNA sequencing, and evaluate these strains for their ability to reduce nitrate and nitrite, which are associated with TSNA development. Researchers will also analyze the total microbial DNA in snuff to determine the relative proportions of microorganisms present in the samples, and will screen them by polymerase chain reaction (PCR) for nitrate and nitrite reductase genes. Some bacteria and fungi can convert the nitrate in tobacco to nitrite, which then reacts with chemicals such as nicotine to yield TSNAs; thus, strains able to reduce nitrate and/or nitrite will be spiked into snuff to determine whether they affect TSNA development. Nitrosamine content in snuff samples will be measured by ultra-performance liquid chromatography and tandem mass spectrometry-based methods. Finally, researchers will evaluate the impact of storage conditions to determine the effects of time and temperature on microbial changes and TSNA production. The results should clarify the additional factors that contribute to TSNA development and identify additional conditions that can minimize the impact of TSNAs on user health, and thus may inform regulatory activities related to smokeless tobacco.

Steve Foley and Colleen Rogers Funding Mechanism:  Internal FDA
ID number: C13061/E07568.01
Institution: National Center for Toxicological Research (NCTR)
03/01/2015

Analysis of Smokeless Tobacco Products for NNN

A chemical analysis of smokeless tobacco products to determine quantities of N’-nitrosonornicotine (NNN), a known tobacco product carcinogen, can aid FDA in the review and assessment of product reports that include  this reporting requirement.  This project will measure NNN quantities and moisture levels in 35 smokeless tobacco products currently marketed in the U.S. using a validated testing method. (Project completed in 2015.)

Andrew Mooney and Matthew Walters Funding Mechanism: Research Contract
ID Number: HHSF223201310037I
Institution: Labstat International ULC
03/01/2015

Comparison of TNCO Yields Generated by the ISO and a Modified ISO Smoking Regimen

Measurement of the quantities of tar, nicotine, and carbon monoxide (TNCO) in the mainstream smoke of cigarettes currently marketed in the U.S. will provide important information about these constituents. The purpose of this project is to determine the differences between TNCO yields generated under the smoking regimen defined by the International Standards Organization (ISO) and yields generated under a modified version of the ISO regimen. Researchers will test approximately 35 different cigarette brands using smoking machines using the ISO and modified ISO smoking regimens; researchers will determine whether there are differences in TNCO smoke yields between these two regimens.  (Project completed in 2015.)

Andrew Mooney and Matthew Walters Funding Mechanism: Research Contract
ID Number: HHSF223201310037I
Institution: Labstat International ULC
02/22/2015

UMD TCORS: Sweet Flavors in E-Liquids

Initial data indicate that e-cigarette flavors perceived as sweet are appealing to young adults and smokers trying to quit combustible cigarette smoking; however, little is known about how sweet e-cigarette flavors influence initiation, maintenance, and smoking cessation. There are also little data on the identity and amounts of the chemicals users inhale when using an e-cigarette flavor perceived as sweet. In this supplement to an ongoing study, investigators will measure the subjective responses (using sensory and hedonistic scales) to seven flavors of a popular commercial e-cigarette of 80 established e-cigarette users (ages 18 and older); participants will include both former and current combustible cigarette smokers. Investigators will then use standard liquid chromatography techniques and two-dimensional gas chromatography with time-of-flight mass spectrometry to analyze the e-cigarette liquids to identify and quantify the chemicals most likely associated with perceptions of sweetness, and will evaluate these compounds for toxicity. Finally, to determine how sweet flavors may be used to mask the bitterness of nicotine, investigators will quantify the sweet-associated chemicals across varying nicotine strengths to determine how levels of these compounds may change with changing nicotine level. Study results may inform regulatory activities related to e-cigarettes and flavors.

Pamela I. Clark Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 CA180523-02S1
Institution: University of Maryland
02/12/2015

Impact of Flavors in Tobacco Products: An Experimental Market Analysis

The impact of flavors on the attractiveness and use of tobacco products warrants further study. The aims of this supplement to an ongoing study are: (1) to estimate the impact of flavors on tobacco product attractiveness and use in experimental markets in which low socioeconomic status (SES) adult tobacco users (ages 18 and older) will make choices between cigarettes, smokeless tobacco, little cigars and cigarillos, and e-cigarettes; and (2) to cross-validate the experimental market analysis through analysis of existing data on consumer purchases and retailer sales of cigarettes, smokeless, little cigars, cigarillos, and e-cigarettes in actual markets. To accomplish Aim 1, investigators will use a mobile laboratory to conduct discrete choice experiments with 500 low-SES adult tobacco users; participants will be asked to make purchase decisions under multiple scenarios in which the products stay the same but the products’ characteristics, such as flavors, vary. To accomplish Aim 2, investigators will analyze existing Nielsen consumer panel and retailer scanner data in several markets; investigators will then develop a model that predicts consumer product choices under different market conditions. Study findings may inform regulatory activities related to tobacco product flavors.

Sahara Byrne Funding Mechanism:  National Institutes of Health- Grant
ID number: 3 R01 HD079612-01S1
Institution: Cornell University
02/10/2015

USC TCORS: Abuse Liability of Flavored E-Cigarettes with and without Nicotine

Data characterizing the variation in abuse liability across different types of e-cigarettes are scant. Flavoring in e-cigarettes is a critical dimension of product diversity that may modulate abuse liability. Young adults may be especially vulnerable to using sweet-flavored e-cigarettes. The goal of this supplement to an ongoing study is to evaluate the abuse liability of sweet-flavored e-cigarettes with and without nicotine in 30 young adult e-cigarette users (ages 18-35). Study aims are: (1) to identify the main effects of sweet flavored (vs. unflavored) e-cigarettes on abuse liability; (2) to identify the main effects of nicotine (vs. placebo) e-cigarettes on abuse liability; and (3) to identify the interactive effects of flavoring and nicotine on abuse liability. Participants will attend four laboratory sessions following 16-hour abstinence; all sessions will be identical except the study e-cigarette flavor/drug combination supplied in a particular visit will vary (flavored + nicotine [18 mg/mL]; unflavored + nicotine [18 mg/mL]; flavored + placebo [0 mg/mL]; unflavored + placebo [0 mg/mL]). At each visit, investigators will evaluate subjective and physiological abuse liability measures (e.g., mood enhancement, nicotine withdrawal suppression, food craving suppression, heart rate); participants will also complete an objective behavioral task to measure product reinforcement. Study findings may inform regulatory activities related to e-cigarette flavors.

Jonathan Samet Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 CA180905-02S1
Institution: University of Southern California
02/10/2015

The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence

E-cigarettes contain variable quantities of nicotine and non-nicotine tobacco alkaloids (NNTAs) (including anabasine, anatabine, nornicotine and myosmine), which are also present in conventional cigarettes. However, virtually no information is available concerning the role of e-cigarette nicotine or NNTA content in influencing the concurrent use of cigarettes and e-cigarettes (dual use); additionally, it is not known whether the presence of nicotine and NNTAs in e-cigarettes sustain dependence. This study will assess the effects of e-cigarette nicotine and NNTA content on 375 adult daily cigarette smokers (ages 18-65). Study aims are: (1) to assess the role of e-cigarette NNTA content in affecting dual use; (2) to assess the role of e-cigarette nicotine content in affecting dual use; and (3) to determine the relationship between dependence and systemic levels of nicotine and NNTAs. Participants will be randomized to one of three groups. Group 1 will use e-cigarettes that yield nicotine and NNTAs in the range of typical commercial cigarettes (e.g., 0.6 mg nicotine delivered in 10 puffs of 35 mL, with a ratio of NNTA to nicotine yield that is also typical of cigarettes). Group 2 will use e-cigarettes that contain minimal nicotine and NNTAs (less than 1/10 that of Group 1). Group 3 will use e-cigarettes that contain propylene glycol and extract from low nicotine/NNTA content tobacco (this group will control for changes in cigarette consumption that may occur due to study participation or to the non-nicotine behavioral/sensory factors associated with e-cigarette use, which could influence cigarette consumption). Dependence and dual use will be assessed according to: self-report diaries in which participants will track daily number of cigarettes smoked and number of occasions of e-cigarette use; cotinine concentrations and NNTA levels measured in urine, plasma, and saliva; various nicotine dependence, craving, and withdrawal measures; and tobacco abstinence after 12 weeks. Study findings may inform regulatory activities related to e-cigarettes.

Jed E. Rose Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 DA038554-01
Institution: Duke University
02/03/2015

E-Cigarettes: Dynamic Patterns of Use and Health Effects

E-cigarettes have been rapidly adopted in the U.S., but data on e-cigarette use and its effects are limited. This study will generate in-depth, long-term data based on real-time reports that will examine the relationship between e-cigarette use and: 1) nicotine dependence; 2) reductions in conventional cigarette use; 3) health-related indicators such as biomarkers of exposure, carcinogens, and acute and long-term pulmonary health; and 4) attempts to quit conventional cigarette use and the success of those attempts. Over two years, investigators will collect data from 150 adult smokers (ages 18 and older) who exclusively smoke conventional cigarettes and 250 adult dual users of e-cigarettes (ages 18 and older) and conventional cigarettes. Investigators will use ecological momentary assessment to determine: 1) changing patterns of e-cigarette and conventional cigarette use and related outcomes (e.g., dependence, withdrawal symptoms, reward value, conventional cigarette quit attempts and quitting success); 2) stable and episodic variables (e.g., lifestyle factors, demographics) that vary with e-cigarette and conventional cigarette use and related outcomes; and 3) targeted biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., pulmonary function). Investigators will analyze data gathered over time and will compare the dual use and conventional cigarette use groups. This study will yield information about patterns of real-world e-cigarette use and how such use is related to conventional cigarette smoking and associated health risks, and may inform future regulatory activities.

Megan Piper and Douglas E. Jorenby Funding Mechanism:  National Institutes of Health – Grant
ID number: 1 R01 CA190025-01
Institution: University of Wisconsin-Madison
01/30/2015

CTP Supplement to Parent Grant: Improved Models to Inform Tobacco Product Regulation

The impact of flavors and packaging of cigarettes, cigars, e-cigarettes, and smokeless tobacco are not well known. This supplement to an ongoing study will expand two projects of the University of California San Francisco Tobacco Center of Regulatory Science to include a focus on flavors and package characteristics. Study aims are: 1) to determine how flavors affect perceptions of risks, benefits, attractiveness and acceptability of tobacco products across age groups; 2) to determine how packaging characteristics affect perceptions of whether a product is flavored and perceptions of risks, benefits, attractiveness and acceptability of the product across age groups; 3) to determine the relationships among perceptions of flavored tobacco products and the onset, experimentation, continuation, cessation, relapse, re-initiation, switching, and dual/poly use of tobacco products including cigarettes, cigars, e-cigarettes, and smokeless tobacco; and 4) to determine the effect of flavors on the uptake, retention and rewarding effects of nicotine in users of second-generation e-cigarette devices. The project will collect the needed data by expanding the data collection in existing projects; data will be collected from urban and rural youth and from e-cigarette users who have been recruited to participate in studies of the dynamics of nicotine in the blood of e-cigarette users. Project expansions will extend the Center’s current research examining how flavor effects are mediated by psychosocial and bio-behavioral determinants. Study findings may inform regulatory actions related to tobacco product flavors and packaging.

Stanton Glantz Funding Mechanism: National Institutes of Health – Grant
ID number: 3 P50 CA180890-02S1
Institution: University of California – San Francisco
01/29/2015

CTP Supplement to Parent Grant: Fetal Behavior, Brain & Stress Response: Ultrasound Markers of Maternal Smoking

Maternal tobacco use during pregnancy is a significant public health problem. Pregnant women may be vulnerable to the appeal of tobacco product flavorings due to alterations in taste, cravings, nausea, as well as to variable patterns of tobacco use during pregnancy. In this supplement to an ongoing study, 50 pregnant smokers and non-smokers (ages 18-40) will complete detailed interviews and self-report measures regarding perceptions and use of flavors/flavored products. Study aims are: (1) to evaluate the impact of flavors/sweetness on perceptions and attractiveness of tobacco products in pregnant smokers and non-smokers, and (2) to evaluate the impact of perceptions of flavors/sweetness on use of flavored tobacco products in pregnant smokers and non-smokers. Study findings may inform regulatory activities related to tobacco product flavors.

Laura Stroud Funding Mechanism: National Institutes of Health – Grant
ID number: 3 R01 DA036999-02S2
Institution: The Miriam Hospital
01/23/2015

Yale TCORS: Chemosensory and Physicochemical Factors in Flavor Sweetness of Tobacco Products

Flavors and sweeteners are present in most e-cigarette solutions and cigars/cigarillos, and are emerging as important determinants of use behaviors; thus, an understanding of how characteristics like smell, taste and constituents alter tobacco product perceptions is critical. This supplement to ongoing research conducted by the Yale Tobacco Center of Regulatory will combine systematic psychophysical measurements of sweet flavor perception and liking with detailed chemical analyses of the base constituents, flavoring and sweetener agents in e-liquids/vapors. The psychophysical measurements will be conducted on 60 adult smokers (ages 18-45) and will include subjective ratings of perceived sweetness, overall flavor intensity, irritation/harshness, and liking/disliking collected using computerized labeled magnitude scales Investigators will also conduct preliminary chemical analyses of the flavor/sweetener composition of cigars/cigarillos, which will be used to support future psychophysical experiments on these products. Study aims are: 1) to determine whether the vegetable glycerin/propylene glycol ratio in e-liquid bases affects the sweetness of e-cigarette flavors; (2) to determine how flavor additives interact to produce the perceived sweetness of e-cigarette liquids containing nicotine; (3) to conduct analytical characterizations of flavors, sweeteners, and nicotine in e-liquids and aerosols, and (4) to initiate exploratory characterizations of flavors and sweeteners in cigar/cigarillo wrapping papers. Study findings may inform regulatory activities related to flavors in e-cigarettes and cigars/cigarillos.

Suchitra Krishnan-Sarin Funding Mechanism:  National Institutes of Health – Grant
ID number: 3 P50 DA036151-02S1
Institution: Yale University
01/22/2015

VCU TCORS: Evaluating Flavors in Novel Tobacco Products: A Transdisciplinary Approach

A model for predicting the harm or risk associated with potential modified risk tobacco products (tobacco products marketed with the claim that they reduce harm or risk associated with conventional products) is needed. This project, conducted by the Center for the Study of Tobacco Products (CSTP) at Virginia Commonwealth University, will extend CSTP’s evaluation model to examine the effects of tobacco product flavors and nicotine content on measures related to initiation and subsequent use in young adults. Specifically, the goal of this project is to evaluate the influence of e-cigarette flavor and nicotine content on user perceptions and measures of abuse liability. In one study, investigators will characterize the perceived effects of e-cigarette flavors by analyzing data gathered from 45 young adult e-cigarette users (ages 18-21) who report a history or preference for flavored (tobacco/menthol, fruit, and food/dessert) e-liquids; investigators will also examine the influence of preferred e-cigarette nicotine content. In a second study, investigators will examine the individual and combined effects of e-cigarette flavors and nicotine content on subjective measures of abuse liability among 28 young adult conventional tobacco cigarette smokers (ages 18-21). Results from the first study will inform the choice of specific flavors to be tested in the second study. Study findings may inform regulatory activities related to flavorings and nicotine content in e-cigarettes and other tobacco products.

Thomas Eissenberg Funding Mechanism:  National Institutes of Health – Grant
ID number: 3 P50 DA036105-02S1
Institution: Virginia Commonwealth University
12/10/2014

The Time Course and Clinical Significance of Early E-cigarette Withdrawal Effects

Data on the time course and clinical significance of e-cigarette withdrawal do not exist, and therefore a complete understanding of the addictive nature of these products is unknown. This study will characterize the early time course, clinical significance, and moderators of e-cigarette withdrawal effects, and will compare the early withdrawal effects of e-cigarettes to those of tobacco cigarettes. Participants will include 150 e-cigarette users and 150 tobacco cigarette users (ages 18 and older); some participants may be exclusive users of their product. Baseline measures will include demographic characteristics, e-cigarette history and use characteristics, nicotine dependence, abstinence-related thoughts and expectations, and intolerance for abstinence discomfort. Participants will then participate in one of two experimental sessions: four hours of abstinence or use as usual. Withdrawal effects will be measured every 30 minutes, and will include negative affect (Wisconsin Smoking Withdrawal Scale), physical symptoms (Minnesota Nicotine Withdrawal Scale), multifaceted craving (Tobacco Craving Questionnaire), anhedonia (Tripartite Pleasure Inventory), perceived reinforcement value of smoking (Cigarette Choice Procedure), and open-ended report. At the conclusion of the four-hour period, participants will complete the Behavioral Smoking Lapse Analogue Task, a task that measures the ability to resist the temptation to use e-cigarettes or cigarettes under conditions in which it is advantageous to remain abstinent. Analyses will evaluate e-cigarette withdrawal effect differences between abstinent and non-abstinent sessions, test the relationships between e-cigarette withdrawal effects and Behavioral Smoking Lapse Analogue Task performance, and determine if withdrawal effects and Behavioral Smoking Lapse Analogue Task performance differ between e-cigarette and tobacco cigarette users and across baseline measures. Study findings may inform regulatory activities related to e-cigarettes.

Peter S. Hendricks Funding Mechanism: National Institutes of Health – Grant
ID number: 1 R01 DA036027-01A1
Institution: University of Alabama at Birmingham
12/09/2014

Adolescent Rodent fMRI Model of Nicotine Dependence

A cingulate-striatal addiction circuit, a neurological connection in the brain that has been identified in humans who are addicted to tobacco (but not in tobacco users who are not addicted), has been developed for use as a rodent model of nicotine addiction. This project extends the pilot study that established this circuit in rodents by examining factors that could alter the development of addiction. The circuit will be evaluated using resting state functional connectivity MRI, an imaging technique that measures brain activity while the subject is not engaging in any particular task or activity. Since adolescence is the time of susceptibility to developing nicotine addiction, this project will examine the developmental trajectory of the circuit as a biomarker of nicotine addiction in adult versus adolescent rats. The impact of nicotine dose, age, and time course of nicotine exposure on circuit development and strength will be examined and analyzed in relation to the withdrawal/extinction time course. Specific aims are: 1) to compare the dose response range of nicotine exposure that elicits enhanced nicotine dependence in adolescent versus adult rats; 2) to identify the circuit strength associated with increased behavioral measures of nicotine dependence following adolescent rat nicotine exposure; and 3) to identify adolescent rat brain structure changes associated with enhanced behavioral measures of nicotine dependence. As a biomarker of addiction, this circuit may subsequently be used to investigate the abuse liability of various tobacco products and constituents, which could inform future regulatory activities.

Elliot Stein and Kia Jackson Funding Mechanism: Interagency Agreement
ID number: 224-15-9004
Institution: National Institutes of Health – Contract
11/05/2014

Pharmacokinetic Analysis of Nicotine in Sprague-Dawley Rats

Accurately predicting nicotine uptake and disposition would be useful for assessing the dose-response effects of nicotine across organ systems. This study will: (1) establish data on nicotine distribution in rats following exposure through three different routes of administration (intravenous, oral, and inhalation), and (2) generate a mathematical model that determines the parameters of nicotine distribution, metabolism, and excretion in rats. The results of this study will aid in the understanding of nicotine disposition in blood and other tissues based on the route of administration and will inform model development.

Susan Chemerynski and Steven Yee Funding Mechanism: Internal FDA
ID number: C14049 / E07607.01
Institution: National Center for Toxicological Research (NCTR)
09/30/2014

Implementation of Evaluation Plan to Evaluate the City of Chicago Flavored Tobacco Ban Near Schools

The City of Chicago ban on the retail sale of all flavored tobacco products within 500 feet of elementary, middle or secondary schools went into effect in July 2014. Investigators at the Research Triangle Institute, the Institute of Health Research and Policy at the University of Illinois at Chicago, and the Chicago Department of Public Health will evaluate how this ban affects Chicago’s retail marketing environment. Specifically, investigators will assess the immediate (five weeks post-ban) and short-run (seven months post-ban) impact of marketing-related policies and how this impact varies by communities’ socio-economic, demographic and geographic characteristics. Study aims are: (1) to determine whether product availability, placement, promotion, and price of tobacco products have been affected by the ban, and (2) to determine whether the ban has affected the retail market for tobacco products in general. Investigators will collect data on flavored tobacco product availability, placement, promotion (i.e., advertising) and price post-implementation (5 weeks and 7-month follow-up) in 277 retail stores directly affected by the ban and two comparison groups: (1) 312 licensed tobacco retail outlets within 501-1000 feet of schools; and (2) 335 licensed tobacco retail outlets beyond 1000 feet of schools. Post-implementation data will be compared to baseline data (which was collected in May and June 2014). In addition to the store observations, investigators will interview 90 tobacco retailers and conduct focus groups with 40 youth (ages 14-17) in order to understand how the flavored tobacco ban impacts each of these populations. Study findings may inform potential regulatory actions regarding the sale of flavored tobacco products.

Todd Rogers and Tarsha McCrae Funding Mechanism: Research Contract
ID number: HHSF223201310007B
Institution: Research Triangle Institute
09/30/2014

Implementation of Evaluation Plan of the NYC Ban on Non-cigarette Flavored Tobacco Products

The New York City ban on non-cigarette flavored tobacco products, which went into effect in October 2009, prohibited the sale of all non-cigarette flavored tobacco products in the city. This evaluation will focus on how the ban was implemented and whether implementation had the intended effects and/or yielded any unintended consequences. In particular, the evaluation will address the effects of the ban on retailers and consumers, exploring compliance with the law, sales of specific products, purchasing patterns, product use, and quitting behavior. The investigators will employ a multi-method approach, including the compilation and analysis of existing survey data as well as and the collection of newly-collected quantitative (e.g., retail observational studies) and qualitative (e.g., policy analysis, interviews with tobacco retailers and other stakeholders) data. Findings may inform potential regulatory actions regarding flavored tobacco products.

Todd Rogers and Tarsha McCrae Funding Mechanism: Research Contract
ID number: HHSF223201310007B
Institution: Research Triangle Institute
09/30/2014

Enhancing Tobacco Surveillance through Online Monitoring

Epidemico, a research and informatics company, has developed a social media monitoring tool (MedWatcher Social) that mines online sources (e.g., Twitter, Facebook, online forums, blogs, electronic news sites, Internet searches) for information that can be used for a wide range of activities, including supporting drug safety surveillance and tracking disease outbreaks.  This project will expand that monitoring tool to provide new information about tobacco use, perceptions, attitudes and adverse health experiences reported by tobacco product users. Toward that end, Epidemico will develop unique acquisition and storage technology, mapping strategies, and algorithms to gather and classify data in social media, and will develop methods for analyzing and presenting this data. Research areas that may be explored include (1) examining time-related patterns in the volume of social media posts according to tobacco product type, brand, and subbrand; (2) describing social media posts related to the adverse health experiences of users of new products; and (3) describing feelings (positive/negative/neutral) associated with social media posts, including how feelings vary across tobacco product types, brands and subbrands. This project is intended to complement traditional methods of tobacco monitoring and surveillance by providing additional sources of information on tobacco use and related behaviors.

Nabarun Dasgupta and Katherine Margolis Funding Mechanism: Broad Agency Announcement (BAA)
ID number: HHSF223201400184C
Institution: Epidemico
09/16/2014

Behavior and Toxicant Exposure among Dual Users of Cigarettes and E-Cigarettes

Little is known about how dual use of traditional cigarettes and electronic cigarettes (e-cigarettes) influences measures of tobacco-related harm, including use patterns and toxicant exposure. The goal of this study is to evaluate measures of potential harm associated with dual cigarette and e-cigarette use. Specific aims are: (1) to evaluate changes in tobacco product consumption during dual use in comparison to single product use; and (2) to evaluate changes in toxicant exposure during dual use in comparison to single product use and no tobacco/nicotine use. Researchers will enroll 28 dual users of cigarettes and e-cigarettes aged 18-60 to complete four study conditions (dual use, cigarette-only use, e-cigarette-only use, and no tobacco/nicotine use), each lasting five days. Researchers will evaluate and compare conditions by measuring product consumption, toxicant exposure (i.e., carbon monoxide, cotinine, and total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL]), physiological data (i.e., heart rate, blood pressure), and subjective indicators related to nicotine effects and nicotine abstinence-related symptoms. Results may provide new information about whether dual use of cigarettes and e-cigarettes decreases, has little effect on, or increases measures of potential harm relative to single product use and no tobacco/nicotine use.

Caroline O. Cobb Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R21CA184634-01
Institution: Virginia Commonwealth University
09/12/2014

Cognitive Testing of Measurement Instruments for the Consumer Comprehension of Displays of Harmful and Potentially Harmful Constituents (HPHCs) in Tobacco Products Study

This qualitative study will gather information about different ways of presenting harmful and potentially harmful constituent (HPHC) information by brand and by quantity in a format that is understandable and not misleading to a layperson. Qualitative and in-depth interviews will be with a total of nine participants. Adult participants (aged 18 and older) will be current or former tobacco (cigarette and smokeless) users; youth participants (aged 14-17) will also include those who are susceptible to tobacco use. Topics covered in the interviews will include what participants know and perceive about HPHCs in tobacco products, how and in what formats do they prefer to receive information regarding HPHCs, and how they understand and perceive the information about HPHCs provided in four sample formats. Findings may inform regulatory activities related to the presentation of HPHC information.

Anh “Bao” Zarndt Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: Research Triangle Institute International
09/12/2014

Cognitive Testing of Cigarette and Snus Perception Items

Researchers will conduct cognitive interviews with eight tobacco users in May 2015 to test survey questions proposed for use in research on consumer perceptions, awareness, beliefs, and behaviors related to cigarettes and snus. The objectives of the cognitive interviews are: (1) to assess participants’ comprehension of survey questions; (2) to understand how new or revised questions affect the usability of existing surveys; and (3) to provide insights that may be used to improve the survey design as needed. Findings from these interviews will be used to inform the measurement of consumer perceptions, awareness, beliefs, and behaviors regarding tobacco use.

Anh “Bao” Zarndt Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: Research Triangle Institute International
09/12/2014

Cognitive Interviews with Adult E-Cigarette Users to Inform Label Development

The goal of this study is to conduct cognitive interviews with adult male and female e-cigarette users to inform the development of e-cigarette warnings. Nine participants will be interviewed in Philadelphia, PA. The interviewer will use a semi-structured guide to obtain participants’ reactions to and input on various e-liquid warning text and images describing the acute toxic effects of e-liquids.

Anh “Bao” Zarndt Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: Research Triangle Institute International
09/12/2014

Developing and Testing Warning Statements about E-cigarettes

Few research studies have explored whether smokers have concerns about the safety of e-cigarettes and whether such information might impact e-cigarette risk perceptions and use intentions. The goal of this project is to develop and test potential future warning statements for e-cigarette products and advertisements. Specific aims are: (1) to explore smokers’ perceptions of e-cigarette risks and potential warning statements; (2) to obtain feedback from tobacco control experts on potential e-cigarette warning statements; and (3) to examine the impact of different e-cigarette warning statements on smokers’ e-cigarette risk perceptions and use intentions. To accomplish Aim 1, researchers will conduct eight focus groups with adult smokers and e-cigarette users (four in-person and four online groups, 8-12 participants each, aged 18 and older) to explore their e-cigarette risk perceptions, learn their beliefs about whether e-cigarette products should carry warning labels, and obtain feedback on preliminary concepts for e-cigarette warning statements and ideas for alternative statements. To accomplish Aim 2, researchers will survey 50-75 tobacco control professionals with expertise in e-cigarettes and warning label research to obtain their feedback on warning statements. To accomplish Aim 3, researchers will randomly assign 600 adult smokers to view one of three potential e-cigarette warning labels and then survey participants about various attributes, including efficacy. Researchers will also use eye-tracking technology on 30 adult smokers to assess the potential impact of different warning sizes and placements. Research findings may help inform future regulation related to e-cigarette labeling and warnings and evaluation of e-cigarette communication messages.

Olivia Wackowski Funding Mechanism:  National Institutes of Health- Grant
ID Number: 1K01CA189301-01
Institution:  RBHS School of Public Health
09/12/2014

Communicating Harm of New Tobacco Products

Despite significant gains achieved by public education campaigns, many people still underestimate the risks of tobacco use. The situation is compounded by aggressive marketing of new and alternative tobacco products, such as snus, dissolvables, and electronic cigarettes. The goal of this project is to determine effective ways to communicate the harm of tobacco products. Specific aims are: (1) to identify the key features (e.g., naming specific diseases, depicting affected body parts, listing harmful chemicals) of anti-tobacco messages with high informational and emotional ratings; (2) to compare the effects of “information only” and “information + emotion” messages on harm perceptions, use intentions, and attitudes toward tobacco control regulation; and (3) to determine how communication about cigarettes vs. new and alternative tobacco products impacts message processing and responses to anti-tobacco messages among different subpopulations (i.e., current smokers, former smokers, and non-smokers). To accomplish these aims, a total of 7,050 adult (aged 18 and older) current, former, and non-smokers will participate in five studies. Participants will be shown text- and image-based messages conveying the harms of established and new tobacco products and then complete a self-administered online survey evaluating emotion, informativeness, message efficacy, processing time, and other variables such as perceived harm and support for tobacco regulation. This research may inform the FDA’s policymaking and educational efforts related to new and established tobacco products.

Lyudmila Popova
 
Funding Mechanism:  National Institutes of Health- Grant
ID Number: 1K99CA187460-01
Institution:  University of California-San Francisco 
09/12/2014

Cognitive Testing of Tobacco-Related Questions and Concepts

Cognitive testing can reveal how consumers understand tobacco-related concepts and answer tobacco-related questions, and can inform the development and revision of survey questions and text. The cognitive testing in this study will involve one-hour, in-person, moderator-facilitated individual interviews with approximately 45 youth (ages 12-17) and adults (ages 18+)in which participants will be asked to answer and react to tobacco-related survey questions and text. The objectives of the interviews are: 1) to determine age appropriateness and reader comprehension of questions; 2) to understand how new or revised questions affect the usability of existing surveys and questionnaires; and 3) to provide insights that may be used to improve the questions and survey questionnaires. Newly-developed and/or existing survey questions involving tobacco product-related perceptions and behaviors will be tested; tobacco products covered will include chewing tobacco, cigarettes, cigarillos, dissolvables, modified risk tobacco products, new and emerging tobacco products, nicotine, snus, pipe tobacco, e-cigarettes, hookah/waterpipe, large cigars, little cigars, roll-your-own tobacco, and smokeless tobacco. This research may inform the development and revision of questionnaires used in experimental studies as well as national tobacco surveys.

Jennifer Alexander and Ann Nguyen Funding Mechanism: Research Contract
ID number: HHSF22320111005B
Institution: Research Triangle Institute
09/11/2014

Meta-Analysis of Psychological Measures Predicting Consumer Adoption of Tobacco and other Products

Identification of the best predictors of consumer adoption of new and emerging tobacco products will inform social science research involving these products. The goal of this project is to identify and evaluate the strongest and most valid predictors of consumer adoption of novel products. Data collection will involve a systematic review and meta-analysis focused on measures of perceived risk and other psychological determinants of behavior, and their association with consumer adoption. Data will be collected in two interrelated phases. The first phase consists of a systematic literature review. The second phase consists of coding, data entry and analysis of literature review findings. Study aims are: 1) to identify the best predictors of consumer adoption of novel products; 2) to identify the best item-level measurement techniques to determine consumer adoption predictors, and 3) to develop a manuscript for publication in a peer-reviewed journal By identifying predictors of novel product adoption, this study may inform future consumer-focused research and education initiatives and regulatory activities.

Jon Blitstein and Amber Koblitz Funding Mechanism: Research Contract
ID number: HHSF223201110005B; HHSF22314004
Institution: Research Triangle Institute
09/08/2014

Evaluation of Very Low Nicotine Content Cigarettes in Adolescent Smokers

Reducing cigarette nicotine content to a non-addictive level could reduce smoking rates by making cigarettes less reinforcing. However, little is known about the effects of very low nicotine content (VLNC) cigarettes on adolescent smoking behavior. Specific aims are: (1) to compare the effects of cigarettes varying in nicotine content on abstinence-induced craving and withdrawal, risk perceptions, product acceptability, and demand for usual brand cigarettes; and (2) to compare the effects of cigarettes varying in nicotine content on measures of smoking behavior and toxicant exposure in adolescent smokers aged 13-18. To accomplish Aim 1, researchers will compare the effects of cigarettes varying in nicotine content (normal nicotine content [0.83 mg per cigarette], moderate and low nicotine content [0.28 mg, 0.10 mg per cigarette] and very low nicotine content [0.06 mg per cigarette]) on abstinence-induced craving and withdrawal, affect, risk perceptions, product acceptability, and demand for usual brand cigarettes in 78 adolescent daily smokers. To accomplish Aim 2, researchers will randomize 90 adolescent smokers to either receive VLNC cigarettes or normal nicotine content (0.83 mg) research cigarettes for three weeks. Researchers will conduct daily assessments of total cigarette use, craving, and withdrawal; weekly assessments of breath carbon monoxide levels, cigarette acceptability, risk perceptions of VLNC and normal nicotine content cigarettes, and demand for usual-brand cigarettes; and pre- vs. post-use measures of nicotine and toxicant exposure (cotinine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL]). By illuminating how VLNC cigarettes affect real-world smoking behavior in adolescents, research findings may inform future policy decisions.

Rachel N. Cassidy Funding Mechanism: Intra-Departmental Delegation of Authority (IDDA)
ID Number: 1K01CA189300-01
Institution:  Brown University
09/01/2014

Center for Evaluation and Coordination of Training and Research in Tobacco Regulatory Science (CECTR)

This project establishes the Center for Evaluation and Coordination of Training and Research in Tobacco Regulatory Science (CECTR), formed as a joint effort by Westat and the Legacy Foundation’s Schroeder Institute for Tobacco Research and Policy Studies. CECTR — which will be staffed by tobacco scientists, evaluators, training developers, epidemiologists, analysts, and statisticians – will serve as an efficient infrastructure for providing scientific leadership and technical research expertise. CECTR’s specific aims are: (1) to accelerate knowledge sharing and innovation by facilitating collaboration and communication; (2) to increase the timely availability of tobacco regulatory science conceptual models, common measures, and other policy-relevant research tools; (3) to enhance the capacity of the research community to conduct more rapid and impactful tobacco regulatory science research by coordinating cross-disciplinary training of CTP-funded scientists and facilitating data sharing, analysis, and synthesis; and (4) to enhance the quality and innovativeness of tobacco regulatory science and expand research capacity through a rigorous evaluation process. Results will include sustained and significant improvements in tobacco regulatory science methods, standards and applications; development of a shared conceptual framework for tobacco regulatory science; and training of the next generation of tobacco regulatory scientists.

Jeanne Rosenthal and David Brian Abrams Funding Mechanism: National Institutes of Health- Grant
ID Number: 1U54CA189222-01
Institution: Westat, Inc.
09/01/2014

Novel Approach to Quantify Nicotinic Receptor Upregulation in Smokers

A reliable and minimally invasive biomarker of extended nicotine exposure could be useful in measuring changes in nicotine intake and evaluating reduced nicotine content tobacco products. The goal of this project is to evaluate the utility of nicotinic receptor (nAChR) upregulation in two types of white blood cells (granulocytes and lymphocytes) as a biomarker of extended nicotine exposure. Specific aims are: (1) to determine the minimum blood volume required for quantification of β2-containing and β4-containing nAChRs in granulocytes and lymphocytes; (2) to assess upregulation of β4-containing and β2-containing nAChRs in smokers’ granulocytes and lymphocytes; and (3) to assess the relationship between upregulation of β2-containing and β4-containing nAChRs in white blood cells and nicotine exposure, measured by nicotine intake per day and plasma cotinine level. To investigate these aims, researchers will analyze blood samples from 50 smokers and 30 nonsmokers aged 18-60. Study results may provide data indicating whether nAChR upregulation in white blood cells is a potential biomarker of extended nicotine exposure.

Alexey Mukhin Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R21DA038242-01
Institution: Duke University
08/26/2014

Nicotine Delivery from Novel Non-Tobacco Electronic Systems

Electronic nicotine delivery devices (ENDS) are novel products that electronically generate a nicotine-containing vapor that is inhaled by the user. Electronic cigarettes (e-cigarettes) are the most popular ENDS on the market, but various types and brands exist and are engineered differently, and thus vary in their nicotine delivery to the user. The goal of this project is to evaluate various e-cigarettes and to establish an evidence base for evaluating their potential for nicotine delivery. Specific aims are: (1) to measure the amounts of nicotine present in various brands and types of e-cigarettes as well as the nicotine yields in vapors generated by the devices; (2) to investigate the levels of nicotine delivered by e-cigarettes to the bloodstream compared to levels delivered by conventional cigarettes (in a group of 18 adult smokers aged 18 and older), and the effect of e-cigarette nicotine solution flavorings on puff topography and nicotine delivery (in a second group of 18 adult smokers aged 18 and older); and (3) to develop a machine smoking protocol for various types of e-cigarettes that reflect users’ puffing behavior and product characteristics. These findings may inform the development and implementation of e-cigarette quality standards and testing methods.

Maciej Lukasz Goniewicz Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R01DA037446-01
Institution: Roswell Park Cancer Institute Corporation 
08/25/2014

Emerging Product Perceptions and Use among African-Americans

African-American youth are at high risk of tobacco use. Of particular concern is a significant increase in their use of emerging products such as cigars and cigarillos and a high likelihood of multiple product use. The goal of this study is to evaluate their perceptions, attitudes, and beliefs regarding the health and social effects of tobacco products — particularly emerging and unregulated flavored (e.g., menthol, fruit, candy) products — and to determine whether these cognitive and affective factors are related to experimentation. Specific aims are: (1) to determine whether there are distinct classes of African-American tobacco users with shared patterns of tobacco use, and whether certain characteristics define high-risk groups; and (2) to evaluate the impact of marketing exposure, risk perceptions, attitudes toward tobacco products, and use of flavored products on use patterns. Researchers will recruit 560 African-American youth aged 14-18 who have ever tried a tobacco product. In the first phase of the study, researchers will conduct six focus groups (8-10 participants each) to gather information on awareness and perceptions of emerging tobacco products, advertisements, advertisement and product exposure, and sources of product information and perceptions. In the second phase, 500 youth will complete a 30-45 minute paper-and-pencil survey about tobacco-related behaviors (e.g., use, intentions, cessation), nicotine dependence, use and perceptions of tobacco products (including mentholated and flavored products), perceptions of health and social risks, and marketing exposure. Distinguishing patterns of tobacco use among African-American youth may inform strategies for prevention, cessation, and regulatory action that address tobacco consumption by this vulnerable population.

Kari-Lyn Kobayakawa Sakuma Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R03CA180935-01A1
Institution: Oregon State University 
08/20/2014

Development of Methods to Expose Cells in Culture to Volatile Chemicals

Tobacco smoke is a mixture of more than 7,000 chemicals, and more than 70 of them have been classified as carcinogens by the International Agency for Research on Cancer (IARC). Airborne particles and volatile chemicals from tobacco smoke have harmful effects on public health; as a result, it would be useful to develop standardized analytical procedures that can be used to evaluate the cell toxicity and gene toxicity potential of these chemicals. The goal of this study is to develop and demonstrate the reproducibility of a cell culture exposure protocol for aerosols and volatile chemicals. Study aims are: (1) to develop a test procedure for the mouse lymphoma assay (MLA) using cultured suspension cells, a smoking machine, exposure chambers, and whole cigarette smoke as the test material; and (2) to demonstrate the reproducibility of the MLA exposure conditions by conducting exposures with different concentrations of whole smoke over a period of six months. The standard gene toxicity assay procedures will generate data to help determine the risks associated with exposure to aerosols and volatile chemicals in tobacco smoke.

Xiaoqing Guo and Carmine Leggett Funding Mechanism: Internal FDA
ID number: E07543.01
Institution: National Center for Toxicological Research (NCTR)
08/20/2014

Preliminary Study for Whole Smoke Acute Exposure in Lung Cells

Tobacco use can cause toxic damage to cells that can be identified by in vitro models. Using these models in conjunction with “omics” technologies may lead to the identification of biomarkers of harm associated with tobacco product use. The goals of this study are: (1) to test smoking machine performance using Kentucky reference cigarettes that are smoked under different smoking conditions, and (2) to develop an exposure model using human bronchial epithelial cells. A general cell toxicity test (lactate dehydrogenase release) will be used to assess the adverse effects caused by whole tobacco smoke at different concentrations and over time. Researchers will measure total particulate matter, total carbon monoxide, and nicotine yield of Kentucky reference cigarettes. Study results may be used to design subsequent “omics” studies.

Xi Yang and Arianne Motter Funding Mechanism: Internal FDA
ID number: E07553.01
Institution: National Center for Toxicological Research (NCTR)
08/15/2014

Ecological Momentary Assessment (EMA) and Laboratory Assessment of Nicotine Dependence among Dual ENDS

Electronic cigarettes (e-cigarettes) are available in two types: “ciga-like” models that resemble cigarettes and “pen-like” models, which may be preferred by exclusive e-cigarette users because they can deliver more nicotine per puff, are customizable, and offer a better “throat hit” than ciga-like models. More information about how e-cigarette characteristics affect whether cigarette smokers transition from e-cigarette experimentation to habitual exclusive use, use both e-cigarettes and regular cigarettes, try and abandon e-cigarettes in favor of continued cigarette smoking, or stop using all tobacco products including e-cigarettes would enhance our knowledge about these products. Specific aims are: (1) to compare how measures of abuse liability (i.e., plasma nicotine concentration, subjective effects including craving and satisfaction, behavioral reinforcement) and measures of product appeal (i.e., perceived norms and liking, design, packaging) vary by e-cigarette device type; (2) to contrast the differences in abuse liability and measures of product appeal between usual cigarette brand and e-cigarette device; and (3) to examine the extent to which measures of abuse liability predict e-cigarette use at one, three, and six months. Researchers will randomize 128 current smokers aged 18-65 who have never used e-cigarettes but are curious about them to use either ciga-like or pen-like e-cigarettes during four laboratory visits over 8-12 days; visits will include assessment of plasma nicotine concentration and subjective ratings linked to abuse liability and product appeal. Research findings related to the differential effects of ciga-like and pen-like e-cigarettes on e-cigarette experimentation and subsequent use patterns may inform future regulatory actions.

Jennifer Lynn Pearson Funding Mechanism:  National Institutes of Health- Grant
ID Number: 1K01DA037950-01
Institution:  American Legacy Foundation 
08/15/2014

Beta2 Nicotine Receptor Subunits: Biomarkers for Dependence

Nicotine dependence is the tobacco-related disorder that underlies tobacco-related diseases. Ongoing exposure to nicotine produces upregulation of beta2 nicotinic acetylcholine receptors (nAChRs), which is associated with nicotine dependence. Menthol may increase nicotine dependence by affecting neurons, increasing nicotine absorption through airway epithelium, and/or decreasing the breakdown of nicotine. The goal of this project is to develop a production-level assay for determining the upregulation of beta2 nAChRs in a mouse model. Specific aims are: (1) to develop an efficient, quantitative, low-resolution approach based on the immunoblot technique (“western blots”) for quantifying the amount of beta2 subunits in various regions of mouse brain; (2) to develop a higher resolution, semi-quantitative approach based on fluorescence that identifies the neuronal cell types and the subcellular regions where upregulation occurs; and (3) to use these tools to test the hypothesis that menthol upregulates nAChRs even when delivered intravenously. Establishing a biomarker for nicotine dependence in mice, and then using this biomarker to investigate menthol’s actions, may contribute to tobacco-related research activities.

Henry A. Lester Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R01DA036061-01A1
Institution: California Institute of Technology 
08/11/2014

Econometric Research on Regulating Menthol Cigarettes and Smoking Cessation

An estimated 18.1 million U.S. adults, or about 30% of adult smokers, smoke menthol cigarettes. Some evidence suggests that the availability of menthol cigarettes increases the number of smokers, partly by reducing cessation. The goal of this project is to use econometric methods to study relationships between menthol cigarette use and smoking cessation. Specific aims are: (1) to study the relationship between menthol cigarette use and smoking cessation; (2) to investigate the economics of consumer choices about menthol cigarettes and smoking cessation; and (3) to investigate the economics of consumer choices about menthol cigarettes over the life course. To accomplish Aim 1, researchers will analyze data from the 2003, 2006-07, and 2010-11 cycles of the Tobacco Use Supplements to the Current Population Survey (TUS-CPS) and data from the Simmons National Consumer Survey (NCS) from 1995 onward, which together provide data on nearly 80,000 current and past-year smokers. To accomplish Aim 2, researchers will use geocode information to merge the individual-level data from the TUS-CPS and NCS with market-level demand influences (e.g., price and advertising), and will use information on respondents’ magazine-reading habits to create individual-level measures of potential exposure to cigarette advertisements. This will enable researchers to investigate the extent to which smokers perceive menthol and non-menthol cigarettes to be close substitutes and evaluate the role of advertising in consumer choices. To accomplish Aim 3, researchers will use TUS-CPS data (e.g., ever use of menthol cigarettes; whether smokers used menthol cigarettes all or nearly all, most, half, or less than half the years they smoked) to build approximate lifetime histories of menthol use. By evaluating the impact of menthol use on smoking cessation, this research may inform regulatory actions related to menthol.

Donald S. Kenkel Funding Mechanism:  Intra-Departmental Delegation of Authority (IDDA)
ID Number: 1R21DA037408-01
Institution:  Cornell University 
08/05/2014

Assessment of the Addictive Potential of Cotinine, Anatabine, and Myosmine in Rodents

Although nicotine is the primary addictive constituent in tobacco, studies indicate that tobacco also contains non-nicotine constituents (including, but not limited to, anatabine, cotinine, and myosmine) that may have addictive potential.  Previously, researchers used a locomotor activity paradigm to determine behaviorally-active dose ranges of anatabine, cotinine, and myosmine for use in future studies of abuse liability. In this study, the researchers will use that previously-generated data to conduct pharmacological and behavioral studies in adult and adolescent rats to determine the addictive potential of these three constituents and highlight potential differences between adults and adolescents. The rats will be tested using three models of abuse liability — conditioned place preference, withdrawal signs, and central nervous system activity – that were identified based on acceptable measures of abuse liability used to include constituents on FDA’s harmful and potentially harmful constituent (HPHC) list with an addiction indication. Three doses of each constituent (selected based on the previous research results) will be tested in each paradigm; each does will be tested in 10 rats.  Midbrain dopamine release via in vivo microdialysis will be used to assess effects on central nervous system activity, and nicotine will be used as a positive control in all assessments.  The projected timeframe for completion of these studies is 1.5 years. By identifying tobacco constituents with addictive potential, study results may be used to inform product review or other regulatory activities.

Jenny Wiley and Kia Jackson Funding Mechanism: Research Contract
ID number: HHSF223201310034I
Institution: Research Triangle Institute
08/05/2014

Optimizing Graphic Warning Labels to Promote Cessation among Young Adult Smokers

Young adult smokers are susceptible to tobacco industry marketing and have a high risk of becoming lifelong smokers. The goal of this study is to examine whether two potential cigarette packaging regulations — requiring graphic health warning labels on cigarette packs and requiring plain (unbranded) packaging — reduce cigarettes’ appeal and lead to cessation. Specific aims are: (1) to determine whether graphic warning labels reduce the likelihood of cigarette purchases and to identify the factors that enhance this effect; (2) to investigate the short-term impact of warning message framing and plain packaging on the motivation to quit or reduce smoking; and (3) to assess the long-term durability of the effects of warning message framing and plain packaging. The study will involve a sample of 400 young adult smokers aged 18-30. First, participants will be shown cigarette packs that vary based on warning message framing (gain- or loss-framed) and packaging (branded or plain) and will be asked about their preferences regarding cigarette purchases based on the packs. Second, participants will be randomized to either use their regular cigarette packs or one of four adapted packs that contain their own cigarettes but vary based on message framing and packaging; all participants will respond to daily mobile phone text message prompts assessing motivation to quit and cigarettes smoked per day for four weeks and will complete an in-person final assessment. Finally, researchers will examine the durability of the effects of the adapted packs by assessing motivation to quit, cigarettes smoked per day, quit attempts, and pack-related behaviors (such as hiding the pack) one and three months after the study’s conclusion. Study results may inform regulatory policies related to cigarette packaging.

Darren M. Mays Funding Mechanism:  National Institutes of Health- Grant
ID Number: 1K07CA172217-01A1
Institution:  Georgetown University 
07/31/2014

Perceptions of E-Cigarettes and Effects on Craving, Withdrawal, and Smoking Severity after Exposure to Virtual Reality Cues

Little is known about the behavioral, physiological, and neurobiological effects of e-cigarettes on smokers, particularly with regard to craving and withdrawal. An important target for investigation is how effective e-cigarettes are in alleviating cravings when smokers are exposed to smoking-related stimuli. Smoking cues (e.g., sight and smell of cigarettes, smoking environments, emotional states) often lead to intense episodic spikes in craving, which in turn can lead to smoking. The goal of this research is to assess smokers’ reactions to virtual reality cues — photo-realistic and interactive environments closely resembling situations in which participants are likely to smoke in the real world. Researchers will evaluate changes in craving, smoking severity, and withdrawal symptoms in 90 cigarette smokers aged 18-55 who have never used e-cigarettes following use of either an e-cigarette or their own (preferred) cigarette brand on three separate laboratory visits. Specific aims are: (1) to evaluate the effects of e-cigarettes (0 or 18 mg) or own cigarettes on virtual reality-induced craving, perceptions, and withdrawal symptoms; (2) to evaluate the physiological effects produced by nicotine obtained by smoking e-cigarettes or own cigarettes; and (3) to evaluate the effects of e-cigarettes or own cigarettes on smoking severity (i.e., increased latency to first cigarette, fewer cigarettes chosen, puff duration, puff volume). Information generated about whether e-cigarette exposure affects smoking severity by altering craving, withdrawal, and physiological responses may be used to inform regulatory actions.

C. Kent Osborne and Jin Yoon Funding Mechanism:  National Institutes of Health- Grant
ID Number: 3P30CA125123-08S2
Institution: Baylor College of Medicine
07/31/2014

Neural Markers of Use and Perception of E-cigarettes among Cigarette Smokers

Little scientific data are available on the effects of e-cigarettes on the brain. A non-biased biological tool such as brain imaging could provide important new information about the effects of acute e-cigarette exposure and smokers’ perceptions of these devices. The goal of this study is to use functional magnetic resonance imaging (fMRI) to study the different effects that regular and e-cigarettes have on the reward system in the brains of 90 cigarette smokers aged 18-55 who have never used e-cigarettes. Specific aims are: (1) to determine if use of e-cigarettes and regular cigarettes have similar effects on activation of the brain’s reward system; (2) to determine if perceptions of e-cigarettes and Surgeon General warnings affect brain activity during a picture-viewing experiment; and (3) to determine whether the reward activity and neural perceptions measured in Aims 1 and 2 are associated with changes in cigarette use and e-cigarette perceptions, satisfaction, and acceptability. By providing new information about the association between reward system activation and perceptions of regular and e-cigarettes, study findings may be used to inform regulatory activities related to e-cigarettes.

C. Kent Osborne and Ramiro Salas Funding Mechanism:  National Institutes of Health- Grant
ID Number: 3P30CA125123-08S2
Institution: Baylor College of Medicine 
07/25/2014

Unjust Targeting: How Marketing Features Impact Consumer Response and Tobacco Use

Certain “high impact” tobacco marketing features (e.g., colors, descriptors, branding, marketing claims) may be effective in appealing to particular ethic groups and thus may produce inequitable outcomes in tobacco use. The goal of this project is to connect tobacco marketing features with consumer affective, cognitive and physiological responses to marketing images, product perceptions, and use outcomes in ethnically diverse populations. Specific aims are: (1) to describe tobacco marketing features targeted towards African Americans, Asian Americans, Latinos, and non-Hispanic whites; (2) to identify how marketing features impact responses to ads among Latinos and Latino subgroups (e.g., Mexican American, Puerto Rican, Dominican, Central American, South American); and (3) for each ethnic group, to demonstrate how people initiate and change tobacco product use as a result of advertising awareness and to identify marketing features associated with product use. To accomplish Aim 1, researchers will link tobacco marketing data from the Population Assessment of Tobacco and Health (PATH) study to data from a PATH ad-hoc study of tobacco marketing images in order to identify which ads appeal to each ethnic group and to generate an inventory of high-impact marketing features for each product. To accomplish Aim 2, researchers will conduct online and laboratory-based studies with 1,100 subjects aged 18-24; the researchers will manipulate ad features in order to investigate which features most impact product perceptions and use intentions. To accomplish Aim 3, researchers will link PATH study data to data from the PATH ad hoc study to determine which ads have the greatest impact on tobacco use over time in each ethnic group and to identify the marketing features associated with ad effectiveness. By identifying the key marketing features that impact consumer responses and connecting those responses to tobacco use outcomes over time, project findings may be used to inform regulation regarding tobacco marketing.

Meghan Bridgid Moran Funding Mechanism: National Institutes of Health- Grant
ID Number: 1K01DA037903-01
Institution: Johns Hopkins Bloomberg School of Public Health
07/21/2014

Cancer Center Support Grant: Impact of Cigar Product Characteristics on Young People’s Cigar Use and Perceptions

While cigarette consumption in the United States is declining, cigar consumption has more than doubled since 2000. Cigar product and marketing characteristics (including flavorings such as fruit, candy, and alcohol) may increase cigars’ appeal to young people, but data on the extent to which cigar product and marketing characteristics influence use are limited. The goal of this project is to explore the impact of product features such as brand, flavor, and packaging on young adults’ cigar initiation, use, and perceptions. Specific aims are: (1) to understand consumer perceptions of cigar features; and (2) to examine the impact of cigar packaging features on consumer perceptions. Researchers will conduct semi-structured interviews with 40 cigar smokers aged 18-30 to understand their reasons for using cigars and assess their perceptions of product characteristics (e.g., flavor, packaging). Qualitative findings will be used to inform the development and implementation of a nationally-representative population-based Internet survey of approximately 800 past-year cigar smokers aged 18-30. In this survey, participants will be randomly assigned to one of 12 cigar pack conditions (2 brands x 3 flavors x 2 packaging types) and asked to rate the product on a number of consumer perception measures. As a secondary research effort, researchers will analyze national Nielsen market data from 2008-2014 to better understand the impact of product features on cigar sales; researchers will evaluate attributes such as type, brand, flavoring, size (e.g., little cigar or cigarillo), packaging, and promotions (e.g., buy-one-get-one-free) and calculate their impact on total sales, market share, and contribution to overall cigar growth. Research findings will provide information about the impact of cigar product and marketing characteristics on initiation, use, and perceptions, and may inform regulatory activities related to cigars.

Robert S. DiPaola and Cristine Delnevo Funding Mechanism: Intra-Departmental Delegation of Authority (IDDA)
ID Number: 3P30CA072720-17S1
Institution: Rutgers Cancer Institute of New Jersey
07/03/2014

Exploratory Study on the Effect the Format of Moist Smokeless Tobacco (Loose vs. Portioned) has on the Use Behaviors, Nicotine Exposure and Tobacco Dependence in Current Users

Use patterns may be different for portioned and loose (non-portioned) smokeless tobacco (ST) products; depending upon type of product used, users may alter their use behavior along measures such as frequency of use (e.g., mean use per day, total use per day), deposition time in the mouth, and amount of product used per occasion. Such changes in use behavior may affect nicotine exposure. However, little is known about the relationship between type of product, use behavior, and resulting nicotine exposure. The primary aim of this study is to investigate the behavioral aspects of ST use among users of loose and portioned moist ST products.  Endpoints of interest include amount used, deposition time in the mouth, and frequency of use. This study will also characterize differences in nicotine exposure from normal use of loose or portioned ST products and investigate the potential for nicotine dependence among adult moist ST product users (ages 18-65). Investigators will enroll 30 adult users of portioned ST and 30 adult users of loose ST for a one-day study session to evaluate the way they use the ST product and the resulting nicotine exposure. In addition, subjects will be administered a number of questionnaires to evaluate their ST dependence.  This study will provide new information about comparative ST use patterns and nicotine exposure that may be used to inform regulatory activities.

Wallace Pickworth and Lynn Hull Funding Mechanism:  Research Contract
ID number: HHSF223201310030I; HHSF22301002T
Institution: Battelle Health and Analytics
07/02/2014

/Metals in Electronic Cigarette Aerosol

A number of metals and elements in electronic cigarette (e-cigarette) aerosol – such as lead, chromium, iron, strontium, and aluminum – are known carcinogens, respiratory toxicants/irritants, reproductive and developmental toxicants, or have other human health effects. The goal of this project is to identify and quantify the metal content of e-cigarette aerosols generated by a variety of products and designs, to examine the cytoxicity (i.e. toxicity to cells) and genotoxicity (i.e., toxicity to genetic information within cells) of aerosols with metal content, and to examine biomarkers of metal exposure and effects in users. Specific aims are: (1) to identify and quantify the metals in the fluid and aerosol of a broad range of e-cigarettes from different manufacturers and of different styles; (2) to use an embryonic model and a three-dimensional adult lung air-interface model to evaluate the cytotoxicity and genotoxicity of aerosols from products that contain metals; and (3) to measure biomarkers of metal exposure and effects in e-cigarette users by comparing 75 adults aged 21-40 who use e-cigarettes only, conventional cigarettes only, or no tobacco products, by analyzing metals in oral cavity cells and metal concentrations in saliva, blood, and urine. Research findings may inform regulatory policies related to e-cigarettes.

Prudence Talbot Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R01DA036493-01A1
Institution: University of California-Riverside
07/02/2014

Alternative Tobacco Products: Use, Adverse Effects, and Communication Patterns; Adverse Effects of Mainstream Tobacco-Based Hookah Smoke in Young Adults

The health effects of waterpipe (hookah) tobacco use are not fully understood. Of particular concern is the common misconception that inhaling hookah smoke is less harmful than inhaling cigarette smoke because it is “filtered” through water. The goal of this clinical exposure study is to evaluate whether the inhalation of mainstream tobacco smoke generated by hookah smoking produces changes in the cardiopulmonary system that could result in acute and chronic adverse health effects. Specific aims are: (1) to ask current hookah users to smoke hookah in a clinical setting and then to characterize the exposure concentrations of particulate matter, carbon monoxide, black carbon, elemental and organic carbon, carcinogenic agents, and trace elements; and (2) to examine cardiopulmonary changes and inflammatory markers of tobacco exposure. To accomplish these aims, researchers will recruit 40 healthy young adults aged 21 to 30 who are current hookah smokers to smoke hookah tobacco in a controlled clinical setting. Researchers will measure a variety of indicators, including changes in pulmonary function (e.g., forced vital capacity, forced expiratory volume), cardiovascular function (e.g., blood pressure, heart rate, blood cotinine levels), airway epithelial cells, and blood and exhaled breath condensate markers of inflammation. Researchers will also evaluate the chemical composition and carcinogenic components of particulate matter and gases in mainstream hookah smoke. Research findings may be used to inform regulatory actions related to waterpipe tobacco.

William Carroll, Terry Gordon Funding Mechanism:  National Institutes of Health- Grant
ID Number: 3P30CA016087-34S1
Institution: New York University School of Medicine
07/02/2014

Alternative Tobacco Products: Use, Adverse Effects, and Communication Patterns; Patterns of Communication and Information Transfer among Hookah Users

Little is known about what factors could lead to initiation and maintenance of hookah (waterpipe) use. The goal of this project is to assess risk perceptions, attitudes, and beliefs about waterpipe tobacco smoking, use intentions, and patterns of use among a diverse population of young adults, and to explore the nature and extent of communication about waterpipe tobacco. Specific aims are: (1) to study a diverse urban population of young adults and measure the percentage of respondents who either currently use waterpipe tobacco or are likely to start using it in the near future; and (2) to assess how hookah users gather and share information about waterpipe smoking. To accomplish these aims, researchers will conduct a cross-sectional Internet survey of a representative sample of 1,500 young adults aged 18-30 who are full- or part-time students at the City University of New York. Survey questions will address use history, knowledge, beliefs, attitudes, and communication patterns related to waterpipe tobacco. Next, researchers will conduct 12 focus groups (8-10 participants each) with a subset of survey respondents in order to explore beliefs, attitudes, and communication patterns regarding waterpipe tobacco smoking in more detail. Eight focus groups will include current waterpipe tobacco users and four will include people who do not currently use waterpipe tobacco but report a high intention to use it in the next six months. After the focus groups, researchers will code each participant’s use of social media to track communication about hookah use. Study findings may inform regulatory actions related to waterpipe tobacco. 

William Carroll and Scott Sherman Funding Mechanism:  Intra-Departmental Delegation of Authority (IDDA)
ID Number: 3P30CA016087-34S1
Institution: New York University School of Medicine 
07/02/2014

Do Electronic Cigarettes Reduce Harm?

Relatively little is known about the health effects of electronic cigarettes (e-cigarettes). The goal of this project is to understand how e-cigarettes affect human health by evaluating the cytoxicity (i.e. toxicity to cells) and genotoxicity (i.e., toxicity to genetic information within cells) of e-cigarette aerosols, flavorings, and chemicals. Specific aims are: (1) to quantify and compare the cytotoxicity and genotoxicity of mainstream smoke from established cigarette products with e-cigarette aerosols by analyzing effects on embryonic and differentiated human cells; and (2) to identify the chemicals that cause cytotoxicity and genotoxicity in the products tested in Aim 1. Research findings may be used to inform policies for regulating e-cigarettes.

Prudence Talbot Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R21DA037365-01
Institution: University of California-Riverside 
06/23/2014

Dual Cigarette and Smokeless Tobacco Use: Behavior Patterns and Toxicant Exposure

Many smokers have become “dual users” of both cigarettes and smokeless tobacco (SLT). The goal of this project is to understand how smokers’ health risks are affected as a result of dual use by characterizing their natural patterns of tobacco use. Specific aims are: (1) to determine whether cigarette smokers alter their smoking behavior on days when they also use SLT; and (2) to profile the patterns of SLT use among cigarette smokers within and across days. Researchers will study 120 adult smokers who also use SLT aged 18-55 for two weeks to determine their patterns of dual use of cigarettes and SLT. Participants will use electronic diaries to record various behaviors, contextual factors, and subjective experiences; they will also provide saliva samples so that cotinine levels can be analyzed to determine daily levels of nicotine exposure. Researchers will compare cigarette use on single (cigarettes only) versus dual use days, and will evaluate dual use as a function of various factors including indoor vs. outdoor activities, other drug use (i.e., caffeine, alcohol), type of SLT product used, mood, SLT use motivations and beliefs, and nicotine/tobacco craving level. Study results will shed light on whether cigarette smokers’ use of SLT is consistent with product supplementation or replacement, and thus how SLT use influences exposure to nicotine.

Melissa D. Blank Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R03DA037583-01
Institution: West Virginia University
06/20/2014

Measure Acrolein in Bidis and Little Cigars

A chemical analysis can inform the evaluation of the harmful and potentially harmful constituents (HPHCs) present in the mainstream smoke produced from little cigars and bidis. The goal of this project is to measure acrolein quantities in little cigar and bidi smoke using a variety of little cigar and bidi tobacco products currently marketed in the US. A total of 15 little cigar products and one bidi product will be examined under both the International Organization of Standardization (ISO) and Canadian Intense (CI) smoking regimens.  The results may be used to inform HPHC-related regulatory activities.

Stephanie Hobaugh Funding Mechanism: Research Contract
ID number: HHSF223201310038I
Institution: Arista Laboratories, Inc.
06/16/2014

Evaluating the Toxicity and Inflammation Produced by Cigarette Smoke using Human In Vitro Airway Models

Traditionally, tobacco smoke toxicity has been evaluated with cell cultures grown on plastic surfaces using laboratory tests that are not specifically designed to measure smoke toxicity in the human respiratory system. In recent years, air-liquid-interface (ALI) airway tissue models derived from human bronchial epithelial cells have been developed that have many of the complex structural and functional properties of human airway epithelium. In this study, researchers will use a human airway ALI tissue model to evaluate the toxicity of cigarette smoke generated from University of Kentucky reference cigarettes using both the International Organization for Standardization (ISO) and Canadian Intense (CI) smoking machine protocols. The goal is to use an in vitro system having properties similar to the intact human airway to assess and compare the adverse respiratory health effects of tobacco smoke produced under different smoking conditions. The resulting data on airway-related outcomes may inform future regulatory actions related to products claimed to be equivalent or “modified risk.”

Xuefei Cao and Sheila M. Healy Funding Mechanism: NCTR
ID number: C13030/E0754901
Institution: National Center for Toxicological Research
06/13/2014

High-Throughput Screening Tobacco Constituents for Addiction Potential Using Docking of Nicotinic Acetylcholine Receptors

More than 8,000 chemicals identified in tobacco products and smoke have not been thoroughly evaluated for their potential to cause addiction. One of the mechanisms of addiction is nicotine binding to nicotinic acetylcholine receptors (nAChRs). In humans, two nAChR subtypes (α4β2 and α7) are most commonly found in the central nervous system; thus, chemicals that bind to α4β2 and α7 have potential to cause addiction. However, experimentally measuring the nAChR binding affinity of all tobacco constituents is difficult, if not impossible; thus, efficient screening methods for evaluating the addiction potential of these constituents are needed.  In this project, researchers will develop three-dimensional computer simulations of α4β2 and α7 structures; using these simulations, researchers will then screen more than 8,000 tobacco constituents in order to estimate their nAChR binding affinity (and, thus, their potential to cause addiction). The results will be presented as a database of tobacco constituents and their addiction potential estimates. Project results may be used to inform regulatory decision making or to select chemicals for laboratory testing.

Huixiao Hong Funding Mechanism: NCTR
ID number: C13025/E0754801
Institution: National Center for Toxicological Research
06/12/2014

Interactions between Tobacco Smoke Constituents in Rodent Tumor Models

Tobacco smoke is a complex mixture of chemicals, many of which are toxic and carcinogenic. However, it is unclear how individual components of the mixture interact to trigger cancer. Reducing the levels of one chemical may not reduce the overall carcinogenic properties of the tobacco product if the interaction between chemicals amplifies the effects of residual carcinogen levels. The goal of this project is to characterize the potential interactions between known human carcinogens (4-methylnitrosoamino-1-(3-pyridyl)-1-butanone [NNK], N’-nitrosonornicotine [NNN], and benzo[a]pyrene [BaP]) and volatile components of tobacco smoke (acetaldehyde, acrolein, and formaldehyde) in established rodent tumor models. Specific aims are: (1) to determine if acetaldehyde influences the carcinogenic properties of NNN in a rat esophageal tumor model; (2) to determine if inhaled aldehydes (i.e., formaldehyde, acetaldehyde, acrolein) modulate the carcinogenic properties of NNK in a mouse lung tumor model; and (3) to determine if inhaled aldehydes modulate the carcinogenic properties of BaP in a mouse lung tumor model. These studies may provide important new information about the ability of volatile compounds to influence the tumor-related activity of tobacco carcinogens, and may be used to inform product regulation.

Lisa A. Peterson Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R01CA184987-01
Institution: University of Minnesota
06/12/2014

Menthol: An Accomplice of Nicotine in Tobacco Smoking

A fundamental question regarding menthol, a tobacco product additive that causes a cooling sensation, is whether it directly enhances the reinforcing effects of nicotine and thus promotes tobacco addiction. The goal of this project is to conduct behavioral tests in rats to examine whether menthol promotes the initiation, maintenance/progression, and relapse to nicotine self-administration without the involvement of its sensory effects. Specific aims are: (1) to examine whether menthol promotes the initiation of nicotine self-administration; (2) to examine whether menthol facilitates the transition to greater nicotine self-administration; (3) to examine whether menthol facilitates nicotine-seeking behavior; and (4) to examine interactions between menthol and nicotine in the release of dopamine in the nucleus accumbens, a region of the brain’s reward circuit. Project results may inform regulatory policies related to the use of menthol in tobacco products.

Xiu Liu Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R01DA037277-01
Institution: University of Mississippi Medical Center 
06/06/2014

Understanding E-Cigarette Adoption and Marketing: A Social Media Study

Although the e-cigarette research literature is growing steadily, a more detailed understanding of e-cigarettes’ health risks, their efficacy for smoking reduction and/or switching, and the marketing practices of e-cigarette vendors is required. The goal of this project is to use a social media data mining and analytics approach to gather comprehensive data related to e-cigarettes, including reasons for use, health effects, efficacy as a smoking reduction and/or switching aid, and industry marketing and promotional efforts in the U.S. Specific aims are: (1) to develop a continuously-updated dataset containing a significant portion of e-cigarette-related social media content and user social networking activities; (2) to understand the reasons for and health consequences of e-cigarette use (including efficacy as a smoking reduction and/or switching aid) as reported in social media; (3) to understand how e-cigarette vendors conduct social media-based marketing campaigns and evaluate responses in social media; and (4) to develop and evaluate a social media-based informatics platform for e-cigarette regulatory research. The results of this research project may inform tobacco-related regulatory activities related to e-cigarettes.

Daniel Dajun Zeng and Scott J. Leischow Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R01DA037378-01
Institution: University of Arizona and Mayo Clinic
06/06/2014

Constitutional Compliance, Credibility, and FDA-Regulated Tobacco Warning Labels

As groups at high risk of smoking, youth under age 18 and adults with low socioeconomic status (SES) are two main targets of tobacco control efforts. The goal of this project is to examine which variations of FDA-regulated health warnings are most effective for youth and low SES adults by testing various message strategies. Specific aims are: (1) to test message effectiveness by manipulating message elements (such as full color images and warning size) and to identify the elements capable of maintaining or increasing message effectiveness; and (2) to test strategies such as including third-party sponsorship on warning labels in order to increase perceptions of credibility and varying warning label language . To accomplish these aims, researchers will conduct seven randomized controlled experiments with a total of 3,840 participants by traveling in a mobile laboratory to locations where vulnerable populations reside. Populations studied will include: (1) low SES adult smokers over age 18 from rural communities (primarily Caucasian), (2) low SES pre-teens aged 11-13 from rural communities (Caucasian non-smokers), (3) low SES inner-city adult smokers over age 18 (Caucasian, Black, and Hispanic), and (4) low SES inner-city pre-teen non-smokers aged 11-13 (Caucasian, Black, and Hispanic). By using eye-tracking technology and evaluating participant reactions to various advertisements and packages with manipulated elements (e.g., color, images, language), researchers will measure attention to specific message attributes, message recall, health risk beliefs, perceived message effectiveness, intentions to smoke and to quit, emotional reactions, perceived message credibility, cognitive appraisal, self-efficacy, and message preference. Study findings may provide new information about how to design messages that achieve maximum effectiveness.

Sahara Elizabeth Byrne and Jeffrey D. Niederdeppe Funding Mechanism:  National Institutes of Health- Grant
ID Number: 1R01HD079612-01
Institution: Cornell University 
06/06/2014

Comparative Transcriptomic Signatures of Inhaled Tobacco Smoke

Tobacco smoke exposure results in a significantly increased lifelong risk of numerous inflammatory lung diseases. While the health risks of tobacco smoke exposure are widely appreciated, there are no existing in vitro tests to ascertain the risks associated with exposure to different types of tobacco products. Hypothetically, reliable changes in gene expression can serve as biomarkers of tobacco smoke exposure that can predict human disease risk. The goal of this project is to detect specific disease-relevant gene expression signatures of smoke exposure from cigarettes, e-cigarettes, flavored little cigars, and hookah (waterpipe). Specific aims are: (1) to conduct comprehensive gene expression profiling of cell responses to different doses and types of tobacco and to develop assays that report tobacco smoke exposure; (2) to use animal models to define physiological responses to the inhalation of specific tobacco types and doses; and (3) to assess the human disease relevance of specific gene expression biomarkers. The proposed studies will generate an extensive database describing comprehensive gene expression responses to tobacco smoke exposure. This database may be used to develop assays that quantitatively and qualitatively measure the adverse impact of tobacco smoke exposure.

Thomas J. Mariani Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R01DA037447-01
Institution: University of Rochester 
06/01/2014

Pregnancy Risk Assessment Monitoring System (PRAMS)

Limited information is available about the use of new and non-traditional tobacco products during pregnancy and the impacts of these products on mother and baby health. To better understand the use of e-cigarettes and waterpipes during pregnancy and during the first three months preceding pregnancy, as well as the impacts of these products on birth and infant outcomes, questions about e-cigarettes and waterpipes will be added to the next phase of the Pregnancy Risk Assessment Monitoring System (PRAMS). PRAMS, a surveillance project of the Centers for Disease Control and Prevention (CDC) and state health departments, enrolls women who have had a recent live birth, with each participating state sampling 1,300-3,400 women per year. Topics addressed in the PRAMS questionnaire include barriers to and content of prenatal care, obstetric history, maternal use of alcohol and cigarettes, physical abuse, contraception, economic status, maternal stress, and early infant development and health status. New questions about e-cigarette and waterpipe use will address frequency of use, use behaviors, and dual use of e-cigarettes and traditional cigarettes. Data generated by these new questions will help researchers evaluate tobacco product use patterns during pregnancy and will increase the understanding of the impact of use in this vulnerable population.

Leslie Harrison and Elizabeth Durmowicz Funding Mechanism: Interagency Agreement
ID number: 224-11-9002/CE11-002
Institution: Centers for Disease Control and Prevention
05/23/2014

Measuring Relative Cardiovascular Health Risks of Inhaled Tobacco Products

Cardiovascular toxicity is a major consequence of both active and passive smoking. The goal of this project is to quantify the relative cardiovascular toxicity of different inhaled tobacco products (e.g., different types of cigarettes, cigarillos, little cigars, e-cigarettes). To achieve this goal, researchers will assess endothelial function in rats by measuring arterial flow-mediated dilation (FMD) using an innovative micro-ultrasound approach; FMD, the process by which arteries dilate in response to increased fluid shear stress (i.e., the stress of blood flow against arterial walls), is a marker of cardiovascular risk that can provide information about the cardiovascular toxicity of different tobacco products. Specific aims are: (1) to assess differences in the acute vascular toxicity of different types of smoked tobacco products (including menthol and non-menthol cigarettes, research cigarettes, cigarillos, and little cigars); (2) to determine the role of specific smoke components (including nicotine, acrolein, acetaldehyde, and cadmium) in acute endothelial toxicity; and (3) to evaluate and understand the acute cardiovascular toxicity of e-cigarette emissions. This research will yield new information about tobacco product toxicity that may be used to inform regulatory activities.

Matthew Lawrence Springer Funding Mechanism:  National Institutes of Health- Grant
ID Number: 1R01HL120062-01A1
Institution:  University of California, San Francisco
05/20/2014

MicroRNAs as Biomarkers for Tobacco Exposure and Heart Disease

Altered expression of microRNAs — short 20-25 nucleotide RNA molecules that negatively regulate gene expression — has been reported in various tobacco-related diseases, such as cardiovascular dysfunction. Tobacco smoke substantially alters the microRNA profile, but the role of microRNAs in the association between tobacco exposure and heart disease has yet to be determined. The specific aim of this study is to explore whether microRNAs can serve as blood-based biomarkers that link heart disease to tobacco use. Researchers will evaluate differences in the plasma microRNA profiles of 40 adult smokers divided into four groups: smokers with or without myocardial infarction and nonsmokers with or without myocardial infarction. Researchers will also profile circulating microRNAs in smokers with or without myocardial infarction who attempt smoking cessation. Next, researchers will profile the circulating microRNAs in mice exposed to acute or chronic tobacco smoke and induced to have acute myocardial infarction in order to examine the effect of tobacco smoke exposure and heart injury on the microRNA profile. Finally, researchers will analyze microRNA alterations in both humans and mice, compare them to the circulating microRNA profiles of various human cardiovascular pathologies, and formulate a microRNA signature that can be used as a biomarker to associate heart disease with tobacco exposure. Research findings will reveal biologically relevant changes associated with tobacco use and exposure in humans and mice and indicate whether microRNAs could be predictive of tobacco-related adverse cardiovascular conditions.

Yong Li Funding Mechanism: National Institutes of Health- Grant
ID Number: 1R21HL120050-01A1
Institution: University of Louisville
05/07/2014

Cancer Center Support Grant: Effects of Very Low Nicotine Content Cigarettes on Intermittent Smokers

Reduced nicotine content cigarettes have the potential to mitigate addiction and the appeal of smoking, thereby reducing cigarette use. Initial studies involving use of very low nicotine content cigarettes (VLNCCs) by daily/heavy smokers have been conducted; although these smokers might potentially escalate smoking in order to avoid nicotine withdrawal symptoms, these studies suggest that increased smoking does not occur in response to lower nicotine content. However, it is not clear whether these findings apply to the large population of non-daily (intermittent) smokers. The goal of this study is to assess the effects of VLNCC use among intermittent smokers. After a two-week baseline period of smoking their own cigarettes, 455 intermittent smokers aged 21 and older will be randomized to smoke one of two types of experimental cigarettes for ten weeks: normal nicotine content cigarettes (NNCCs; 0.8 mg per cigarette) or VLNCCs (0.07 mg per cigarette), matched to the menthol status of subjects’ preferred brand. Specific aims are: (1) to assess cigarette consumption changes between smoking own cigarettes and smoking VLNCCs or NNCCs; and (2) to assess changes in per-cigarette smoking intensity, measured by the two smoking biomarkers cotinine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), solanesol (a stable marker assayed in cigarette butts), butt weight and length, and smoking topography measures. Investigators will also evaluate individual differences that could moderate response to VLNCCs, including ethnicity (African-Americans vs. white smokers), history of past daily smoking, and starting level of dependence, and will assess changes in smoking behaviors and temporal smoking patterns. Findings from this study may inform the regulation of nicotine levels in cigarettes.

Nancy Davidson Funding Mechanism:  Intra-Departmental Delegation of Authority (IDDA)
ID Number: 3P30CA047904-25S4
Institution:  University of Pittsburgh Cancer Institute 
05/01/2014

Cigarette Warning Labels: Research Synthesis and Impact on Smoking Behavior

The FDA has a legislative mandate to require new warnings on cigarette packs that communicate the health risks of smoking. In this supplement to an existing research grant, researchers will synthesize the published literature on the impact of warnings on smoking-related outcomes and then will conduct an experiment in which they label smokers’ own cigarette packs with text or graphic warnings to examine real-world impact on smoking behavior.  Specific aims are: (1) to assess the impact of cigarette pack warnings by conducting a systematic review and meta-analysis of the existing literature; and (2) to test the impact of cigarette pack warnings on smoking behavior. To accomplish Aim 1, researchers will search research databases and examine references in review and primary articles, code relevant articles for important study characteristics, and conduct a separate analysis for each key outcome (i.e., cognitive and emotional reactions, risk perception, intention to quit, and the moderating effects of income, race/ethnicity, age, smoking status, sampling method, and study design). To accomplish Aim 2, researchers will randomly assign 2,250 smokers aged 18-65 to one of seven experimental conditions in which smokers’ cigarette packs are labeled with a warning (i.e., three text-only warnings, three graphic warnings, and the current Surgeon General’s warning as a control condition). Researchers will then assess the relationship between warning type (i.e., text or graphic) and cessation behaviors (i.e., quitting, attempting to quit, smoking fewer cigarettes); evaluate the impact of graphic warnings on emotional and cognitive reactions, perceived risk of smoking-related harm, discouragement from smoking, and quit intentions; and examine whether the impact of warnings varies by income level. This research may inform future regulatory activities related to cigarette pack warning labels.

Norman Sharpless (previous P.I.: H. Shelton Earp) Funding Mechanism:  Intra-Departmental Delegation of Authority
ID Number: 3P30CA016086-38S2
Institution:  University of North Carolina-Chapel Hill 
 
04/30/2014

Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure

N’-nitrosonornicotine (NNN), a tobacco-specific carcinogen, is believed to play an important role in causing esophageal and oral cavity cancer in tobacco users.  NNN is formed from the nitrosation of tobacco alkaloids such as nornicotine. Nornicotine in tobacco products is nitrosated during tobacco processing, but it may also be nitrosated endogenously (i.e., within the body) in the oral cavity, the stomach, or elsewhere.  This is particularly relevant to smokeless tobacco product use, given that keeping smokeless tobacco in the oral cavity for prolonged time periods creates favorable conditions for nitrosation. Information on nornicotine content in individual smokeless tobacco brands does not exist, and the extent of variation among products is unknown. The goal of this study is to generate information on endogenous nitrosation of nornicotine as a function of its content in smokeless products. Specific aims are: (1) to determine the variation of nornicotine content in smokeless products currently marketed in the U.S.; and (2) to investigate the endogenous formation of NNN in smokeless tobacco users. To investigate Aim 1, researchers will analyze a variety of smokeless products (e.g., moist snuff, snus, lozenges, sticks, strips) for nornicotine, nitrate, and nitrite content using liquid chromatography tandem mass spectrometry (LC-MS/MS).  To investigate Aim 2, researchers will randomize 130 smokeless tobacco users aged 18-65 to use a tobacco-free herbal snuff containing various added amounts of stable isotope-labeled nornicotine. Isotope-labeled urinary total NNN will be measured in these subjects by using LC-MS/MS, allowing researchers to differentiate the amount of NNN from endogenous nitrosation of nornicotine versus that from exposure to NNN in tobacco products. The results of this study will provide new information on endogenous NNN formation that may inform regulatory decisions related to nornicotine in tobacco products.

Irina Stepanov Funding Mechanism:  National Institutes of Health- Grant
ID Number: 1R01CA180880-01
Institution:  University of Minnesota 
04/25/2014

Does Real World Exposure to FDA Graphic Warnings Affect Tobacco Use Behavior?

To date, experimental research on the effectiveness of FDA graphic warning labels on cigarette packages has involved one-time exposure to the labels, an exposure duration that is too brief to generate accurate measurements of changes in tobacco use behavior. The goal of this research is to develop and test an experimental approach that simulates real-world prolonged exposure to graphic warning labels. Researchers will recruit 450 smokers aged 18 and older from three residential addiction treatment programs. After a baseline interview, researchers will affix one of nine experimental graphic warning labels (or a transparent label as a control condition) to patients’ own cigarette packs; after a 30-day exposure period, researchers will conduct follow-up interviews to identify any changes in smoking-related behaviors. Specific aims are: (1) to expose smokers to graphic warning labels repeatedly over time in the course of their usual tobacco use; and (2) to measure the impact of prolonged exposure to graphic warning labels on behavioral (i.e., intent to quit, quit attempts, cigarettes per day, initiation of cessation services) and communication-related (i.e., tobacco risk perception, impacts of cigarette pack warnings, thoughts about abstinence) outcomes. Research findings will provide information about the impact of real-world extended exposure to graphic warning labels on tobacco use-related factors and may inform FDA regulatory activities.

Frank McCormick Funding Mechanism: Intra-Departmental Delegation of Authority
ID Number: 3P30CA082103-15S2
Institution: University of California-San Francisco 
04/14/2014

University of Hawaii Cancer Center CCSG: Laboratory Studies of Tobacco Advertising and Labeling Effects on Adolescents

Tobacco marketing practices are known to influence adolescent smoking; however, there is a limited understanding of what characteristics make them effective. The goal of this project is to determine what aspects of marketing and packaging create positive reactions toward cigarettes and may encourage adolescents to smoke. Specific aims are: (1) to investigate the role of colors and male and female models in producing positive reactions to cigarette advertising; (2) to investigate the impact of colors and health labels in producing reactions to cigarettes; (3) to examine gender differences in reactions to advertising and packaging; and (4) to investigate ethnic differences in reactions to advertising and packaging. Researchers will conduct two studies, each with an ethnically diverse group of 200 adolescents aged 12-14. In the first study, researchers will modify existing tobacco advertising materials to emphasize different advertisement elements (e.g., colors, use of models); participants will then be asked about their reactions to the modified and unmodified ads. In the second study, researchers will modify existing cigarette packages in two ways: one in which colors are retained but health warning size is increased, and one in which all color and branding information is removed (i.e., plain packaging); participants will be asked about their reactions to the modified and unmodified packages. The studies will assess participant evaluations of the ads, expectancies about smoking, affective reactions, identification with smokers, willingness to smoke, and (in the second study) the extent to which the package makes smoking seem attractive. Research findings will yield information about how aspects of cigarette advertising and packaging could make smoking appear attractive; these findings may be used to inform regulations to address smoking among adolescents. 

Jerris Hedges and Thomas Wills Funding Mechanism:  Intra-Departmental Delegation of Authority (IDDA)
ID Number: 3P30CA071789-14S4
Institution:  University of Hawaii at Manoa 
04/14/2014

University of Hawaii Cancer Center CCSG: E-cigarette Advertising Exposure, Attitudes, and Use Susceptibility among Cigarette Smokers

Electronic cigarettes (e-cigarettes) may be considered as an alternative to traditional cigarettes, especially among younger smokers. E-cigarettes may be perceived as less dangerous than cigarettes, despite the fact that the health consequences of e-cigarette use are not well understood. The goal of the study is to evaluate whether e-cigarette marketing encourages consumer perceptions that e-cigarettes are less dangerous than cigarettes. Specific aims are: (1) to qualitatively assess young adult cigarette smokers’ perceptions of e-cigarette advertisements and develop explicit and implicit measures of e-cigarette-related attitudes; and (2) to test whether exposure to e-cigarette advertisements is associated with attitudes that e-cigarettes are healthier alternatives to cigarettes and with greater e-cigarette use susceptibility, as well as whether the relationship between e-cigarette advertisement exposure and use susceptibility is mediated by attitude measures. To address Aim 1, researchers will conduct 12 focus groups with 72 young adult daily cigarette smokers (aged 18-35) in order to qualitatively assess perceptions of real e-cigarette advertisements and to develop attitude measures that will be used to pursue the second aim. To address Aim 2, researchers will conduct a laboratory-based study with 400 young adult cigarette smokers who will be exposed to either real e-cigarette advertisements or control images. After exposure, all participants will be assessed on explicit and implicit measures of attitudes toward e-cigarettes as less dangerous alternatives to cigarettes and on measures of susceptibility to future e-cigarette use. Research findings may demonstrate the association between exposure to e-cigarette advertising and attitudes toward e-cigarettes and e-cigarette use susceptibility, and may inform marketing-related regulatory activities.

Michele Carbone, Pallav Pokhrel Funding Mechanism:  Intra-Departmental Delegation of Authority (IDDA)
ID Number: 3P30CA07178914S4
Institution:  University of Hawaii at Manoa 
04/09/2014

Dependence Behaviors and Nicotine Pharmacokinetics Associated with blu Electronic Cigarettes in Current Users

Due to their capacity to deliver substantial amounts of nicotine, e-cigarettes may precipitate or perpetuate nicotine dependence. Although systematic assessments of e-cigarette dependence behaviors are limited, it is important to understand how these products affect nicotine dependence and withdrawal behaviors. This study will investigate dependence behaviors and nicotine pharmacokinetics associated with e-cigarette use in experienced users. The investigators will conduct a clinical study measuring use behaviors, nicotine pharmacokinetics, subjective effects, and dependence in 20 experienced adult e-cigarette users (ages 18-55) who are either former smokers or current dual users. Participants will be randomized to use their own brand e-cigarette and two rechargeable e-cigarettes of different nicotine strengths on three study days. Participants will use these products several times each day; use behaviors and nicotine pharmacology will be compared among products and between the first and last use of each day. Plasma nicotine will be measured to assess pharmacokinetics; pharmacodynamics will be measured with heart rate, blood pressure, and oxygen saturation. E-cigarette topography and subjective effects will also be assessed. Findings will reveal if and how experienced users are able to adjust their nicotine exposure with different e-cigarettes and whether these products may be sufficient to maintain dependence. Research findings regarding how e-cigarettes are used and users’ resulting nicotine exposure may inform potential regulatory actions regarding e-cigarettes.

Bartosz Koszowski and Megan Schroeder Funding Mechanism: Research Contract
ID number: HHSF223201310030I; HHSF22301002T
Institution: Battelle Health and Analytics
02/14/2014

14-Day Nose-Only Inhalation Toxicity Study of NNK in Rats

Human exposure to 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific nitrosamine that has been classified as a human lung carcinogen, occurs through smoking tobacco products, using oral smokeless tobacco products, or being exposed to environmental tobacco smoke. The goal of this study is to determine the sub-acute inhalation toxicity of NNK in rats over 14 days of inhalation exposure to NNK aerosols. In this study, six groups of 32 Sprague-Dawley rats (16 males and 16 females per group) will be exposed by nose-only inhalation to one of four dose levels of NNK aerosols or one of two control conditions (vehicle or air) for one hour per day, seven days per week for 14 days. Each study group will contain toxicology (10 rats/sex/group) and exposure assessment (6 rats/sex/group) subgroups. Moreover, three additional groups of toxicology animals (7 rats/sex/group) will be exposed to NNK aerosols by nose-only inhalation for four hours per day, seven days per week for 14 days, and their biological responses will be compared to the one-hour exposure group animals who receive the same exposure doses (i.e., the product of NNK concentration and exposure time will be constant). During the 14-day exposure phase of the study, the rats’ mortality, clinical signs, body weights, food consumption, and pulmonary physiology (breathing rate and minute volume) will be evaluated periodically. One day after the last inhalation dose, researchers will collect tissues from the rats in the toxicology subgroups for histopathological evaluation. Researchers will also evaluate the organ weights, hematology, and blood chemistry of the rats in the toxicology subgroups in order to determine biological responses. Finally, researchers will collect blood and urine from rats in the exposure assessment subgroups at days 1, 8, and 14, and will measure plasma and urine NNK and its metabolites. This project will yield data indicating the risk associated with exposure to NNK.

Shu-Chieh Hu and Raymond Yeager Funding Mechanism: NCTR
ID number: C13036/E0753401
Institution: National Center for Toxicological Research
02/20/2014

Chemical Evaluation of Electronic Cigarettes

Electronic cigarettes (e-cigarettes) are gaining popularity in the United States, exacerbating concerns regarding limited research on these products’ safety. In order to understand the chemistry of e-cigarettes, a detailed chemical evaluation of their design and chemical composition, including the aerosol generated with use, is necessary. This study will collect and evaluate the chemical composition of e-cigarette liquids and aerosol. Researchers will test approximately 20 e-cigarette product lines from nine different brands to qualitatively screen for constituents present in the e-liquid and the vapor. Data collected from this study may inform the science base needed to effectively evaluate and regulate e-cigarettes.

Clifford H. Watson and Candice Jongsma Funding Mechanism: Interagency Agreement
ID number: 224-11-9002/CDC IAA #: CE11-002
Institution: Centers for Disease Control and Prevention
02/03/2014

13-Week Nose-Only Inhalation Toxicity Study of NNK in Rats

Human exposure to 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific nitrosamine that has been classified as a human lung carcinogen, occurs through smoking tobacco products, using oral smokeless tobacco products, or being exposed to environmental tobacco smoke. The goal of this study is to determine the sub-chronic inhalation toxicity of NNK in rats over 90 days of inhalation exposure to NNK aerosols.  In this study, six groups of 46 Sprague-Dawley rats (23 males and 23 females per group) will be exposed by nose-only inhalation to one of four dose levels of NNK aerosols or one of two control conditions (vehicle or air) for one hour per day, seven days per week for 90 days.  Each study group will contain core toxicology, recovery toxicology, and exposure assessment subgroups.  During the 90-day exposure phase of the study, the rats’ mortality, clinical signs, body weights, food consumption, opthalmology, and pulmonary physiology (breathing rate and minute volume) will be evaluated periodically.  One day after the last inhalation dose, researchers will collect tissues from the core toxicology subgroup (10 rats/sex/group) for histopathological evaluation. Researchers will maintain the recovery toxicology subgroup (10 rats/sex/group) for six weeks following the exposure phase, at which time they will analyze tissues in order to evaluate post-exposure recovery. Researchers will also evaluate the organ weights, hematology, blood chemistry, and urinalysis on core and recovery toxicology rats in order to determine biological responses. Finally, researchers will collect blood and urine from exposure assessment (3 rats/sex/group) at weeks 1, 5, 9, and 13, and will measure plasma and urine NNK and its metabolites.  This project will yield data indicating the risk associated with exposure to NNK.

Shu-Chieh Hu and Raymond Yeager Funding Mechanism: NCTR
ID number: C13038/E0753101
Institution: National Center for Toxicological Research
01/22/2014

Drug Dependence Clinical Research Program: New Biomarkers for Tobacco Exposure

While data are available on the chemical composition of, and human exposure to, tobacco toxicants in cigarettes, much less is known about new and emerging tobacco products such as snus, electronic cigarettes, and hookah (waterpipe).  The goal of this study is to develop two new biomarkers of exposure: the tobacco alkaloid nicotelline as a biomarker for tobacco smoke particulate matter (TPM, or “tar”), and pseudooxynicotine (PON), the chemical precursor to the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). To develop these biomarkers, researchers will analyze urine samples from 120 subjects aged 18-70 using hookah (waterpipe), snus, electronic cigarettes, cigarettes, cigars, or oral snuff. Researchers will also analyze these tobacco products for toxic substances and their precursors. Specific aims are: (1) to explore the utility of nicotelline as a biomarker for the particle phase of tobacco smoke by characterizing levels in smokers’ urine and correlating these levels with existing measures of smoke exposure, including cigarettes per day, amount of tobacco burned, and established biomarkers such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and polycyclic aromatic hydrocarbons (PAH); (2) to evaluate PON and its metabolites as biomarkers of exposure to NNK and other tobacco-specific nitrosamines by developing analytical methods for determining urine concentrations of PON and likely metabolites; and (3) to measure concentrations of PON, NNK, other alkaloids, and toxic substances in new and emerging tobacco products in order to determine whether concentrations in the products correlate with urine biomarker concentrations. These new biomarkers will advance the field of tobacco exposure assessment and may inform future regulatory activities.

Reese Jones Funding Mechanism:  Intra-Departmental Delegation of Authority (IDDA)
ID Number: 3P30DA012393-14S1
Institution:  University of California-San Francisco 
09/30/2013

Taste, Preferences, and Behavior: Effects of Nicotine and Flavorings in Electronic Cigarettes

Electronic cigarette (e-cigarette) usage patterns and health risks are not well understood. The purpose of this project is to determine the effects of e-cigarette nicotine concentration and flavor additives on the preferences, cognitions, affects, and behaviors associated with e-cigarette use, particularly in women of reproductive age. Specific aims are: (1) to determine the effects of altering concentrations of nicotine and various flavors on e-cigarette preference and palatability; and (2) to determine the extent to which different flavor additives determine e-cigarette usage. To meet these aims, investigators will conduct a two-phase study of e-cigarettes with 120 male and female smokers aged 18-45 who report no intention to quit. Phase I will entail a laboratory baseline test of preferences, liking, satisfaction, and effects on craving using high versus low concentrations of nicotine crossed with tobacco-flavored or sweet/masking flavor additives; subjects will identify a preferred e-cigarette flavoring. Phase II will evaluate subjects’ usage patterns of preferred cigarettes and e-cigarettes in their home environments. Subjects will be asked to refrain from smoking cigarettes and will be randomized to one of four e-cigarette conditions (no nicotine–tobacco flavoring; high nicotine–tobacco flavoring; no nicotine–preferred flavoring; high nicotine–preferred flavoring). Subjects will call an interactive voice response (IVR) system each evening for six weeks to answer questions about: daily cigarette and e-cigarette use; nicotine cravings before and after e-cigarette use; e-cigarette liking, affects and cognitions related to use; and situational determinants of e-cigarette use. Subjects will also be asked about regular cigarette use, and cigarette smoking will be tested weekly. Investigators will follow up with subjects at three months to determine if cigarette smoking habits have been altered by the e-cigarette experience. Results will provide information about daily motivations to use cigarettes and e-cigarettes, the influence of flavors and nicotine levels on e-cigarette consumption, and the effects of e-cigarette use on subsequent cigarette smoking. These findings may inform future regulation of alternative tobacco products, particularly if certain flavors or nicotine concentrations are found to be associated with greater use.

Mark Litt Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01DA036492-01
Institution: University of Connecticut Health Center
09/30/2013

GSU TCORS: Testing Tobacco Ad Restrictions and Counterads in a 3D Virtual Retail Store

Exposure to point-of-sale (POS) cigarette advertising and promotions is associated with youth smoking experimentation, progression to regular smoking, unplanned tobacco purchases, and urges to smoke. This project will use a previously-developed virtual convenience store to compare policy options to curb and counter the influence of POS cigarette advertising and pack displays as well as increased visibility of other products such as electronic cigarettes. Studies will be conducted with youth (aged 13-17) current smokers and nonsmokers susceptible to smoking and adult (aged 18 and older) current smokers and recent quitters. Specific aims are: (1) to develop and pilot test virtual store conditions with POS tobacco advertising/product display restrictions, graphic health warnings, and product mix changes using 3D gaming software and eye tracking technology; and (2) to conduct randomized controlled experiments to test the impact of policy options to regulate POS tobacco ads and displays, promotions, graphic health warning signs, and product mix on purchase attempts, urges to smoke, and quit intentions. This study will provide policy-relevant data on the potential impact of restricting and countering tobacco marketing efforts at the POS on youth and adult smoking outcomes.

Matthew Farrelly Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036128-01
Institution: RTI International
09/30/2013

GSU TCORS: Enhancing the Economic Impact Analysis Used in FDA’s Rules for Tobacco Products

There are numerous challenges inherent in conducting the type of economic impact analysis the U.S. Food and Drug Administration (FDA) uses to inform its regulatory activities. This project will produce new evidence to inform and refine the FDA’s economic impact assessments of future proposed rules related to tobacco use. This will be accomplished through a combination of behavioral economics experiments involving original data collection; acquisition of existing archival, survey, and commercial databases; and merged data analyses that address current and emerging issues. Specific aims are: (1) to assess the impact of FDA regulatory actions and other tobacco control policies (e.g., graphic health warnings, point-of-sale marketing restrictions, flavor bans, pack size restrictions) on tobacco use and related outcomes, including the impact on tobacco use trajectories among young people and adults, the differential impact of these actions on disparate populations, and the differential impact on the use of traditional and emerging tobacco products; (2) to assess the impact of FDA regulatory actions and other tobacco control policies on the consumer surplus (i.e., enjoyment) obtained by tobacco users, via a behavioral economics experiment that will quantify the extent of present bias, projection bias and time inconsistencies in decisions about tobacco use and the implications of these biases for assessing changes in consumer surplus; and (3) to extend the range of costs and benefits involved in assessing the economic impact of FDA regulatory actions to include a broader set of health and economic benefits (e.g. benefits related to reductions in secondhand smoke exposure and maternal smoking during and after pregnancy) than that included in previous FDA assessments. This project may produce new evidence to inform the FDA’s economic impact assessments of future proposed rules concerning tobacco products.

Frank Chaloupka Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036128-01
Institution: University of Illinois at Chicago
09/30/2013

GSU TCORS: Conducting Consumer Behavior, Risk Perception and Media Research on Novel Tobacco Products

Tobacco companies are rapidly transitioning from combusted products to novel nicotine delivery systems (e.g., e-cigarettes) and alternative tobacco products (e.g., little cigars); however, the actual risk of these products is uncertain, as is whether these products will be used in conjunction with other tobacco products or possibly deter quitting behavior. Investigators will assess use and perceptions of new and emerging tobacco products in a nationally representative sample of adults aged 18 and older. Specific aims are: (1) to assess the patterns of use and perceptions of risk of novel tobacco products and alternative products using quantitative (i.e., annual surveys conducted in years 1 through 5) and qualitative (i.e., six focus groups conducted in years 1, 3 and 5) research methodologies; and (2) to develop and test traditional and new media messages (based on the findings of Aim 1) to improve the quality and accuracy of consumer perceptions of risk, particularly for novel and alternative products. This project will provide new information about risk perceptions, attitudes, and normative beliefs about an array of tobacco products that may inform FDA communications and regulations related to these products.

Michael Eriksen Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036128-01
Institution: Georgia State University
09/30/2013

Pennsylvania State University Tobacco Center of Regulatory Science (TCORS)

This Center will evaluate the effects of switching smokers from their usual cigarettes to reduced nicotine content cigarettes on nicotine dependence and tobacco harm, with a special focus on vulnerable (e.g. low socioeconomic status [SES], mental disorders) populations. Project 1, a randomized controlled trial, will evaluate the effect of progressive nicotine reduction in cigarettes on smoking behaviors, smoking biomarkers, and stress in smokers with low SES. Project 2, a second randomized controlled trial, will evaluate the effect of progressive nicotine reduction in cigarettes on smoking behavior, toxin exposure, and psychiatric symptoms in smokers with comorbid mood and/or anxiety disorders. Project 3 will evaluate free radical exposure and oxidative stress associated with use of conventional and reduced nicotine cigarettes, via analysis of machine smoking data and a product switch intervention study.

Joshua Muscat and Jonathan Foulds Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036107-01
Institution: Pennsylvania State University
09/30/2013

PSU TCORS: Switching to Progressively Reduced Nicotine Content Cigarettes in Smokers with Lower Socioeconomic Status

A potential strategy to reduce harm from tobacco is reducing nicotine content and delivery to non-addictive levels. The effectiveness of this strategy needs to be demonstrated in different populations whose response to reduced nicotine content (RNC) cigarettes might be substantially mediated by personal or environmental factors. To address the question of whether progressively lowering nicotine content in cigarettes can reduce or eliminate nicotine dependence in low socioeconomic status (SES) populations, investigators will test the following specific aims: (1) to determine the effect of progressive nicotine content reduction on biological levels of nicotine, its metabolites, and other biomarkers of smoking exposure; (2) to determine the predictors of participant drop-out/relapse; and (3) to determine if a gradual reduction in nicotine content versus same nicotine content is associated with a reduction in stress. This randomized double-blinded controlled trial will evaluate nicotine intake in 400 adult smokers with lower socioeconomic status who switch to progressively reduced nicotine content test cigarettes. Investigators will randomize smokers to either an RNC group with a gradual step-wise reduction in nicotine from 11 mg to 0.3 mg per cigarette in five stages, or a control group with nicotine content that approximates that of their usual cigarette brand. Test nicotine research cigarettes will be obtained through the National Institute on Drug Abuse (NIDA) Drug Supply Program (part of the National Institutes of Health). The RNC group will include menthol and non-menthol flavors. Additional measures will include changes in psychological scales and biomarkers of stress. This study will provide empirical data that could inform regulatory actions related to reducing cigarette nicotine content.

Joshua Muscat and Jonathan Foulds Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036107-01
Institution: Pennsylvania State University
09/30/2013

PSU TCORS: Reduced Nicotine Cigarettes in Smokers with Mood and Anxiety Disorders

A potential strategy to reduce harm from tobacco is reducing nicotine content and delivery to non-addictive levels. The effectiveness of this strategy needs to be demonstrated in different populations whose response to reduced nicotine content (RNC) cigarettes might be substantially mediated by personal or environmental factors. This randomized controlled trial will evaluate the effect of progressive cigarette nicotine reduction on smoking behavior, toxin exposure, and psychiatric symptoms in smokers with comorbid mood and/or anxiety disorders. Specific aims include: (1) to assess the effect of switching to gradually reduced nicotine content cigarettes on product use patterns and biomarkers of exposure in smokers with mood and/or anxiety disorders; (2) to assess the effect of switching to gradually reduced nicotine content cigarettes on psychiatric and nicotine withdrawal symptoms in smokers with unipolar mood and/or anxiety disorders; and (3) to assess the effect of switching to gradually reduced nicotine content cigarettes on self-perception of tobacco dependence, self-report of intention to quit smoking, and actual smoking cessation attempts. Investigators will randomly assign 200 adult smokers with a unipolar mood and/or anxiety disorder to smoke research cigarettes containing either usual nicotine content (similar to their usual brand) or reduced nicotine content (progressively reduced from approximately 11 mg to 0.3 mg over five steps). This study is designed to test the hypotheses that nicotine intake, as measured by plasma cotinine concentrations, will decline as a function of cigarette nicotine content, and that reducing the nicotine content of the cigarettes on a gradual basis will minimize potential compensatory increases in tobacco exposure biomarkers and psychiatric symptoms compared to the usual brand group. This study will provide empirical data that could inform regulatory actions related to reducing cigarette nicotine content.

Jonathan Foulds and Eden Evins Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036107-01
Institution: Pennsylvania State University, Harvard University
09/30/2013

PSU TCORS: Free Radical Exposure and Oxidative Stress from Conventional and Reduced Nicotine Cigarettes

Oxidative stress from tobacco smoke exposure has a widespread impact on many critical cellular pathways, including cell proliferation, survival and inflammation. A major source of smoking-related oxidative stress is from exposure to free radicals such as reactive oxygen and nitrogen species, which play fundamental roles in the development of many diseases including cancer and heart disease. An assessment of free radical exposure and oxidative stress is critical to help gauge the relative harm of current and new tobacco products. This project will evaluate free radical exposure and oxidative stress associated with the use of conventional and reduced nicotine cigarettes, via a series of laboratory-based machine smoking studies and product switch intervention studies in healthy adult smokers (aged 21 or older). Specific aims include: (1) to determine the free radical content of mainstream tobacco smoke from popular U.S. menthol and non-menthol cigarettes as well as newer and developing low and ultra-low nicotine products; (2) to determine if smoking behavior in 80 smokers is impacted by switching to lower nicotine or lower free radical products, and if behavior changes lead to altered exposure to tobacco smoke free radicals; and (3) to determine if 108 smokers who switch from their usual high nicotine/free radical products to low nicotine or low free radical products exhibit increased or decreased levels of oxidative stress and damage. Together, these studies will result in a comparative assessment of exposure to toxic and harmful free radicals for smokers of different tobacco products. This project constitutes the first formal assessment of exposure of smokers of different tobacco products to toxic and harmful free radicals and has the potential to inform regulatory decisions intended to limit user exposure to these toxic agents.

John Richie Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036107-01
Institution: Pennsylvania State University
09/30/2013

Yale Tobacco Center of Regulatory Science

The Center will conduct research to evaluate how flavors (including menthol), sweeteners, and related factors affect the initiation of, preference for, and development of addiction to current tobacco and potential modified risk tobacco products. Populations studied will include adolescent and adult mice and rats, adolescent and young adult smokers and nonsmokers, and chronic smokers. Project 1 will study the effects of flavors on nicotine choice and dopaminergic/central reward mechanisms in mice and rat models. Project 2 will study menthol’s effects on nicotine reinforcement in smokers. Project 3 will evaluate whether commonly used flavor constituents, including menthol, alter reinforcement from e-cigarettes in adolescent smokers. Project 4 will examine factors (including product attributes and informal/formal sources of information about risks) that influence both the perceptions of risk and interest in using tobacco products in different populations (i.e. populations that vary by age, race, smoking status, and socioeconomic status).

Suchitra Krishnan-Sarin and Stephanie O’Malley Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036151-01
Institution: Yale University
09/30/2013

Project 3: Conducting Consumer Behavior, Risk Perception and Media Research on Novel

Tobacco companies are rapidly transitioning from combusted products to novel nicotine delivery systems (e.g., e-cigarettes) and alternative tobacco products (e.g., little cigars); however, the actual risk of these products is uncertain, as is whether these products will be used in conjunction with other tobacco products or possibly deter quitting behavior. Investigators will assess use and perceptions of new and emerging tobacco products in a nationally representative sample of adults aged 18 and older. Specific aims are: (1) to assess the patterns of use and perceptions of risk of novel tobacco products and alternative products using quantitative (i.e., annual surveys conducted in years 1 through 5) and qualitative (i.e., six focus groups conducted in years 1, 3 and 5) research methodologies; and (2) to develop and test traditional and new media messages (based on the findings of Aim 1) to improve the quality and accuracy of consumer perceptions of risk, particularly for novel and alternative products. This project will provide new information about risk perceptions, attitudes, and normative beliefs about an array of tobacco products to inform FDA communications and regulations related to these products.

Michael Eriksen Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1P50DA036128-01
Institution: Georgia State University
09/30/2013

The Science of Decision-Making: Connecting People and Policy (GSU TCORS)

This Center will investigate the human and economic factors that contribute to decision-making regarding the use of tobacco products. Specifically, the Center‘s projects will examine the economic, point of sale, consumer behavior, risk perception, and communication factors that influence tobacco use behaviors, particularly for novel and alternative tobacco products, and will provide evidence that has direct implications for FDA regulatory actions. Project 1 will involve human economic behavioral experiments that produce new evidence to inform the FDA’s economic impact assessments of future proposed rules. Project 2 will study consumer reactions to tobacco marketing using visual immersion methodology in order to examine the point of sale environment and how it can be changed to influence consumer behavior. Project 3, which focuses on individual perception of risk of tobacco product use, will conduct qualitative research to monitor the use and perceptions of tobacco products, with a special emphasis on alternative and novel products.

Michael Eriksen Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036128-01
Institution: Georgia State University
09/30/2013

Vermont Center on Tobacco Regulatory Science

The Center will focus on researching tobacco product use and effects in vulnerable populations, including women of childbearing age/pregnant women, individuals with comorbid substance use disorders, and individuals with comorbid serious mental illness. In this context, the Center will study the following: (1) reducing the addiction potential of cigarettes and other tobacco products by reducing their nicotine content, and (2) the impact of new products on biomarkers of exposure and health outcomes in vulnerable populations. The Center will complete three multi-site research projects evaluating the effects of very low nicotine content (VLNC) cigarettes in vulnerable populations. Project 1 will examine response to VLNC cigarettes among women of childbearing age including pregnant women, investigating (a) behavioral-economic tests of reinforcing effects/abuse liability, (b) compensatory smoking, (c) ability to substitute for higher-nicotine content cigarettes, (d) effects on motivation to quit, (e) neurobiological response (e.g., neuroimaging with non-pregnant women only), and (f) biomarkers of tobacco-smoke/carcinogen exposure, pulmonary and cardiovascular effects, and birth outcomes. Project 2 will investigate response to VLNC cigarettes in smokers with substance use disorders. Project 3 will focus on testing VLNC cigarettes in smokers with major depression.

Stephen Higgins Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036114-01
Institution: University of Vermont and State Agricultural College
09/30/2013

UVM TCORS: Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Abusers

Reducing the nicotine content of cigarettes has shown promising beneficial effects (e.g., decreased smoking rate, reduced toxicant exposure, and increased cessation) in the general population, but studies have excluded vulnerable populations such as individuals with comorbid drug dependence, who may respond with compensatory increases in smoking rate or inhalation patterns, potentially increasing exposure and adverse health effects. Investigators will conduct two studies to evaluate the abuse liability and health effects of reduced nicotine content (RNC) cigarettes in 60 opioid-dependent smokers (aged 18-70) by comparing cigarettes varying in nicotine content across a range of doses starting from levels approximating those in normal nicotine content (NNC) cigarettes to low nicotine levels using brief- and extended-exposure protocols. Study 1 will evaluate the effects of brief exposure to RNC cigarettes among opioid-maintained smokers in the clinical laboratory under double-blind conditions, using a within-subjects design to examine the effects of RNC nicotine cigarettes on subjective measures (e.g., satisfaction, craving relief) and the extent to which the RNC cigarettes substitute for NNC cigarettes (0.80 mg) under conditions of varying constraints on the latter. Study 2 will evaluate the effects of extended exposure to RNC cigarettes in 400 opioid-maintained smokers using a between-subjects design that randomly assigns participants to one of four cigarette conditions (0.80, 0.26, 0.12 or 0.03 mg nicotine) for a 12-week period. Specific aims are: (1) to evaluate whether RNC cigarettes substitute for NNC cigarettes during brief exposure without producing compensatory increases in smoking, assessed by expired-breath carbon monoxide (CO); (2) to compare extended exposure to RNC and NNC cigarettes with regard to daily smoking rates (i.e., self-report, cotinine), tobacco smoke exposure levels (e.g., breath CO, urine cotinine), and nicotine dependence severity; (3) to assess adherence to assigned tobacco products and use of other nicotine products during the extended exposure conditions; (4) to quantify the effects of RNC cigarettes on biomarkers of exposure to tobacco carcinogens (e.g., cotinine, nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL], polycyclic aromatic hydrocarbons [PAH]), markers of pulmonary and cardiovascular risk, and use of other non-prescribed drugs during extended exposure; and (5) to compare RNC and NNC cigarettes on abstinence-induced craving, withdrawal, cigarette demand and neurocognitive function. Data from this study may inform FDA policy decisions regarding reduced-nicotine tobacco products.

Stacey Sigmon Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036114-01
Institution: University of Vermont
09/30/2013

UVM TCORS: Low Nicotine Content Cigarettes in Vulnerable Populations: Childbearing Age Women

Reducing the nicotine content of cigarettes has shown promising beneficial effects (e.g., decreased smoking rate, reduced toxicant exposure, and increased cessation) in the general population, but studies have excluded vulnerable populations such as low-income pregnant women, who may respond differently due to greater vulnerability to smoking and nicotine dependence. This project involves two studies that will evaluate how pregnant and non-pregnant smokers aged 18-44 might respond to reduced nicotine content (RNC) cigarettes. In Study 1, investigators will assess the effects of brief exposure to cigarettes of varying nicotine yield (0.80, 0.26, 0.12, 0.03 mg in 60 non-pregnant women; usual brand, 0.10, 0.03 mg in 60 pregnant women) on craving, nicotine withdrawal, and the degree to which the RNC cigarettes substitute for typical nicotine content cigarettes in behavioral-economic tests of smoking preference. In Study 2, 400 non-pregnant and 200 pregnant smokers will be randomized to smoke one of the above doses during an extended exposure phase (12 weeks in non-pregnant women; through delivery in pregnant women). Specific aims are: (1) to compare the subjective and behavioral effects of cigarettes varying in nicotine content in non-pregnant and pregnant women; (2) to compare extended exposure to these cigarettes on measures of smoking rate (cigarettes per day, urine cotinine levels) and nicotine dependence severity in non-pregnant and pregnant women; (3) to assess adherence to assigned tobacco products during the extended exposure study; (4) to quantify the effects of extended exposure to RNC cigarettes on biomarkers of exposure (e.g., total cotinine, nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL], polycyclic aromatic hydrocarbons [PAH]), markers of thrombotic risk and lung function, and sonographic estimates of fetal growth and birth outcomes; and (5) to compare the effects of these cigarettes on abstinence-induced craving, withdrawal, cigarette demand, and neurocognitive function in non-pregnant and pregnant women. This project will provide new information about how this highly vulnerable subgroup of smokers might respond to a nicotine reduction policy.

Sarah Heil and Stephen Higgins Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036114-01
Institution: University of Vermont
09/30/2013

UVM TCORS: Low Nicotine Content Cigarettes in Vulnerable Populations: Currently Depressed

Reducing the nicotine content of cigarettes has shown promising beneficial effects (e.g., decreased smoking rate, reduced toxicant exposure, and increased cessation) in the general population. Studies to date have excluded vulnerable populations such as individuals with comorbid psychiatric illness, who may respond to reductions in the nicotine content of cigarettes with increases in psychiatric symptoms and/or with compensatory smoking. This project involves two studies that will evaluate relationships between the nicotine content of cigarettes and outcomes in smokers (aged 18-70) with major depressive disorder (MDD). Study 1, conducted in 60 subjects, will use a within-subjects design to compare effects of cigarettes varying in nicotine content on reinforcing efficacy, compensatory smoking, amelioration of abstinence-induced craving and withdrawal, and smoker preference for normal nicotine content (NNC) vs. reduced nicotine content (RNC) cigarettes under different cost conditions. Study 2, a randomized clinical trial including 400 subjects, will examine the effects of 12-week exposure to these cigarettes on smoking rate, nicotine dependence, depression severity, neurocognitive function, acceptability, and biomarkers of toxicant exposure and other health outcomes. Specific aims are: (1) to compare the subjective and behavioral effects of cigarettes varying in nicotine content (0.80, 0.26, 0.12, 0.03 mg) in smokers with MDD; (2) to compare these cigarettes with regard to measures of use (e.g., cigarettes per day, total cotinine) and nicotine dependence severity in smokers with MDD over a 12-week exposure period; (3) to assess adherence to assigned tobacco products during the extended exposure study; (4) to quantify the effects of extended exposure on biomarkers of exposure to tobacco carcinogens (e.g., nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL], polycyclic aromatic hydrocarbons [PAH] metabolites), markers of pulmonary and cardiovascular risk, depression symptoms, cognitive dysfunction and smoking topography; and (5) to compare the effects of these cigarettes on abstinence-induced craving, withdrawal, cigarette demand, and neurocognitive function in smokers with MDD. This study will provide new information about the effects a nicotine reduction policy may have on smokers with MDD.

Jennifer Tidey Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036114-01
Institution: Brown University
09/30/2013

VCU Center for the Study of Tobacco Products

The Center will create an integrated, iterative modified risk tobacco product evaluation model that incorporates analytic laboratory methods, toxicant exposure, abuse liability testing using human laboratory methods, longer-term effects using randomized control trial methods, and studies of attitudes, beliefs, and perceived effects using quantitative and qualitative methods to inform tobacco product regulation across all product types (combustible, oral, or vapor). The first product category to be studied will be e-cigarettes. Project 1 will examine factors (e.g., design features, topography, unorthodox use behaviors) that influence e-cigarette nicotine and toxicant yield. Project 2 will determine the use behaviors, effects, and toxicant exposure associated with e-cigarette use and abuse liability. Project 3 will characterize the effects of real-world e-cigarette use in the natural environment via a randomized controlled trial. Project 4 will study user attitudes, beliefs, and perceived effects of e-cigarettes using qualitative and quantitative methods, and examine unorthodox e-cigarette use behaviors.

Thomas Eissenberg / Robert Balster Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1P50DA036105-01
Institution: Virginia Commonwealth University
09/30/2013

VCU TCORS: Analytical Lab Methods for MRTP Evaluation

Understanding yields of toxicants in combustible tobacco products generally requires chemical analysis of product emissions. Emissions analysis historically relied on smoking machines; however, few models have been developed for evaluating the health risks associated with novel tobacco products such as e-cigarettes. This project will examine factors (e.g., design features, topography, and unorthodox use behaviors) that influence e-cigarette nicotine and toxicant yield utilizing a “playback” puffing machine method that mimics human puffing behavior. Specific aims are: (1) to develop a heat and mass transfer model to predict e-cigarette nicotine yields as a function of product design and puff parameters; (2) to use a validated playback puffing machine to generate e-cigarette emissions using puffing behavior recorded from e-cigarette users (collected as part of Project 2, below); and (3) to study how unorthodox use behaviors and product manipulation influence nicotine and other toxicant yields of e-cigarettes and other novel products. This project has the potential to inform the regulation of novel tobacco products by developing a model for measuring toxicant yields under real-life use conditions.

Alan Shihadeh Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036105-01
Institution: American University of Beirut
09/30/2013

VCU TCORS: Randomized Control Trial Methods for MRTP Evaluation

Data addressing how long-term e-cigarette use influences toxicant exposure, user health, and concurrent cigarette smoking are very limited. This project will characterize the effects of real-world e-cigarette use in the natural environment via a multi-site randomized controlled trial. Specific aims are: (1) to characterize product influence on toxicants, biomarkers, health indicators, and disease risk; (2) to determine the tobacco abstinence symptom and adverse event profile associated with real-world product use; and (3) to examine the influence of novel product use on conventional tobacco product use. Investigators will randomly assign 520 e-cigarette-naïve cigarette smokers (aged 18-59) who are interested in reducing their tobacco use to one of four conditions for six months: high-nicotine dose e-cigarette, mid-nicotine dose e-cigarette, zero nicotine dose (placebo) e-cigarette, or a control condition that includes use of a non-combustion, non-nicotine, non-vapor, imitation cigarette substitute. Investigators will measure exposure to the carcinogenic nitrosamine NNK (via its metabolite NNAL in urine); carbon monoxide (via exhaled air); nicotine (via its metabolite cotinine in urine); heart rate; blood pressure; biochemical and hematologic health indices (e.g., lipoproteins, hemoglobin, hematocrit); pulmonary function (via spirometry); biomarkers of oxidative stress (e.g., 8-lsoprostane, glutathione, 8-OHDG); abstinence symptoms; and adverse effects (e.g., dry mouth, throat, and eyes; heart pounding; nausea). This project will develop a randomized controlled trial model that can be used to evaluate any novel tobacco product, not just e-cigarettes.

Thomas Eissenberg and Jonathan Foulds Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036105-01
Institution: Virginia Commonwealth University
09/30/2013

VCU TCORS: Human Lab Methods for MRTP Evaluation

E-cigarette safety and use behaviors require further study. This project will determine the behavioral effects and toxicant exposure associated with e-cigarette use and their abuse liability. Specific aims are: (1) to demonstrate how human laboratory methods can reveal product use behaviors, toxicant exposure, and effects, (2) to demonstrate how human laboratory methods can determine product abuse liability; and (3) to determine how unorthodox use behavior influences e-cigarette effects. Six studies in subjects aged 18-55 will be conducted as part of this project: a two-condition (topography measurement with mouthpiece vs. no mouthpiece) within-subject study involving experienced e-cigarette users; a study in which a nicotine-delivering e-cigarette is used to examine the effects of varying nicotine concentrations in experienced e-cigarette users and e-cigarette-naïve cigarette smokers; a five-day study conducted in e-cigarette-naïve cigarette smokers that compares the toxicant exposures and other effects of an e-cigarette, an inhaler, conventional tobacco cigarettes, and tobacco abstinence; two separate within-subject short-term laboratory studies evaluating the reinforcing efficacy of a low-dose e-cigarette, a high-dose e-cigarette, and a nicotine inhaler, conducted with experienced e-cigarette users and e-cigarette-naive cigarette smokers; and a within-subject study with two conditions (unorthodox e-cigarette use vs. conventional use) conducted in subjects experienced with both methods to test whether unorthodox use (i.e., “dripping” nicotine liquid onto the e-cigarette heater) alters user nicotine exposure and effects. This project will demonstrate how human laboratory methods can inform tobacco product evaluation by determining the behavior, effects, and toxicant exposure associated with product use and how these methods can inform abuse liability assessment.

Alison Breland and Michael Weaver Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036105-01
Institution: Virginia Commonwealth University
09/30/2013

VSU TCORS: Quantitative and Qualitative Methods for MRTP Evaluation

New evaluation methods are needed to help explain patterns of modified risk tobacco product (MRTP) consumption and prevalence. This project will demonstrate how a mixed methods approach can be used to generate empirically-based, descriptive models of MRTP-related attitudes, beliefs, motivations and perceived effects (including adverse events) associated with product use and intentional misuse. Specific aims are: (1) to characterize and describe the attitudes and beliefs, motivations, and perceived effects associated with e-cigarette use behaviors; and (2) to examine methods of unorthodox e-cigarette use behaviors. Concept mapping, an integrated mixed method participatory research approach, will be used to describe user attitudes and beliefs regarding e-cigarettes, motivations for e-cigarette use; and perceived beneficial and adverse effects of e-cigarette use. The study will include 500 e-cigarette users (aged 18 and older) who will complete online activities that involve brainstorming statements in response to a prompt about e-cigarette use, sorting these statements into conceptually similar categories, and then rating the importance of each statement. Investigators will also conduct a content analysis of YouTube videos and Internet forums that depict unorthodox e-cigarette use behaviors, such as mixing high-dose nicotine liquids and/or dripping liquid directly on the e-cigarette heater. This project will demonstrate how a mixed methods approach can be used to generate empirically-based, descriptive models of MRTP-related attitudes, beliefs, motivations and perceived effects that can be used to inform the development of comprehensive MRTP regulation.

Aashir Nasim Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036105-01
Institution: Virginia Commonwealth University
09/30/2013

Yale TCORS: Effects of Flavors on Nicotine Choice and Central Reward Mechanisms

In addition to nicotine, dissolvable tobacco products contain high amounts of sweeteners, flavors, menthol and other cooling agents. Nicotine, sweeteners, flavors and menthol in tobacco products have a complex effect on peripheral sensory systems (mouth, nose and throat) as well as on central reward circuits in the mesolimbic dopamine system, thereby signaling brain reward pathways that influence use behaviors and addiction. This project will study the effects of flavors on nicotine choice and dopaminergic/central reward mechanisms in mice and rat models. Specific aims are: (1) to determine whether flavor constituents in dissolvable tobacco products alter oral nicotine intake; and (2) to examine whether flavor constituents of dissolvable tobacco products increase nicotine reinforcement and nicotine-taking by enhancing phasic dopamine release. Together, these aims will test the hypotheses that flavorings such as sweeteners and menthol affect initiation and the addictive properties of dissolvable tobacco products.

Sven-Eric Jordt and Marina Picciotto Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036151-01
Institution: Yale University
09/30/2013

Yale TCORS: Menthol’s Effects on the Nicotine Reinforcement in Smokers

Menthol is an additive in the majority of cigarettes, although at widely different concentrations. Research suggests that menthol may facilitate addiction dependence and maintenance when combined with nicotine. However, the potential reinforcing properties of menthol have not been examined with systematic studies in controlled settings, and human studies examining the reinforcing effects of menthol in combination with nicotine are lacking. This study is designed to test one overarching specific aim: to determine if menthol administered by inhalation via e-cigarettes or orally via sublingual tablet changes the reinforcing effects of pure nicotine administered intravenously in cigarette smokers who smoke mentholated or non-mentholated cigarettes. Exploratory aims include: (1) to determine if menthol’s reinforcing effects are dose dependent; and (2) to determine if inhaled or sublingual menthol changes the cardiovascular, cognitive, and withdrawal suppressing effects of intravenous nicotine; and to determine if sublingual or inhaled menthol will be reinforcing by itself. In two double-blind, placebo-controlled studies (one using e-cigarettes and one using a menthol sublingual tablet), investigators will enroll 160 young adult smokers (aged 18-30) stratified for menthol preference; nicotine will be delivered intravenously, and menthol will be delivered via inhalation and sublingual routes.  For both studies, the main outcome measure will be subjective drug effects, which will be measured using the Drug Effects Questionnaire (DEQ). Determining the reinforcing effects of menthol in combination with nicotine in this study will contribute to the knowledge needed to inform science-based policies regarding additives in tobacco products.

Mehmet Sofouglu
 
Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036151-01
Institution: Yale University
09/30/2013

Yale TCORS: Flavors and E-cigarette Effects in Adolescent Smokers

Adolescents are highly susceptible to using novel tobacco products like e-cigarettes. This project will evaluate whether commonly-used flavor constituents, including menthol, alter reinforcement from e-cigarettes in adolescent smokers. The project will include two studies conducted with 140 adolescent smokers aged 15-18. The first study will examine the following: whether menthol at doses that produce low and high cooling sensations alters reinforcement experienced from e-cigarettes that contain low (6 mg/ml) or high (12 mg/ml) levels of nicotine; whether these menthol doses are by themselves reinforcing; and whether preference for menthol vs. non-menthol e-cigarettes in the laboratory is related to the tobacco product type (i.e. menthol/non-menthol) used at one- and two-year follow-up. The second study will determine if a flavor (e.g. cherry, chocolate), when compared to menthol or in combination with menthol, alters the reinforcement from e-cigarettes containing nicotine. Specific aims are: (1) to examine if inhaled menthol doses that produce low and high cooling effects alter reinforcement from e-cigarettes containing low and high nicotine doses; (2) to explore if response to e-cigarettes containing menthol in the laboratory predicts preference for mentholated tobacco products at one- and two-year follow-up; and (3) to examine the independent and combined effects of inhaled doses of menthol and a second flavor on reinforcement from e-cigarettes containing nicotine. Investigators will also explore how smoking e-cigarettes relates to smoking regular cigarettes. This study will elucidate the responses of adolescent smokers to e-cigarettes and determine if flavors alter their addictive potential.

Suchitra Krishnan-Sarin Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036151-01
Institution: Yale University
09/30/2013

Yale TCORS: Economics, Experiments and PATH Data: Creating Knowledge for Tobacco Regulation

A wide array of tobacco product-related factors, including product attributes and informal/formal sources of information about risks, influence risk perceptions and interest in use. Investigators will conduct school-based and online experiments that will provide information about emerging combinations of product attributes in advance of widespread use. Experiments will be conducted in 4000 subjects, including youth (aged 13-17) in largely minority high schools, young adults (aged 18-25), and adult current smokers (aged 18 and older). Specific aims are: (1) to understand how individuals who vary by age, race, smoking status and socioeconomic status perceive and trade-off the potential risks, attributes, and design features of cigarettes, including low levels of nicotine, low levels of toxins, menthol, and sweet flavoring; (2) to examine perceptions of e-cigarette risk and attributes, specifically flavorings (menthol and sweet), levels of nicotine, and non-combustibility (i.e., ability to use despite smoking bans); (3) to study how source and media types (including graphic warning labels) affect the credibility of information about menthol added to cigarettes and e-cigarettes; (4) to analyze peer effects on e-cigarette use; and (5) to use secondary data from the Population Assessment of Tobacco and Health Study (PATH) and the Current Population Survey-Tobacco Use Supplement (CPS-TUS) (both of which include data on conventional cigarette smoking as well as emerging tobacco products) in combination with experiment results to predict the impact of potential regulations on tobacco use nationally and by subgroup. This project will yield data concerning risk perceptions and use intentions among youth and other vulnerable populations that may inform regulatory decisions related to product attributes and communication campaigns that convey the risks of product use.

Jody Sindelar Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50DA036151-01
Institution:  Yale University
09/30/2013

A Mixed Methods EMA Assessment of Cognition and Behavior among New ENDS Users

Electronic nicotine delivery systems (ENDS), also known as e-cigarettes, are the most prevalent of the emerging noncombustible products. Research suggests that African-American smokers are less likely than White smokers to try or use ENDS, perhaps due to a greater degree of perceived harm associated with ENDS, a preference for menthol, or cultural norms. However, differential adoption of ENDS by race may not continue as mentholated ENDS are increasingly marketed to African-Americans. The goal of this study is to evaluate how all smokers, including African-American and menthol smokers, experience and initiate ENDS use. Specific aims are: (1) to examine how the immediate environmental and psychological contexts of cigarette and ENDS use vary within subjects; (2) to examine how these contexts vary between subjects by menthol preference and race; and (3) to examine participants’ “lived experience” of the meaning, influences, and utility of cigarette and ENDS use. To meet these aims, investigators will conduct an observational study involving three weeks of ecological momentary assessment (EMA) and in-depth interview data collection, followed by 30-day follow-up telephone contact to assess cigarette and ENDS use. Subjects will include 100 daily cigarette smokers aged 18 and older, stratified into four groups by menthol use and race (non-Hispanic White and non-Hispanic Black). In Week 1, participants will collect baseline data on their usual smoking pattern. In Week 2, participants will receive a week’s supply of ENDS and instructions to use the products at least three times daily. In Week 3, investigators will replenish participants’ ENDS supply and encourage participants to use the products as they see fit. Over the three weeks, participants will use a previously-developed EMA data collection system to provide real-time data (at four random times per day) on immediate environmental context (location, smoking restrictions and presence of others), current psychological states (self-efficacy, outcome expectancies about ENDS and cigarette use, mood), and tobacco use-related items (craving, satisfaction, cigarette or ENDS use, and duration/amount of product used). Participants will also take part in a semi-structured in-depth interview at the end of each week; Week 1 interviews will focus on a process evaluation of the EMA data collection experience, while Week 2 and 3 interviews will focus on how ENDS-associated cognitions, expectancies and norms evolve with ENDS use and increasing familiarity with the product. Findings will provide information about the immediate environmental contexts and psychological correlates associated with ENDS initiation in menthol and non-menthol smokers interested in trying ENDS.

Jennifer Pearson Funding Mechanism: National Institutes of Health- Grant
ID number: 1R21DA036472-01
Institution: American Legacy Foundation
09/30/2013

A Regulatory Framework for Substantial Equivalence Product Applications under the FSPTCA

The Family Smoking Prevention and Tobacco Control Act of 2009 grants FDA the authority to conduct a pre-market review of new, revised and modified tobacco products. Under the law, tobacco product sponsors may file an application for exemption from pre-market review if they believe that a new product is “substantially equivalent” (SE) to an existing product. The FDA may grant an SE marketing order if it determines that the new product either has the same characteristics (i.e., materials, ingredients, design, composition, heating source, or other features) as a product on the market as of February 15, 2007, or has different characteristics but does not raise different questions of public health. The goal of this project is to establish a foundation for SE regulatory science by harnessing the science of product equivalence from other realms, understanding the economics and incentives facing tobacco product sponsors when submitting an SE application versus other types of applications, generating a body of research that can inform rigorous evaluation of product applications, and generating a body of research to inform and advance the study of tobacco product equivalence and potential health outcomes. Investigators will demonstrate potential effects on the cigarette market of a relatively low threshold for SE and develop a theoretical model of population outcomes depending on the stringency of research requirements for SE applications. Specific aims are: (1) to analyze the statutory, legislative, and regulatory history and the scientific methods for determining equivalence in FDA-regulated product arenas other than tobacco products as well as internal tobacco industry research on product modification and SE; (2) to conduct a preliminary investigation of the tobacco market and population effects of industry response to the ban on “light” descriptors under a permissive versus restrictive SE approach; and (3) to develop and empirically test a mathematical model of SE review, possible tobacco market incentives, and population health outcomes. This research will provide both a theoretical framework and an empirical basis for FDA’s SE pre-market review criteria.

Gregory Connolly Funding Mechanism: National Institutes of Health- Grant
ID number: 1 R21 DA036485-01
Institution: Harvard School of Public Health
09/30/2013

Assessment of Tobacco Constituent Pharmacology and Behavior in Nonclinical Models: Determination of Behaviorally Effective Tobacco Constituent Doses in Rodents

Although nicotine is the primary addictive constituent in tobacco, studies indicate that tobacco contains additional non-nicotine constituents that may have addictive potential. These constituents include, but are not limited to, anatabine, cotinine, and myosmine. Because no previous studies have evaluated these compounds in nonclinical models, the goal of this project is to define behaviorally active doses of anatabine, cotinine, and myosmine. Investigators will test five doses of continine, anatabine, and myosmine in adult rodents using a locomotor activity protocol to establish dose response curves for each constituent. Study aims are: (1) to characterize dose response curves for the non-nicotine tobacco constituents anatabine, cotinine, and myosmine; and (2) to use these dose response curves to determine relevant constituent doses for subsequent studies of abuse liability in rodents. Once behaviorally active doses have been established, these doses can be used in future behavioral pharmacology studies; furthermore, information on non-nicotinic tobacco constituents may help inform FDA product review and regulation.

Kia Jackson Funding Mechanism: Research Contract
ID number: HHSF223201310034I
Institution: RTI
09/30/2013

Modeling the Policy Impact of Cigarette and Smokeless Use on U.S. Mortality

Smokeless products have been proposed as less harmful alternatives to cigarette smoking. However, among groups with the highest cigarette smoking rates (i.e., males and young adults), smokeless use may be added to, rather than substituted for, cigarette smoking, thereby increasing overall toxicant exposure and/or delaying cessation. The goal of this project is to conduct statistical analyses of the transitions to and from cigarette and smokeless tobacco use in light of policy effects on initiation, cessation, multiple product use, and quantity smoked. Investigators will apply statistical analyses to three existing models, a tobacco control policy model (SimSmoke) and two natural history of disease models (the Michigan-Fred Hutchinson model and the Massachusetts General Hospital Lung Cancer Policy Model [LCPM]). These models were developed as part of the National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET). Specific aims are: (1) to conduct a descriptive analysis of cigarette and smokeless tobacco use patterns, quit rates and addiction measures by age and gender, using the Tobacco Use Supplement (TUS); (2) to collect state- and federal-level policy data and review the literature on policy effects on cigarette and smokeless use; (3) to conduct multivariable analyses to distinguish use, initiation, cessation and dose patterns of sole and dual use and to determine how policies are associated with these patterns for cigarette and smokeless users; (4) to extend the SimSmoke, Michigan and LCPM models to examine trends in cigarette and smokeless use, and to develop SimSmoke models for two states with different policy structures (Minnesota and Kentucky) to gauge how the effects of FDA regulations may vary depending on state policies; (5) to adapt the models to estimate the incidence of tobacco-related disease (e.g., lung, head and neck and pancreatic cancers; chronic obstructive pulmonary disease, all cause-mortality) resulting from sole and dual use of cigarettes and smokeless tobacco; and (6) to adapt the models to compare the impact of FDA regulations (e.g. health warnings, retail point-of-sale restrictions, regulation of product content) on national cigarette and smokeless tobacco use prevalence (in total and by age and gender), use patterns, and tobacco-attributable deaths. The models will be developed with the capacity and flexibility to incorporate new data (e.g., Population Assessment of Tobacco and Health [PATH] study data) as it becomes available. This research will provide new information about the effects of possible FDA marketing and product regulations on the sole and dual use of cigarettes and smokeless tobacco products.

David Levy Funding Mechanism: National Institutes of Health- Grant
ID number: 1 R01 DA036497-01
Institution: Georgetown University
09/30/2013

Marketing, FDA Communication, Tobacco Perceptions and Use in Addiction Treatment

Over four million individuals receive some type of addiction treatment annually; in this vulnerable population, smoking rates are high (67-75%) and resistant to tobacco control efforts. Because these individuals are highly likely to smoke, they are also likely to try, use, and adopt emerging and potentially modified risk tobacco products (e.g., e-cigarettes, snus, and smokeless tobacco). Working in collaboration with the National Institute on Drug Abuse (NIDA) Clinical Trials Network, investigators will identify a national random sample of 25 addiction treatment programs where 3,000 patients (1,000 patients per year for three years) plus 25 program directors will be recruited; using web-based computer-assisted strategies, participants will be interviewed concerning use of traditional and emerging tobacco products, exposure to federal tobacco education efforts and industry marketing campaigns, risk perceptions related to a range of tobacco products, and tobacco use behavior. Project goals are to understand tobacco product use, marketing, messaging, and perceptions in addiction treatment populations, and to inform regulatory activities that reduce tobacco use and risks in this vulnerable population. Specific aims are: (1) to assess the prevalence, and changes in prevalence over time, of smoking and use of alternative tobacco products in this population; (2) to assess exposure, and changes in exposure over time, to FDA tobacco-related communications, the role of the FDA, and tobacco marketing, and to examine the relationship of these exposures to risk perceptions regarding tobacco products and their use; and (3) to assess relationships between exposure to FDA communications, tobacco marketing, and perceived tobacco risk and health services measures (tobacco-related attitudes and utilization of tobacco cessation services) and tobacco behavior outcomes (prevalence, quit attempts, cigarettes per day).

Joseph Guydish Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01DA036066-01
Institution: University of California San Francisco
09/30/2013

Manipulating Tobacco Constituents in Female Menthol Smokers

The FDA has the regulatory authority to reduce nicotine levels and ban menthol in cigarettes, but has yet to take either of these actions. Available evidence suggests that women are more sensitive to the non-nicotine aspects of smoking (such as taste and smell) and may have a harder time quitting than men. The purpose of this study is to examine the effects of reducing nicotine content and/or removing menthol from cigarettes on measures of smoking behavior, nicotine dependence and cigarette abstinence in 320 female menthol smokers aged 18 and older. Investigators will examine the effects and safety of these two possible regulatory actions alone and in combination by randomizing subjects to one of four alternatives: reduced nicotine content (0.07 mg) cigarettes without menthol; reduced nicotine content (0.07 mg) menthol cigarettes; conventional nicotine cigarettes without menthol; or own brand (conventional nicotine menthol cigarettes). Specific aims are: (1) to examine the effects of reducing nicotine content and/or removing menthol from cigarettes on measures of smoking behavior, nicotine dependence and abstinence; (2) to examine the effects of reducing nicotine content and/or removing menthol from cigarettes on measures of toxicant exposure (e.g, cotinine, exhaled carbon monoxide, and urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL]) and other tobacco-specific nitrosamines; (3) to examine the mechanisms by which cigarette content manipulations may decrease smoking behavior in female menthol cigarette smokers; and (4) to explore the moderating effect of “supertaster status” (i.e., the tendency to experience flavors and irritation with far greater intensity than average) on tolerability of experimental cigarettes, smoking satisfaction, and smoking behavior. This study will provide new information about the impact of menthol and reduced nicotine content cigarettes in this vulnerable population.

Cheryl Oncken Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01DA036486-01
Institution: University of Connecticut Health Center
09/30/2013

Influence of Advertising and Product Type on E-Cigarette Demand among Smokers

Some new and emerging tobacco products may be less harmful than cigarettes, but research is needed to examine the extent to which broader adoption of these products could impact the public health. In this project, investigators will use an experimental auction method to study willingness to pay for various e-cigarette products that offer different features and costs. Investigators will assess which smokers may be more likely to purchase reusable versus disposable e-cigarettes and how print and television advertising impacts each of these preferences. Investigators will follow auction participants for up to six months to examine whether they continue to independently purchase and use the products obtained in the auction and the extent of dual use with or substitution for cigarettes. Specific aims are: (1) to examine the influence of product composition and print and television advertising on willingness to pay for e-cigarettes and cigarettes in the context of an experimental auction; and (2) to examine the extent to which e-cigarettes obtained in the auction are used as a supplement to or substitute for cigarettes. This project will provide new information regarding the factors affecting consumer demand for e-cigarettes and will offer important insights into the adoption process underlying product switching.

Richard O’Connor Funding Mechanism: National Institutes of Health- Grant
ID number: 1R21DA036476-01
Institution: Roswell Park Cancer Institute
09/30/2013

Behavioral and Neural Response to Reduced Nicotine Cigarettes in Young Smokers

The optimal cigarette nicotine content that would reduce tobacco dependence while still alleviating nicotine craving and withdrawal symptoms and the effects of nicotine content reductions on large smoker subpopulations are critical issues that could inform FDA tobacco product regulation. The goal of this project is to test the effects of reduced nicotine content cigarettes in 40 young adult daily smokers (aged 18-25 years). Investigators will compare the responses to smoking research cigarettes with four levels of nicotine content (<0.05, 0.1, 0.282, or 0.68 mg nicotine) and preferred cigarette brand smoked as the first cigarette of the day in the context of the following specific aims: (1) to obtain self-report ratings of the smoking experience, relief of craving and withdrawal, and affect; (2) to measure how the different cigarettes affect attention and neural biomarkers of withdrawal and executive functioning; and (3) to measure how the different cigarettes affect neural biomarkers of craving and its regulation. Functional magnetic resonance imaging (fMRI) will be used to provide a brain biomarker of response to the different nicotine yields, which can further elucidate subjective and cognitive effects. Findings will provide novel data that may inform decision-making regarding a standard for cigarette nicotine content.

Edythe London
 
Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01DA036487-01
Institution: University of California Los Angeles
09/26/2013

Assessment of Tobacco Product Pharmacology and Behavior in Humans: Behavioral Pharmacology Associated with Cigar Smoking

Although many studies have investigated the effects of cigarette smoking on human behavior and biomarkers of exposure, our knowledge of how cigar smoking affects human behavior and pharmacology remains limited. The goal of this project is to better understand the dependence behaviors and biomarkers of exposure associated with cigar use. In 66 adult cigar-only smokers, the investigators will conduct a clinical study measuring dependence (both real and perceived), withdrawal relief, and craving using existing and modified behavioral scales and assessments. In addition, investigators will gather data on participants’ smoking topography (including latency to first puff, puff number, interpuff interval, and smoking duration) associated with smoking their usual type and brand of cigar, self-reported inhalation behaviors, and exhaled carbon monoxide. Investigators will also collect urine and blood samples to measure biomarkers of exposure (including nicotine, cotinine, and total NNAL).  The study will compare the dependence behaviors and pharmacology associated with the use of small versus large cigars, as well as biomarkers of exposure in cigar smokers who are and are not former cigarette smokers. This study will yield information on dependence behaviors and biomarkers of exposure associated with cigar smoking and may provide critical information on the impact of these tobacco products on the public health.

Darlene Harbour and Megan Schroeder Funding Mechanism: Research Contract
ID number: HHSF223201310033I
Institution: Lovelace
09/26/2013

Measure Acrolein in Cigarettes

A chemical analysis is required to evaluate the harmful and potentially harmful constituents (HPHCs) present in mainstream cigarette smoke. The goal of this project is to measure acrolein quantities in the mainstream smoke produced from a variety of cigarettes currently marketed in the US. A total of 35 cigarettes will be examined under both the International Organization of Standardization (ISO) and Canadian Intense (CI) smoking regimens.  The results may be used to inform HPHC-related regulatory activities. (Project completed in 2014.)

Andrew Masters and Timothy Brewer  Funding Mechanism: Research Contract
ID number: HHSF223201310037I
Institution: Labstat International
09/24/2013

Tobacco Lab Analysis-Carbonyl Measurements in Mainstream Cigarette Smoke

Carbonyls are formed during the combustion of tobacco products, and many are included on FDA’s list of harmful and potentially harmful constituents (HPHCs). The purpose of this project is to measure quantities of carbonyls using a validated testing method in a variety of cigarettes currently marketed in the US. A total of 35 different cigarette products will be examined under both the International Organization of Standardization (ISO) and Canadian Intense (CI) smoking regimens. The results may be used to inform HPHC-related regulatory activities.

Andrew Mooney and Candice Jongsma Funding Mechanism: Research Contract
ID number: HHSF22301310037I
Institution: Labstat International ULC
09/20/2013

Point-of-Sale Strategic Concept Testing – Focus Groups with Current Adult Smokers

Tobacco industry marketing efforts occur at the point-of-sale (i.e., at retail stores where tobacco is sold); point-of-sale marketing is associated with smoking experimentation, unplanned tobacco purchases, and urges to smoke. The goal of this project is to assess strategic concepts for a point-of-sale campaign to encourage tobacco cessation. The campaign’s target audience is current cigarette smokers (ages 25-54) who have made an attempt to quit smoking within the past year. Specific aims are: (1) to determine strategic concepts that resonate most with the target audience, and (2) to provide a deeper understanding of how to optimize messaging that can encourage and support smoking cessation. To accomplish this, 24 focus groups will be conducted with up to 144 participants who fit the target audience. Focus group participants will be asked to respond to a range of topics, including questions about their in-store cigarette purchasing behaviors, personal experiences with quit attempts, and emotional and cognitive reactions to the strategic concepts. This study is the first part of a phased approach to formative research that will inform a point-of-sale tobacco cessation campaign designed to encourage future quit attempts.

Kara Marsh and Chaunetta Jones Funding Mechanism: Research Contract
ID number: HHSF223201210039I
Institution: Fors Marsh Group
09/19/2013

A-TRAC TCORS: Perception of Tobacco Use in Vulnerable Populations

Youth, women, low socioeconomic status populations, and racial/ethnic minorities are especially vulnerable to tobacco use. Data documenting use, addiction and perception among these groups are limited, and little information is available on best-practice tobacco risk communication campaigns for targeted populations. This project will assess tobacco use patterns, perceptions, attitudes, beliefs and communication channel use among African-Americans, Hispanics, and youth to determine strategies likely to be effective in communicating information on tobacco use risks, and will implement a communication intervention to facilitate quit attempts and cessation. Investigators will conduct 6-12 focus groups (with 8-10 participants per group) to examine channel use frequency (i.e., the most frequent channels for seeking tobacco-related communications and for communicating with others about tobacco) and the influence of factors that modify channel use, including age (i.e., 11-14.4 years, 14.5-18 years), gender, tobacco knowledge, and family and peer tobacco use. Investigators will also develop health communications targeted for different ethnic and socioeconomic groups and test them in 600-800 individuals in appropriate communities. Investigators will study the behavioral aspects of consumption of all forms of tobacco products, including smokeless products and new and emerging products. Specific aims are: (1) to examine the clinical and non-clinical correlates and outcomes (including cardiovascular outcomes) associated with tobacco use in blacks and Hispanics, using data from the Jackson (Mississippi) Heart Study and the Hispanic Community Health Study/Study of Latinos; (2) to evaluate communication channel use, knowledge, risk perception, and tobacco use intention; and (3) to implement a communication intervention to support tobacco use quit attempts and cessation among specific populations vulnerable to tobacco use. This project will generate data that can inform optimal tobacco risk communication campaigns that target vulnerable minority populations.

Herman Taylor Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50HL120163-01
Institution: University of Mississippi
09/19/2013

A-TRAC TCORS: Cardiovascular Injury Due to Tobacco Use

Tobacco smoke and tobacco products contain many harmful and potentially harmful constituents (HPHCs) that affect different organ systems and physiological processes. Therefore, an organ-systems approach is the preferred model to understand the adverse health consequences of tobacco use and to reduce tobacco-associated disease. The goal of this project is to understand the cardiovascular effects of tobacco products, with emphasis on early preclinical changes and their subsequent impact on health outcomes. Investigators will determine which cardiovascular disease (CVD) biomarkers are associated with specific measures of tobacco exposure and what magnitude of change in these biomarkers translates into a clinically meaningful impact on CVD outcomes. Specific aims are: (1) to elucidate the relationship between biomarkers of cardiovascular dysfunction/injury and specific measures of exposure to tobacco smoke and smokeless tobacco, by evaluating biomarkers of endothelial damage and predilection for thrombosis in a cross-sectional study of 480 smokers, smokeless tobacco users, and non-smokers without overt CVD (aged 26-45); (2) to identify and compare the dose-dependent associations between tobacco use, measures of subclinical cardiovascular disease, and clinical cardiovascular events, using data from the Multi-Ethnic Study of Atherosclerosis (which includes 6814 participants aged 45-84); and (3) to validate candidate biomarkers associated with tobacco exposure in independent human cohorts, using data from the Jackson Heart Study (which includes 5,301 African American residents of Jackson, Mississippi, aged 35-84). This project will improve the understanding of the cardiovascular consequences of tobacco use, particularly among vulnerable minority populations.

Aruni Bhatnagar Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50HL120163-01
Institution: University of Louisville, American Heart Association
09/19/2013

Communicating the Risks of Harmful Cigarette Smoke Constituents

New information about tobacco smoke constituents will have an uncertain impact on smoker behavior. It may prompt smokers to quit, or it may prompt them to switch to brands they perceive as less harmful and possibly smoke more. This project will identify the impact of new constituent information on smokers’ risk beliefs and cigarette smoking; all studies and focus groups will include representation from vulnerable populations, including adolescents, low income populations, African-Americans, Hispanics, gays, lesbians, and bisexuals. Specific aims are: (1) to identify cigarette smoke constituents that adolescents (aged 13-17) and adults (aged 18-65) find threatening and discourage them from wanting to smoke, by conducting 10 focus groups (with approximately 7-10 participants each) and a population-based telephone survey of 800 adolescents and 3800 adults; (2) to develop a library of cigarette smoke constituent risk messages that have been vetted in 14 focus groups (approximately 10 participants each) of adult and adolescent smokers and non-smokers and tested in 2654 Internet survey participants; and (3) to determine which pack labels most effectively increase adult smokers’ cessation behaviors in a randomized controlled trial of 672 adult smokers. The results of this project may inform decisions regarding the type and placement of constituent-related health messages on cigarette packaging.

Noel Brewer Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180907-01
Institution: The University of North Carolina at Chapel Hill
09/19/2013

American Heart Association Tobacco Regulation and Addiction Center (A-TRAC)

This virtual Center will study the cardiovascular toxicity of tobacco products and the relationship between tobacco product use and subclinical progression of cardiovascular disease (CVD) in order to identify biomarkers of cardiovascular injury related to tobacco product exposure. Studies will identify specific domains of cardiovascular injury that are sensitive to tobacco exposure, facilitate the identification of harmful and potentially harmful constituents (HPHCs), and measure the impact of these constituents on cardiovascular disease outcomes. In cohorts of varying ethnicities, investigators will study behavior, perceptions, and attitudes regarding tobacco products in order to identify which communications channels are used by vulnerable populations to obtain information about tobacco products, as well as strategies that are likely to be effective in discouraging initiation and continuation of tobacco use. Project 1 will identify biomarkers of tobacco product exposure and relate them to biomarkers of cardiovascular injury in a well-controlled animal model; to determine the relationship between these two sets of biomarkers, investigators will identify metabolites of tobacco constituents, establish their relationship with the extent and duration of exposure, and determine how they are related to the extent of cardiovascular injury. Project 2 will determine which CVD biomarkers are associated with specific measures of tobacco exposure and what magnitude of change in these biomarkers translates into a clinically meaningful impact on CVD outcomes. Project 3 will evaluate the tobacco use pattern, clinical and non-clinical correlates, outcomes, and knowledge/perceptions among vulnerable populations (i.e. African-Americans, Hispanics, and youth), generating data that can inform optimal tobacco risk communication campaigns that target vulnerable minority populations.

Aruni Bhatnagar and Rose Robertson Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50HL120163-01
Institution: American Heart Association
09/19/2013

A-TRAC TCORS: Cardiovascular Toxicity of Tobacco Products

Tobacco use is associated with an increase in cardiovascular disease risk factors; however, tobacco constituents that mediate the cardiovascular toxicity of tobacco use remain largely unknown. Biomarkers of tobacco-induced cardiovascular injury associated with exposure to cigarette smoke, smokeless tobacco and their constituents may inform the FDAs regulation of tobacco products to protect public health. This project will identify biomarkers of tobacco product exposure and relate them to biomarkers of cardiovascular injury in a well-controlled animal model. To determine the relationship between these two sets of biomarkers, investigators will identify metabolites of tobacco constituents, establish their relationship with the extent and duration of exposure, and determine how they are related to the extent of cardiovascular injury. Specific aims are: (1) to examine tobacco-induced endothelial injury in adult mice exposed to varying intensities of tobacco smoke and smokeless tobacco; and (2) to delineate the contribution of harmful and potentially harmful (HPHC) constituents, such as aldehydes, to endothelial injury induced by tobacco exposure, by examining changes in endothelial injury biomarkers in mice exposed to individual constituents (i.e., nicotine, acrolein and crotonaldehyde). This project will provide information regarding how tobacco products could be evaluated for cardiovascular toxicity and how product constituents might be regulated to reduce the risk of cardiovascular injury.

Sanjay Srivastava Funding Mechanism: National Institutes of Health-TCORS Grant
ID number: 1P50HL120163-01
Institution: University of Louisville
09/19/2013

Effective Risk Communication on New and Emerging Tobacco

Current evidence is limited on consumer knowledge and perceptions of risks related to new and emerging tobacco products and the messages that most effectively increase perceptions of risk. This project will evaluate the impact of health warnings for new and emerging tobacco products (e.g., e-cigarettes, hookah tobacco, cigarillos/little cigars) on adolescents, young adults, and the gay, lesbian and bisexual population. Specific aims are: (1) to identify perceived risks of, knowledge about, and attitudes towards harmful constituents and health risks of cigarettes and new and emerging tobacco products in 800 adolescents (aged 13-17) and 800 young adults (age 18-25) to inform development of product-specific risk messages; (2) to develop risk messages for each product that increase risk perceptions among adolescents and young adults, by conducting an Internet survey of 400 adolescents and 400 young adults; and (3) to establish the real-world impact of product risk messages (developed in Aim 2) appearing at the point-of-sale on risk perceptions, attitudes, knowledge, susceptibility and quit intentions of adolescents and young adults. This study will provide information about how best to inform youth and young adults about the health risks associated with using a variety of tobacco products.

Erin Sutfin Funding Mechanism: National Institutes of Health-TCORS Grant
ID number: 1P50CA180907-01
Institution: Wake Forest University
09/19/2013

OSU Center of Excellence in Regulatory Tobacco Science (OSU-CERTS)

The goal of this Center is to understand the reasons for tobacco product preferences, especially related to dual and poly-use, and how these reasons influence use in a diverse, ever-changing tobacco product environment. The Center will conduct four projects involving both rural (Appalachian Ohio) and urban (Columbus, Ohio) adolescents and adults. Projects 1 and 2 will use a three-year cohort of adolescents and their families to establish and compare (1) the prevalence of smoking, smokeless tobacco use and dual use, and (2) tobacco use risk factors, with an emphasis on environment, advertising and marketing, and trajectories to regular use. Studies will include an assessment of carcinogen exposure and genetic factors for taste perception and tobacco use behavior. Project 3 will establish a three-year cohort of adults to characterize the diversity of tobacco products used over time and examine individual, cognitive and affective risk factors; the project will evaluate purchasing factors and marketing practices in retail environments. Project 4 will include several experimental studies that examine psychological constructs and decision-making models for choosing tobacco products.

Peter Shields and Mary Ellen Wewers Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180908-01
Institution: Ohio State University
09/19/2013

OSU TCORS: Understanding Adolescent Trajectories, Exposures and Susceptibilities

Most smokers and smokeless tobacco (ST) users initiate use prior to the age of 18. ST use among adolescents has been increasing and the prevalence of dual use of ST and cigarettes is especially high in Ohio. However, almost nothing is known about adolescent initiation of ST and dual use, trajectories to regular use and dependence, exposures through biomarkers, and environmental and genetic risk factors. Investigators will survey 1050 rural and 1050 urban Ohio males aged 11-14 and analyze oral rinses and urine samples to evaluate trajectories from experimentation to regular use and dependence, degree of nicotine exposure with biochemical confirmation, and level of nicotine dependence; investigators will also measure carcinogen exposures and consider various genetic risk factors. Specific aims are: 1) to determine the time from experimentation to regular use of and dependence on various tobacco products (including cigarettes, chew, snuff, snus, and dissolvables), based on product nicotine levels and adjusted for environmental predictors of initiation (e.g., family and peer tobacco use, advertising and media); 2) to determine the differences in tobacco toxicant exposure among daily or near-daily ST users, smokers, and dual users using conventional and novel biomarkers of exposure (e.g., metabolomics); and 3) to identify genetic susceptibilities that influence ST use, smoking and dual use (i.e., nicotine metabolic ratio and genes associated with nicotine metabolism, neurobehavior and taste perception), using mouthwash samples from 2570 adolescents and 4626 parents. This project will provide new information about tobacco use trajectories among youth with regard to ST and dual use.

Peter Shields Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180908-01
Institution: Ohio State University
09/19/2013

OSU TCORS: Urban and Rural Male Youth Cohort Study of Tobacco Use

The rate of smokeless tobacco (ST) use among high school males in Ohio is nearly twice as high as the national rate, and dual use with cigarettes is common; with new products on the market and marketing efforts targeting urban users and smokers, youth may be even more likely to initiate ST and dual use. In this three-year project, investigators will examine male youth initiation of ST (i.e., chew, snuff, snus, and dissolvables) and dual use, as well as the marketing, advertising and other environmental factors that may contribute to initiation, by administering self-report questionnaires to a cohort of 1050 rural and 1050 urban Ohio males aged 11-14 and their families. Specific aims are: (1) to examine how cognitive and affective responses and attitudes towards tobacco advertisements relate to ST and dual use initiation; 2) to examine how exposure to tobacco marketing and level of smoking media literacy relate to ST and dual use initiation; and 3) to conduct a ten-day exploratory study using ecological momentary assessment (EMA) to compare real-time exposures between tobacco users and nonusers. Findings from this project will provide new information about why youth initiate ST and dual use of ST and cigarettes.

Amy Ferketich Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180908-01
Institution: Ohio State University
09/19/2013

OSU TCORS: Diversity of Tobacco Products Used and Purchased

Dual use of cigarettes and smokeless tobacco (ST) products is becoming more common. However, stable estimates of dual use prevalence are difficult to ascertain, as studies have used differing operational definitions (i.e., frequency of use and type of tobacco product) to describe behavior. This project involves a longitudinal characterization of diverse product preferences among a cohort of 796 Ohio adults (aged 18 and older) who are exclusive smokers (using cigarettes, little cigars, and/or cigarillos), exclusive ST users (using chew, snuff, and/or snus), and dual users at baseline; participants will be interviewed at baseline and every six months over a three-year period. Specific aims are: 1) to compare tobacco product use (i.e. combustible, ST, new and emerging products) between rural and urban adults who are smokers, ST users, and dual tobacco users at baseline; 2) to compare associations between product use and various factors, including individual factors (i.e. dependence, previous quit attempts, stage of change, cessation interest/efficacy, household smoking, home and work indoor air policies), cognitive and affective factors (i.e., risk perceptions, risk-reduction beliefs), and purchasing factors (brand loyalty, price promotions); and 3) to determine the association between purchasing factors (i.e., exposure to coupons, multi-pack specials, special discounts at point-of-sale tobacco retail outlets, and brand loyalty) and product use among subsets of rural and urban users. This project will provide information about the prevalence of cigarette use, ST use and dual use in adults and the individual and environmental factors associated with product use.

Mary Ellen Wewers Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180908-01
Institution: Ohio State University
09/19/2013

OSU TCORS: Comprehension of Health Risks in More and Less Arousing Affective Contexts

Prior research suggests that the affect (e.g., goodness vs. badness, calming vs. exciting) aroused by health messages is a critical factor in tobacco users’ long-term understanding of risk, and, therefore, in influencing quit intentions and usage. Investigators will evaluate the role of affective arousal in increasing cigarette warning label effectiveness and in making products appear less risky in brand advertising and promotion in smokers; affect will be manipulated through graphic images of health effects and smoking cues (e.g., a lit cigarette). Specific aims are: (1) to test the effects of graphic images that vary in arousal on smoker understanding of text-based smoking risk information; investigators will randomize adult smokers and adolescent smokers to an image condition that varies in arousal (no image, low, medium, or high arousal) and to a time point (immediate, one week, or six weeks) to test risk understanding, perceptions, and use; (2) to use a similar experimental design to examine arousal effects on long-term understanding of numerically-expressed health risks; investigators will test absolute vs. relative risks (in adult and adolescent smokers) and percentage vs. frequency formats (in adult smokers); and (3) to examine the effects of the presence/absence of pro-tobacco smoking cues on adult and adolescent smokers’ understanding of health risks at exposure and one and six weeks. This research will provide new information about how to present cigarette warning label health information in ways that maximize user understanding.

Ellen Peters Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180908-01
Institution: Ohio State University
09/19/2013

Improved Models to Inform Tobacco Product Regulation (UCSF TCORS)

This Center will study (1) the economic impacts of tobacco use on health costs; (2) risk perceptions, perceived acceptability, consumer responses to pro-tobacco marketing and anti-tobacco messages and other behavioral and social determinants of tobacco use; and (3) rapid changes in risk due to tobacco use and secondhand smoke exposure as manifested in cardiovascular and pulmonary dysfunction, allowing the identification of functional biomarkers of acute cardiopulmonary responses to tobacco use. Project 1 will develop microeconomic models to characterize the impact of changing tobacco product use on tobacco-related disease and healthcare costs. Project 2 will use a longitudinal cohort design to study the role of adolescents’ and young adults’ risk and benefit perceptions related to tobacco use, marketing, and control. Project 3 will study smokeless tobacco use among rural high school males. Project 4 will quantify, and identify biomarkers of, the short-term pulmonary effects of smoking and secondhand smoke exposure. Project 5, a cardiovascular assessment of the effects of tobacco and nicotine, will involve controlled short-term exposures of human subjects to test products that provide a wide range of nicotine, particle and other cardiovascular toxin concentrations to determine how these components adversely affect cardiovascular risk.

Stanton Glantz Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1P50CA180890-01
Institution: University of California, San Francisco
09/19/2013

UCSF TCORS: The Impact of Changing Tobacco Product Use on Tobacco-Related Disease and Healthcare Costs

Current models of the health-related economic costs of cigarette smoking reflect the complex relationship between smoking, health, and healthcare expenditures; however, research on healthcare costs attributable to the use of tobacco products other than cigarettes is lacking. This project will use individual-level data from national surveys to develop microeconomic models that estimate and compare tobacco-related healthcare costs. Specific aims are: (1) to develop microeconomic models to estimate the healthcare costs attributable to the use of different tobacco products (e.g., cigarettes, menthol cigarettes, cigars, moist snuff, chewing tobacco) to determine whether product type substantially affects costs; (2) to develop microeconomic models to estimate the healthcare costs attributable to secondhand smoke exposure; (3) to evaluate the impact of potential FDA regulations on healthcare costs due to projected changes in tobacco use and secondhand smoke exposure, using a time series analysis with national survey data, longitudinal model analysis of Population Assessment of Tobacco and Health Study (PATH) data, simulations of tobacco use prevalence changes, and simulations of short-term pulmonary and cardiovascular disease risk. This project will provide improved models of the costs associated with cigarette smoking and the use of other tobacco products, which will be useful for analyzing the economic impact of potential FDA regulations.

Wendy Max Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180890-01
Institution: University of California San Francisco
09/19/2013

UCSF TCORS: The Role of Risk and Benefit Perceptions in Tobacco Control and Product Usage

Prospective longitudinal studies using comprehensive measures of tobacco use, perceptions and marketing are needed to provide specific scientific evidence about how marketing shapes decisions to use and stop using different tobacco products. This project will use a longitudinal cohort design to study the role of adolescents’ and young adults’ risk and benefit perceptions related to tobacco use, marketing, and control. Investigators will develop and test a comprehensive model concerning the relationships among pro- and anti-tobacco marketing messages, perceptions of tobacco risks and benefits, perceived product acceptability, and patterns of tobacco use. Subjects will include 1000 ninth graders (age 14) followed through high school and 1000 twelfth graders (ages 17-18) followed into young adulthood. Specific aims are: (1) to determine adolescents’ and young adults’ perceptions of risk (for disease, addiction, and death), acceptability, and benefits of using conventional, new, and emerging tobacco products (e.g., cigarettes, e-cigarettes, little cigars, cigarillos, smokeless tobacco, snus, dissolvables, compressed tobacco); (2) to determine the predictive relationships among perceptions of tobacco product risks, benefits, and acceptability and the onset, continuation, cessation, relapse, switching, and dual use of tobacco products; and (3) to identify contextual factors (exposure to pro-tobacco media, anti-tobacco media, warning labels, and smoking images) that influence perceptions of risks, benefits, acceptability, and subsequent tobacco use. This study will contribute to the understanding of how tobacco marketing impacts risk perceptions and tobacco use among adolescents and young adults.

Bonnie Halpern-Felsher and Pamela Ling Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180890-01
Institution: University of California San Francisco
09/19/2013

UCSF TCORS: Smokeless Tobacco Use among Rural High School Males and Resulting Nicotine and Carcinogen Exposure

Smokeless tobacco (ST) use among US high school students is much higher among males and is especially high in rural areas. Data regarding the addictive potential and nicotine and carcinogen exposure in adolescents using new ST products alone or in dual use with cigarettes is needed. This clustered longitudinal observational study of 1000 rural adolescent male baseball athletes will use web-based surveys and saliva specimen analysis to provide information about the cognitive and social determinants of use (and non-use) of conventional ST products, new ST products (e.g., snus, dissolvables), dual use with cigarettes, and use of other alternative products (e.g., e-cigarettes, cigarillos, hookah/waterpipe). In addition, the impact of exposure to marketing and anti-tobacco messages (e.g. graphic warning labels) on risk and benefit perceptions, change in ST use status (i.e., experimentation, initiation, relapse, switching, and cessation) and actual exposure to nicotine and carcinogens will be evaluated over time. Specific aims are: (1) to measure patterns and determinants of conventional and new ST product use and dual/poly use with cigarettes over time; (2) to measure exposure to tobacco marketing and anti-tobacco messages and their association with ST use, perceived risks and benefits of use, and future expectations of ST and dual/poly use over time; (3) to use existing and new biomarkers to evaluate nicotine and carcinogen exposure and their association with nicotine metabolism rate in ST and dual users; and (4) to identify factors in addition to product type and brand that predict nicotine and carcinogen exposure (e.g., measures of risk and benefit perception, nicotine metabolism rate). This study will enhance the understanding of the relationship of marketing exposure to risk and benefit perceptions, tobacco use status, and intentions to use conventional and new ST products and their dual use with cigarettes in a population at high risk of use.

Margaret Walsh Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180890-01
Institution: University of California San Francisco
09/19/2013

UCSF TCORS: Quantification and Biomarkers of Short-Term Pulmonary Effects of Tobacco Smoke Exposure: Infection-Related Acute Lung Injury

Additional research is needed to evaluate the link between smoking and acute lung injury (ALI), a common cause of acute respiratory failure in critically ill patients. This project will quantify, and identify biomarkers of, the short-term pulmonary effects of smoking and secondhand smoke exposure. Investigators will collect plasma specimens from 570 critically ill patients with severe infection (aged 18 and older) to measure biomarkers of cigarette smoke exposure and lung epithelial and endothelial injury, and will evaluate the impact of cigarette smoke exposure in mouse models. Specific aims are: (1) to quantify the strength, dose-response curve, and time course of the association between cigarette smoke exposure, as measured by validated biomarkers, and the development of ALI in patients admitted to the hospital with severe infection; (2) to test the effects of cigarette smoke exposure and varying nicotine content on the development of infection-related ALI in mouse models, with a focus on identifying plasma biomarkers of tobacco-related lung epithelial or endothelial injury that can then be tested in critically ill patients; and (3) to validate the association between biomarkers of tobacco-related lung epithelial and endothelial injury and the development of ALI in critically ill patients with severe infection. The results of this project will inform more accurate models of the economic and public health effects of cigarette smoke exposure. In addition, these data will identify biomarkers of tobacco-related ALI that may be used in future toxicity studies.

Carolyn Calfee and Michael Matthay Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180890-01
Institution: University of California San Francisco
09/19/2013

UCSF TCORS: Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products

The cardiovascular risks of secondhand cigarette smoke, smokeless tobacco (i.e., moist snuff), and e-cigarettes are not adequately understood. This project, a cardiovascular assessment of the effects of tobacco and nicotine, will involve controlled short-term exposures of 88 adult smokers and nonsmokers (aged 21-50) to test products that provide a wide range of nicotine, particle and other cardiovascular toxin concentrations to determine how these components adversely affect cardiovascular risk. Assessment methods will include flow-mediated dilation, heart rate measurement, thromboelastography, Doppler testing, digital vasoconstriction testing, peripheral arterial tonometry, and blood biomarker measurement, and others. Specific aims are: (1) to determine the relative contributions of nicotine and combustion products to the cardiovascular risk associated with active cigarette smoking; (2) to determine which cardiovascular risk biomarkers are affected by exposure to low concentrations of other constituents and secondhand smoke; (3) to determine the cardiovascular risk of smokeless tobacco use; and (4) to determine the cardiovascular risk of electronic cigarettes and the respective contributions of nicotine and electronic cigarette vapor. New biomarkers that can detect differences in the cardiovascular safety of various tobacco products may help inform FDA regulation of conventional, new and emerging products.

Peter Ganz and Suzaynn Schick Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180890-01
Institution: University of California San Francisco
09/19/2013

Effective Communication on Tobacco Product Risk and FDA Authority (Center for Regulatory Research on Tobacco Communication)

This Center will use communication science to improve messages about cigarette smoke constituents, emerging tobacco products, and the FDA’s regulatory authority over tobacco products. The Center’s scientific aims are: (1) to characterize the public’s awareness and beliefs about tobacco products and FDA regulatory authority through mixed methods approaches, using focus groups and multiple population-based telephone surveys; (2) to create potent messages regarding risk and FDA authority; and (3) to conduct randomized controlled trials that assess message impact on tobacco use intentions and behaviors in real-world contexts. Project 1 will determine the effectiveness of different constituent labels/messages on cigarette packs with regard to changing perceived risk and altering cessation behavior. Project 2 will evaluate the impact of health warnings for new and emerging tobacco products not yet regulated by FDA, including e-cigarettes, hookah tobacco, and cigarillos/little cigars on adolescents and young adults. Project 3 will test FDA communication messages regarding regulatory authority over tobacco products in order to assess how to improve the credibility of these messages in targeted populations. All studies will oversample vulnerable populations with high rates of smoking (Black, Hispanic, gay, lesbian, bisexual, low income) as well as adolescents and young adults who are at greatest risk for tobacco use initiation.

Kurt M Ribisl Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180907-01
Institution: The University of North Carolina at Chapel Hill
09/19/2013

UNC TCORS: Enhancing Source Credibility in Tobacco Regulatory Communications

New communications about the dangers of smoking and the benefits of quitting can help improve the public health, but little research exists about how to frame and deliver these messages most effectively. This project will test FDA messages regarding its regulatory authority over tobacco products in order to assess how to improve message credibility in targeted populations. Specific aims are: (1) to characterize perceptions of the FDA in terms of its regulatory authority, credibility, and tobacco control communication campaigns among adolescents (aged 13-17), young adults (aged 18-25) and adults (aged 26-65), and among vulnerable populations (African American and gay, lesbian, and bisexual), in seven focus groups (7-10 participants each) and phone surveys of 3800 individuals; (2) to use FDA messages to experimentally examine three determinants of source credibility (i.e., source sponsor, source depiction and source engagement) to create optimally-framed messages and test them among current smokers (participating in ten focus groups and 300 interviews); and (3) to conduct a randomized controlled trial of 352 young adult and adult smokers to test the hypothesis that optimally-framed (i.e., high source credibility) FDA cigarette constituent messages will increase intentions to quit more than suboptimally-framed (i.e., no source attached) cigarette constituent messages. This research will provide information regarding the effectiveness and credibility of FDA communication campaigns that convey the health risks of cigarette use.

Adam Goldstein Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1P50CA180907-01
Institution: The University of North Carolina at Chapel Hill
09/19/2013

UCSF TCORS: The Role of Risk and Benefit Perceptions in Tobacco Control and Product Usage

Prospective longitudinal studies using comprehensive measures of tobacco use, perceptions and marketing are needed to provide specific scientific evidence about how marketing shapes decisions to use and stop using different tobacco products. This project will use a longitudinal cohort design to study the role of adolescents’ and young adults’ risk and benefit perceptions related to tobacco use, marketing, and control. Investigators will develop and test a comprehensive model concerning the relationships among pro- and anti-tobacco marketing messages, perceptions of tobacco risks and benefits, perceived product acceptability, and patterns of tobacco use. Subjects will include 1000 ninth graders (age 14) followed through high school and 1000 twelfth graders (ages 17-18) followed into young adulthood. Specific aims are: (1) to determine adolescents’ and young adults’ perceptions of risk (for disease, addiction, and death), acceptability, and benefits of using conventional, new, and emerging tobacco products (e.g., cigarettes, e-cigarettes, little cigars, cigarillos, smokeless tobacco, snus, dissolvables, compressed tobacco); (2) to determine the predictive relationships among perceptions of tobacco product risks, benefits, and acceptability and the onset, continuation, cessation, relapse, switching, and dual use of tobacco products; and (3) to identify contextual factors (exposure to pro-tobacco media, anti-tobacco media, warning labels, and smoking images) that influence perceptions of risks, benefits, acceptability, and subsequent tobacco use. This study will contribute to the understanding of how tobacco marketing impacts risk perceptions and tobacco use among adolescents and young adults.

Bonnie Halpern-Felsher and Pamela Ling Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180890-01
Institution: University of California San Francisco
09/19/2013

The Impact of Tobacco Exposure on the Lung’s Innate Defense System (UNC TCORS)

This Center will study the potential adverse impact of tobacco alternatives (e.g., little cigars and hookah/waterpipe tobacco) on the lung’s innate defense system; using human and mouse in vivo and in vitro models, this project will identify novel biomarkers associated with tobacco-induced changes in lung innate defense, which can be applied to understand the potential toxicity of new and emerging tobacco products. Projects I and 2 will determine the impact of tobacco products on specific aspects of this system (i.e., airway surface liquid homeostasis and mucin/mucus); investigators will use an innovative in vitro smoke exposure system to measure specific biomarkers of innate lung defense and will obtain airway samples from smokers of alternate tobacco. In Project 3, investigators will develop a novel mouse model of smoke exposure that more closely mimics the chronic bronchitis phenotype seen in humans with COPD. This model will be used to validate tobacco exposure biomarkers seen in Projects 1 and 2 as well as to determine epigenetic changes following in vivo exposure to alternative tobacco. Project 4 will determine genomic biomarkers of smoke exposure associated with tobacco products from samples obtained from human volunteers; focusing on changes in antiviral host defense in these subjects, this model will be used to integrate observations made in the other projects with findings obtained from humans infected with live attenuated influenza virus.

Robert Tarran Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50HL120100-01
Institution: University of North Carolina Chapel Hill
09/19/2013

UNC TCORS: The Effects of New and Emerging Tobacco Products on Lung Hydration and Inflammation

Airway surface hydration is critical to normal lung function and defense against disease. This project will identify the tobacco smoke constituents and the emerging tobacco products that inhibit the epithelial mechanisms that maintain airway surface hydration. Investigators will systematically compare the hydration responses (mucus/airway surface liquid [ASL] volume) of airway epithelia to new and emerging tobacco products and their constituents; they will also assess whether markers of ASL volume homeostasis constitute novel biomarkers of tobacco exposure. Experiments will use human bronchial airway epithelial cells and lung tissue obtained from transplanted donor lungs or donor lungs not suitable for transplantation. Specific aims are: (1) to determine which chemicals in tobacco smoke affect ASL nucleotide levels, ASL volume, and unfolded protein response in a human bronchial epithelial culture system (using Kentucky reference cigarettes); (2) to determine the impact of new and emerging tobacco products (e.g., little cigars, hookah) on ASL homeostasis and unfolded protein response in well-differentiated human bronchial epithelial cultures; and (3) to assess ASL nucleotide levels, ASL volume, and unfolded protein response as in vivo biomarkers of product exposure. This project will provide new information about the impact of tobacco smoke and emerging tobacco products on the lung’s innate defense system.

Robert Tarran Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50HL120100-01
Institution: University of North Carolina Chapel Hill
09/19/2013

UNC TCORS: The Effects of Tobacco Exposure on the Airway Proteome and Mucus/Mucin Integrity

Mucus is a complex network of mucins, antimicrobial peptides, enzymes and proteins that detect, immobilize, destroy, and/or remove a range of foreign bodies, toxins and pathological factors that would otherwise overwhelm the body’s defense system. Tobacco exposure dehydrates airway surfaces, and recent studies suggest that airway surface liquid (ASL) dehydration and reduced anion secretion may permanently alter mucin maturation. Investigators will analyze mucus from in vitro and in vivo models and from human subjects to identify novel biomarkers of tobacco exposure (mucomarkers) and to determine the effects of exposure to new and emerging tobacco products (e.g., flavored cigarettes, little cigars, hookah) on the expression of potential mucomarkers to assess the relative toxicology of these products. Airway epithelial cells will be derived from excess surgical pathology tissue from 63 elective surgery patients and from organ donor lungs not suitable for transplantation. Specific aims are: (1) to assess the impact of new and emerging tobacco products and their constituents on mucus/mucin biophysical and barrier properties, including their integrity, mucin polymeric structure, and maturation in mucus; (2) to identify mucomarkers in response to products with respect to both muco-proteome and mucin interactome in human bronchial cell cultures, mouse and human bronchoalveolar lavage fluid, and induced sputum; and (3) to test whether tobacco products change the proteins, messenger ribonucleic acid (mRNA), and microRNA (miR) contained in extracellular vesicles in responses to different tobacco products. This project will provide important information on the effect of tobacco exposure on mucus and its ability to protect airway surfaces.

Mehmet Kesimer Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50HL120100-01
Institution: University of North Carolina Chapel Hill
09/19/2013

UNC TCORS: Mouse Models of Smoking-related Diseases: What is the Best Mimic of Human Disease?

Most mouse models of tobacco smoke-related lung disease have produced evidence of mild-to-moderate emphysema but little or no evidence of chronic bronchitis, which is a large component of chronic obstructive pulmonary disease (COPD) in humans. This project will establish a novel mouse model of tobacco smoke-induced lung injury that mimics the chronic bronchitis phenotype seen in humans with COPD. Investigators will identify validated animal models that can establish standard toxicity changes and confirm what magnitudes correlate with changes in human health outcomes. Specific aims are: (1) to determine the effects of cigarette smoke on inflammatory and innate immunity, muco-ciliary and bacterial clearances, messenger ribonucleic acid (mRNA) and microRNA (miR) expression, and intracellular signaling pathways induced by 1-day, 5-day and 6-month exposure; and (2) to determine the effects of little cigars and other new and emerging tobacco products (e.g., hookah) on these same parameters induced by 1-day, 5-day and 6-month exposure. This project will provide new information about the adverse respiratory consequences of tobacco smoke and will inform FDA evaluation of new tobacco products.

Claire Doerschuk Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50HL120100-01
Institution: University of North Carolina Chapel Hill
09/19/2013

UNC TCORS: Translational Studies to Identify Epithelial Biomarkers of Smoke Exposure

The respiratory epithelium is the primary target of most common respiratory viruses in humans. Cigarette smoke-induced changes in epithelial function have a significant impact on respiratory host defense and are important in determining the final outcome of infection; however, it is unknown whether tobacco alternatives (e.g., hookah, little cigars) have similar effects on epithelial host defense responses. This project will identify genomic biomarkers of smoke exposure associated with tobacco alternatives from nasal epithelial cell samples obtained from 240 adults (aged 18-45) and will evaluate respiratory host defense in subjects infected with live attenuated influenza virus. Specific aims are: (1) to use superficial nasal scrape biopsies to compare genomic and epigenomic signatures induced in epithelial cells following exposure to cigarette smoking and tobacco alternatives; (2) to use an in vitro model of differentiated human nasal epithelial cells to compare host defense responses following exposure to cigarette smoke and tobacco alternatives; and (3) to compare influenza-induced responses in cigarette smokers, hookah smokers, and e-cigarette smokers in vivo. This research will provide new information about the impact of new and emerging tobacco products on respiratory defense systems.

Ilona Jaspers Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50HL120100-01
Institution: University of North Carolina Chapel Hill
09/19/2013

Tobacco Products and Atherosclerotic Disease

Cigarette smoking and, potentially, smokeless tobacco use are associated with an increase in cardiovascular disease (CVD) risk. Nevertheless, the tobacco constituents that mediate the cardiovascular toxicity of tobacco use remain unknown. Although several studies have examined the effect of cigarette smoke on surrogate markers of heart disease, the direct effect of tobacco smoke and smokeless tobacco on atherosclerosis, the underlying cause of CVD, has not been rigorously studied. Because CVD is a chronic disease that develops over several years, biomarkers of tobacco-induced cardiovascular injury are needed to assess CVD risk in a timeframe sufficient for product evaluation; biomarkers of exposure to specific tobacco product constituents must also be identified. The goal of this project is to identify biomarkers of exposure to tobacco products and relate them to atherosclerosis. Specific aims are: (1) to examine tobacco-induced atherosclerosis in mice and rats exposed to tobacco smoke and smokeless tobacco; and (2) to delineate the contribution of certain harmful and potentially harmful constituents (HPHCs) to atherosclerosis development. To achieve the first aim, investigators will expose apoE-null mice and rats to varying intensities of tobacco smoke and smokeless tobacco in order to: identify urinary metabolites of exposure-derived aldehydes and determine how they relate to the extent and duration of exposure and to atherosclerotic lesion formation and stability; evaluate the effects of gender, species, and exposure duration on the relationship between biomarkers of injury and biomarkers of exposure; and identify specific indices of atherosclerosis and thrombosis and determine how these biomarkers of injury are related to biomarkers of exposure. To achieve the second aim, investigators will examine changes in cholesterol metabolism, platelet function and atherosclerotic lesion formation, composition and nature in apoE-null mice exposed to individual tobacco constituents (i.e., nicotine, acrolein, crotonaldehyde); investigators will also determine how removal of these constituents affects atherogenesis and whether an increase in exposure to aldehydes and related reactive chemicals exacerbates atherosclerosis. This project will contribute to the development of validated animal models to establish standard toxicity changes and the discovery of novel biomarkers of cardiovascular injury that can be associated with measures of tobacco exposure. These findings will be useful in evaluating the contribution of HPHCs to tobacco product toxicity; assessing the extent of harm reduction associated with potentially modified risk products; informing policies for regulating HPHCs in smokeless tobacco, cigarettes and emerging tobacco products; and informing the design of future human studies for evaluating the cardiovascular effects of tobacco use.

Sanjay Srivastava Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01HL120746-01
Institution: University of Louisville
09/19/2013

USC Tobacco Center of Regulatory Science (TCORS) for Vulnerable Populations

This Center will address tobacco use among vulnerable populations through three overall research aims: (1) to evaluate marketing, social influences, social media, and network influences on tobacco use and product choice, emphasizing vulnerable populations, with the ultimate aim of identifying ways to reverse or counteract these influences; (2) to examine tobacco product distribution and regulation among local vendors, whose stores are a key point for purchase, contact with industry marketing and promotion, and regulatory education initiatives; and (3) to examine different longitudinal patterns of tobacco use, integrating phenotypic variables with personal, social, cultural and environmental variables to determine how future tobacco control initiatives may be tailored to different vulnerable groups. Project 1 is an Internet-based investigation of marketing and social media influences; it will evaluate the ways in which tobacco companies communicate with customers and potential customers through social media, as well as how tobacco users transform and disseminate these messages through their social networks. Project 2, a study of small independent tobacco retailers in vulnerable communities in California, will examine the knowledge, attitudes, beliefs and behaviors of these retailers regarding FDA tobacco regulation compliance and the impact of the community environment and local regulatory campaign efforts on vendor practices and consumer behavior. Project 3 is a study of adolescent and young adult smoking, tobacco use trajectories, use topography, and susceptibility to marketing in an established population-based cohort.

Mary Ann Pentz and Jonathan Samet Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180905-01
Institution: University of Southern California
09/19/2013

USC TCORS: Diffusion of Marketing Messages about Tobacco Products through Social Media

More information is needed about how individuals receive, perceive, and disseminate information about tobacco products, and how this information impacts tobacco product use. Investigators will monitor tobacco websites to describe the content of messages about emerging tobacco product risks and benefits, and determine whether the messages presented to vulnerable populations differ from the messages presented to less vulnerable populations. Investigators will also monitor social media sites (e.g., Twitter, YouTube) and online message boards to identify trends in product-related content over time; they will conduct automated content analyses to identify keywords, themes, and sentiments and determine whether new marketing campaigns and themes on the brand websites are subsequently disseminated through social media. Specific aims are: (1) to document how the tobacco industry communicates with potential customers online about risks and benefits of emerging tobacco products (e.g., snus, dissolvables, e-cigarettes, little cigars); (2) to understand how individuals respond to online tobacco messages by surveying and monitoring the online activity of 32 adults aged 21 and older; and (3) to understand and compare the characteristics and tobacco use patterns of 1800 online opinion leaders and non-leaders aged 21 and older to identify differences in socio-demographic characteristics (including gender, age, and ethnicity), perception of source credibility, attitudes and beliefs about tobacco, and tobacco product use. An increased understanding of the tobacco product messages appearing in social media and the role of social media in normalizing tobacco products may inform FDA regarding the production and dissemination of relevant social media communications to inform the public about tobacco use consequences.

Jennifer Unger and Tess Boley Cruz Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180905-01
Institution: University of Southern California
09/19/2013

USC TCORS: Maximizing Retailers’ Responsiveness to FDA Regulatory Authority in Minority

This project, a study of small independent tobacco retailers in vulnerable communities in California, will examine retailer knowledge, attitudes, beliefs and behaviors regarding FDA tobacco regulation compliance and will evaluate the impact of the community environment and local regulatory campaign efforts on retailer practices and consumer behavior. Investigators will conduct 16 focus groups with a total of 192 participants (any age), a survey of 600 retailers, 200 store observations (randomly selected from the 600 retailers surveyed), and an environmental scan. Vulnerable communities to be studied include those that are low income and predominantly include African-Americans, Hispanics, Asians, and American Indians. Specific aims are: (1) to examine knowledge, attitudes, beliefs and behaviors of small independent retailers in vulnerable communities regarding FDA tobacco regulation compliance and knowledge about traditional and new and emerging products; (2) to examine traditional and nontraditional media (e.g., social media sites, online videos, text messaging, blogs, smartphone applications, wireless communication, Facebook, Twitter, use of cell phones) and traditional broadcast media that FDA can use to communicate with retailers and the public in vulnerable minority communities; and (3) to examine factors that influence key community informants’ public perception of the FDA as a credible source of tobacco product information. This research will provide information about the optimal messages and communication mechanisms the FDA can use to maximize retailer compliance with regulations in vulnerable communities.

Lourdes Baezconde-Garbanati Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180905-01
Institution: University of Southern California
09/19/2013

USC TCORS: Adolescent Smoking: Vulnerability to Tobacco Use and Marketing across Life

This project will study adolescent smoking, tobacco use trajectories, use topography, and susceptibility to marketing in an established population-based cohort. Using smoking data from 12,078 largely Hispanic and non-Hispanic White participants recruited from Southern California schools into the Children’s Health Study cohort between 1993 and 2002, investigators will use statistical modeling to characterize adolescent cigarette smoking trajectories based on initiation and progression patterns. Investigators will assess associations of these trajectories with neighborhood and community environmental, demographic, and social factors, and with marketing exposure, based on tobacco retailer proximity and density at home, school, and a novel route-to-school metric. Samples of 300 smokers and 300 at-risk non-smokers in the younger wave of recruitment (currently aged 17-18) and 450 smokers from earlier waves (currently aged 26-36) will be re-interviewed and followed prospectively to assess the relationships of early life smoking trajectory with tobacco product perception, attitudes, beliefs, persistence of use and cessation difficulty. Point-of-sale marketing, electronic, social media, and interpersonal influences that amplify the risk of different trajectories of childhood tobacco use will be identified. Specific aims are: (1) to characterize adolescent cigarette smoking trajectories based on initiation and progression; (2) to examine the impact of early life smoking trajectory on new and traditional tobacco product use and on perceptions, attitudes and beliefs about these products, (3) to assess the relationship between specific tobacco product use (e.g., cigarettes, smokeless tobacco, cigars, little cigars, cigarillos, bidis, kreteks, pipes, snus, dissolvables, e-cigarettes, hookah) and prior perceptions, attitudes, beliefs, and marketing exposure; and (4) to use structural equation modeling to integrate information on early life smoking phenotype, marketing, perceptions, attitudes, and beliefs across life stage. Study findings related to smoking trajectories, new and traditional product use, and marketing exposure may help inform FDA regulatory efforts.

Rob McConnell Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180905-01
Institution: University of Southern California
09/19/2013

Tobacco Center of Regulatory Science on Youth and Young Adults (UT TCORS)

The Center’s activities will focus on the epidemiology of tobacco use among youth and young adults (particularly with regard to alternative, new, and emerging tobacco products), how tobacco products are marketed to this population, the effect of marketing on youth and young adult tobacco use, and how communication programs can be implemented to educate young adults about the harms of tobacco use. Project 1 will establish a rapid-response surveillance system that will provide information about the diversity of tobacco products youth (12-17 years old) use (including flavored tobacco products of all kinds as well as other tobacco products, like cigars) and the impact of tobacco product marketing on use behaviors. Semi-annual surveys will assess a broad range of tobacco use behaviors, cognitive and affective factors specific to these behaviors, and self-reported exposure and receptivity to tobacco marketing. Audits of the tobacco marketing environment at point-of-sale and in print media (e.g., magazines) will provide objective data. Project 2 will establish a similar surveillance system among college students, including those with lower socioeconomic status. Project 3 will develop an innovative mobile phone text messaging system to educate young adults about the risks associated with tobacco use and tobacco product constituents; this project will assess awareness, attitudes, receptivity, and comprehension regarding the harmful effects of conventional, new and emerging tobacco products, and will compare the efficacy of different types of text messages for different types of tobacco products.

Cheryl L. Perry Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1P50CA180906-01
Institution: University of Texas
09/19/2013

UT TCORS: The Texas Adolescent Tobacco and Marketing Surveillance Study (TATAMS)

New and emerging tobacco products, such as e-cigarettes, are growing in popularity among youth. This project will establish the Texas Adolescent Tobacco and Marketing Surveillance system (TATAMS). A total of 4000 students in the sixth, eighth, and tenth grades (aged 12-17) in the four largest Texas cities (Houston, Dallas-Ft. Worth, San Antonio, and Austin) will be recruited and surveyed semi-annually for three years, in eighth, tenth, and twelfth grades. Surveys will assess tobacco use behaviors, cognitive and affective factors specific to these behaviors, and self-reported exposure and receptivity to tobacco marketing. Investigators will also conduct direct observation of tobacco marketing at point-of-sale locations near schools (e.g., in convenience stores), use regional Nielsen data to further understand the characteristics of tobacco products that youth prefer (e.g., flavors), and conduct content and impact analyses of tobacco marketing at point-of-sale and in magazines and other print publications. The project addresses many types of tobacco products, including menthol cigarettes, e-cigarettes, cigar products, snus, smokeless tobacco, and hookah. Specific aims are: (1) to describe trajectories and transitions in tobacco use behaviors among youth over time and examine features of tobacco products (e.g., characterizing flavors) that youth prefer; (2) to identify cognitive and affective factors that affect tobacco use trajectories, transitions, and preferences; (3) to characterize tobacco marketing at the point-of-sale and in print publications over time and document youth exposure; and (4) to investigate the impact of these tobacco marketing activities on youth beliefs, attitudes, preferences, and tobacco use behaviors. This project will inform FDA regulation and activities to prevent youth initiation of tobacco use.

Melissa Stigler Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180906-01
Institution: University of Texas Health Sciences Center at Houston
09/19/2013

UT TCORS: Tobacco Marketing and Alternative Tobacco Use among College Students

Use of non-cigarette tobacco products is becoming increasingly prevalent in the United States, particularly among young adults. However, there is limited information on the diversity of tobacco products used by young adults, patterns of use over time, and the impact of tobacco marketing on use of non-cigarette alternatives. This project will establish a rapid response surveillance system to monitor and respond to changes in tobacco marketing and trends in young adults’ use of cigarettes and non-cigarette alternatives, such as smokeless tobacco, cigars, little cigars, cigarillos, hookah, e-cigarettes, and flavored products. Data will be collected semi-annually over a three-year period from two groups of young adults in Texas (4056 subjects aged 18-29): students enrolled in four-year colleges and those enrolled in two-year vocational programs (who are more likely to have lower socio-economic status, be racial/ethnic minorities, and have higher rates of tobacco use than students enrolled in four-year colleges). In addition, investigators will evaluate and characterize the tobacco marketing activities (including print advertisements, brand websites, direct mail/email, and point-of-sale promotions) to which the two groups are exposed and examine the impact of marketing on tobacco use changes over time. Specific aims are: (1) to describe the trajectories and transitions of tobacco use over time and identify associated cognitive and affective factors; (2) to document and describe the tobacco marketing activitie s to which young adults are exposed; and (3) to determine the impact of marketing on young adults’ tobacco use. This project may inform FDA’s regulatory activities to protect the public health.

Alexandra Loukas Funding Mechanism: National Institutes of Health – TCORS Grant
ID number: 1P50CA180906-01
Institution: University of Texas at Austin
09/19/2013

UT TCORS: Informing and Correcting Perceptions Regarding Tobacco Products in Young Adults

Mobile phone text messaging represents a highly promising delivery mechanism for information campaigns that provide accurate, easy-to-understand information about the potential harmful effects of tobacco products. This project will develop an innovative mobile phone text messaging system to educate young adults about the risks associated with tobacco use and tobacco product constituents. Investigators will conduct a baseline survey of 640 low-income community college students (aged 18-25) to evaluate their attitudes, beliefs, and receptivity regarding conventional and new and emerging tobacco products, intentions to use, and comprehension of the risks of tobacco products and their constituents. Subjects will then be randomly assigned to receive one of eight text messages that represent a unique combination of depth, appeal, and framing. Investigators will again assess awareness, attitudes, receptivity, and comprehension regarding the harmful effects of conventional, new and emerging tobacco products (e.g., cigarettes, cigars, little cigars, cigarillos, bidis, e-cigarettes, chewing tobacco, snuff, snus, dissolvables, hookah), and will compare the efficacy of different types of text messages for different products. Investigators will also analyze whether demographic characteristics (e.g., race/ethnicity, gender, tobacco use, health literacy) moderate comprehension prior to and after receiving text messages and moderate the effectiveness of particular text message combinations for specific products. Specific aims are: (1) to assess the awareness, attitudes, receptivity, and comprehension of the harmful effects of conventional and new and emerging tobacco products among young adults; (2) to identify the most effective combinations of text message framing for communicating information about the potential harmful effects of tobacco products to young adults; and (3) to define and analyze key moderators of young adult awareness, attitudes, receptivity, and understanding of the harmful risks and constituents of conventional and new and emerging tobacco products. Findings from this study may help inform the development of new, impactful information campaigns that deliver messages to young adults that are easily understood and not misleading.

Alexander Prokhorov Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180906-01
Institution: University of Texas MD Anderson Cancer Center
09/19/2013

Assessing Risk Perceptions of Flavored Small Cigars/Cigarillos Among Young Adults

Research suggests that young adult smokers have positive attitudes, normative beliefs and self-efficacy towards flavored little cigars and cigarillos, perhaps due to perceptions that these products are less harmful than cigarettes; however, little is known about how young adult cigarette smokers form these risk perceptions. The goal of this project is to develop a prognostic tool that identifies little cigar/cigarillo risk perceptions and predicts initiation behaviors among young adult cigarette smokers aged 18-34. Specific aims are: (1) to use qualitative methods to elicit young adult cigarette smokers’ beliefs, feelings, and knowledge about flavored little cigars and cigarillos and their risks; (2) to develop a new little cigar/cigarillo risk perception scale; and (3) to determine what factors predict susceptibility/intention to smoke little cigars and cigarillos. To meet Aim 1, investigators will conduct 12 focus groups (with approximately 8-10 members/group) to elicit information about beliefs, feelings and knowledge about little cigars and cigarillos. To meet Aim 2, investigators will modify an existing tobacco risk perception scale based on focus group findings; they will convene a seven-member multidisciplinary expert review panel to ensure the scale’s face validity and then conduct cognitive testing among six ethnically diverse young adult little cigar/cigarillo smokers. To meet Aim 3, investigators will use the perception scale in an online survey of 900 young adult cigarette smokers and will use exploratory structural equation modeling to test the hypothesis that little cigar/cigarillo risk perceptions mediate the relationship between attitudes/norms/self-efficacy and susceptibility/intention.  This study will produce a prognostic tool that can be used to assess little cigar/cigarillo risk perceptions and can be modified to explore risk perceptions for other tobacco products (i.e., hookah); furthermore, research findings will help inform health communications that convey accurate risks about little cigar/cigarillo smoking in order to prevent initiation among young adults.

Kymberle Sterling Funding Mechanism: National Institutes of Health- Grant
ID number: 1R21CA180934-01
Institution: Georgia State University
09/19/2013

Predicting Consumer Interest in Using a Very Low Nicotine Cigarette

While there are many published studies evaluating the use of very low nicotine content (VLNC) cigarettes as a cessation method, only a handful of studies have attempted to assess consumer interest and initial response to the commercial marketing of a VLNC cigarette. The specific aims of this study, which supplements a larger project examining the effectiveness of tobacco control policies in high versus low income countries, are: 1) to monitor the marketing (distribution channels and sales) and marketing claims for a new VLNC cigarette (Dutch Magic), which will be introduced into the marketplace in the Netherlands in August/September 2013; and 2) to conduct a consumer marketing study to assess interest and uptake of the product over a six-month period. The study includes three data collection elements: 1) a web-based prospective cohort survey of 2000 smokers and 1000 non-smokers designed to measure exposure, awareness, interest, and use of Dutch Magic tobacco products; 2) a conjoint experimental study to test how consumer interest in trying Dutch Magic is shaped by various product attributes and claims (i.e., style of product, nicotine levels, marketing claims, price); and 3) an environmental scan to track the marketing of Dutch Magic along with some limited product testing to compare Dutch Magic to other popular tobacco brands. This research will provide insight into how tobacco control policies and product marketing can influence tobacco use behaviors.

K. Michael Cummings Funding Mechanism: National Institutes of Health- Grant
ID number: 3P01CA138389-06S2
Institution: Medical University of South Carolina
09/18/2013

Rapid Response Characterization of New and Manipulated Tobacco Products (UMD TCORS)

This Center will characterize combustible and non-combustible, conventional, new and manipulated nicotine/tobacco products and the impact of product variations on human behavior and exposure. The Center’s projects will measure harm in three contexts: toxicity, consumer acceptance and liking, and bacterial exposure in order to clarify where a product lies in a continuum of harm and provide a scientific basis to inform the regulation of particular product design features. Project 1 will characterize the chemical profiles and physical properties of combustible, noncombustible, conventional, new, emerging, and manipulated tobacco products; using human within-subject crossover acute laboratory trials and an established boost method paradigm, investigators will measure subjects’ relative exposures to HPHCs from new and manipulated tobacco products. Through a series of within-subject crossover trials, Project 2 will compare the appeal, consumer acceptance, and likelihood of adoption of combustible tobacco products that differ only on a single characteristic of interest (e.g., menthol concentration, smoke pH). Project 3 will evaluate tobacco microbial constituents and characterize the oral microbiome of tobacco users; investigators will conduct a longitudinal study of tobacco users and nonusers and crossover trials of users who test new and manipulated products.

Pamela Clark Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180523-01
Institution: University of Maryland College Park
09/18/2013

UMD TCORS: Exploring Tobacco Microbial Constituents and the Oral Microbiome of Tobacco Users

Tobacco microbial constituents may play significant roles in the development of infectious and chronic diseases among tobacco users, yet data regarding the microbial constituents of tobacco and smoke and their associated adverse health effects is lacking. This project will evaluate tobacco microbial constituents and characterize the oral microbiome of tobacco users. Specific aims are: (1) to explore the bacterial microbiome of conventional, new and manipulated smoked and smokeless tobacco products and smoke, and examine the role of tobacco-specific N-nitrosamine formation, in laboratory-based time-course experiments; (2) to gather novel baseline data on the composition of the oral microbiome and its associated expressed activities in 24 smokers, 24 smokeless tobacco users and 24 non-users (aged 18-35) in a longitudinal study involving self-administered tobacco use questionnaires and buccal swabs and saliva samples (enabling an analysis of nicotine and cotinine); and (3) to characterize the transient changes (i.e., bacterial community composition, expressed metabolic activities) in the oral microbiome after single use of new and manipulated smoked and smokeless tobacco products, in crossover trials of 20 users (aged 18 and older). These data may improve scientific knowledge of the role that tobacco bacterial communities may play in the development of both acute infectious diseases and chronic diseases, and could inform potential new tobacco standards that would address the public health implications associated with the microbial constituents of tobacco.

Amy Sapkota and Emmanuel Mongodin Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180523-01
Institution: University of Maryland
09/18/2013

UPenn TCORS: Information and Misleading Information about Tobacco Products in the “New” and “Old” Public Communication Environment

Public communications about tobacco products – including pro-tobacco messages promulgated by manufacturers, anti-tobacco public education messages, and communications shared on social media – can influence public opinion and behavior. This prospective, repeated measure, observational study will examine information and misinformation about tobacco products in traditional and emerging media and how exposure to this information alters beliefs, attitudes, intentions, and tobacco use in a nationally representative sample of 10,800 youth and young adults aged 13-25. Specific aims are: (1) to conduct a content analysis that characterizes “opportunities for exposure” to anti- and pro-tobacco product and smoking information presented in traditional and emerging social media over 36 months, for the total study population as well as for subgroups defined by age, socioeconomic status, gender, race/ethnicity, and smoking status; and (2) to conduct 36 monthly telephone surveys evaluating whether variation in anti- and pro-tobacco message content is associated with attitudes and beliefs about tobacco products, and whether exposure to pro-tobacco content predicts subsequent tobacco beliefs, attitudes and use. By describing tobacco message themes and developing tools to monitor the traditional and emerging communication environment, this project may inform the FDA’s efforts to communicate effectively about tobacco products.

Robert Hornik Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA179546-01
Institution: University of Pennsylvania
09/18/2013

Tobacco Product Messaging in a Complex Communication Environment (UPenn TCORS)

The Center will investigate tobacco-related messaging, information and misinformation, all of which is readily available through mass media, social media, user commentary, and the cigarette package itself. The Center will: (1) generate novel data about how public communication affects what people know and believe about tobacco products and how they use these products; (2) determine the most effective ways to convey information and correct misinformation about tobacco products and use; and (3) develop and deploy novel methodologies and tools for the acquisition and analysis of tobacco product information. Project 1 will examine information and misinformation about tobacco products in traditional and emerging media and how exposure to this information alters beliefs, attitudes, intentions, and tobacco use. Project 2 will examine the “staying power” of beliefs about tobacco products and use based on misinformation in social media and will evaluate corrective interventions. Projects 1 and 2 will focus on youth and young adults, whose perceptions and behavior may be most affected by Internet-based information. Project 3 will analyze the effects of packaging color, which can mislead the public to underestimate product harm.

Robert Hornik and Caryn Lerman Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA179546-01
Institution: University of Pennsylvania
09/18/2013

UPenn TCORS: Belief Echoes: Interventions to Correct Misleading Information about Tobacco Products

Misinformation about tobacco products communicated in today’s complex public communication environment can mislead the public into underestimating the dangers or overestimating the benefits of various tobacco products. Even if information is corrected, traces of the misinformation (called “belief echoes”) can persist and influence subsequent judgments and decisions. This five-year project will examine the “staying power” of beliefs about tobacco products and use based on misinformation in social media and will evaluate corrective interventions by surveying a sample of 2700 adolescents aged 13-17 and 6000 young adults aged 18-30. Specific aims are: (1) to establish the presence and durability of belief echoes and evaluate their effects on attitudes, beliefs, and intentions, even after immediate corrective information is provided; (2) to examine whether repetition of simple corrective information intensifies, rather than attenuates, belief echoes; (3) to test the effectiveness of three classes of enhanced correctives in reducing the impact of misleading information; and (4) to test the likelihood of re-transmission of enhanced versus simple correctives from Tobacco FactCheck.org. This project may facilitate the FDA’s efforts to communicate effectively about tobacco products by identifying corrective communication interventions that will have the greatest impact on tobacco use beliefs and behaviors.

Joseph Cappella Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA179546-01
Institution: University of Pennsylvania
09/18/2013

UPenn TCORS: Effects of Implicit Messaging by Cigarette Pack Color on Smoking Behaviors

Cigarette pack colors may impact smokers’ perceptions regarding product safety. This project will analyze the impact of packaging color as a form of implicit misinformation on tobacco use behavior in 360 daily Marlboro non-menthol red (n=180) and gold (n=180) cigarette smokers aged 21-60. The study’s 50-day protocol will randomize participants to the following study conditions: cigarette pack color manipulation (red, gold, or plain olive-brown packaging) and warning label manipulation (graphic vs. standard text). Participants will (unknowingly) smoke their own-brand cigarettes throughout the study, but will receive them in different colored packages during three 15-day study periods; each subject’s packages will consistently include either a graphic or a text warning label. Specific aims are: (1) to examine the effects of changes in cigarette package color versus plain packaging on tobacco product use (smoking rate and topography); (2) to determine whether graphic versus text warning labels moderate the impact of changes in package color on product use; and (3) to identify specific attitudes and beliefs that mediate the effects of color packaging and warning labels on tobacco use behaviors. This project will provide information about how factors related to tobacco packaging and labeling influence risk perception and product use.

Andrew Strasser Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA179546-01
Institution: University of Pennsylvania
09/18/2013

UMD TCORS: Toxicity Testing of New and Manipulated Tobacco Products

Traditional test methods used to classify cigarette smoke by determining tar, nicotine, and carbon monoxide (CO) yields per cigarette do not account for differences in user behavior. Measuring actual exposures experienced by most tobacco users is critical to understanding differences in harmful and potentially harmful constituents (HPHCs) in the many tobacco product types and brands available. This project will characterize the chemical profiles and physical properties of combustible, noncombustible, conventional, new, emerging, and manipulated tobacco products (e.g., cigarettes, electronic cigarettes, smokeless tobacco, little cigars, waterpipes, snus, and dissolvables). Using within-subject crossover acute laboratory trials and an established boost method paradigm in 72 subjects (aged 18 and older), investigators will measure subjects’ relative exposures to HPHCs (via puff topography, exhaled breath particle size distribution, and chemical analysis of blood and saliva samples) from new and manipulated tobacco products. Specific aims are: (1) to determine effects of combustible tobacco products designed for consumer inhalation (i.e., standard cigarettes, electronic cigarettes) on toxicity and uptake of select HPHCs; and (2) to determine effects of smokeless tobacco products (including dissolvables) designed for buccal absorption on toxicity and uptake of select HPHCs. This study will further inform the FDA’s ongoing efforts to identify and measure the tobacco product toxins that directly contribute to the risk of tobacco-related disease.

Courtney Granville Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180523-01
Institution: Battelle Centers
09/18/2013

UMD TCORS: Consumer Acceptability Testing of New and Manipulated Tobacco Products

Learned associations between nicotine and other sensory characteristics of cigarettes (such as “throat grab”) contribute to the rewarding characteristics of smoked tobacco products. This project will characterize and contrast consumer acceptance and the likelihood of adoption of smoked products that differ only on a single characteristic of interest (e.g., menthol/non-menthol cigarettes, high/low smoke pH). Investigators will conduct a series of within-subject crossover trials and use electroencephalography (EEG) to evaluate a test tobacco product and a comparison product in four laboratory smoking sessions; participants will include 120 subjects aged 18 and older. Specific aims are: (1) to characterize and contrast consumer acceptability and likelihood of adoption of combustible tobacco products by comparing neurocognitive function (as indexed by event-related brain potentials [ERPs]) in response to smoking test cigarettes with and without characteristics of interest; and (2) to determine the contribution of “throat grab” to tobacco product acceptability and likelihood of adoption. This project may inform regulatory decisions and standards that protect the public health by clarifying our understanding of the interactions among certain product characteristics and their effects on tobacco use behaviors.

Pamela Clark Funding Mechanism: National Institutes of Health- TCORS Grant
ID number: 1P50CA180523-01
Institution: University of Maryland
09/17/2013

Marketing and Explanatory Processes in Tobacco Progression Among Vulnerable Youth

Previous longitudinal research on the effects of tobacco marketing has not focused on vulnerable populations or on youth in later adolescence, when tobacco use experimentation often escalates and consolidates into life-long habits; in particular, point-of-sale (POS) advertising may have especially strong, explainable effects in low socioeconomic status (SES) neighborhoods and vulnerable populations. This three-wave, multi-cohort, prospective longitudinal study will investigate the effects of tobacco marketing on tobacco use escalation in a low SES, multi-ethnic population of 1000 adolescents (aged 16-20) with substantially higher rates of smoking than the national norm. Investigators will apply various models of behavior, memory, and decision-making to understand tobacco use progression in this population. Specific aims are: (1) to evaluate the use of explanatory models in analyzing tobacco use progression and tobacco marketing, including the impact of POS tobacco advertising and price promotions on tobacco use trajectories (i.e., onset, escalation, and cessation); (2) to compare the relative influence of two fundamental classes of mediators of tobacco marketing effects (spontaneous associations and explicit cognitive processes); (3) to examine the specific influence of POS marketing on smokeless tobacco use and test the explanatory models evaluated in Aim 1; (4) to evaluate the influence of POS marketing on a vulnerable population of Hispanic and non-Hispanic white adolescents with a documented higher risk of tobacco use; and (5) to summarize findings in terms of FDA policy implications.

Alan Stacy and Susan Ames Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01HD077560-01
Institution: Claremont Graduate University
09/12/2013

Improving Cost-Benefit Analysis of Tobacco Regulation

Understanding the economic case for tobacco regulation will be supported by impact analyses of health benefits related to smoking reduction. The costs of increased tobacco regulation include smokers’ foregone enjoyment of smoking (also known as “lost consumer surplus”); thus, an accurate method for valuing lost consumer surplus is essential to effective tobacco regulation. The goal of this project is to apply relevant economic theories and empirical evidence to determine how the FDA could estimate the value of smokers’ lost consumer surplus associated with regulation-induced changes in smoking. Specific aims are: (1) to determine the appropriate theoretical model for estimating lost consumer surplus associated with regulation-induced changes in smoking; and (2) to define the appropriate range of values for key empirical parameters, such as the price elasticity of demand for cigarettes, that regulatory impact analyses should incorporate.

Edward Norton Funding Mechanism: National Institutes of Health- Grant
ID number: 1R03CA182990-01
Institution: University of Michigan
09/11/2013

American Indian/Alaska Native Campaign: Focus Group Study of Reactions to Strategic Concepts Designed to Prevent Youth Tobacco Use

American Indian and Alaska Native youth are especially susceptible to tobacco use. The goal of this study is to gather qualitative data to inform the development of a public education campaign to prevent tobacco use by American Indian and Alaska Native youth. Twenty-two focus groups will be conducted among approximately 140 American Indian and Alaska Native youth (ages 10-16) and 80 adults, parents, and community leaders in five American Indian and Alaska Native communities. Study aims are: (1) to inform the definition of the target populations in terms of age, cultural identity, and community participation; (2) to inform message content development by describing the perceptions of tobacco initiation, use, and access among youth in American Indian and Alaska Native communities, including relevant knowledge, attitudes, and beliefs; (3) to identify influencers and how they impact tobacco use behaviors; and (4) to identify appropriate traditional, digital (e.g., social media), and community engagement channels through which to reach American Indian and Alaska Native at-risk youth.

Terry Cross, Sarah Kastelic, and Leah Hoffman Funding Mechanism: Contract
ID number: HHSF223201210005I
Institution: Better World Advertising, Inc.
09/05/2013

Using Eye Tracking to Understand and Improve Graphic Warning Label Effectiveness

Population-level research indicates that graphic warning labels (GWLs) are effective in eliciting negative responses to smoking, increasing reported intention to quit, and modifying beliefs about the dangers of smoking; however, this research does not evaluate which aspects of GWLs make them effective. A critical indicator of GWL effectiveness is whether smokers can correctly recall their content; recent eye tracking research has revealed that how quickly individuals attend to the text in the label and how long they dwell on the image are positively associated with correct recall, and other research indicates that congruent label features (i.e., the text and image have similar or complementary messages) also leads to better recall. The goal of this study is to provide empirical data regarding the aspects of GWLs that make them effective, how viewing patterns impact effectiveness, and the effect of recall on smoking attitudes and beliefs, intention to quit, and smoking behavior. Investigators will randomize 360 adult daily smokers (aged 21-60) to exposure to one of the nine FDA-approved GWLs, paired with a text warning that is congruent or incongruent. Participants will have their eye tracking assessed during the initial exposure to the GWL and then receive their own brand cigarettes with the same GWL affixed to their packs. Over ten days, participants will attend three additional laboratory visits, where they will: complete measures of recall, cigarette risk beliefs, attitudes, and intentions to quit smoking; report daily cigarette consumption and smoking topography (i.e., puffs, puff volume, puff duration, maximum flow, interpuff interval); and participate in eye tracking assessments that reveal label feature viewing order and dwell duration. Specific aims are: (1) to examine the effect of GWL format and eye tracking patterns on initial recall; (2) to examine the effect of viewing patterns, GWL type and initial recall on long term recall, beliefs, attitudes, intentions, and smoking behaviors; and (3) to examine the effects of individual differences (i.e., education, nicotine dependence, numeracy-literacy) on the above stated outcomes to identify prone sub-groups.

Andrew Strasser Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01CA180929-01
Institution: University of Pennsylvania
09/03/2013

Exploring Smokers’ Perceptions of Differing Smokeless Tobacco News Messages

Communicating the risks of smokeless tobacco products (SLT) relative to cigarettes is complicated, and no tobacco companies have yet been authorized to make modified risk claims in their advertising; nevertheless, messages about the risk reduction potential of SLT are currently being communicated through the news media and thus may already be influencing the public’s SLT knowledge, perceptions and attitudes towards trying or switching to SLT. The goal of this study is to investigate smokers’ interpretations of and potential reactions to SLT information presented in news stories. Specific aims are: (1) to explore interpretations of different SLT news story messages and risk information by conducting in-depth interviews with up to 30 adult smokers (aged 18 and older); smokers will be randomly assigned to read one of three different constructed news stories: a “favorable” news story describing modern SLT products as more acceptable versions of SLT and as potentially safer than cigarettes, a “traditional” news story including messages that SLT is risky and not a safe smoking alternative, and a “mixed” new story with both message types (i.e., that SLT is harmful and also that SLT is less risky than smoking); and 2) to examine the impact of different SLT message frames on smokers’ perceptions of and interest in SLT by conducting a national web-based survey with 500 adult smokers randomly assigned to one of four SLT news story conditions (“favorable”, “traditional”, “mixed”, or control [i.e., no news story]).

Olivia Wackowski Funding Mechanism: National Institutes of Health- Grant
ID number: 1 R03 CA175901-01
Institution: University of Medicine and Dentistry of New Jersey
09/02/2013

Constituent Yields and Biomarkers of Exposure for Tobacco Product Regulation

The issue of how to test and regulate the contents of cigarette smoke represents a critical challenge; currently-used standard machine testing methods do not account for the complexities of smoker-cigarette interaction and are widely recognized to be inadequate for the prediction of human exposures.  This project will analyze carcinogenic tobacco-specific nitrosamines (TSNA) per mg nicotine emissions in currently marketed U.S. cigarettes; investigate the effect of different smoking machine regimens on these emissions; investigate how smoking cigarettes that differ in TSNA yield affects smoker uptake of these carcinogens; and explore a novel approach to the assessment of TSNA per mg nicotine intake by analyzing mouth-level exposure to these carcinogens based on an analysis of cigarette filters. The goal of this project is to develop a testing approach that can produce meaningful predictions of changes in human exposure due to changes in smoke constituent levels, and hence serve as a reliable measure for product regulation. Specific aims are: (1) to analyze N-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) per mg nicotine emissions in cigarettes representing 11 U.S. cigarette brands using different smoking machine regimens; (2) to examine the extent to which differences in smoke yields of NNN and NNK per mg nicotine predict differences in smoker exposure to these carcinogens by analyzing the urine of 300 adult smokers (aged 18-65); and (3) to determine which individual factors (e.g., duration and intensity of smoking, nicotine metabolism, demographics) may affect the relationship between machine-measured TSNA per mg nicotine and smoker exposures.

Irina Stepanov Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01CA179246-01
Institution: University of Minnesota
09/01/2013

Reducing the Effect of Tobacco Power Wall Displays at Retail Point-of-Sale

Point-of-sale (POS) tobacco advertising includes prominent, expansive displays (called “power wall displays”) of many different types of tobacco products at the POS location. Investigators will conduct two studies that evaluate the extent to which the location of tobacco power wall displays (Study 1) and inclusion of anti-tobacco POS messages (Study 2) influence tobacco use risk in middle and high school students (aged 11-17). Participants will enter an experimental POS convenience store that “sells” tobacco products in addition to other products typically found in such stores (e.g., soda, water, candy) and spend four minutes selecting and “purchasing” $5 worth of (non-tobacco) products in the store; after exiting the store, they will complete a survey that evaluates cigarette, smokeless tobacco, cigarillo, and e-cigarette use risk. Specific aims are: (1) to evaluate the effects of power wall display location on tobacco use risk by comparing three power wall display locations: behind the cashier, side-wall display away from cashier; and display hidden from view (360 participants); (2) to examine the effects of including anti-tobacco use posters in the POS environment on tobacco use risk by comparing four anti-tobacco poster conditions: no poster, a small poster at the cash register, a large poster on the power wall display, and posters placed both at the cash register and on the power wall (480 participants); and (3) to analyze whether tobacco use norms and attitudes and tobacco brand popularity mediate relationships found between the power wall displays and anti-tobacco posters and tobacco use risk.

William Shadel Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01CA175209-01
Institution: Rand Corporation
08/29/2013

Tobacco Retailer Education Program: In-depth Interviews to Inform the Development of Educational Materials

In support of FDA’s efforts to monitor compliance with and enforce restrictions on sales to minors, CTP will conduct research to evaluate tobacco retailers’ receptivity and cognitive reactions to draft creative educational materials intended to raise their awareness of federal tobacco regulations with respect to cigarettes, smokeless tobacco, and roll-your-own tobacco. The specific aim is to gather initial impressions on two program variants, as well as more detailed feedback on several types of educational materials and tobacco facts in order to determine and optimize the final direction of the program prior to launch. To accomplish this, 61 in-depth interviews will be conducted with tobacco retailer managers and clerks over age 18 working in convenience and convenience/gas stores; grocery, discount and drug stores; and tobacco outlets. The information will inform CTP’s efforts to develop and implement a retailer education program. (Project completed in July 2015.)

Matthew Walker and Kara Marsh Funding Mechanism: Research contract
ID Number: HHSF223201210039I
Institution: Fors Marsh Group
08/24/2013

Qualitative Study on Nicotine: Knowledge, Beliefs, and Misperceptions

Consumer perceptions and misperceptions about nicotine, the highly addictive component in tobacco products, may impact tobacco initiation, use, and cessation. This project will employ focus groups to examine consumer knowledge, beliefs, and misperceptions about nicotine as it relates to the use of tobacco products. Investigators will conduct 16 focus groups (including 8-10 participants each) with adults and adolescents, including both users and non-users of tobacco products, in three different U.S. cities. Four groups will be conducted with adolescents aged 16-17; two groups will include current tobacco users, and two will include adolescents classified as “at risk” of initiating tobacco use. The remaining twelve groups will include adults aged 18 and older who are current tobacco users. Focus group participants will vary in terms of race, age, and educational attainment in order to represent the diversity of the population. Topics will relate to participants’ knowledge and perceptions about nicotine in tobacco products, including the health effects associated with nicotine. Findings may inform the FDA’s efforts to implement the provisions of the Family Smoking Prevention and Tobacco Control Act related to educating the public about the harms of tobacco use.

Denise Dickinson and Sarah Johnson Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: RTI
08/15/2013

Threshold Dose for Nicotine Discrimination in Cigarettes

Despite extensive animal research on nicotine discrimination and human studies of threshold dose for discriminating drugs other than nicotine, no studies have clearly assessed the nicotine discrimination threshold in humans because of the difficulty in controlling nicotine dosing with tobacco intake. Investigators will employ a well-validated behavioral discrimination methodology to identify the cigarette nicotine threshold dose for discrimination using a nicotine research cigarette from the National Institute on Drug Abuse (NIDA) Drug Supply Program; the study will assess threshold doses in a diverse sample of 100 healthy male and female smokers (aged 18-65) who vary in dependence level and menthol preference. This study will also separately assess self-administration of nicotine to determine the relationship between nicotine discrimination threshold dose and reinforcement threshold dose. The primary aim is to reliably assess the threshold dose for nicotine discrimination via cigarettes; hypotheses investigated will include the following: (1) the threshold dose will be 0.4 mg or lower (below the yield of most commercial brands) for greater than 95% of the study population; (2) the threshold dose will be lower in nondependent vs. dependent smokers and in men vs. women, consistent with research on subgroup differences in nicotine sensitivity; (3) a significant association will exist between discrimination threshold and self-administration threshold; and (4) the threshold dose will vary by menthol preference. Identification of the lowest dose of nicotine that reinforces tobacco use and promotes nicotine dependence will have implications for understanding the onset and maintenance of dependence.

Kenneth Perkins Funding Mechanism: National Institutes of Health- Grant
ID number: 1R21DA035968-01
Institution: University of Pittsburgh
08/02/2013

Nicscreen: Screening Tools to Identify Nicotine Receptor Activity

Nicotine is the main addictive component in tobacco that acts through binding to the nicotine receptor. There are other components of tobacco that can mimic nicotine by altering the activity of the nicotine receptor, potentially increasing the addictiveness of the product. The NicScreen project will involve the development and use of screening tools to rapidly identify tobacco product constituents with selective nicotine receptor subtype modulation properties; the goal is to identify nicotine-like constituents that could potentially alter the nicotine receptor activity. As part of this project, investigators will develop in vitro pharmacological assays (receptor and cell level) to detect similarities and differences between tobacco products at the molecular level. The five different cell types and a to-be-determined high-throughput technique for assessing direct receptor function will be used to determine if tobacco product constituents (individual and mixtures of compounds) have selective nicotine receptor activity. In addition, the projects may attempt to develop methods for evaluating similarities and differences in the pharmacological profiles of tobacco products marketed in the U.S. A more detailed understanding of tobacco product pharmacology and constituents will help inform FDA’s work in setting tobacco product standards and regulatory policy.

Glenn Kirsch and Michael Orr Funding Mechanism: Research Contract 
ID number: HHSF223201310070C
Institution: ChanTest Corporation
08/01/2013

A Comparative Effectiveness and Long-Term Health Study in Wisconsin Smokers

Little is known about whether smoking menthol cigarettes produces a different level of tobacco addiction than smoking non-menthol cigarettes. Investigators will analyze the effect of menthol and non-menthol cigarette smoking on tobacco dependence and quitting motivation and success using data from the Wisconsin Smokers Health Study, a five-year longitudinal study that comprises two comparative effectiveness research trials involving 1504 and 1050 subjects. Specific aims are: (1) to use data from the Wisconsin Smokers Health Study to evaluate the relationship between menthol and smoking cessation using biochemically-confirmed smoking abstinence at end-of-treatment and six months post-quit; to collect longitudinal abstinence data at 8-, 12-, and 26-week follow-ups; and to determine the relationship between menthol and smoking cessation specifically for African-Americans; (2) to assess the relationship between menthol smoking and spontaneous quit attempts by measuring quit attempts, abstinent days, and latency to a successful quit attempt among menthol smokers; (3) to identify the most effective smoking cessation pharmacotherapies (i.e., nicotine patch, nicotine lozenge, bupropion, varenicline, nicotine patch plus lozenge, and bupropion plus lozenge) for menthol smokers, and whether menthol and non-menthol smokers differ in response to pharmacotherapies; (4) to identify the factors that mediate menthol smoking status and smoking cessation outcomes, including craving and tobacco dependence severity; and (5) to determine the participant characteristics associated with menthol smoking (e.g., demographics, smoking history, tobacco dependence, genetic markers of tobacco dependence, motivation to quit, attitudinal factors, quality of life, psychiatric status, social network variables, and prequit measures of daily smoking behaviors).

Michael Fiore Funding Mechanism: National Institutes of Health- Grant
ID number: 3R01HL109031-02S1
Institution: University of Wisconsin
08/01/2013

Nicotine Emissions, Toxicity, and Behavior Related to Electronic Cigarettes

Data describing the realistic use of electronic cigarettes (e-cigarettes) and resulting health impacts, including toxicity and abuse liability, is required. This study will compare the nicotine emissions and doses in e-cigarettes and conventional cigarettes and will evaluate whether these doses result in toxicological responses in vivo in mice. Investigators will test the hypothesis that e-cigarette users are exposed to lower amounts of nicotine than conventional cigarette users, but that these exposure levels induce toxic oxidative and inflammatory responses in vivo and will result in addiction comparable to that seen in conventional cigarette smokers. As part of the study, investigators will analyze the nicotine concentration and other constituents in e-cigarette liquid cartridges and verify levels relative to the product labels; quantify the difference in nicotine yield from a single puff of an e-cigarette versus that of a conventional cigarette for a range of machine-generated puffing topographies; compare nicotine doses between a single session of e-cigarette smoking and smoking one conventional cigarette; and compare cumulative daily doses of nicotine for e-cigarette users and conventional cigarette smokers. Specific aims are: (1) to determine how the constituents, components and design features of e-cigarettes vary by brand and how emissions are affected by consumer use behaviors; and (2) to determine if e-cigarettes cause toxic oxidative damage and pro-inflammatory effects similar to conventional cigarette smoke in vivo in mouse models, and determine the dependence potential and addictive properties of e-cigarettes in mice following chronic e-cigarette exposure.

Risa Robinson Funding Mechanism: National Institutes of Health- Grant
ID number: 1R21DA036057-01
Institution: Rochester Institute of Technology
07/25/2013

Menthol Levels in Cigarettes

FDA is interested in understanding the use of menthol in cigarettes that are marketed to United States consumers. Menthol is a common chemical additive in cigarettes, cigarette packaging material, and cigarette filters. Its analgesic and non-irritating properties impart a distinctive cooling flavor and reduce smoke harshness. The amount of menthol added to cigarettes has been previously reported to vary from approximately 1 to 5 milligrams per gram of tobacco filler among various products1. However, available studies appear to precede the Tobacco Control Act of 2009; thus, studies are needed to evaluate the use of menthol in currently available commercial cigarette brands. This collaborative project with the Centers for Disease Control and Prevention examines menthol quantities in randomly selected brands of mentholated and non-mentholated cigarettes. This market survey is intended to enable FDA to evaluate the use of menthol in cigarettes and related potential health consequences.

Cliff Watson / Kenneth Taylor Funding Mechanism: Interagency Agreement
ID number: 224-11-9022
Institution: Centers for Disease Control and Prevention
07/15/2013

Exploring Persuasiveness of Non-Cigarette Tobacco Product (NCTP) Advertising on Young Adults

Non-cigarette tobacco products such as snus, dissolvables, and electronic cigarettes are aggressively advertised in magazines, particularly those read by young adults; high awareness of and experimentation with these products suggests an imminent need to develop interventions that create resistance to tobacco companies’ marketing strategies. This one-year, two-phase project will apply a well-established social-psychological framework (the Elaboration Likelihood Model of Persuasion) to understand the persuasive framing of tobacco product advertisements and the subsequent impact on young adults. The first phase, a content analysis of approximately 100 distinct print advertisements for snus, dissolvables, and electronic cigarettes in magazines with the highest young adult readership, will provide qualitative data on an array of persuasive strategies used to promote these products. The second phase will involve an online survey of a nationally representative sample of 1,000 young adults (aged 18-24, stratified by gender and smoking status); the goal is to understand the impact of non-cigarette tobacco product advertisements by measuring response cues and immediate audience reactions.  Specific aims are: (1) to understand the tobacco industry’s efforts to market non-cigarette tobacco products in consumer magazines with the highest young adult readership by conducting a content analysis that identifies persuasive rhetorical, textual and visual themes; and (2) to investigate young adults’ attitudes towards  non-cigarette tobacco product advertisements.

Smita Banerjee Funding Mechanism: National Institutes of Health- Grant
ID number: 1R03DA035242-01
Institution: Sloan-Kettering Institute for Cancer Research
07/02/2013

Tobacco Use Supplements to the Current Population Survey (TUS-CPS)

The 2014-2015 Tobacco Use Supplement to the Current Population Survey (TUS-CPS) is co-sponsored by the National Cancer Institute (NCI) and the U.S. Food and Drug Administration (FDA) and will be conducted by the U.S. Census Bureau. Since 1992, the nationally-representative TUS-CPS has been a key source of national, state, some local-level, and health disparity data; a unique feature of the TUS-CPS is the ability to link other social and economic Census Bureau and Bureau of Labor Statistics data and health data from the National Longitudinal Mortality Study. In the 2014-2015 TUS-CPS, data related to cigarette smoking, other tobacco use, and cessation attempts will be collected in July 2014, January 2015, and May 2015 from approximately 240,000 unique respondents; questionnaire items will address patterns of cigarette smoking and use of other tobacco products, such as cigars, pipes, hookah, electronic cigarettes, dissolvables, and smokeless tobacco. (Note: Because the NCI requires some information that falls outside of FDA’s regulatory authority — such as home and workplace smoking policies, health professional smoking cessation advice, and changes in smoking norms and attitudes – NCI is co-sponsoring a smaller part of the survey through a parallel but separate agreement with the U.S. Census Bureau.) Research findings will provide information that may inform the FDA’s regulatory activites.

Lisa A. Clement / Enver Holder-Hayes Funding Mechanism: Interagency Agreement
ID number: 224-13-9016
Institution: U.S. Census Bureau
07/01/2013

Brain and Behavioral Effects of Graphic Cigarette Warning Labels

Additional scientific evidence regarding the impact of graphic warning labels (GWLs) will inform mechanisms underlying the effectiveness of strongly salient format and content in persuasive health communications. This project addresses this issue from both a clinical and neurophysiological perspective; investigators will use biochemical assays (urine cotinine levels) and neuroimaging (functional magnetic resonance imaging [fMRI]), as well as traditional measures of persuasion, to compare brain and bio-behavioral responses to GWLs that were rated high or low on the emotional response (ER) scale. Investigators will image the brain response to GWLs and monitor urine cotinine levels before and after four-week exposure to real-life cigarette packs carrying high or low ER GWLs in adult smokers who are not seeking smoking cessation treatment. Specific aims are: (1) to compare the effects of exposure to high or low ER GWLs on urine cotinine levels, a quantitative measure of smoking behavior/severity, and (2) to characterize the longitudinal effects of exposure to high or low ER GWLs on fMRI response in the key brain regions that are involved in processing and responding to affective stimuli. By evaluating the effects of the long-term exposure to GWLs of different affective levels on the brain and behavioral correlates of smoking behaviors, this study can inform science-driven regulation of cigarette packaging.

Daniel Langleben Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01DA036028-01
Institution: University of Pennsylvania
07/01/2013

Are E-cigarettes Marketed to Encourage Consumers to Think that E-cigarettes are Safer Alternatives to Cigarettes?

E-cigarettes are growing in popularity, particularly among younger smokers who may perceive e-cigarettes to be safer than cigarettes. The goal of this supplemental study is to evaluate whether e-cigarettes are marketed to encourage consumer perceptions that e-cigarettes are safer alternatives to cigarettes. Specific aims are: (1) to conduct 12 focus groups with 72 young adult (aged 18-35) current daily cigarette smokers in order to assess smokers’ perceptions of real e-cigarette ads and develop measures, including explicit and implicit attitude measures, that will be used to pursue the second aim; and (2) to conduct a laboratory-based experimental study with 400 young adult cigarette smokers. In the experimental study, half the participants will be randomly assigned to the experimental condition and exposed to real e-cigarette ads; the other half will be exposed to control images. Post exposure, all participants will be assessed on explicit and implicit measures of attitudes toward e-cigarettes as safer alternatives to cigarettes, and on measures of susceptibility to future e-cigarette use. Study findings may inform regulatory activities related to e-cigarettes. (Project completed in 2014.)

Jerris Hedges and Pallav Pokhrel Funding Mechanism: National Institutes of Health – Grant
ID Number: 3 P30 CA071789-13S1
Institution: University of Hawaii at Manoa
06/13/2013

Evaluation of the FDA’s Rural Smokeless Tobacco Education Campaign (RuSTEC)

In support of FDA’s efforts to inform the public on tobacco-related health issues, the Center for Tobacco Products (CTP) is developing a public education campaign to prevent and reduce smokeless tobacco use among rural male youth. The goal of this study is to evaluate FDA’s “The Real Cost” smokeless tobacco prevention campaign. The evaluation will be a longitudinal study with 1,969 rural male youth ages 11-16 in 30 geographic areas. Baseline data will also be collected from 1,969 adult guardians of these participants (i.e., a total of 3,938 participants). Four rounds of data collection will be conducted over two years consisting of an in-person baseline questionnaire before campaign launch, followed by three online follow-up surveys (with youth participants only) at eight-month intervals. Study aims are: (1) to gauge campaign awareness; and (2) to examine the statistical relationships between campaign exposure and changes in outcome variables of interest, including changes in targeted attitudes and beliefs and intentions to use smokeless tobacco. Study results will be used to improve the current campaign and inform the development of future youth-oriented tobacco prevention campaigns.

Matthew Farrelly and Tesfa Alexander Funding Mechanism: Research Contract
ID number: HHSF223201310001B
Institution: RTI International
06/13/2013

Evaluation of the FDA’s Public Education Campaign on Teen Tobacco (ExPECTT)

In order to assess the effectiveness of the FDA’s efforts to reduce or prevent tobacco use by youth, CTP will conduct an evaluation of “The Real Cost” public education campaign targeting youth ages 12-17 years who are at risk for smoking cigarettes. The specific aims of the study are to gauge campaign awareness and to examine the statistical relationships between exposure to the campaigns and changes in outcome variables of interest, which include changes in cigarette smoking-related attitudes, beliefs, and behaviors. Data will be collected through in-person and online surveys of adults and youth in the United States. Approximately 6,000 at-risk youth and their parents will complete questionnaires at four time points over the two-year life of the campaign (baseline and three follow-up surveys) at eight-month intervals. The results of the study will inform the development and enhancement of future implementations of this and other youth-oriented tobacco public education campaigns.

Alexandra Smith and Jennifer Duke Funding Mechanism: Contract
ID Number: HHSF223201310001B
Institution: RTI International
06/13/2013

Research and Evaluation Survey for the Public Education Campaign on Tobacco among LGBT (RESPECT LGBT)

In support of the U.S. Food and Drug Administration’s efforts to inform the public on tobacco-related health issues, the Center for Tobacco Products (CTP) will conduct a study to evaluate “This Free Life,” a multi-strategy campaign designed to reduce cigarette smoking among Lesbian/Gay/Bisexual/Transgender young adults aged 18 to 24. The goal of the study is to evaluate the effectiveness of “This Free Life” in affecting specific cognitive outcomes related to tobacco use that are addressed by the campaign. The study will consist of a baseline survey before campaign launch, followed by three cross-sectional surveys at six-month intervals. Participants will be recruited in 12 campaign-targeted markets and 12 control markets, with a total of 12,600 surveys planned for the evaluation study. Study aims are: (1) to gauge campaign awareness; and (2) to examine the statistical relationships between campaign exposure and changes in outcome variables of interest, including changes in campaign attitudes and beliefs and smoking intentions. Findings from the evaluation study will be used to improve the current campaign and inform development of future campaigns targeting similar populations.

Youn Lee and Tesfa Alexander Funding Mechanism: Research Contract
ID number: HHSF223201310001B
Institution: RTI International
06/13/2013

Evaluation of the Fresh Empire Campaign on Tobacco (EFECT)

In order to assess FDA’s efforts to reduce and prevent youth tobacco use, CTP will conduct an evaluation of “Fresh Empire,” a multi-strategy public education campaign to reduce tobacco use among multicultural youth ages 12-17. The target audience is youth who are: at risk for smoking cigarettes; are influenced by the hip hop peer crowd; and are predominantly non-Hispanic African American, Hispanic, non-Hispanic Asian/Pacific Islander, and/or multiracial. The specific aims are to evaluate the effectiveness of “Fresh Empire” in affecting specific cognitive outcomes related to tobacco use that are addressed by the campaign. The study consists of six surveys, which can be taken online or in person: a baseline survey conducted prior to campaign launch, followed by five cross-sectional surveys with an embedded longitudinal cohort. Surveys will be conducted in campaign and control cities over the three years of the campaign. The results of the study will inform the development and enhancement of this and other tobacco public education campaigns targeting at-risk multicultural youth.

Leah Hoffman and Matthew Farrelly Funding Mechanism: Research contract
ID Number: HHSF223201310001B
Institution: RTI International
06/01/2013

Using Standard Genetic Toxicology Assays to Assess the Genotoxic Potential of Smokeless Tobacco Products

This project will produce data that CTP can use to evaluate smokeless tobacco product toxicity. The project has two goals: (1) to determine the efficiency and relevancy of several solvents (i.e., acid, base, aqueous, organic, and artificial saliva) for extracting the active constituents from smokeless tobacco products, and (2) to measure the DNA damage caused by the active components in the smokeless tobacco extracts. The extent of DNA damage produced by different extracts will be evaluated using standard in vitro genetic toxicology assays that measure alterations in DNA integrity. Specific aims are: (1) to compare the impact of various extraction procedures on genotoxic potency; and (2) to determine if standard genetic toxicology assays distinguish among smokeless tobacco extracts from products with different chemical and/or physical properties. The results will provide information that will help inform how to conduct smokeless tobacco product analysis using in vitro systems and will help assess the ability of standard genetic toxicology methodologies to assess smokeless tobacco product genotoxicity.

Roberta Mittelstaedt and Patricia Richter Funding Mechanism: JV
ID number: C13006
Institution: National Center for Toxicological Research
06/01/2013

Tobacco Trends: A Real-Time Sentinel for Tobacco Control Evaluations

Evaluations of tobacco control initiatives may be confounded when multiple initiatives take effect in the same year; tracking smoking trends in real time would allow researchers to temporally associate population smoking with specific tobacco control initiatives, leading to better estimates of initiative effectiveness. No adequate data source for real-time population smoking surveillance exists; however, infectious disease epidemiology research indicates that aggregate Internet search queries may be used to estimate population heath trends. Investigators will analyze changes in smoking-related Internet search queries to identify population smoking trends and will use these trends to evaluate the effectiveness of two tobacco control initiatives. Specific aims are: (1) to model adult smoking trends in the U.S. using aggregate Internet search queries and previously validated behavioral measures; this includes identifying a criterion to validate against, selecting candidate queries, building a validation model and adjusting for potential bias; and (2) to use validated population smoking trend data and apply metrics retrospectively to evaluate the Great American Smokeout and New York’s 2010 cigarette excise tax increase as a model for using these metrics. This evaluation involves using daily search query data to relate the timing of these measures to the timing of changes in smoking trends. The real-time smoking trends will be disseminated through a public web application, Tobacco Trends (www.tobaccotrends.org), giving investigators, sponsors, and policymakers the ability to rapidly evaluate tobacco control measures.

John Ayers Funding Mechanism: National Institutes of Health- Grant
ID number: 1 R21 CA173299-01
Institution: San Diego State University Research Foundation
06/01/2013

High-Throughput Assay Development for Non-Nicotine Tobacco Components

Investigators will develop a pair of high throughput screening (HTS) assays suitable for identifying non-nicotine tobacco product compounds with activity at α3β4 and α4β2nicotinic receptors. Specific aims are: (1) to establish and optimize HTS-ready assays for a pair of existing, highly-functional, monoclonal cell lines; and (2) to configure the optimized assays for HTS conditions. This project will yield a set of validated assays that target nicotinic acetylcholine receptor subtypes tied to the use of and dependence on tobacco products and that can be used to rapidly test the large range of compounds found in existing and emerging tobacco products.

Paul Whiteaker Funding Mechanism: National Institutes of Health- Grant
ID number: 1R21DA036059-01
Institution: St. Joseph’s Hospital and Medical Center
04/01/2013

Extending a School-Based Cohort to Improve Longitudinal Modeling

Social influences are an important factor that drives tobacco use or nonuse in adolescents. In this project, investigators will re-interview an existing cohort of approximately 1,260 12th grade students (approximately 18 years of age) in five southern California schools with a majority Hispanic/Latino population; many of these students had previously been interviewed twice in 10th grade (in five schools) and once in 11th grade (in four schools). In this fourth survey, data on multiple types of relationships will again be collected along with tobacco use behaviors; investigators will use the data to analyze the social influences that account for both changes in behavior and changes in social networks over time. In addition, investigators will collect new data assessing two dimensions of tobacco attitudes (affective and utilitarian) needed to empirically calibrate an agent-based model of smoking initiation; the affective component consists of mostly socially constructed imagery (e.g., smoking is cool, smoking is trashy/low class), and the utilitarian component measures concepts such as weight control, stress relief, and health risks. Specific aims are: (1): to collect social network and tobacco use data from these 12th grade students so that the previously-developed dynamic diffusion network/stochastic actor model can be applied to these data; and (2) to measure tobacco use attitudes among this cohort of students so that agent-based models of tobacco use dynamics may be accurately calibrated with empirical data.

Thomas Valente Funding Mechanism: National Institutes of Health- Grant
ID number: 3R01CA157577-02S1
Institution: University of Southern California
04/01/2013

Differential Redox & Electrophilic Toxicities of Modified Tobacco Products

Cigarette smoke is a toxic mixture of approximately 4,700 chemical compounds that can cause irreversible oxidative stress-induced damage to lung epithelial cells, resulting in cardiovascular disorders, chronic obstructive pulmonary disease, and lung cancer. However, comparative emission data for combustible potential “modified risk” tobacco products are rare, and a comprehensive toxicity assessment outside of the tobacco industry is lacking. The goal of this project is to characterize the toxic effects of electrophilic and/or redox-active conjugated ketones from 10-15different brands of cigarettes, including reference cigarettes, cigarettes with a wide range of tar and nicotine content, no-filter and charcoal filter cigarettes, a low combustion potential modified risk tobacco product, and electronic cigarettes. Specific aims are: (1) to develop methods to generate, sample and quantify electrophilic gas-phase carbonyls and tar-phase quinones in cigarette smoke; (2) to assess the electrophilic and redox potential of gas phase carbonyls and tar phase quinones in cigarette smoke extracts derived from different types of cigarettes; and (3) to assess the differential effects of modified tobacco product smoke components on the antioxidant defense mechanisms of cultivated primary small airway epithelial cells.

Norbert Staimer Funding Mechanism: National Institutes of Health- Grant
ID number: 1R21CA164540-01A1
Institution: University of California Irvine
03/26/2013

Population Assessment of Tobacco and Health: Measurement of Tobacco-Related Biomarkers in the Field Study

The Tobacco Control Act mandates the regulation of tobacco products using a population health standard including both users and non-users of tobacco products. To help meet this mandate, the Population Assessment of Tobacco and Health (PATH) study — a nationally representative, longitudinal cohort study that will survey tobacco product users, never users, and former users including youth aged 12-17 and adults aged 18 and older – is gathering data on tobacco product use, attitudes, and health conditions and is collecting biological specimens (buccal cells, urine, and blood) from consenting adults. GenWay Biotech, a company that specializes in bioinformatic analyses of protein targets, will measure biomarkers in a subset of these biological specimens. GenWay will measure fibrinogen antigen, IL-6, sICAM and F2-Isoprostane in approximately 150 participant blood or urine samples. These data will inform the development of final baseline study procedures related to the collection, shipment, processing, storage, and requisitioning of biospecimens.

Dana van Bemmel Funding Mechanism: Research Contract
ID number: HHSF223201300169P
Institution: GenWay Biotech
03/20/2013

Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors; CTP Supplement to Parent Grant: Models For Tobacco Product Evaluation

Regulating reductions in cigarette nicotine content has the potential to reduce tobacco use-related morbidity and mortality, but these positive effects might be mitigated depending on whether cigarette smokers switch to other nicotine-containing products and the type of products they use (e.g., cigars, cigarillos, smokeless products, nicotine replacement therapy). The goal of this study is to address the likelihood of product switching behavior and the type of product use following assignment to very low nicotine content (VLNC) cigarettes and access to different types of nicotine-containing products. Investigators will randomly assign subjects to one of three experimental groups reflecting different scenarios of tobacco availability: (1) VLNC cigarettes and access to non-combusted and combusted nicotine-containing products (with the exception of cigarettes) (n=50); (2) VLNC cigarettes and access to non-combusted products only (n=50); and (3) experimental cigarettes with conventional levels of nicotine (0.8 mg nicotine yield) with access to both combusted and non-combusted products (n=25). Over an eight-week experimental phase, participants will be assessed for patterns of tobacco use and biomarkers of exposure.

Dorothy Hatsukami Funding Mechanism: National Institutes of Health – Grant
ID number: U19CA157345-01A1
Institution: University of Minnesota
03/15/2013

Alpha 5 Nicotinic Receptor Subunit Gene Polymorphisms and Smoking Addiction

Recent animal studies of nicotine self-administration have indicated the critical role of the habenula α5 nicotinic receptor subunit in the suppression of excessive nicotine intake. Approximately 60% of smokers carry the risk allele for the non-synonymous coding SNP α5 subunit gene (SNP rs16969968, rs588765), which causes the substitution of an aspartic acid with asparagine and results in decreased function of the nicotinic receptor. This risk allele is associated with number of cigarettes smoked per day, nicotine dependence, and lung cancer. The goal of this project is to assess how smokers with different α5 nicotinic receptor subunit genotypes respond to switching between cigarettes with varied nicotine yields and to nicotine patch application. Specific aims are: (1) to demonstrate that α5 risk allele carriers, relative to controls, have greater increases in nicotine intake after switching to higher nicotine yield cigarettes; (2) to determine if smokers with the α5 risk allele have a lower reduction of nicotine intake from cigarettes while on the nicotine patch than smokers without this allele; and (3) to show that α5 risk allele carriers demonstrate greater smoking compensation after switching to low nicotine yield cigarettes. Two hundred adult cigarette smokers (aged 18-65) will be genotyped for the α5 subunit gene and will complete a 13-week protocol consisting of one screening/evaluation visit, eight laboratory visits, and seven phases of monitored smoking under assigned conditions involving the use of own-brand cigarettes, nicotine patch, and research cigarettes with varying nicotine yields (0.3-1.6 mg). Results from this study will contribute to the understanding of individual differences in vulnerability to tobacco dependence and may inform FDA activities related to product standards addressing nicotine.

Alexey Mukhin Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01DA034862-01
Institution: Duke University
03/07/2013

The Effect of Point-of-Sale Tobacco Marketing on Smoking Cessation

Most tobacco industry marketing efforts occur at the point-of-sale (POS) (i.e., at retail stores where tobacco is sold), yet empirical studies on the effect of POS tobacco marketing on smoking cessation in the U.S. do not exist. Smokers who are exposed to a higher level of POS marketing may more frequently crave cigarettes, have the urge to buy cigarettes, make unplanned purchases of cigarettes, and believe that smoking is socially acceptable, all of which lower the chances of making a quit attempt and successfully quitting. This longitudinal study will investigate the effect of POS tobacco marketing on smoking behavior (i.e., making a quit attempt and quit success) in 971 adult smokers (aged 18 and older) in Omaha, Nebraska. Specifically, the study will investigate the following hypotheses: (1) smokers who are exposed to a higher amount of POS marketing are less likely to make a quit attempt; (2) the mechanism of the effect of POS marketing on making a quit attempt is through noticing POS marketing, which leads to craving, an urge to buy cigarettes, an unplanned purchase of cigarettes, and the perception that smoking is socially acceptable; (3) among smokers who have made a quit attempt, those who are exposed to a higher amount of POS marketing are less likely to successfully quit smoking; and (4) among smokers who have made a quit attempt, the mechanism of the effect of POS marketing on quit success is through the mechanism described above. Participants will be recruited through random telephone contact and will be interviewed at baseline and at six months. At baseline, participants will be surveyed about noticing POS marketing, craving to smoke, urge to buy cigarettes, unplanned purchase of cigarettes, and the perception of social acceptability of smoking; data on POS tobacco marketing will be collected from stores that sell tobacco in each participant’s neighborhood. At six-month follow-up, investigators will assess participants’ quit attempts in the previous six months and quit success.

Mohammad Siahpush Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01CA166156-01A1
Institution: University of Nebraska Medical Center
03/01/2013

Childhood and Adolescent Predictors of Substance Abuse in Emerging Adulthood

Novel tobacco products (e.g., snus, dissolvables, e-cigarettes, little cigars, and hookah) are perceived to be less harmful and addictive than traditional products, particularly by young adults, who are more likely to use them. This underscores the need for post-market surveillance of consumer awareness and uptake of these products, as well as an understanding of the factors leading to perceptions of their risks. This study will examine the perceptions, beliefs, and use of novel tobacco products in a large cohort of young adults (aged 20-26). Study aims are: (1) to examine the prevalence, frequency and quantity of use of the novel products listed above, the existence of dual- or poly-use, and product use as a function of demographics (i.e., age, gender, race/minority status, income status, education, current employment and student status); (2) to examine the association between various factors (i.e., favorable social images, risk perceptions, perceived benefits, personality traits) and quantity and frequency of use; (3) to examine why subjects use/change products, their order of product adoption, how they learned about the product, and their exposure and receptivity to advertising messages; (4) to chart the association between novel product use and traditional tobacco product use and dependence; and (5) to examine predictors of use. Investigators will conduct two questionnaire-based assessments 10 months apart in approximately 900 young adults who have been followed since childhood by the Oregon Youth Substance Use Project. Investigators will also conduct follow-up interviews with 300 and 225 participants, respectively, after each of the two assessments. Findings will provide information that can inform tobacco regulatory activities and future epidemiological studies that assess pathways to tobacco use at a critical developmental stage.

Judy Andrews Funding Mechanism: National Institutes of Health- Grant
ID number: 3 R01 DA010767-15S2
Institution: Oregon Research Institute
02/04/2013

Interviews with Tobacco Retailers to Inform Retailer Education

Tobacco retailers are responsible for complying with FDA regulations related to the sale, distribution, and marketing of cigarettes and smokeless tobacco, which were designed in part to reduce tobacco initiation and use among youth, and face penalties if they do not comply. The goal of this project is to better understand the factors impacting retailer compliance with FDA regulations, including (but not limited to) awareness and understanding of new tobacco regulations; conceptualization of the health risks associated with tobacco and nicotine; perceptions of the addictiveness of nicotine and youth vulnerability to addiction; self-efficacy around regulation implementation; and motivators and rewards for compliance. This project includes three phases. Phase 1 was a literature review that described the retailer “audience” and summarized what is known about retailer beliefs, practices, and communication programs (completed in 2011). Phase 2 involved 20 interviews with key stakeholders, such as leaders of retailer trade associations, community members, law enforcement personnel, and health educators (completed in 2012). Phase 3, to be completed in Spring 2014, will involve 99 telephone and in-person interviews with tobacco retailers in Seattle, WA, Raleigh-Durham, NC, and Cleveland, OH. Phase 3 participants will include a representative mix of roles (e.g., owners, managers, clerks), business sizes (e.g., mom-and-pop stores, small retail chains, large retail chains), and locations (e.g., urban, suburban, rural); interview topics will include retailer motivations, attitudes, behaviors, communication practices, influencers and compliance challenges related to new tobacco regulations. These research efforts may provide FDA with insights into the decision-making processes of tobacco retailers, and may inform the development of retailer communication strategies and a targeted educational campaign. 

Sarah Thorne and Greta Tessman Funding Mechanism: Research Contract
ID number: HHSF223200510007I / HHSF22301003T
Institution: Decision Partners
01/01/2013

microRNA as Noninvasive Biomarkers for Tobacco Smoke Associate Bladder Cancer

Recent epidemiological studies have strengthened the association between cigarette smoking and bladder cancer. Changes in cigarette composition over the past 50 years, including increased concentration of β–napthylamine (a known bladder carcinogen) and tobacco-specific nitrosamines, may contribute to the stronger association between cigarette smoking and bladder cancer. However, few biomarkers of smoking-induced bladder cancer exist. microRNA expression patterns found in body fluids (i.e. blood and/or urine) may mirror microRNA changes in bladder tumors and could be potentially be used as noninvasive early biomarkers for bladder cancer diagnosis or to distinguish between bladder cancers in smokers and non-smokers. The goal of this study is to investigate new microRNA biomarkers of bladder cancer that are affected by tobacco product use. Specific aims are: (1) to identify and compare the genome-wide microRNA profiles in serum and urine samples from bladder cancer patients (smokers and non-smokers) and individuals without bladder cancer (smokers and non-smokers) using Next Generation sequencing; (2) to correlate biofluid microRNA biomarkers with changes in tumor specimens from bladder cancer patients; and (3) to identify the differential expression patterns of blood and/or urine microRNA in patients with smoking-associated and non-smoking-associated bladder cancer. Identification and validation of novel biomarkers may inform FDA-CTP’s mission to promote and protect the public health.

Xi Yang / Patricia Richter Funding Mechanism: JV
ID number: C12050/E0751801
Institution: National Center for Toxicological Research
12/20/2012

Rural Smokeless Focus Groups – Strategic Concept Testing with Rural Adolescent and Young Adults

In support of FDA’s efforts to reduce tobacco use or prevent tobacco initiation among youth, CTP will conduct a qualitative research study to inform the development of appropriate messaging for a smokeless tobacco prevention campaign. The specific aim of the study is to understand the reactions to various campaign strategic concepts of rural males ages 12-17 who are at risk for smokeless tobacco initiation or who are experimenting with smokeless tobacco. Sixteen focus groups with six to eight participants each will be conducted in four locations with a total of 106 at-risk rural white male youth. This study is the second part of a phased approach to formative research for developing the smokeless tobacco prevention campaign. (Project completed in February 2014.)

Matthew Walker and Kara Marsh Funding Mechanism: Research contract
ID Number: HHSF223201210039I
Institution: Fors Marsh Group
12/20/2012

Focus Group Study of Youth Reactions to Tobacco Prevention Campaign Messaging (General Market At-Risk Youth Tobacco Prevention Wave 2 Phase 1)

In support of FDA’s efforts to reduce or prevent tobacco use by youth, CTP will conduct a study to inform the development of educational advertisements that have the greatest potential to discourage initiation of cigarette smoking by youth ages 12-17. The specific aim of the study is to assess the emotional and cognitive reactions to creative advertising concepts and messages designed to reduce youth cigarette smoking. Twenty-four focus groups will be conducted with 127 youth who were either open to smoking or already experimenting with cigarettes. Participants will be exposed to up to ten creative advertising concepts or six strategic messaging concepts, after which they will answer questions regarding message comprehension, relevance, and impact. This study is the first part of a phased approach to formative research for the second wave of advertisements for “The Real Cost,” the FDA’s national tobacco prevention campaign targeting at-risk youth. (Project completed in March 2015.)

Tesfa Alexander and Charlie Cook Funding Mechanism: Research contract
ID Number: HHSF22301002T
Institution: Draftfcb
12/20/2012

Online Quantitative Study of Youth Reactions to Rough-Cut Advertising Designed to Prevent Youth Tobacco Use among General Market Youth (Wave 2)

In support of FDA’s efforts to reduce or prevent tobacco use by youth, CTP will conduct a study to obtain youth reactions to a series of CTP-developed advertisements intended to prevent cigarette smoking. The specific aim of the study is to assess whether the advertisements were understandable and engaging, and whether there might be any unintentional negative consequences as a result of viewing the advertisement. A total of 1,261 youth ages 13-17 will be randomly assigned to either view or not view advertisements (i.e., exposure or control condition) online. All participants will be asked about their tobacco use and exposure, and about their attitudes and beliefs about cigarettes and smoking. Those who view advertisements will also complete a questionnaire to assess whether the advertisements provide understandable and engaging messages about the harms of cigarette smoking. This is the second part of a phased approach to formative research to identify the most promising advertisements for the second wave of “The Real Cost” campaign. (Project completed in June 2015.)

Tesfa Alexander and Charlie Cook Funding Mechanism: Research contract
ID Number: HHSF223201210039I
Institution: Draftfcb
12/20/2012

Wave 3 Phase 1 Qualitative Research: General Market At-Risk Youth Tobacco Prevention Focus Groups

In 2014, FDA launched its first youth tobacco prevention campaign, “The Real Cost,” targeting youth ages 12-17 who are at risk of initiating cigarette use or who have experimented with cigarettes. To keep the target audience engaged with the campaign, FDA will research new smoking prevention advertisements. In support of these efforts, CTP will conduct a qualitative research study to inform the development of the new advertisements. The specific aim of the study is to identify those advertisements that have the greatest potential to discourage tobacco initiation. An estimated 197 youth ages 12-17 will participate in focus groups designed to explore their reactions to a new set of strategic and creative advertisement concepts for “The Real Cost” campaign. (Project completed in May 2016.)

Tesfa Alexander and David Cortes Funding Mechanism: Research contract
ID Number: HHSF223201210039I
Institution: FCB Garfinkel
12/20/2012

Rural Smokeless Ethnographies – Digital Research Interviews with Adolescent Males

In support of FDA’s efforts to reduce or prevent tobacco use by youth, CTP will conduct a qualitative research study to inform the development of digital campaign elements to be used in public education campaigns. The goal of the study is to gain insight into use of digital technologies by at-risk youth so that the digital messages, strategies, and materials designed for the campaign would be authentic, persuasive, and reflective of the target. The specific aim is to understand how youth at risk for smokeless tobacco use interact with digital media, including when they are online, what they do online, what devices they use to access the Internet, what sites they visit, and how their digital behavior is affected by their environment. In-depth in-home interviews will be conducted with nine at-risk rural white male youth ages 12-17 at risk for smokeless tobacco use. This study is the second part of a phased approach to the formative research to inform development of the rural smokeless prevention campaign. (Project completed in July 2014.)

Matthew Walker and Kara Marsh Funding Mechanism: Research contract
ID Number: HHSF223201210039I
Institution: Fors Marsh Group
12/20/2012

Non Trier Phase 1: Focus Group Study of Youth Reactions to Tobacco Prevention Campaign Messaging

In support of FDA’s efforts to reduce or prevent tobacco use by susceptible youth, CTP will conduct an online qualitative research study with the goal of informing the development of appropriate anti-tobacco messaging. The specific aim is to obtain insight into consumer perceptions related to cigarette smoking initiation and initial perceptions of tobacco prevention messaging concepts. Sixty youth ages 12-17 who have never tried tobacco products will be grouped into four online discussion groups of 15 respondents each based on age and self-reported “openness” to trying tobacco. The online discussion groups will take place over a three-day period, during which participants will be exposed to strategic messaging approaches and asked to “blog” their responses. An online moderator will prompt youth to answer questions regarding understanding, relevance, appeal, and motivation of the concepts shared, ultimately converging on the most promising strategic concepts. The results of this study will serve as the foundation for creative concept development for the campaign. (Project completed in May 2014.)

Matthew Walker and Tanya White Funding Mechanism: Research contract
ID Number: HHSF22301002T
Institution: DraftFCB
12/20/2012

Focus Group Study of Youth Reactions to Tobacco Prevention Campaign Messaging (Experimenter Phase 1)

In support of FDA’s efforts to reduce or prevent tobacco use by susceptible youth, CTP will conduct a qualitative research study with the goal of informing the development of appropriate campaign messaging. The specific aim is to gain insight into consumer perceptions related to cigarette smoking initiation and initial perceptions of tobacco prevention messaging concepts. Focus groups will be conducted with 68 youth who have experimented with cigarettes grouped by grade, gender, and menthol use preference. Discussions will be conducted to assess their perceptions about advertising concepts designed to reduce youth tobacco use. This study is the first part of a phased approach to formative research for the national campaign targeting at-risk youth, and the results will provide the foundation for creative concept development. [Project completed in June 2014.)

Matthew Walker and Tanya White Funding Mechanism: Research contract
ID Number: HHSF22301002T
Institution: Draftfcb
12/20/2012

Rural Smokeless Ethnographies – In-depth Interviews with Rural Adolescents and Young Adults

In support of FDA’s efforts to reduce or prevent tobacco use by youth, the Center for Tobacco Products will conduct a qualitative study with rural white males ages 14-17 who are at risk for smokeless tobacco use. The goal of the study is to inform the development of a rural smokeless campaign that is authentic, persuasive, and reflective of the target. The specific aim is to explore the participants’ attitudes and beliefs regarding tobacco use, as well as their habits, activities, preferences, and perceptions of daily life. A series of interviews will be conducted with nine teenage boys in Iowa and Kentucky; three boys will complete one-on-one interviews, while the other six will participate in two peer group interviews with three boys each. This study is the first part of a phased approach to formative research to develop and implement a public health education campaign to reduce smokeless tobacco use by rural males ages 12-17. (Project completed in July 2014.)

Matthew Walker and Kara Marsh Funding Mechanism: Research contract
ID Number: HHSF223201210039I
Institution: Fors Marsh Group
12/20/2012

Online Quantitative Study of Youth Reactions to Tobacco Prevention Campaign Messaging (Experimenter Phase 2)

In support of FDA’s efforts to reduce or prevent youth tobacco use, CTP will conduct an online quantitative study to assess the effectiveness of its anti-tobacco messaging with youth who have experimented with cigarettes. The specific aim of this study is to determine whether rough-cut advertisements designed to prevent youth cigarette use provided an understandable and engaging message about the harms of tobacco use without potential unintended adverse or counterproductive effects. A total of 1,600 experimenters aged 13-17 will be assigned to either an advertisement viewing group (n=1,376) or a no-advertisement control group (n=224). All participants will be asked about their attitudes and beliefs about the harms of tobacco use. In addition, after viewing two of six advertisements, participants in the advertisement viewing group will be asked about the advertisements’ effectiveness and about their cognitive and emotional responses. This study is the second and last phase of formative research to inform the development of FDA’s national youth tobacco prevention campaign. (Project completed in September 2014.)

Tesfa Alexander and Tanya White Funding Mechanism: Research contract
ID Number: HHSF223201210039I
Institution: Draftfcb
12/20/2012

Rural Smokeless Creative Concept Testing – Focus Groups with Rural Youth

In support of FDA’s efforts to reduce or prevent tobacco use by youth, CTP will conduct a qualitative study to inform the development of a targeted tobacco prevention campaign. The target of the campaign is rural white (non-Hispanic) male youth ages 12-17 who are at risk for using or experimenting with smokeless tobacco. The specific aim of the study is to obtain feedback on creative concepts developed for the campaign. Twenty-four focus groups with four to eight participants each will be conducted with 146 youth who fit the criteria of the target audience. Discussions explored the participants’ reactions to six creative concepts. This study is the third part of a phased approach to formative research to develop the rural smokeless campaign. (Project completed in August 2016.)

Matthew Walker and Kara Marsh Funding Mechanism: Contract
ID Number: HHSF223201210039I
Institution: Fors Marsh Group
12/20/2012

Online Quantitative Study of Youth Reactions to Rough-Cut Advertising Designed to Prevent Youth Tobacco Use among General Market Youth (Wave 3)

In support of FDA’s efforts to inform the public on tobacco-related health issues, the Center for Tobacco Products (CTP) is conducting research to assess rough-cut advertisements designed for one of its youth tobacco prevention campaigns. The goal of this project is to gain insight into youth perceptions of four new rough-cut advertisements developed for CTP’s “The Real Cost” campaign to determine whether they provide an understandable and engaging message about the harms of tobacco use without unintended adverse or counterproductive effects. The target audience for this campaign is youth aged 12-17 youth who have experimented with cigarettes or who are at risk of initiating cigarette use. A sample of 1,292 youth will be recruited via mall intercepts across the United States, and the quantitative data collection will be administered via an online survey system that solicits feedback about the four new advertisements. This is the final part of a phased approach to formative research to identify a new set of messages intended to keep the target audience engaged with the campaign.

David Cortés and Tesfa Alexander Funding Mechanism: Research Contract
ID number: HHSF223201210039I
Institution: Foote, Cone, & Belding (FCB) New York
12/20/2012

Rural Smokeless Campaign: Online Copy Testing of Youth Reactions to Advertising Designed to Prevent Smokeless Tobacco Use

Most smokers and smokeless tobacco users initiate use prior to age 18; rural youth are at particular risk of initiating smokeless tobacco use. The goal of this quantitative study is to assess youth reactions to a series of advertisements intended to prevent the use of smokeless tobacco. The target audience is rural white males aged 12 to 17 years who are at risk for using or experimenting with smokeless tobacco. Study aims are: (1) to determine whether the advertisements are understandable and engaging; and (2) to determine whether any unintentional negative consequences result from viewing the advertisements. Up to 798 youth who fit the criteria of the target audience will be asked to complete a survey focusing on smokeless tobacco knowledge, attitudes and beliefs; a subset of participants will also view advertisements intended to prevent smokeless tobacco use. The survey responses of the advertisement viewers will be used to assess overall advertisement performance; in addition, these responses will be compared to those of participants who did not view the advertisements in order to determine whether any unintended consequences result from viewing the advertisements. This study is the fourth part of a phased approach to formative research that will inform the development of an evidence-based smokeless tobacco use prevention campaign. (Project completed in January 2016.)

Kara Marsh and Matthew Walker Funding Mechanism: Research Contract
ID number: HHSF223201210039I
Institution: Fors Marsh Group
12/20/2012

Population Assessment of Tobacco and Health: Fibrinogen Activity Assay in the Field Study

The Tobacco Control Act mandates the regulation of tobacco products using a population health standard including both users and non-users of tobacco products. To help meet this mandate, the Population Assessment of Tobacco and Health (PATH) study — a nationally representative, longitudinal cohort study that will survey tobacco product users, never users, and former users including youth aged 12-17 and adults aged 18 and older – is gathering data on tobacco product use, attitudes, and health conditions and is collecting biological specimens (buccal cells, urine, and blood) from consenting adults. Quest Diagnostics Clinical Laboratories, a private contract laboratory that assays human biological specimens for diagnostic purposes as well as for chemical exposure, will measure human fibrinogen activity in 150 participant plasma samples. These data may inform the development of final baseline study procedures related to the collection, shipment, processing, storage, and requisitioning of biospecimens.

Dana van Bemmel Funding Mechanism: Research Contract
ID number: HHSF223201300052P
Institution: Quest
12/01/2012

Development of a Cingulate-striatal Addiction Circuit in a Rodent Model of Nicotine Dependence

A circuit in the human brain between the dorsal anterior cingulate (dACC) and the ventral striatum (VS, including the nucleus accumbens and extended amygdala) has been linked to nicotine dependence severity; however, it is unclear if changes in the circuit reflect a consequence of neuroplastic changes during the addiction process or if they were pre-existing, thus reflecting intrinsic neuronal processes that predispose an individual to develop nicotine dependence. The goal of this project is to develop a functional magnetic resonance imaging (fMRI) rodent model of nicotine dependence as a biomarker of addiction, and to evaluate the utility of this circuit as a signal that can be used to evaluate potentially addictive constituents of tobacco products. Adult rats will receive intermittent delivery of nicotine (approximating the phasic nicotine delivery that is experienced by human users) via osmotic mini-pumps for seven days. fMRI scans will be conducted prior to, during, and up to 21 days following drug administration. Precipitated nicotine withdrawal will be assessed as a behavioral correlate of circuit strength alterations with nicotine dependence.  Study aims are: (1) to develop a rodent fMRI model of nicotine dependence; (2) to determine the dose range and time to alter the dACC-VS circuit; (3) to determine the relationship between objective behavioral indicators of dependence severity (e.g., precipitated nicotine withdrawal) and circuit strength; and (4) to investigate alterations in the levels of two key neurotransmitters important in addiction, gamma-aminobutyric acid (GABA) and glutamate, in both nodes of the circuit (i.e., dACC and VS). This study may identify biomarkers of addiction that can be used to inform FDA about the abuse liability of tobacco constituents and emerging products.

Elliot Stein Funding Mechanism: Interagency Agreement
ID number: 224-13-9001
Institution: National Institutes of Health (NIH)
11/20/2012

LGBT Young Adult Tobacco Use Prevention Campaign: Copy Testing

In support of FDA’s efforts to inform the public on tobacco-related health issues, the Cent er for Tobacco Products (CTP) will conduct research to assess reactions to creative concepts developed for CTP’s smoking prevention campaign designed to prevent lesbian, gay, bisexual, and transgender (LGBT) young adults from smoking cigarettes. The target audience for this campaign is young adults ages 18-24 years who identify as LGBT and are non-daily smokers. The specific aim is to assess whether the concepts provide an understandable and engaging message about the harms of tobacco use without potential unintended adverse or counterproductive effects. Participants (n=1,150) will be recruited for an online survey at LGBT social venues, through advertisements on social media, and through an online research panel. This is the second part of a phased approach to formative research to identify the most promising advertisemsents for the LGBT smoking prevention campaign.

Leah Hoffman and Mayo Djakaria Funding Mechanism: Research contract
ID Number: HHSF223201210006I
Institution: Rescue Social Change Group
11/20/2012

Multicultural Youth Tobacco Prevention Campaign: Pilot (Brand and Creative Concept Phase)

In support of FDA’s efforts to reduce or prevent tobacco use by youth, CTP will conduct a study to inform the development of a targeted tobacco prevention campaign. The target of the campaign is youth ages 12-17 who identify with hip hop culture; are Black/African American, Hispanic, and/or Asian/Pacific Islander; and have either tried cigarettes or report risk factors for initiating cigarette smoking. The specific aim is to gain insight into their perceptions related to potential campaign brands and preliminary concepts for campaign creative concept development. Eighty youth who meet the criteria of the target audience will be recruited to participate in focus groups at middle and high schools. The discussions will address comprehension, relevance, and impact of the presented campaign brand and creative concepts. This study is the first part of a phased approach to the formative research for developing and implementing the campaign. (Project completed in March 2014.)

Matthew Walker and Dana Wagner Funding Mechanism: Research contract
ID Number: 201210006I
Institution: Rescue Social Change Group
11/20/2012

Multicultural Campaign: Wave 3 Focus Group Study of Reactions to Creative Advertising Concepts Designed to Prevent Multicultural Youth Tobacco Use

In support of FDA’s efforts to inform the public on tobacco-related health issues, the Center for Tobacco Products (CTP) will conduct research to inform the development of messaging and creative concepts for the “Fresh Empire” youth tobacco public education campaign. The target audience for this campaign is at-risk multicultural youth (i.e., youth who are African American, Asian/Pacific Islander, or Hispanic) who are 12-17 years old and are influenced by Hip Hop culture. Focus groups will be conducted with 180 youth in the target audience who are at risk for, have experimented with, or are susceptible to smoking cigarettes, little cigars, cigarillos, or hookah. Participants will be recruited from middle and high schools in multiple metropolitan areas representing the campaign target population. Each 90-minute focus group will include 3-12 participants, and will involve a discussion of preliminary creative concepts being developed for the “Fresh Empire” campaign. The purpose is to gain insight into youth perceptions related to tobacco use and creative concepts to inform campaign development.

Dana Wagner and Matthew Walker Funding Mechanism: Research Contract
ID number: HHSF223201210006I
Institution: Rescue Social Change Group
11/20/2012

LGBT Campaign: Focus Group Study of Brand and Creative Concepts Designed to Prevent LGBT Young Adult Tobacco Use

In support of FDA’s efforts to inform the public about tobacco-related health issues, protect public health, and reduce harm caused by cigarette smoking, CTP will conduct a study to inform the development of an educational campaign targeting lesbian, gay, bisexual and transgender (LGBT) young adults. The specific aim is to identify the most promising campaign brand and creative concepts, as well as areas for further refinement, to guide creation of effective advertisements. Twenty-eight focus groups will be conducted with up to 224 young adults ages 18-24 who identify as LGBT and who have smoked at least one cigarette within the past 30 days, but who have not smoked every day. The study is the first part of a phased approach to formative research providing the foundation for developing the campaign.

Leah Hoffman and Mayo Djakaria Funding Mechanism: Contract
ID Number: HHSF223201210006I
Institution: Rescue Social Change Group
11/20/2012

Multicultural Youth Tobacco Prevention Campaign: Copy Testing Wave 2

In support of FDA’s efforts to inform the public on tobacco-related health issues, the Center for Tobacco Products (CTP) is conducting research to assess the effectiveness of educational messages about the harms of tobacco use designed to prevent youth from smoking cigarettes. This project focuses on a specific target audience: at-risk multicultural youth (i.e., youth who are African American, Asian-Pacific Islander, Hispanic, or Multiracial) who are 12-17 years old and are influenced by the Hip Hop peer crowd. Hip Hop-influenced youth were chosen as the campaign target audience because they are a relatively prominent youth peer crowd and demonstrate above-average rates of smoking prevalence. The project’s goal is to assess whether a set of messages developed for this target audience are understandable and engaging without producing unintended adverse or counterproductive effects. Up to 1,410 Hip Hop youth ages 12-17 years old will view four rough-cut video ads and complete a copy testing questionnaire. Study findings will be used to clear the rough-cut ads to be aired as part of the Fresh Empire campaign. (Study completed in 2015.)

Dana Wagner and Matthew Walker Funding Mechanism: Research Contract
ID number: HHSF223201210006I
Institution: Rescue Social Change Group
11/20/2012

Multicultural Campaign Wave 2: Focus Group Study of Youth Reactions to Creative Advertising

In the U.S., Asian, African American, and Hispanic youth who are influenced by hip hop culture are at particular risk of tobacco use. The goal of this project is to conduct formative research to inform the development of messaging and creative concepts for the FDA Center for Tobacco Products (CTP) Multicultural Youth Tobacco Prevention Campaign.  The target audience for this campaign is at-risk multicultural youth (i.e., youth who are African American, Asian/Pacific Islander, or Hispanic/Latino) aged 12-17 years who are experimenting with or at risk for tobacco use, and are influenced by hip hop culture. Data will be collected during 19 school-based focus groups with approximately eight participants per group. Focus group activities will include discussions and survey activities to gain insight into youth perceptions of cigarettes, smoking, and tobacco-related facts, as well as their reactions to creative concepts to inform campaign development.  This study is the first phase in the development of new messaging for the second wave of the Multicultural Campaign to prevent tobacco use among this at-risk population. (Project completed in February 2016.)

Dana Wagner and Matthew Walker Funding Mechanism: Research Contract
ID number: HHSF223201210006I
Institution: Rescue Social Change Group
10/01/2012

Epigenetic Biomarkers of Tobacco Smoke Exposure

In previous research, the investigators used genomic arrays to identify specific DNA methylation changes associated with maternal smoking; they have identified a set of epigenetic biomarkers as well as mechanistic pathways for transplacental and adult smoking-associated diseases. The goal of the study is to extend these findings by examining the dose, time course, and persistence of the epigenetic changes spurred by tobacco product use, identifying the target cells for epigenetic-mediated change, and characterizing toxic effects at the molecular and cellular level. Study aims are: (1) to test the previously-developed methylation biomarker profile in DNA samples from 230 adult subjects with well-characterized smoking histories including measurements of cotinine, chromosome aberrations, somatic gene mutations, and genetic polymorphisms; (2) to conduct a prospective cohort study (including approximately 500 subjects with smoking-induced bladder cancer and 500 controls) to test the relationship between tobacco exposure, methylation biomarkers, and risk of developing tobacco-induced bladder cancer in order to evaluate the biomarkers’ predictive value; (3) to test the methylation biomarker in blood and other tissues from newly-recruited tobacco product users in order to determine the best tissue for regulatory-related population monitoring, assess profiles of DNA methylation and identify biomarkers that are shared by or unique to a specific tobacco exposure, and examine samples from recent quitters to determine the persistence of biomarkers; subjects will include never smokers, light smokers (1 pack day), ex-smokers (6-12 months), menthol smokers, smokeless tobacco users, and e-cigarette users; and (4) to determine target cell types in blood (i.e., lymphoid, granulocytes, erythroid, and CD34+ cells) and compare the relationship between exposure, methylation, and gene expression to improve accuracy and sensitivity of the tobacco exposure biomarker. This study will reveal important epigenetic biomarker effects related to tobacco use, particularly with regard to the specific cell types affected, and will make connections between epigenetic biomarkers of effect, intermediate molecular phenotypes and tobacco-induced disease outcomes that could support regulatory review of the biomarker.

Douglas Bell Funding Mechanism: National Institutes of Health-Intramural
ID number: 251945
Institution: National Institute of Environmental Health Sciences (NIEHS)
10/01/2012

Genetics of Cellular Sensitivity to Tobacco Compounds

Tobacco compounds damage vascular endothelial cells (VECs) and vascular smooth muscle cells (VSMCs), often with life-threatening consequences. Tobacco’s effects on vascular integrity vary across individuals, suggesting that genetic variations contribute to differences in patient outcomes; however, the genetic components of tobacco-induced vascular disease susceptibility are unknown. The investigators will use induced pluripotent stem cell (iPSC) technology to investigate the susceptibility of patient-specific VECs and VSMCs to tobacco compounds and determine the effects of these compounds on genetically-susceptible individuals. Study aims are: (1) to determine the impact of 20 known and suspected toxic tobacco smoke compounds on patient-specific vascular cells to define individual susceptibility; and (2) to develop iPSC lines engineered for high-throughput screening of tobacco component chemicals and chemical admixtures. The investigators will generate patient-specific iPSC lines from 20 subjects (10 long-term smokers with severe coronary artery disease and 10 long-term smokers without coronary artery disease). These 20 iPSC lines will be differentiated into VECs and VSMCs in order to survey the genetic bases of vascular susceptibility/resistance to tobacco smoke. Investigators will individually test 20 tobacco smoke components for adverse effects on the iPSC lines using an 8-dose range of each chemical and a 1-5 biomarker assay endpoint. A second verification screen will contain 10 patient-specific iPSC lines from smokers unrelated to the initial patient population. Information from this study may inform the development of new biomarkers that will distinguish the impact of different tobacco products on vascular disease.

Manfred Boehm Funding Mechanism: National Institutes of Health-Intramural
ID number: 252406
Institution: National Heart Lung and Blood Institute (NHLBI)
10/01/2012

Genetic Factors in Taste Perception and Tobacco Usage

The importance of taste in tobacco product use is underscored by the widespread addition of flavorings to tobacco products. Added flavorings – including various sweeteners, fruit flavors, and menthol – improve product taste while masking the unpleasant flavor of nicotine and other bitter substances present in tobacco. Understanding genetic differences in taste perceptions in the context of tobacco use could help inform the development of more effective tobacco control campaigns targeted toward specific racial/ethnic population groups. To investigate the role of inherited differences in taste perceptions in tobacco use, researchers will catalog and quantify genetic variations in taste perceptions and then measure the association between these variations and tobacco use. Using DNA samples provided by the Dallas Heart Study (DHS) – a comprehensive multi-year study of cardiovascular health involving 4,700 subjects (including approximately 2,300 African Americans, 1,600 Caucasians and 800 Latinos) – the investigators will analyze 36 genes that encode a variety of taste perceptions, including menthol, bitter, sweet and savory, sour, and burning tastes. Study aims are: (1) to ascertain and characterize naturally occurring genetic variations in taste perceptions; (2) to use detailed genetic analysis and modeling techniques and tools to describe variations in taste perception characteristics (i.e., mutation properties, functional predictions, genomic architecture, and population distribution); and (3) to test the association between variants in taste perception and other genes and tobacco use using data from the Dallas Heart Study population. By analyzing variation in a broad array of genes involved in taste perception, this study will separate genetic variation in taste perceptions – much of which is specific to particular human racial populations – from other factors that affect tobacco use.

Dennis Drayna Funding Mechanism: National Institutes of Health-Intramural
ID number: 252311
Institution: National Institute on Deafness and Other Communication Disorders (NIDCD)
10/01/2012

Multi-model Neuroimaging Genetic Biomarkers of Nicotine Addiction

Emerging evidence suggests a biological basis for nicotine addiction; however, no consensus biomarkers that can objectively measure nicotine addiction severity, follow the trajectory of developing addition, or predict outcome for tobacco users exist. The goal of this project is to develop a quantitative, genetically-informed, brain-based nicotine addiction biomarker that predicts smoking and smokeless tobacco adverse health outcomes, quantifies addiction severity and reflects the addiction potential of alternative tobacco products. Study aims are: (1) to determine whether support vector machine (SVM)/network pattern classifiers identify ex-smokers as “current smokers” or “never smokers,” and whether SVM/network classification can separate non-treatment seeking smokers from treatment seekers; (2) to determine whether switching cigarette smokers to e-cigarettes yields a unique biomarker pattern that distinguishes them from smokers, ex-smokers and nonsmokers; (3) to determine whether changes in biomarkers predict successful tobacco use cessation; and (4) to determine the time course of biomarker changes as a function of abstinence duration. Subjects will include treatment-seeking smokers and three comparison groups: ex-smokers, non-treatment-seeking smokers, and healthy controls aged 18-55. The biomarker will be created using neuroimaging, genotyping and epigenetic data with multivariate feature selection techniques. Researchers will first engage subjects in a 12-week monitored cessation phase (with e-cigarettes substituting for tobacco cigarettes), which will allow an assessment of addiction severity based on withdrawal symptoms; anatomical and functional measures will be taken before a quit attempt and post-quit at days 2 and 7 and again at 3, 6 and 12 months. Analysis of neuroanatomical, functional activation and resting data, informed by genetic markers, will classify cigarette smokers by addiction severity, differentiate traditional smokers from alternative tobacco users, and describe brain circuits that follow dependence severity and predict outcome success or failure.

Elliot Stein Funding Mechanism: National Institutes of Health-Intramural
ID number: 252400
Institution: National Institute on Drug Abuse (NIDA)
10/01/2012

Identification of Active Component Patterns in Tobacco Smoke

The majority of the thousands of compounds present in tobacco smoke have not been structurally identified, nor have their pharmacological activities been determined. In previously published research, investigators described an improved technique – called missing peak chromatography – for determining the pharmacologically active components of tobacco smoke based on online liquid chromatography affinity screens; the investigators demonstrated that a column containing immobilized nicotinic acetylcholine receptors (nAChRs) can be used to screen tobacco smoke condensates, to identify known and unknown compounds that bind to individual nAChR subtypes, and to produce a chromatographic fingerprint that can be used to establish active component patterns (ACPs). The goals of this project are to use missing peak chromatography to optimize and validate the determination of ACPs, to establish the role of this technique in the regulation of tobacco products, and to determine the effect of additives on the products produced by tobacco leaf combustion. Study aims include: (1) to screen tobacco smoke condensates obtained from standard, light and flavored cigarette brands for compounds that bind to the nAChRs and to establish ACPs; (2) to determine the binding affinity and functional activity of individual compounds contained in the ACP at several nAChR subtypes, and to determine if the compounds are agonists, competitive or non-competitive antagonists, and positive or negative allosteric modifiers; (3) to repeat the study using extracts from the same cigarettes used to obtain the tobacco smoke condensates in order to compare the ACPs, to identify the source of active components in the tobacco smoke condensates, and to establish ACPs that can be used to control tobacco products; and (4) to determine whether menthol affects the pyrolysis of tobacco leaf constituents that interact with nAChRs and whether vaporized menthol affects the binding of tobacco smoke condensate constituents with nAChRs. The study methodology will use missing peak chromatography to analyze tobacco smoke extracts and condensates and to characterize the pharmacological activity of compounds at the nAChR; the analysis will be repeated using non-combusted cigarettes and again after adding menthol to the tobacco leaves before combustion.

Irving Wainer Funding Mechanism: National Institutes of Health-Intramural
ID number: 252346
Institution: National Institute on Aging (NIA)
10/01/2012

Epigenomic Effects of Hookah Tobacco Smoke in Human Respiratory Epithelia

The decreasing prevalence of cigarette smoking in the U.S. has coincided with the emergence of alternatives such as smoking flavored tobacco (shisha) via waterpipe (hookah). Although hookah smoke contains a number of carcinogens present in cigarette smoke, epidemiologic associations between hookah tobacco and lung cancer risk have not been firmly established, and the effects of hookah smoke on human respiratory epithelial cells have not been thoroughly investigated. The goal of this study is to determine whether, like cigarette smoke, hookah tobacco smoke will induce lung cancer-associated alterations in normal human respiratory epithelia in a time- and dose-dependent manner, and whether hookah smoke will increase stem cell signaling and enhance the malignant phenotype of human lung cancer cells. Study aims are: (1) to compare the effects of hookah tobacco and conventional cigarette smoke on DNA methylation, the histone code and global gene expression in cultured normal human respiratory epithelia and lung cancer cells; (2) to compare the effects of hookah tobacco and conventional cigarette smoke on microRNA expression in normal respiratory epithelia and lung cancer cells; (3) to compare the effects of hookah smoke and conventional cigarette smoke on stem cell gene expression in normal respiratory epithelia and lung cancer cells; and (4) to examine if hookah smoke enhances the malignant phenotype of lung cancer cells. Briefly, human small airway epithelial cells, human bronchial epithelial cells, and lung cancer cells derived from smokers and never-smokers will be cultured in the presence or absence of hookah or cigarette smoke condensates for up to 24 months. The investigators will perform various analyses and experiments to examine the effects of hookah smoke on DNA methylation, messenger RNA and microRNA profiles, and the histone code relative to the effects of conventional un-mentholated and mentholated cigarette smoke. They will also perform comparative genomic hybridization and DNA/RNA sequencing experiments to evaluate DNA mutations induced by hookah tobacco relative to conventional cigarette smoke. Additional experiments will determine if hookah smoke enhances the malignant phenotype of lung cancer cells. Results of these analyses will provide insights about hookah tobacco’s carcinogenic effects.

David Schrump Funding Mechanism: National Institutes of Health-Intramural
ID number: 252451
Institution: National Cancer Institute (NCI)
10/01/2012

Impact of Tobacco Oral Health and the Oral Microbiome

Tobacco use is the primary cause of periodontal disease and causes other health consequences in the oral cavity including leukoplakia and cancers of the head and neck. Periodontal disease and the resulting tooth loss have been linked to other adverse health consequences including diabetes, heart disease, stroke, and premature births; gum bleeding associated with periodontal disease leads to chronic exposure to oral microbes, causing persistent inflammation and exposure to toxic secondary bacterial metabolites. However, no previous study has characterized the oral microbiome (i.e., the complete oral bacterial population) and assessed the effect of tobacco on oral bacteria in a large representative sample of the U.S. population. The goal of this study is to conduct a comprehensive assessment of the association between tobacco use and oral health measures using data from two cycles (2009-2010 and 2011-2012) of the National Health and Nutrition Examination Survey (NHANES), an extensive exposure and health information survey of a nationally representative sample of the U.S. population with oversampling of persons aged 60 and older, African-Americans, Asian-Americans, and Hispanics. Study aims are: (1) to characterize the association between tobacco and oral health in 11,000 NHANES participants (men and women aged 14-69; approximately 55% never smokers, 20% former smokers, 23% current smokers, and 2% tobacco chewers); (2) to investigate the association between types of tobacco use (e.g. cigarettes, pipes, cigars, and chewing tobacco) and the oral microbiome; and (3) to investigate the association between the oral microbiome and tobacco-related diseases (e.g., periodontitis, cardiovascular and respiratory disease, diabetes, etc.) and evaluate the degree to which the oral microbiome mediates the adverse health effects of tobacco use. To achieve these aims, investigators will use data and oral wash samples already collected by NHANES. Investigators will characterize the oral microbiome by using DNA extracted from oral samples and describe the bacterial species in each sample. They will then examine the effects of tobacco on the full microbiomic community; determine whether associations vary by type of tobacco used (e.g. menthol, filter, smokeless), household tobacco exposure, and ethnicity; and evaluate associations with tobacco-related diseases. Characterizing the effect of tobacco use on the oral microbiome may suggest new biomarkers of exposure that can be used to assess the effects of new and emerging tobacco products.

Christian Abnet Funding Mechanism: National Institutes of Health-Intramural
ID number: 252304
Institution: National Cancer Institute (NCI)
10/01/2012

Impact of Tobacco Oral Health and the Oral Microbiome (NIH-Intramural)

Tobacco use is the primary cause of periodontal disease and causes other health consequences in the oral cavity including leukoplakia and cancers of the head and neck. Periodontal disease and the resulting tooth loss have been linked to other adverse health consequences including diabetes, heart disease, stroke, and premature births; gum bleeding associated with periodontal disease leads to chronic exposure to oral microbes, causing persistent inflammation and exposure to toxic secondary bacterial metabolites. However, no previous study has characterized the oral microbiome (i.e., the complete oral bacterial population) and assessed the effect of tobacco on oral bacteria in a large representative sample of the U.S. population. The goal of this study is to conduct a comprehensive assessment of the association between tobacco use and oral health measures using data from two cycles (2009-2010 and 2011-2012) of the National Health and Nutrition Examination Survey (NHANES), an extensive exposure and health information survey of a nationally representative sample of the U.S. population with oversampling of persons aged 60 and older, African-Americans, Asian-Americans, and Hispanics. Study aims are: (1) to characterize the association between tobacco and oral health in 11,000 NHANES participants (men and women aged 14-69; approximately 55% never smokers, 20% former smokers, 23% current smokers, and 2% tobacco chewers); (2) to investigate the association between types of tobacco use (e.g. cigarettes, pipes, cigars, and chewing tobacco) and the oral microbiome; and (3) to investigate the association between the oral microbiome and tobacco-related diseases (e.g., periodontitis, cardiovascular and respiratory disease, diabetes, etc.) and evaluate the degree to which the oral microbiome mediates the adverse health effects of tobacco use. To achieve these aims, investigators will use data and oral wash samples already collected by NHANES. Investigators will characterize the oral microbiome by using DNA extracted from oral samples and describe the bacterial species in each sample. They will then examine the effects of tobacco on the full microbiomic community; determine whether associations vary by type of tobacco used (e.g. menthol, filter, smokeless), household tobacco exposure, and ethnicity; and evaluate associations with tobacco-related diseases. Characterizing the effect of tobacco use on the oral microbiome may suggest new biomarkers of exposure that can be used to assess the effects of new and emerging tobacco products.

Christian Abnet Funding Mechanism: National Institutes of Health-Intramural
ID number: 252304
Institution: National Cancer Institute (NCI)
09/24/2012

Subjective, Physiological and Puff Topography Measures and Perceptions of Flavored Little Cigars

Little cigars are tobacco products that resemble cigarettes in size, packing and nicotine levels; however, characterizing flavors (except menthol) have been banned in cigarettes, but are still permitted in little cigars. The purpose of this study is to assess whether flavored little cigars, because of their appearance or other characteristics, are perceived as cigarettes and thus are more likely to be consumed by tobacco users. In this repeated measures study, 48 cigarette smokers aged 18-55 will complete four randomized double-blind sessions after a period of overnight abstinence. During each 90-minute session, participants will be randomized to one of four groups in which they will have the opportunity to smoke two of the same-flavor little cigars or cigarettes: their own brand of cigarette, cherry-flavored little cigars, menthol-flavored little cigars, or little cigars without a characterizing flavor (“natural” or “tobacco”). Investigators will generate data including (but not limited to) measures of puff topography, physiological measures, subjective measures, and consumer perceptions of flavored little cigars. This information may elucidate whether users perceive and use little cigars as though they are cigarettes or whether little cigars represent a distinct category of tobacco products.

Wallace Bruce Pickworth / Sarah Evans Funding Mechanism: Research Contract
ID number: HHSF223201210186C
Institution: Battelle Memorial Institute
09/20/2012

Priority Setting of Harmful and Potentially Harmful Constituents (HPHCs) in Tobacco Smoke Products with Bioinformatics

Based on available information, FDA established a list of 93 HPHCs found in tobacco products and/or tobacco smoke and identified a representative subset of 20 HPHCs to be reported by tobacco product manufacturers. Well-established testing methods are available for these 20 HPHCs; however, tobacco and tobacco smoke include approximately 8,400 constituents. New scientific information about constituents may prompt FDA to add to or remove HPHCs from the current list. Unfortunately, health-related data regarding most tobacco constituents is not readily available to support informed decision-making. Some data can be extracted using bioinformatics from public domains such as PubMed. NCTR has established several bioinformatics approaches to analyze data from published literature and public databases for drug safety; investigators have successfully applied these methodologies to set drug analysis priorities based on toxicity profiles. These methodologies can be refined and modified to inform prioritization of HPHCs by health risk. The goal of this project is to identify and predict the major health endpoints associated with tobacco constituents; specific aims are: (1) to develop and apply the bioinformatics methods to prioritize the HPHCs using data from the literature and public databases, and (2) to extend the application of these methods to the entire list of tobacco and tobacco smoke constituents for priority setting. This project will facilitate an understanding of the risks of tobacco products to users and non-users, and may inform regulatory activities.

Weida Tong / Michael Orr Funding Mechanism: JV
ID number: C12038/E0750901
Institution: National Center for Toxicological Research
09/20/2012

Metabolism of Carcinogenic Tobacco-Specific Nitrosamines

Smokeless tobacco products are accepted causes of oral cavity cancer. Tobacco-specific nitrosamines such as N′-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) are recognized as likely causative agents for oral cancer in smokeless tobacco users.  In a recent study, one form of NNN called (S)-NNN was found to be a potent oral cavity carcinogen in rats.  Based on this observation, the goal of this study is to determine the likely role of (S)-NNN as a cause of oral cavity cancer in smokeless tobacco users.  Specific aims are: (1) to quantify levels of (S)-NNN in traditional and emerging smokeless tobacco products; (2) to quantify levels of (S)-NNN and (S)-NNN-N-glucuronide in the urine of smokeless tobacco users; and (3) to develop a new urinary biomarker for assessing NNN uptake in humans. To meet these aims, investigators will analyze 129 product samples representing 29 brands/flavors collected as part of an ongoing research effort and will analyze urine samples collected from 900 smokeless tobacco users. The results of this study will help define the risks associated with smokeless tobacco use and may inform FDA regulation of NNN in smokeless tobacco products.

Stephen Hecht Funding Mechanism: National Institutes of Health- Grant
ID number: 3 R37 CA081301-14S1
Institution: University of Minnesota Twin Cities
09/19/2012

Social-Emotional Contexts of Adolescent Smoking Patterns

The use of alternative (non-cigarette) forms of tobacco is gaining in popularity among young adults. This project, which builds on current research on the social and emotional contexts of adolescent and young adult smoking patterns, will examine the phenomenon of alternative tobacco use among young adults. The project involves two studies. The specific aims of the first study are: (1) to evaluate the tobacco use behaviors of individuals using new and emerging tobacco products, including multiple tobacco use behaviors; and (2) to evaluate the cognitive and affective factors associated with the use of new and emerging tobacco products. Investigators will recruit 230 young adults who regularly use alternative forms of tobacco and conduct an in-depth ecological momentary assessment of the objective (e.g., with whom, where, under what conditions) and subjective (e.g., emotional and attitudinal prompts, responses to alternative tobacco use) factors associated with use. Investigators will also assess whether acute mood changes are associated with alternative tobacco product use, and how mood and contexts interact with use and subjective experience. The second study’s specific aims are: (1) to evaluate the impact of image type on tobacco product messages and communications among young adult non-cigarette users; and (2) to evaluate how smartphone application use affects tobacco use and attitudes. Investigators will conduct a series of young adult focus groups in order to understand how smartphones are used to access health information and messages, as well as user reactions to various images and message delivery vehicles (including the use of realistic, personalized avatars to deliver messages). Based on these results, investigators will develop a smartphone application to deliver persuasive messages, test its feasibility, and assess the responses of young adult non-cigarette tobacco users. Study findings will provide data that may inform policies related to non-cigarette tobacco use.

Robin Mermelstein Funding Mechanism: National Institutes of Health- Grant
ID number: 3P01CA98262-08S1
Institution: University of Illinois at Chicago
09/19/2012

Smokeless Tobacco Use in College Students

Very little is known about individuals’ exposure to, and perceptions and use of, smokeless tobacco products such as snus and dissolvable tobacco products (i.e., strips, orbs and sticks). Markets where tobacco companies test these new products provide a unique laboratory for understanding the extent and correlates of exposure, perceptions, and use of these products in a real-world setting. Investigators will expand their ongoing research on smokeless tobacco use in college students by measuring exposure to advertising, perceptions, likelihood of trying, and use of new tobacco products in young adults (aged 18-35) in three test markets (Charlotte, NC; Denver, CO; and Wichita, KS). Specific aims are: (1) to measure awareness, exposure to advertising, perceptions, likelihood of trying, and use of snus and dissolvables by conducting a survey of 4,000 young adults; and (2) to identify individual, interpersonal and environmental correlates of exposure, perceptions, likelihood of trying, and use of these products by analyzing the survey data (for individual and interpersonal correlates) and by conducting an assessment of point-of-purchase availability, advertising and sales in 510 tobacco retailers (for environmental correlates). This information may inform the regulation of these products by creating a science base regarding their impact.

Mark Wolfson Funding Mechanism: National Institutes of Health- Grant
ID number: 3 R01 CA141643-04S2
Institution: Wake Forest University Health Sciences
09/19/2012

Framing Messages for Teen Smoking Prevention in Primary Care

Anti-smoking messages are typically framed to emphasize either the benefits of smoking avoidance (gain-framed) or the costs of smoking to health (loss-framed). Message framing theory suggests that gain-framed messages are superior to loss-framed messages for preventing teen smoking, but research in this area remains scarce. Understanding the effects of framed messages and the factors that influence message framing effects is critical to optimize their impact as a public health tool to prevent teen smoking. The goal of the study is to determine whether brief gain- and/or loss-framed messages are an effective strategy to motivate teens to use online prevention resources offered following a primary care visit. Study aims are: (1) to develop and evaluate the effects of gain- and loss-framed messages on teens’ utilization of an evidence-based online smoking prevention resource (“A Smoking Prevention Interactive Experience,” or ASPIRE) offered as an adjunct to pediatric primary care; (2) to investigate the influence of social and psychological moderators on the impact of framed messages on ASPIRE utilization; and (3) to examine the impact of framed messages and ASPIRE utilization on teens’ smoking susceptibility. Participants will include a total of 295 healthy teens (10 subjects for message development, 285 subjects for the experimental study) aged 12-17 receiving pediatric primary care. In a three-group experimental study design, subjects will receive either a gain- or loss-framed message or a generic message that will introduce teens to ASPIRE. After viewing messages, subjects will have the option to access ASPIRE online immediately with continued access for 30 days and will complete a one-month follow-up assessment of ASPIRE use and smoking-related outcomes. This study may inform national prevention strategies leveraging framed messages to prevent youth smoking, such as the use of loss-framed health warning labels on cigarette packages.

Darren Mays / Cindy Tworek Funding Mechanism: National Institutes of Health- Grant
ID number: 1 R03 CA162839-01A1
Institution: Georgetown University
09/19/2012

Evaluation of Tobacco Use and Cardiovascular Diseases

The goal of this project is to examine tobacco use patterns in a representative nationwide sample of patients with mild cardiovascular diseases using an existing database, and evaluate the associations between the use of various tobacco products and health outcomes. The project will use data collected in the PINNACLE Registry, which is the largest practice-based cardiovascular registry in the United States and includes more than six million patient encounter records. Investigators will analyze records from 1,318,235 patients treated at 114 medical practices from January 2008 to March 2013. Tobacco use patterns (e.g., prevalence of current use, recent use, and poly use by calendar year, and recent cessation patterns), cardiac event history, new comorbidities, new cardiovascular events, and progression of coronary heart disease associated with tobacco use will be analyzed. Study aims are: (1) to describe the patterns of use of various tobacco products (i.e., cigarettes, cigars, pipes, smokeless tobacco) and changes in use over time among individuals with mild cardiovascular diseases; and (2) to analyze the associations between current and former tobacco use and various cardiovascular health outcomes. Study findings may help inform FDA regulatory activities.

Jiping Chen Funding Mechanism: Research Contract
ID number: HHSF223201210415A
Institution: American College of Cardiology
09/19/2012

Cognitive Testing of New Questions for Surveys and Questionnaires on Tobacco

Surveys and questionnaires related to tobacco use and perceptions are critical for generating data that can inform regulatory and public education activities geared toward improving the public health. The purpose of this project is to conduct a series of cognitive interviews with consumers that will inform the development of tobacco-related surveys and questionnaires. Questions tested will relate to various tobacco products as well as user perceptions and behaviors. The objectives of the cognitive interviews are: (1) to determine the developmental appropriateness and comprehension of questions; (2) to understand how new or revised questions affect the usability of existing surveys and questionnaires; and (3) to provide insights that may be used to improve the questions and survey questionnaires as needed. Interviews with approximately 45 youth and adults can be conducted under this contract. This research may inform the development of questionnaires used in experimental studies as well as national tobacco surveys.

Jennifer Alexander and Greta Tessman Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: RTI
09/17/2012

2-Amino-9H-pyrido[2,3-b]indole: A Potential Colorectal Carcinogen Formed in Tobacco

Although smoking is a known risk factor for cancers of the gastrointestinal (GI) tract, little is known about the tobacco constituents that are potentially responsible for GI cancer development. Investigators previously reported that the heterocyclic aromatic amine 2-amino-9H-pyrido[2,3-b]indole (AαC) — the most abundant aromatic amine carcinogen formed in tobacco smoke and a rodent GI genotoxicant — is present in the urine of tobacco smokers in a dose-dependent manner but is absent in the urine of nonsmokers. The parent grant characterized the metabolic pathways involved in AαC bioactivation and detoxication in order to elucidate the causal role of AαC exposure in smoking-related GI cancers in humans. The objective of this study is to examine the reaction products of the carcinogenic metabolites of AαC with serum albumin and hemoglobin in order to eventually develop biomarkers of AαC adducts of these blood proteins as potential human biomarkers. Specific aims are: (1) to examine the reaction products of the carcinogenic metabolites of AαC with serum albumin and hemoglobin, in order to establish AαC adducts of these blood proteins as biomarkers; and (2) to develop analytical mass spectrometry methods to measure AαC blood protein biomarkers. Investigators will develop biomarkers based on blood samples obtained from seven habitual smokers and three nonsmokers. This investigation will establish a set of AαC biomarkers that can be used in population-based cohort studies of smoking and GI cancer and in analyses that measure and compare tobacco products’ toxicity and carcinogenicity.

Robert Turesky Funding Mechanism: National Institutes of Health- Grant
ID number: 3 R01 CA134700-03S1
Institution: Wadsworth Center
09/17/2012

Stem Cells and Cardiovascular Repair

This supplement to an ongoing research project is aimed at determining the effect of smoke exposure on the differentiation of human embryonic stem cells into cardiomyocytes (hESC-CMs) and the effect that smoke exposure has on remodeling of the coronary circulation in mice. Investigators will compare the effect of exposure to smoke generated by traditional cigarettes to that generated by e-cigarettes. Specific aims are: (1) to determine the effect of traditional and e-cigarette smoke on the differentiation and function of hESC-CMs in vitro (e.g., differentiation, migration, proliferation, Ca2+ handling, excitation-contraction [EC] coupling); and (2) to determine the effect of traditional smoke exposure on the remodeling of the coronary circulation in a mouse model of myocardial infarction.

Charles Murry Funding Mechanism: National Institutes of Health- Grant
ID number: 3P01HL094374-03S1
Institution: University of Washington
09/17/2012

Regulation of Pulmonary Inflammation by Leukocytes and Extracellular Matrix

In this project, which supplements ongoing research on how communication between lung tissue and leukocytes directs inflammatory response, investigators will assess how specific tobacco products impact specific lung immune responses. Studies will focus on airway tissue and macrophage cells related to the role of an airway tissue-derived cytokine in lung inflammation and immunity and the role of the enzyme stromelysin-2 (MMP-10) in lung immunity. MMP10 drives macrophage activation towards immunosuppression and has been linked to the development and severity of chronic obstructive pulmonary disease (COPD) in human smokers. Studies will be conducted in both mouse and cell-based models to explore how this cytokine and enzyme influence airway and macrophage response to menthol cigarette smoke and menthol-flavored e-cigarettes. Together, the two study models may inform regulatory activities related to the development of tobacco product standards and review.

Steven Ziegler Funding Mechanism: National Institutes of Health- Grant
ID number: 3P01HL098067-03S1
Institution: Benaroya Institute
09/17/2012

Human CYP2A and Respiratory Tract Xenobiotic Toxicity

Animal models of cigarette smoke-induced cancer are important for evaluating new tobacco products that want to claim decreased toxicity and carcinogenicity, chemopreventive agent efficacy, and mechanisms of cigarette smoke-induced cancer. However, currently available animal models of smoke-induced lung cancer have significant downsides: studies require a large number of animals and a long exposure period, and the models tend to induce a relatively small number of tumors. The proposed studies will test a novel approach for increasing mouse model sensitivity to lung tumor formation in order to elucidate the signaling pathways that regulate smoke toxicant effects. The goal of this study is to clarify the role of the respiratory tract cytochrome P450 family of biotransformation enzymes in modulating cigarette smoke-induced lung tumor formation in mouse models. Investigators will use two novel transgenic mouse models. The first model will test whether hepatic P450 activity suppression leads to increased circulating and tissue levels of carcinogens and, consequently, increased lung DNA damage and tumor formation in mice chronically exposed to cigarette smoke; the ability to show increased tumorigenic responses in tumor bioassays would enable their use in testing new potential “reduced toxicity” tobacco products and lung tumor chemoprevention agents. The second model will test whether tumor formation depends on P450 enzyme bioactivation of tobacco carcinogens; results will provide further insight about whether lung tumors observed in smoke-exposed mouse models are due to direct tumor initiation by smoke (through genotoxic pathways that depend on P450-mediated bioactivation of procarcinogens), rather than spontaneous tumor promotion. These investigations may provide support for the mouse model’s predictive value regarding human lung cancer risk.

Xinxin Ding Funding Mechanism: National Institutes of Health- Grant
ID number: 3 R01 CA092596-09S1
Institution: Wadsworth Center
09/15/2012

Who and Why Cigarette Smokers Use E-Cigarettes after Hospitalization

Use of electronic cigarettes (e-cigarettes) is increasing, particularly among smokers trying to quit; however, their potential for benefit and harm remains uncertain. The goal of this study is to collect epidemiologic and explanatory data on e-cigarette use among hospitalized smokers. Specific aims are: (1) to test a longitudinal mediation model elucidating mechanisms involved in e-cigarette use, including an identification of who uses e-cigarettes and the predictors of susceptibility to product marketing messages; and (2) to collect data regarding the prevalence of e-cigarette use among smokers before and after hospitalization, thus contributing to the epidemiologic knowledge base characterizing the scope of e-cigarette use. This observational study will involve 980 cigarette smokers aged 19-80 recruited during hospitalization. Participants will be interviewed at hospital bedside and via telephone at 6 and 12 months post-discharge regarding factors hypothesized to predict e-cigarette use (e.g., intention to use, e-cigarette-related expectancies, e-cigarette exposure, tobacco dependence, abstinence-related expectancies, health literacy, demographics, abstinence self-efficacy, motivation to quit smoking, need for cognition, and personal involvement). This research will reveal the mechanisms driving e-cigarette use among hospitalized cigarette smokers, evaluate the contribution of e-cigarette marketing activities, and clarify perceptions of e-cigarettes and their perceived role in the health of current smokers.

Kathy Harrington (formerly William C. Bailey) Funding Mechanism: National Institutes of Health- Grant
ID number: 3 U01 DA031515-03S1
Institution: University of Alabama at Birmingham
09/15/2012

Social Normative Conditions and the Diffusion of Electronic Nicotine Delivery Systems

Electronic cigarettes (e-cigarettes) deliver nicotine through the vaporization of a liquid; they are becoming more commonly used in public spaces where tobacco smoking is otherwise prohibited. The purpose of this study is to provide insight into how e-cigarettes may affect the social norms for tobacco use among young adults, who are increasingly targeted in e-cigarette marketing efforts. The investigators will interview a random sample of young adults (400 students and 400 non-students aged 18-24) to examine the knowledge, acceptability, use, and potential uptake of e-cigarettes, as well as how they learned about e-cigarettes, how they associate or integrate e-cigarette use with other tobacco use behaviors, and whether they perceive e-cigarettes as an innovation. Study aims are: (1) to assess the degree to which young adults have become aware of and are using e-cigarettes; (2) to evaluate attitudes toward the use of e-cigarettes in public spaces, compared to attitudes toward tobacco smoking in public spaces; and (3) to assess the potential for more widespread uptake of e-cigarettes. The study will produce new information about how young people react to the introduction of a new nicotine delivery mode, and may inform the development of regulations related to nicotine-containing products.

Craig Trumbo Funding Mechanism: National Institutes of Health- Grant
ID number: 1 R03 DA033578-01
Institution: Colorado State University Fort Collins
09/15/2012

Should Smokeless Tobacco be Promoted as an Alternative for Smokers?

The promotion of smokeless tobacco (ST) as a cigarette substitute is one of the most concerning issues in tobacco control. In this study, investigators will use survey data to evaluate the effects of marketing on ST use initiation among adolescents (aged 12-17) and to analyze past-year use of tobacco (cigarettes, cigars and ST) and nicotine dependence in adults; they will also perform a content analysis of ST magazine advertisements. Study aims are: (1) to examine the effect of marketing on the current and lifetime use of ST among approximately 2,200 adolescents followed for six years in the 1993-1999 Teen Longitudinal California Tobacco Survey, a statewide cross-sectional survey of tobacco-related prevalence, knowledge and attitudes; (2) to perform a content analysis of three years (2008-2010) of Camel Snus ST magazine advertisements in order to assess marketing to non-smoking adolescents, smokers receptive to a situational substitute, and smokers receptive to a permanent substitute; (2a) to examine advertising expenditures and the demographic readership of the magazines displaying advertisements for Camel Snus and other ST brands; and (3) to examine transitions in the use of tobacco products and nicotine dependence among 12,238 participants in two waves (2001-2002 and 2004-2005) of the National Epidemiologic Survey on Alcohol and Related Conditions, which includes a nationally representative sample of non-institutionalized U.S. adults over age 17; this analysis will evaluate past-year frequency of use of cigarettes, cigars and ST, as well as nicotine dependence symptoms. This research effort will enhance the understanding of ST marketing practices and impact, as well as how ST use is associated with nicotine dependence.

David Timberlake Funding Mechanism: National Institutes of Health-Grant
ID number: 1R03DA027950-01A1
Institution: University of California Irvine
09/15/2012

Graphic Health Warnings and Young Adult Attitudes Toward Smoking

Research suggests that graphic warning labels on cigarette packages are effective in changing smoking-related attitudes, beliefs, and intentions. Previous studies of exposure to graphic warnings have examined explicit cognitive measures and proxy behaviors; however, recent data suggest that implicit cognition is also an important determinant of smoking initiation and cessation. The goal of this study is to examine the effect of graphic health warnings and warning statements on young adults’ explicit and implicit attitudes toward smoking. Specific aims are: (1) to test whether exposure to the FDA graphic health warnings influences implicit and explicit attitudes toward smoking, perceived probability of future smoking and other tobacco use, and engagement with anti-smoking information among young adults; (2) to apply an innovative process model (the Quad model) to implicit attitude measures to identify the components of implicit attitudes that change following exposure to graphic health warnings; and (3) to determine whether the effects of exposure to graphic health warnings differ for males and females and for African Americans, Hispanics, and non-Hispanic Caucasians. Young adults (aged 18-26) who vary in race/ethnicity, gender, and smoking status will be recruited to a two-session web-based study. Investigators will examine the effects of graphic images plus corresponding warning statements on implicit attitudes toward smoking (measured both before and after exposure), compared to warning statements only. The study will provide information about the effectiveness of the FDA warning labels in helping to limit or deter smoking, and will provide a methodology for investigating the effects of anti-smoking warning labels on implicit measures and underlying processes.

Laurie Chassin Funding Mechanism: National Institutes of Health – Grant
ID number: 3 R01 DA013555-30S1
Institution: Arizona State University Tempe
09/14/2012

Overlapping Airway Basal Cell Transcriptome Reprogramming in COPD and Lung Cancer

Cigarette smoking causes major changes in the biology of the small airway epithelium (SAE), the primary site of pathology for smoking-induced lung diseases such as chronic obstructive pulmonary disease and lung cancer. In the parent grant, investigators compared the biology of SAE from cigarette smokers, smokers with chronic obstructive pulmonary disease (COPD), and smokers with lung cancer with and without COPD to that of healthy nonsmokers. The goals of this study supplement are to identify the effects of shisha and electronic cigarettes (e-cigarettes) on SAE and to compare these effects to those associated with cigarette smoking (as identified in previous research). Specific aims are: (1) to assess the hypothesis that smoking shisha disorders SAE biologic parameters, and that these changes are distinct from those in cigarette smokers; and (2) to evaluate the hypothesis that when smokers switch from cigarettes to e-cigarettes, there is a partial normalization of the disordered SAE biology, but that this partial normalization is different than that associated with complete smoking cessation. The study population will include 125 participants, 25 from each of five groups (nonsmokers, current cigarette smokers, current shisha smokers [non-cigarette smokers], current smokers who stop smoking, and current smokers who switch to e-cigarettes), who will provide SAE samples at baseline and three months. Investigators will compare SAE gene expression, DNA methylation, telomere length and cilia length in shisha smokers to the same parameters in matched nonsmokers and chronic cigarette smokers. Investigators will also compare the disordered SAE biology of cigarette smokers who switch to e-cigarettes to that of cigarette smokers who stop smoking, and will also compare these samples to those of matched nonsmokers and chronic cigarette smokers. This investigation will result in a molecular catalog of SAE changes associated with shisha and e-cigarette smoking, providing information to guide public health education and regulatory measures related to these alternative nicotine delivery mechanisms.

Ronald Crystal Funding Mechanism: National Institutes of Health- Grant
ID number: 3 R01 HL107882-02S1
Institution: Weill Medical College of Cornell University
09/14/2012

Focus Groups on Hookah: Awareness, Perceptions, & Behavior

Hookah use is increasing among young people, but information about consumer attitudes, perceptions, and behaviors related to the use of hookah is limited. The goal of this study is to ascertain the diversity of knowledge, attitudes, and awareness related to hookah held by youth and young adults. This project will focus on young adults and college students (ages 18-24) who have smoked tobacco using a hookah. Investigators will conduct 16 focus groups (with approximately 8-10 participants per group) that will be segmented by sex and age group (young adults vs. adolescents) but may vary in terms of race, income and/or other tobacco use status. Topics will include (but not be limited to) participants’ hookah use; attitudes and beliefs about the risks of smoking tobacco using a hookah, including perceptions of the relative harm compared to more traditional forms of tobacco use; and reactions to advertising and/or labeling for tobacco products. Focus groups will be conducted in Orlando, Los Angeles, Providence, and Washington, D.C. This research may inform the design of future experimental studies and surveys related to hookah and other tobacco products, and may inform the FDA’s efforts to implement the provisions of the Family Smoking Prevention and Tobacco Control Act related to educating the public about the harms of tobacco use.

Elizabeth Adams (RTI) / Sarah Johnson Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: RTI
09/14/2012

Evaluating the Impact of Federal Legislation on Internet Tobacco Sales

In the past, internet tobacco vendors (ITVs) have had relatively few regulatory restrictions compared to retail stores, resulting in widespread excise tax evasion and poor youth access prevention; therefore, in-depth surveillance of ITVs is important in determining the extent to which these vendors comply with new and existing governmental regulations. This study will use state-of-the-art research methods to conduct extensive surveillance of the online tobacco retail environment, evaluate the effect of state and federal policies on industry practices, and disseminate findings to policymakers. Study aims are: (1) to prepare a comprehensive, annually-updated list of online sellers of cigarettes, e-cigarettes, little cigars, and other tobacco products; (2) to conduct annual ITV website content analyses; (3) to conduct annual ITV youth purchase surveys to assess vendor compliance with existing and new regulations; (4) to conduct laboratory tests on cigarettes purchased online to determine if they are smuggled, counterfeit and/or contain abnormally high levels of hazardous ingredients (i.e., heavy metals such as arsenic, cadmium, chromium, lead, nickel, selenium and mercury); and (5) to continually monitor news and Google keyword searches to assess trends related to ITVs.

Rebecca Williams Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01CA169189-01
Institution: University of North Carolina Chapel Hill
09/14/2012

Cigarillo Smoking: Smoke Toxicant Content and User Toxicant Exposure and Effects

Cigarillo smoking has increased in recent years, especially among young adults, who comprise two-thirds of current users. Cigarillos appeal to young consumers because of their enticing flavors (e.g., grape, cherry, vanilla), their sweet aroma, their flexibility as an easily modified product, and perceptions of reduced harm compared to cigarettes. The goal of this study is to provide a comprehensive evaluation of cigarillo smoke toxicant yield, cigarillo user toxicant exposure, and cardiovascular and subjective effects associated with cigarillo use. Study aims are: (1) to compare the toxicant yield of original cigarillos and cigarillos modified according to a commonly-used practice known as “hyping,” in which the reconstituted tobacco binder is removed; (2) to investigate toxicant exposure and effects of original and modified cigarillos in the laboratory; and (3) to examine toxicant exposure and effects when participants smoke original or modified cigarillos in their natural environment. Investigators will conduct three studies that correspond to the three study aims. In Study 1, samples of original and modified cigarillos will be connected to a smoking machine, which will generate smoke using human puff parameters derived from Study 2 (described below); the smoke will be analyzed to determine tar, nicotine, carbon monoxide (CO), and TSNA yield. In Study 2, which will evaluate acute toxicant exposure and effects, 32 subjects will complete three 2.5-hour sessions that differ by product used: original cigarillo, modified cigarillo, or unlit cigarillo (negative control condition with no toxicant exposure); investigators will evaluate plasma nicotine, expired air carbon monoxide, heart rate and blood pressure, subjective response measures, and smoking topography. Study 3 will evaluate longer-term toxicant exposure and effects caused by chronic original and modified cigarillo use in the natural environment. In Study 3, 32 subjects will complete three five-day conditions that differ by product used (original cigarillo, modified cigarillo, tobacco abstinence); investigators will evaluate urine concentration of metabolites of nicotine (cotinine) and TSNAs (NNAL).

Aashir Nasim Funding Mechanism: National Institutes of Health- Grant
ID number: 1R21CA161317-01A1
Institution: Virginia Commonwealth University
09/12/2012

PGP, A Possible Biomarker for COPD Exacerbations and/or Progression

The body controls lung inflammation via a natural mechanism that interrupts the production of a neutrophil chemokine called proline-glycine-proline (PGP); when acute inflammation occurs, the enzyme leukotriene A4 hydrolase (LTA4H) becomes activated and terminates the PGP inflammatory pathway. Cigarette smoking and chronic obstructive pulmonary disease (COPD) prevent this natural mechanism from occurring, causing a self-propagating multi-step pathway of PGP-mediated inflammation. Once a chronic inflammatory environment is established, elevated acetyl PGP (N–PGP) levels persist in COPD patients even after smoking cessation; elevated N–PGP levels may be associated with COPD exacerbations and may define a subpopulation of patients who experience frequent COPD exacerbations. This study will evaluate body fluid samples from a large cohort of COPD patients to determine whether disturbances in the anti-inflammatory mechanism and increased PGP levels are biomarkers for COPD exacerbations and disease progression. The study population will include 600 patients with severe COPD, 1,800 patients with mild to moderate COPD, 600 healthy smokers and 200 non-smokers. The study aims are: (1) to correlate PGP and LTA4H in COPD patients’ sputum, plasma, and urine with disease parameters such as exacerbations, degree of emphysema and disease progression; (2) to test whether aberrant LTA4H triaminopeptidase (TAP) activity continues in COPD even after smoking cessation, and whether this defect is associated with PGP levels; (3) to correlate baseline sputum PGP levels with those of plasma and urine; and (4) to assess whether plasma and urine PGP levels change over time and associate with particular COPD subpopulations and/or disease parameters. Together, these data will evaluate whether PGP levels can be used as biomarkers for COPD exacerbation associated with tobacco use.

Edwin Blalock Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01HL114439-01
Institution: University of Alabama at Birmingham
09/12/2012

AMPK as a Redox Sensor and Modulator

Abdominal aortic aneurysm (AAA) is the most common form of aortic aneurysm and uncontrolled growth of AAAs frequently leads to rupture resulting in approximately 80% mortality. Epidemiological studies suggest that cigarette smoke increases the risk of AAAs 7.6-fold and smoking is the only modifiable factor associated with the development, expansion, and rupture of AAAs. In this study, a combination of pharmacological, molecular, and genetic methodologies will be used to explore the link between cigarette smoke and AAAs in animals in vivo. The completion of this project will increase our understanding of aneurismal degeneration associated with smoking and may inform cardiovascular models of toxicity associated with tobacco exposure.

Ming-Hui Zou Funding Mechanism: National Institutes of Health- Grant
ID number: 2R01HL089920-05
Institution: University of Oklahoma Health Sciences Center
09/11/2012

Measurement of Tobacco Use among South Asians in the U.S.

Although immigrants from South Asia (including India, Pakistan, Bangladesh, Sri Lanka, Nepal, and the Maldives) comprise the second largest Asian group in the U.S. and one of the fastest growing immigrant groups, existing studies of tobacco use in South Asian immigrants are limited. Such studies tend to be geographically restricted or focused only on “western” cigarette smoking, despite the fact that South Asian tobacco consumption is characterized by significant use of strong native tobacco products – such as bidis (small brown hand-rolled cigarettes) and gutkha and paan masala (two types of chew tobacco) – that are readily available in ethnic enclaves in the U.S. Furthermore, South Asians are almost always aggregated into a broad “Asian” category, potentially masking subgroup differences. Studies conducted in the United Kingdom suggest that immigrant South Asians have high rates of tobacco use and continue use of their native tobacco products. Furthermore, given the health risks of tobacco use and the explosive growth of South Asians in the U.S., methodological research is warranted to assess inaccuracies in measuring tobacco use in this population. The goal of this study is to improve tobacco surveillance methodologies and generate a better understanding of indigenous tobacco use among South Asian immigrants in order to inform tobacco control efforts. Study aims are: (1) to understand tobacco use behaviors in this population by conducting eight focus groups (8-12 participants each); (2) to develop, refine and pre-test a survey instrument (including standard tobacco use survey questions and new questions about indigenous products) to assess the prevalence of tobacco products used by South Asian immigrants; (3) to implement a population-based split sample randomized survey of 150 South Asian immigrants that compares standard tobacco use measures and new questions developed to measure indigenous tobacco product use; and (4) to explore the feasibility of a respondent-driven sampling (RDS) approach (a “snowball sampling” methodology in which survey participants recruit their peers), in which investigators will attempt to reach an additional 450 South Asian immigrants through the original 150 participants. The findings from this study will lay the groundwork for a future investigation into the epidemiology of health behavior risks (including tobacco use) among South Asians residing in the U.S.

Cristine Delnevo Funding Mechanism: National Institutes of Health- Grant
ID number: 1 R21 CA164913-01A1
Institution: University of Medicine and Dentistry of New Jersey School of Public Health
09/10/2012

Mainstream Smoke Composition and Toxin Exposure from Prototypical Cigar Products

Despite evidence suggesting that cigar smoke delivers nicotine and more than 60 carcinogens, there are no systematic studies that consider both the use patterns and toxin delivery of various cigar products. Using a clinical study design, investigators will compare cigarettes to three prototypical cigar products (i.e., cigarillo, small cigar and conventional cigar) to examine behavioral aspects of smoking. The study team will also examine the chemistry and particle distribution of the products’ mainstream smoke. The goal is to characterize the behavioral and physiological differences between cigar and cigarette smoking and subsequent toxin exposure. Study aims are: (1) to determine the range of immediate and chronic toxin exposure and smoking behavior associated with cigars and cigarettes; and (2) to comprehensively characterize particle size distribution and content of selected carcinogens and other compounds in machine-generated mainstream smoke. In the clinical study, 75 adult subjects of either gender and any racial/ethnic background who smoke both cigarettes and cigars will be assigned to one of three experimental groups (cigarillo, small cigar, conventional cigar; 25 subjects per group), based on their usual cigar product. Puff topography and inhalation measures will be collected simultaneously while the subjects smoke the cigar (at one visit) and their own brand cigarette (at a second visit); puff and inhalation measures will distinguish smoking patterns between cigars (generally thought not to be inhaled) and cigarettes (almost always inhaled). Chemical measures of acute (nicotine and carbon monoxide boost) and chronic (cotinine and 3-OH-cotinine NNAL, 1-HOP) exposure will be obtained from the participants. The chemical laboratory study will assess the particle size (fine and ultra fine) distribution and gas-phase toxic/carcinogenic components in mainstream smoke from the cigars and cigarettes. Investigators will analyze mainstream smoke generated with a smoking machine based on the puff profiles of the clinical study participants. In addition, investigators will analyze mainstream smoke generated from standardized puff protocols (ISO/FTC37 and ICCSS36) such that each puff (volume, velocity and duration and the inter-puff interval) is identical; both protocols will be used to test the cigars and five representative cigarettes (full flavor, light, ultra light, unfiltered and menthol). This study will provide information about the addictive and health risks of cigar smoking and may inform regulatory decisions related to cigar products.

Wallace Bruce Pickworth Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01CA158045-01A1
Institution: Battelle Centers/Public Health Research and Evaluation
09/10/2012

Focus Groups on E-Cigarettes: Awareness, Perceptions, & Behavior

Despite limited evidence of the actual short- and long-term health effects associated with electronic cigarette (e-cigarette) use, these products are growing in popularity. The goal of this study is to ascertain the diversity of consumer knowledge, attitudes, and awareness related to e-cigarettes. A total of 12 focus groups will be conducted in four locations in different regions of the United States: six groups will include young adults (ages 18-25), and six groups will include older adults (ages 25 and older).  Focus groups will include 8-10 individuals each and will be diverse in terms of race, income and/or other tobacco use status; all focus groups except for the older adult groups will be segmented by gender. Topics covered will include participants’ e-cigarette use, attitudes and beliefs about risks of e-cigarettes including perceptions of relative harm compared to other tobacco products, and reactions to advertising and/or labeling relevant to e-cigarettes. This research may inform the design of future experimental studies and surveys related to e-cigarettes and other tobacco products, and may inform the FDA’s efforts to implement the provisions of the Family Smoking Prevention and Tobacco Control Act related to educating the public about the harms of tobacco use.

Jennifer Alexander (RTI) and Sarah Johnson Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: RTI
09/01/2012

Treatment for Complex Patients: Continuing and Extended Care (supplement)

Tobacco use is highly prevalent among individuals in drug abuse treatment programs. In previous research, the San Francisco Treatment Research Center developed tobacco-related staff and client survey measures and used those measures to study a New York policy to reduce tobacco use in addiction treatment. In this supplemental study, investigators will survey 552 individuals (252 of whom are smokers) in eight New York drug abuse treatment clinics. Investigators will assess tobacco-related risk perceptions, responses to health warning labels (including graphic warning labels), use of existing and novel tobacco products, receptivity to tobacco marketing/advertising, receptivity to tobacco cessation services, and awareness of FDA regulations. Investigators will also survey treatment program staff members to determine smoking prevalence and responsiveness to health warnings. Finally, investigators will perform a secondary analysis of New York administrative data to assess factors associated with smoking prevalence in statewide adult drug treatment program admissions from 2006-2012. Findings may inform regulatory activities regarding tobacco use by individuals with mental health and substance abuse diagnoses. (Project completed in 2014.)

Joseph Guydish Funding Mechanism: National Institutes of Health – Grant
ID Number: 3P50DA009253-18S1
Institution: University of California San Francisco
09/01/2012

Rapid Response Human Testing of Smokeless Tobacco Products

Smokeless tobacco (ST) use is increasing. Since 2005, virtually every major cigarette producer has entered the ST market. The proliferation of new products is adding to the already wide array of available non-smoked tobacco (e.g., moist snuff, chewing tobacco, iqmik, pellets). Characterizing ST products in such a rapidly changing landscape requires a more rapid testing methodology than traditional long-term cross-over trials. The goal of this three-year study is to apply a testing paradigm that relies only on “boost” measures so that products can be tested in single-use sessions. Investigators will perform a series of acute single-blind cross-over trials to characterize and compare the abuse liability potential, likelihood of adoption and potential toxicity of a range of ST products currently on the market. Study aims are: (1) to assess subjects’ liking and relief of craving/withdrawal symptoms associated with a variety of ST products and a medical nicotine lozenge (a control with a known low abuse potential); (2) to compare subjects’ neurocognitive function (EEG spectral analysis and event-related potentials) during use of various ST products and medicinal nicotine; (3) to measure and compare boost biomarkers that are sensitive to one-time use of a tobacco product — including salivary tobacco-specific nitrosamines (TSNAs), polycyclic aromatic hydrocarbons (PAHs) and exhaled breath volatile organic compounds (VOCs) — before and after a single use of each ST product; and (4) to characterize ST products according to levels of VOCs, TSNAs, PAHs, pH, moisture, total nicotine, and free nicotine. The study population will include 90 adults aged 18 or older with established ST use (defined as using ST products at least daily in the previous month and a history of use for at least a year). Aims 1 through 3 will be accomplished through a series of trials that will each include five smokeless products: four tobacco products with a wide range of free-nicotine levels and toxicants and a medicinal nicotine lozenge (Commit). Aim 4 will be accomplished via measurements of VOCs, TSNAs, PAHs, total nicotine, and free nicotine, pH and moisture levels. All of these results will be used to inform testing of breath and saliva samples obtained before, during, and after use of ST and medicinal nicotine. This research creates a new testing paradigm for rapid, high throughput, acute human testing of ST products.

Pamela Clark Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01DA31142-01A1
Institution: University of Maryland College Park
09/01/2012

Predictors of Smokeless Tobacco and Dual Use in the U.S. Military

Prevalence rates for cigarette smoking and smokeless tobacco use are far greater in the U.S. military than in the civilian population. The goal of this study is to expand an ongoing longitudinal survey of cigarette smoking, smokeless tobacco use and dual use in 30,000 Air Force Airmen by recruiting a new cohort of 12,000; the investigators will also expand the existing survey by developing new questions to more fully characterize new and emerging product use. Study aims are: (1) to determine baseline and follow-up prevalence and predictors of use of smokeless products (i.e., snus and dissolvable orbs, sticks, and strips), electronic nicotine delivery devices, hookah tobacco, and roll-your-own cigarettes; (2) to determine perceptions of health benefits and harm reduction of these products relative to cigarettes; (3) to evaluate the natural history of behaviors related to harm reduction (e.g., quitting cigarette smoking by using a new and emerging product) and harm escalation (e.g., transitioning from nonsmoker to smoker); and (4) to assess the communication channels military personnel use to receive information and communicate about tobacco and related health issues. This project will provide comprehensive data on the changing prevalence and predictors of new and emerging tobacco product use by U.S. military members.

Robert Klesges Funding Mechanism: National Institutes of Health- Grant
ID number: D 3 R01 DA036510-05S1
Institution: University of Tennessee Health Science Center
09/01/2012

A Comprehensive Approach to Secondary HIV Prevention and Care among Positives

Chronically-ill, low income African-Americans have high smoking rates and exhibit disparities in smoking-related morbidity and mortality. This study will evaluate tobacco use behaviors and perceptions among former or current drug using, low income African-American smokers who are (n=250) and are not (n=250) HIV positive; the study expands the scope of an ongoing randomized controlled trial of a social network intervention for HIV-positive African-American drug users that attempts to reduce HIV behavioral risk and increase entry into care. Specific aims are: (1) to explore the context of tobacco communication channels and messages in low income African-American smokers and subgroups characterized by drug use and HIV status; (2) to examine associations between tobacco products, labels and claims and subjects’ perceptions and behaviors; and (3) to identify communication channels and messages promoting tobacco use, and consider their potential for promoting tobacco cessation and tobacco-related health resource utilization. Investigators will conduct a series of focus groups to explore the social, cultural and economic factors that influence tobacco use; test the impact of variations in health warnings, package design, product appeal and health claims; and conduct a computer-administered evaluation of the impact of health warnings and tobacco claims on tobacco perceptions and behaviors. Study findings may inform regulatory activities relevant to this under-studied, under-served population; results from the proposed and parent studies will also inform the investigators’ development of tailored social network interventions and other community and media approaches to tobacco control and prevention.

Carl Latkin Funding Mechanism: National Institutes of Health- Grant
ID number: 3 R01 DA032217-02S1
Institution: Johns Hopkins University
09/01/2012

Barriers to Effective Tobacco Control Policy Implementation in the U.S. Military

Tobacco product use by U.S. military personnel negatively impacts health, combat readiness and healthcare costs. Military personnel have easy access to deeply-discounted tobacco products in military retail outlets and exhibit historically high rates of tobacco use, which has been identified as “part of the military culture.” Military personnel of all ranks believe that tobacco use is an effective method for combating the stress associated with military life and that its risks are inconsequential compared to the other dangers they face, and troops strongly believe that their commanders perceive tobacco to be a relatively unimportant threat to readiness and health. This study, which builds upon ongoing research on U.S. military tobacco control policy, will explore the factors that underlie these misperceptions and support tobacco use acceptance in military culture. The aim of this project is to explore military commanders’ perceptions about tobacco products’ impact on military personnel health and combat readiness.  By conducting semi-structured interviews with 60 commanders from the four armed services and the Coast Guard, investigators will determine (i) what military commanders believe about the harms and/or benefits of using various types of tobacco products (smokeless, cigars, cigarettes, and others) and their impact on the military mission; (ii) how tobacco product use figures into daily military culture and practices; (iii) how commanders construct and deploy arguments supporting the use of different tobacco products; (iv) where commanders obtain information that influences their perceptions of tobacco product risks; (v) what information about tobacco is presented to commanders in Professional Military Education (PME) courses; and (vi) what tobacco-related information commanders believe should be presented in PME.

Christopher Haddock Funding Mechanism: National Institutes of Health – Grant
ID number: 3R01CA109153-07S1
Institution: National Development and Research Institutes
09/01/2012

Developing Measures of Little Cigar Use for Young Adults

Little cigar consumption has increased, particularly among African-American and Hispanic young adults living in low-income communities.  Currently, national surveys of tobacco use include one “catch all” item that assesses all forms of cigar use (e.g., big cigars, little cigars, and cigarillos); this item does not allow for precise estimates of the frequency, duration, or quantity of use of little cigars and often underreports little cigar use among minorities, who are not typically targeted in tobacco-related measurement development studies. This study will develop and pilot test measures of little cigar use and its psychosocial determinants in a group of racially/ethnically diverse young adults. Study aims are: (1) to conduct 10 focus groups of 6 to 8 racially/ethnically diverse young adults (aged 18-25) to identify salient attitudinal, normative, and behavioral control beliefs related to little cigar smoking; (2) to develop questionnaire items that assess little cigar use and attitudes, subjective norms, and perceived behavioral control regarding little cigar use; (3) to conduct cognitive testing of the little cigar items; and (4) to pilot test the questionnaire items and measures of intention, duration, frequency, quantity, and type of little cigar use in a small sample of racially/ethnically diverse young adults. Researchers will use the National Cancer Institute (NCI) Cigar Monitoring recommendations, NCI Measures Guide for Tobacco Control Researchers, and existing tobacco use questions from national surveys to develop the little cigar use items.

Kimberle Sterling Funding Mechanism: National Institutes of Health- Grant
ID number: 1 R03 CA159909-01A1
Institution: Georgia State University
09/01/2012

Impact of Graphic vs. Text-Based Health Warning Labels

While numerous studies have demonstrated the effectiveness of larger, more graphic health warnings for promoting tobacco cessation, nearly all have focused on warning labels on product packaging rather than in advertisements. The purpose of this investigation — which complements ongoing research on tobacco cessation interventions in Ohio Appalachia, a region characterized by economic disadvantage, low educational levels, and high prevalence of tobacco use — is to assess the effects of warning labels embedded within tobacco product advertisements. The study will evaluate whether modifications to warning labels in advertisements can impact the attention, recall, perceived health risks, and tobacco cravings of adult smokers and smokeless tobacco users in this vulnerable population. Specific aims are: (1) to evaluate the influence of size on attention to graphic warning labels in cigarette advertisements, by determining if exposure to larger versus smaller labels has an impact on fixation time, message recall, perception of health risks, craving, and cessation self-efficacy and interest; and (2) to test the influence of graphic imagery on attention to warning labels in smokeless tobacco advertisements, by determining if exposure to graphic versus text-based labels has an impact on fixation time, message recall, perception of health risks, craving, and perceptions of relative risk compared to cigarettes, as well as the influence of health literacy on these factors. Investigators will study 172 cigarette smokers and 172 smokeless tobacco users using eye tracking technology that captures detailed information about attention to the advertisement’s warning label and other elements; participants will be randomly assigned to view advertisements with the proposed FDA health warning labels or either a larger health warning label (for smokers) or an advertisement including graphic imagery (for smokeless tobacco users). Study results will reveal the effects of the health warning labels on tobacco users, yield information about potential modifications that may offer greater public health protection, and may inform policy decisions regarding the regulation of tobacco product advertisements.

Mary Ellen Wewers Funding Mechanism: National Institutes of Health- Grant
ID number: 3 R01 CA129771-04S1
Institution: Ohio State University
09/01/2012

Smoking Behaviors Associated with Low Nicotine and Little Cigars

Adaptive smoking behaviors associated with new and emerging tobacco products can have important implications for toxin exposure. For example, low nicotine content (LNC) cigarettes may offer a reasonable strategy to reduce the reinforcing properties of cigarette smoking; however, some smokers compensate for lower nicotine yield by smoking more intensely or by smoking more cigarettes daily. Little cigars may also pose an emerging problem. Little cigars (both small and medium) are significantly less expensive than cigarettes, and thus can be used to cheaply obtain desired nicotine levels; furthermore, their perceived risks are generally underestimated, leading to more intense use and increased exposure. Certain subgroups of smokers may be more vulnerable to adaptive smoking behaviors, and, therefore, to increased harm. One subgroup of interest is differentiated by nicotine metabolism, a heritable trait known to alter smoking behaviors and associated toxin exposure: faster nicotine metabolizers, defined by genotype or a nicotine metabolite biomarker, are more susceptible to more intense smoking behaviors. This investigation – which supplements ongoing research on nicotine metabolism rate as a predictor of response to different nicotine dependence treatments – will identify behavioral and exposure variations in LNC cigarette and little cigar smokers with slow versus fast nicotine metabolism. Specific aims, corresponding to two studies, are as follows: (1) to examine the compensatory effects of LNC cigarettes on smoking behaviors (e.g., daily cigarette consumption, total puff volume) and toxin exposure in 50 slow and 50 rapid nicotine metabolizers; and (2) to examine the compensatory effects of little cigars on smoking behaviors (e.g., daily cigar consumption, number of puffs taken, interpuff interval, total time lit, and amount smoked by mass and length) and toxin exposure in 40 slow and 40 rapid nicotine metabolizers. Both studies will use a validated phenotypic marker of nicotine metabolism rate that may identify those individuals at greatest risk of harm when using these tobacco products. This investigation will provide empirical evidence on use patterns and harm exposure related to LNC cigarettes and little cigars that can be used to inform regulatory activities related to these products.

Caryn Lerman Funding Mechanism: National Institutes of Health- Grant
ID number: 3U01DA020830-08S1
Institution: University of Pennsylvania
09/01/2012

Examining Dual Users of E-cigarettes and Cigarettes

Smokers’ dual use of cigarettes and alternative tobacco products such as electronic cigarettes (e-cigarettes) may impact motivational and behavioral factors that affect smoking cessation success.  The goal of this project is to clarify the relationship between dual use and various health related outcomes. Researchers will recruit 150 daily smokers (75 who smoke cigarettes exclusively and 75 dual users of cigarettes and e-cigarettes) who will generate real-time data during periods of ad libitum tobacco use and periods of reduced smoking and abstinence.  Specific aims are to compare dual users and exclusive smokers on the following measures: ratings of liking cigarettes, cigarette use, daily patterns of tobacco product use, mood, suppression of cigarette withdrawal, contexts of use, and exposure biomarkers.  Dual users will also be examined with regard to e-cigarette use and ratings of liking.  This information may be used to inform regulatory actions regarding alternative tobacco products.

Michael C. Fiore and Timothy B. Baker Funding Mechanism: National Institutes of Health – Grant
ID number: 3P50CA143188-14S1
Institution: University of Wisconsin
09/01/2012

Counter-Irritation by Menthol: Molecular Targets and Role in Airway Disease

The tobacco industry has added a wide range of chemicals to cigarettes in order to increase product stability and modify taste and sensory qualities. As a cigarette additive, menthol is suspected to accelerate and maintain nicotine dependence and to increase tobacco smoke toxicity; mentholated cigarettes are especially popular with beginning smokers and in minority populations disproportionally affected by chronic obstructive pulmonary disease (COPD), lung cancer and hypertension. Electronic cigarettes (e-cigarettes), rapidly gaining market share as supposedly non-toxic nicotine delivery devices, also contain flavor additives and other chemicals with unknown health effects. The goal of this investigation, which expands ongoing research on menthol, is to reveal how cigarette additives affect respiratory system function and, potentially, promote addiction and lung disease. Investigators will use mouse models and physiological, biochemical, molecular and behavioral approaches to meet the following specific aims: (1) to define the roles of the sensory transient receptor protein channels TRPA1 and TRPM8 in menthol-induced inhibition of acute respiratory irritation; (2) to examine the pharmacological effects of menthol and menthol-related compounds on irritant-induced activation of sensory neurons; (3) to determine the effects of menthol inhalation on smoking-induced lung inflammation and emphysema; and (4) to investigate the sensory and inflammatory effects of e-cigarette aerosols and their chemical additives. This research will provide new insights into neuronal mechanisms of airway irritation and remodeling, and will inform a scientific basis for regulatory efforts targeting menthol and other additives to tobacco cigarettes and e-cigarettes.

Sven-Eric Jordt Funding Mechanism: National Institutes of Health- Grant
ID number: 3 R01 HL105635-02S1
Institution: Yale University
09/01/2012

Communicating Smoking Risks Through Graphic Warning Labels

Although decreasing cigarette use requires a range of strategies, one particularly effective way to reach smokers is through graphic warning labels on cigarette packaging. The goal of these studies is to identify warning label components that can maximize quit intentions by decreasing the motivation to smoke and/or increasing the motivation to quit.  Study aims are: (1) to determine whether different combinations of graphic label components lead to greater overall quit intentions among adult smokers; (2) to determine in an Internet study how well the most effective warning labels from Aim 1 perform for adolescent smokers and vulnerable nonsmokers; (3) to determine in an Internet study how well these same most effective warning labels perform for adult smokers; and (4) to examine the effects of the program on individuals with low education/literacy levels to determine whether the labels are effective for them. To fulfill Aim 1, investigators will conduct a randomized controlled trial of adult smokers given their own brand of cigarettes with one of three sets of warning labels for a period of 28 days. The three sets of labels include one control text-only condition with no image, an experimental condition with the same text plus images originally mandated by the FDA, and a second experimental condition that includes the same text and images plus additional text elaborating the hazards of smoking each additional cigarette. The trial will involve weekly assessments to evaluate responses to the labels and the effects on quit intention, amount smoked, motivation to smoke, and motivation to quit; expired breath carbon monoxide will also be measured at each visit as an indicator of cigarette smoke exposure. To fulfill Aims 2 and 3, investigators will conduct a second study in which they will examine the effects of warning labels used in the U.S. on adolescents vulnerable to smoking, adolescent smokers and adult smokers. To fulfill Aim 4, investigators will analyze the data from the second study to determine whether graphic warnings increase quit contemplations among less-educated populations by comparing the relationship between health literacy and quit intentions observed at baseline vs. follow-up; a reduction in the relationship between health literacy and quit intentions will serve as evidence that the program reduces disparities. These research outcomes could inform the optimal design of new tobacco warning labels.

Daniel Romer Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01CA157824-01A1
Institution: University of Pennsylvania
08/15/2012

Supplement to “Dissecting Heterogeneity of Treatment Response of First-Episode Schizophrenia”: Response to Tobacco Warnings by Young Adults with First-Episode Schizophrenia

Half of young adults with schizophrenia smoke. No research studies have assessed how young people with schizophrenia respond to tobacco warnings (which were designed for the general population), despite the likelihood that schizophrenia patients may respond differently to warning messages due to the effects of their condition (e.g., psychotic symptoms, cognitive deficits). The goal of this supplement is to provide data on the acceptability and efficacy of tobacco warnings for young people with and without schizophrenia . Specific aims are: (1) to compare young people with and without schizophrenia with regard to responses to tobacco warnings and perceptions of warning effectiveness; (2) to assess responses to, and effectiveness of, video tobacco warnings; and (3) to examine the impact of warnings on smoking knowledge, attitudes and behavior in both groups and the effects of symptoms and cognition on warning effectiveness among smokers with schizophrenia. To accomplish these aims, researchers will recruit 100 subjects with first-episode schizophrenia (50 smokers and 50 non-smokers) and 100 healthy subjects matched for age, sex and smoking status. Researchers will present subjects with text/picture and video warnings and, for each warning, will assess subjects’ perceptions of the warning’s effectiveness and subjective responses. One month later, researchers will assess subjects for retained knowledge and effects of the warnings. Study findings may inform the development of tobacco warnings that are effective for young people with and without schizophrenia.

Anil Malhotra Funding Mechanism: National Institutes of Health- Grant
ID Number: 3P50MH080173-05S2
Institution: Feinstein Institute for Medical Research
08/15/2012

Health Effects of Adolescent Waterpipe Smoking With & Without Cigarette Smoking

The use of waterpipe is growing across the U.S. The goal of this study is to identify the respiratory health effects of waterpipe smoking in 684 waterpipe smokers aged 18-21. Specific aims are: (1) to evaluate the effects of waterpipe smoking on air capacity measures of lung function; and (2) to compare and contrast the patterns, predictors, and health consequences of waterpipe smoking with and without cigarette smoking and with never smoking. Participants will be classified into four groups — cigarette-only smokers, waterpipe-only smokers, cigarette and waterpipe smokers (dual users), and nonsmokers. There will be a minimum of 100 participants in each of the three tobacco use groups and 300 in the nonsmoking group. Researchers will compare gender, ethnicity, education, and smoking history across groups. In addition, researchers will analyze the effects of smoking status on each of the spirometry outcomes (FEV1, FVC, FEV1/FVC, FEV25-75), and will determine the effects of cigarette smoking, waterpipe use, and dual use.  Participants will also provide information about coughing and health problems (wheezing, difficulty breathing, exercise, and ability to exercise without shortness of breath). Findings may inform regulatory activities related to waterpipe use. (Project completed in 2015.)

Virginia Rice Funding Mechanism: National Institutes of Health – Grant
ID Number: 1 R15 DA032822-01
Institution: Wayne State University
08/06/2012

A Survey of Microbes in a Selection of Moist Snuff Smokeless Tobacco Products

Tobacco products may be contaminated with microorganisms that could be detrimental to human health. Smokeless tobacco users may be at particular risk, since these products are consumed orally. Furthermore, some smokeless tobacco manufacturing processes involve extra fermentation and high-temperature aging processes, which encourage bacterial growth. The few studies that address tobacco product microorganisms and their byproducts indicate the likely existence of bacterial pathogens in smokeless tobacco products. In this study, investigators will analyze a diverse collection of moist snuff products in order to develop a microbiological characterization of these products. Study aims are: (1) to define the microbiological risks associated with smokeless tobacco product use; and (2) to collect baseline microbiological data that could inform tobacco product manufacturing changes. The data generated by this study may help elucidate the risks associated with microorganisms in smokeless tobacco products and may provide data to inform science-based policies and regulations.

Steven Foley / Norma Duncan Funding Mechanism: JV
ID number: C12034
Institution: National Center for Toxicological Research
08/01/2012

Real-Time Measurements and Uptake of Carcinogens by Menthol Cigarette Smokers

Menthol, the only cigarette additive that is actively marketed by manufacturers, is particularly favored by youth and racial/ethnic minorities. Growing evidence suggests that menthol cigarettes are starter products for youth, impede smoking cessation, increase relapse following cessation, and foster racial health disparities via incessant targeted marketing to communities of color. Because cigarettes are so highly engineered, there are many differences between menthol and non-menthol cigarettes other than menthol levels, making it difficult to definitively link menthol to increased risk of tobacco-related diseases. To adequately study the effect of mentholation, the investigators are evaluating the acute effects of smoking cigarettes that are equivalent except for menthol level. Study aims are: (1) to fully characterize a set of four test cigarettes: a commercial non-menthol cigarette that investigators mentholate at one level (with menthol distributed between the tobacco, filter, and paper), and Camel Crush, with the embedded pellet crushed and uncrushed (in which menthol is generated in the filter); (2) to determine whether cigarette mentholation influences size-fractionated particle deposition and uptake of semi-volatile and volatile toxins/carcinogens (based on real-time human toxicity measurements taken following the use of the test cigarettes by 72 established smokers over two separate data collection periods, one week apart); and (3) to use human-generated smoking topography data to compare subject-specific smoke emissions produced by machine-smoking of the test cigarettes. This study offers a model for testing cigarette products.

Stephanie Buehler Funding Mechanism: National Institutes of Health – Grant
ID number: 5R01CA162085-02
Institution: Battelle Centers
08/01/2012

Pharmacokinetic Analysis of NNK in Sprague-Dawley Rats

The tobacco-specific nitrosamine NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone] occurs naturally in cigarette smoke. It is a potent genotoxin and carcinogen and is considered to be one of the compounds responsible for the induction of lung cancer in humans exposed to tobacco smoke. Parenteral administration of NNK in laboratory animals indicates that its absorption, metabolism, and distribution occur rapidly; however, current pharmacokinetic data on NNK following inhalation are insufficient to accurately predict NNK blood distribution. The goal of this project is to evaluate the pharmacokinetic profile of NNK in rats by determining the blood and tissue distribution of NNK and metabolites following NNK administration via oral, intraperitoneal and inhalation routes. Specific aims are: (1) to establish pharmacokinetic data on the distribution of NNK following inhalation exposure; and (2) to provide pharmacokinetic data on the distribution of NNK following oral and intraperitoneal administration in rats. This will be the first complete current pharmacokinetic analysis following inhalation administration of NNK; analyses following the oral and intraperitoneal administrations will allow a comparison with the few previous studies using oral and intraperitoneal administration of NNK. Data developed by this project will help determine the risk associated with exposure to specific levels of NNK found in cigarette smoke; this data may inform the design of future inhalation toxicology studies that will determine the dose-response of NNK for respiratory and other target-organ toxicities.

Shu-Chieh Hu / Phil Yeager Funding Mechanism: JV
ID number: C13040/E07525.01
Institution: National Center for Toxicological Research
07/30/2012

Cigarette Smoke-Derived Electrophilic Aldehydes and Airway Inflammation

While cigarette smoking is generally associated with chronic inflammation, it also possesses immunosuppressive properties that result in increased sensitivity to respiratory bacterial or viral infection. Exposure to acrolein and other related unsaturated aldehydes that are thiol-reactive agents in cigarette smoke inhibits respiratory immune response, but the mechanisms mediating its toxic effects in the respiratory tract are not well understood. Acrolein exposure also mimics some of the effects of cigarette smoking on asthma development and severity by promoting allergic sensitization and suppressing allergic inflammation. The goals of this research effort are to study how acrolein alters innate macrophage and epithelial immune responses and allergic inflammation using in vivo mouse models of acute lung injury and allergic asthma, and to identify enzymatic and metabolic systems that mediate detoxification of acrolein to determine whether changes in these systems alter acrolein susceptibility. Study aims are: (1) to determine the importance of direct protein modifications in acrolein-induced suppression of innate immune responses; (2) to explore the effects of acrolein exposure on allergic inflammation and sensitization; and (3) to explore the importance of GSTP1 and CBS/H2S in modulating acrolein-induced alterations in immune responses. To achieve Aim 1, investigators will evaluate acute mechanisms by which acrolein alters macrophage and epithelial responses to LPS by conducting in vitro studies with mouse (alveolar) macrophages and tracheal epithelial cells. The investigators will use newly-developed proteomic approaches to determine direct protein modifications in proteins of interest (e.g., RelA, JNK2, TrxR), and will explore the functional importance of these modifications. To achieve Aim 2, investigators will explore the effects of in vivo acrolein inhalation on allergic airway inflammation in sensitized mice and on allergic sensitization; these effects will be analyzed in the context of alterations in inflammatory cytokine profiles and changes in epithelial barrier function and mediator production, in association with direct alkylation or relevant target proteins. To achieve Aim 3, investigators will use siRNA approaches or cells from transgenic/knockout mice to explore the impact of these metabolic systems on acrolein-mediated alterations of macrophage/epithelial responses and on acrolein-mediated allergic sensitization. Collectively, these studies will provide further insight into the importance of acrolein in the development of respiratory disease associated with smoking and will help determine factors that may contribute to susceptibility to cigarette smoking-induced respiratory infections and allergic airway disease.

Albert Van der Vliet Funding Mechanism: National Institutes of Health- Grant
ID number: 1R01ES021476-01
Institution: University of Vermont and State Agriculture College
07/25/2012

Assessing and Magnifying the Impact of Cigarette Pack Health Warnings among Vulnerable Populations: An Integrated Study

Research is limited on the influence of factors such as social class, race, and ethnicity on the effectiveness of proposed graphic health warnings (GHWs) in the U.S. This one-year supplement will investigate the impact of proposed GHWs on smokers and non-smokers with a particular focus on low socioeconomic status (SES) and minority groups. Specific aims are: (1) to study the impact of GHWs on smokers and non-smokers from vulnerable population groups; (2) to assess which GHWs resonate with different population groups; (3) to examine if GHW effects last beyond the period of immediate exposure; (4) to examine the impact of GHW exposure on the diffusion and flow of information in online and off-line social networks; (5) to assess the community capacity to support local tobacco control efforts after GHW implementation; (6) to determine the cognitive, emotional, social, and potential behavioral responses GHWs produce in groups by ethnicity, teens who smoke or are at risk of smoking, and pregnant women who smoke or who are at risk of smoking relapse; (7) to test message strategies for campaign materials that could accompany the introduction of GHWs. Aims 1-5 will be investigated at the Dana-Farber Cancer Institute/Harvard College; populations of interest are young adults (18-24) and adults (25+) with a specific focus on African-Americans, Hispanics, people of lower SES, adults with chronic disease, gay/lesbian/bisexual/transgender individuals, and blue collar workers. Aims 6 and 7 will be studied at the University of Connecticut; populations of interest are teens (aged 13-17) who smoke or are at risk of smoking and pregnant women who smoke or who are at risk of smoking relapse. Findings may be used to develop campaigns to support quitting or to reduce the likelihood of smoking initiation among targeted underserved populations. (Project completed in 2013.)

David R. Williams Funding Mechanism: National Institutes of Health- Grant
ID Number: 3P50CA148596-03S1
Institution: Harvard School of Public Health 
07/16/2012

Population Assessment of Tobacco and Health: Measurement of Tobacco-Related Biomarkers

The Tobacco Control Act mandates the regulation of tobacco products using a population health standard including both users and non-users of tobacco products. To help meet this mandate, the Population Assessment of Tobacco and Health (PATH) study — a nationally representative, longitudinal cohort study that will survey tobacco product users, never users, and former users including youth aged 12-17 and adults aged 18 and older – is gathering data on tobacco product use, attitudes, and health conditions and is collecting biological specimens (buccal cells, urine, and blood) from consenting adults. The Center for Disease Control and Prevention Division of Laboratory Sciences will test a subset of these specimens for known biomarkers of tobacco product exposure and biomarkers of harmful and potentially harmful constituents (HPHCs) in tobacco products. Biomarkers to be analyzed include nicotine and nicotine metabolites; tobacco-specific nitrosamines (TSNAs); metabolites of polycyclic aromatic hydrocarbons (PAHs); various metals; multiple species of arsenic; 4-aminobiphenyl (4-ABP) hemoglobin; volatile organic compound (VOCs) metabolites; volatile nitrosamines; aromatic amines; cyanide; high-sensitivity C-reactive protein (hsCRP); cotinine; and creatinine. The full panel of tobacco exposure biomarkers listed above will be measured in the PATH Field Study and a subset of these biomarkers will be measured in up to 10,000 participant samples annually through August 2016. Together with the data collected form the main PATH questionnaire, these analyte measurements will provide information that can be used to analyze between-person differences and within-person changes over time in tobacco product use patterns and behaviors, attitudes and risk perceptions, tobacco-related biomarkers of exposure and harm, and health conditions.

Ben Blount Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
07/13/2012

Psychotherapy Development Research Center

Reducing adolescent and young adult tobacco use is an important public health objective. The goal of this project is to evaluate the possible impact of reduced nicotine tobacco products on adolescents and young adults, who are highly vulnerable to smoking. Specific aims are: (1) to develop and refine messages conveying the risk of reduced nicotine tobacco products by gathering information from 24 focus groups (approximately 8 participants each) of smoking and nonsmoking students attending two middle schools, two high schools and two colleges in Connecticut, and to determine the types of communication channels that are used by these students to seek information and communicate about tobacco and health issues; and (2) to determine how the messages created in Aim 1 correlate with intent to initiate product use, switch products, or quit tobacco by conducting surveys of approximately 2000 middle school, 2000 high school, and 2000 college students. The results of this investigation may inform educational and regulatory activities related to the use of potential modified risk tobacco products by adolescents and young adults.

Kathleen Carroll Funding Mechanism: National Institutes of Health- Grant
ID number: 3P50 DA009241-19S1
Institution: Yale University
07/01/2012

The UCLA-Boston University Lung Cancer Biomarker Development Laboratory

There is an urgent need to rapidly assess the physiologic impact of new tobacco products to identify those that pose serious health risks. In the parent grant, investigators demonstrated that gene-expression profiling of intra- and extra-thoracic airway epithelium is a sensitive indicator of cellular response to cigarette smoke exposure, yielding a bronchial airway gene-expression signature that is an early lung cancer biomarker. The goals of this study are to determine whether this same approach might identify responses to other tobacco products and to establish in vitro exposure systems that can accurately model physiological exposures and rapidly assess the potential carcinogenicity of tobacco-related products. This study will also identify molecular signatures of the potential carcinogenicity of tobacco and tobacco-related products; these new signatures will then be evaluated as potential biomarkers of cancer risk in the lung cancer cohorts being studied in the parent grant. Investigators will examine gene expression differences in airway epithelial cells from 160 subjects including electronic cigarette (e-cigarette) users, tobacco cigarette smokers, and former smokers, and will compare these differences to the in vitro effects of cigarette smoke or e-cigarette vapor. Specific aims are: (1) to identify physiologic responses to e-cigarette usage in intra-thoracic airway epithelial cells through transcriptome profiling; (2) to determine the utility of transcriptome profiling of extra-thoracic nasal epithelial cells in identifying physiologic responses to e-cigarette use; and (3) to establish in vitro exposure systems using human bronchial airway epithelial cells for assessing e-cigarette exposure effects and potential carcinogenicity. This research characterizing cellular responses to e-cigarettes will provide insight into their potential long-term health effects.

Steven Dubinett Funding Mechanism: National Institutes of Health- Grant
ID number: 3 U01 CA152751-03S1
Institution: University of California Los Angeles
06/22/2012

Use of New Technologies to Develop Biomarkers of Harm for New Tobacco Products

Omics technologies (i.e., genomics, metabolomics, and proteomics) have the potential to identify new biomarkers of harm from various types of products (e.g., drugs and general chemicals) and provide more sensitive indicators of cellular injury. Gene expression changes in target tissue or cells often occur before clear phenotypic signs of injury are observed. In this study, investigators will conduct omics analyses to detect subtle changes in cellular function in response to toxicants in tobacco smoke and smokeless tobacco products, and will identify biomarkers that may inform the evaluation of new tobacco products making reduced health risk claims. Study aims are: (1) to conduct in vitro and in vivo toxicological assessments to identify biomarkers, quantify toxicities, and establish dose responses for chemicals of interest to the Center for Tobacco Products (CTP); (2) to improve the predictive value of toxicological assays by determining biological mechanisms of action and applying translational studies using traditional, pharmacogenomic, proteomic, metabolomic, and bioimaging approaches; and (3) to develop, evaluate and compare in vitro and in vivo toxicity testing models and computer-assisted toxicology knowledge bases in order to provide quantitative data for improved safety assessments. This study may provide a foundation for discovering new biomarkers of harm in key cell types (i.e., lung and heart cells) affected by tobacco smoke; these biomarkers could potentially then be used in the clinical setting to support tobacco use risk assessment.

William Salminen/Maocheng (Tony) Yang Funding Mechanism: JV
ID number: E0744711
Institution: National Center for Toxicological Research
06/06/2012

Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors

The tobacco industry is introducing several potential “modified risk” tobacco products (MRTPs) that can be promoted to be safer or less addictive than conventional products, but scientific methodologies to evaluate these claims are lacking. The overall goal of this research effort is to provide scientists and regulatory agencies with scientifically-based guidelines for methods and measures to assess tobacco products and to test a framework for product evaluation. This five-year research effort will involve four interrelated projects. Project 1 will examine the abuse liability of aqueous tobacco extracts from four different MRTPs and a conventional product in an animal model; these extracts provide an extensive range of nicotine and other tobacco constituents to more closely model actual product exposure in humans. Project 2 will use three abuse liability assessment methods (i.e., human laboratory, ecological assessment, and questionnaire) to evaluate tobacco product demand when the product(s) vary in price; up to 360 cigarette smokers will be recruited for this study. Project 3 will evaluate various aspects of consumer perceptions of new oral tobacco products. Consumer perceptions include reactions to messaging (i.e., knowledge, attitudes, beliefs, product expectancies and risk perceptions) and to product response and use (i.e., behavioral, sensory and other subjective effects); study subjects will include 3,000 subjects per year for a Web survey, 180 participants for an advertising evaluation study incorporating individual-level data collection and group discussion, and 690 current smokers participating in a one-week trial of Camel Snus. Project 4, a human clinical trial of Camel Snus, will assess tobacco product use and its effects on toxicant exposure in 690 subjects randomized to one of five experimental conditions for a period of 8 weeks. This research effort will produce evidence on the reliability and validity of an array of methods and measures that can be applied to predict how consumers are likely to use and abuse new and modified tobacco products, and will enhance understanding of how product characteristics, product abuse liability, consumer perceptions, and moderating influences (i.e., sex, age, race/ethnicity) affect product uptake and use and resulting toxicant exposure.

Dorothy K. Hatsukami Funding Mechanism: National Institutes of Health- Grant
ID number: 1U19CA157345-01A1
Institution: University of Minnesota
06/06/2012

Expanding U.S. ITC cohort – Effectiveness of Tobacco Control Policies in High vs. Low Income Countries–Graphic Health Warnings

This project is a supplement to an existing study that focused on evaluating the style and content of graphic health warning labels (HWLs) that have been implemented in various countries; this evaluation was conducted as part of the International Tobacco Control Policy Evaluation Survey (ITC). The goal of this supplement is to expand the U.S. ITC cohort to include: (1) newly-recruited youth aged 12-17 years, regardless of tobacco use status; (2) newly-recruited young adults aged 18-24 years, regardless of tobacco use status; (3) newly-recruited adult cigarette and non-cigarette tobacco users; and (4) newly recruited former smokers who have quit within the past two years. Data collection will include phone and online interviews with 3,121 adult tobacco users (aged 25+ years), 1,174 young adults tobacco users and non-users (aged 18-14 years), and 1,208 adolescent tobacco users and non-users (aged 12-17 years).  Prior to conducting the surveys, researchers will conduct a series of smaller studies aimed at identifying the measurement methods with the strongest validity, reliability, and feasibility for use in population surveys designed to evaluate how consumers respond to HWLs. These studies will involve:  (1) determining the measurement properties of self-report measures used in the ITC Survey on the cognitive, affective and behavioral impacts of HWLs; 2) testing new questions designed to enhance measurement of key domains of HWL impact (i.e., perceived magnitude of risk, perceived relevance of message, quit-related cognitions and behaviors); and 3) cross-validating self-report measures  identified in the previous stages with “objective” biomarker data from eye-tracking and brain imaging in response to viewing HWLs.  Findings may inform regulatory activities related to HWLs. (Project completed in 2015.) 

K. Michael Cummings Funding Mechanism: National Institutes of Health – Grant
ID Number: 3 P01 CA138389-05S1
Institution: Medical University of South Carolina
06/05/2012

Developing Methods for the Evaluation of Smokeless Tobacco-Associated Carcinogenesis

Epidemiological studies have shown that smokeless tobacco use is associated with elevated risk of oral cavity cancers, esophageal cancer and pancreatic cancer.  About 30 carcinogens have been identified in smokeless tobacco products, with alkaloid derived tobacco-specific N-nitrosamines (TSNAs) being the most important.  Two major types of TSNAs are found in smokeless tobacco: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N’-nitrosonornicotine (NNN).  NNK and NNN have been detected in saliva samples collected from smokeless tobacco users, and nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a major metabolite of NNK, has been detected in the saliva, plasma and urine of smokeless tobacco users, indicating that these carcinogens are absorbed and metabolized by the body.  These metabolites could potentially be used as sensitive biomarkers for smokeless tobacco-associated toxicity/carcinogenicity.  The carcinogenic activity of smokeless tobacco has been studied using various animal models; the hamster cheek pouch and the rat artificial lip canal appear to be the best models currently available for studying the effects of smokeless tobacco products. This study will determine the appropriate animal models for long-term carcinogenesis studies, evaluate and compare the carcinogenicity of smokeless tobacco products, and develop biomarkers for the risks associated with smokeless tobacco exposure.

Lei Guo and Frederick Beland / Kimberly Benson Funding Mechanism: JV
ID number: E0748801
Institution: National Center for Toxicological Research
06/01/2012

Focus Groups on Cigars, Cigarillos, and Little Cigars: Awareness, Perceptions, & Behavior

Sales of cigars, especially little cigars and cigarillos, have risen dramatically in the United States in recent years. The goal of this study is to ascertain the diversity of consumer knowledge, attitudes, and awareness related to cigars, cigarillos, and little cigars. Investigators will conduct 16 focus groups (including approximately 6-10 participants per group) with young adults (ages 18-24) and adults (ages 25 and older). Young adult groups will be segmented by gender, and groups may be further segmented by race and socioeconomic status. Focus groups will be conducted in Orlando, Los Angeles, Providence, Richmond, and Washington, D.C.; each city will have at least one focus group for each of the following high-prevalence demographic populations: (a) African-American males; (b) Hispanic males; and (c) white males from lower socioeconomic backgrounds. Focus groups will cover topics including (but not limited to) participants’ cigar, cigarillo, and/or little cigar use; attitudes and beliefs about the risks of using these products, including perceptions of relative harm compared to other forms of tobacco (e.g., cigarettes); and reactions to advertising and/or labeling for tobacco products. This study may inform the design of future experimental studies and surveys related to cigars, cigarillos, and little cigars, and may inform the FDA’s efforts to implement the provisions of the Family Smoking Prevention and Tobacco Control Act related to educating the public about the harms of tobacco use.

Denise Dickinson and Sarah Johnson Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: RTI
04/20/2012

Evaluation of Product and Physiological Variables Influencing Smokeless Tobacco ToxicityVariables Influencing Smokeless Tobacco Toxicity

Smokeless tobacco products contain more than 30 carcinogens, including tobacco-specific N-nitrosamines (TSNAs), polycyclic aromatic hydrocarbons (PAHs), and radioactive metals that contribute to numerous health problems including cancer and cardiovascular disease. Much of the risk associated with oral cancer from smokeless tobacco use has been attributed to TSNAs. The physiologic and product variables of smokeless tobacco products can significantly affect TSNA levels and their bioavailability, leading to different degrees of product toxicity. A combination of factors — such as pH, tobacco type, nitrate fertilization/uptake, curing, fermentation, and storage conditions — can contribute to extremely high TSNA concentrations. Furthermore, the genotoxicity of smokeless tobacco products may increase or decrease through metabolism by oral bacteria; the potential roles that oral bacteria play in converting smokeless tobacco ingredients to more or less genotoxic and carcinogenetic substances have not been well studied. This study will evaluate smokeless tobacco genotoxicity levels due to microbial metabolism, the effects of physiological variables on harmful and potentially harmful constituent (HPHC) bioactivation, and the effects of smokeless tobacco on the microbial ecology of the oral cavity. Study aims are: (1) to identify physiological and product variables that influence smokeless tobacco toxicity and metabolic activation of TSNAs, PAHs, and other select HPHCs by oral bacteria; and (2) to conduct a pilot study to investigate how smokeless tobacco genotoxicity is affected by metabolism by oral bacteria and to determine the effect of smokeless tobacco on the ecological balance of human oral microbiota.

Huizhong Chen/Maocheng (Tony) Yeng & Patricia Richter Funding Mechanism: JV
ID number: E0747201
Institution: National Center for Toxicological Research
04/15/2012

COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function

Cigarette smoking is the major cause of chronic obstructive pulmonary disease (COPD), the fourth leading cause of mortality in the U.S. Central to COPD pathogenesis is ciliopathy, a dysfunction of the airway ciliated cells that mediate transport of mucus to remove inhaled pathogens; ciliopathy leads to mucus accumulation, impaired host defense and recurrent infections. While cigarette smoking is known to be the major cause of ciliopathy, the molecular mechanisms underlying smoking-induced airway ciliopathy are unknown. The goal of this five-year investigation is to examine metabolomic changes in smoking-related airway ciliopathy in order to identify a link between smoking, burden of oxidants to the lung epithelium and COPD pathogenesis. Study aims are: (1) to perform global metabolic profiling of banked biologic samples from two existing patient cohorts to assess the hypothesis that smoking-induced COPD is associated with a unique serum and lung metabolome and that subsets of this metabolome are linked to COPD ciliopathy; (2) to combine metabolic profiling and in vitro studies of human and murine airway epithelial cells to evaluate the link between the COPD metabolome and mechanisms underlying COPD ciliopathy; and (3) to characterize and quantify the cigarette smoke-induced “redoxome” of redox-prone metabolites in lung and serum that could be affected by the oxidants in cigarette smoke, and to assess its role in ciliopathy. The two existing cohorts include (1) 159 individuals in five groups (30 healthy nonsmokers, 12 healthy smokers, 61 healthy smokers undergoing smoking cessation, 10 COPD smokers and 46 COPD smokers undergoing smoking cessation) who provided serum, bronchoalveolar lavage (lung epithelial lining fluid) and airway epithelium samples at 0, 3, 6 and 12 months, and (2) 67 smokers (34 active smokers with normal spirometry and low diffusing capacity of whom 24% developed COPD and 33 normal smoking controls of whom 3% developed COPD) who were followed with lung function studies for up to six years. The investigators will recruit 50 new subjects (healthy nonsmokers, healthy smokers and COPD smokers) who will provide live airway epithelial cells for the human mechanistic studies.

Ronald Crystal Funding Mechanism: National Institutes of Health- Grant
ID number: 1P20HL113443-01
Institution: Weill Medical College of Cornell University
04/05/2012

Supplement to “Supporting the Diffusion of the Tobacco Graphic Warning Labels”

There were two major aims of the supplement: (1) Previous research undertaken by FDA and RTI tested 36 potential tobacco graphic warning labels (GWLs) in groups of teens (aged 13-17), young people (aged 18-24) and other adults. While surveys included respondents from a wide range of backgrounds, the number of subjects in several important population groups was insufficient to indicate whether specific GWLs would be effective in those groups. The first major research program under the supplement compared responses to the nine proposed GWLs relative to text-only labels among four priority smoker sub-populations (i.e., African-Americans, Latinos, those with a high school education or less, women of child-bearing age). Responses for each sub-population were compared to responses from the general population of smokers. (2) The FDA was developing the youth public education program that eventually became “The Real Cost” campaign. The second major research program under the supplement compared prospective message themes (sets of beliefs), and specific beliefs within each theme, for campaigns aimed at preventing smoking initiation among 13-17 year olds and 18-25 year olds who had never used tobacco, stopping progression among 18-25 year olds who are intermittent tobacco users, and encouraging cessation among 18-25 year olds who are current established cigarette smokers. The research incorporated a methodological approach that used cross-sectional quantitative data to assess the association between beliefs about the consequences of smoking and intentions to smoke in the future. The FDA used these results to inform the themes to emphasize in the campaign. (Project completed in 2013.)

Robert Hornik Funding Mechanism: Intra-Departmental Delegation of Authority (IDDA)
ID Number: 3P20CA095856-09S1
Institution: University of Pennsylvania
04/01/2012

Quantification of Aflatoxin B1 in Smokeless Tobacco Products

Aflatoxin B1 is a known carcinogenic compound that is produced by food-borne molds and has previously been found in smokeless tobacco products. Continued exposure to aflatoxin B1 may lead to the onset of cancer through protein or DNA adducts. The goal of this project is to measure aflatoxin B1 in approximately 30 different smokeless tobacco products representing various subclasses of smokeless products. Quantities of aflatoxin B1 will be determined analytically using liquid chromatography/mass spectrometry (LC/MS) technology. Data regarding the quantities of aflatoxin B1 in smokeless products may be used to inform FDA’s regulatory authorities related to product standard development and product application review.

Michael Rybak / Matt Walters Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
03/13/2012

Understanding Reactions to Graphic Warning Labels on Cigarettes in Diverse Populations of Youth and Young Adults at Increased Risk of Smoking

Existing research consistently supports that graphic warning labels (GWLs) have a stronger impact than text-only messages on smoking-related beliefs and behaviors; however, most GWL studies have included only adults and smokers. To inform the development of effective GWL awareness and promotion campaigns, investigators will conduct research activities among diverse groups of smokers, those at risk of smoking, and non-smokers. Specific aims are: (1) to recruit 875 youth (ages 13-17) smokers, young adult (ages 18-24) smokers, at-risk smokers, and non-smokers from diverse population subgroups with high smoking prevalence or smoking risk into research activities to evaluate a wide range of reactions to GWLs; (2) to conduct surveys, card sort exercises, interviews, and experiments to assess eight outcomes of interest (i.e., affective response, understanding, personal relevance, anticipated social reaction, perceived effectiveness, novelty, reactance, and action steps) that might follow GWL exposure; (3) to translate findings from these studies into recommendations that could inform and support GWLs; and (4) to adapt and conduct research activities from Aim 2 in a sample of 400 adults (ages 25+) from diverse population subgroups with high smoking prevalence or smoking risk. Findings may help inform regulatory activities related to GWLs. (Project completed in 2012.)

Matthew Kreuter Funding Mechanism: National Institutes of Health – Grant
ID Number: 3P50CA095815-09S1
Institution: Washington University, St. Louis
02/12/2012

FDA Cycle of the Health Information National Trends Survey

Communication to the public about tobacco products represents one of the strongest influences on tobacco use behavior and can have a meaningful impact on public health. The goal of this survey, called the Health Information National Trends Survey (HINTS), is to examine communications about tobacco, trust in various information sources, and perceptions of tobacco products. This mail-based survey, which will be available in both English and Spanish, will be administered to a nationally representative sample of approximately 3,500 adults; the survey will attempt to include larger numbers of current and former smokers than were included in earlier cycles of HINTS. Study aims are: (1) to examine tobacco-related communications received by current, former and never tobacco users, as well as exposure to certain messages; and (2) to examine beliefs about tobacco products, tobacco product contents, and modified risk claims. This study may inform FDA’s public education campaigns and regulatory activities, including regulation of modified risk claims.

Kelly Blake / David Portnoy Funding Mechanism: Interagency Agreement
ID number: XPC12012-0000-00000
Institution: National Institutes of Health, National Cancer Institute
11/09/2011

Perceptions of Health Risk from Smokeless Tobacco Products and Nicotine Replacement Therapy among Pregnant Women and Women Planning a Pregnancy

In recent years, tobacco product manufacturers have invested heavily in new smokeless products that may be perceived as safer alternatives to cigarettes. Because pregnant women and women intending to become pregnant are often highly motivated to protect the health of their unborn babies, they may be especially attuned to non-combustible tobacco product messages that expressly state or imply reduced harm. The goal of this study is to explore awareness, knowledge, and perceptions of various smokeless nicotine delivery products (e.g., e-cigarettes, snus, dissolvables) among pregnant women and women who are planning to become pregnant. Focus groups and individual interviews with approximately 100 participants (aged 18-40) will be conducted with pregnant smokers, pregnant women who quit smoking after they became pregnant, and smokers who plan to become pregnant. Focus groups will be conducted in Oklahoma City, OK; Billings, MT; Lexington, KY; and Manchester, NH. Topics will include awareness of various products; perceptions of health risks (to self and fetus/infant/child) associated with product use; perceptions of the potential for nicotine addiction associated with various products; factors that might influence a product switch or resumption of product use following tobacco cessation; and responses to packaging, advertising, and graphic health warnings. Data will be collected from September 2013 to December 2013. Understanding how non-combustible products are viewed by pregnant women and women intending to become pregnant may help shape communications, policies, and interventions designed to prevent tobacco use in this vulnerable population.

Lucinda England / Amber Koblitz Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
11/03/2011

Evaluating the Toxicity of Tobacco Products Using In Vitro 3D Tissue Models

Tests for comparing the relative toxicity of tobacco products are not presently available due to the lack of appropriate in vitro and validated assays. Researchers have developed and validated human in vitro 3D tissue models for toxicity testing; 3D airway models have an air-tissue interface similar to that of the human respiratory tract, a target of tobacco smoke exposure. This study will investigate preliminary 3D tissue model data indicating that tobacco smoke exposure results in cytotoxicity, induction of cytochrome P450 drug metabolizing enzymes (CYPs), and inflammatory responses in the human airway.  In addition, investigators will evaluate endpoints suitable for use in tissue models (including histopathological evaluations), endpoints related to intercellular interactions, and biomarkers developed by NCTR Project ID E0744701.  Study aims are: (1) to identify 3D tissue models that may be applicable for evaluating tobacco product toxicity; (2) to perform preliminary studies to develop and verify 3D tissue model baseline characteristics and measurement methods and to identify positive controls for major toxicity endpoints; and (3) to evaluate the ability of these models to differentiate between toxicity and inflammation produced by a series of cigarette smoke condensates. This study will provide information that may inform the generation of toxicity data using models that are human-based, untransformed and simulate normal human tissue targets for tobacco, thus mitigating the need for animal studies.

Robert H. Heflich / Patricia Richter Funding Mechanism: JV
ID number: E0746801
Institution: National Center for Toxicological Research
10/01/2011

Expanded Samples Analysis of NHANES Self-Reporting Smokers Project

The National Health and Nutrition Examination Survey (NHANES) – conducted by the Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS) — is a national survey of non-institutionalized youth and adult civilians in the United States. NHANES includes a representative sample of approximately 10,000 participants in each two-year survey cycle and combines interviews and physical examinations to identify the prevalence of major diseases and disease risk factors. Information collected includes detailed cigarette smoking information as well as data on recent use of other tobacco/nicotine-containing products including pipes, cigars, smokeless tobacco, snuff, and nicotine replacement therapy. As part of NHANES, the CDC Division of Laboratory Sciences analyzes participant urine samples in order to measure biomarkers of different analytes, some of which have been shown to be markers of harmful and potentially harmful constituents (HPHCs) in tobacco smoke. The goal of this project, an enrichment of the 2011-2012 NHANES wave, is to expand the urine biomarker analysis to include approximately 960 self-reported smokers age 20 or older. DLS will analyze urine samples for four classes of tobacco exposure biomarkers: polycyclic aromatic hydrocarbons (PAHs), metals, volatile organic compound (VOC) metabolites, and thiocyanate. The expanded measurement of tobacco exposure biomarkers will enhance epidemiological and health sciences research studies that use NHANES data; furthermore, this project has the potential to inform FDA’s regulatory activities related to setting product standards and conducting application review.

Ben Blount Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
09/16/2011

Population Assessment of Tobacco and Health (PATH)

Population-level longitudinal data on tobacco product use, attitudes, biomarkers, and health conditions are currently not available for the U.S. The goal of this study, called the Population Assessment of Tobacco and Health (PATH) Study, is to provide in-depth population-level longitudinal data to monitor and assess behavioral and biological between-person differences and within-person changes over time in tobacco product use patterns and behaviors, attitudes and risk perceptions, tobacco-related biomarkers of exposure and harm, and health conditions. The PATH Study, a nationally representative, longitudinal cohort study, will track approximately 59,000 tobacco product users, never users, and former users including 16,100 youth aged 12-17 and 42,700 adults aged 18 and older. The study uses computer-assisted interviews to collect information from adults, youth, and parents of youth; in addition, biospecimens (i.e., buccal cell, urine, blood) are collected from consenting adults. Participants are assessed annually for at least three years. Specific aims are: (1) to identify and explain between-person differences and within-person changes in tobacco-use patterns (e.g., switching, dual use, polyuse); (2) to identify between-person differences and within-person changes in risk perceptions and attitudes; (3) to characterize the natural history of tobacco dependence, cessation, and relapse related to various tobacco products; (4) to establish a baseline on tobacco use behaviors and related health conditions, including markers of exposure and tobacco-related disease processes; (5) to assess associations between regulatory actions and tobacco use patterns, behaviors, risk perceptions, attitudes, and associated health outcomes; (6) to assess between-person differences and within-person changes over time in population subgroups (e.g., gender, age, race/ethnicity); (7) to assess between-person differences and within-person changes over time in former and never users; and (8) to conduct small-scale research studies (e.g., cognitive testing, methodological studies, topic-based research studies) that focus on new and emerging tobacco-related behaviors, attitudes, and health issues. Study findings may inform FDA regulatory activities related to product standards (e.g., toxicity, appeal, abuse liability/addictiveness), health warnings, and new and modified risk tobacco products, as well as FDA’s public education efforts.

Andy Hyland / Nicolette Borek Funding Mechanism: Interagency Agreement
ID number: 224-12-9020
Institution: National Institutes of Health
09/15/2011

Evaluating New Reduced Nicotine Standards for Cigarettes

Reduction in nicotine content has been proposed as a potential regulatory measure to render cigarettes non-addictive and, consequently, to reduce smoke exposure and improve public health. The goal of this research effort is to determine how a marked reduction in the nicotine content of cigarettes impacts the use and effects of tobacco in current smokers. This five-year research effort involves four interrelated projects. Project 1, a multisite trial, includes two human studies evaluating the dose-response relationship for nicotine yield within the range thought to be at or below threshold for dependence and the potential use of concurrent nicotine replacement therapy (NRT) to facilitate the transition to very low nicotine content (VLNC) cigarettes; study subjects include 1,080 daily smokers aged 18 and older. Project 2, a multi-site trial involving 1,250 subjects, assesses the effects of prolonged VLNC use and compares an immediate switch to VLNC cigarettes with a gradual reduction in cigarette nicotine content over 20 weeks. Project 3 focuses on the impact of VLNC cigarettes on smokers with schizophrenia; this project begins to address an important concern about the impact of a new nicotine content standard in smoker sub-populations who might be particularly vulnerable to the effects of nicotine reduction. Project 4 addresses concerns that the manipulation of other tobacco constituents could offset the predicted gains of VLNC cigarettes by investigating the relationship between the threshold dose for maintaining rat nicotine self-administration and the presence of minor alkaloids, beta-carbolines, acetaldehyde, and monoamine oxidase inhibitors (MAOIs). These four projects will reveal important information about whether establishing new lower nicotine standards for cigarettes would reduce cigarette use and, consequently, reduce the morbidity and mortality associated with smoking.

Eric C. Donny Funding Mechanism: National Institutes of Health- Grant
ID number: 1U54 DA031659-01
Institution: University of Pittsburgh at Pittsburgh
09/01/2011

Consumer Risk Perceptions of Tobacco Products

Consumer perceptions of tobacco product risk play a critical role in decisions to use tobacco, switch tobacco products, or stop tobacco use. The purpose of this project is to evaluate consumer perceptions of the relative risks of various commercially-available tobacco products and the potential impact of possible modified risk products and claims on those perceptions. The project consists of qualitative and quantitative research conducted with various groups of consumers, including current and former adult tobacco users, young adult tobacco users and adolescents who either use tobacco or are susceptible to tobacco use initiation. The qualitative phase of the project will involve two sets of 16 focus groups (including 8-10 participants each) conducted in person. One set of focus groups will gather information about consumer beliefs about the risks from use of various tobacco products; the second set will gather information about the impact of (hypothetical) expressed modified risk claims on consumer perceptions of risks and the potential impact on tobacco use. The quantitative phase of the project will consist of an experimental study to measure the effect of various types of (hypothetical) modified risk products and claims on consumers’ perceptions, attitudes, beliefs and possible behaviors related to tobacco products. Three thousand participants will view online images of real and hypothetical tobacco product packages and advertisements and respond to a 15-minute questionnaire that measures responses to the images and collects demographic and tobacco use information. The information collected from the study may inform the FDA’s efforts to implement the provisions of the Tobacco Control Act related to modified risk tobacco products.

Carol Schmitt and Sarah Johnson Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: RTI
08/18/2011

Evaluation of the Ability of Standard Genetic Toxicology Assays to Assess the Relative Genotoxic Potential of Cigarette Smoke Condensates

Genetic toxicology tests are used as part of hazard identification for a variety of FDA-regulated products. This study will evaluate recommended in vitro assays to determine if they can be used to assist the Center for Tobacco Products (CTP) in making science-based regulatory decisions related to tobacco product toxicity. These assays include a gene mutation assay in bacteria (i.e., Ames test or E. coli) and an in vitro mammalian cell assay capable of detecting chromosomal damage (i.e., mouse lymphoma Tk assay, in vitro micronucleus assay or gross chromosomal aberration analysis). Study aims are: (1) to determine if genetic toxicology assays or a combination of assays provide an adequate potency range to detect reductions of selected harmful and potentially harmful constituents (HPHCs) in tobacco products in varying amounts; and (2) to evaluate, develop and validate quantitative assays to detect statistically significant differences in cigarette cytotoxicity over a range of biologically-relevant concentrations. This study may establish whether standard genetic toxicology assays are capable of assessing the genotoxic potential of cigarette smoke solutions and aerosolized smoke. Suitable assays will provide data to allow potential comparisons of current and new tobacco products.

Martha M. Moore / Patricia Richter Funding Mechanism: JV
ID number: E0745901
Institution: National Center for Toxicological Research
06/07/2011

Experimental Study of the Presentation of HPHC Information to Consumers

Section 904(d) of the Tobacco Control Act requires FDA to publish its list of harmful and potentially harmful constituents (HPHCs) in tobacco products (including quantity of each HPHC by brand and sub-brand) in a format that is understandable and not misleading to the public. Building upon research conducted in 2013, investigators will conduct (1) a series of focus groups and individual in-depth interviews with consumers to gather information about different ways of presenting HPHC information, and (2) an experimental study to evaluate the most effective way to convey HPHC information. Focus groups and interviews will evaluate participants’ understanding and perceptions of HPHCs in tobacco smoke and reactions to test images of HPHC list formats. Fourteen focus groups of 8-10 participants each will include adults aged 18-65 who are tobacco product users or former users; 10 interviews will be conducted with adolescents aged 13-17 who are at risk for smoking. The experimental study will empirically test the impact of three different HPHC list formats on consumer risk perceptions of three types of tobacco products: cigarettes, smokeless tobacco, and roll-your own tobacco; the study will be conducted in a demographically and geographically diverse Internet panel of 4,500 participants aged 13 and older. Results from these research activities may be used to inform the development of a list of HPHCs for public display.

Jon Blitstein and Greta Tessman Funding Mechanism: Research Contract
ID number: HHSF223201110005B
Institution: Research Triangle Institute
05/06/2011

Nicotine Uptake as a Function of its Free-Base Dose

The public health community has long been concerned that smoking high free-base nicotine cigarettes results in higher amounts and rates of nicotine accumulation in the brain, which increases the addictive potential of cigarette smoking. However, this assertion is controversial, since a comparison of the amount of nicotine delivered to the human brain for high and low free-base nicotine cigarettes has never been conducted. The goal of this project is to determine whether the rates of nicotine absorption and nicotine distribution in the brain correlate with free-base nicotine concentrations in cigarettes. Investigators will examine nicotine uptake in 20 smokers by having them smoke high or low free-base nicotine cigarettes spiked with [11C]nicotine (a radiotraceable form of nicotine). Six smokers will have repeated positron emission tomography (PET) scans to image their brains under the same conditions to test for reproducibility; the remaining 14 will have two PET scans each after taking a puff from a high and a low free-base nicotine cigarette to compare the rate and amount of uptake of [11C]nicotine at high and low free-base nicotine levels. By elucidating the role of free-base nicotine in tobacco on nicotine delivery to the brain, this project may inform FDA regulatory activities related to product standards and application review.

Cliff Watson / Elena Mishina Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
05/06/2011

Establishing Baseline Levels of Priority Harmful/Potentially Harmful Constituents in Tobacco Smoke and Smokeless Tobacco Products

In order to develop the scientific basis for product standards and evaluate the impact of FDA’s regulatory activities on tobacco products, the FDA will measure current ranges for harmful and potentially harmful constituents (HPHCs) in smoke and smokeless tobacco products. Currently, 93 constituents are included in FDA’s established HPHC list. Using the analytical methods established in the project entitled “Method Development for Priority HPHCs in Tobacco Smoke and Smokeless Tobacco Products,” investigators will analyze HPHC levels in 30 common cigarette brands and 15 common smokeless brands in order to establish baseline HPHC levels. Both International Organization for Standardization (ISO) and Health Canada’s Canadian Intense (CI) smoking regimens will be used to measure HPHCs in cigarettes and smokeless tobacco products.

Cliff Watson / Matt Walters Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
04/01/2011

Method Development for Priority HPHCs in Tobacco Smoke and Smokeless Tobacco Products

Select test methods for specific harmful and potentially harmful constituents (HPHCs) exist; however, FDA wants to develop new, more robust methods for those HPHCs that have not been well characterized. This project involves the development and confirmation of analytical methods and procedures to measure HPHC levels in smoke and smokeless tobacco products. The contracted laboratory will develop high quality, robust methods for constituents in smoke and smokeless tobacco products. Methods may include tandem mass spectrometry (MS-MS), inductively coupled plasma mass spectrometry (ICP-MS), ion chromatography (IC), ultra-performance liquid chromatography mass spectrometry (UPLC-MS), and/or gas chromatography/mass spectrometry (GC/MS). The development and robustness of methods and procedures will ensure that FDA receives high quality and accurate data to inform regulatory decision-making related to HPHCs.

Cliff Watson / Matt Walters Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
04/01/2011

Comparative Brand Analysis (FDA 50)

The chemical composition and product design features of cigarettes are extremely diverse. In this project, investigators will analyze the 50 top-selling cigarette brands for select harmful and potentially harmful constituents (HPHCs), product design and composition. HPHCs will be analyzed under both International Organization of Standardization (ISO) and Canadian Intense (CI) smoking regimens. Smoke yields and tobacco filler will be quantified using various analytical methods including ion chromatography (IC), liquid chromatography/mass spectrometry (LC/MS), and gas chromatography/mass spectrometry (GC/MS). This information will inform FDA about the current cigarette marketplace and may be useful for FDA during product application reviews.

Cliff Watson / Matt Walters Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
03/21/2011

Nicotine Threshold: Establishing a Pilot Protocol

Reducing the nicotine content in cigarettes may facilitate cessation and discourage initiation. However, in order to maintain a desired nicotine dose, smokers might change their smoking behaviors (i.e., increase “compensatory smoking”) to maximize nicotine uptake, thus increasing their exposure to smoke constituents. The goal of this un-blinded clinical study was to study the effects of low-nicotine cigarettes on smoking behavior by using solanesol as a marker for exposure to smoke constituents. Investigators analyzed solanesol levels in approximately 2,500 cigarette butts collected by 72 participants smoking 39 different cigarette brands over four weeks. Participants smoked their own brand of cigarette (approximately 12 mg nicotine/cigarette) during the first week; Quest 1 (6 mg nicotine/cigarette) during the second week; Quest 2 (3 mg nicotine/cigarette) during the third week; and Quest 3 (0.05 mg nicotine/cigarette) during the fourth week. Study findings indicate that participants demonstrated moderate compensation when smoking cigarettes with minor nicotine reduction, did not compensate by smoking more cigarettes per day, and demonstrated minimal compensation when smoking cigarettes with major nicotine reduction. These data may be used to inform FDA’s regulatory activities.

Cliff Watson / Sarah Evans Funding Mechanism: Interagency Agreement
ID number: 224-11-9002
Institution: Centers for Disease Control and Prevention
02/11/2011

Consumer Perceptions of Dissolvable Tobacco Products

This two-phase research study explored consumer attitudes, beliefs, perceptions, and intended behaviors related to the use of dissolvable tobacco products. The first phase of the research involved a review of the literature related to consumer perceptions of dissolvable tobacco products. The second phase involved a series of focus groups held in March 2011 with 106 youth and young adults living in three dissolvable tobacco product test markets in the U.S. (i.e., Portland, OR, Charlotte, NC, and Denver, CO). Participants were asked to discuss their awareness of the products, perceptions of harm, perceptions of the products, and reactions to available marketing. Research findings may inform FDA’s understanding of dissolvable tobacco products and how these products may be perceived and used by consumers.

Annice Kim and Greta Tessman Funding Mechanism: Research Contract
ID Number: HHSF223201110005B
Institution: Research Triangle Institute (RTI)
01/01/2011

Poison Events Associated with Tobacco Products

Tobacco-related poison events such as accidental ingestion of tobacco and accidental exposure to the nicotine in electronic cigarettes are a public health concern, particularly among young children. The goal of this project is to understand the frequency and characteristics of poison events associated with tobacco products. This descriptive study will analyze 2001-2012 data from the National Poison Data System (NPDS), which contains information on poison exposures reported by consumers across the United States. Specific study aims are: (1) to compute and describe the frequency of poison events associated with tobacco products; and (2) to describe the characteristics of these poison events. Findings from this study may inform CTP’s regulatory authority over surveillance of poison events associated with tobacco products.

Deborah Carr / Baoguang Wang Funding Mechanism: Interagency Agreement
ID number: 1119530
Institution: American Association of Poison Control Centers
01/01/2011

National Adult Tobacco Survey 2012-2013, 2013-2014

The National Adult Tobacco Survey (NATS) — a nationally-representative cross-sectional random-digit-dialed annual telephone survey of U.S. adults aged 18 and older — seeks to determine tobacco use prevalence and the factors promoting and impeding tobacco use.  Questionnaire items measure cigarette use (including menthol and roll-your-own cigarette use); young adult susceptibility to use of cigarettes; cigarette purchasing behaviors; use of cigars and physical properties of cigars used; use of smokeless tobacco, snus, dissolvable tobacco, pipes, waterpipes, and electronic cigarettes; susceptibility to use of non-cigarette tobacco products; use of flavored non-cigarette tobacco products;  and measures of addiction, cessation, tobacco marketing exposure, and knowledge, attitudes, and beliefs regarding tobacco use.  In 2012-2013, the overall response rate for the survey was 44.9% with a sample size of 60,064 adults; the target sample size for 2013-2014 is 75,000 adults.  Study aims are: (1) to estimate the national burden of tobacco use among adults, including the use of new and emerging products and dual/poly tobacco use, and assess the degree to which tobacco use behaviors vary as a function of gender, age, race/ethnicity, socioeconomic status, and sexual orientation; (2) to assess trends in product preferences, such as menthol and flavored product use, and examine potential associated differences in frequency of product use, dependence, cessation and risk perceptions; (3) to monitor susceptibility to tobacco product use and consumer perceptions regarding tobacco products, and monitor whether perceptions change over time; and (4) to monitor population-level exposure to tobacco health warnings and determine levels of exposure to prohibited marketing.  This survey may yield nationally representative data to inform FDA regulatory activities and may generate hypotheses regarding underlying mechanisms that may inform future research.

Sean Hu / Hannah Day Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
01/01/2011

Method Development for Biomarkers of Priority HPHCs

An understanding of the levels of harmful and potentially harmful constituents (HPHCs) in tobacco smoke and smokeless tobacco products will inform FDA regulatory activities. This project involves further development of analytical procedures to measure HPHC levels in smoke and smokeless tobacco products and, when possible, development into high-throughput methods. The contracted laboratory will work to develop high quality methods for all select HPHCs identified by the Center for Tobacco Products (CTP) in smoke and smokeless tobacco products. When technically feasible, the laboratory will incorporate these constituents into existing analysis methods or develop new methods that encompass multiple constituents of a similar nature. Once developed and validated, these test methods may be used to measure HPHC levels in tobacco products.

Maocheng (Tony) Yang Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
01/01/2011

Establishing Baseline Levels of Biomarkers of HPHCs in Tobacco Smoke and Smokeless Tobacco Products

Establishing baseline levels of exposure to harmful and potentially harmful constituents (HPHCs) in tobacco products may help establish the relationship between HPHC levels and consumer risk. Using a variety of new analytical methods, the laboratory will analyze urine samples from adult, non-institutionalized, civilian, self-identified smokers in order to establish baseline biomarker levels. This baseline data may be used to inform manufacturer application review, development of product standards and other regulatory activities.

Ben Blount / Maocheng (Tony) Yang Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
08/23/2010

Supplement to “The Effects of Minnesota State and Local Programs on Young Adult Tobacco Use”

Young adults represent a target market for the tobacco industry. The goal of the Minnesota Adolescent Community Cohort (MACC) Study is to describe current and potential tobacco marketing strategies targeting youth and young adults. The MACC Study is a population-based cohort study that initially enrolled 4,825 youth (4,220 from Minnesota and 605 from comparison states) aged 12-16. Every six months since October 2000, participants have been surveyed by telephone about their tobacco use and related attitudes and beliefs. The aims of this study supplement are: (1) to prepare background materials (including a summary of a literature search and a summary of pertinent regulations) for the May 2010 expert panel discussion on tobacco marketing; (2) to conduct and analyze the results of the expert panel discussion; (3) to recruit and conduct focus groups with 47 young adults about tobacco marketing strategies; and (4) to analyze focus group transcripts to create survey items to add to the MACC Round 21 survey. These findings may inform policies and regulations regarding the potential tobacco marketing strategies targeted toward young adults. (Project completed in 2011.)

Jean Forster Funding Mechanism: Interagency Agreement (IAA)
ID Number: 3R01CA086191-10A1S1
Institution: University of Minnesota
08/16/2010

Supplement to Impact of Retail Tobacco Advertising on Youth Smoking

Adolescents and young adults may be targets of tobacco industry marketing. The goal of this study is to assess smokeless tobacco market awareness, risk perceptions, use, and the effects of flavor and sensory descriptors on product appeal and perceived risk among young people ages 13-25. Specific aims are: (1) to assess marketing awareness, risk perceptions and use of new smokeless products (i.e., snus and dissolvable nicotine products) in a cross-sectional survey; and (2) to examine the effects of flavor (e.g., “peppermint,” “spice,” “berry,” “vanilla”) and sensory (e.g., “mellow,” “smooth,” “natural,” “fresh”) descriptors on product appeal and perceived risk. To accomplish Aim 1, researchers will administer a survey to 3,000 adolescents and young adults aged 13-25. To accomplish Aim 2, researchers will conduct an experiment in which they randomize 497 young adult smokers and nonsmokers aged 18-25 to one of eight experimental groups (either Camel or Marlboro snus packaged in one of four packages characterized by either flavor descriptors, sensory descriptors, no descriptors, or plain packaging) to test how the packaging affects perceptions of appeal and harm. Participants will rate their assigned product on their perceptions of various attributes, including perceived appeal, taste, enjoyment, addictiveness, harm, and safety compared to other snus products and to cigarettes, as well as purchase intentions. Research findings may inform regulatory actions related to tobacco product packaging.

Lisa A. Henriksen Funding Mechanism: Inter-Agency Agreement (IAA)
ID Number: 3R01CA067850-10A1S1
Institution: Stanford University
08/10/2010

National Health Interview Survey (NHIS)

The National Health Interview Survey (NHIS), conducted annually by the National Center for Health Statistics (NCHS), is the principal source of information on the health of the U.S. civilian non-institutionalized household population.  The NHIS has been conducted continuously since its inception in 1957 with the goal of monitoring the health of the nation.  The NHIS is a cross-sectional, multistage area probability design with a representative sample of households and non-institutional group quarters; Black, Hispanic and Asian persons are oversampled.  Sampling is at the household level; tobacco use questions are asked of one randomly selected adult (aged 18 or older) in each family. The sample size of adults participating in the 2010-2012 surveys has ranged from 27,157 to 34,525. The goal of this specific project is to expand the annual NHIS tobacco use questions to capture non-cigarette product use; specifically, new survey questions will assess ever and current use of e-cigarettes, non-cigarette combustible products and non-combustible tobacco products to complement annual NHIS data on cigarette prevalence. These data may be used to monitor trends in non-cigarette tobacco use over time and among various socio-demographic groups.

Renee Gindi / Catherine Corey Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
08/10/2010

Expansion of National Youth Tobacco Survey Data Analyses and Data Collection (NYTS) (Tobacco Research Collaboration Project)

The overwhelming majority of adult tobacco users initiated tobacco use in adolescence. The goal of the National Youth Tobacco Survey (NYTS) is to assess and monitor tobacco use and the factors that influence use among youth in order to inform effective programs, policies, and regulations for tobacco use prevention. NYTS is the only national, cross-sectional survey with representative samples of middle (grades 6-8) and high school (grades 9-12) students focusing exclusively on tobacco use and its correlates. Beginning in 2012, FDA entered into an agreement with CDC to conduct the NYTS on an annual basis, with each Agency funding alternate years. Approximately 20,000 students from all 50 states and the District of Columbia will be surveyed each year. Survey items will cover the following topics: susceptibility to use of a variety of tobacco products; quitting intentions and behaviors; knowledge, attitudes, and perceptions; symptoms of tobacco dependence; access to tobacco products; exposure to tobacco marketing and promotions; and exposure to health warnings. NYTS will provide national prevalence estimates of tobacco product use and key tobacco-related measures related to FDA’s regulatory activities to protect youth from tobacco.

Catherine Corey Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Institution: Centers for Disease Control and Prevention
08/01/2010

Understanding the Potential Impact of Product and Package Shape and Size on Consumer Perceptions (supplement)

Research has shown that cigarette manufacturers use descriptors, colors, and design features of cigarette packages to convey reduced risk to consumers, increase product appeal, and mitigate the impact of package warning labels. As descriptors and colors are increasingly regulated and restricted by FDA, manufacturers may turn to other design features, such as package size or shape, as marketing tools. The goal of this supplemental study is to evaluate the impact of these other design features on consumer perceptions of product appeal and health risks. Specific aims are: (1) to evaluate the potential impact of product and package shape and size on consumer perceptions of health risks and on the impact of tobacco product warning labels; and (2) to evaluate the potential impact of standardized packaging and plain packaging. Young adults aged 18-35 will be recruited from public spaces (e.g., libraries, parks, sporting events, shopping malls) in three cities (408 in Buffalo, NY; 406 in Columbia, SC; and 406 in Morgantown, WV). Participants will be shown different styles of tobacco products (i.e., package shapes, colors and sizes) and asked to rate them in terms of appeal, health risks, and willingness to try. Findings may inform regulatory activities related to product packaging and design specifications (i.e., length, color of tipping paper). (Project completed in 2011.)

K. Michael Cummings and Mannsi Bansal-Travers Funding Mechanism: Interagency Agreement
ID Number: 3 P01 CA138389-02S1
Institution: Roswell Park Cancer Institute
05/31/2010

Sandia Modeling Project

This project – resulting from an Interagency Agreement between the FDA Center for Tobacco Products (CTP) and the Department of Energy/Sandia National Laboratories – involves the development of models to help understand the potential impact of various policies and other activities (such as public health campaigns) on tobacco-related disease and death in the United States. Several models are being developed to examine: (1) the short-term impact of policy actions on tobacco-related knowledge, attitudes, perceptions, and behavior; and (2) the long-term impact of changes in tobacco use behavior on prevalence, morbidity, and mortality in the U.S. population. These models may be used to help CTP prioritize policy options and identify potential synergies to reduce tobacco-related disease and death as quickly and sharply as possible.

Nancy Brodsky and Antonio Paredes Funding Mechanism: Interagency Agreement
ID number: 224-10-9011
Institution: DOE/NNSA/SFO Sandia National Laboratories
05/06/2010

Research Experimental Study of Graphic Cigarette Warning Labels

The Tobacco Control Act required nine new health warning statements on cigarette packages and advertising and directed FDA to issue regulations requiring color graphic images depicting the negative health consequences of smoking to accompany the nine warning statements. The objective of the study was to assess the labels’ effectiveness at conveying information about various health risks of smoking and at encouraging smoking cessation and discouraging smoking initiation. Study aims were: (1) to measure consumer attitudes, beliefs, perceptions, and intended behaviors related to cigarette smoking in response to graphic warning labels; (2) to evaluate the relative efficacy of various graphic images associated with each of the nine warning statements for achieving each of the communication goals; and 3) determine whether consumer responses to graphic warning labels differ across target groups based on age or other demographic variables. The warning labels and images were tested with an online sample of 18,759 youth, young adults and adults in Fall 2010. Participants were exposed to either a cigarette package (entire sample) or advertisements (adult sample only) with one of the nine warning statements paired with one of the graphic images (treatment condition) or just the warning statement on packages (control condition) and were asked to respond to a series of questions immediately following exposure and one week later. Key outcomes measured included reactions to the warning statements, labels, and ads; recall of the statements, images, and ads; beliefs about health risks of smoking and secondhand smoke; emotional reactions; quit intentions; and self-reported likelihood of smoking in the next year (youth only). (Project completed in 2012.)

Matthew Farrelly and Conrad Choiniere Funding Mechanism: Research Contract
ID number: HHSF223200910135G
Institution: RTI
09/03/2010

Focus Group Study of Consumer Perceptions Related to Harmful and Potentially Harmful Constituents

Section 904 of the Food, Drug, & Cosmetic Act directs FDA to publicly display a list of HPHCs (by brand and by quantity in each brand and subbrand) that is understandable and not misleading to a lay person. The goal of this study is to collect qualitative data from consumers in order to understand what lay people know about the chemicals in tobacco products and/or tobacco smoke, how they respond to information about these chemicals, and their interest in learning more about these chemicals. Investigators will conduct 16 focus groups with adolescent and adult tobacco users and adolescents at risk for tobacco initiation. Focus groups will be conducted in four locations (Washington, DC, Nashville, TN, Miami, FL, and Baton Rouge, LA) and include 149 participants (35 youth and 114 adults). A trained moderator will use a semi-structured moderator’s guide to facilitate 90-minute discussions with focus group participants. Participants will be asked to discuss their general knowledge of tobacco products, chemicals in tobacco products, and perceptions of harm. They will then be asked to react to HPHC list prototypes of cigarettes, smokeless tobacco, and roll-your-own tobacco products. These data will be used to inform a subsequent experimental study designed to assess various list formats. (Project completed in 2011.)

Karen Sollod and Laura Shay Funding Mechanism: Research Contract
ID Number: HHSF22320051008I
Institution: Harvey Marketing Inc./OMR
Short Title
CTP-Supported Tobacco Regulatory Research Projects (3-1-23 TEST)

Source Organization

Short Description
CTP-Supported Tobacco Regulatory Research Projects (3-1-23 TEST)

Publish Date
Wed, 03/01/2023 – 10:18

Review Date
Fri, 03/01/2024 – 00:00

Last Reviewed Date
Wed, 03/01/2023 – 00:00

Site Structure

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Wed, 03/01/2023 – 10:17

Generic Boolean
Off

Regulated Product*

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/tobacco-products/ctp-supported-tobacco-regulatory-research-projects-3-1-23-test March 1, 2023 3:17 pm

The Work of FDA Continues in Thousands of Workstreams that Americans and the World Count on Every Day

The Work of FDA Continues in Thousands of Workstreams that Americans and the World Count on Every Day The Work of FDA Continues in Thousands of Workstreams that Americans and the World Count on Every Day Anonymous (not verified) Fri, 02/24/2023 – 08:30

Detailed Description
This FDA Voices is part two of FDA Commissioner Robert M. Califf’s reflection on his one-year anniversary at the agency.

This FDA Voices is part two of FDA Commissioner Robert M. Califf’s reflection on his one-year anniversary at the agency. Part one, “Highlighting Major Issues Critical to FDA Across Our Diverse Agency After One Year Back,” published on Fri., Feb. 17, 2023.

By: Robert M. Califf, M.D., Commissioner of Food and Drugs

Evidence Generation

Robert M. Califf, M.D.
Robert M. Califf, M.D.

My career has been devoted to evidence based clinical care—many hours in direct patient care convinced me we needed much better and more plentiful high quality evidence generation to guide our decisions about health. There is now a consensus among many experts that while the early phases of medical product development could be more efficient, the system basically works. But the evidentiary basis for late phase to post-market evaluation needs to be upgraded to take advantage of the dramatically different information landscape. Beginning with a joint project with the U.S. Food and Drug Administration and the National Institutes of Health (NIH) to move towards a standard terminology to describe evidence generation methods, I’m excited about the opportunity to contribute to a new infrastructure that will enable much more high-quality evidence to inform decisions. You’ll hear much more about this during the upcoming year. I’ve asked Dr. Hilary Marston, our Chief Medical Officer, to lead this effort, which will include work across federal agencies and with the broad ecosystem of evidence generation.

Supply Chain

Every industry we regulate is at risk from supply chain issues, deeply embedded in “just in time” methodology and sole sourcing to maximize profit, leading to low inventories, and offshoring of key elements. In the face of international strife and economic distortions, these risks have resulted in real world consequences, for example related to availability of certain drug products and infant formula. The agency has a patchwork of authorities that are helpful, but in no way match the public expectations that for essential products there will be a plentiful supply readily available. Efforts are underway across government to address these challenges, including a role for the FDA and encouraging redundancy throughout the supply chain, but also requiring a broad USG effort and responsibility. Federal partners will have to work on these challenges together. For example, in the case of infant formula supply chain resilience, the FDA, USDA, and other federal partners each have respective roles to play.

Diagnostic Testing

Understanding our risk of illness, the prediction of outcomes given our choices and specific diagnosis of disease together form the bedrock of rational, effective health decisions and healthcare delivery. All of these goals fall under the broad rubric of “diagnostic testing.” A significant part of my career was spent trying to understand how to interpret probabilistic output from diagnostic testing, and while that issue is fascinating, it is predicated upon the assumption that the test is yielding reliable results grounded in fundamental principles of quality test development and production. We will continue to engage Congress on the VALID Act; it’s time to reach societal agreement on a modern framework that supports the amazing new ability to assess health and disease using diagnostic tests, but also assures Americans that the test results are reliable and developed in a manner that leads to better decisions. 

Dietary Supplements

Along with VALID, I hope to see an improved framework to appropriately regulate dietary supplements during my tenure. This enormous industry continues to grow and it’s now part of everyday life for many families. Dietary supplements should be required to list with the FDA and companies should be accountable for revealing what is in the supplement being sold. In the long run we will have more information about the benefits and risks of dietary supplements as our methods of evidence generation improve, and I hope for a regulatory regime that can encourage better information for consumers to be informed about their choices. Although it will take some time to achieve the optimal regulatory framework, given the size and impact of the industry, we need to constantly update our internal approach and build awareness.

FDA Advisory Committees

As a former long-term advisory committee member, I believe strongly in the value of interchange between our experts at the FDA and experts who work outside the agency. It not only makes our decisions better, but it also adds an element of transparency and societal discussion that is important. My observation is that the agency needs to tune up our advisory committee system in a way that enables our experts to get the best advice possible. I’ve been using the analogy that it’s like democracy—messy, but hard to imagine a better way of achieving our goals. 

Chronic Diseases, Including Mental Health

As we experience an unprecedented reversal of previous progress in chronic diseases, including mental health, leading to an unprecedented decline in life expectancy (along with COVID-19 and overdose), we are reviewing what we can do to help the industries we regulate to be more successful in developing therapies in these areas. The dramatic improvement in cancer and rare disease therapies and the COVID response shows that if we’re strategic, we can move disease outcomes in a positive direction. Recognizing fully the importance of social determinants of health and health system priorities, I want to explore all that we can do within our sphere of direct influence to reverse these negative trends. And I believe that particularly at the interface of our interactions with the Centers for Medicare and Medicaid Services (CMS), much could be gained by a more effective handoff between our accountability for “safe and effective” and CMS’s accountability for “reasonable and necessary.” 

Interagency Collaboration

My experience is that federal agencies do an excellent job within their “swim lanes,” but much public benefit is lost when interagency collaboration is suboptimal and opportunities “fall between the cracks.” Examples of critical interagency handoffs where I intend to continue to work closely with my counterparts include vaccine evaluation by the FDA and practice recommendations by the Centers for Disease Control and Prevention (CDC), approval for marketing by the FDA and payment by the CMS and the need for research gaps to be filled in for the FDA to make decisions and the NIH’s massive research capability. Recent interactions with regard to genomic alterations in plants and animals have focused attention on FDA-U.S. Department of Agriculture (USDA) interactions. The FDA and USDA each have unique expertise and missions that can be complimentary and synergistic when it comes to nutrition, food safety, the resilience of food supply chains, and innovation.

Data Science and Statistics

As we develop much better systems of evidence generation, data science and statistics form the bedrock of generating evidence from data and information. The FDA has a talented and influential group of quantitative experts, but to regulate the information-rich, digital world of the future we need to make it a conscious focus. An effective organization for knowledge sharing and professional advancement is needed across the multiple professional disciplines with a role in quantitative analysis, data management and computer science. The emergence of ChatGPT and its competitors is a reminder that we must stay a step ahead of the industry—how long before we have “AI assisted” applications submitted to the FDA?

Genome Modification

In 2015/16 it was clear to me that modification of the genome would be a major technology.  There is broad agreement that across the spectrum of human beings, animals and plants, genome modification is here to stay and that its benefits could be profound for human disease and could provide much more environment-friendly and predictable food in the face of climate change and supply chain stresses. User fees are funding a major workforce investment in the Center for Biologics Evaluation and Research, while the Human Foods Program and the Center for Veterinary Medicine will emphasize genomic alteration as key technologies for the future. I’ve asked Dr. Namandjé Bumpus, our Chief Scientist, to pull together our experts across the enterprise to make sure we’re sharing knowledge in a way that reinforces regulation that supports innovation, enabling the benefit and preventing avoidable risk as the science continues to grow.

Substance Use Disorder and Associated Overdose Deaths

Preventing and reducing substance use disorders and overdose deaths remains an area of major focus. We continue to take actions in response to the four priorities outlined in FDA’s Overdose Prevention Framework, including primary prevention, encouraging harm reduction, advancing evidence-based treatments, and protecting the public from unapproved, diverted, or counterfeit drugs. With opioid-related deaths at an all-time high, the FDA is doing all it can to ensure live-saving naloxone is more accessible. In response to recommendations by an independent evaluation of our opioid activities by experts affiliated with the Ohio State University, the FDA is focusing on evidence generation for long term use and clinical trial designs, as well as considering additional authorities needed. 

Cannabis and Its More Than 30 Derivatives

And, we are addressing cannabis and its more than 30 derivatives by seeking a new regulatory pathway that can provide access, safeguards, protection and oversight in ways that existing pathways cannot. I’m grateful to Dr. Woodcock that she has taken on this issue, developing novel approaches to regulation in the face of controversy that has caused others to shy away and “kick the can down the road.”

In addition to all of the topics covered in these two articles, the essential work of the agency continues in thousands of workstreams that Americans and the world count on every day. I look forward to doing all I can to improve the working conditions of the agency’s staff and the legal and operational framework that defines our mission. I also want to recognize the enormous work in progress on the response to the Reagan Udall reports on the Human Foods Program and the Center for Tobacco Products, and in the building of a more effective enterprise-wide information technology approach.

Finally, I want to thank all of our staff for their hard work in such an extraordinary time, and especially my staff in the Commissioner’s Office for their “around the clock” perseverance, good work and tolerance for my passions. I look forward to a productive and engaging year in which the agency thrives.

Image
Photo collage image: Upper left image of pregnant woman feeding child. Center image of Dr. Califf. Upper center image of pill bottle with pills spilling out. Lower center image of researcher in lab. Right image of entrance of FDA Headquarters.

Communication Type

Short Title
The Work of FDA Continues in Workstreams that Americans Count On

Source Organization

Health Topics

Short Description
This FDA Voices is part two of FDA Commissioner Robert M. Califf’s reflection on his one-year anniversary at the agency.

Publish Date
Fri, 02/24/2023 – 12:57

Review Date
Sat, 02/24/2024 – 00:00

Last Reviewed Date
Fri, 02/24/2023 – 00:00

Site Structure

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Fri, 02/24/2023 – 12:57

Generic Boolean
Off

Language

Number of Related Information to Display
3

Add Subscription Box
On

Description
Subscribe to receive FDA Voices email notifications.

Email Subscription List

Header
FDA Voices Email

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/news-events/fda-voices/work-fda-continues-thousands-workstreams-americans-and-world-count-every-day February 24, 2023 1:30 pm

FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners – March 28, 2023

FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners – March 28, 2023 FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners – March 28, 2023 Anonymous (not verified) Wed, 02/22/2023 – 11:23

Detailed Description
On Tuesday, March 28, 2023, CDER’s Office of Communication, Division of Drug Information (DDI) will host a webinar titled: FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners. This webinar will provide a general understanding of the Cannabis sativa L. plant and how

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!

On Tuesday, March 28, 2023, CDER’s Office of Communication, Division of Drug Information (DDI) will host a webinar titled: FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners. This webinar will provide a general understanding of the Cannabis sativa L. plant and how products are generally produced utilizing cannabis raw materials. The presentation will explain why manufacturing controls surrounding cannabis and cannabis-derived products are an integral part of protecting the public health. Will provide attendees with greater knowledge of the many products available on the marketplace, a discussion on potential benefits and risks, ways to report adverse events associated with these products to FDA, as well as suggestions on how to create a safe space to discuss patient use of these products.

Register Here

Activity Outline and Continuing Education Information


If you have never attended an Adobe Connect meeting before:

Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.

Resources For You

Short Title
FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthca

Source Organization

Content Owner

Publish Date
Wed, 02/22/2023 – 11:24

Review Date
Thu, 02/22/2024 – 00:00

Last Reviewed Date
Wed, 02/22/2023 – 00:00

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Wed, 02/22/2023 – 11:24

Generic Boolean
Off

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/about-fda/fda-pharmacy-student-experiential-program/fda-drug-topics-cannabis-and-cannabis-derived-products-healthcare-practitioners-march-28-2023 February 22, 2023 4:23 pm

Objectives for marijuana

Objectives for marijuana

A friend asked, “What are your objectives with regard to both medicinal and recreational marijuana?”  Here’s a quick answer.

A long-run objective is good government –  to have laws that people will actually obey.  Since citizens are to going consume marijuana recreationally, I’d say the law needs to adapt to the citizens, since the citizens won’t adapt to the law.  

That’s in line with the view of John D. Rockefeller, Jr., expressed in the foreword to “For Liquor Control”:  “law must always be the articulate organ of the desires of living men. Men cannot be made good by force. In the end, intelligent lawmaking rests on the knowledge or estimate of what will be obeyed. Law does not enforce itself.”

Marginalize the illegal market, too, by enforcing laws that citizens will support.

But that’s for the long run.

Between now and then, some other objectives intervene:

Keep the noise down on medical and recreational marijuana.  Make the drug available, but tamp down on promotion.  Make retailing low-key and discreet, and out of the eyes of kids.  If the 1st Amendment won’t allow advertising bans, then keep advertising, celebrity endorsements, and other selling expense tax expenses non-tax deductible (as they are now under federal section 280E and will be under conforming North Carolina tax law).

Keep both the medical and recreational wealth in North Carolina rather than letting out-of-state operators grab the lion’s share (as SB3 would do).  Beyond keeping it here, share the wealth here – that is, don’t let rich North Carolinians get it all.  

Get legalization underway, even medical only.  

State retailing, via public health departments or otherwise (state delivery or brick-and-mortar retailing), would satisfy those intermediate objectives.  But selling via health departments will not smooth the transition to careful recreational legalization.


#CBD #Hemp
Objectives for marijuana
February 14, 2023 2:52 pm

Medical marijuana in North Carolina – Drafting glitch?

Medical marijuana in North Carolina – Drafting glitch?

Some of the wording in the new North Carolina medical marijuana bill, SB3, confuses me.  The bill puts two “industry representatives” named by the Governor on the “Production Commission” (proposed section 90-113.118(a)(1)b.), but then makes it hard for anyone to be an industry representative on the Commission. The bill says, “Conflicts of Interest — No member of the Commission shall own, operate, have a direct or indirect financial interest in, or be employed by a licensed medical cannabis supplier, or a licensed medical cannabis testing laboratory, or a subcontractor thereof” (Proposed section 90-113.118(l)).   How can someone be an “industry representative” and not “own, operate, have a direct or indirect financial interest in, or be employed by a licensed medical cannabis supplier, or a licensed medical cannabis testing laboratory, or a subcontractor thereof”?

Am I missing something?  This kind of little technical glitch, if indeed it is one, could cause the system to freeze up before it gets started.

The quotes are from pages 9 and 10 of the latest version, https://www.ncleg.gov/Sessions/2023/Bills/Senate/PDF/S3v1.pdf.  The “representative” language first showed up in version 2 of last session’s bill, https://www.ncleg.gov/Sessions/2021/Bills/Senate/PDF/S711v6.pdf; the “conflicts” language first showed up in version 5 — but I just noticed this issue.

Would, say, a lawyer for industry qualify as a “representative”? If the lawyer were paid anything by an industry participant or applicant, she or he would be “employed by” industry, I think, and thus ineligible. And the “indirect financial interest” language is quite broad.

So maybe this issue will get cleaned up as the bill progresses.


#CBD #Hemp
Medical marijuana in North Carolina – Drafting glitch?
February 12, 2023 9:40 pm

Audio Transcript | FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds

Audio Transcript | FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds Audio Transcript | FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds Anonymous (not verified) Mon, 02/06/2023 – 12:59

Detailed Description
Audio Transcript | FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds

 

Dr. Weber: Welcome to the CDER Small Business and Industry Assistance (SBIA) Chronicles Podcast Series.

Today’s topic: FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds. There is increasing interest in the potential utility of cannabis for a variety of medical conditions. Studies in clinical trial settings are needed to assess the safety and effectiveness of cannabis and cannabis-derived products for the treatment of any disease or condition, and FDA has an important role to play in supporting this scientific research and providing guidance.

My name is Dr. Ellicia Weber, and today we are joined by Dr. Cassandra Taylor, Chemist and FDA Cannabis Subject Matter Expert from the Botanical Review Team within FDA’s Center for Drug Evaluation and Research (or CDER) Office of Pharmaceutical Quality.

Hi Dr. Taylor, thanks for joining us today to discuss the recently finalized Guidance for Industry, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research”.

Dr. Taylor: Glad to be here!

Dr. Weber: Dr. Taylor, it may be helpful to begin by clarifying the various cannabis related terms.

Dr. Taylor: Sure! There’s quite a few of them. Cannabis sativa L. is a plant that contains over 500 different naturally occurring compounds. 100 of those 500 compounds are called “cannabinoids,” and we kind of categorize them in 3 main buckets:

  • The first one is Cannabis-derived compounds, so (or call them CDPs), and those occur naturally. They are extracted directly from the plant, and some examples are cannabidiol (or CBD), delta-9-tetrahydrocannabinol (or delta-9 THC). And these CDPs, they can be used to manufacture drug products and drug substances, and they include botanical raw materials; they include extracts, highly purified substances of botanical origin.
  • The second bucket is something called Cannabis-related compounds. These are synthetic compounds that are made in a laboratory. Sometimes they are also found in nature in small quantities, but they can also be used to manufacture drug products.
  • And the third bucket is Hemp. Hemp, which is a legal term defined by the 2018 Agricultural Improvement Act (also known as the Farm Bill) and is generally defined as Cannabis sativa L. and any part of the plant with a delta-9 THC concentration of not more than 0.3% delta-9 THC on a dry weight basis.

Dr. Weber: CDPs are held to the same regulatory standards as any other botanical raw materials, botanical drug substance or botanical drug product, correct?

Dr. Taylor: Yes, that’s right. When a researcher intends to study botanical products – that includes products that contains cannabis, CDPs, or those cannabis-related synthetic compounds we just talked about – in order to determine effects of either the diagnosis, cure, mitigation, treatment, or prevention of a disease, then those products are drugs under the Federal Food, Drug, and Cosmetic Act. Researchers must meet all FDA requirements to conduct human clinical trials, regardless of their source of cannabis or any other botanical product under study in the trial. FDA has a guidance that’s available, it’s called the “Botanical Drug Development Guidance for Industry.” It’s a very helpful resource that provides FDA’s current thinking on the appropriate development plans for botanical drugs.

Dr. Weber: FDA recently finalized a guidance, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research” to provide recommendations for researchers interested in developing cannabis and CDPs for use in human drugs for clinical research. Can you describe how this final guidance differs from the previous draft guidance?

Dr. Taylor: Sure. There’s quite a few differences, but a few of the highlights include clarifying sources of cannabis for clinical research (that does include using Schedule I sources for clinical research), adding resources explaining expectations for investigational new drug applications (or INDs as we call them) throughout the various stages of drug development, and providing guidance on quality considerations for INDs. It’s important that listeners understand the guidance does not address development of cannabis-related compounds, or those synthetic ones – those are regulated just like any other synthetic drugs at FDA.

Dr. Weber: Are these products all controlled substances?

Dr. Taylor: No, they are not. The Farm Bill, which we just talked about, removed hemp from the Federal Controlled Substances Act (or the CSA). And botanical raw materials, extracts, and derivatives that contain CDPs with delta-9 THC content that’s above that 0.3 percent by dry weight – those remain Schedule I controlled substances. So that means that activities related to, you know, the growing and manufacturing these products for use as investigational drugs for research must comply with the Controlled Substances Act and the Drug Enforcement Agency (or the DEA) requirements.

DEA should be consulted regarding the control status of cannabis or cannabis-derived materials in manufacturing or investigational drugs that are under development. And even if the starting materials meet that legal definition of hemp, intermediates or drug products could be created that contain greater than 0.3 percent delta-9 THC by dry weight, and they may no longer meet that definition of hemp, and they might be considered controlled substances.

Dr. Weber: Per the guidance, in clinical research, sources of cannabis defined as hemp and those containing greater than 0.3% delta-9 THC on a dry weight basis may be used if deemed to be of adequate quality by FDA when reviewed as part of an IND. What can researchers use as a source of cannabis for their studies?

Dr. Taylor: You can use botanical sources that meet all the FDA requirements to conduct human clinical trials. The National Institute on Drug Abuse (or NIDA) has a Drug Supply Program, and they’re a source of cannabis over that 0.3 percent delta-9 THC threshold that we’ve been talking about, and those can be used. DEA also continues to update their list of authorized growers, and researchers may also use those as sources of Schedule I cannabis materials for researchers, or excuse me, for research. Researchers at each study site who are planning to conduct studies with controlled cannabis study drugs need to be registered with the DEA and comply with all applicable DEA regulations.

Dr. Weber: To gain insight into their product’s potential abuse liability and control status, researchers may find it useful to calculate the delta-9 THC content in their proposed cannabis or cannabis-derived investigational drug product early in the development process – which is also addressed in the guidance. Can you explain this further?

Dr. Taylor: Of course. FDA recommends that the calculation of total delta-9 THC percentage be based on the composition of your proposed formulation with that amount of water removed. This includes any water that might be in your excipients, and so you need to make sure that that’s also removed from your calculation. Researchers should not rely on the 0.3% delta-9 THC by dry weight threshold when they’re evaluating tetrahydrocannabinols as impurities for the purposes of quality control and commercial drug application submission. The documentation regarding the steps for the delta-9 THC calculation should be submitted in the IND.

Dr. Weber: To conduct clinical research, researchers work with the FDA to submit an IND application to CDER, which must include information from three broad areas: animal pharmacology and toxicology studies, clinical protocols and investigator information, and manufacturing information. Can you generally describe the required manufacturing information for inclusion?

Dr. Taylor: Absolutely. Researchers submitting an IND must submit sufficient information to demonstrate the identity, quality, purity, and potency or strength of the investigational drug in each phase of clinical investigation. The final guidance lists applicable United States Pharmacopeia (or USP) chapters on quality and testing, and also identifies relevant International Council for Harmonisation (or ICH) guidelines, as well as FDA guidances and considerations for devices used in combination with a drug. It also contains a listing of principles, regulations, and guidance documents that FDA recommends researchers using CDPs consider before submitting INDs to FDA for review.

Now, the manufacturing information should also include quantitative data indicating the percent delta-9 THC by dry weight in the botanical raw materials. And if the study proposes to use cannabis that contains greater than that 0.3 percent delta-9 THC on a dry weight basis, the researcher should contact NIDA or another DEA-registered source of cannabis and/or the cannabis-derived substance to obtain information on the specific cultivars that are available for research.

Dr. Weber: And regardless of the delta-9 THC content, the researcher should provide all necessary chemistry manufacturing and controls (or CMC) and botanical raw materials information in the IND, correct?

Dr. Taylor: That’s correct. Cannabis researchers are encouraged to use Drug Master Files (or DMFs) to help support their cannabis research, speed their drug development, address concerns regarding protection of proprietary information, while participating in the drug development process. If the selected hemp, or botanical raw materials, or drug substance manufacturer holds a DMF, the researcher must obtain a Letter of Authorization (often called an LOA) to reference the CMC and botanical raw material information in the DMF when they submit their IND.

Dr. Weber: Thank you again Dr. Taylor for joining us today and providing your expertise on this topic. Are there any final words you would like to share with us today?

Dr. Taylor: Thank you so much Dr. Weber. I would like to say that here at the FDA we’re really committed to supporting robust scientific research into understanding therapeutic uses and safety of cannabis and cannabis-derived products, and we offer quite a number of resources to help researchers and investigators. That includes “FDA and Cannabis: Research and Drug Approval Process” and “FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol” webpages. They’re available for everyone. The resources also provide contact information for the CDER’s Botanical Review Team (BRT), which is what I’m a part of. We serve as the expert resource on botanical issues. The agency also continues to conduct research on various cannabis quality consideration, including BRT’s recent publications on quality standards in state programs permitting cannabis for medical uses and investigation of microorganisms in cannabis after heating in a commercial vaporizer.

Dr. Weber: You can find a link to the full SBIA Chronicles article at www.fda.gov/cdersbiachronicles. Also visit www.fda.gov/cdersbia to stay connected with upcoming webinars and conferences, sign up for SBIA email updates, and follow SBIA on LinkedIn. Thanks for tuning in!

Related Information

Short Title
Cannabis and Cannabis-Derived Compounds

Source Organization

Short Description
Audio Transcript | FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds

Content Owner

Publish Date
Tue, 02/07/2023 – 14:16

Review Date
Tue, 02/06/2024 – 00:00

Last Reviewed Date
Mon, 02/06/2023 – 00:00

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Mon, 02/06/2023 – 16:13

Generic Boolean
Off

Regulated Product*

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/audio-transcript-fda-regulation-and-quality-considerations-cannabis-and-cannabis-derived-compounds February 6, 2023 5:59 pm

FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds

FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds Anonymous (not verified) Mon, 02/06/2023 – 10:50

Detailed Description
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds

Podcast and newsletter

Podcast   Transcript

Cassandra Taylor photo

Dr. Cassandra Taylor – Chemist and FDA Cannabis Subject Matter Expert
Botanical Review Team; Office of Pharmaceutical Quality | CDER | FDA

There is increasing interest in the potential utility of cannabis for a variety of medical conditions, as well as research on possible adverse health effects. Studies in clinical trial settings are needed to assess the safety and effectiveness of cannabis and cannabis-derived products for the treatment of any disease or condition, and FDA has an important role to play in supporting this scientific research and providing guidance. To clarify some terminology:

  • Cannabis sativa L. is a plant that contains over 100 different naturally occurring compounds called “cannabinoids.”
  • Cannabis-derived compounds are compounds occurring naturally in the plant, like cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), that are extracted directly from the plant. Cannabis-derived compounds that may be used in manufacturing human drugs include botanical raw materials (BRMs), extracts, and highly purified substances of botanical origin.
  • Cannabis-related compounds are synthetic compounds created in a laboratory and can be used to manufacture drug products. Some may also occur naturally in the plant.
  • Hemp is a legal term defined by the 2018 Agricultural Improvement Act (Farm Bill) and is generally defined as Cannabis sativa L. and any part of the plant with a delta-9 THC concentration of not more than 0.3% on a dry weight basis.

Though the Farm Bill removed hemp from the federal Controlled Substances Act (CSA), BRMs, extracts, and derivatives that contain cannabis-derived products (CDPs) with delta-9 THC content above 0.3 percent by dry weight remain Schedule I controlled substances. Thus, activities related to growing and manufacturing these products for use as an investigational drug for research must comply with the CSA and Drug Enforcement Agency (DEA) requirements.

FDA recently issued a final guidance “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research” to provide recommendations for sponsors interested in developing cannabis and CDPs for use in human drugs for clinical research. Notable changes that were made from the 2020 draft guidance include clarifying sources of cannabis for clinical research (including Schedule I sources), adding resources explaining expectations for investigational new drug (IND) applications in various stages of drug development, and providing guidance on quality considerations for INDs. Note that this guidance does not address development of cannabis-related compounds, which are regulated like other synthetic drugs.

Sources of Cannabis: Both sources of cannabis defined as hemp and those containing >0.3% delta-9 THC on a dry weight basis may be used for clinical research if deemed to be of adequate quality by FDA when reviewed as part of an IND. Researchers may use the National Institute on Drug Abuse (NIDA) Drug Supply Program (DSP) as a source of cannabis over the 0.3% delta-9 THC threshold, or they may use other sources authorized by DEA to provide Schedule I cannabis materials for research. The DEA webpage also contains a list of DEA-authorized growers of Schedule I cannabis and information on importation of controlled substances (21 CFR 1312).

Control Status: Sponsors and investigators may find it useful to calculate the delta-9 THC content in their proposed cannabis or cannabis-derived investigational drug product early in the development process to gain insight into their product’s potential abuse liability and control status. However, they should not rely on the 0.3% delta-9 THC by dry weight threshold when evaluating tetrahydrocannabinols as impurities for the purposes of quality control and application submission. FDA recommends that the calculation of total delta-9 THC percentage be based on the composition of the formulation with the amount of water removed, including any water that excipients may contain. The calculation of THC percentage is detailed in the final guidance document, and the documentation regarding the steps of the delta-9 THC calculation should be submitted in the IND.

The DEA should be consulted regarding the control status of cannabis or cannabis-derived materials in manufacturing or investigational drug products that are under development. Even if the starting materials meet the definition of hemp, intermediates or drug products that contain greater than 0.3% delta-9 THC by dry weight may no longer meet the definition of hemp and may be considered Schedule I controlled substances.

Regulation of botanical drug products: CDPs are held to the same regulatory standards as any other BRM, botanical drug substance or botanical drug product. When a researcher intends to study botanical products (including one that contains cannabis, CDPs, or cannabis-related compounds) to determine their effects in the diagnosis, cure, mitigation, treatment, or prevention of a disease, these products are considered to be drugs under the Food, Drug, and Cosmetic Act. Researchers must meet all FDA requirements to conduct human clinical trials, regardless of the source of cannabis or any other botanical product under study in the trial. FDA’s “Botanical Drug Development Guidance for Industry” is a helpful resource that provides FDA’s current thinking on appropriate development plans for botanical drugs and recommendations for researchers to consider.

IND submission: To conduct clinical research, including research in humans using materials from plants such as cannabis, researchers work with the FDA to submit an IND application to FDA’s Center for Drug Evaluation and Research (CDER). The IND must include information from three broad areas: animal pharmacology and toxicology studies, clinical protocols and investigator information, and manufacturing information. This includes protocols describing proposed studies, the qualifications of the investigators who will conduct the clinical studies, assurances of informed consent and protection of the rights, safety, and welfare of the human subjects, and quality control information for the drug(s) proposed for use.

IND sponsors must submit sufficient information to demonstrate the identity, quality, purity, and potency or strength of the investigational drug in each phase of clinical investigation and should take into account key considerations, including the impurity profile, selection of a container closure system, metabolic profile, and literature to support clinical development. The final guidance lists applicable United States Pharmacopeia (USP) chapters on quality testing, including the assessment of leachables from packaging and delivery systems, and identifies relevant International Council for Harmonisation guidelines, FDA guidances, and considerations for devices used in combination with a drug. It also contains a listing of principles, regulations, and guidance documents that FDA recommends that those pursuing research and/or drug development using CDPs consider before submitting INDs to FDA for review.

Manufacturing information should also include quantitative data indicating the percent delta-9 THC by dry weight in the BRM. If the study proposes to use cannabis that contains greater than 0.3% delta-9 THC on a dry weight basis, the sponsor should contact NIDA or another DEA-registered source of cannabis and/or cannabis-derived substances to obtain information on the specific cultivars available.

Regardless of the delta-9 THC content, the sponsor should provide all necessary chemistry manufacturing and controls (CMC) and BRM information in the IND. Cannabis researchers are encouraged to use Drug Master Files (DMFs) to support cannabis research, speed drug development, and address concerns regarding protection of proprietary information while participating in drug development. If the selected hemp, BRM or drug substance manufacturer holds a DMF, the sponsor must obtain a Letter of Authorization (LOA) to reference the CMC and BRM information in the DMF. To learn more, we have made available a recorded webinar, “Cannabis Clinical Research: Drug Master Files (DMFs) & Quality Considerations.”

Prior to submission of the IND, FDA offers an optional pre-IND meeting, which is very valuable in planning a drug development program. This meeting can provide researchers information that will assist them in preparing to submit complete IND applications and is a valuable opportunity to obtain FDA guidance on research plans and required content for IND submission.

Once the IND submission is ready, the researcher should send a copy of the IND and clinical protocol, including a LOA (if applicable), to FDA for review as highlighted on our website “IND Forms and Instructions.” The sponsor must wait 30 calendar days after submission before initiating any clinical trials. During this time, FDA reviewers assess if the study is safe to proceed or will be placed on clinical hold.

All investigators at each study site who are planning to conduct studies with cannabis study drugs need to be registered with the DEA and comply with all applicable DEA regulations, including the regulations for the use, manufacturing, handling, and storage of a Schedule I drug. Schedule I licenses from the DEA are needed prior to the initiation of a clinical study with cannabis study drugs with greater than 0.3% delta-9 THC on a dry weight basis. If the cannabis study drug is synthetic or semi-synthetic, the chemist who is synthesizing the drug should also be doing so under a Schedule I license. If a sponsor already possesses a Schedule I research registration with DEA for a specific cannabis study drug, all new protocols must be submitted to DEA as an amendment to that registration. Once the Schedule I license is granted by DEA, the sponsor should contact NIDA or another DEA-registered source to obtain the substances so they can then begin the study.

The agency is committed to supporting robust scientific research into understanding therapeutic uses and safety of cannabis and CDPs. In addition to the final guidance, our “FDA and Cannabis: Research and Drug Approval Process” and “FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabadiol” webpages provide sponsors and researchers with resources, including contact information for the CDER’s Botanical Review Team (BRT), which is serves as an expert resource on botanical issues.

Resources

  1. Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research – Guidance for Industry”
  2. FDA and Cannabis: Research and Drug Approval Process webpage
  3. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabadiol
  4. CDER’s Botanical Review Team
  5. NIDA Drug Supply Program
  6. Investigator-Initiated INDs
  7. Pruyn SA, Wang Q, Wu CG, Taylor CL (2022) Quality standards in state programs permitting cannabis for medical uses, Cannabis and Cannabinoid Research 7:6, 728–735, DOI: 10.1089/can.2021.0164.
  8. Sopovski DS, Han J, Stevens-Riley M, Wang Q, Erickson BD, Oktem B, Vanlandingham M, Taylor CL and Foley SL (2023) Investigation of microorganisms in cannabis after heating in a commercial vaporizer. Front. Cell. Infect. Microbiol. 12:1051272. doi: 10.3389/fcimb.2022.1051272
Short Title
Cannabis and Cannabis-Derived Compounds

Source Organization

Short Description
CDER Small Business and Industry Assistance Chronicles

Content Owner

Publish Date
Tue, 02/07/2023 – 14:13

Review Date
Wed, 02/07/2024 – 00:00

Last Reviewed Date
Tue, 02/07/2023 – 00:00

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
On

First Publish Date
Mon, 02/06/2023 – 16:15

Generic Boolean
Off

Regulated Product*

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/fda-regulation-and-quality-considerations-cannabis-and-cannabis-derived-compounds February 6, 2023 3:50 pm

FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward

FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward Anonymous (not verified) Thu, 01/26/2023 – 08:55

Short Title
FDA Statement on Cannabidiol

FDA Statement
No

Statement Author

Leadership Role
Principal Deputy Commissioner – Office of the Commissioner

Janet Woodcock M.D.

Press Release Date
January 26, 2023

Detailed Description
The FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks. The agency is prepared to work with Congress on this matter.

Short Description
A new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.

Audience

Body

Given the growing cannabidiol (CBD) products market, the U.S. Food and Drug Administration convened a high-level internal working group to explore potential regulatory pathways for CBD products. Today we are announcing that after careful review, the FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks. The agency is prepared to work with Congress on this matter. Today, we are also denying three citizen petitions that had asked the agency to conduct rulemaking to allow the marketing of CBD products as dietary supplements.  

The use of CBD raises various safety concerns, especially with long-term use. Studies have shown the potential for harm to the liver, interactions with certain medications and possible harm to the male reproductive system. CBD exposure is also concerning when it comes to certain vulnerable populations such as children and those who are pregnant. 

A new regulatory pathway would benefit consumers by providing safeguards and oversight to manage and minimize risks related to CBD products. Some risk management tools could include clear labels, prevention of contaminants, CBD content limits, and measures, such as minimum purchase age, to mitigate the risk of ingestion by children. In addition, a new pathway could provide access and oversight for certain CBD-containing products for animals.

The FDA’s existing foods and dietary supplement authorities provide only limited tools for managing many of the risks associated with CBD products. Under the law, any substance, including CBD, must meet specific safety standards to be lawfully marketed as a dietary supplement or food additive. 

The working group, which I chair, has closely examined studies related to the CBD-based drug Epidiolex, published scientific literature, information submitted to a public docket, as well as studies both conducted and commissioned by the agency. Given the available evidence, it is not apparent how CBD products could meet safety standards for dietary supplements or food additives. For example, we have not found adequate evidence to determine how much CBD can be consumed, and for how long, before causing harm. Therefore, we do not intend to pursue rulemaking allowing the use of CBD in dietary supplements or conventional foods. 

CBD also poses risks to animals, and people could be unknowingly exposed to CBD through meat, milk and eggs from animals fed CBD. Because it is not apparent how CBD products could meet the safety standard for substances in animal food, we also do not intend to pursue rulemaking allowing the use of CBD in animal food. A new regulatory pathway could provide access and oversight for certain CBD-containing products for animals.

The FDA will continue to take action against CBD and other cannabis-derived products to protect the public, in coordination with state regulatory partners, when appropriate. We will remain diligent in monitoring the marketplace, identifying products that pose risks and acting within our authorities. The FDA looks forward to working with Congress to develop a cross-agency strategy for the regulation of these products to protect the public’s health and safety.

Content Owner

Contributing Office

Publish Date
Thu, 01/26/2023 – 10:12

Review Date
Fri, 01/26/2024 – 09:00

Last Reviewed Date
Thu, 01/26/2023 – 09:00

Site Structure

Next Review Date
1 Year

Source Organization

Bulk Approved
Off

Hide main image
hide

Display Short Description
Off

Language

Media Contact
Media Contact Name
Courtney Rhodes

Media Contact Phone
202-281-5237

Media Contact Email

First Publish Date
Thu, 01/26/2023 – 10:12

Add Subscription Box
Off

Boilerplate
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Quote Attribution

Announcement Type
FDA Statement

#CBD #Hemp http://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol January 26, 2023 1:55 pm

FDA Roundup: January 24, 2023

FDA Roundup: January 24, 2023 FDA Roundup: January 24, 2023 Anonymous (not verified) Tue, 01/24/2023 – 12:35

Short Title
FDA Roundup: January 24, 2023

FDA Statement
No

Press Release Date
January 24, 2023

Detailed Description
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Short Description
FDA Roundup: January 24, 2023

Body

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

  • On Monday, the FDA issued a final guidance “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Guidance for Industry.” This guidance provides the FDA’s current thinking on several topics relevant to clinical research related to the development of drugs containing cannabis and cannabis-derived compounds. The agency is committed to supporting robust scientific research into understanding therapeutic uses and safety of cannabis products. The FDA believes the drug development and approval process represents the best way to ensure safe, effective, and high-quality new medicines, including any drugs derived from cannabis, are available to patients in need of appropriate medical therapy.
  • On Monday, the FDA reopened the comment period for 45 days for the proposed rule entitled Color Additive Certification; Increase in Fees for Certification Services that appeared in the Federal Register on November 2, 2022. The FDA is reopening the comment period in response to a recent request from stakeholders to allow additional time for interested persons to develop and submit comments. 
  • On Monday, the FDA cleared for marketing the Tidepool Loop, a mobile application intended for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in persons six years of age and older. The human pancreas naturally supplies a low, continuous rate of insulin, known as basal or background insulin. In patients with diabetes, the body’s ability to produce or respond to insulin is impaired.  The Tidepool app is a prescription-only device for single patient use that works with integrated continuous glucose monitors (iCGMs) and alternate controller enabled pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose (sugar) values. The app can also recommend, and with the user’s confirmation, control the delivery of correction insulin amounts when glucose values are predicted to exceed user configurable thresholds. Tidepool Loop’s algorithm technology is designed to be compatible with other individual interoperable devices that meet pre-specified acceptance criteria set forth in a validation and integration plan provided by the sponsor and cleared by the FDA as part of the premarket submission. 
  • COVID-19 testing updates: 
    • As of today, 443 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 298 molecular tests and sample collection devices, 85 antibody and other immune response tests, 59 antigen tests, and one diagnostic breath test. There are 79 molecular authorizations and one antibody authorization that can be used with home-collected samples. There is one EUA for a molecular prescription at-home test, two EUAs for antigen prescription at-home tests, 26 EUAs for antigen over-the-counter (OTC) at-home tests, and four for molecular OTC at-home tests.
    • The FDA has authorized 44 antigen tests and eight molecular tests for serial screening programs. The FDA has also authorized 1217 revisions to EUA authorizations.
       
Incident ID

Content Owner

Contributing Office

Publish Date
Tue, 01/24/2023 – 13:37

Review Date
Wed, 01/24/2024 – 13:00

Last Reviewed Date
Tue, 01/24/2023 – 13:00

Site Structure

Next Review Date
1 Year

Source Organization

Bulk Approved
Off

Hide main image
hide

Display Short Description
Off

Language

Media Contact
Media Contact Name
FDA Office of Media Affairs

Media Contact Phone
888-INFO-FDA

Media Contact Email

First Publish Date
Tue, 01/24/2023 – 13:37

Add Subscription Box
Off

Boilerplate
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Quote Attribution

Announcement Type
FDA News Release

#CBD #Hemp http://www.fda.gov/news-events/press-announcements/fda-roundup-january-24-2023 January 24, 2023 5:35 pm

Public Calendar: October 30 – November 5, 2022

Public Calendar: October 30 – November 5, 2022 Public Calendar: October 30 – November 5, 2022 Anonymous (not verified) Tue, 11/15/2022 – 11:28

Detailed Description
Significant meetings held by FDA officials with persons outside of the executive branch of the federal government, October 30 – November 5, 2022

This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.

Official Name: Robert M. Califf, M.D., MACC, Commissioner of Food and Drugs

Event Date: 10/31/2022
Location: Virtual
Subject: Vaccine Hesitancy and Misinformiaton
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several members of public health advocacy groups

Event Date: 11/01/2022
Location: Virtual
Subject: Infant Formula Update
FDA Participant/Group: TRISTAN COLONIUS; MARK RAZA;
Non FDA Participant/Group: Eugenia Pierson, Kevin O’Neill (Arnold & Porter); Kyle Hanson, Murray Kessler (Perrigo);

Event Date: 11/01/2022
Location: Virtual
Subject: Vaccine Hesitancy and Misinformation
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several members of public health advocacy groups

Event Date: 11/01/2022
Location: Washington, DC
Subject: Dinner in Honor of Sir Patrick Vallance, UK Government Chief Scientific Advisor
FDA Participant/Group: N/A
Non FDA Participant/Group: Government, academia, and other invited guests

Event Date: 11/02/2022
Location: Washington, DC
Subject: Clinical and Translational Science Award Program Annual Meeting
FDA Participant/Group: N/A
Non FDA Participant/Group: Government, academia, and other registered attendees

Event Date: 11/03/2022
Location: Virtual
Subject: Annual Cocaine, Meth and Stimulant Summit
FDA Participant/Group: MICHELLE ADAMS;
Non FDA Participant/Group: Government, academia, media, industry, and other registered attendees

Event Date: 11/03/2022
Location: Virtual
Subject: Virginia Tech Maury Strauss Distinguished Public Lecture: The Role of Translational Science in Addressing the Decline in Health Status in the U.S.: A Perspective from FDA
FDA Participant/Group: N/A
Non FDA Participant/Group: Government, academia, industry, media, and other registered attendees

Event Date: 11/04/2022
Location: Chicago, IL
Subject: American Heart Association Scientific Sessions
FDA Participant/Group: N/A
Non FDA Participant/Group: Government, academia, industry, media, and other registered attendees

Official Name: Janet Woodcock, M.D., Principal Deputy Commissioner

Event Date: 11/01/2022
Location: Virtual
Subject: Regulatory Pathways for Hemp Products, Including Cannabidiol (CBD)
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Representatives from the Office of the Secretary and Executive Office of the President

Official Name: Andi Lipstein Fristedt, Deputy Commissioner for Policy, Legislation, and International Affairs

No Significant Event

Official Name: Jim Sigg, Deputy Commissioner for Operations

No Significant Event

Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response

Event Date: 11/01/2022
Location: Virtual
Subject: Food Safety Issues of Mutual Interest
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several leaders and staff from the Canadian Food Inspection Agency and Health Canada

Event Date: 11/02/2022
Location: Virtual
Subject: Food Safety Issues of Mutual Interest
FDA Participant/Group: LARRY MORRIS;
Non FDA Participant/Group: Brian Olney, Danny Wegman, Dave Corsi, Kathleen O’Donnell, Martha Hilton (Wegmans Food Markets, Inc.);

Event Date: 11/04/2022
Location: Virtual
Subject: Infant Formula Issues of Mutual Interest
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several members of industry, trade, and retail associations

Official Name: Mark Abdoo, Associate Commissioner for Global Policy and Strategy

No Significant Event

Official Name: Judy McMeekin, Associate Commissioner for Regulatory Affairs

No Significant Event

Official Name: Erica Jefferson, Associate Commissioner for External Affairs

No Significant Event

Official Name: Namandjé N. Bumpus, Ph.D., Chief Scientist

No Significant Event

Official Name: Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research

Event Date: 11/04/2022
Location: Virtual
Subject: C-Path / FDA 2022 Annual Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Bri Sullivan, Cecile Ollivier, Graham Higson, Huong Huynh, Julie Strzyzewski, Karen Stamm, Kevin B. Perkins, Klaus Romero, Kristen Swingle, Rebecca Yuan, Richard Liwski, Stephen Joel Coons, Sudhir Sivakumaran, Wain Fishburn (Critical Path (C-Path) Institute);

Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research

Event Date: 10/31/2022
Location: Virtual
Subject: In Vivo Gene Therapy and Genome Editing Summit; FDA Efforts to Advance Gene Therapy
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, research, and academia stakeholders

Event Date: 11/02/2022
Location: Virtual
Subject: International Society for Pharmaceutical Engineering; Regulatory Keynote: The Potential Impact of Global Convergence on the Availability of Cell and Gene Therapy
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, government, research, and academia stakeholders

Event Date: 11/02/2022
Location: Virtual
Subject: International Society for Pharmaceutical Engineering; Global Regulatory Town Hall
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, government, research, and academia stakeholders

Event Date: 11/03/2022
Location: Virtual
Subject: Perinatal Stem Cell Society; Advancing the Development of Safe and Effective Regenerative Medicine Products
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, research, and academia stakeholders

Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health

Event Date: 10/31/2022
Location: Virtual
Subject: Real World Evidence Data Collection
FDA Participant/Group: WILLIAM MAISEL; ANGELA KRUEGER; MARY RITCHEY; BRENDAN O’LEARY; DANIEL CANOS; SONJA FULMER;
Non FDA Participant/Group: Ladd Wiley, Sam Butler, Stirling Martin, Sumit Rana (Epic Systems Corporation);

Event Date: 11/04/2022
Location: Virtual
Subject: Diabetes Technology Meeting; Keynote
FDA Participant/Group: N/A
Non FDA Participant/Group: Members of government, industry, technology developers, and users

Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition

Event Date: 10/31/2022
Location: Virtual
Subject: Health and Chemicals Coalition Meeting; Food Chemical Safety Work Including Chemical Contaminants and Toxic Elements
FDA Participant/Group: DOUGLAS STEARN; KRISTI MULDOON JACOBS; CONRAD CHOINIERE; PAUL SOUTH; STEVEN MUSSER; STEVE HERMANSKY; REBECCA BUCKNER;
Non FDA Participant/Group: Lisette Van Vliet (Breast Cancer Prevention Partners); Jose Jensen, Sarah Sorscher, Thomas Galligan (Center for Science in the Public Interest); Jaydee Hanson (Center for Food Safety);

Official Name: Brian King, Ph.D., Director, Center for Tobacco Products

Event Date: 11/01/2022
Location: Virtual
Subject: Update on Premarket Tobacco Product Applications (PMTA) and Non-Tobacco Nicotine (NTN) Enforcement
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Katlin Backfield (US Senate, Health, Education, Labor and Pension (HELP) Staff); Jacquelyn Bolen (US House of Representatives, Energy and Commerce (E&C) Staff);

Event Date: 11/01/2022
Location: Virtual
Subject: American Association for Cancer Research (AACR) Introductory Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several Representatives from the American Association for Cancer Research (AACR)

Event Date: 11/03/2022
Location: Virtual
Subject: Public Health Law Center (PHLC) Webinar; Future Priorities for Federal Commercial Tobacco Regulation: A Conversation with Dr. Brian King
FDA Participant/Group: N/A
Non FDA Participant/Group: Several Representatives from the Public Health Law Center (PHLC)

Official Name: Steven Solomon, Director, Center for Veterinary Medicine

No Significant Event

Official Name: Tucker Patterson, Ph.D., Acting Director, National Center for Toxicological Research

No Significant Event

Official Name: Mark Raza, J.D., Chief Counsel

No Significant Event

 

Short Title
Public Calendar: October 30 – November 5, 2022

Source Organization

Short Description
Significant meetings held by FDA officials with persons outside of the executive branch of the federal government, October 30 – November 5, 2022

Publish Date
Tue, 11/15/2022 – 12:09

Review Date
Wed, 11/15/2023 – 11:00

Last Reviewed Date
Tue, 11/15/2022 – 11:00

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Tue, 11/15/2022 – 12:08

Generic Boolean
Off

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/news-events/public-calendar-meetings-fda-officials/public-calendar-october-30-november-5-2022 November 15, 2022 4:28 pm

Public Calendar: October 23-29, 2022

Public Calendar: October 23-29, 2022 Public Calendar: October 23-29, 2022 Anonymous (not verified) Fri, 11/04/2022 – 10:44

Detailed Description
Significant meetings held by FDA officials with persons outside of the executive branch of the federal government, October 23-29, 2022

This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.

Official Name: Robert M. Califf, M.D., MACC, Commissioner of Food and Drugs

Event Date: 10/24/2022
Location: Virtual
Subject: Food Industry Issues
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several members of the Food and Beverage Issue Alliance

Event Date: 10/24/2022
Location: Virtual
Subject: Diagnostic Testing Issues
FDA Participant/Group: JEFFREY SHUREN;
Non FDA Participant/Group: Stakeholders from several academic medical centers

Event Date: 10/25/2022
Location: Washington, DC
Subject: Friends of Cancer Research 26th Annual Cancer Leadership Awards Reception
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several members of the Friends of Cancer Research, industry, academia, government and other invited guests

Event Date: 10/25/2022
Location: Boston, MA
Subject: Vision for the FDA
FDA Participant/Group: JEFFREY SHUREN; MICHAEL FELBERBAUM;
Non FDA Participant/Group: Several members of the Advanced Medical Technology Association Board

Event Date: 10/25/2022
Location: Boston, MA
Subject: The MedTech Conference; Fireside Chat
FDA Participant/Group: MICHAEL FELBERBAUM; JEFFREY SHUREN;
Non FDA Participant/Group: Government, academia, industry, media and other registered attendees

Event Date: 10/26/2022
Location: Plano, TX
Subject: Vision for the FDA
FDA Participant/Group: N/A
Non FDA Participant/Group: Several members of the American Heart Association Board of Directors, staff and other invited guests

Event Date: 10/27/2022
Location: New York, NY
Subject: 2022 Galien Forum; Speaker: Keynote Address
FDA Participant/Group: N/A
Non FDA Participant/Group: Government, academia, industry, media, and other registered attendees

Event Date: 10/28/2022
Location: Virtual
Subject: Infant Formula Issues
FDA Participant/Group: JULIA TIERNEY; MARK RAZA; SUSAN MAYNE; TRISTAN COLONIUS; FRANK YIANNAS;
Non FDA Participant/Group: Allen Hubert, Monica Wilkins, Robert Ford (Abbott Laboratories);

Official Name: Janet Woodcock, M.D., Principal Deputy Commissioner

Event Date: 10/25/2022
Location: Virtual
Subject: Data Standardization
FDA Participant/Group: RAM IYER; VIDYUT DESAI; JAMES MULHOLLAND; THOMAS BEACH; MEREDITH CHUK; MOHAMMED CHAUDHRY;
Non FDA Participant/Group: Jessica Wasserman (WassermanRowe); Kari Finch (General Mills); Alycia Sohn (American Association of Exporters and Importers (AAEI));

Event Date: 10/27/2022
Location: Virtual
Subject: Council for Federal Cannabis Regulation (CFCR) | FDA Webinar
FDA Participant/Group: N/A
Non FDA Participant/Group: CFCR members, industry, and other stakeholders

Official Name: Andi Lipstein Fristedt, Deputy Commissioner for Policy, Legislation, and International Affairs

No Significant Event

Official Name: Jim Sigg, Deputy Commissioner for Operations

No Significant Event

Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response

Event Date: 10/24/2022
Location: Salinas, CA
Subject: Leafy Greens and Food Safety Issues of Mutual Interest
FDA Participant/Group: JEFFREY FARRAR; KAREN MEISTER;
Non FDA Participant/Group: Representative Jimmy Panetta (D-CA) and staff, Representative Zoe Lofgren (D-CA) and staff, representatives from the California Leafy Green Products Handling Marketing Agreement, representatives from the California Department of Food and Agriculture, farmers, and food manufacturers

Event Date: 10/28/2022
Location: Virtual
Subject: Food Safety Culture
FDA Participant/Group: N/A
Non FDA Participant/Group: Anju Rao (Starbucks);

Official Name: Mark Abdoo, Associate Commissioner for Global Policy and Strategy

Event Date: 10/26/2022
Location: Virtual
Subject: Introductory Meeting
FDA Participant/Group: N/A
Non FDA Participant/Group: Jigar Raval (Indian Embassy);

Event Date: 10/27/2022
Location: Virtual
Subject: 11th Meeting of the WHO Member State Mechanism on Substandard and Falsified Medicines
FDA Participant/Group: N/A
Non FDA Participant/Group: Members of the Pan American Health Organization

Official Name: Judy McMeekin, Associate Commissioner for Regulatory Affairs

No Significant Event

Official Name: Erica Jefferson, Associate Commissioner for External Affairs

No Significant Event

Official Name: Namandjé N. Bumpus, Ph.D., Chief Scientist

No Significant Event

Official Name: Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research

Event Date: 10/25/2022
Location: Virtual
Subject: 2022 C-Path Neuroscience Annual Meeting
FDA Participant/Group: JACQUELINE CORRIGAN CURAY;
Non FDA Participant/Group: Industry, academia, regulatory agencies, and other stakeholders

Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research

Event Date: 10/24/2022
Location: Boston, MA
Subject: Massachusetts Consortium on Pathogen Readiness Symposium – Illuminating Our Path Forward: Lessons from an Evolving Pandemic; Facilitating the Development and Availability of COVID-19 Vaccines
FDA Participant/Group: N/A
Non FDA Participant/Group: Attendees of the Massachusetts Consortium on Pathogen Readiness Symposium

Event Date: 10/26/2022
Location: Virtual
Subject: Pharmaceutical Executive Summit; Gene Therapy – Unlocking the Promise
FDA Participant/Group: N/A
Non FDA Participant/Group: Attendees of Pharmaceutical Executive Summit

Event Date: 10/27/2022
Location: New York, NY
Subject: Galien Forum 2022; Panelist: COVID Pandemic Science 2022: Current Vaccines and Treatments and the Future Outlook
FDA Participant/Group: N/A
Non FDA Participant/Group: Attendees of Galien Forum 2022

Event Date: 10/28/2022
Location: Virtual
Subject: Alliance for Regenerative Medicine/FDA Liaison Meeting
FDA Participant/Group: SHERYL LARD WHITEFORD; ANITA RICHARDSON; WILSON BRYAN; RACHAEL ANATOL; CHRISTOPHER JONECKIS; MELISSA MENDOZA;
Non FDA Participant/Group: Representatives from the Alliance for Regenerative Medicine

Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health

Event Date: 10/26/2022
Location: Boston, MA
Subject: The MedTech Conference; CDRH Town Hall
FDA Participant/Group: ELI TOMAR; WILLIAM MAISEL; DOUGLAS KELLY; SUZANNE SCHWARTZ; MICHELLE TARVER;
Non FDA Participant/Group: Government, academia, industry, media and other registered attendees

Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition

No Significant Event

Official Name: Brian King, Ph.D., Director, Center for Tobacco Products

Event Date: 10/24/2022
Location: Bethesda, MD
Subject: Tobacco Centers of Regulatory Science (TCORS) Fall Conference; Speaker
FDA Participant/Group: BRIAN KING;
Non FDA Participant/Group: Several representatives from the Tobacco Centers of Regulatory Science (TCORS)

Event Date: 10/26/2022
Location: Washington, DC
Subject: Update on FDA Product Standards
FDA Participant/Group: BRIAN KING;
Non FDA Participant/Group: Several representatives from the Council on Foreign Relations

Event Date: 10/26/2022
Location: Virtual
Subject: American Thoracic Society (ATS) Introductory Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several representatives from the American Thoracic Society (ATS)

Event Date: 10/26/2022
Location: Virtual
Subject: Health Canada Introductory Meeting
FDA Participant/Group: ESHAEL JOHNSON; PRISCILLA LYON; BRIAN KING; MEGAN HICKS;
Non FDA Participant/Group: Several representatives from Health Canada

Event Date: 10/27/2022
Location: Virtual
Subject: American Society for Clinical Oncology (ASCO) Introductory Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several representatives from American Society for Clinical Oncology (ASCO)

Official Name: Steven Solomon, Director, Center for Veterinary Medicine

Event Date: 10/27/2022
Location: Virtual
Subject: Veterinary Issues of Mutual Interest
FDA Participant/Group: N/A
Non FDA Participant/Group: Several representatives of the Generic Animal Drug Alliance (GADA)

Official Name: Tucker Patterson, Ph.D., Acting Director, National Center for Toxicological Research

No Significant Event

Official Name: Mark Raza, J.D., Chief Counsel

No Significant Event

Short Title
Public Calendar: October 23-29, 2022

Source Organization

Short Description
Significant meetings held by FDA officials with persons outside of the executive branch of the federal government, October 23-29, 2022

Publish Date
Fri, 11/04/2022 – 11:54

Review Date
Sat, 11/04/2023 – 10:00

Last Reviewed Date
Fri, 11/04/2022 – 10:00

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Fri, 11/04/2022 – 11:54

Generic Boolean
Off

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/news-events/public-calendar-meetings-fda-officials/public-calendar-october-23-29-2022 November 4, 2022 2:44 pm

Public Calendar: October 16-22, 2022

Public Calendar: October 16-22, 2022 Public Calendar: October 16-22, 2022 Anonymous (not verified) Fri, 10/28/2022 – 15:23

Detailed Description
Significant meetings held by FDA officials with persons outside of the executive branch of the federal government, October 16-22, 2022

This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.

Official Name: Robert M. Califf, M.D., MACC, Commissioner of Food and Drugs

Event Date: 10/16/2022
Location: Washington, DC
Subject: National Academy of Medicine 50th Anniversary Celebration
FDA Participant/Group: N/A
Non FDA Participant/Group: Several members of the National Academy of Medicine, academia, industry, government, and other invited guests

Event Date: 10/17/2022
Location: Virtual
Subject: The Organization for Professionals in Regulatory Affairs (TOPRA) 2022 Human Medicines Symposium: Lessons Learned and Strategic Priorities
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, government, media, and other invited attendees

Event Date: 10/17/2022
Location: Washington, DC
Subject: National Organization for Rare Disorders, Rare Diseases, and Orphan Products Breakthrough Summit
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Industry, academia, government, media, and other registered attendees

Event Date: 10/17/2022
Location: Virtual
Subject: Great Plains IDeA-CTR Annual Scientific Meeting: Biomedical Research & Healthcare Informatics Conference
FDA Participant/Group: N/A
Non FDA Participant/Group: Academia, government, media, and other invited attendees

Event Date: 10/18/2022
Location: Virtual
Subject: Infant Formula Issues
FDA Participant/Group: TRISTAN COLONIUS;
Non FDA Participant/Group: Robert Ford (Abbott Laboratories);

Event Date: 10/19/2022
Location: Virtual
Subject: Foundation for the National Institutes of Health Awards Ceremony
FDA Participant/Group: N/A
Non FDA Participant/Group: Several members of the Foundation for the National Institutes of Health, industry, academia, government, and other invited attendees

Event Date: 10/19/2022
Location: Virtual
Subject: Continued Transformation of the Health Research Enterprise
FDA Participant/Group: N/A
Non FDA Participant/Group: Lisa Simpson (AcademyHealth); Lucas Tramontozzi (SCI Solution);

Event Date: 10/19/2022
Location: Virtual
Subject: 12th Annual Conference of Global Summit on Regulatory Science
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Government, academia, industry, and other registered attendees

Event Date: 10/20/2022
Location: Virtual
Subject: Reagan Udall Foundation COVID-19 Evidence Accelerator Public Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Government, academia, industry, media, and other registered attendees

Event Date: 10/20/2022
Location: Virtual
Subject: Foundation for the National Institutes of Health (FNIH) Board of Directors Meeting
FDA Participant/Group: N/A
Non FDA Participant/Group: Several members of the FNIH Board of Directors and staff

Event Date: 10/20/2022
Location: Virtual
Subject: Biosimilars Forum Board of Directors Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several board members of the Biosimilars Forum

Official Name: Janet Woodcock, M.D., Principal Deputy Commissioner

Event Date: 10/17/2022
Location: Virtual
Subject: Foods Program Funding Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Jennifer McEntire (Fresh Produce Association); Donna Garren (American Frozen Food Institute); Mitzi Baum (Stop Foodborne Illness); Brian Ronholm (Consumer Reports); Scott Faber (Environmental Working Group (EWG)); De Ann Davis (Western Growers); Roberta Wagner (Consumer Brands Association);

Event Date: 10/17/2022
Location: Virtual
Subject: Milken Institute FasterCures Virtual Roundtable – Community-Based Infrastructure for Inclusive Research; Speaker: Opening Remarks
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Industry, regulatory organizations, and other stakeholders

Event Date: 10/18/2022
Location: Virtual
Subject: People for the Ethical Treatment of Animals (PETA) Science Consortium International (SCI) Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: April Naab, Jeffrey Brown (People for the Ethical Treatment of Animals (PETA));

Event Date: 10/19/2022
Location: Virtual
Subject: Tobacco Expert Panel Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Charlene Frizzera (CF Health Advisors); Jane Axelrad, Lauren Silvis, Susan Winckler (Reagan-Udall Foundation);

Event Date: 10/19/2022
Location: Virtual
Subject: Cannabis Product Regulation
FDA Participant/Group: N/A
Non FDA Participant/Group: Brian Miller (Miller Research Group);

Official Name: Andi Lipstein Fristedt, Deputy Commissioner for Policy, Legislation, and International Affairs

No Significant Event

Official Name: Jim Sigg, Deputy Commissioner for Operations

No Significant Event

Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response

No Significant Event

Official Name: Mark Abdoo, Associate Commissioner for Global Policy and Strategy

Event Date: 10/17/2022
Location: Geneva, Switzerland
Subject: Substandard and Falsified Medical Products Meeting
FDA Participant/Group: N/A
Non FDA Participant/Group: Paul Huleatt (World Health Organization Substandard and Falsified Medical Products Steering Committee);

Event Date: 10/17/2022
Location: Geneva, Switzerland
Subject: World Health Organization Substandard and Falsified Medical Products Projects Update
FDA Participant/Group: LEIGH VERBOIS, RUSSELL CAMPBELL
Non FDA Participant/Group: Rutendo Kuwana (World Health Organization);

Event Date: 10/17/2022
Location: Geneva, Switzerland
Subject: Substandard and Falsified Medical Products Meeting
FDA Participant/Group: LEIGH VERBOIS, RUSSELL CAMPBELL
Non FDA Participant/Group: Rogerio Gaspar (World Health Organization);

Event Date: 10/19/2022
Location: Virtual
Subject: European Medicines Agency (EMA) – FDA Collaboration with African Medicines Agency Meeting
FDA Participant/Group: RAVI BHARWANI, ANNA FERUS, DOUGLAS SHAFFER, SEMA HASHEMI, DANIJELA STOJANOVIC
Non FDA Participant/Group: Martin Harvey (European Medicines Agency);

Official Name: Judy McMeekin, Associate Commissioner for Regulatory Affairs

No Significant Event

Official Name: Erica Jefferson, Associate Commissioner for External Affairs

No Significant Event

Official Name: Namandjé N. Bumpus, Ph.D., Chief Scientist

No Significant Event

Official Name: Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research

Event Date: 10/18/2022
Location: Washington, DC
Subject: National Organization for Rare Disorders, Rare Diseases, and Orphan Products Breakthrough Summit; Panelist: Fireside Chat Session with FDA Center Directors
FDA Participant/Group: PETER MARKS; JEFFREY SHUREN;
Non FDA Participant/Group: Industry, patient advocacy organizations, academia, and other stakeholders

Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research

Event Date: 10/19/2022
Location: Silver Spring, MD
Subject: American Society of Gene and Cell Therapy and Alliance for Regenerative Medicine Public Meeting; Potency Assays for Cell and Gene Therapies
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, research, and academia stakeholders

Event Date: 10/21/2022
Location: Washington, DC
Subject: ID (Infectious Disease) Week; Moderator: COVID-19 Late Breaking Abstracts
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, research, and academia stakeholders

Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health

No Significant Event

Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition

No Significant Event

Official Name: Brian King, Ph.D., Director, Center for Tobacco Products

Event Date: 10/19/2022
Location: Virtual
Subject: Introductory Meeting
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Several representatives from the National Association of Tobacco Outlets (NATO)

Event Date: 10/20/2022
Location: Washington, DC
Subject: Food and Drug Law Institute’s (FDLI) Tobacco and Nicotine Products Regulation and Policy Conference; Keynote Address: Programmatic Updates
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, government, and other stakeholders

Event Date: 10/21/2022
Location: Virtual
Subject: Introductory Meeting
FDA Participant/Group: N/A
Non FDA Participant/Group: Representative Raja Krishnamoorthi (D-IL)

Official Name: Steven Solomon, Director, Center for Veterinary Medicine

Event Date: 10/17/2022
Location: Virtual
Subject: Veterinary Issues of Mutual Interest
FDA Participant/Group: TRACEY FORFA; PATRICK MCDERMOTT; ANTONIA MONIQUE SENNETT; CHARLOTTE CONWAY; TIMOTHY SCHELL; JEANETTE MURPHY; SIOBHAN DELANCEY; ANNE NORRIS; JENNIFER ERICKSON; DAVID EDWARDS; WILLIAM FLYNN;
Non FDA Participant/Group: Representatives of the Pet Food Institute (PFI)

Official Name: Tucker Patterson, Ph.D., Acting Director, National Center for Toxicological Research

No Significant Event

Official Name: Mark Raza, J.D., Chief Counsel

No Significant Event

 

Short Title
Public Calendar: October 16-22, 2022

Source Organization

Short Description
Significant meetings held by FDA officials with persons outside of the executive branch of the federal government, October 16-22, 2022

Publish Date
Fri, 10/28/2022 – 15:28

Review Date
Sat, 10/28/2023 – 15:00

Last Reviewed Date
Fri, 10/28/2022 – 15:00

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Fri, 10/28/2022 – 15:28

Generic Boolean
Off

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/news-events/public-calendar-meetings-fda-officials/public-calendar-october-16-22-2022 October 28, 2022 7:23 pm

Oversight and onward

Oversight and onward

After spending weeks writing an article warning of the dangers of interstate commerce or federal legalization for states that tax marijuana by weight (Alaska, California, Colorado, Maine, and Nevada) or collect pre-processing (Canada; Alaska, California, Colorado, Illinois, Maine, and Nevada) and publishing it in Tax Notes, I remembered that New Jersey did both.

I’ve made lots of mistakes before; and list some here:  https://newrevenue.org/2015/01/28/3-errors-in-laws-to-tax/.  And for this recent article, I skipped the step, so useful in earlier writing, of soliciting comments before publication, like in 2011:

Still, overlooking New Jersey at age 75 is kind of embarrassing. But it may mean I can slow down, maybe to the point of being a critic or second set of eyes, and take comfort from some tax policy scholars who have been looking at and writing about cannabis revenue:

Carl Davis of the Institute on Taxation and Economic Policy, https://itep.org/?s=cannabis#gsc.tab=0&gsc.q=cannabis&gsc.page=1(Richard Phillips and Misha Hill contributed to some of this work.

Ulrik Boesen, when he was at the Tax Foundation, https://taxfoundation.org/individual-and-consumption-taxes/excise-taxes/marijuana-taxes/

Richard Auxier of the Tax Policy Center, https://www.taxpolicycenter.org/publications/pros-and-cons-cannabis-taxes (with Nikhita Airi)

Ben Leff of American University Law School, https://www.bu.edu/bulawreview/files/2021/07/LEFF.pdf

Jane Gravelle and Sean Lowry from the Congressional Research Service way back in 2014, https://newtax.files.wordpress.com/2015/01/fed-mj-tax-r43785.pdf

Lots of drug policy scholars look at cannabis revenue policy too, but my own background in tax leads me to appreciate these tax policy people who have taken up this work especially.


#CBD #Hemp
Oversight and onward
October 25, 2022 2:56 pm

CTP Supplement to Parent Grant: Impact of Flavor on Youth & Young Adults Use Intention, Abuse Liability and Perceptions of Cigarillos

CTP Supplement to Parent Grant: Impact of Flavor on Youth & Young Adults Use Intention, Abuse Liability and Perceptions of Cigarillos CTP Supplement to Parent Grant: Impact of Flavor on Youth & Young Adults Use Intention, Abuse Liability and Perceptions of Cigarillos Anonymous (not verified) Tue, 10/18/2022 – 08:55

Detailed Description
CTP Supplement to Parent Grant: Impact of Flavor on Youth & Young Adults Use Intention, Abuse Liability and Perceptions of Cigarillos

Principal Investigator: Erika Trapl
Funding Mechanism: National Institutes of Health – Grant
ID Number: 3R01DA048529-03S1
Award Date: 8/20/2021
Institution: Case Western Reserve University 


The goal of this project supplement to the parent grant is to determine how the removal of flavors from cigarillos could impact co-use of cigarillos and cannabis, and whether that impact is related to perceptions of appeal or harm. Specific aims are: (1) to analyze parent study data on 361 young adult (ages 21-28) cigarillo users to determine the relationship between use of flavored cigarillos and co-use with cannabis (including blunts), and (2) to conduct one-on-one interviews with a subset of 38 participants to expand findings from the parent study, including understanding flavor appeal, perceived harm, and product substitution, and to assess these factors in the context of co-use with cannabis. Findings will provide new information about the influence of flavor on young adult co-use of cannabis and cigarillos.

Short Title
CTP Supplement to Parent Grant: Impact of Flavor on Youth & Young Adul

Source Organization

Short Description
CTP Supplement to Parent Grant: Impact of Flavor on Youth & Young Adults Use Intention, Abuse Liability and Perceptions of Cigarillos

Publish Date
Tue, 10/18/2022 – 08:57

Review Date
Wed, 10/18/2023 – 00:00

Last Reviewed Date
Tue, 10/18/2022 – 00:00

Site Structure

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Tue, 10/18/2022 – 08:57

Generic Boolean
Off

Regulated Product*

Language

Number of Related Information to Display
3

Add Subscription Box
Off

Display Short Title
Off

#CBD #Hemp http://www.fda.gov/tobacco-products/research/ctp-supplement-parent-grant-impact-flavor-youth-young-adults-use-intention-abuse-liability-and October 18, 2022 12:55 pm

Partial abandonment of hope on DCC and marijuana

Partial abandonment of hope on DCC and marijuana

Yesterday, I posted a hope that the Dormant Commerce Doctrine does not apply to federally illegal cannabis.

My friend Rob Mikos, a law professor at Vanderbilt and probably the leading expert on marijuana federalism, graciously responded to an email copying that post, writing, “I agree with the policy argument, but not the legal one.”

He points out that the Dormant Commerce Doctrine is old and settled law, operating in the face of the 10thAmendment for centuries.  He’s the expert, so I’ll back off from any hope that as a practical matter the 10th Amendment will come to the rescue of state freedom here.

He says, “There’s a recognized solution to the policy problems the DCC is going to cause for cannabis – it’s to have Congress pass legislation suspending the Dormant Commerce Clause,” and links to this piece with Scott Bloomberg: https://digitalcommons.pepperdineedu/plr/vol49/iss4/2/.

I’m afraid Congress is too dysfunctional to get this right, so I’m wishfully hoping the courts can find a way. 


#CBD #Hemp
Partial abandonment of hope on DCC and marijuana
October 7, 2022 3:27 pm

The Dormant Commerce Clause and Marijuana

The Dormant Commerce Clause and Marijuana

The Dormant Commerce Clause cases that force states to accept out of state owners for local cannabis licenses strike me as wrongly decided.  

Congress’s faint, implied, “dormant” display of intention to open markets in an illegal substance to all comers seems dwarfed by the 10th Amendment’s express and overriding reservation of power to the states to do whatever the heck they want.  “The powers not delegated to the United States by the Constitution, nor prohibited by it to the States, are reserved to the States respectively, or to the people.” The Constitution doesn’t prohibit states from regulating commerce – Congress can allow them to regulate commerce, though it rarely does.

From a policy perspective, too, discarding the Dormant Commerce Clause argument is helpful.  Congress doesn’t know how to do legalize cannabis.  In my field of tax, states are experimenting with all kinds of approaches, and there’s no consensus about which is best.  Some experiments haven’t even gotten underway.  But tax is just a small piece of the cannabis legalization puzzle:  There are tricky problems like testing and packaging where states are experimenting in many ways.  And states are experimenting with ways to share this new cannabis wealth, and to allow ownership for deserving parties.

So Congress is shrewdly waiting to figure out how to legalize before legalizing.   The freer the rein the states have, the more evidence Congress can examine.  Artificially restricting state experiments will not help the process.

Plus, when the profit motive is involved with sales of a problematic and federally illegal drug, isn’t it rational to think that local people might have more of a community spirit than outsiders?  Local people seem more likely to balance the profit motive with a spirit of looking after the good of the community in which they (but not outside investors) live.  

The DCC and cannabis are discussed here: https://ylpr.yale.edu/inter_alia/sleeping-giant-how-dormant-commerce-clause-looms-over-cannabis-marketplace#_ftn37


#CBD #Hemp
The Dormant Commerce Clause and Marijuana
October 6, 2022 2:16 pm

FluxxLab LLC – 637158 – 08/04/2022

FluxxLab LLC – 637158 – 08/04/2022 FluxxLab LLC – 637158 – 08/04/2022 Anonymous (not verified) Thu, 08/04/2022 – 13:05

Company Name

FEIN

Short Title
FluxxLab LLC

WARNING LETTER

RE: 637158

Date: August 4, 2022

TO: 
Arend John Kuijvenhoven
FluxxLab LLC
Arendis, LLC
6124 County Road 5
Ridgeway, CO 81432

RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https://fluxxlab.com/ on July 12, 2022, and August 1, 2022, respectively. The FDA has observed that your website offers the Covid-19 Immune Support Tincture and the CBDA+CBD Oil Tincture products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).

There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.

Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19 include:

 “CBD+CBDa
Immune Support
Special Formulation
In a recent study, CBDa was examined to determine how cannabinoids interact with Covid-19.
Researchers discovered that cannabidiolic acid, also known as CBDA, binds to the spike protein of SARS-CoV-2, the virus that causes Covid-19.
As the compounds bind to the spike protein, they prevent the virus from infecting cells and causing infection, opening up new avenues for the prevention and treatment of the disease.” [From your webpage https://fluxxlab.com/product-category/cbda/]

 “Special
Immune Support Formulation
See Covid-19 Research”

“Researchers have very recently discovered that CBDa, and CBGa bind to the spike protein of SARS-CoV-2, the virus that causes Covid-19.
As the compounds bind to the spike protein, they can prevent the virus from infecting cells and causing infection.”

The product name: “Covid-19 Immune Support” [From your webpage https://fluxxlab.com/product/cbda-cbga-immune-support-special-formulation/]

You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA’s implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to [email protected] describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.

FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.

This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.

If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.

Please direct any inquiries to FDA at [email protected]

FTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at [email protected] certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.

Sincerely,
/S/

Carolyn E. Becker
Director
Office of Unapproved Drugs and Labeling Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

Sincerely,
/S/

Serena Viswanathan
Associate Director
Division of Advertising Practices
Federal Trade Commission

_____________

1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).

2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https://www.phe.gov/emergency/news/healthactions/phe/Pages/default.aspx.

3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https://trumpwhitehouse.archives.gov/presidential-actions/proclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/.

Fri, 08/05/2022 – 10:00
Review Date
Sat, 08/05/2023 – 10:00

Source Organization

Recipient Name
Arend John Kuijvenhoven

Last Reviewed Date
Fri, 08/05/2022 – 10:00

Site Structure

Letter Issue Date
August 04, 2022

Federal Trade Commission
Issuing Office Building Name
Center for Drug Evaluation and Research | CDER

Next Review Date
1 Year

Detailed Description
Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

[email protected]
MARCS CMS ID

Bulk Approved
Off

Address

United States

Display Short Description
Off

Regulated Product*

Sender Address

United States

Recipient Address

1681 Niagara Rd.
Montrose, CO 81401
United States

Language

Address

United States

Add Subscription Box
Off

#CBD #Hemp http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fluxxlab-llc-637158-08042022 August 4, 2022 5:05 pm

Congress: H.R. 8454: Medical Marijuana and Cannabidiol Research Expansion Act

Congress: 
H.R. 8454: Medical Marijuana and Cannabidiol Research Expansion Act
Introduced: Sponsor: Rep. Earl Blumenauer [D-OR3]

This bill was referred to the House Committee on Energy and Commerce and House Committee on the Judiciary which will consider it before sending it to the House floor for consideration.

1 cosponsor is on those committees.

#CBD #Hemp
https://www.govtrack.us/congress/bills/117/hr8454?utm_campaign=govtrack_feed&utm_source=govtrack/feed&utm_medium=rss
July 21, 2022 4:00 am

The Dormant Commerce Clause and Marijuana 

The Dormant Commerce Clause and Marijuana 

Whatever we think of judge-made law attempting to read Congress’s unexpressed mind, allowing states to restrict commerce in something the federal government expressly refrains from legalizing (because it doesn’t know how ) helps the goal of allowing states to run experiments, even bad ones, with all the freedom we can muster , as we try to figure out how to legalize federally.  Let the Labs of Democracy percolate.

And wouldn’t Congress opposed to marijuana applaud any restrictions states might put on?


#CBD #Hemp
The Dormant Commerce Clause and Marijuana 
July 12, 2022 9:55 pm

A book I won’t read

A book I won’t read

In a Time magazine interview, an author of a new book, Can Legal Weed Win?: The Blunt Realities of Cannabis Economics, says this:

“Legal weed producers and sellers in Washington and Colorado have a better chance at capturing market share than they do in other states. That’s not just because of lower taxes and regulations. It’s also because those two states have been open for recreational and adult use the longest.”

The casual reader would think that cannabis taxes in Washington are low, but they are the highest in the world.  

When I look at cannabis writing, I search for the tax part to judge the whole thing.   Since the authors are off-base on what little I’ve seen from them on taxes, I won’t bother reading this book.


#CBD #Hemp
A book I won’t read
July 2, 2022 2:04 pm

Slides for Chief Judge Foley’s class

Slides for Chief Judge Foley’s class

My old friend Maurice Foley from Senate Finance staff days has risen to become Chief Judge of the U.S. Tax Court, and is teaching a class at the University of San Diego Law School. I’m to make a remote guest appearance June 21 on marijuana taxation.; here are the slides for that appearance.


#CBD #Hemp
Slides for Chief Judge Foley’s class
June 20, 2022 9:16 pm

Federal legalization of cannabis in connection with taxes, pricing, and illegal markets

Federal legalization of cannabis in connection with taxes, pricing, and illegal markets

I’m having to miss a conference in Seattle starting tomorrow on federal legalization of cannabis in connection with taxes, pricing, and illegal markets.  Here are notes for what I hoped to say.

States fall into 4 categories:

  1. 7 states with weight-based taxes or producer taxes that will be eviscerated by interstate commerce in products like imported edibles:  Alaska, Colorado, Illinois, Maine, New Jersey, and Nevada – and California, unless its Legislature acts.  [Those states could use a separate small session.]
  2. 2 states, New York and Connecticut, whose potency taxes may be tested locally by imports that haven’t been tested in-state.  
  3. States with other taxes on the books.
  4. States without taxes yet, like my state of North Carolina, where state monopoly retailing seems a better choice for revenue and public health, and legally avoids the federal 280E selling expense tax. (https://digitalcommons.wcl.american.edu/facsch_lawrev/410/)

For any state with taxes, federal legalization brings problems and maybe opportunities:

Federal legalization and elimination of the federal prohibition premium would probably make pre-tax prices lower, leaving more room for state taxes, but new federal taxes might crowd out state taxes. 

Federal taxes might bring standardization of measurement and piggybacking opportunities – like tobacco taxes today, where the federal government’s blessing of the weight of a pack of cigarettes means states don’t have to weigh packs independently.  Federal weight or potency standards could make state weight or potency taxes just peel off.

Interstate commerce could bring a race to the bottom on marijuana taxes, as we have today with tobacco taxes, as the Eric Garner case shows.  Now some states may want to race to the bottom, and become marijuana tax havens, but Congress could solve that problem in advance, by giving a capped rebate, or a credit against federal marijuana tax for state taxes paid.  So if the federal tax rate is $10, they could give states a credit up to say $8.  If the state tax is zero, the federal tax is $10.  If the state tax is $5, the federal tax is $5.  If the state tax is $8, the federal tax is $2.    If the state tax is $9, the federal tax is still $2, because the credit is capped at $2.  States would have no incentive to race to the bottom.  If the states get together, Congress will listen.  We’re still at the starting gate.


#CBD #Hemp
Federal legalization of cannabis in connection with taxes, pricing, and illegal markets
June 5, 2022 9:22 pm

Medical marijuana in the North Carolina Senate 

Medical marijuana in the North Carolina Senate 

Medical marijuana passed the North Carolina Senate, 35-10, after this hearing in the Rules Committee, where I speak at the 36’45” mark — mostly about how state retail sales are safer, more lucrative, and maybe faster than issuing licenses to just 10 vertically integrated corporations.

https://www.wral.com/nc-senate-committee-votes-on-legalizing-medical-marijuana/20309778/

My two-minute appearance starts this way: “Thank you, Mr. Chairman, I’m Pat Oglesby, a lawyer with the nonprofit Center for New Revenue.Marijuana is coming.  Iit makes people nervous but we’re gonna have it and the patients are gonna be getting their medicine — and I like to think about where the money goes.  And right now [under SB711] you’ve got these 10 corporations set up.  Antitrust? [Maybe] you can’t bring an antitrust action for selling a federal illegal product. But the antitrust policy of not concentrating all this economic power in these 10 companies:  It’s the same policy.”

Full transcript:

DISCLAIMER: This transcript is automatically generated and may contain spelling and grammatical errors, and mistaken words. WRAL can not guarantee the accuracy of the transcript.
Transcript:

Dwight grain dane Peterson ha Matthew lee and linda Matthews, thank you. Our pages today are john Eagle, Bessemer City sponsored by Senator Cathy Harrington uh telecheck from Saulsberry sponsored by Senator carl ford and David smith from Lexington sponsored by senator steve Jarvis. Thank you all I think you all three were here yesterday. Uh and so you’re you’re having a a good oversight of what’s going on in the Senate this week. So thank you Two bills on the agenda today. We will start with Senate Bill 774 D. O. T. Legislative changes and agency Bill, Senator Mcinnis. Good morning. You have that. Thank you. Mr Chair ladies and gentlemen, the committee. This is the annual D. O. T. Agency bill. It’s pretty self explanatory. It is non controversial. Uh We did amend the bill yesterday for uh some clarity and uh issued the bill to you for your consideration and appreciate your support. Glad to answer any questions. Thank you questions and comments. None are anyone in the audience. Anyone from the agency in the audience who cares? Okay, Senator Waddell don’t go now. Right. Oh I hope the cameras are rolling because that’s the first mr. We clarified, we clarified in regards to the fee for record request where they’re charging a dollar for somebody to uh to get the records request of a of a of a official document. And uh they they’ve been doing it and we just codified that with the amendment yesterday and make sure it was clarified nothing new. Thank you. Find bill. Well thank you any further discussion or debate. I see no one from the audience that cares to speak on a motion from so what they offer a favorable report uh for Senate Bill 774 D. O. T. Legislative changes. Agency bill all in favor. Please say I oppose no motion carried. Thank you. Thank you. Senator. Uh I’ll call this bill and ask senator heist if he will chair please because I will present along with some other Senate bill 7 11, the N. C. Compassionate Care Act and Senator lee and Senator love. And I will just get us all through this help. Mm hmm. Okay. Thank you. Lord. Thank you. Members of the committee bill before us. Senate Bill 7 11. I will recognize Senator raven to speak first on the bill. Thank you. Mr Chairman uh Members and members of the public uh public Member thank you for being here. Uh No bill in my tenure of of the Senate has gone through more committees. Uh I’ve been more open to comment and uh I’ve been adjusted and readjusted more than this bill had. Uh It’s personally very, very important to me. I want you to know that going in. Uh and I hope that I have been fair and giving everyone uh their chance to uh be for it or against it. And having said that I will give you an overview of the bill and what it does the purpose of the bill is to allow carefully regulated use of medical cannabis for the treatment of debilitating diseases. The recreational sale or use of marijuana will remain illegal under north Carolina law to receive medical cannabis patients must have at least one qualifying debilitating condition as certified in writing by bona fide physician with a patient. Uh relationship qualifying conditions Are defined in the bill. There are 15 of them. Uh we don’t need to go through all of them, but I will uh just highlight some uh cancer, hospice care, uh Ataxia, Crohn’s disease, A. L. S. Uh and other end of life diseases uh that are very debilitating, very horrible ways to die. And this is just a compassionate way to address that. Uh and and help these folks that need it. And I certainly don’t want to leave out the veterans and the PTSD that is associated with some of the problems that are veterans and first responders and other members of society have the patients And design caregivers must apply to DHHS for a registration card in order to receive cannabis from the center. Uh qualified patient caregiver may only possess 30 days. Uh 30 day supply of cannabis. We uh we realized that in the past some of the other uh Bad drugs that have been uh available in cannabis is not one of those by the way have been pretty much a free free prescription from uh physicians in 90 days, 120 days refill as you want. This is not the case and this this is very tightly regulated and designed to be used as necessary again uh in most cases uh in in in end of life hospice care uh for various things. Uh The bill establishes the medical cannabis uh production commission within the D. H. S. To develop a supply system that authorizes uh suppliers to produce cannabis and cannabis infused products uh in the production facilities and produce them uh through uh provide them through medical medical cannabis centers. The bill calls for uh 10 licenses to be issued issued stay wide, and a supplier may only sell cannabis through its own medical centers and not for resale and other centers by another supplier. Each supplier may operate uh no more than eight uh centers that will be an amendment right now. The bill as it reads as four, which will put 80 statewide Uh DHHS will charge an initial non refundable license fee of $50,000 plus $5,000 for each medical cannabis facility. Um And the licensed cannabis suppliers shall pay to DHHS a monthly fee of 10% of gross revenues from the sale of the cannabis or cannabis and Hughes products In in inhalation of cannabis. And that has been a sticking point with some folks is prohibited uh in anyone under 18. Uh it is also uh the smokable products are prohibited in uh many places that you would assume ah like all public places ah nowhere near school grounds. Uh huh. It’s it’s pretty tightly done. Uh And I think if you if you have read it and I think everyone in here, probably everyone in the room has uh good, pretty darn good thing. Closing it, what the bill does, 37 other states have already done this. Uh It is my opinion that no state has done it as well as we are attempting to do it. This is the tightest uh the best written following the models of other states and talking to other states and seeing what they did wrong. We have tried to admit those pitfalls and come up with something that will do just what the bill title does and just what the intention of this bill is. And that is give the citizens the citizens of this state who need and deserve compassionate care just that and it is nothing more than trying to help those people ah with the care that they need ah and augment their treatments as decided upon by the patient and buy a a physician uh and some very very very sad and serious situations. So I would thank you for your support. I will give you a couple of statistics Before I turn it over to the other two about this bill. And I will give you the question on this pole because it was not a push poll. This was not done for my benefit or the other sponsors benefit. This was a straight up question and the question to the voters was this quote, would you support or oppose the General Assembly legalizing medical marijuana for patients with a prescription from a doctor. The end quote, 82% of the voters supported the legislation of medical marijuana, including 57% of the voters who strongly supported the measure, 75% Republicans, 87% unaffiliated, 86%,, democrats backed the measure, At least 78% of male and female, white and black. Matted, moderate conservative voters support medical marijuana. 77% of evangelical voters support medical marijuana. It’s hard for me to say that I have ever seen a poll In my 40 years of the political spectrum one way or another, The polls, 82-77% on anything other than maybe is water wet. Those are amazing numbers. And it shows uh it shows that uh north Carolina and north Carolinian voters do have compassion for their fellow man. Ah and I think that we’re going to have overwhelming support for this measure and I appreciate everyone that has helped me work on this uh for the last five years or so, and I certainly hope that it moves forward and mr chairman, I will turn this over to my other two committee members if they would like to sara low was recognized explains. Mhm. My the reason that I have taken part with this bill is because I believe it will help north Carolinians. I think there are individuals with chronic ailments and other kinds of conditions. And cannabis will help someone and that’s why I support it. Um Other states have done it and as far as I’m concerned, there’s no reason in the world why we shouldn’t open things up so that our citizens can take part in medicine that will help them. Now. I know that a lot of times people when we look at things like this, we in our system of medicine, all kinds of things have been used. One of the things that have been used is opiates which are extremely dangerous, but they’re used and they continue to be used. And those of you that are in this room that have had operations, opiates were used in most cases. Um I think cannabis is much safer and I think that it is something that will help our citizens. So I would encourage you to support this bill as we move forward. Under the thank you mr Chairman, um Over the memorial day weekend, I was hanging out with a friend of mine who was diagnosed with cancer, had surgery about, I think it was six weeks ago, had a scar from here to here. And he was talking about, you know, Delta eight and things that you can buy in the store gummies. They’re completely unregulated to help him through um the chemo that he’s getting ready to go through and for us as a state to be able to find a way where patients can consult with their physician as opposed to their friend on something that they’re going through is incredibly important and so a lot has already been said in committee meetings and other places. But hopefully you would support the bill and to open up this access for physicians to be able to speak with their patients on the best course of treatment may not always be this particular the path that they head down, but at least it’ll be an option for a lot of those folks. Thank you. Questions or comments from members of the committee still dives. Um Thanks so much. Mr Chair I just have three questions in particular. I would like to maybe start out with today, ask your first question. Thank you. Um The first question is when I look at the list of no and I’m just trying to pull it up on my screen. Medical conditions on this is on page two on this listed. Um I’m just curious because often sometimes you know and dealing with other bills that list out conditions. Um The feel that this is an exhaustive list of david deep until they the um but debe Attila I’m gonna get it right the basilica di but I’m gonna get it, your work on me afterwards. Um Is this an exhaustive list. Um Is it a comprehensive list or is this something we’re gonna I mean I may not be here but find ourselves just coming back every session to amend. Thank you on that question. Uh I think that list is uh numerically a through oh with elm and then being halfway through the alphabet, which means that’s 15. So there’ll be 17 of both. Oh right. uh and those 17 things are things that are Mhm. Have some scientific evidence of medical cannabis having a positive effect on or Ameliorating. Ah those diseases somewhat it lists things like growing disease, A. L. S. Hospice care end of life. Uh Cancers. It’s at the uh if you go down that list and those are things that uh let’s say we know that medical cannabis can be useful for and can give some relief or completely satisfied. PTSD is a big one among that as well. Uh And and that is not the end of it all. Um Glaucoma is one that is not on that list that it has been proven that cannabis can help with. But in order for cannabis to work on glaucoma, it has to be a constant a constant infusion or profusion. And that simply can’t happen with today’s uh methodologies and and delivery methods that we have for this product. But the uh the commission. Mhm. It does have the ability to add as they see fit uh other conditions and that will be a plus when you look at the makeup of the commission. Uh It it’s not just one that you’re gonna be put on because you just want to an appointment is gonna be one, you’re gonna be put on to work and help people in north Carolina. Okay. Follow up to that question. So based on this list is currently that’s listed in the bill of debilitating. How do we do that time um conditions? Is this consistent would you say? What other states? Um I think what you’ll find is there’s kind of a hodgepodge around the United States. Although there’s a core group of those that I think are within that. And as Senator raven mentioned the advisory board which has medical professionals, pharmacists and others that will be kind of looking at the research moving forward to be able to make those determinations As two additional debilitating conditions that may qualify. Okay. And if if I actually that was some subsequent questions that they have a question specifically, I do have a question specifically about PTSD. And the question regarding the PTSD is what exactly is the purpose of um In line 43 and 40 for it says details of the Trauma shall not be required because if I understand correctly wooden a veteran in this case or military personnel go to a physician. And would this limit then that conversation with the physician. I’m just trying to understand ah what the the purpose or the intent of quote details of the trauma shall not be required. So while while the commission will be adopting rules, I think if you’ll look on the written certification, it talks about um, mm about how the physician has to outline what the debilitating condition is. And I think the intent is that it’s not required to release that information to the commission. Um, excuse me to DHHS for purposes of the written certification. So you go to a physician, you talk to them about what has given rise to the PTSD, they write your certification, the state’s PTSD, but they don’t have to go into the in depth with DHHS as to what that is. That that’s my understanding of what’s there. Okay. And then the last question then. Okay, looking at the advisory board. Um, I’m just curious and especially with the commitment the General assembly has already made in particular. Um, and I think everybody here voted for it and supported eight spot. Um, if we believe there could be some positive benefit, you know, from veterans, I’m still curious. Um, looking at the composition of the board, you know, we do have some patients that are identified to be participants of the board. Um, is there any specific reason why we would not have a veteran um, on the board? Mm hmm. Let me check back through. And I hate, I hate to air on this with without being exact, but I believe in the seven, uh, in the seven positions, uh, I’m mistaken, but appointed by the governor, that one of those, uh, either is or treats, um that specifically I think he’s human with. Yeah I think you’re I think we’re okay on that. I think you’re talking about the advisory, I’m talking about the advisable and page four you can handle that. Uh No there’s not a specific reference um There is a reference to a cardholder, a patient and then also um a parent of a minor qualified patients. Um You know, I don’t know that we we dug that deep into the advisory board. It’s not exclusive. Such that subsection f on page for uh you know that that particular patient maybe a veteran or someone suffering from PTSD, it’s not excluded but it is not specifically included at this time. Just a final comment. Final final final. Now the question that’s a comment. No, you know I put it as well, I understand what you’re attempting to do, you know? But again I would just emphasize, you know, we understand that Um the number I tend to hear 22 or so veterans, you’ll on average commit suicide a day across the nation and we have made a commitment as a general assembly, you know, just trying to do what we can to address, you know the veteran population out there. So when it’s gone um served the country, they they’ve come back and if you know we think there’s some benefit here and we’ve already made a commitment with the hyperbaric oxygen therapy treatment and we now think perhaps you know those with um debilitating conditions, medical conditions could benefit. I I would just wonder if there would be utility and if if you all would consider, you know, opening, you know, some opportunity for a veteran. So that’s just a thought for you other questions or comments from the committee. Senator Children. Mhm. Thank you. Mr Chair. Um I want to just thank the bill sponsors for the work on this and especially you Senator raben. I um no from my personal experience when I first began to serve here in the legislature. Uh some of the early meetings I had were with patients that um had used medical marijuana to deal with the conditions that they had in place and it was really eye opening to to see how cannabis can heal the pain that so many people experience. And I want to thank you for this. Um Just one a couple of questions I think related to the economics of the bill that you and I have uh chatted about. Uh I know that this is what’s called a vertically mandated um Bill, vertically integrated mandated bill in the sense that uh there will be 10 licenses that are gonna be issued for those that will go that will provide seed to sale. And um and I and I understand, I believe the argument really is that it allows for efficiency and also consumer safety um if the state were to go forward because I guess there is some concern that with the vertically integrated model that growers will be excluded manufacturers will be, were excluded. Um My question to you is, I guess the medical cannabis production commission cannot make that decision and we would have to make those changes would have to be made through state through legislative changes. Is that is that correct? So senator, Yes, it is, but we would certainly, I think those changes would cut them about upon the recommendation of that commission. Uh and and that’s what I see going forward. You know, this is uh I think it is necessary to do the uh beginning to the end the the seed to sale product to absolutely ensure quality control and to know that uh that the product that we are producing uh is safe and that the amount uh of THC in that product is going to be the same every time. And just standardization is part of it. I’m sure that if the industry grows as, I think it will grow, um changes will come. Uh but I don’t know what those are, the commission will, will have to in order to change that, Make recommendations to the legislature and this body will then decide, okay, just 1, 1 other follow up. I know that this vertically integrated model I believe exists and um the mandated model exists in florida and new Mexico. Are we aware of any and maybe literally you can answer this if if there had been any any trust challenges for the fact that a limited licenses have been issued. That that may or may not be concerned just a question. Yeah, I’m not aware of that. I mean the process and the bill provides for 20 recommendations to come out of the HHS and the commission has, you know, the ability to choose up to 10 of those from a vertical integration perspective. I don’t know that, that I’m not sure that that any other state is, has had any kind of inquiry um, with the Department of justice or whatever federal agency handles that. Thank you center. Whatever my questions were similar to what um my colleague senator charge we just mentioned, but I have something to other questions concerning that. I did visit a marijuana plant in las Vegas when I went to training and we saw how they were doing what they did from start to finish. But I’m concerned about the business aspect of it in that um, it said here that for business to get licensed, all medical marijuana companies must manage every aspect from farming to the final sale, including owning and operating storefronts and expensive barrier for entry and sometimes the majority of north Carolina farmers are not ready to do so. So is there any sense that this would be like so that the small farmer or the person who’s entering it for the first time would have an opportunity. So I think what the bill allows for is for to be able to work with those who have the expertise that’s required in the application process. Um, So I do think there are opportunities and options in that regard. However, I will say that this is an expensive operation. Um, so you want to make sure that, that the licenses have the ability to produce a product that is of of the quality that you would expect for a physician to write a recommendation for. So the requirements in the application process does not exclude anyone allows them the ability to bring in those with the expertise um, that are required in the application process. But again, it is a, an expensive venture to begin in order to hit the quality measurements that will be needed for a physician to write a recommendation. All right. Thank you. Yes, follow up. And then there’s further stated here that um, The commission will be allowed to issue 10 medical cannabis supplier license. Each supplier would be allowed to operate no more than four medical centers, one of which must be located in a tear one county. So if you’re limited 1 to 81 county. What about the others? Is there any specifications for them? So, um, I think Senator raven mentioned we’re going to increase that to eight. So double the amount of, of access points for patients. Um, the idea behind having at least one in a tier one county was so that um, the suppliers, we’re not just focused around the larger areas and so that folks in rural areas would still have access. So that was kind of the gist behind that having at least one follow up, but it does not say specifically If you have one in one tier one county that some of the others could not Be operating and then in addition to go to till one county. So there’s no limitations. I’m not sure I understand the question. You think there’s not a limitation on how many you can have it here with? There is not, there’s not. So you could put them all in a tier one county if if a licensee wanted to. The idea was that most licenses you’re gonna want to be in in where the major medical centers are because most of the debilitating conditions are those of which folks would be going to some of the major cities not just have a comment. I’m concerned because I had several constituents who approached me, they’re in business already, but not this kind of business. They know how to operate a business because they’ve been doing it that they will be not included and not have the opportunity to be included in this. And we are explicit that we are open. Even if you are running another kind of business, it does not allow you to do this. I think we should open it up and that’s my comment. Any other questions, comments center, Fitch. Look to the legal side I believe similarly responded there was they were not aware of any that’s for coming in. Any other questions or comments. I’ll hold. I’ll come back to you for the motion any other questions or comments from the committee. I don’t have a list up but any members of the public who have signed up for others to speak on this bill. Uh huh. Three. Okay, excuse me. Thank you. Mr. Chairman members of the committee. My name is jerry Royal. I’m counsel for the north Carolina Family Policy Council. Yeah, Based on current medical research and the cost of the harmful effects have been found. We strongly encourage you to oppose Senate Bill 7 11. We all want to be compassionate and to help people in need. As we look at potential health benefits of medical marijuana. We must also weigh the harms and costs to individuals, their families, their community in our state. To find the facts, we need to look to medical professionals and see what they have found so far in their research. We have provided information for you from the Food and Drug Administration, american Academy of neurology, american psychiatric association and american Medical Association. All of these groups encourage continuing research but currently do not support medicinal use of marijuana. A good overview is provided at 2021 article on the A. M. A. Website about a friend of the court brief. They have filed quote. While it is possible, there may be beneficial medicinal uses of marijuana, numerous evidence based studies demonstrate that significant deleterious effects abound. The brief tells the court going on to say without question. The public health risks are immense. Drug abuse and addiction change in brain function, lung disease, intoxication and impaired driving developmental interference, impaired cognition, psychological illness, cardiovascular abnormalities, negative social functioning effects and cancer. The A. M. A. Brief went on to say a massive amount of future systemic research and controlled trials are needed to study the safety and efficacy of cannabis for medicinal purposes. At this point in time, the research clearly shows that the harms and costs to individuals, families and the state greatly outweigh any potential benefits. We therefore encourage you to oppose Senate Bill 7 11. Thank you. Next up, I have reverend Mark Creech, thank you. Mr Chairman and members of the committee reverend Mark Creech, executive director of the christian Action League. Over recent months we’ve heard some emotional testimonies in favor of this bill but I just want to remind you that all of these testimonies are anecdotal evidence, not scientific. I believe that everything that the christian Action League has meant to say on this proposal is summed up in a statement by Dr Samuel Wilkinson and Deepak Cyril D’Souza of the Yale School of Medicine in the Journal of the American Medical Association. If marijuana is to be used for medical purposes, it should be subjected to the same evidence based review and regulatory oversight as other medications prescribed by physicians. Potentially therapeutic compounds of marijuana should be purified and tested and randomized double blind placebo and active controlled clinical trials. Towards this end, the federal government should actively support research examining marijuana’s potentially therapeutic compounds. These compounds should be approved by the F. D. A. Not by popular vote or state legislature, produced according to good manufacturing practice standards distributed by regulated pharmacies and dispensed via a conventional and safe route of administration. Otherwise, states are essentially legalizing recreational marijuana but forcing physicians to act as gatekeepers for those who wish to obtain it. And I would just refer to you. There was a poll mentioned earlier which seemed to indicate complete or vast support on this. But uh that pole that was mentioned suggest if you will that a physician can prescribe uh medical marijuana. But I’m reading for the from the american Association Journal of of Ethics. Currently it is illegal for physicians, even in states where medicinal marijuana is legal to prescribe the drug because it is a scheduled one and prescribing it would constitute aiding and abetting the acquisition of marijuana which could result in revocation of D. E. A licensor and even prison time time has expired. Next. I have Pat Oglesby. Okay, thanks, thank you. Mr chairman, I’m Pat ogles beyond the lawyer with the non profit center for new revenue and marijuana is coming. I mean it makes people nervous but we’re gonna have it and we’re gonna have um the patients are gonna be getting their medicine and I like to think about where the money goes And right now you’ve got these 10 corporations set up now, antitrust, you can’t bring an antitrust action for something of federal illegal product. But the pope, the antitrust policy of not concentrating all this economic power in these 10 companies. It’s the same policy. And I wonder what would happen if if if I mean this state setting it up? Well, I’m an old timer, I’m older than that. I’m not probably not the oldest person here, but I but I keep thinking about a safe model of the state store, fixing up the abc model and doing that where you have patients can get the medicine where you provide the medicine to the patients, but you don’t have these for profit entities promoting it and pushing it because you get a I mean, I love the free enterprise system, I’m gonna go buy things from it today, but when you when you have it, when you unleash the full power of it to deal with a with a drug that we don’t know a lot about and that people are nervous about. It makes me nervous When these, when these folks get there when these 10 companies get their feet in the door, they’re gonna be standing right in line to get first to sell recreational and pushing for that licensing has been, you know, so you’re gonna get this board, give out these licenses, what happens over and over in state after state as lawyers? Well, that’s our hearts come after him and say, well that’s you, you did this wrong, you hold off, there’s abuse of discretion, don’t issue this license and it’s been, they put them on hold and so you said the government can be clunky and slow, but it may be that that state sales could get started even faster and licenses in a in a situation where you’re trying to figure out who gets them and it’s not quite sure who could, who should. So we don’t know, I’d say let’s let’s keep the profit moving down here, keep the noise down marijuana sells itself and thank you all for all your work and and the support of this effort, thank you. Thank you back to the committee. Any other questions or comments from the committee? Senator Harrington, thank you. Thank you Mr Chair. And I’d like to thank the bill sponsors for bringing us through. Um it’s been quite an interesting um, journey to see this bill move through and we’ve seen and heard some of the most compelling and moving testimony in the 12 years that I’ve been here um in favor of this bill and I just wanted to thank you any other questions or comments? Um I hadn’t signed up beforehand, but um I’ll give you one minute, um my name is Sean Perich um I’ve been an entrepreneur in the hemp industry for the last five years and I wasn’t planning on saying something but because of senator chaudhary bringing up the issue or not an issue, but bringing up vertical integration, I just wanted to speak on behalf of how, I don’t necessarily think that might be the best long term thing for the patients. Just seeing what’s happened in other states, seeing what’s happened in the hemp industry, even in this state, the processing of growing is so intricate, there’s like 100 different strains, there’s turbines, the process of processing is so intricate, there’s ethanol extraction, there’s C. 02 extraction in the process of retail is so different in itself or like yes, a physician can give you a prescription, but do we expect all physicians to be up to date with the latest um you know, different types of strains that might work for a certain illness or different types of turbines or different ratios between CBD and THC, I don’t think that’s long term feasible to have that level of quality. Um when you vertically integrate, I believe things would slip up in the cycle and it’s just my fear that that’s something that if it’s still something that can be looked at which earlier didn’t think so, but if it can I would strongly strongly or just all to look at that and I’m happy to give anyone like evidence based on this and other states. Thank you. Thank you very much. I’ll hold I’m holding center Fitch for the motion but any other questions or comments, Senator Newt. So just just one comment, it really goes to whether you’re for this bill is gonna vote for it or against it. I just wanted to commend the bill sponsors. Um I have seen this, you know, sort of not from the beginning because they worked on it before it ever became visible to the rest of us all the way through to today. And I have never seen such a respectful, thorough process of listening to members, uh making changes to the bill every step of the way to try to alleviate concerns that were raised about the bill. So I just want to commend you for that best in class in terms of how to bring a bill through listening to members and the public. And so again, when you’re gonna vote for it or against it. The process has been a plus and I just commend you for the way you handled it. Thank you other questions or comments from the committee scene. Unrecognized center Fitch for emotion. No bill is perfect. That’s why we are in fact the legislative body. I do believe that this is the right thing to do if there are problems that crop up from the latest standpoint, be a legislative body ready, willing and able to make the adjustment. Mr Chairman. If I may at this time, I would move for a favorable report as the bill. I believe it was this a committee substitute. It is not here to it is uh Bill as the bill is before us. Alright, I would move for a favorable report for the bill as before. Um Any final comments from bill sponsors. Seeing none all those in favor of the passage of Senate Bill 7 11. Please signify by saying Aye opposed. No. The eyes have it. The bill will be referred to the floor. I believe senator Ravens running it on the floor. Is that coming in? So I believe it’s scheduled for tomorrow. I would turn the gavel back over to center raven for bringing this thing. Uh Ladies and gentlemen, thank you for your attendance today and for the comments from the public. We appreciate everyone being here and pages And our sergeant at arms staff concludes. The agenda of the meeting is adjourned. Thank you


#CBD #Hemp
Medical marijuana in the North Carolina Senate 
June 5, 2022 12:52 pm

2022 Meeting Announcement, Science Board to the FDA – 06/14/2022

2022 Meeting Announcement, Science Board to the FDA – 06/14/2022 2022 Meeting Announcement, Science Board to the FDA – 06/14/2022 Anonymous (not verified) Wed, 06/01/2022 – 14:56

Event Title
2022 Meeting Announcement, Science Board to the FDA

Event Attendance

June 14, 2022
June 14, 2022
Publish Date
Thu, 06/02/2022 – 00:23

Review Date
Thu, 06/01/2023 – 00:00

Last Reviewed Date
Wed, 06/01/2022 – 00:00

Short Title
2022 Meeting Announcement, Science Board to the FDA

Detailed Description
2022 meeting announcement for the Science Board to the Food and Drug Administration

Event Format

Next Review Date
1 Year

Navigational Page
Off

CE Credit
Off

Source Organization

Bulk Approved
Off

Body

Agenda

The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The Science Board to the Food and Drug Administration will consider challenges in evaluating the safety of dietary supplement and food ingredients with predicted pharmacological activity, utilizing cannabinoids as a case study. The Science Board to the Food and Drug Administration will also hear about the Agency’s enhanced efforts to spur the development, qualification, and adoption of new alternative methods for regulatory use that can replace, reduce, and refine animal testing and have the potential to provide both more timely and more predictive information to accelerate product development and enhance emergency preparedness. The Science Board to the Food and Drug Administration will also hear about the Agency’s enhanced efforts to ensure optimal organization, infrastructure, and expertise for data science efforts in alignment with its regulatory scope and evidence-based decision making, in support of FDA’s public health priorities.

Meeting Materials

FDA intends to make background material available to the public no later than two (2) business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available on FDA’s website at the time of the advisory committee meeting. Background material and the link to the online teleconference meeting room will be available at:

Public Participation Information

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

  • Written submissions may be made to the contact person on or before June 7, 2022.
  • Oral presentations from the public will be scheduled between approximately 11:00 a.m. and 12:00 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before June 1, 2022.

Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by June 7, 2012.

Contact Information

Rakesh Raghuwanshi
Office of the Chief Scientist
Office of the Commissioner
Food and Drug Administration
White Oak Bldg 1, Room 3309
10903 New Hampshire Ave
Silver Spring, Maryland 20993
Phone: 301–796-4769
E-mail: [email protected]

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

  • FDA Advisory Committee Information Line 1-800-741-8138
    (301-443-0572 in the Washington DC area).

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Rakesh Raghuwanshi at (301) 796-4769 at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).

Display Short Description
Off

UCM Sorting
5

Language

Event Duration
1 day

Add Subscription Box
Off

#CBD #Hemp http://www.fda.gov/advisory-committees/committees-and-meeting-materials/2022-meeting-announcement-science-board-fda-06142022 June 1, 2022 6:56 pm

Help HempToday support refugees fleeing the war in Ukraine

HempToday operates under the auspices of the Nakło Foundation in Poland. Our foundation is serving as a safe haven for families forced out of their home country due to the war in Ukraine.

We appeal to the hemp community to support us in this effort. Your donation goes to help cover the costs associated with our hosting of mothers and children, as men between the ages of 18-60 must stay in the country to support the war effort.

The funds will also be used to transport refugees from the border, to contribute to local food banks and to purchase additional items for other refugees who are being relocated in our local community.

We thank you in advance for your support. – Kehrt & Marzenna Reyher

Click here to read more.

Will New Hemp-Infused Drink be a Trendsetter Among Big Brands?

From the Food Institute article “Will New Hemp-Infused Drink be a Trendsetter Among Big Brands?:”

[…]
“Richard Rose, founder of hemp-foods-related therichardrosereport.com, said: “Hemp energy drinks typically have 50 milligrams of hemp seed oil per can, or a less-than-.01 percent hemp content. Thus, with virtually no functionality, it is purely a marketing ploy, but at least it gets the ‘H’ word in front of new consumers.””

Read more at: https://foodinstitute.com/focus/will-new-hemp-infused-drink-be-a-trendsetter-among-big-brands/

Help Provide a Safe Haven for Ukrainian Refugees

From our friends at HempToday:

“Help us provide a safe haven for Ukrainian refugees

Nakło Foundation is serving as a safe haven for families forced out of their home country due to the war in Ukraine. Your donation goes to help cover the costs associated with our hosting of mothers and children, as men between the ages of 18-60 must stay in the country to support the war effort. The funds will also be used to contribute to local food banks and to purchase additional items for other refugees who are being relocated in our local community. We thank you in advance for your support.

– Kehrt & Marzenna”

Read more and donate at: https://naklofoundation.org/donate/

Marijuana tax policy webinar, January 26 at noon Eastern

Marijuana tax policy webinar, January 26 at noon Eastern

My friend, Center for New Revenue board member, and law professor Doug Berman of the Ohio State University heads up the Drug Education and Policy Center there. That Center and the Center for New Revenue are sponsoring a webinar Wednesday, January 26 at noon Eastern time – on marijuana tax policy.

My co-panelists are Ulrik Boesen of the D.C. think tank Tax Foundation, Tax Professor Ben Leff of American University Law School, and prominent California cannabis lawyer Hilary Bricken.  Shaleen Title of the Parabola Center will moderate.

More info is here https://moritzlaw.osu.edu/solving-cannabis-tax-puzzle-approaches-emergent-industry?utm_campaign=law_marketing-activity_fy22&utm_content=1638540324&utm_medium=social&utm_source=twitter

Registration is required, and to the right of that page.


#CBD #Hemp
Marijuana tax policy webinar, January 26 at noon Eastern
January 21, 2022 8:34 pm

Candidate questionnaire draft

Candidate questionnaire draft

Having given money to Democratic candidates in the past, I’ve been getting calls from candidates asking for my support.

I’m working up a questionnaire to see whom to support; here’s a draft. There will be more questions; suggestions welcomed.

Do you support taking away the carried interest tax advantage for hedge fund operators?

Do you support increasing the federal estate tax?

Do you support eliminating planning opportunities that allow avoidance of the federal estate tax?

Do you propose to let marijuana companies start deducting their advertising and marketing expenses on either federal and North Carolina tax returns?  That is, would you take away the 280E Selling Expense Tax on the books now? 

Do you support government rather than for-profit private marijuana retailing in North Carolina?

My own answers would be yes to all questions except the fourth one about 280E.  


#CBD #Hemp
Candidate questionnaire draft
December 13, 2021 11:11 pm

Remembering Bob Dole

Remembering Bob Dole

I was a big fan of Bob Dole when I worked for Congressional tax-writing committees in the 1980s.  He chaired the Senate Finance Committee until he became Majority Leader, and he stayed on the committee.  He was a statesman in his own way, and funny.  After Dole died, Al Franken started claiming to be the funniest living ex-Senator.

Here’s some marijuana tax trivia.  Bob Dole inserted the 280E Selling Expense Tax into the tax law in 1982 when he was Senate Finance Committee chair.  I was on the staff of the Joint Committee on Taxation then, and must have known about 280E back then, because the staff had proofed the technical explanation of the entire bill during Congressional downtime for staff, but I didn’t work on it.

Dole got the idea from Senator Bill Armstrong (R-CO) who was on the Finance Committee.  Armstrong was a pretty shrewd operator.  He was described by Dole as the “the father of tax indexing” – a change called the most dramatic tax law development in a generation by Ken Kies on the right and Jim Wetzler on the left.  So that makes Armstrong a key figure in tax policy.  280E is hated by the marijuana industry, but by making advertising and marketing non-deductible, 280E keeps the noise down.  


#CBD #Hemp
Remembering Bob Dole
December 11, 2021 7:04 pm

Marijuana policy reading

Marijuana policy reading

Drafting a pamphlet: “What North Carolinians Need To Know About Marijuana Money.” Here’s what I’m thinking for background reading references:  

For marijuana issues generally, I don’t know a better place to start than Mark Kleiman’s Marijuana Legalization:  What Everyone Needs to Know (2d ed. 2016, with Caulkins and Kilmer, under $20), which inspired the title here.  A more technical 2015 analysis by Kleiman and others for the State of Vermont is in the public domain at https://www.rand.org/pubs/research_reports/RR864.html.

Kleiman’s work is a little dated; a recent multi-author issue of the B.U. Law Review provides a good update in the public domain. https://www.bu.edu/bulawreview/2021/07/14/volume-101-number-3-may-2021/.

For an ideological prohibitionist view, the group Smart Approaches to Marijuana, https://learnaboutsam.org, provides online material and offers a book for sale.  

An anti-prohibition view is thought through in a free online book by the U.K. Transform Drugs Foundation: https://transformdrugs.org/publications/how-to-regulate-cannabis-a-practical-guide


#CBD #Hemp
Marijuana policy reading
September 25, 2021 2:25 pm

5 Cosas que Debe Saber Sobre el Delta-8 Tetrahidrocannabinol – Delta-8 THC

5 Cosas que Debe Saber Sobre el Delta-8 Tetrahidrocannabinol – Delta-8 THC 5 Cosas que Debe Saber Sobre el Delta-8 Tetrahidrocannabinol – Delta-8 THC Anonymous (not verified) Thu, 09/16/2021 – 12:02

Detailed Description
Los productos de Delta-8 THC no están aprobados por la FDA y pueden ponerle en riesgo.

Audience

Topics
Public Awareness

English

El delta-8 tetrahidrocannabinol, también conocido como Delta-8 THC, es una sustancia psicoactiva que se encuentra en la planta de Cannabis sativa, de la que la marihuana y el cáñamo son dos variedades. El Delta-8 THC es uno de más de 100 cannabinoides producidos naturalmente por la planta de cannabis, pero no se encuentra en cantidades significativas en la planta de cannabis. Por ello, las cantidades concentradas de Delta-8 THC se fabrican normalmente a partir de cannabidiol (CBD) derivado del cáñamo.

Es importante que los consumidores sepan que los productos de Delta-8 THC no han sido evaluados ni aprobados por la FDA para su uso seguro en ningún contexto.  Pueden comercializarse de forma que ponen en peligro la salud pública y, sobre todo, deben mantenerse fuera del alcance de los niños y las mascotas. 

A continuación, se presentan 5 cosas que debe saber sobre el Delta-8 THC para mantenerse a usted y a sus seres queridos protegidos de productos que pueden suponer graves riesgos para la salud:

1. Los productos de Delta-8 THC no han sido evaluados ni aprobados por la FDA para su uso seguro y pueden comercializarse de forma que ponen en riesgo la salud pública.

La FDA está consciente de la creciente preocupación sobre los productos de Delta-8 THC que se venden actualmente en línea y en las tiendas. Estos productos no han sido evaluados ni aprobados por la FDA para su uso seguro en ningún contexto. Algunas de las preocupaciones incluyen la variabilidad en las formulaciones y las etiquetas de los productos, el contenido de otros cannabinoides y terpenos, y las concentraciones variables de Delta-8 TCH. Además, algunos de estos productos pueden estar etiquetados simplemente como “productos de cáñamo”, lo que puede confundir a los consumidores que asocian “cáñamo” con “no psicoactivo”. Además, la FDA está preocupada por la proliferación de productos que contienen Delta-8 THC y se comercializan para usos terapéuticos o médicos, aunque no hayan sido aprobados por la FDA. La venta de productos no aprobados con afirmaciones terapéuticas sin fundamento no sólo constituye una infracción de la ley federal, sino que también puede poner en riesgo a los consumidores, ya que no se ha demostrado que estos productos sean seguros o eficaces. Esta comercialización engañosa de tratamientos no probados plantea importantes problemas de salud pública porque los pacientes y otros consumidores pueden utilizarlos en lugar de las terapias aprobadas para tratar enfermedades graves e incluso mortales.

2. La FDA ha recibido informes de eventos adversos relacionados con productos que contienen Delta-8 THC.

Desde diciembre de 2020 hasta julio de 2021, la FDA recibió informes de eventos adversos tanto de consumidores como de las fuerzas policiales que describían a 22 pacientes que consumieron productos con Delta-8 THC; de ellos, 14 se presentaron en un hospital o sala de emergencias para recibir tratamiento después del consumo. De los 22 pacientes, 19 experimentaron efectos adversos tras consumir productos alimenticios que contenían Delta-8-THC (por ejemplo, brownies, gomitas). Los eventos adversos incluyeron vómitos, alucinaciones, problemas para mantenerse en pie y pérdida de conciencia.  

Los centros nacionales de control de envenenamiento recibieron 661 casos de exposición a productos con Delta-8-THC entre enero de 2018 y el 31 de julio de 2021, 660 de los cuales ocurrieron entre el 1 de enero de 2021 y el 31 de julio de 2021. De los 661 casos de exposición:

  • El 41% implicó una exposición no intencional al Delta-8-THC y el 77% de estas exposiciones no intencionales afectaron a pacientes pediátricos menores de 18 años.
  • El 39% afectó a pacientes pediátricos menores de 18 años.
  • El 18% requirió hospitalizaciones, incluyendo niños que requirieron ingreso en la unidad de cuidados intensivos (ICU, por sus siglas en inglés) tras la exposición a estos productos.

3. El Delta-8 THC tiene efectos psicoactivos y embriagantes.

El Delta-8 THC tiene efectos psicoactivos y embriagantes, similares a los del Delta-9 THC (es decir, el componente responsable del “subidón” que pueden experimentar las personas al consumir cannabis). La FDA está al tanto de los informes de los medios de comunicación sobre productos con Delta-8 THC que hacen que los consumidores estén “drogados”.  La FDA también está preocupada por el hecho de que los productos con Delta-8 THC probablemente expongan a los consumidores a niveles de la sustancia mucho más elevados que los que se dan de forma natural en los extractos crudos de cáñamo. Por lo tanto, no se puede confiar en el uso histórico del cannabis para establecer un nivel de seguridad para estos productos en los seres humanos.   

4. Los productos de Delta-8 THC a menudo implican el uso de productos químicos potencialmente dañinos para crear las concentraciones de Delta-8 THC que se afirman en el mercado.

La cantidad natural de Delta-8 THC en el cáñamo es muy baja, y se necesitan productos químicos adicionales para convertir otros cannabinoides del cáñamo, como el CBD, en Delta-8 THC (es decir, conversión sintética). Las preocupaciones con este proceso incluyen:

  • Algunos fabricantes pueden utilizar productos químicos domésticos potencialmente nocivos para fabricar Delta-8 THC mediante este proceso de síntesis química. Se pueden utilizar productos químicos adicionales para cambiar el color del producto final. El producto final de Delta-8 THC puede tener subproductos potencialmente dañinos (contaminantes) debido a los productos químicos utilizados en el proceso, y hay incertidumbre con respecto a otros contaminantes potenciales que pueden estar presentes o producirse dependiendo de la composición de la materia prima inicial. Si se consumen o inhalan, estas sustancias químicas, incluidas algunas utilizadas para fabricar (sintetizar) el Delta-8 THC y los subproductos creados durante la síntesis, pueden ser perjudiciales.
  • La fabricación de productos de Delta-8 THC puede llevarse a cabo en entornos no controlados o antihigiénicos, lo que puede dar lugar a la presencia de contaminantes nocivos u otras sustancias potencialmente dañinas.   

5. Los productos de Delta-8 THC deben mantenerse fuera del alcance de los niños y las mascotas.

Los fabricantes están envasando y etiquetando estos productos de forma que puedan resultar atractivos para los niños (gomitas, chocolates, galletas, dulces, etc.).  Estos productos pueden comprarse en línea, así como en una variedad de establecimientos, incluyendo tiendas de conveniencia y gasolineras, donde puede que no haya límites de edad sobre quién puede comprar estos productos. Como se ha comentado anteriormente, se han producido numerosas alertas de centros de control de envenenamiento que implican a pacientes pediátricos que estuvieron expuestos a productos que contienen Delta-8-THC. Además, los centros de control de envenenamiento de animales han indicado un fuerte aumento general de la exposición accidental de las mascotas a estos productos. Mantenga estos productos fuera del alcance de los niños y las mascotas.

¿Por qué está notificando la FDA al público sobre el Delta-8 THC?

Una combinación de factores ha llevado a la FDA a proporcionar a los consumidores esta información. Estos factores incluyen:

  • Un aumento de los informes de eventos adversos a la FDA y a los centros de control de envenenamientos del país.
  • La comercialización, incluida la comercialización en línea de productos que resulta atractiva para los niños.
  • Preocupación por la contaminación debida a los métodos de fabricación que en algunos casos pueden utilizarse para elaborar productos comercializados de Delta-8 THC. 

La FDA está trabajando activamente con socios federales y estatales para seguir abordando las preocupaciones relacionadas con estos productos y vigilando el mercado en busca de quejas sobre los productos, eventos adversos y otros productos emergentes derivados del cannabis de potencial preocupación. La FDA advertirá a los consumidores sobre problemas de salud pública y seguridad, y tomará medidas, cuando sea necesario, cuando los productos regulados por la FDA infrinjan la ley.

Cómo reportar quejas y casos de exposición accidental o eventos adversos:

Si cree que tiene un efecto secundario grave que supone un peligro inmediato para su salud, llame al 9-1-1 o la sala de emergencias de su localidad. Se alienta a los profesionales de la salud y a los pacientes a que comuniquen las quejas, los casos de exposición accidental y los acontecimientos adversos al programa MedWatch de Información de Seguridad y Reporte de Eventos Adversos de la FDA:

Para más información sobre el Delta-8 THC:  RED DE ALERTA DE SALUD DE LOS CDC (HAN, POR SUS SIGLAS EN INGLÉS) – añada el enlace cuando esté disponible

La Asociación Americana de Centros de Control de Envenenamientos (AAPCC, por sus siglas en inglés) mantiene el Sistema Nacional de Datos sobre Envenenamientos (NPDS, por sus siglas en inglés), que alberga registros de casos no identificados de información recopilada de las personas que llamaron durante la gestión de la exposición, y llamadas de información sobre envenenamientos gestionadas por los centros de control de envenenamientos del país (PCC, por sus siglas en inglés).  Los datos del NPDS no reflejan todo el universo de exposiciones a una sustancia concreta, ya que puede haber exposiciones adicionales que no se reporten a los PCC; por lo tanto, no debe interpretarse que los datos del NPDS representen la incidencia completa de las exposiciones a cualquier sustancia en los EE. UU.  Las exposiciones no representan necesariamente un envenenamiento o sobredosis, y la AAPCC no puede verificar completamente la exactitud de cada informe.  Las conclusiones basadas en los datos del NPDS no reflejan necesariamente las opiniones de la AAPCC.
 

Image
el Delta-8 THC Tiene Graves Riesgos Para la Salud

Communication Type

Short Title
5 Cosas que Debe Saber Sobre el Delta-8 Tetrahidrocannabinol – Delta-8

Source Organization

Short Description
Los productos de Delta-8 THC no están aprobados por la FDA y pueden ponerle en riesgo.

Publish Date
Thu, 09/16/2021 – 18:05

Review Date
Fri, 09/16/2022 – 12:00

Last Reviewed Date
Thu, 09/16/2021 – 12:00

Site Structure

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Thu, 09/16/2021 – 12:26

Generic Boolean
Off

Language

Number of Related Information to Display
3

Add Subscription Box
On

Description
Haga clic en “Consumer Health Info” y luego marque “Artículos en español”

Email Subscription List

Header
Subscríbase a los Artículos para el Consumidor en español

#CBD #Hemp http://www.fda.gov/consumers/articulos-en-espanol/5-cosas-que-debe-saber-sobre-el-delta-8-tetrahidrocannabinol-delta-8-thc September 16, 2021 4:02 pm

Ad valorem excise taxes are not the way to go for marijuana. 

Ad valorem excise taxes are not the way to go for marijuana. 

Ad valorem excise taxes are not the way to go for marijuana.  Ideological adversaries agree on that, if on little else!  The left-leaning Institute for Taxation and Economic Policy warned, in a detailed report, that ad valorem price-based “ad valorem” taxes on marijuana are a recipe for trouble when prices go down – as they do in every jurisdiction where legalization takes hold. https://itep.org/taxing-cannabis/  

More recently, the right-leaning Tax Foundation has joined the warning:  “states risk losing out on forecasted revenue if prices continue to go down.” https://taxfoundation.org/safe-banking-act-state-marijuana-revenues/

We needn’t use ad valorem taxes at all for marijuana.  The bill phases ad valorem taxes out, but keeps them too long, then compounds the error by de facto freezing them.  

The draft sticks precisely to the early 2017 design of the old Blumenauer-Wyden bill, with ad valorem taxes for five years before switching to “specific” (non-ad valorem) taxes, only at that late date taxing flower by weight and concentrates by THC.  See http://thehill.com/blogs/pundits-blog/economy-budget/327694-marijuana-legalization-grows-closer-with-senate-tax

2017 is a long time ago for a drug that was first legalized in 2012; we’ve come a long way in what we know since then.

That five-year delay may have had some possible justification in 2017, but not now.  But even then, ad valorem taxes were outdated.  Sure, no one was taxing anything by THC content then – but several states had already worked out taxing raw plant matter by weight, the state of the art tax system in 2017.  In the intervening four years since the 2017 bill, Canada, legalizing in 2018, moved straight into taxing flower by weight immediately, and concentrates by THC content about a year later.  No five-year delay!  The system up north seems to be humming.  Lots of states tax by weight already, and Canada has the gold standard using both bases, weight and THC.  I don’t know why we don’t just go ahead and copy it — now.

Taxing by price means that when the pre-tax price goes down, taxes do, too. So do after-tax prices.  Low taxes and cheap weed are not on some people’s wish list, but not everyone’s. After legalization, pre-tax prices are bound to wither.  Fully legal marijuana won’t sell for hundreds or even dozens of dollars per ounce, pre-tax.

But price taxes create another problem. In case of “vertical integration” like a farm-to-market operation, the bill shies away from taxing the actual price the consumer pays, so it imagines an artificial — and probably arbitrary — “constructive sale price” in section 5903.   This is the amount one person, who is both retail clerk and farmer, supposedly pays his farmer self as a wholesale price.  Shenanigans galore!  Colorado has this kind of unworkable producer price tax on the books but, finding it doesn’t work, has quietly given up. Colorado taxes producers by weight instead of by the de jure price-based ad valorem method in related party transactions.  Nevada taxes producers by weight instead of the de jure price-based ad valorem tax on its statute books, last I heard – in all transactions.

— Sent to sponsors of U.S. Senate marijuana bill.


#CBD #Hemp
Ad valorem excise taxes are not the way to go for marijuana. 
September 1, 2021 7:03 pm

Hold Hearings before legalizaing marijuana federally

Hold Hearings before legalizaing marijuana federally

Here’s one of my messages to sponsors of federal marijuana legalization bill:

Dear Senators and Staffers,

On the joint Congressional Committee that devoted four full days of public hearings to liquor taxes alone in December 1933 were a future Supreme Court Justice (Vinson), a future Speaker of the House (McCormack), and a future Vice President (Barkley).  That kind of work might well help Congress today.  The 1933 hearings were hardly a political graveyard for those who took time to listen and study tricky issues.

Those four days covered only taxes, and only liquor – not beer, not wine.  Marijuana legalization needs more work than liquor taxes did in 1933. Unlike with cannabis, we had already had lots of experience taxing liquor.  But Congress studied liquor taxation thoroughly anyway.

Hearings in the Senate Finance Committee on taxes would help, I’d say, as a tax scholar and a former staffer there.  The tax structure in the draft is going to receive severe criticism, only some of it from me, and things have changed dramatically from the Wyden-Blumenauer bill of 2017, whose tax provisions the CAOA basically copies.  Canada has started taxing THC in concentrates, for instance, and New York and Connecticut are going to try to tax it in flower.  These are new developments since 2017 – and warrant a new tax structure.  But what structure?  No one knows. 

There is lot of work for Senators and your staffs to do – and plenty of time to do it in, I suspect, as marijuana legalization will not happen overnight.

In 1933, the Committee heard input from staff, the executive branch, academics, and interested private parties (once known as special interests, now known as stakeholders).  The Ways & Means and Finance Committees reported out a bill in short order, and President Roosevelt signed it in January.  A success story — the result of listening and working.

Here’s the source material, attached. [Newrevenue readers — ask by email for a google drive copy of the large file if you want.]

 Tax on Intoxicating Liquor, Joint Hearings Before the Committee on Ways and Means, House of Representatives and the Committee on Finance, United States Senate, 73d Congress, Interim, 1st and 2d Sessions, Dec. 11-14, 1933, at 309.  


#CBD #Hemp
Hold Hearings before legalizaing marijuana federally
August 29, 2021 9:51 pm

Technical tax comment on federal marijuana bill

Technical tax comment on federal marijuana bill

Comment on the Cannabis Administration and Opportunity Act draft submitted to the Act’s authors:

I don’t understand what (B) is doing in new 26 U.S.C. 5902(a)(2).  

‘‘(2) THC-MEASURABLE CANNABIS PRODUCT.—

The term ‘THC-measurable cannabis product’ means any cannabis product—

‘‘(A) with respect to which the Secretary has made a determination that the amount of tetrahydrocannabinol in such product (or any particular category of products which includes such product) can be measured with a reasonable degree of accuracy—

 ‘‘(i) consistent with good commercial practice, and

 ‘‘(ii) sufficient to protect the revenue and the public, or

 ‘‘(B) which is not cannabis flower and the concentration of tetrahydrocannabinol in which
is significantly higher than the average such concentration in cannabis flower.

+++

 If (A) is satisfied, OK, we know how to measure THC in this product.  Case closed.

If (A) is not satisfied, THC can’t be accurately measured, so at first blush, tax should not be calculated by THC.  

But maybe (B) taxes by THC content something where THC can’t be certifiably accurately measured.  I don’t understand.  (A) alone, without (B), seems to do the job.

(B) seems unnecessary and confusing.  What is (B) supposed to do?  I don’t know.

Thank you.


#CBD #Hemp
Technical tax comment on federal marijuana bill
August 28, 2021 3:43 pm

The profit motive and medical marijuana in North Carolina

The profit motive and medical marijuana in North Carolina

Here are comments on North Carolina SB711 sent to Senators on the Health Committee.

++++

John D. Rockefeller, Jr., was a Baptist teetotaler who opposed alcohol and a Republican businessman who liked the profit motive.  When prohibition was repealed in 1933, Rockefeller didn’t want profit-maximizers retailing liquor.  For health and temperance, he said, let the states themselves sell liquor—and that’s the North Carolina way.  

This bill would let just 10 big companies sell medical cannabis.  If the recreational kind is legalized, those companies will say, “Hooray,” and line up to control the recreational market.  That’s the profit motive.

There’s a more restrictive way than SB711, proven in Canada: Sell medical cannabis only through government retailers—online only, delivered to the patient’s door.  No glitzy storefronts, no marketing to tempt the weak.  No lawsuits claiming cartoons and advertising are protected free speech under the North Carolina Constitution.

Marijuana sellers will say state-run sales are a nonstarter because marijuana is federally illegal, but that’s a diversion.  The federal government simply doesn’t care.  The State of Louisiana has been openly growing and selling marijuana for years – with impunity.  The federal government hasn’t batted an eye.

How about the voters?  In a 2013 North Carolina poll, state marijuana sales beat private sales by 3-to-1.  The full poll with cross-tabs is at https://newtax.files.wordpress.com/2013/03/nc-marijuana-polling-march-2013.pdf.

Sure, if state sales are inept and bureaucratic, the illegal market will step up.  But the kind of licensing proposed in SB711 creates a host of problems.  Medicine will be delayed as folks who didn’t get licenses go to court to protest.  Out-of-state interests will go to court to say the bill’s residence restrictions are unconstitutional.  Winning licensees will go to court to say the bill’s advertising rules improperly restrict free speech under the North Carolina Constitution.  Winning licensees may “flip” valuable licenses for huge sums – and shareholders in winning corporate licensees may “flip” their ownership interests to new shareholders – all for huge windfalls.  And naturally enough, winning licensees will aim to maximize sales and profits.

State sales are no easy answer, but they can be safe, quiet, and restrictive.  The profit motive has its place, but for marijuana, maybe North Carolina can restrict it.

+++

Thank you for this opportunity, and for listening to me and others.  


#CBD #Hemp
The profit motive and medical marijuana in North Carolina
August 28, 2021 2:25 pm

Improving the Medical Cannabis Production Commission in North Carolina

Improving the Medical Cannabis Production Commission in North Carolina

Draft statement of Pat Oglesby, Center for New Revenue, for the North Carolina Senate Judiciary Committee meeting August 18 at 2 p.m.

Medical marijuana is coming to North Carolina, like it or not.  Like most people, I’m for that.

But Senate Bill 711 could be improved in a lot of ways, I think.

Here’s one.

New N.C.G.S. section 90-113.122 would say the Medical Cannabis Production Commission is to have two industry representatives among its nine members.  The industry doesn’t need representatives on the Commission. Marijuana sellers can lobby the Commission quite readily, just as they can present their views to the North Carolina Senate without being Senators.

The industry naturally wants to maximize profits, and maximize sales.  That’s the American way.  But why should industry representatives vote about how to regulate themselves?  That’s regulatory capture.  The Commission needs to serve the general public interest.  We don’t mandate power companies on the Utilities Commission.  We don’t mandate liquor companies and bar owners on the North Carolina Alcoholic Beverage Control Commission.  We mandate professors on the UNC Board of Governors.  The way the bill is written now, the Commission is of the marijuana sellers, by the marijuana sellers, for the marijuana sellers.  

Let’s not put any foxes on the Henhouse Commission.


#CBD #Hemp
Improving the Medical Cannabis Production Commission in North Carolina
August 18, 2021 2:21 pm

Prepared remarks for NC Senate Finance Committee, July 22, 2021, on medical marijuana

Prepared remarks for NC Senate Finance Committee, July 22, 2021, on medical marijuana

Mr. Chairman and Members of the Committee:

Thank you for having me.  I’m Pat Oglesby.  I live in Senator Foushee’s district now, but I’m originally from the home of the Shad Festival, Grifton.  I’ve practiced tax law, been a staff lawyer for the Joint Congressional Committee on Taxation and the U.S. Senate Finance Committee, taught classes at the Kenan-Flagler Business School, and been a member of angel investment groups.  I’ve founded the Center for New Revenue, a non-profit that looks at marijuana revenue, and advised state governments on marijuana, pro bono and for pay.  

I’m an analyst, not an advocate.  There’s a lot of money on the table.  A billion dollars’ worth of medical marijuana was soldin the first 40 months of medical-only legalization in Maryland.  This month, a single medical marijuana license there sold for $8 million.

There’s another way.  In Canada, provinces started out having a government retail medical marijuana monopoly – online only, delivery only, no glitz.  In Louisiana, the 2 land grant universities, LSU and Southern, have had a monopoly on growing medical marijuana for years.  Federally illegal!  Yes, but the federal government knows that, and is winking – and not lifting a finger.

There are pros and cons.  The for-profit model is likely to be more efficient and patient-friendly.  Government can be bureaucratic.  Buying from the government is like chowing down at the school cafeteria; buying from entrepreneurs is like dining on Restaurant Row. Government sales cost more to start up, though they bring in more revenue in the long run. Government sellers can set fair prices and prevent diversion.  They won’t try to boost demand, and won’t say advertising restrictions are unconstitutional. 

Maybe people don’t trust government.  But in a 2013 poll, North Carolina voters preferred government marijuana sales over private sales by a 3 to 1 margin.  The poll is available at www.newrevenue.org.  

Patients need medicine.  Someday, somehow, we’ll stop making them break the law.  There’s no single right way to do it – but a lot to think about.  I wish you well.

+++

Speakers were given only 2 minutes instead of the 3 I hoped for, so I ad libbed. More to come.


#CBD #Hemp
Prepared remarks for NC Senate Finance Committee, July 22, 2021, on medical marijuana
July 28, 2021 8:05 pm

Marijuana sales in North Carolina, public or private? 2013 poll

Marijuana sales in North Carolina, public or private? 2013 poll

Full results with more cross-tabs are at https://newtax.files.wordpress.com/2013/03/nc-marijuana-polling-march-2013.pdf. I hope to refer to this poll at a meeting of the North Carolina Senate Finance Committee the afternoon of July 21, 2021.


#CBD #Hemp
Marijuana sales in North Carolina, public or private? 2013 poll
July 21, 2021 6:32 am

Senate Marijuana Bill’s Taxes Are Old-Fashioned.

Senate Marijuana Bill’s Taxes Are Old-Fashioned.

The new Schumer-Wyden-Booker marijuana legalization bill is available.

It’s disappointing that the sticks precisely to the early 2017 design of the Blumenauer-Wyden bill, with ad valorem taxes for five years before switching to “specific” (non-ad valorem) taxes, only at that late date taxing flower by weight and concentrates by THC.  See http://thehill.com/blogs/pundits-blog/economy-budget/327694-marijuana-legalization-grows-closer-with-senate-tax. 2017 is a long time ago for a drug that was first legalized in 2012; we’ve come a long way in what we know since then.

That five-year delay may have had some possible justification in 2017, but not now.  But even then, ad valorem taxes were outdated.  Sure, no one was taxing anything by THC content – but several states had already worked out taxing raw plant matter by weight, the state of the art tax system in 2017.  In the intervening four years, Canada, legalizing in 2018, moved straight into taxing flower by weight immediately, and concentrates by THC content almost immediately.  No five-year delay!  The system up north seems to be humming.  Lots of states tax by weight already, and Canada has the gold standard using both bases, weight and THC.  I don’t know why we don’t just go ahead and copy it — now.



#CBD #Hemp
Senate Marijuana Bill’s Taxes Are Old-Fashioned.
July 15, 2021 6:41 pm

Hemp & Fascism

Regarding Hemp in Italy, from Canapando:

“Cannabis & Fascism

A small excerpt from the history of Hemp at the time of Fascism.

Many know the numerous uses that can be made of hemp and that its cultivation and exploitation by man dates back more than 2500 years ago.

However, not everyone knows that Italy has a prestigious tradition in this field both for the quality and quantity of cannabis produced.

Among other things, paradoxically, the heyday for the Italian hemp sector was between the early 1920s and the mid 1940s, in the midst of the Fascist period.

Between the end of the 19th century and the beginning of the 20th century, the Italian hemp yarn was renowned all over the world for its softness, luster and whiteness.

These crops were mainly distributed in Northern Italy and it is estimated that in 1923 the sector employed about 20,000 people as reported in the Catalog of the Linificio e Canapificio Nazionale. This catalog was an expression of the national industrial association. In short, it was not the stuff of long-haired junkies as a certain part of public opinion wants to pass those who do business with this plant, but prestigious businessmen.

Important processing plants for this plant were located in Cassano d’Adda, where already in 1895 there was a rope factory that exported all over the world and in Genoa which boasted a company of yarns for the naval industry first in the whole Mediterranean for production.

Italy was so advanced in Europe that in 1913 the Reich Office for the Interior drafted a report on the cultivation and processing of hemp in Italy.

This is an excerpt: “ The overall extension of hemp cultivation in Italy is currently to be estimated at around 90,000-100,000 hectares. In the first place is definitely Emilia, in particular the province of Ferrara, where about 12% of the entire surface is worked with hemp ”.

In 1918 the union of Spinners and Hemp Weavers was born.

Of course, this sector too was coordinated and supervised by the Fascist Farmers Confederation, which controlled all the consortia.

In practice, it regulated production, proportioning it to the demand for consumption, using the most suitable land and areas, but also valued the products, seeds and derivatives, and promoted the maceration processes of the fiber and the technical evolution.

The importance of the hemp sector was such that the Duce himself put it this way in 1925 : “Hemp was placed by the Duce, on the agenda of the nation, because autarchic par excellence is destined to emancipate us as much as possible from the heavy tax we have again abroad in the textile fiber sector. It is not only the agricultural economic side, there is also the social side whose impact could not be better highlighted than by the following figure: 30,000 workers to whom the Italian hemp industry employs”.

The beginning of the decline in the reputation of cannabis came a few years later when the historical process that led us to the falsifications and mystifications of today begins.

Hashish, its recreational derivative, is declared an enemy of race and drugs by “ner**i”.

Despite this, the industrial use of the plant continued to grow until the end of the Second World War.

In 1941, ENEC , the National Hemp Exporting Body, was born , which has a monopoly on the sale abroad of both raw and combed hemp and hemp tow and controls the export of manufactured goods. Also in the same year, the area cultivated with hemp went from 60 thousand hectares in 1934 to 102 thousand .

This is the peak of production in Italy, from here on an unstoppable meltdown will begin.

A decline desired by politics and international lobbies, which have pushed the use of fibers derived from petroleum such as rayon, nylon or cotton.

On the other hand, Italy had entered the western bloc and the Marshall Plan did not allow for replicas in terms of industrial and economic strategic choices.

Thus the American boycott together with its prohibition makes it an ideological question and defines the contours of an evil work: the slow decline of one of the most useful plants for man and its demonization.

The result was the national extinction of all types of crops in 1971.”

Congress: S. 1698: A bill to allow for hemp-derived cannabidiol and hemp-derived cannabidiol containing substances in dietary supplements and food.

Congress: 
S. 1698: A bill to allow for hemp-derived cannabidiol and hemp-derived cannabidiol containing substances in dietary supplements and food.
Introduced: Sponsor: Sen. Ron Wyden [D-OR]

This bill was referred to the Senate Committee on Health, Education, Labor, and Pensions which will consider it before sending it to the Senate floor for consideration.

1 cosponsor is on that committee.

#CBD #Hemp
https://www.govtrack.us/congress/bills/117/s1698?utm_campaign=govtrack_feed&utm_source=govtrack/feed&utm_medium=rss
May 19, 2021 4:00 am

Cheese = Schedule 1?

Cheese is dangerous and of “no medical value” with a “high potential for abuse.” It meets all the requirements for Schedule I, unlike Cannabis.

I actually sold over $100 million in TofuRella cheese alternative, so I know all-too-well the heartbreak of cheese addiction. It starts with a little cheddar or jack, then increases to brie and gouda. Eventually they’re found hustling the streets for american processed cheese food slices.

“Oral administration of a form of sugar found in milk causes brain damage in rats. If we use the current model and justification for marijuana prohibition, it looks like milk, cheese and ice cream should be placed in Schedule 1.” Clint Werner

Read more at: https://pubmed.ncbi.nlm.nih.gov/26748256/

DEA Opens Up Pot Research With Scientist Agreements

DEA Opens Up Pot Research With Scientist Agreements The U.S. Drug Enforcement Administration told researchers on Friday that it is likely to allow them to grow marijuana for their work, opening up the field of cannabis science after President Joe Biden said he wanted more information before he would consider federal legalization. #CBD #Hemp https://www.law360.com/cannabis/articles/1385153?utm_source=rss&utm_medium=rss&utm_campaign=section May 14, 2021 10:01 pm

Cannabis Bill Roundup: Neb. Advocates Eye Medical Pot Redo

Cannabis Bill Roundup: Neb. Advocates Eye Medical Pot Redo In the past week, Republican members of Congress pitched their own proposal for decriminalizing cannabis while medical marijuana advocates in Nebraska announced they would take the battle from the statehouse to the ballot box. Here are the major developments in cannabis law reform. #CBD #Hemp https://www.law360.com/cannabis/articles/1384905?utm_source=rss&utm_medium=rss&utm_campaign=section May 14, 2021 9:25 pm

REIT Innovative Industrial Buys Pa. Property For $42M

REIT Innovative Industrial Buys Pa. Property For $42M Innovative Industrial Properties has purchased an industrial property in Pittsburgh from cannabis operator Parallel for roughly $41.8 million, according to an announcement Friday from the cannabis-focused real estate investment trust. #CBD #Hemp https://www.law360.com/cannabis/articles/1384875?utm_source=rss&utm_medium=rss&utm_campaign=section May 14, 2021 5:58 pm

Minn. House OKs Legalizing, Taxing Recreational Marijuana

Minn. House OKs Legalizing, Taxing Recreational Marijuana Minnesota would legalize recreational marijuana and impose gross receipts and use taxes on sales of cannabis products under a bill passed by the state House of Representatives. #CBD #Hemp https://www.law360.com/cannabis/articles/1384910?utm_source=rss&utm_medium=rss&utm_campaign=section May 14, 2021 5:41 pm

Fla. Appellate Court Tosses Investors From $17M Pot Co. Suit

Fla. Appellate Court Tosses Investors From $17M Pot Co. Suit A Florida appellate panel dismissed nine investors’ fraud claims Friday against cannabis company American Patriot Brands in a wide-ranging lawsuit after finding they had agreed to litigate any disputes over their investments in the California-based company. #CBD #Hemp https://www.law360.com/cannabis/articles/1384988?utm_source=rss&utm_medium=rss&utm_campaign=section May 14, 2021 5:35 pm

Miss. High Court Overturns Medical Pot Ballot Measure

Miss. High Court Overturns Medical Pot Ballot Measure Mississippi’s Supreme Court on Friday overturned a voter-approved measure to legalize medical cannabis, ruling that the election law governing ballot referendums in the state has been out of date for nearly 20 years. #CBD #Hemp https://www.law360.com/cannabis/articles/1385105?utm_source=rss&utm_medium=rss&utm_campaign=section May 14, 2021 5:07 pm

Ex-Mayor Convicted In Boston's 1st Big Trial Of Pandemic

Ex-Mayor Convicted In Boston's 1st Big Trial Of Pandemic A Boston federal jury on Friday convicted the former mayor of Fall River, Massachusetts, on most counts in a case alleging he stole from investors and separately extorted cannabis businesses, handing prosecutors a win in the district’s first high-profile criminal trial since the COVID-19 pandemic began. #CBD #Hemp https://www.law360.com/cannabis/articles/1383266?utm_source=rss&utm_medium=rss&utm_campaign=section May 14, 2021 12:22 pm

Pot Businesses Face Texting Bans, Industry Group Says

Pot Businesses Face Texting Bans, Industry Group Says The National Cannabis Industry Association says some of its members that use text messaging to market their products and stores are finding themselves shut out of texting platforms, as the industry faces lawsuits over unwanted texts and cell service providers crack down on marketing messages. #CBD #Hemp https://www.law360.com/cannabis/articles/1384667?utm_source=rss&utm_medium=rss&utm_campaign=section May 13, 2021 9:56 pm

CDB Processor Wins Extension In Contract Dispute Case

CDB Processor Wins Extension In Contract Dispute Case A Kentucky federal judge granted a CBD processor an additional three weeks Thursday to potentially avoid a $634,500 default judgment arising from its dispute with a hemp supplier, despite months of inaction on the CBD company’s part. #CBD #Hemp https://www.law360.com/cannabis/articles/1383628?utm_source=rss&utm_medium=rss&utm_campaign=section May 13, 2021 8:48 pm

Okla. Says Pot's Federal Illegality Dooms Residency Challenge

Okla. Says Pot's Federal Illegality Dooms Residency Challenge The state of Oklahoma once again defended its residency rules for medical cannabis licensees, telling a federal judge on Wednesday that there can be no constitutional protections for interstate marijuana commerce because the drug is federally illegal. #CBD #Hemp https://www.law360.com/cannabis/articles/1384556?utm_source=rss&utm_medium=rss&utm_campaign=section May 13, 2021 8:22 pm

Trulieve Says Investors' Moldy Pot Suit Doesn't Pass Muster

Trulieve Says Investors' Moldy Pot Suit Doesn't Pass Muster Florida’s largest medical cannabis company has asked a federal judge to toss a consolidated securities suit once and for all, saying the investors had failed to allege that the company misled anyone about the risks of crop contamination. #CBD #Hemp https://www.law360.com/cannabis/articles/1383620?utm_source=rss&utm_medium=rss&utm_campaign=section May 12, 2021 9:21 pm

GOP Reps. Pitch Bill To Federally Decriminalize Cannabis

GOP Reps. Pitch Bill To Federally Decriminalize Cannabis Republican congressmen on Wednesday introduced a bill that would decriminalize cannabis federally, direct federal regulators to develop rules overseeing its sale and grant safe harbor to financial institutions that bank with the industry. #CBD #Hemp https://www.law360.com/cannabis/articles/1384247?utm_source=rss&utm_medium=rss&utm_campaign=section May 12, 2021 8:23 pm

2 Charged For Roles In $650M Weed, Cattle Ponzi Scheme

2 Charged For Roles In $650M Weed, Cattle Ponzi Scheme An indictment unsealed Tuesday in Colorado federal court charged an Illinois woman and a Georgia man over their roles in a Ponzi scheme involving cannabis and cattle that raised around $650 million from investors nationwide, the U.S. Department of Justice said Wednesday. #CBD #Hemp https://www.law360.com/cannabis/articles/1384177?utm_source=rss&utm_medium=rss&utm_campaign=section May 12, 2021 7:18 pm

Privately Held Pot Co. Raises $55M In Deal Led By 2 Firms

Privately Held Pot Co. Raises $55M In Deal Led By 2 Firms Privately held multistate cannabis company Holistic Industries raised $55 million through a convertible note in a transaction guided by Feuerstein Kulick LLP and Stroock & Stroock & Lavan LLP, it said Tuesday. #CBD #Hemp https://www.law360.com/cannabis/articles/1383728?utm_source=rss&utm_medium=rss&utm_campaign=section May 11, 2021 8:14 pm

Boston Weighing Tighter Restrictions On Pot Delivery

Boston Weighing Tighter Restrictions On Pot Delivery Boston’s cannabis regulator announced Tuesday that it was considering changing city rules to require marijuana sellers to get the agency’s permission in order to make deliveries. #CBD #Hemp https://www.law360.com/cannabis/articles/1383812?utm_source=rss&utm_medium=rss&utm_campaign=section May 11, 2021 7:43 pm

Court Tosses RICO Claims Against Cannabis Cos.

Court Tosses RICO Claims Against Cannabis Cos. A Massachusetts federal judge on Tuesday dismissed racketeering claims against a group of New Mexico cannabis companies, saying that a purported plan to open a medical marijuana treatment center did not amount to coordinated criminal activity. #CBD #Hemp https://www.law360.com/cannabis/articles/1383658?utm_source=rss&utm_medium=rss&utm_campaign=section May 11, 2021 7:35 pm

Cannabis Co. Says It Was Elbowed Out Of Extractor Deal

Cannabis Co. Says It Was Elbowed Out Of Extractor Deal Cannabis tech company SHO Products LLC is seeking at least $1 million in damages in California federal court from an inventor that it claims violated an exclusivity agreement by leasing a commercial cannabis resin extraction unit called the Hashatron without including SHO in the deal. #CBD #Hemp https://www.law360.com/cannabis/articles/1382837?utm_source=rss&utm_medium=rss&utm_campaign=section May 11, 2021 6:41 pm

Pepsi Must Cover Med Pot Costs After NJ High Court Ruling

Pepsi Must Cover Med Pot Costs After NJ High Court Ruling A New Jersey state appeals court on Tuesday said Pepsi Bottling Group must reimburse a onetime employee for his medical cannabis costs in light of a recent state Supreme Court decision that employers can be compelled to cover those expenses despite the federal marijuana prohibition under the Controlled Substances Act. #CBD #Hemp https://www.law360.com/cannabis/articles/1383507?utm_source=rss&utm_medium=rss&utm_campaign=section May 11, 2021 4:09 pm

Congress: H.R. 841: Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021

Congress: 
H.R. 841: Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
New Cosponsors: New Cosponsor: Rep. Antonio Delgado [D-NY19]
New Cosponsor: Rep. Nancy Mace [R-SC1]

The bill now has 25 cosponsors (16 Democrats, 9 Republicans).

#CBD #Hemp
https://www.govtrack.us/congress/bills/117/hr841?utm_campaign=govtrack_feed&utm_source=govtrack/feed&utm_medium=rss
May 11, 2021 4:00 am

Canopy Didn't Mean To Mislead Investors, Judge Says

Canopy Didn't Mean To Mislead Investors, Judge Says A New Jersey federal judge has granted major pot company Canopy Growth’s bid to escape an investor class action accusing it of misleading them about the strength of the Canadian cannabis market, ruling the investors didn’t show that the company intentionally deceived them. #CBD #Hemp https://www.law360.com/cannabis/articles/1383075?utm_source=rss&utm_medium=rss&utm_campaign=section May 10, 2021 7:59 pm

CBD Co. Agrees To Pay $500K Over Health Claims

CBD Co. Agrees To Pay $500K Over Health Claims Cannabis company Cannacraft agreed to pay more than $500,000 in penalties to settle charges brought by a California consumer protection task force accusing it of improperly marketing CBD products as treatments for cancer, Alzheimer’s disease and more. #CBD #Hemp https://www.law360.com/cannabis/articles/1383109?utm_source=rss&utm_medium=rss&utm_campaign=section May 10, 2021 4:11 pm

4 Firms Guide Trulieve's $2.1B Deal For Pot Industry Peer

4 Firms Guide Trulieve's $2.1B Deal For Pot Industry Peer Trulieve Cannabis Corp. will absorb Harvest Health & Recreation Inc. for roughly $2.1 billion to create a premier player in the U.S. pot industry, the companies said Monday, in a transaction put together with help from four law firms. #CBD #Hemp https://www.law360.com/cannabis/articles/1382968?utm_source=rss&utm_medium=rss&utm_campaign=section May 10, 2021 11:04 am

THC + CBD and Memory Study

THC + CBD and Memory Study

Conditions: Marijuana Use; Cannabis Use; Cannabis Intoxication
Interventions: Drug: High THC/No CBD Marihuana; Drug: High THC/High CBD Marihuana; Drug: No THC/No CBD Marihuana
Sponsors: Hartford Hospital; Yale University. Not yet recruiting
http://www.clinicaltrials.gov/ct2/show/NCT04855526?term=cannabinoid+OR+cannabidiol+OR+Cannabis+OR+THC&lupd_s=04%2F08%2F2021&lupd_d=14

Cannabis Bill Roundup: Medical Pot Advances In The South

Cannabis Bill Roundup: Medical Pot Advances In The South Lawmakers in a host of southern states this week advanced or approved bills to reform or create a medical cannabis program, while in states where marijuana is already fully legal, legislators are moving ahead with policies allowing for home grow and union participation in the space. Here are the major legislative developments in cannabis from the last week. #CBD #Hemp https://www.law360.com/cannabis/articles/1382639?utm_source=rss&utm_medium=rss&utm_campaign=section May 7, 2021 8:55 pm

Medical Pot Co. Says IT Biz Faked Signature In $10M Contract

Medical Pot Co. Says IT Biz Faked Signature In $10M Contract A cannabis sales software company has asked a Pennsylvania federal judge to dismiss a subcontractor’s suit over its termination from a $10 million state contract it said was secured based on its status as a Black-owned IT company, saying the subcontractor forged a signature for an unaccepted counteroffer. #CBD #Hemp https://www.law360.com/cannabis/articles/1382529?utm_source=rss&utm_medium=rss&utm_campaign=section May 7, 2021 7:12 pm

NYS Hemp Regs Set Standard

By the New York state definition, Full Spectrum CBD extract up to 0.3% THC made from hemp and containing large amounts of CBD or CBG is legal, since any cannabinoids present are incidental and not added. FDA has a similar loophole for hempseed oil containing up to 0.3% THC and say 9% CBD, as the cannabinoids are incidental and not added.

New York state defines “full spectrum” as:
• Derived from a hemp extract.
• Contains cannabinoids, aromatics, essential vitamins and minerals, fatty acids, protein, chlorophyll, flavonoids or terpenes.
• Has not been reformulated or has not had cannabinoid isolates or distillates added to it.